2021-01-18 16:33:33 | INFO | fairseq_cli.generate | {'_name': None, 'common': {'_name': None, 'no_progress_bar': False, 'log_interval': 100, 'log_format': None, 'tensorboard_logdir': None, 'wandb_project': None, 'azureml_logging': False, 'seed': 1, 'cpu': False, 'tpu': False, 'bf16': False, 'memory_efficient_bf16': False, 'fp16': False, 'memory_efficient_fp16': False, 'fp16_no_flatten_grads': False, 'fp16_init_scale': 128, 'fp16_scale_window': None, 'fp16_scale_tolerance': 0.0, 'min_loss_scale': 0.0001, 'threshold_loss_scale': None, 'user_dir': None, 'empty_cache_freq': 0, 'all_gather_list_size': 16384, 'model_parallel_size': 1, 'quantization_config_path': None, 'profile': False, 'reset_logging': True}, 'common_eval': {'_name': None, 'path': '/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_en_comma/checkpoint_best.pt', 'post_process': None, 'quiet': False, 'model_overrides': '{}', 'results_path': './out_fp32_best/en_comma_en'}, 'distributed_training': {'_name': None, 'distributed_world_size': 1, 'distributed_rank': 0, 'distributed_backend': 'nccl', 'distributed_init_method': None, 'distributed_port': -1, 'device_id': 0, 'distributed_no_spawn': False, 'ddp_backend': 'c10d', 'bucket_cap_mb': 25, 'fix_batches_to_gpus': False, 'find_unused_parameters': False, 'fast_stat_sync': False, 'heartbeat_timeout': -1, 'broadcast_buffers': False, 'distributed_wrapper': 'DDP', 'slowmo_momentum': None, 'slowmo_algorithm': 'LocalSGD', 'localsgd_frequency': 3, 'nprocs_per_node': 1, 'pipeline_model_parallel': False, 'pipeline_balance': None, 'pipeline_devices': None, 'pipeline_chunks': 0, 'pipeline_encoder_balance': None, 'pipeline_encoder_devices': None, 'pipeline_decoder_balance': None, 'pipeline_decoder_devices': None, 'pipeline_checkpoint': 'never', 'zero_sharding': 'none', 'tpu': False}, 'dataset': {'_name': None, 'num_workers': 1, 'skip_invalid_size_inputs_valid_test': False, 'max_tokens': 768, 'batch_size': None, 'required_batch_size_multiple': 8, 'required_seq_len_multiple': 1, 'dataset_impl': None, 'data_buffer_size': 10, 'train_subset': 'train', 'valid_subset': 'valid', 'validate_interval': 1, 'validate_interval_updates': 0, 'validate_after_updates': 0, 'fixed_validation_seed': None, 'disable_validation': False, 'max_tokens_valid': 768, 'batch_size_valid': None, 'curriculum': 0, 'gen_subset': 'test', 'num_shards': 1, 'shard_id': 0}, 'optimization': {'_name': None, 'max_epoch': 0, 'max_update': 0, 'stop_time_hours': 0.0, 'clip_norm': 0.0, 'sentence_avg': False, 'update_freq': [1], 'lr': [0.25], 'stop_min_lr': -1.0, 'use_bmuf': False}, 'checkpoint': {'_name': None, 'save_dir': 'checkpoints', 'restore_file': 'checkpoint_last.pt', 'finetune_from_model': None, 'reset_dataloader': False, 'reset_lr_scheduler': False, 'reset_meters': False, 'reset_optimizer': False, 'optimizer_overrides': '{}', 'save_interval': 1, 'save_interval_updates': 0, 'keep_interval_updates': -1, 'keep_last_epochs': -1, 'keep_best_checkpoints': -1, 'no_save': False, 'no_epoch_checkpoints': False, 'no_last_checkpoints': False, 'no_save_optimizer_state': False, 'best_checkpoint_metric': 'loss', 'maximize_best_checkpoint_metric': False, 'patience': -1, 'checkpoint_suffix': '', 'checkpoint_shard_count': 1, 'load_checkpoint_on_all_dp_ranks': False, 'model_parallel_size': 1, 'distributed_rank': 0}, 'bmuf': {'_name': None, 'block_lr': 1.0, 'block_momentum': 0.875, 'global_sync_iter': 50, 'warmup_iterations': 500, 'use_nbm': False, 'average_sync': False, 'distributed_world_size': 1}, 'generation': {'_name': None, 'beam': 5, 'nbest': 1, 'max_len_a': 0.0, 'max_len_b': 200, 'min_len': 1, 'match_source_len': False, 'unnormalized': False, 'no_early_stop': False, 'no_beamable_mm': False, 'lenpen': 1.0, 'unkpen': 0.0, 'replace_unk': None, 'sacrebleu': False, 'score_reference': False, 'prefix_size': 0, 'no_repeat_ngram_size': 0, 'sampling': False, 'sampling_topk': -1, 'sampling_topp': -1.0, 'constraints': None, 'temperature': 1.0, 'diverse_beam_groups': -1, 'diverse_beam_strength': 0.5, 'diversity_rate': -1.0, 'print_alignment': None, 'print_step': False, 'lm_path': None, 'lm_weight': 0.0, 'iter_decode_eos_penalty': 0.0, 'iter_decode_max_iter': 10, 'iter_decode_force_max_iter': False, 'iter_decode_with_beam': 1, 'iter_decode_with_external_reranker': False, 'retain_iter_history': False, 'retain_dropout': False, 'retain_dropout_modules': None, 'decoding_format': None, 'no_seed_provided': False}, 'eval_lm': {'_name': None, 'output_word_probs': False, 'output_word_stats': False, 'context_window': 0, 'softmax_batch': 9223372036854775807}, 'interactive': {'_name': None, 'buffer_size': 0, 'input': '-'}, 'model': None, 'task': Namespace(_name='translation_from_pretrained_bart', all_gather_list_size=16384, azureml_logging=False, batch_size=None, batch_size_valid=None, beam=5, best_checkpoint_metric='loss', bf16=False, bpe='sentencepiece', broadcast_buffers=False, bucket_cap_mb=25, checkpoint_shard_count=1, checkpoint_suffix='', constraints=None, cpu=False, criterion='cross_entropy', curriculum=0, data='./postprocessed/en_comma', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, disable_validation=False, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eos=2, eval_bleu=False, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, finetune_from_model=None, fix_batches_to_gpus=False, fixed_validation_seed=None, force_anneal=None, fp16=False, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', heartbeat_timeout=-1, iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, keep_best_checkpoints=-1, keep_interval_updates=-1, keep_last_epochs=-1, langs='ar_AR,cs_CZ,de_DE,en_XX,es_XX,et_EE,fi_FI,fr_XX,gu_IN,hi_IN,it_IT,ja_XX,kk_KZ,ko_KR,lt_LT,lv_LV,my_MM,ne_NP,nl_XX,ro_RO,ru_RU,si_LK,tr_TR,vi_VN,zh_CN', left_pad_source='True', left_pad_target='False', lenpen=1, lm_path=None, lm_weight=0.0, load_alignments=False, load_checkpoint_on_all_dp_ranks=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_source_positions=1024, max_target_positions=1024, max_tokens=768, max_tokens_valid=768, maximize_best_checkpoint_metric=False, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, nbest=1, no_beamable_mm=False, no_early_stop=False, no_epoch_checkpoints=False, no_last_checkpoints=False, no_progress_bar=False, no_repeat_ngram_size=0, no_save=False, no_save_optimizer_state=False, no_seed_provided=False, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer=None, optimizer_overrides='{}', pad=1, path='/global/lv71502/clang/fairseq/mBART_termeval/checkpoint_en_comma/checkpoint_best.pt', patience=-1, pipeline_balance=None, pipeline_checkpoint='never', pipeline_chunks=0, pipeline_decoder_balance=None, pipeline_decoder_devices=None, pipeline_devices=None, pipeline_encoder_balance=None, pipeline_encoder_devices=None, pipeline_model_parallel=False, post_process=None, prefix_size=0, prepend_bos=False, print_alignment=None, print_step=False, profile=False, quantization_config_path=None, quiet=False, replace_unk=None, required_batch_size_multiple=8, required_seq_len_multiple=1, reset_dataloader=False, reset_logging=True, reset_lr_scheduler=False, reset_meters=False, reset_optimizer=False, restore_file='checkpoint_last.pt', results_path='./out_fp32_best/en_comma_en', retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, save_dir='checkpoints', save_interval=1, save_interval_updates=0, score_reference=False, scoring='bleu', seed=1, sentencepiece_model='../models/mbart.cc25/sentence.bpe.model', shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang='src', target_lang='label', task='translation_from_pretrained_bart', temperature=1.0, tensorboard_logdir=None, threshold_loss_scale=None, tokenizer=None, tpu=False, train_subset='train', truncate_source=False, unk=3, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, valid_subset='valid', validate_after_updates=0, validate_interval=1, validate_interval_updates=0, wandb_project=None, warmup_updates=0, zero_sharding='none'), 'criterion': {'_name': 'cross_entropy', 'sentence_avg': True}, 'optimizer': None, 'lr_scheduler': {'_name': 'fixed', 'force_anneal': None, 'lr_shrink': 0.1, 'warmup_updates': 0, 'lr': [0.25]}, 'scoring': {'_name': 'bleu', 'pad': 1, 'eos': 2, 'unk': 3}, 'bpe': {'_name': 'sentencepiece', 'sentencepiece_model': '../models/mbart.cc25/sentence.bpe.model'}, 'tokenizer': None}
2021-01-18 16:33:34 | INFO | fairseq.tasks.translation | [src] dictionary: 250001 types
2021-01-18 16:33:34 | INFO | fairseq.tasks.translation | [label] dictionary: 250001 types
2021-01-18 16:33:34 | INFO | fairseq_cli.generate | loading model(s) from /global/lv71502/clang/fairseq/mBART_termeval/checkpoint_en_comma/checkpoint_best.pt
2021-01-18 16:37:07 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_comma/test.src-label.src
2021-01-18 16:37:07 | INFO | fairseq.data.data_utils | loaded 2,024 examples from: ./postprocessed/en_comma/test.src-label.label
2021-01-18 16:37:07 | INFO | fairseq.tasks.translation | ./postprocessed/en_comma test src-label 2024 examples
S-1900	The benefits of exercise extend well beyond the cardiovascular system.<unk>
T-1900	exercise ; cardiovascular
H-1900	-0.3577894866466522	▁exercise ▁; ▁cardiovascular ▁system
D-1900	-0.3577894866466522	exercise ; cardiovascular system
P-1900	-0.7877 -0.5039 -0.1774 -0.0736 -0.3371 -0.2670
S-1988	There were no study-related serious adverse events.<unk>
T-1988	adverse events
H-1988	-0.7828439474105835	
D-1988	-0.7828439474105835	
P-1988	-1.4302 -0.1355
S-712	Two Cox proportional hazards models were developed.<unk>
T-712	cox proportional hazards models
H-712	-0.7384884357452393	▁co x ▁proportion al ▁hazard s ▁models
D-712	-0.7384884357452393	cox proportional hazards models
P-712	-0.1609 -0.7040 -0.0761 -0.0472 -2.3811 -0.5862 -1.8242 -0.5572 -0.3095
S-1451	A nested case-control study design was used.<unk>
T-1451	
H-1451	-0.5740928053855896	▁case - control ▁study
D-1451	-0.5740928053855896	case-control study
P-1451	-0.8075 -0.5774 -0.0670 -0.9674 -0.7706 -0.2547
S-1528	Of 402 patients, 48 (12%) had EH.<unk>
T-1528	patients
H-1528	-0.24281039834022522	▁EH
D-1528	-0.24281039834022522	EH
P-1528	-0.2214 -0.2363 -0.2707
S-664	We identified 12 556 patients from 45 practices.<unk>
T-664	patients
H-664	-0.7493060231208801	▁practice s
D-664	-0.7493060231208801	practices
P-664	-2.3878 -0.1350 -0.2236 -0.2508
S-133	The basis for these differences requires further examination.<unk>
T-133	
H-133	-0.2310890406370163	
D-133	-0.2310890406370163	
P-133	-0.3219 -0.1402
S-1685	The young woman and her family adamantly refuse.<unk>
T-1685	
H-1685	-1.3247040510177612	
D-1685	-1.3247040510177612	
P-1685	-2.1875 -0.4619
S-228	Clinical comparisons were made between the 2 groups.<unk>
T-228	clinical
H-228	-0.39317283034324646	▁Clinic al
D-228	-0.39317283034324646	Clinical
P-228	-0.6156 -0.1270 -0.7154 -0.1148
S-364	However, this patient developed HF 4 years later.<unk>
T-364	patient ; hf
H-364	-0.7216753363609314	▁ HF
D-364	-0.7216753363609314	HF
P-364	-1.8522 -0.2986 -0.3445 -0.3915
S-949	No major complications occurred during follow-up.<unk>
T-949	complications ; follow-up
H-949	-0.5069507360458374	
D-949	-0.5069507360458374	
P-949	-0.8929 -0.1210
S-1037	Now, reporting in Cell, Anand et al.<unk>
T-1037	reporting ; cell ; anand
H-1037	-0.1989891678094864	▁report ing ▁; ▁Cell ▁; ▁Anand
D-1037	-0.1989891678094864	reporting ; Cell ; Anand
P-1037	-0.0491 -0.0159 -0.2120 -0.1534 -0.4402 -0.0007 -0.5727 -0.1479
S-957	Doxorubicin was injected i.p.<unk>
T-957	doxorubicin ; injected
H-957	-0.46554669737815857	▁do xor ubi cin ▁; ▁inject ed
D-957	-0.46554669737815857	doxorubicin ; injected
P-957	-0.2938 -0.1753 -0.0478 -0.5606 -1.2119 -0.0962 -0.3756 -0.9783 -0.4504
S-1684	Her doctors urgently recommend blood transfusions.<unk>
T-1684	doctors ; blood transfusions
H-1684	-0.7452179193496704	▁doctor s ▁; ▁blood ▁trans fusion s
D-1684	-0.7452179193496704	doctors ; blood transfusions
P-1684	-2.1251 -0.4485 -0.5180 -2.0760 -0.0349 -0.0252 -0.5145 -0.5272 -0.4377
S-18	No correlation to changes in FM was found.<unk>
T-18	correlation
H-18	-0.3781806528568268	▁FM
D-18	-0.3781806528568268	FM
P-18	-0.7406 -0.2122 -0.1818
S-1916	RESULTS: No adverse events occurred.<unk>
T-1916	adverse events
H-1916	-0.8724431395530701	▁advers e ▁events
D-1916	-0.8724431395530701	adverse events
P-1916	-3.1340 -0.2081 -0.3298 -0.3503 -0.3401
S-1066	Contemporary use of devices in heart failure.<unk>
T-1066	heart failure
H-1066	-0.6706995964050293	▁devices ▁; ▁heart ▁failure
D-1066	-0.6706995964050293	devices ; heart failure
P-1066	-2.0414 -0.6721 -0.6493 -0.0685 -0.2983 -0.2946
S-1496	DXA results were compared with Australian reference data.<unk>
T-1496	dxa
H-1496	-1.251753568649292	▁d XA
D-1496	-1.251753568649292	dXA
P-1496	-0.4760 -0.8778 -3.3795 -0.2737
S-233	Liver disease in the adults was more advanced.<unk>
T-233	liver disease
H-233	-0.47720128297805786	▁Live r ▁disease ▁; ▁adults
D-233	-0.47720128297805786	Liver disease ; adults
P-233	-0.2858 -0.4535 -0.3380 -1.1330 -0.7489 -0.1545 -0.2268
S-307	Recommendations based on a systematic review.<unk>
T-307	
H-307	-0.3160788416862488	
D-307	-0.3160788416862488	
P-307	-0.4650 -0.1672
S-1699	Results were similar for HF and PNA.<unk>
T-1699	hf ; pna
H-1699	-0.5860211849212646	▁ HF ▁; ▁p na
D-1699	-0.5860211849212646	HF ; pna
P-1699	-1.2900 -1.0850 -0.1879 -0.3663 -0.4669 -0.5097 -0.1964
S-1897	Playing it safe: exercise and cardiovascular health.<unk>
T-1897	exercise ; cardiovascular ; health
H-1897	-0.4636034667491913	▁exercise ▁; ▁cardiovascular ▁health
D-1897	-0.4636034667491913	exercise ; cardiovascular health
P-1897	-1.2829 -0.5037 -0.0447 -0.2469 -0.3981 -0.3053
S-1592	Renal artery stenosis - an update.<unk>
T-1592	renal artery stenosis
H-1592	-0.15502052009105682	▁Ren al ▁arter y ▁sten osis
D-1592	-0.15502052009105682	Renal artery stenosis
P-1592	-0.0501 -0.0324 -0.0832 -0.1181 -0.1202 -0.0519 -0.6074 -0.1769
S-1712	DESIGN: Retrospective cohort study.<unk>
T-1712	retrospective cohort study
H-1712	-0.609681248664856	
D-1712	-0.609681248664856	
P-1712	-1.0501 -0.1692
S-1279	Acute care surgery in heart transplant recipients.<unk>
T-1279	acute care surgery ; heart transplant
H-1279	-0.7196686267852783	▁surgery ▁; ▁heart ▁transplant ▁recipient s
D-1279	-0.7196686267852783	surgery ; heart transplant recipients
P-1279	-4.1764 -0.3057 -0.2452 -0.0203 -0.0682 -0.2171 -0.5182 -0.2063
S-190	The primary end point was inhospital mortality.<unk>
T-190	primary end point ; inhospital ; mortality
H-190	-0.3775613307952881	▁in hospital ▁mortal ity
D-190	-0.3775613307952881	inhospital mortality
P-190	-1.1400 -0.0146 -0.1966 -0.0674 -0.5193 -0.3275
S-1607	However, the molecular mechanism is still unclear.<unk>
T-1607	
H-1607	-0.22048743069171906	▁molecular ▁mechanism
D-1607	-0.22048743069171906	molecular mechanism
P-1607	-0.2751 -0.0056 -0.3620 -0.2393
S-1497	SETTING: Single tertiary referral centre.<unk>
T-1497	
H-1497	-0.1780960112810135	▁tertia ry ▁refer ral ▁centre
D-1497	-0.1780960112810135	tertiary referral centre
P-1497	-0.3721 -0.0372 -0.0267 -0.1080 -0.3370 -0.2398 -0.1259
S-256	This was associated with lower NO production of EC.<unk>
T-256	
H-256	-0.8368028998374939	▁NO ▁production ▁; ▁EC
D-256	-0.8368028998374939	NO production ; EC
P-256	-2.4580 -0.0154 -0.6831 -1.2957 -0.3409 -0.2277
S-346	He developed HF again 4 years later.<unk>
T-346	hf
H-346	-0.5799439549446106	▁ HF
D-346	-0.5799439549446106	HF
P-346	-1.0799 -0.4671 -0.4312 -0.3415
S-241	Two final multivariate models were developed.<unk>
T-241	multivariate models
H-241	-0.28509631752967834	
D-241	-0.28509631752967834	
P-241	-0.3128 -0.2574
S-1944	Similar results were observed after 6 months.<unk>
T-1944	
H-1944	-0.13066966831684113	
D-1944	-0.13066966831684113	
P-1944	-0.1621 -0.0992
S-1982	Of these, 92 participants completed the trial.<unk>
T-1982	
H-1982	-0.6084651350975037	▁trial
D-1982	-0.6084651350975037	trial
P-1982	-1.2039 -0.1846 -0.4369
S-589	The 90-day mortality was 28%.<unk>
T-589	mortality
H-589	-0.564987063407898	▁mortal ity
D-589	-0.564987063407898	mortality
P-589	-1.8159 -0.0284 -0.2332 -0.1824
S-1345	Periodic breathing with no heart beat.<unk>
T-1345	periodic breathing ; heart beat
H-1345	-0.5354244112968445	▁Period ic ▁breath ing ▁; ▁heart ▁beat
D-1345	-0.5354244112968445	Periodic breathing ; heart beat
P-1345	-2.9422 -0.0457 -0.3667 -0.1066 -0.1870 -0.6120 -0.0105 -0.3699 -0.1784
S-796	SETTING: Patients' home environment.<unk>
T-796	patients
H-796	-0.7843161821365356	
D-796	-0.7843161821365356	
P-796	-1.3408 -0.2278
S-211	DESIGN: Retrospective cohort.<unk>
T-211	retrospective cohort
H-211	-1.183616280555725	▁Retro spec tive ▁co
D-211	-1.183616280555725	Retrospective co
P-211	-1.4272 -0.1106 -0.0613 -0.1092 -5.0766 -0.3168
S-1788	The reality of heart failure in Latin America.<unk>
T-1788	heart failure ; latin america
H-1788	-0.6209313273429871	▁heart ▁failure ▁; ▁Latin ▁America
D-1788	-0.6209313273429871	heart failure ; Latin America
P-1788	-2.4196 -0.0833 -0.5579 -0.1793 -0.2270 -0.5155 -0.3639
S-811	DESIGN: Observational cohort study.<unk>
T-811	observational cohort study
H-811	-0.656846821308136	
D-811	-0.656846821308136	
P-811	-1.0789 -0.2348
S-44	Trials were assessed for quality.<unk>
T-44	
H-44	-0.8462715148925781	▁Tri als
D-44	-0.8462715148925781	Trials
P-44	-2.6737 -0.1732 -0.2687 -0.2695
S-422	Heart rate was minimally altered.<unk>
T-422	heart rate
H-422	-0.3333747684955597	▁Heart ▁rate
D-422	-0.3333747684955597	Heart rate
P-422	-0.2154 -0.0188 -0.7516 -0.3478
S-1846	We will extract data in duplicate.<unk>
T-1846	
H-1846	-0.7963373064994812	
D-1846	-0.7963373064994812	
P-1846	-1.1646 -0.4280
S-1686	Should the doctors let her die?<unk>
T-1686	doctors
H-1686	-0.6743559241294861	▁doctor s ▁; ▁die
D-1686	-0.6743559241294861	doctors ; die
P-1686	-0.8762 -0.1385 -0.9661 -1.3094 -0.5578 -0.1981
S-1356	Nutrition in heart failure: an update.<unk>
T-1356	heart failure
H-1356	-0.3696853816509247	▁nutrition ▁; ▁heart ▁failure
D-1356	-0.3696853816509247	nutrition ; heart failure
P-1356	-1.4758 -0.2051 -0.1399 -0.0352 -0.1856 -0.1765
S-1620	SETTING: Northwest United States.<unk>
T-1620	united states
H-1620	-0.5078129768371582	▁North west ▁United ▁states
D-1620	-0.5078129768371582	Northwest United states
P-1620	-0.9361 -0.0098 -0.8472 -0.8017 -0.3194 -0.1327
S-795	DESIGN: Cross-sectional.<unk>
T-795	
H-795	-1.5325500965118408	
D-795	-1.5325500965118408	
P-795	-2.7520 -0.3131
S-1595	It is predominantly unilateral.<unk>
T-1595	
H-1595	-0.2847171127796173	▁unilateral
D-1595	-0.2847171127796173	unilateral
P-1595	-0.2086 -0.2130 -0.4325
S-363	Therefore, the surgery was successful.<unk>
T-363	surgery
H-363	-0.3428839445114136	▁surgery
D-363	-0.3428839445114136	surgery
P-363	-0.6684 -0.1590 -0.2013
S-1683	She is going into heart failure.<unk>
T-1683	heart failure
H-1683	-0.8121030926704407	▁heart ▁failure
D-1683	-0.8121030926704407	heart failure
P-1683	-2.4379 -0.0850 -0.3362 -0.3894
S-798	INTERVENTIONS: Not applicable.<unk>
T-798	
H-798	-0.8827049732208252	▁INTER ven tions
D-798	-0.8827049732208252	INTERventions
P-798	-2.5218 -1.0471 -0.3305 -0.3614 -0.1527
S-1249	5, 43-47].<unk>
T-1249	
H-1249	-0.45675593614578247	
D-1249	-0.45675593614578247	
P-1249	-0.4298 -0.4837
S-979	Heart failure in the young.<unk>
T-979	heart failure
H-979	-0.5200455188751221	▁Heart ▁failure ▁; ▁young
D-979	-0.5200455188751221	Heart failure ; young
P-979	-0.2870 -0.0309 -1.0106 -1.0244 -0.4618 -0.3056
S-1687	Is there any alternative?<unk>
T-1687	
H-1687	-0.2883879542350769	
D-1687	-0.2883879542350769	
P-1687	-0.4190 -0.1578
S-1246	(2012) Clin.<unk>
T-1246	
H-1246	-0.5678837895393372	▁c lin
D-1246	-0.5678837895393372	clin
P-1246	-0.4282 -0.0896 -1.4320 -0.3218
S-1248	Sci.<unk>
T-1248	
H-1248	-0.9133360385894775	▁Sci
D-1248	-0.9133360385894775	Sci
P-1248	-0.2246 -2.1042 -0.4112
S-1247	Trans.<unk>
T-1247	
H-1247	-1.2777336835861206	▁trans
D-1247	-1.2777336835861206	trans
P-1247	-0.1820 -3.2098 -0.4414
S-1963	Further large-scale randomised studies are warranted.<unk>
T-1963	randomised
H-1963	-0.40646812319755554	
D-1963	-0.40646812319755554	
P-1963	-0.6396 -0.1733
S-222	These decreases are most likely due to better CHF treatments.<unk>
T-222	chf
H-222	-0.6697580218315125	▁CHF ▁treatment s
D-222	-0.6697580218315125	CHF treatments
P-222	-0.1316 -2.6228 -0.0965 -0.3800 -0.1180
S-1375	We examined several markers indicative of autonomic balance.<unk>
T-1375	autonomic balance
H-1375	-0.3587721288204193	▁autonomi c ▁balance
D-1375	-0.3587721288204193	autonomic balance
P-1375	-0.4164 -0.7693 -0.0156 -0.3045 -0.2882
S-511	Dynamic and competitive collateral growth patterns were observed.<unk>
T-511	collateral growth
H-511	-0.8973354697227478	▁competitive ▁; ▁col lateral ▁growth
D-511	-0.8973354697227478	competitive ; collateral growth
P-511	-2.0680 -1.4480 -0.4931 -0.0046 -0.6366 -1.2776 -0.3535
S-1005	Intermediate frailty was defined as 1 to 2.<unk>
T-1005	frailty
H-1005	-0.509637713432312	▁inter media te ▁fra il ty
D-1005	-0.509637713432312	intermediate frailty
P-1005	-1.8220 -0.0747 -0.7049 -0.2133 -0.2158 -0.6048 -0.2552 -0.1863
S-1078	However, treatment of HFpEF still poses significant challenges.<unk>
T-1078	hfpef
H-1078	-0.6399547457695007	▁ HF p EF
D-1078	-0.6399547457695007	HFpEF
P-1078	-1.3668 -0.9836 -0.0137 -0.6486 -0.6780 -0.1488
S-702	ST2 was modestly associated with measures of functional capacity.<unk>
T-702	st2 ; functional capacity
H-702	-0.8453298211097717	▁ST 2
D-702	-0.8453298211097717	ST2
P-702	-1.4310 -0.1520 -1.4428 -0.3554
S-1763	Similar results were obtained for the secondary study end point.<unk>
T-1763	end point
H-1763	-0.6574620008468628	
D-1763	-0.6574620008468628	
P-1763	-1.1609 -0.1540
S-205	We read the article by Dodson et al with interest.<unk>
T-205	dodson
H-205	-0.3452523350715637	▁do d son ▁; ▁interest
D-205	-0.3452523350715637	dodson ; interest
P-205	-0.3846 -0.2147 -0.0283 -1.1061 -0.1156 -0.3374 -0.2301
S-392	A total of 8204 patients were included in the analyses.<unk>
T-392	patients
H-392	-0.6258575916290283	
D-392	-0.6258575916290283	
P-392	-0.9670 -0.2847
S-280	Severe LV fibrosis was found in ANS mice.<unk>
T-280	lv fibrosis
H-280	-0.3072504699230194	▁LV ▁fibro sis ▁; ▁ ANS ▁mi ce
D-280	-0.3072504699230194	LV fibrosis ; ANS mice
P-280	-0.2499 -0.1094 -0.7173 -0.2561 -0.5014 -0.1208 -0.2592 -0.2319 -0.4760 -0.1506
S-126	RESULTS: The mean age was 55 ± 15 years.<unk>
T-126	
H-126	-0.500156819820404	
D-126	-0.500156819820404	
P-126	-0.7316 -0.2687
S-1679	A young adult Jehovah's Witness with severe anemia.<unk>
T-1679	witness ; anemia
H-1679	-0.7354118824005127	▁Jehovah ▁; ▁Wit ness ▁; ▁severe ▁an emia
D-1679	-0.7354118824005127	Jehovah ; Witness ; severe anemia
P-1679	-0.0674 -3.2908 -0.5865 -0.4268 -0.2922 -1.4941 -0.1133 -0.1819 -0.6252 -0.2759
S-1688	Composite quality measures for common inpatient medical conditions.<unk>
T-1688	inpatient ; medical ; conditions
H-1688	-0.5402560234069824	▁medical ▁conditions
D-1688	-0.5402560234069824	medical conditions
P-1688	-1.3854 -0.1335 -0.2962 -0.3459
S-1960	No patient was admitted to hospital for worsening heart failure.<unk>
T-1960	patient ; hospital ; heart failure
H-1960	-1.2415494918823242	▁hospital ▁; ▁heart ▁failure
D-1960	-1.2415494918823242	hospital ; heart failure
P-1960	-4.2354 -0.3465 -2.2376 -0.0951 -0.2611 -0.2736
S-707	Ten-year experience with extended criteria cardiac transplantation.<unk>
T-707	extended criteria cardiac transplantation
H-707	-0.423270583152771	▁cardiac ▁transplant ation
D-707	-0.423270583152771	cardiac transplantation
P-707	-1.0441 -0.0807 -0.3836 -0.3786 -0.2295
S-325	Indices were correlated against CO with mixed linear models.<unk>
T-325	correlated ; mixed linear models
H-325	-0.6975765824317932	▁Indi ces ▁; ▁co
D-325	-0.6975765824317932	Indices ; co
P-325	-2.0215 -0.0090 -0.3273 -0.4083 -1.1491 -0.2703
S-624	Impact of frailty on HF risk is not known.<unk>
T-624	frailty ; hf
H-624	-0.48542097210884094	▁impact ▁of ▁fra il ty ▁; ▁ HF
D-624	-0.48542097210884094	impact of frailty ; HF
P-624	-0.4284 -0.9302 -0.8487 -0.2195 -0.2098 -0.3223 -0.3315 -0.1548 -1.0738 -0.3352
S-1654	Key secondary outcomes include cognitive function and quality of life.<unk>
T-1654	secondary outcomes ; quality of life
H-1654	-0.8326107263565063	▁cognitive ▁function
D-1654	-0.8326107263565063	cognitive function
P-1654	-0.7460 -0.2389 -2.0912 -0.2544
S-204	Heart failure and cognitive impairment: relationships with mortality.<unk>
T-204	heart failure ; mortality
H-204	-0.22437378764152527	▁Heart ▁failure ▁; ▁cognitive ▁im pair ment ▁; ▁mortal ity
D-204	-0.22437378764152527	Heart failure ; cognitive impairment ; mortality
P-204	-0.2211 -0.0156 -0.2559 -0.0834 -0.0171 -0.0219 -0.0591 -1.0596 -0.3979 -0.0197 -0.3276 -0.2136
S-1309	Concurrent HF comprised 75% of incident HF cases.<unk>
T-1309	hf ; hf
H-1309	-0.9975189566612244	▁ HF ▁; ▁ HF ▁cases
D-1309	-0.9975189566612244	HF ; HF cases
P-1309	-1.9144 -0.8545 -0.7226 -2.1138 -0.6705 -0.6795 -0.6240 -0.4008
S-495	The median follow-up duration was 20.8 mo.<unk>
T-495	follow-up duration
H-495	-0.4427448511123657	▁follow - up ▁du ration
D-495	-0.4427448511123657	follow-up duration
P-495	-1.8329 -0.2313 -0.0568 -0.2546 -0.1501 -0.3815 -0.1920
S-812	SETTING: Department of cardiology in a university hospital.<unk>
T-812	cardiology ; hospital
H-812	-0.861542284488678	▁card i ology ▁; ▁university ▁hospital
D-812	-0.861542284488678	cardiology ; university hospital
P-812	-4.2852 -1.1741 -0.0962 -0.6734 -0.0213 -0.2950 -0.2243 -0.1228
S-575	This exercise modality is a promising alternative for this population.<unk>
T-575	exercise
H-575	-0.6056952476501465	▁exercise ▁modal ity
D-575	-0.6056952476501465	exercise modality
P-575	-0.7837 -1.1607 -0.1686 -0.7569 -0.1586
S-1584	Heart rate variability in risk stratification of cardiac patients.<unk>
T-1584	heart rate variability ; risk stratification ; cardiac ; patients
H-1584	-0.7871077656745911	▁Heart ▁rate ▁variabil ity ▁; ▁cardiac ▁patients
D-1584	-0.7871077656745911	Heart rate variability ; cardiac patients
P-1584	-0.2701 -0.0333 -0.7717 -0.0864 -0.3654 -3.3534 -1.4393 -0.4151 -0.3493
S-53	Remote ischemic conditioning for patients with heart failure?<unk>
T-53	remote ischemic conditioning ; patients ; heart failure
H-53	-0.5086924433708191	▁remote ▁ ische mic ▁condition ing ▁; ▁patients ▁; ▁heart ▁failure
D-53	-0.5086924433708191	remote ischemic conditioning ; patients ; heart failure
P-53	-0.2263 -0.8618 -0.3661 -0.2505 -0.1001 -0.2532 -0.3941 -2.5102 -0.7697 -0.3230 -0.0721 -0.3293 -0.1565
S-1805	Assessing the link between air pollution and heart failure.<unk>
T-1805	air ; heart failure
H-1805	-0.24380402266979218	▁air ▁pollution ▁; ▁heart ▁failure
D-1805	-0.24380402266979218	air pollution ; heart failure
P-1805	-0.0382 -0.2234 -0.1701 -0.2730 -0.0677 -0.5319 -0.4023
S-1399	A retrospective descriptive research design was used.<unk>
T-1399	
H-1399	-0.6724942922592163	
D-1399	-0.6724942922592163	
P-1399	-1.1297 -0.2153
S-1339	Sham-operated animals were used as a control group.<unk>
T-1339	
H-1339	-0.48361873626708984	▁Sham - opera ted ▁animals
D-1339	-0.48361873626708984	Sham-operated animals
P-1339	-0.3119 -0.3402 -0.0104 -0.2189 -1.2620 -0.9185 -0.3234
S-885	A total of 1483 patients were included in this study.<unk>
T-885	patients
H-885	-0.6844301223754883	
D-885	-0.6844301223754883	
P-885	-1.1290 -0.2399
S-311	Data were, however, limited to 2-3 studies per outcome.<unk>
T-311	outcome
H-311	-0.2628116011619568	
D-311	-0.2628116011619568	
P-311	-0.3703 -0.1553
S-312	We made policy recommendations on the basis of our systematic review.<unk>
T-312	policy
H-312	-0.46850860118865967	▁policy ▁recommendations
D-312	-0.46850860118865967	policy recommendations
P-312	-0.0278 -1.1371 -0.5779 -0.1312
S-749	Compliance with treatment had a more remarkable role.<unk>
T-749	compliance
H-749	-0.5275008082389832	▁compliance ▁; ▁treatment
D-749	-0.5275008082389832	compliance ; treatment
P-749	-0.8132 -0.8242 -0.5500 -0.2216 -0.2285
S-1754	We evaluated whether this finding has a prognostic meaning.<unk>
T-1754	prognostic
H-1754	-0.8502257466316223	
D-1754	-0.8502257466316223	
P-1754	-1.4083 -0.2922
S-1125	These reasons were classified using a published taxonomy.<unk>
T-1125	
H-1125	-0.7535194158554077	▁tax ono my
D-1125	-0.7535194158554077	taxonomy
P-1125	-0.3360 -0.0871 -2.4643 -0.5794 -0.3008
S-673	The rates and risk factors associated with CHF were evaluated.<unk>
T-673	chf
H-673	-0.8684174418449402	▁CHF
D-673	-0.8684174418449402	CHF
P-673	-1.8113 -0.4973 -0.2967
S-1886	Heart failure affects nearly one million people in the UK.<unk>
T-1886	heart failure
H-1886	-0.7539653778076172	▁Heart ▁failure ▁; ▁UK
D-1886	-0.7539653778076172	Heart failure ; UK
P-1886	-1.2490 -0.1695 -0.4090 -1.7489 -0.5774 -0.3700
S-825	Patients were followed up for 3.0 ± 1.8 years.<unk>
T-825	patients ; followed up
H-825	-0.9789308905601501	
D-825	-0.9789308905601501	
P-825	-1.7350 -0.2228
S-247	This function is impaired in patients with cardiovascular disease.<unk>
T-247	patients ; cardiovascular disease
H-247	-0.5977280735969543	▁cardiovascular ▁disease
D-247	-0.5977280735969543	cardiovascular disease
P-247	-1.0260 -0.7868 -0.2692 -0.3089
S-1101	We evaluated temporal trends in HF after MI.<unk>
T-1101	hf ; mi
H-1101	-0.966206967830658	▁ HF ▁; ▁MI
D-1101	-0.966206967830658	HF ; MI
P-1101	-3.0093 -0.3842 -0.4513 -0.4965 -1.0555 -0.4006
S-1296	The extracorporeal support was needed for three days.<unk>
T-1296	extracorporeal support
H-1296	-0.45651447772979736	▁extra corp o real
D-1296	-0.45651447772979736	extracorporeal
P-1296	-1.5274 -0.0112 -0.1505 -0.0432 -0.8670 -0.1398
S-1073	Heart failure: a disease complex with challenging therapeutics.<unk>
T-1073	heart failure ; disease ; therapeutics
H-1073	-0.6028733849525452	▁Heart ▁failure ▁; ▁disease
D-1073	-0.6028733849525452	Heart failure ; disease
P-1073	-0.3325 -0.0224 -0.8311 -1.1993 -1.0571 -0.1749
S-1116	Secondary outcomes included markers of hemostasis.<unk>
T-1116	secondary outcomes ; hemostasis
H-1116	-0.6145623922348022	▁marker s ▁of ▁hemos tas is
D-1116	-0.6145623922348022	markers of hemostasis
P-1116	-2.3141 -0.0713 -1.0745 -0.2590 -0.0898 -0.4556 -0.3925 -0.2596
S-1619	DESIGN: Retrospective matched cohort study.<unk>
T-1619	retrospective matched cohort study
H-1619	-0.7089466452598572	
D-1619	-0.7089466452598572	
P-1619	-1.2504 -0.1675
S-169	Caspase-3 gene expression increased in heart failure.<unk>
T-169	caspase-3 ; gene expression ; heart failure
H-169	-0.5282925367355347	▁Cas pas e -3 ▁gene ▁expression ▁; ▁heart ▁failure
D-169	-0.5282925367355347	Caspase-3 gene expression ; heart failure
P-169	-0.0599 -0.0626 -0.3224 -0.9806 -2.4322 -0.1175 -0.1890 -0.3565 -0.3083 -0.6048 -0.3774
S-1198	Diuretic use in heart failure and outcomes.<unk>
T-1198	diuretic ; heart failure ; outcomes
H-1198	-0.3092197775840759	▁di ure tic ▁; ▁heart ▁failure
D-1198	-0.3092197775840759	diuretic ; heart failure
P-1198	-0.1783 -0.0366 -0.1449 -0.7644 -0.5168 -0.0756 -0.5580 -0.1991
S-1090	Acute right heart failure in pulmonary hypertension.<unk>
T-1090	acute right heart failure ; pulmonary hypertension
H-1090	-0.25136977434158325	▁right ▁heart ▁failure ▁; ▁pulmonar y ▁hyper tension
D-1090	-0.25136977434158325	right heart failure ; pulmonary hypertension
P-1090	-0.3660 -1.0499 -0.0267 -0.2193 -0.0017 -0.0370 -0.1736 -0.0753 -0.3873 -0.1768
S-1534	Heart failure in patients treated with bisphosphonates.<unk>
T-1534	heart failure ; patients ; bisphosphonates
H-1534	-0.3470841348171234	▁Heart ▁failure ▁; ▁bis phos phon ates
D-1534	-0.3470841348171234	Heart failure ; bisphosphonates
P-1534	-0.3370 -0.0244 -0.3120 -0.3834 -0.0593 -0.5082 -0.5437 -0.6894 -0.2664
S-550	Of the 6 patients, 5 experienced significant improvement in functional capacity and symptoms.<unk>
T-550	patients ; functional capacity ; symptoms
H-550	-1.0780388116836548	
D-550	-1.0780388116836548	
P-550	-1.8086 -0.3475
S-352	The etiology of the MR and MS was diagnosed as functional.<unk>
T-352	etiology ; diagnosed
H-352	-0.883512556552887	▁MR ▁; ▁MS
D-352	-0.883512556552887	MR ; MS
P-352	-3.3652 -0.4969 -0.1408 -0.2318 -0.1828
S-1889	Patients are likely to be older women with a history of hypertension.<unk>
T-1889	patients ; hypertension
H-1889	-1.1676476001739502	▁patients ▁; ▁hyper tension
D-1889	-1.1676476001739502	patients ; hypertension
P-1889	-4.6087 -0.5122 -1.2824 -0.1240 -0.1660 -0.3125
S-1843	We will use American, Canadian and European HF guidelines as our reference.<unk>
T-1843	american ; hf
H-1843	-1.2358120679855347	▁american ▁; ▁european ▁ HF
D-1843	-1.2358120679855347	american ; european HF
P-1843	-4.8425 -0.1745 -1.2777 -0.7833 -0.2495 -1.0649 -0.2582
S-424	Heart rate was unchanged, and arterial pressure declined modestly.<unk>
T-424	heart rate ; arterial pressure
H-424	-0.26866379380226135	▁Heart ▁rate ▁; ▁arterial ▁pressure
D-424	-0.26866379380226135	Heart rate ; arterial pressure
P-424	-0.2953 -0.0082 -0.4748 -0.3239 -0.2497 -0.3178 -0.2109
S-1009	Over a mean follow-up of 2.4 years, 63 patients died.<unk>
T-1009	follow-up ; patients
H-1009	-0.6619129180908203	
D-1009	-0.6619129180908203	
P-1009	-1.1491 -0.1747
S-1796	Chronic HF is the cause of death in 6.3% of cases.<unk>
T-1796	chronic hf ; death
H-1796	-0.3495965301990509	▁Chro nic ▁ HF
D-1796	-0.3495965301990509	Chronic HF
P-1796	-0.0218 -0.0048 -0.1787 -0.0410 -1.5861 -0.2652
S-997	Cardiac amyloidosis, about an atypical case.<unk>
T-997	cardiac amyloidosis
H-997	-0.6050565242767334	▁Card iac ▁a my lo idos is
D-997	-0.6050565242767334	Cardiac amyloidosis
P-997	-0.4604 -0.0276 -0.0700 -1.0963 -0.6968 -0.8773 -1.2330 -0.8745 -0.1098
S-1911	Robot-assisted training for heart failure patients - a small pilot study.<unk>
T-1911	training ; heart failure ; patients
H-1911	-0.5313684940338135	▁Robot - assist ed ▁training ▁; ▁heart ▁failure ▁patients
D-1911	-0.5313684940338135	Robot-assisted training ; heart failure patients
P-1911	-0.9842 -0.3201 -0.0041 -0.1382 -0.2681 -0.4187 -0.5522 -0.0859 -2.3991 -0.4464 -0.2280
S-1616	Besides, these genes can be targets to develop treatments.<unk>
T-1616	genes
H-1616	-0.7358912229537964	▁gene s
D-1616	-0.7358912229537964	genes
P-1616	-1.6222 -0.1792 -0.9670 -0.1752
S-786	Internal reliability was assessed with Cronbach's α.<unk>
T-786	
H-786	-0.7690240144729614	▁internal ▁reli ability ▁; ▁cro n bach
D-786	-0.7690240144729614	internal reliability ; cronbach
P-786	-0.2451 -4.3939 -0.1100 -0.2990 -0.0862 -0.1552 -0.0202 -1.3455 -0.2662
S-787	Among 849 patients, 200 (24%) had HFpEF.<unk>
T-787	patients ; hfpef
H-787	-0.6166872382164001	▁ HF p EF
D-787	-0.6166872382164001	HFpEF
P-787	-1.7995 -0.6066 -0.0262 -0.6460 -0.3149 -0.3070
S-194	Ejection fraction and sex were independently associated with BNP.<unk>
T-194	ejection fraction ; bnp
H-194	-0.5232014060020447	▁e je ction ▁ fraction ▁; ▁b NP
D-194	-0.5232014060020447	ejection fraction ; bNP
P-194	-1.0965 -0.0970 -0.0234 -0.7253 -0.0070 -0.1704 -1.6102 -0.5161 -0.6308 -0.3553
S-507	Pigs were given antiarrhythmic medication to prevent sudden death.<unk>
T-507	antiarrhythmic ; medication ; death
H-507	-0.3199976682662964	▁Pig s ▁; ▁anti ar rhythm ic ▁medication
D-507	-0.3199976682662964	Pigs ; antiarrhythmic medication
P-507	-0.1193 -0.0951 -0.2629 -0.0187 -0.1933 -0.0538 -0.1063 -0.1878 -1.8157 -0.3472
S-1736	Very few of these patients were on standard therapy with beta blockade.<unk>
T-1736	patients ; therapy ; beta blockade
H-1736	-0.7931315898895264	▁ therapy ▁; ▁beta ▁block ade
D-1736	-0.7931315898895264	therapy ; beta blockade
P-1736	-4.8630 -0.1217 -0.3794 -0.2359 -0.1379 -0.0857 -0.3170 -0.2044
S-219	Of the CHF patients, 778 (2.4%) were intubated.<unk>
T-219	chf ; patients ; intubated
H-219	-0.4965536296367645	▁CHF ▁patients ▁; ▁in tuba ted
D-219	-0.4965536296367645	CHF patients ; intubated
P-219	-0.0425 -2.2120 -0.7313 -0.0418 -0.0462 -0.3375 -0.3865 -0.1746
S-598	Surgical tactics included a brief hypothermic circulatory arrest.<unk>
T-598	surgical ; hypothermic circulatory arrest
H-598	-0.6872683167457581	▁Sur g ical ▁tac tics ▁; ▁brief ▁hypothe r mic ▁circula tory ▁arrest
D-598	-0.6872683167457581	Surgical tactics ; brief hypothermic circulatory arrest
P-598	-3.5309 -0.3204 -0.0422 -0.3685 -0.8837 -0.1064 -2.4219 -0.2468 -0.2010 -0.3143 -1.0676 -0.0104 -0.0123 -0.5861 -0.1967
S-616	Primary outcomes were improvements in functional capacity and quality of life.<unk>
T-616	primary outcomes ; functional capacity ; quality of life
H-616	-1.0359126329421997	
D-616	-1.0359126329421997	
P-616	-1.8622 -0.2097
S-266	The end point was survival from the time of inclusion through 4 years.<unk>
T-266	end point
H-266	-0.63490229845047	
D-266	-0.63490229845047	
P-266	-1.1242 -0.1456
S-1069	Most data have been collected in patients with systolic dysfunction.<unk>
T-1069	collected ; patients ; systolic dysfunction
H-1069	-1.1404553651809692	▁sy sto lic ▁dys function
D-1069	-1.1404553651809692	systolic dysfunction
P-1069	-2.7644 -0.5754 -1.4880 -0.3782 -2.0899 -0.4515 -0.2358
S-32	Literature was reassessed in April 2013, and additional studies were included.<unk>
T-32	
H-32	-0.5836687088012695	▁Literatur e
D-32	-0.5836687088012695	Literature
P-32	-1.3883 -0.4437 -0.2987 -0.2040
S-804	The third trial added little or no information to the first 2 trials.<unk>
T-804	
H-804	-0.6056060791015625	▁trial
D-804	-0.6056060791015625	trial
P-804	-0.6742 -0.9136 -0.2290
S-612	Using exercise to improve quality of life for people with heart failure.<unk>
T-612	exercise ; quality of life ; heart failure
H-612	-0.940149188041687	▁exercise ▁; ▁heart ▁failure
D-612	-0.940149188041687	exercise ; heart failure
P-612	-1.9830 -0.3261 -2.4494 -0.1506 -0.4628 -0.2689
S-156	No trial of implanted monitoring devices met the inclusion criteria.<unk>
T-156	implanted
H-156	-0.5439378023147583	▁implant ed ▁monitoring ▁devices
D-156	-0.5439378023147583	implanted monitoring devices
P-156	-2.5297 -0.1071 -0.0195 -0.1654 -0.2542 -0.1878
S-1469	Few treatments have been investigated in clinical trials.<unk>
T-1469	clinical
H-1469	-0.8612746596336365	▁Fe w ▁treatment s
D-1469	-0.8612746596336365	Few treatments
P-1469	-1.8689 -0.0032 -1.5179 -0.0702 -1.6026 -0.1050
S-0	National trends in patient safety for four common conditions, 2005-2011.<unk>
T-0	patient ; conditions
H-0	-0.9368154406547546	▁patient ▁safety ▁; ▁conditions
D-0	-0.9368154406547546	patient safety ; conditions
P-0	-2.6252 -1.1272 -1.1039 -0.0267 -0.3198 -0.4180
S-518	HR modulates Ea, and, therefore, afterload burden.<unk>
T-518	ea ; afterload
H-518	-0.8205774426460266	▁HR ▁; ▁Ea ▁; ▁after load ▁burde n
D-518	-0.8205774426460266	HR ; Ea ; afterload burden
P-518	-2.7529 -0.3128 -2.6609 -0.4291 -0.2258 -0.0807 -0.5617 -0.1449 -0.6359 -0.4011
S-778	There were no periprocedural deaths or strokes.<unk>
T-778	deaths ; strokes
H-778	-0.5869246125221252	▁per i pro ced ural ▁; ▁stroke s
D-778	-0.5869246125221252	periprocedural ; strokes
P-778	-1.4713 -0.1340 -0.0767 -0.1539 -0.0050 -2.3190 -1.2609 -0.0699 -0.2166 -0.1619
S-677	Median age of the entire cohort was 71 years old.<unk>
T-677	
H-677	-0.8883881568908691	▁media n ▁age
D-677	-0.8883881568908691	median age
P-677	-1.2789 -0.0638 -1.4512 -1.4212 -0.2268
S-1594	The most common cause of RAS is atherosclerosis.<unk>
T-1594	ras ; atherosclerosis
H-1594	-0.7451608180999756	▁ RAS ▁; ▁at hero sc ler osis
D-1594	-0.7451608180999756	RAS ; atherosclerosis
P-1594	-1.1367 -0.0336 -0.1178 -0.7571 -1.0732 -0.3998 -3.1450 -0.0795 -0.4362 -0.2728
S-1000	Measuring frailty in heart failure: a community perspective.<unk>
T-1000	frailty ; heart failure
H-1000	-0.3601880967617035	▁fra il ty ▁; ▁heart ▁failure
D-1000	-0.3601880967617035	frailty ; heart failure
P-1000	-0.7754 -0.3588 -0.2548 -0.3358 -0.3067 -0.0328 -0.5878 -0.2294
S-1479	MicroRNAs in heart failure: new targets in disease management.<unk>
T-1479	micrornas ; heart failure ; disease
H-1479	-0.2759641110897064	▁Micro RNA s ▁; ▁heart ▁failure ▁; ▁disease ▁management
D-1479	-0.2759641110897064	MicroRNAs ; heart failure ; disease management
P-1479	-0.5620 -0.0110 -0.0368 -0.4567 -0.1432 -0.0885 -0.6239 -0.2211 -0.4072 -0.3389 -0.1462
S-1770	Hazard ratios were computed with Cox regression analysis.<unk>
T-1770	hazard ratios ; cox regression analysis
H-1770	-0.4304161071777344	▁Hazard ▁ratio s ▁; ▁co x ▁re gression
D-1770	-0.4304161071777344	Hazard ratios ; cox regression
P-1770	-0.6936 -0.0283 -0.1332 -0.3203 -0.0696 -0.8240 -0.0939 -0.0659 -1.6536 -0.4219
S-1932	PSSS did not impact the effect of exercise training on outcomes.<unk>
T-1932	psss ; exercise ; training ; outcomes
H-1932	-0.5066397786140442	▁PS SS ▁; ▁exercise ▁training
D-1932	-0.5066397786140442	PSSS ; exercise training
P-1932	-0.5189 -0.2869 -0.5249 -0.4145 -0.4060 -1.0163 -0.3789
S-1885	Management of heart failure with preserved ejection fraction.<unk>
T-1885	heart failure with preserved ejection fraction
H-1885	-0.32408374547958374	▁management ▁of ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-1885	-0.32408374547958374	management of heart failure ; preserved ejection fraction
P-1885	-1.1305 -0.9840 -0.3971 -0.0323 -0.2074 -0.0361 -0.1471 -0.1882 -0.0369 -0.2269 -0.1154 -0.4582 -0.0064 -0.6156 -0.2792
S-1033	Cardiology: Bromodomain inhibition halts heart failure.<unk>
T-1033	cardiology ; bromodomain ; halts ; heart failure
H-1033	-0.4669910967350006	▁Card i ology ▁; ▁Bro modo main ▁inhibi tion ▁halt s ▁heart ▁failure
D-1033	-0.4669910967350006	Cardiology ; Bromodomain inhibition halts heart failure
P-1033	-0.5381 -0.9438 -0.0423 -0.2518 -0.9502 -0.0045 -0.3567 -0.2052 -0.0738 -0.6099 -0.3023 -1.8772 -0.0657 -0.6402 -0.1431
S-1759	AT was identified in 1935 out of 2137 patients (90.54%).<unk>
T-1759	patients
H-1759	-0.4305005669593811	▁AT
D-1759	-0.4305005669593811	AT
P-1759	-0.2661 -0.6820 -0.3434
S-633	The role of vasopressin in congestive heart failure.<unk>
T-633	vasopressin ; congestive heart failure
H-633	-0.2646370530128479	▁vaso press in ▁; ▁con ges tive ▁heart ▁failure
D-633	-0.2646370530128479	vasopressin ; congestive heart failure
P-633	-0.1271 -0.4515 -0.5892 -0.1823 -0.0204 -0.1212 -0.1144 -0.6985 -0.0670 -0.3923 -0.1473
S-332	Mitral stenosis reversed by medical treatment for heart failure.<unk>
T-332	mitral stenosis ; medical treatment ; heart failure
H-332	-0.44496116042137146	▁Mit ral ▁sten osis ▁rever sed ▁; ▁medical ▁treatment ▁; ▁heart ▁failure
D-332	-0.44496116042137146	Mitral stenosis reversed ; medical treatment ; heart failure
P-332	-0.9009 -0.0271 -0.4144 -0.1637 -0.1880 -0.6552 -0.4027 -0.0199 -1.7479 -0.5668 -0.0984 -0.1707 -0.6246 -0.2492
S-410	Similar results were found for heart failure hospitalization and cardiovascular death.<unk>
T-410	heart failure ; hospitalization ; cardiovascular death
H-410	-0.6347029805183411	▁heart ▁failure ▁hospital ization ▁; ▁cardiovascular ▁death
D-410	-0.6347029805183411	heart failure hospitalization ; cardiovascular death
P-410	-1.3646 -0.1541 -1.6037 -0.3908 -0.4958 -0.0534 -0.9771 -0.4517 -0.2213
S-669	Trastuzumab-related cardiotoxicity among older patients with breast cancer.<unk>
T-669	cardiotoxicity ; patients ; breast cancer
H-669	-0.34201496839523315	▁Tras tuz um ab - related ▁cardio toxic ity ▁; ▁breast ▁cancer
D-669	-0.34201496839523315	Trastuzumab-related cardiotoxicity ; breast cancer
P-669	-0.1197 -0.0515 -0.1250 -0.0269 -0.4846 -0.0355 -0.2570 -0.9418 -0.4734 -0.4518 -0.7457 -0.2126 -0.5894 -0.2733
S-1067	Devices have become a cornerstone of heart failure (HF) therapy.<unk>
T-1067	heart failure ; hf ; therapy
H-1067	-0.7478753328323364	▁device s ▁; ▁corner stone ▁of ▁heart ▁failure ▁; HF ▁; ▁ therapy
D-1067	-0.7478753328323364	devices ; cornerstone of heart failure ;HF ; therapy
P-1067	-4.2187 -0.8117 -0.3309 -1.9436 -0.0269 -0.5335 -0.5361 -0.0782 -0.2341 -0.0969 -1.4183 -0.1938 -0.0484 -0.4986 -0.2485
S-159	No beneficial effect on mortality was observed with STS HM.<unk>
T-159	mortality ; sts
H-159	-0.6749618053436279	▁s ts ▁ HM
D-159	-0.6749618053436279	sts HM
P-159	-1.7399 -0.1914 -0.7987 -0.1721 -0.7720 -0.3757
S-1211	However, the role of PDE2 in HF is poorly understood.<unk>
T-1211	pde2 ; hf
H-1211	-0.3002220094203949	▁p de 2 ▁; ▁ HF
D-1211	-0.3002220094203949	pde2 ; HF
P-1211	-0.4508 -0.8017 -0.0875 -0.1116 -0.0924 -0.3396 -0.2764 -0.2419
S-1651	Nights spent in hospital will be counted as a coprimary outcome.<unk>
T-1651	hospital ; coprimary outcome
H-1651	-0.6326854228973389	▁Night s ▁; ▁hospital
D-1651	-0.6326854228973389	Nights ; hospital
P-1651	-1.7471 -0.0545 -0.9600 -0.1859 -0.4888 -0.3598
S-1606	OBJECTIVES: Heart failure is a major public health problem worldwide.<unk>
T-1606	heart failure ; public ; health
H-1606	-0.7272670865058899	▁Heart ▁failure ▁; ▁public ▁health
D-1606	-0.7272670865058899	Heart failure ; public health
P-1606	-1.4154 -0.2056 -0.3460 -0.0046 -0.3468 -2.3945 -0.3780
S-539	Postoperative normalization of albumin level is associated with improved survival.<unk>
T-539	postoperative ; albumin
H-539	-0.35455262660980225	▁post operativ e ▁normal ization ▁; ▁album in ▁level
D-539	-0.35455262660980225	postoperative normalization ; albumin level
P-539	-0.1387 -0.0111 -0.3617 -0.1731 -0.2363 -0.6503 -0.2178 -0.4680 -0.2492 -1.2412 -0.1528
S-581	LVET was measured from the reconstructed aortic pressure curve.<unk>
T-581	lvet ; aortic pressure
H-581	-0.8565765023231506	▁ VET ▁; ▁a or tic ▁pressure ▁cur ve
D-581	-0.8565765023231506	VET ; aortic pressure curve
P-581	-3.9879 -0.0430 -0.6833 -0.9942 -1.4420 -0.1062 -0.9317 -0.0846 -0.2107 -0.5427 -0.3960
S-1414	We explored whether physician continuity further influences outcomes after discharge.<unk>
T-1414	physician ; outcomes ; discharge
H-1414	-0.3571226894855499	▁physician ▁continu ity ▁; ▁dis charge
D-1414	-0.3571226894855499	physician continuity ; discharge
P-1414	-0.7554 -0.7055 -0.0305 -0.1864 -0.5552 -0.0591 -0.2406 -0.3242
S-403	Medication regimen and sST2 values were obtained during 10 months.<unk>
T-403	medication ; sst2
H-403	-0.7351857423782349	▁Medica tion ▁regime n ▁; ▁s st 2
D-403	-0.7351857423782349	Medication regimen ; sst2
P-403	-0.4530 -0.1100 -0.3529 -0.7380 -0.1798 -0.0009 -3.3595 -0.2719 -1.6164 -0.2694
S-150	STUDY DESIGN: Systematic review and network meta-analysis.<unk>
T-150	meta-analysis
H-150	-1.2776304483413696	
D-150	-1.2776304483413696	
P-150	-2.3985 -0.1568
S-983	Cardiac symptoms in children are usually the result of congenital lesions.<unk>
T-983	cardiac ; symptoms ; congenital ; lesions
H-983	-0.4910021126270294	▁Card iac ▁symptoms ▁; ▁con geni tal ▁les ions
D-983	-0.4910021126270294	Cardiac symptoms ; congenital lesions
P-983	-1.0122 -0.2147 -1.3338 -0.1710 -0.8544 -0.0276 -0.2644 -0.7495 -0.2635 -0.2891 -0.2209
S-437	Effectiveness and safety of spironolactone for systolic heart failure.<unk>
T-437	spironolactone ; systolic heart failure
H-437	-0.43297749757766724	▁spi rono lac tone ▁; ▁sy sto lic ▁heart ▁failure
D-437	-0.43297749757766724	spironolactone ; systolic heart failure
P-437	-1.8907 -0.0340 -0.1005 -0.0797 -0.1677 -0.2609 -0.0909 -0.4531 -1.0396 -0.0958 -0.7182 -0.2648
S-989	Key role of ERK1/2 molecular scaffolds in heart pathology.<unk>
T-989	molecular scaffolds ; heart ; pathology
H-989	-0.5755243897438049	▁e RK 1/2 ▁molecular ▁sc af fold s ▁; ▁heart ▁path ology
D-989	-0.5755243897438049	eRK1/2 molecular scaffolds ; heart pathology
P-989	-1.9342 -0.2294 -0.5137 -0.3271 -0.7403 -2.5363 -0.3699 -0.0631 -0.3013 -0.1719 -0.0912 -0.0821 -0.4414 -0.2555
S-339	Functional MS has not been reported in patients with degenerative MR.<unk>
T-339	functional ms ; reported ; patients ; degenerative mr
H-339	-0.3122049570083618	▁function al ▁MS ▁; ▁de genera tive ▁MR
D-339	-0.3122049570083618	functional MS ; degenerative MR
P-339	-1.0989 -0.0279 -0.2914 -0.3645 -0.5368 -0.0197 -0.0332 -0.0433 -0.5140 -0.1922
S-645	Epidemiology and treatment of chronic heart failure; use of bisoprolol.<unk>
T-645	epidemiology ; chronic heart failure ; bisoprolol
H-645	-0.5040244460105896	▁Epidemi ology ▁; ▁chronic ▁heart ▁failure ▁; ▁bis o pro lol
D-645	-0.5040244460105896	Epidemiology ; chronic heart failure ; bisoprolol
P-645	-2.3162 -0.0178 -0.0658 -0.7059 -1.9400 -0.0840 -0.1133 -0.0851 -0.1429 -0.1410 -0.1101 -0.6218 -0.2084
S-1034	Heart failure (HF) is the leading cause of mortality in modern society.<unk>
T-1034	heart failure ; hf ; leading ; mortality ; society
H-1034	-0.5389823317527771	▁Heart ▁failure ▁; HF ▁; ▁mortal ity
D-1034	-0.5389823317527771	Heart failure ;HF ; mortality
P-1034	-0.5122 -0.0190 -0.1760 -0.1150 -0.6347 -1.1885 -0.0354 -1.9194 -0.2506
S-785	Covariate adjustment was made using Cox proportional hazards models.<unk>
T-785	covariate adjustment ; cox proportional hazards models
H-785	-1.0189757347106934	▁co x ▁proportion al ▁hazard s ▁models
D-785	-1.0189757347106934	cox proportional hazards models
P-785	-0.0807 -4.4863 -0.0580 -0.0381 -2.1173 -0.7041 -0.8289 -0.4482 -0.4092
S-1726	We examined physician volume within strata of hospital volume and physician specialty.<unk>
T-1726	physician ; hospital ; physician
H-1726	-1.1938456296920776	▁physician ▁volume ▁; ▁hospital
D-1726	-1.1938456296920776	physician volume ; hospital
P-1726	-0.8023 -0.5977 -0.2735 -0.5559 -4.5447 -0.3889
S-1195	Tolvaptan is a vasopressin type 2 receptor antagonist.<unk>
T-1195	tolvaptan ; vasopressin type 2 receptor antagonist
H-1195	-0.4090622663497925	▁Tol va p tan ▁; ▁vaso press in ▁; ▁receptor ▁anta gon ist
D-1195	-0.4090622663497925	Tolvaptan ; vasopressin ; receptor antagonist
P-1195	-0.0282 -0.5519 -0.0899 -0.2348 -0.1180 -0.0905 -0.3164 -1.3546 -0.6558 -0.0006 -0.5825 -0.1797 -0.9950 -0.7263 -0.2119
S-1238	Arrhythmia-related costs accounted for 45% of total expenditures.<unk>
T-1238	costs ; expenditures
H-1238	-0.33195191621780396	▁ar rhythm ia - related ▁costs ▁; ▁ex pendi tures
D-1238	-0.33195191621780396	arrhythmia-related costs ; expenditures
P-1238	-0.7710 -0.2656 -0.3531 -0.3556 -0.0156 -0.1665 -1.0564 -0.0246 -0.0045 -0.1486 -0.5644 -0.2574
S-134	Implications of metric choice for common applications of readmission metrics.<unk>
T-134	readmission
H-134	-0.6885504126548767	▁ metric ▁; ▁read mission ▁metri cs
D-134	-0.6885504126548767	metric ; readmission metrics
P-134	-1.2371 -0.0087 -0.6668 -1.6617 -0.6465 -0.4718 -0.6805 -0.5457 -0.2782
S-145	Careful consideration should be placed on readmission metric choice for these applications.<unk>
T-145	readmission
H-145	-0.8733041286468506	▁read mission ▁; metric
D-145	-0.8733041286468506	readmission ;metric
P-145	-1.0420 -0.5712 -1.9242 -0.2240 -1.2710 -0.2074
S-1998	RESULTS: Fifty patients were enrolled at 10 centers.<unk>
T-1998	patients
H-1998	-0.6728307604789734	
D-1998	-0.6728307604789734	
P-1998	-1.1122 -0.2335
S-1758	Median follow-up was 3.01 (1.39-4.98) years.<unk>
T-1758	follow-up
H-1758	-0.6392638087272644	▁media n
D-1758	-0.6392638087272644	median
P-1758	-0.5389 -0.1246 -1.7355 -0.1581
S-1261	RESULTS: Twenty-seven studies with 1887 patients were included.<unk>
T-1261	patients
H-1261	-0.5113867521286011	
D-1261	-0.5113867521286011	
P-1261	-0.7725 -0.2503
S-958	over 2 weeks to obtain a cumulative dose of 18 mg/kg.<unk>
T-958	
H-958	-1.1488802433013916	
D-958	-1.1488802433013916	
P-958	-2.1134 -0.1844
S-1634	RESULTS: There were 749 self-identified black patients (33%).<unk>
T-1634	patients
H-1634	-0.734710156917572	▁black ▁patients
D-1634	-0.734710156917572	black patients
P-1634	-0.2393 -2.0598 -0.3148 -0.3249
S-261	This may be one mechanism how ET exerts beneficial effects in CHF.<unk>
T-261	chf
H-261	-0.8033050894737244	▁mechanism ▁; ▁ET ▁ex ert s ▁; ▁CHF
D-261	-0.8033050894737244	mechanism ; ET exerts ; CHF
P-261	-3.0408 -0.2661 -1.9937 -0.4205 -0.0196 -0.0721 -0.8426 -0.5178 -0.5865 -0.2735
S-481	The objective of this study was to test its reliability in stable HF.<unk>
T-481	stable hf
H-481	-0.9987980723381042	▁ HF
D-481	-0.9987980723381042	HF
P-481	-2.8636 -0.5673 -0.3319 -0.2324
S-1839	LIMITATION: Residual confounding and short follow-up.<unk>
T-1839	follow-up
H-1839	-0.7169291973114014	▁res idu al ▁con found ing ▁; ▁follow - up
D-1839	-0.7169291973114014	residual confounding ; follow-up
P-1839	-5.5283 -0.3856 -0.0487 -0.0234 -0.0983 -0.0584 -1.3916 -0.3694 -0.1848 -0.0459 -0.2309 -0.2379
S-1919	The quality of life assessment indicated better well-being in all participants.<unk>
T-1919	quality of life
H-1919	-0.9224612712860107	▁life ▁; ▁well - be ing
D-1919	-0.9224612712860107	life ; well-being
P-1919	-2.5172 -3.2462 -0.3735 -0.1786 -0.0452 -0.5749 -0.2204 -0.2238
S-1837	Results from the 1:1 propensity score-matched analyses were similar.<unk>
T-1837	
H-1837	-0.30922171473503113	▁pro pens ity
D-1837	-0.30922171473503113	propensity
P-1837	-0.0164 -0.0480 -0.0871 -1.1702 -0.2244
S-840	Hgb level was not significantly correlated with baseline HRQoL.<unk>
T-840	hgb ; correlated ; baseline ; hrqol
H-840	-0.44036492705345154	▁h gb ▁level ▁; ▁base line ▁; ▁HR Qo L
D-840	-0.44036492705345154	hgb level ; baseline ; HRQoL
P-840	-0.3925 -0.0720 -0.4515 -0.1016 -0.0028 -0.0244 -1.7850 -0.8177 -0.0204 -0.9740 -0.4475 -0.1950
S-1464	A preserved ejection fraction outcomes trial is beginning.<unk>
T-1464	preserved ejection fraction ; outcomes
H-1464	-0.6115058660507202	▁e je ction ▁ fraction ▁; ▁trial
D-1464	-0.6115058660507202	ejection fraction ; trial
P-1464	-1.3977 -0.3906 -0.0867 -0.5247 -0.0019 -1.4447 -1.0500 -0.2879 -0.3195
S-1471	Therapeutic implications of biomarkers in chronic heart failure.<unk>
T-1471	therapeutic ; biomarkers ; chronic heart failure
H-1471	-0.6541109085083008	▁bio mark ers ▁; ▁chronic ▁heart ▁failure
D-1471	-0.6541109085083008	biomarkers ; chronic heart failure
P-1471	-3.5734 -0.0355 -0.1903 -0.2097 -0.0878 -1.1203 -0.0803 -0.3987 -0.1911
S-1797	Decompensated HF is the main cause of cardiovascular hospitalization.<unk>
T-1797	decompensated hf ; cardiovascular ; hospitalization
H-1797	-0.4544176161289215	▁ HF ▁; ▁cardiovascular ▁hospital ization
D-1797	-0.4544176161289215	HF ; cardiovascular hospitalization
P-1797	-1.5322 -0.0973 -0.2590 -0.3945 -0.5124 -0.1978 -0.3478 -0.2944
S-1914	Patients underwent testing of cardiac and inflammatory biomarkers.<unk>
T-1914	patients ; cardiac ; inflammatory ; biomarkers
H-1914	-0.33518126606941223	▁cardiac ▁; ▁infla mma tory ▁bio mark ers
D-1914	-0.33518126606941223	cardiac ; inflammatory biomarkers
P-1914	-0.3929 -0.5729 -0.0623 -0.7331 -0.0590 -0.3976 -0.0618 -0.3036 -0.3750 -0.3936
S-64	We meta-analyzed mortality using random-effects models.<unk>
T-64	meta-analyzed ; mortality ; random-effects models
H-64	-0.7223426699638367	▁mortal ity
D-64	-0.7223426699638367	mortality
P-64	-0.4243 -0.0623 -2.1004 -0.3023
S-461	Do outcomes for patients with heart failure vary by emergency department volume?<unk>
T-461	outcomes ; patients ; heart failure ; emergency department
H-461	-0.8992542028427124	▁heart ▁failure ▁; ▁emergency ▁department
D-461	-0.8992542028427124	heart failure ; emergency department
P-461	-3.4190 -0.1935 -0.6323 -0.2472 -0.0176 -1.4540 -0.3312
S-1465	Pharmacological treatment of acute heart failure: current treatment and new targets.<unk>
T-1465	pharmacological ; acute heart failure
H-1465	-0.5399413108825684	▁Pharma c ological ▁; ▁a cute ▁heart ▁failure
D-1465	-0.5399413108825684	Pharmacological ; acute heart failure
P-1465	-1.3563 -0.1220 -0.1168 -0.8271 -0.0666 -0.0307 -1.6982 -0.0638 -0.9183 -0.1996
S-1059	T1-mapping values were compared between the baseline and heart failure scans.<unk>
T-1059	t1-mapping ; baseline ; heart failure
H-1059	-0.37053099274635315	▁base line ▁; ▁heart ▁failure
D-1059	-0.37053099274635315	baseline ; heart failure
P-1059	-0.0382 -0.0540 -0.1664 -0.3435 -0.1280 -1.5952 -0.2684
S-772	Safe, effective off-pump sternal sparing approach for HeartMate II exchange.<unk>
T-772	sternal ; heartmate ii
H-772	-0.4381651282310486	▁off - pump ▁; ▁ster nal ▁spar ing ▁; ▁Heart Mate ▁II ▁exchange
D-772	-0.4381651282310486	off-pump ; sternal sparing ; HeartMate II exchange
P-772	-0.2730 -0.1012 -0.1755 -0.5279 -2.4501 -0.0415 -0.0071 -0.0264 -1.0630 -0.3513 -0.1512 -0.6610 -0.0264 -0.5026 -0.2142
S-913	Certain dialysis patients demonstrated compelling improvement after device implantation.<unk>
T-913	dialysis ; patients ; implantation
H-913	-0.4867264926433563	▁di al ysis ▁; ▁device ▁implant ation
D-913	-0.4867264926433563	dialysis ; device implantation
P-913	-0.1676 -0.1042 -0.2625 -1.5360 -1.1430 -0.2175 -0.2868 -0.4265 -0.2365
S-349	Coronary angiography revealed no significant lesions in the major branches.<unk>
T-349	coronary angiography ; lesions
H-349	-0.48092055320739746	▁Corona ry ▁ang i ography
D-349	-0.48092055320739746	Coronary angiography
P-349	-0.0579 -0.1495 -0.0275 -1.4755 -0.4157 -1.0629 -0.1774
S-223	Hemodynamic phenotype of the failing Fontan in an adult population.<unk>
T-223	hemodynamic phenotype ; fontan
H-223	-0.48047709465026855	▁Hem o dynamic ▁; ▁fail ing ▁Font an
D-223	-0.48047709465026855	Hemodynamic ; failing Fontan
P-223	-0.1730 -0.1469 -0.0086 -0.6756 -1.6845 -0.0480 -0.1581 -0.6034 -1.1367 -0.1699
S-358	In this patient there was no MS before the surgery by echocardiography.<unk>
T-358	patient ; surgery ; echocardiography
H-358	-0.3988664448261261	▁MS ▁; ▁surgery ▁; ▁e cho card i ography
D-358	-0.3988664448261261	MS ; surgery ; echocardiography
P-358	-0.6648 -0.3189 -1.3100 -0.2349 -0.0572 -0.3389 -0.3274 -0.5203 -0.2593 -0.2489 -0.1070
S-1902	Individuals who exercise regularly extend their life expectancy by three to seven years.<unk>
T-1902	exercise ; life expectancy
H-1902	-1.07493257522583	
D-1902	-1.07493257522583	
P-1902	-1.7508 -0.3991
S-826	Univariate and multivariate analyses were used for factors predicting survival.<unk>
T-826	multivariate analyses
H-826	-0.7083784937858582	▁factors ▁; ▁survival
D-826	-0.7083784937858582	factors ; survival
P-826	-0.6677 -1.9813 -0.4731 -0.1367 -0.2831
S-1537	The risk of heart failure was estimated by Cox proportional hazard analyses.<unk>
T-1537	heart failure ; cox proportional hazard analyses
H-1537	-0.5665447115898132	▁heart ▁failure ▁; ▁co x ▁proportion al ▁hazard
D-1537	-0.5665447115898132	heart failure ; cox proportional hazard
P-1537	-2.1049 -0.1503 -0.3309 -0.0351 -0.2829 -0.1600 -0.0120 -1.1808 -1.1250 -0.2835
S-567	Randomized trial of Nordic walking in patients with moderate to severe heart failure.<unk>
T-567	randomized ; walking ; patients ; severe heart failure
H-567	-1.3122752904891968	▁Nordic ▁walking ▁; ▁heart ▁failure
D-567	-1.3122752904891968	Nordic walking ; heart failure
P-567	-0.7002 -3.9063 -0.4276 -3.2597 -0.1337 -0.4536 -0.3049
S-1503	Psychometric testing of the Self-Care of Heart Failure Index Version 6.2.<unk>
T-1503	psychometric ; self-care of heart failure index version 6.2
H-1503	-0.4432201087474823	▁psycho metric ▁testing ▁; ▁self - Car e ▁of ▁Heart ▁Fail ure ▁index
D-1503	-0.4432201087474823	psychometric testing ; self-Care of Heart Failure index
P-1503	-0.7525 -0.0035 -0.3222 -0.2146 -0.5517 -0.0645 -0.6122 -0.0719 -0.6148 -1.1854 -0.4935 -0.0790 -0.9853 -0.4381 -0.2592
S-551	One patient died postoperatively secondary to multiorgan failure and sepsis.<unk>
T-551	patient ; postoperatively ; multiorgan failure ; sepsis
H-551	-0.48892223834991455	▁post operativ ely ▁; ▁multi organ ▁failure ▁; ▁se psis
D-551	-0.48892223834991455	postoperatively ; multiorgan failure ; sepsis
P-551	-2.5279 -0.0672 -0.6326 -1.3945 -0.2138 -0.2429 -0.0736 -0.2320 -0.0048 -0.0060 -0.2439 -0.2278
S-975	In total, 17% of patients developed acute kidney injury postoperatively.<unk>
T-975	patients ; acute kidney injury ; postoperatively
H-975	-0.7613190412521362	▁a cute ▁ki dne y ▁injury
D-975	-0.7613190412521362	acute kidney injury
P-975	-0.9756 -0.0287 -0.2298 -1.2002 -0.0921 -1.3123 -1.8362 -0.4157
S-1255	VO2max increased (~24%) but did not reach statistical significance.<unk>
T-1255	vo2max ; significance
H-1255	-0.8194799423217773	▁VO 2 max
D-1255	-0.8194799423217773	VO2max
P-1255	-1.8760 -0.1892 -0.0346 -1.6938 -0.3037
S-675	Analyses included descriptive statistics and Cox proportional hazards models.<unk>
T-675	descriptive statistics ; cox proportional hazards models
H-675	-0.618547260761261	▁co x ▁proportion al ▁hazard s ▁models
D-675	-0.618547260761261	cox proportional hazards models
P-675	-0.2075 -0.7453 -0.0415 -0.0220 -2.0309 -0.7166 -0.7983 -0.5637 -0.4412
S-2011	Survival projections are based on a modified Seattle Heart Failure Model.<unk>
T-2011	seattle heart failure model
H-2011	-0.6132693290710449	▁Sur vi val ▁project ions ▁; ▁Seattle ▁Heart ▁Fail ure ▁model
D-2011	-0.6132693290710449	Survival projections ; Seattle Heart Failure model
P-2011	-3.9091 -0.0968 -0.4507 -0.2330 -0.4228 -0.2636 -0.1934 -1.0529 -0.2253 -0.0358 -0.4869 -0.4203 -0.1819
S-603	METHODS: We used data from four different US healthcare programmes.<unk>
T-603	healthcare
H-603	-0.8550274968147278	▁health care ▁programme s
D-603	-0.8550274968147278	healthcare programmes
P-603	-3.0317 -0.4706 -0.8622 -0.1381 -0.4060 -0.2216
S-1204	An estimated 5.1 million Americans aged 20 years and older have heart failure.<unk>
T-1204	heart failure
H-1204	-1.2137763500213623	▁heart ▁failure
D-1204	-1.2137763500213623	heart failure
P-1204	-3.8667 -0.2378 -0.4469 -0.3037
S-1854	We will explore why some interventions may succeed in one setting and fail in another.<unk>
T-1854	
H-1854	-0.48743772506713867	
D-1854	-0.48743772506713867	
P-1854	-0.6989 -0.2760
S-1923	Results can only be considered as preliminary and need further validation in larger studies.<unk>
T-1923	
H-1923	-0.37665438652038574	
D-1923	-0.37665438652038574	
P-1923	-0.5544 -0.1989
S-800	Three trials were performed on the same day and by the same assessors.<unk>
T-800	
H-800	-0.37125515937805176	▁trial s
D-800	-0.37125515937805176	trials
P-800	-0.5387 -0.1001 -0.6960 -0.1502
S-746	Abnormal cardiac T2* values determined changes in treatment in most subjects.<unk>
T-746	cardiac
H-746	-0.6318087577819824	▁ab normal ▁cardiac ▁t 2 ▁; ▁treatment
D-746	-0.6318087577819824	abnormal cardiac t2 ; treatment
P-746	-0.5089 -0.0050 -0.0931 -1.3485 -0.0486 -0.8720 -2.1490 -0.4174 -0.2439
S-1028	Appropriately designed clinical trials will be needed to confirm these potential benefits.<unk>
T-1028	clinical
H-1028	-0.4688844084739685	▁clinic al ▁trial s
D-1028	-0.4688844084739685	clinical trials
P-1028	-1.7476 -0.0614 -0.2615 -0.0569 -0.4975 -0.1884
S-1206	Determination of risk and associated treatment strategies is the subject of this brief review.<unk>
T-1206	
H-1206	-0.8811334371566772	
D-1206	-0.8811334371566772	
P-1206	-1.5838 -0.1785
S-608	The HR was also not elevated in subjects with a history of HF.<unk>
T-608	elevated ; hf
H-608	-0.45055872201919556	▁HR ▁; ▁ HF
D-608	-0.45055872201919556	HR ; HF
P-608	-0.3827 -0.3599 -1.0802 -0.0920 -0.4211 -0.3675
S-591	Previously documented prognostic factors were also confirmed in this cohort.<unk>
T-591	prognostic
H-591	-0.5629410147666931	▁prognos tic ▁factors
D-591	-0.5629410147666931	prognostic factors
P-591	-1.0362 -0.8318 -0.1198 -0.4962 -0.3307
S-1197	Our review of this newly introduced drug is based on our experience in Japan.<unk>
T-1197	drug ; japan
H-1197	-1.2205764055252075	▁drug ▁; ▁Japan
D-1197	-1.2205764055252075	drug ; Japan
P-1197	-3.1973 -0.6909 -1.8565 -0.1576 -0.2007
S-70	Further research is needed to study other potential predictors, particularly biomarkers.<unk>
T-70	biomarkers
H-70	-0.6664654612541199	▁bio mark ers
D-70	-0.6664654612541199	biomarkers
P-70	-2.6970 -0.0257 -0.0989 -0.2733 -0.2374
S-799	MAIN OUTCOME MEASURE: Time to complete the TUG test.<unk>
T-799	outcome ; tug test
H-799	-1.675485610961914	▁figure ▁; ▁TU g ▁test
D-799	-1.675485610961914	figure ; TUg test
P-799	-6.4601 -0.3051 -1.1905 -2.4819 -0.8069 -0.2357 -0.2481
S-394	Forty-one patients developed ESRD (1.3/1000 patient-years).<unk>
T-394	patients ; esrd
H-394	-1.4933708906173706	▁ES RD
D-394	-1.4933708906173706	ESRD
P-394	-3.4260 -1.6227 -0.4396 -0.4851
S-1299	Heart failure with preserved left ventricular ejection fraction.<unk>
T-1299	heart failure with preserved left ventricular ejection fraction
H-1299	-0.5413393378257751	▁Heart ▁failure ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-1299	-0.5413393378257751	Heart failure ; preserved left ventricular ejection fraction
P-1299	-0.1605 -0.0178 -0.1288 -2.0485 -0.0591 -0.0659 -0.1230 -2.3668 -1.1770 -0.3269 -0.1939 -0.3557 -0.3157 -0.8692 -0.0084 -0.7786 -0.2069
S-1580	MAIN OUTCOME MEASURE: 30-day all-cause readmissions.<unk>
T-1580	outcome ; all-cause readmissions
H-1580	-1.4860984086990356	
D-1580	-1.4860984086990356	
P-1580	-2.7693 -0.2029
S-1798	The prevalence of systolic HF varies from 64% to 69%.<unk>
T-1798	prevalence ; systolic hf
H-1798	-0.42899176478385925	▁sy sto lic ▁ HF
D-1798	-0.42899176478385925	systolic HF
P-1798	-1.4328 -0.2217 -0.1646 -0.5107 -0.1071 -0.3776 -0.1885
S-617	Secondary outcome measures related to patient satisfaction and sustainability of the intervention post study.<unk>
T-617	secondary outcome ; patient ; post
H-617	-1.1996595859527588	
D-617	-1.1996595859527588	
P-617	-2.1296 -0.2697
S-545	METHODS: From 2005 to 2011, 271 patients underwent LVAD implantation.<unk>
T-545	patients ; lvad ; implantation
H-545	-0.8143184781074524	▁l VAD ▁implant ation
D-545	-0.8143184781074524	lVAD implantation
P-545	-2.4319 -0.5805 -0.7682 -0.3111 -0.5638 -0.2303
S-331	Lack of correlation of remaining indices may reflect postsystolic function.<unk>
T-331	correlation ; postsystolic function
H-331	-0.9584943056106567	▁post y sto lic ▁function
D-331	-0.9584943056106567	postystolic function
P-331	-3.1517 -0.6091 -0.3370 -0.7202 -1.1226 -0.5026 -0.2662
S-828	These groups were not significantly different in terms of medication and resting hemodynamics.<unk>
T-828	medication ; resting hemodynamics
H-828	-0.42114707827568054	▁medication ▁; ▁rest ing ▁hem o dynamic s
D-828	-0.42114707827568054	medication ; resting hemodynamics
P-828	-1.2052 -0.1548 -0.4397 -0.0199 -1.2593 -0.4050 -0.0135 -0.0823 -0.4847 -0.1469
S-1276	In addition to prognosis, the pathophysiological origin is also discussed.<unk>
T-1276	prognosis ; pathophysiological
H-1276	-0.6957157850265503	▁prognos is ▁; ▁pat ho phy si ological
D-1276	-0.6957157850265503	prognosis ; pathophysiological
P-1276	-1.9567 -0.5478 -0.3952 -0.3245 -0.6673 -0.1064 -0.8598 -0.1726 -1.7328 -0.1941
S-1782	Mice subjected to AAC demonstrated a progressive development of cardiac hypertrophy.<unk>
T-1782	aac ; cardiac hypertrophy
H-1782	-0.7969430088996887	▁mi ce ▁; ▁a ac ▁; ▁cardiac ▁hyper trop hy
D-1782	-0.7969430088996887	mice ; aac ; cardiac hypertrophy
P-1782	-2.6106 -0.0453 -0.1911 -0.2560 -0.6961 -0.2014 -0.8514 -1.9916 -0.1927 -1.5780 -0.6031 -0.3460
S-1908	The AHA and the ESC advocate pre-participation screening of young athletes.<unk>
T-1908	aha ; esc
H-1908	-1.1743478775024414	AHA ▁; ▁ AHA ▁; ▁ESC
D-1908	-1.1743478775024414	AHA ; AHA ; ESC
P-1908	-0.8704 -0.1790 -3.8852 -0.2622 -0.1193 -1.5733 -2.0297 -0.4756
S-1720	Physician volume, specialty, and outcomes of care for patients with heart failure.<unk>
T-1720	physician ; outcomes ; patients ; heart failure
H-1720	-1.1589521169662476	▁physical ▁; ▁heart ▁failure
D-1720	-1.1589521169662476	physical ; heart failure
P-1720	-0.6749 -1.7549 -3.5660 -0.1805 -0.3820 -0.3954
S-1491	Skeletal muscle abnormalities and exercise capacity in adults with a Fontan circulation.<unk>
T-1491	skeletal muscle ; exercise capacity ; fontan circulation
H-1491	-0.2553184926509857	▁s kelet al ▁muscle ▁ab normal ities ▁; ▁exercise ▁capacity ▁; ▁Font an ▁circulation
D-1491	-0.2553184926509857	skeletal muscle abnormalities ; exercise capacity ; Fontan circulation
P-1491	-1.0270 -0.0118 -0.0828 -0.2757 -0.0976 -0.0284 -0.0447 -0.1821 -0.1099 -0.0704 -0.3549 -0.7994 -0.2662 -0.0118 -0.4868 -0.2356
S-147	CONTEXT: Readmission to hospital for heart failure is common after recent discharge.<unk>
T-147	readmission ; hospital ; heart failure ; discharge
H-147	-0.7008218765258789	▁Read mission ▁; ▁hospital ▁; ▁heart ▁failure ▁; ▁dis charge
D-147	-0.7008218765258789	Readmission ; hospital ; heart failure ; discharge
P-147	-3.5482 -0.0838 -1.1066 -0.3849 -0.3413 -0.8093 -0.0879 -1.4179 -0.0346 -0.0530 -0.2454 -0.2969
S-1598	This progressive disease can lead to resistant hypertension and end stage kidney failure.<unk>
T-1598	disease ; lead ; hypertension ; kidney failure
H-1598	-0.415946900844574	▁progressive ▁disease ▁; ▁hyper tension ▁; ▁end ▁stage ▁ki dne y ▁failure
D-1598	-0.415946900844574	progressive disease ; hypertension ; end stage kidney failure
P-1598	-0.4130 -0.9978 -0.1094 -2.3049 -0.1035 -0.0694 -0.9353 -0.0667 -0.0214 -0.2186 -0.0334 -0.0238 -0.3578 -0.1683
S-898	9/10 patients were Stage 3 chronic kidney disease (CKD) or worse.<unk>
T-898	patients ; chronic kidney disease ; ckd
H-898	-0.7230675220489502	▁chronic ▁ki dne y ▁disease ▁; CK d
D-898	-0.7230675220489502	chronic kidney disease ;CKd
P-898	-1.4370 -0.3216 -0.6791 -0.2124 -1.1387 -0.4407 -0.5611 -1.3795 -0.6999 -0.3607
S-1792	LA countries have reduced gross income and lower total expenditure on health per capita.<unk>
T-1792	income ; expenditure ; health
H-1792	-0.7079789042472839	▁income ▁; ▁ex pendi ture ▁; ▁health ▁per ▁capita
D-1792	-0.7079789042472839	income ; expenditure ; health per capita
P-1792	-4.6493 -0.1065 -0.6973 -0.0082 -0.0814 -0.4391 -0.1660 -0.1073 -0.0105 -1.1279 -0.3942
S-143	Correlations among metrics were modest when measuring hospital longitudinal change.<unk>
T-143	correlations ; hospital ; longitudinal ; change
H-143	-1.0823607444763184	▁longitud in al ▁change
D-143	-1.0823607444763184	longitudinal change
P-143	-5.4582 -0.3165 -0.0687 -0.0098 -0.2828 -0.3582
S-1589	Abnormal HR variability predicts both sudden and non-sudden cardiac death.<unk>
T-1589	hr variability ; cardiac death
H-1589	-0.49082326889038086	▁ab normal ▁HR ▁variabil ity ▁; ▁sud den ▁; ▁non - sud den ▁cardiac ▁death
D-1589	-0.49082326889038086	abnormal HR variability ; sudden ; non-sudden cardiac death
P-1589	-0.6200 -0.0028 -1.4162 -0.2931 -0.0486 -0.2386 -0.3781 -0.0012 -1.4048 -2.0213 -0.0689 -0.0177 -0.0009 -0.0735 -0.9360 -0.4711 -0.3513
S-1824	Hence, progress has yet to be made regarding appropriate referrals and patient circulation.<unk>
T-1824	patient ; circulation
H-1824	-0.29212796688079834	▁circulation
D-1824	-0.29212796688079834	circulation
P-1824	-0.3444 -0.2329 -0.2991
S-1048	Importantly, no toxicity or effects on systemic blood pressure were observed.<unk>
T-1048	systemic blood pressure
H-1048	-0.6304381489753723	▁ toxic ity ▁; ▁system ic ▁blood ▁pressure
D-1048	-0.6304381489753723	toxicity ; systemic blood pressure
P-1048	-0.2055 -0.2587 -0.1405 -0.1607 -1.5216 -0.0830 -2.9706 -0.2781 -0.4442 -0.2414
S-1881	RESULTS: There were no significant difference between two groups patients (P > 0.05).<unk>
T-1881	patients
H-1881	-0.46729856729507446	
D-1881	-0.46729856729507446	
P-1881	-0.7562 -0.1784
S-1576	DESIGN: Prospective, non-randomized, two-center pilot project.<unk>
T-1576	prospective
H-1576	-0.5400820970535278	
D-1576	-0.5400820970535278	
P-1576	-0.8228 -0.2573
S-1965	Despite that, no major development has occurred in the therapy in recent years.<unk>
T-1965	therapy
H-1965	-0.532310426235199	▁ therapy
D-1965	-0.532310426235199	therapy
P-1965	-1.6339 -0.0972 -0.1706 -0.2276
S-75	Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.<unk>
T-75	north america
H-75	-0.8928011655807495	▁en roll ment
D-75	-0.8928011655807495	enrollment
P-75	-1.1675 -0.0095 -0.1091 -3.0494 -0.1286
S-1848	We will assess the impact of the intervention on adherence to the CPGs.<unk>
T-1848	cpgs
H-1848	-0.6050682067871094	▁ad her ence ▁; ▁c PG s
D-1848	-0.6050682067871094	adherence ; cPGs
P-1848	-1.4248 -1.4996 -0.0390 -0.4099 -0.3701 -0.6919 -0.1217 -0.4667 -0.4219
S-372	At this point, insignificant MS can be considered as not indicative for surgery.<unk>
T-372	surgery
H-372	-0.8132761716842651	▁MS
D-372	-0.8132761716842651	MS
P-372	-1.0201 -1.2793 -0.1404
S-709	There is a paucity of data examining long-term outcomes with this strategy.<unk>
T-709	paucity ; outcomes
H-709	-1.0841723680496216	
D-709	-1.0841723680496216	
P-709	-1.9495 -0.2188
S-1014	Learning from recent trials and shaping the future of acute heart failure trials.<unk>
T-1014	acute heart failure
H-1014	-0.5126270651817322	▁a cute ▁heart ▁failure ▁trial s
D-1014	-0.5126270651817322	acute heart failure trials
P-1014	-1.2553 -0.0514 -0.9025 -0.0436 -1.0255 -0.0655 -0.4895 -0.2677
S-1821	Overall management of patients with heart failure requires the collaboration of professionals from multiple disciplines.<unk>
T-1821	patients ; heart failure
H-1821	-0.9911290407180786	▁patients ▁; ▁heart ▁failure
D-1821	-0.9911290407180786	patients ; heart failure
P-1821	-3.9239 -0.8409 -0.5560 -0.0788 -0.3463 -0.2009
S-1072	In addition, stand-alone diagnostic devices are now also being developed for HF.<unk>
T-1072	diagnostic ; hf
H-1072	-1.0264252424240112	▁diagnostic ▁devices ▁; ▁ HF
D-1072	-1.0264252424240112	diagnostic devices ; HF
P-1072	-5.7695 -0.1707 -0.2383 -0.3459 -0.2212 -0.2249 -0.2143
S-1669	In this article, we describe current strategies for the treatment of end stage heart failure.<unk>
T-1669	end stage heart failure
H-1669	-1.0813205242156982	▁end ▁stage ▁heart ▁failure
D-1669	-1.0813205242156982	end stage heart failure
P-1669	-4.8660 -0.0629 -1.1079 -0.0624 -0.2485 -0.1403
S-1732	Our findings suggest that clinician expertise may play an important role in HF care.<unk>
T-1732	clinician ; hf
H-1732	-1.4088529348373413	▁ HF
D-1732	-1.4088529348373413	HF
P-1732	-3.0398 -0.3536 -2.0645 -0.1775
S-253	Endothelial function was assessed by flow-mediated dilatation.<unk>
T-253	endothelial function ; flow-mediated dilatation
H-253	-0.38121068477630615	▁en dot heli al ▁function ▁; ▁flow - media ted ▁di la tation
D-253	-0.38121068477630615	endothelial function ; flow-mediated dilatation
P-253	-0.2535 -1.6342 -0.5789 -0.0323 -0.2556 -0.5117 -0.0096 -0.0986 -0.1602 -0.3930 -0.1583 -0.5917 -0.0183 -0.7612 -0.2611
S-1701	Race influences the safety and efficacy of spironolactone in severe heart failure.<unk>
T-1701	spironolactone ; severe heart failure
H-1701	-0.5768328309059143	▁Race ▁; ▁spi rono lac tone ▁; ▁severe ▁heart ▁failure
D-1701	-0.5768328309059143	Race ; spironolactone ; severe heart failure
P-1701	-0.8202 -0.1890 -3.0118 -0.0614 -0.2493 -0.1303 -0.1919 -1.2436 -0.2046 -0.0906 -0.4414 -0.2879
S-568	BACKGROUND: Patients with heart failure are a growing population within cardiac rehabilitation.<unk>
T-568	patients ; heart failure ; cardiac rehabilitation
H-568	-0.517880916595459	▁heart ▁failure ▁; ▁cardiac ▁rehabilita tion
D-568	-0.517880916595459	heart failure ; cardiac rehabilitation
P-568	-2.1649 -0.1740 -0.6160 -0.1521 -0.2396 -0.1769 -0.4131 -0.2064
S-1232	Rhythm- and rate-control strategies are associated with similar efficacy outcomes.<unk>
T-1232	rate-control ; outcomes
H-1232	-0.6387872695922852	▁ Rhythm - ▁and ▁rate - control ▁strategie s
D-1232	-0.6387872695922852	Rhythm- and rate-control strategies
P-1232	-0.3166 -0.0498 -0.2087 -2.6515 -0.0056 -0.4343 -0.0671 -2.1138 -0.1515 -0.7448 -0.2831
S-1640	There was no interaction between race and exercise training on outcomes (P > .5).<unk>
T-1640	exercise ; training ; outcomes
H-1640	-0.3964468240737915	▁race ▁; ▁exercise ▁training
D-1640	-0.3964468240737915	race ; exercise training
P-1640	-0.5063 -0.4458 -0.0250 -0.8403 -0.3241 -0.2373
S-39	Background: The benefits of anemia treatment in patients with heart disease are uncertain.<unk>
T-39	anemia ; patients ; heart disease
H-39	-1.0399656295776367	▁an emia ▁; ▁heart ▁disease
D-39	-1.0399656295776367	anemia ; heart disease
P-39	-0.3472 -0.4452 -1.2033 -3.7163 -1.0442 -0.2603 -0.2633
S-1724	We divided physicians into quintiles according to their volume of patients with HF.<unk>
T-1724	physicians ; patients ; hf
H-1724	-0.7613164782524109	▁physician s ▁; ▁ HF
D-1724	-0.7613164782524109	physicians ; HF
P-1724	-2.1857 -0.0897 -0.2217 -2.1367 -0.1117 -0.3413 -0.2423
S-1137	Myocardial infarction was elicited in adult male Wistar rats.<unk>
T-1137	myocardial infarction
H-1137	-0.39258161187171936	▁My o card ial ▁in far ction ▁; ▁Wi star ▁rat s
D-1137	-0.39258161187171936	Myocardial infarction ; Wistar rats
P-1137	-0.6635 -0.1207 -0.4277 -0.0471 -0.0480 -0.2553 -0.1338 -0.3126 -0.9798 -1.1656 -0.1194 -0.0676 -0.8151 -0.3399
S-543	Treatment algorithms for de novo, post-LVAD AI have not been well defined.<unk>
T-543	post-lvad ai
H-543	-0.8177505731582642	▁Treatment ▁algorithm s ▁; ▁post - L VAD ▁AI
D-543	-0.8177505731582642	Treatment algorithms ; post-LVAD AI
P-543	-3.5229 -0.4818 -0.0807 -0.2793 -0.0437 -0.0223 -3.6934 -0.1250 -0.1759 -0.3605 -0.2097
S-547	The patients were examined for new-onset severe AI requiring surgical intervention.<unk>
T-547	patients ; surgical
H-547	-0.9544095993041992	▁AI ▁; ▁sur g ical
D-547	-0.9544095993041992	AI ; surgical
P-547	-1.9102 -1.3327 -0.6139 -0.0861 -0.0179 -2.4714 -0.2488
S-1644	Conceptually, maintenance of sinus rhythm could prevent adverse outcomes related to AF.<unk>
T-1644	sinus rhythm ; adverse outcomes
H-1644	-0.5711125135421753	▁sinus ▁ rhythm ▁; ▁AF
D-1644	-0.5711125135421753	sinus rhythm ; AF
P-1644	-1.5037 -0.1936 -0.1205 -0.3384 -1.4439 -0.2185 -0.1792
S-1689	BACKGROUND: Public reporting on quality aims to help patients select better hospitals.<unk>
T-1689	public reporting ; patients ; hospitals
H-1689	-0.5693531632423401	▁public ▁report ing ▁; ▁quality ▁; ▁hospital s
D-1689	-0.5693531632423401	public reporting ; quality ; hospitals
P-1689	-0.2515 -0.1048 -0.1007 -0.6517 -2.4237 -0.8486 -0.6588 -0.1888 -0.2715 -0.1935
S-299	Preoperative demographics, operative outcomes, and survival were analyzed.<unk>
T-299	preoperative ; operative ; outcomes
H-299	-1.072393774986267	▁pre operativ e ▁demo graphic s
D-299	-1.072393774986267	preoperative demographics
P-299	-1.8438 -0.0062 -0.2106 -1.4516 -0.3876 -0.0834 -4.3931 -0.2029
S-1617	Effects of care management and telehealth: a longitudinal analysis using medicare data.<unk>
T-1617	telehealth ; longitudinal ; medicare
H-1617	-0.6110530495643616	▁care ▁management ▁; ▁tele health ▁; ▁medica re
D-1617	-0.6110530495643616	care management ; telehealth ; medicare
P-1617	-2.3418 -0.4692 -0.1788 -0.0449 -0.9684 -0.4327 -0.0373 -0.0868 -1.2939 -0.2567
S-490	E/e'septal showed good diagnostic performance for detecting normal filling pressures.<unk>
T-490	septal ; diagnostic ; filling pressures
H-490	-1.1192128658294678	▁ec ▁; sept al ▁; ▁fill ing ▁pressure s
D-490	-1.1192128658294678	ec ;septal ; filling pressures
P-490	-5.6053 -2.0720 -1.4123 -0.0288 -0.2097 -1.1460 -0.1617 -0.3344 -0.4229 -0.6634 -0.2549
S-875	This included significant amelioration of all the ingenuity pathway analysis noted above.<unk>
T-875	ingenuity pathway analysis
H-875	-1.069137454032898	
D-875	-1.069137454032898	
P-875	-1.7481 -0.3902
S-1036	At the molecular level, HF has been associated with chromatin hyperacetylation.<unk>
T-1036	hf ; chromatin hyperacetylation
H-1036	-0.7542352080345154	▁ HF ▁; ▁chr omat in ▁hyper ace ty lation
D-1036	-0.7542352080345154	HF ; chromatin hyperacetylation
P-1036	-1.9096 -0.1907 -0.3150 -0.3191 -0.0626 -1.9791 -0.8210 -0.5270 -0.9621 -1.1162 -0.6671 -0.1814
S-1397	Using standardized nursing terminologies makes it possible to measure aspects of nursing care.<unk>
T-1397	nursing ; nursing
H-1397	-1.137137532234192	▁nur sing ▁terminologi es
D-1397	-1.137137532234192	nursing terminologies
P-1397	-1.8814 -0.0516 -1.6318 -0.1222 -2.8816 -0.2542
S-468	Interventions to improve management of acute heart failure are required at low-volume sites.<unk>
T-468	acute heart failure
H-468	-0.5463666915893555	▁a cute ▁heart ▁failure
D-468	-0.5463666915893555	acute heart failure
P-468	-0.5198 -0.0402 -1.7605 -0.0704 -0.5750 -0.3122
S-1263	Most adverse events observed in the studies were not severe and resolved without special treatment.<unk>
T-1263	adverse events
H-1263	-0.7840963006019592	
D-1263	-0.7840963006019592	
P-1263	-1.4355 -0.1327
S-370	According to the guideline, the MS at that time could be considered indicative for surgery.<unk>
T-370	surgery
H-370	-0.8155413866043091	▁ms ▁; ▁surgery
D-370	-0.8155413866043091	ms ; surgery
P-370	-1.3469 -1.5245 -0.7812 -0.1850 -0.2401
S-810	This study sought to examine the ability of GLS in predicting CV events in AF.<unk>
T-810	gls
H-810	-0.8990707397460938	▁g ls ▁; ▁cv ▁events ▁; ▁AF
D-810	-0.8990707397460938	gls ; cv events ; AF
P-810	-0.3673 -2.3469 -0.1717 -2.2930 -0.6320 -1.1914 -0.2534 -0.5742 -0.2617
S-1006	The deficit index was defined as the proportion of deficits present out of 32 deficits.<unk>
T-1006	deficit index
H-1006	-0.4227250814437866	▁deficit ▁index ▁; ▁deficit s
D-1006	-0.4227250814437866	deficit index ; deficits
P-1006	-0.1787 -0.1117 -0.8983 -0.1953 -0.5062 -0.8094 -0.2593
S-1855	We will disseminate our findings through briefing reports, publications and presentations.<unk>
T-1855	
H-1855	-0.6143234968185425	
D-1855	-0.6143234968185425	
P-1855	-0.9517 -0.2769
S-1165	Over a median follow-up of 541 days, there were 150 events (37%).<unk>
T-1165	follow-up
H-1165	-0.3065987527370453	
D-1165	-0.3065987527370453	
P-1165	-0.5269 -0.0863
S-1696	We repeated this analysis using 2005-2008 performance on existing quality indicators, including mortality.<unk>
T-1696	mortality
H-1696	-0.783531129360199	▁mortal ity
D-1696	-0.783531129360199	mortality
P-1696	-2.5183 -0.0610 -0.2169 -0.3379
S-3	The analysis included a large study sample with more than 60,000 patients across 4372 hospitals.<unk>
T-3	patients ; hospitals
H-3	-0.8642468452453613	▁hospital s
D-3	-0.8642468452453613	hospitals
P-3	-2.8417 -0.2885 -0.1456 -0.1812
S-888	Furthermore, there was continuous relationship between QRS duration and extent of benefit.<unk>
T-888	qrs duration
H-888	-0.7460228800773621	▁QR s ▁du ration
D-888	-0.7460228800773621	QRs duration
P-888	-0.7968 -1.8242 -0.4794 -0.0943 -1.0210 -0.2604
S-1829	DESIGN: Population-based, retrospective, new-user cohort study.<unk>
T-1829	cohort study
H-1829	-0.3936057686805725	
D-1829	-0.3936057686805725	
P-1829	-0.6560 -0.1312
S-1372	We hypothesized in CHF, unilateral renal DNx would improve cardiac autonomic balance.<unk>
T-1372	chf ; unilateral renal dnx ; cardiac ; autonomic balance
H-1372	-0.17109183967113495	▁CHF ▁; ▁unilateral ▁renal ▁DN x ▁; ▁cardiac ▁autonomi c ▁balance
D-1372	-0.17109183967113495	CHF ; unilateral renal DNx ; cardiac autonomic balance
P-1372	-0.0069 -0.1280 -0.0321 -0.0186 -0.3066 -0.0820 -0.2443 -0.0539 -0.0927 -0.7196 -0.0388 -0.3670 -0.1337
S-362	Mitral regurgitation as well as HF symptoms disappeared after the surgery.<unk>
T-362	mitral regurgitation ; hf ; symptoms ; surgery
H-362	-0.521234929561615	▁Mit ral ▁re gur gi tation ▁; ▁ HF
D-362	-0.521234929561615	Mitral regurgitation ; HF
P-362	-2.3692 -0.0769 -0.0736 -0.2365 -0.8022 -0.1807 -0.2424 -0.2868 -0.1580 -0.9837 -0.3236
S-1486	Renin-angiotensin-aldosterone system inhibitors in heart failure.<unk>
T-1486	renin-angiotensin-aldosterone system inhibitors ; heart failure
H-1486	-0.34083718061447144	▁re nin - angi oten sin - al do ster one ▁system ▁inhibi tors ▁; ▁heart ▁failure
D-1486	-0.34083718061447144	renin-angiotensin-aldosterone system inhibitors ; heart failure
P-1486	-0.0502 -0.1010 -0.0741 -0.0164 -1.6716 -0.5026 -0.1315 -0.0525 -1.6914 -0.6384 -0.0580 -0.0780 -0.1264 -0.0359 -0.4228 -0.0543 -0.1969 -0.3772 -0.1969
S-1752	Prognostic value of indeterminable anaerobic threshold in heart failure.<unk>
T-1752	prognostic ; anaerobic threshold ; heart failure
H-1752	-0.5902208685874939	▁ana ero bic ▁thre s hold ▁; ▁heart ▁failure
D-1752	-0.5902208685874939	anaerobic threshold ; heart failure
P-1752	-1.5289 -0.4322 -1.9295 -0.3972 -0.1413 -0.8935 -0.2837 -0.0804 -0.1393 -0.4602 -0.2061
S-373	Therefore, the surgical indications need to be carefully evaluated in patients with functional MS.<unk>
T-373	surgical ; patients ; functional ms
H-373	-1.2489423751831055	▁MS
D-373	-1.2489423751831055	MS
P-373	-3.2381 -0.2961 -0.2126
S-813	PATIENTS: 196 persistent AF patients referred for echocardiographic examination.<unk>
T-813	patients ; patients ; echocardiographic
H-813	-1.0389478206634521	▁af ▁pacientes ▁; ▁e cho car dio graphic ▁examina tion
D-813	-1.0389478206634521	af pacientes ; echocardiographic examination
P-813	-1.3278 -2.1808 -0.2228 -0.0834 -0.7614 -1.3965 -2.6917 -1.2377 -1.4405 -0.5043 -0.4332 -0.1873
S-2020	Nurses in all settings have an essential role in supporting patients in managing this disease.<unk>
T-2020	nurses ; patients ; disease
H-2020	-0.8169844150543213	▁Nur ses ▁; ▁patients ▁; ▁man aging
D-2020	-0.8169844150543213	Nurses ; patients ; managing
P-2020	-1.7976 -0.0521 -0.2680 -1.4468 -0.6974 -0.7286 -0.0004 -2.1602 -0.2018
S-1582	This represented a net economic savings, even accounting for the added cost of the intervention.<unk>
T-1582	economic ; accounting ; cost
H-1582	-0.5190964937210083	▁economic ▁sav ings ▁; ▁cost
D-1582	-0.5190964937210083	economic savings ; cost
P-1582	-0.6322 -0.3409 -0.0693 -0.5106 -0.4108 -1.3724 -0.2975
S-1349	PVF and its recovery had no effect on PB characteristics (period or amplitude).<unk>
T-1349	pvf ; pb
H-1349	-0.3987075090408325	▁PV f ▁; ▁recovery ▁; ▁ PB
D-1349	-0.3987075090408325	PVf ; recovery ; PB
P-1349	-0.8226 -0.6415 -0.1587 -0.2384 -0.1877 -0.4232 -0.0491 -0.8988 -0.1683
S-161	Care packages generally improved health-related quality-of-life and were acceptable to patients.<unk>
T-161	quality-of-life ; patients
H-161	-1.1338672637939453	▁care ▁package s ▁; ▁health
D-161	-1.1338672637939453	care packages ; health
P-161	-2.3342 -0.5917 -0.1344 -0.5812 -0.7297 -3.2961 -0.2698
S-985	It is not appropriate to expand on the management of congenital heart lesions in this review.<unk>
T-985	congenital ; heart ; lesions
H-985	-0.5828876495361328	▁con geni tal ▁heart ▁les ions
D-985	-0.5828876495361328	congenital heart lesions
P-985	-0.4902 -0.0153 -0.1164 -1.1675 -1.7589 -0.5956 -0.3126 -0.2065
S-353	As significant MS was associated with HF, surgical indication for MS was discussed.<unk>
T-353	hf ; surgical
H-353	-0.29854127764701843	▁MS ▁; HF ▁; ▁sur g ical ▁indica tion ▁; ▁MS
D-353	-0.29854127764701843	MS ;HF ; surgical indication ; MS
P-353	-0.3972 -0.2152 -0.7083 -0.2938 -0.7120 -0.0791 -0.0123 -0.1340 -0.0569 -0.7869 -0.1771 -0.1484 -0.1599
S-582	RESULTS: Overall ICU mortality (median stay, 5 days) was 17%.<unk>
T-582	icu ; mortality
H-582	-0.5953747630119324	▁ ICU ▁mortal ity
D-582	-0.5953747630119324	ICU mortality
P-582	-0.2849 -0.0989 -2.0583 -0.0357 -0.9143 -0.1801
S-1605	Bioinformatic analysis of microarray data reveals several key genes related to heart failure.<unk>
T-1605	microarray ; genes ; heart failure
H-1605	-1.0248451232910156	▁Bio informati c ▁; ▁micro arra y ▁; ▁heart ▁failure
D-1605	-1.0248451232910156	Bioinformatic ; microarray ; heart failure
P-1605	-0.8961 -0.3273 -0.5003 -0.3679 -3.8646 -0.1391 -0.2214 -0.4617 -4.6698 -0.2045 -0.4129 -0.2326
S-974	During 90 days of follow-up, there were 2,462 cardiovascular events and 617 deaths.<unk>
T-974	follow-up ; cardiovascular events ; deaths
H-974	-0.5731906294822693	▁cardiovascular ▁events ▁; ▁death s
D-974	-0.5731906294822693	cardiovascular events ; deaths
P-974	-0.7069 -0.2169 -1.1662 -1.4074 -0.1927 -0.1818 -0.1403
S-1202	Herein, we review the current knowledge on diuretic use and outcomes in HF.<unk>
T-1202	diuretic ; outcomes ; hf
H-1202	-0.5495098829269409	▁di ure tic ▁; ▁ HF
D-1202	-0.5495098829269409	diuretic ; HF
P-1202	-0.6543 -0.1657 -0.3116 -0.5580 -2.1076 -0.1446 -0.2639 -0.1903
S-1183	Identifying CAD as a cause of systolic HF has prognostic and treatment implications.<unk>
T-1183	cad ; systolic hf ; prognostic
H-1183	-0.4380134046077728	▁CAD ▁; ▁sy sto lic ▁ HF
D-1183	-0.4380134046077728	CAD ; systolic HF
P-1183	-0.6246 -0.1022 -1.4575 -0.1261 -0.1382 -0.3379 -0.0435 -0.9706 -0.1415
S-940	These results further implicate resistin as a link between inflammation, metabolism, and heart disease.<unk>
T-940	resistin ; inflammation ; metabolism ; heart disease
H-940	-0.4300723969936371	▁resist in ▁; ▁ inflammation ▁; ▁metabolism ▁; ▁heart ▁disease
D-940	-0.4300723969936371	resistin ; inflammation ; metabolism ; heart disease
P-940	-0.8346 -1.0138 -0.2892 -0.1623 -0.0319 -0.2251 -0.0300 -0.2723 -0.4130 -1.1555 -0.4016 -0.3315
S-401	It remains unclear whether sST2 concentrations identify benefit of BB therapy, however.<unk>
T-401	sst2 ; therapy
H-401	-1.023574709892273	▁s st 2 ▁; ▁BB ▁ therapy
D-401	-1.023574709892273	sst2 ; BB therapy
P-401	-0.0055 -4.2866 -0.2329 -0.8455 -2.2412 -0.5416 -0.0987 -0.6304 -0.3296
S-322	Heart block was induced, the pulmonary artery snared, and BiVP initiated.<unk>
T-322	heart block ; pulmonary artery ; bivp
H-322	-0.2558830976486206	▁Heart ▁block ▁; ▁pulmonar y ▁arter y ▁snar ed ▁; ▁bi VP
D-322	-0.2558830976486206	Heart block ; pulmonary artery snared ; biVP
P-322	-0.8369 -0.0524 -0.3030 -0.1500 -0.0917 -0.1200 -0.3910 -0.0704 -0.1301 -0.3303 -0.3330 -0.3534 -0.2456 -0.1746
S-1319	Feasibility was assessed in terms of recruitment, intervention compliance, and attrition.<unk>
T-1319	compliance ; attrition
H-1319	-0.6907308101654053	▁compliance
D-1319	-0.6907308101654053	compliance
P-1319	-0.9788 -0.8622 -0.2312
S-905	We therefore studied our center's experience with CRT in dialysis-dependent patients.<unk>
T-905	crt ; patients
H-905	-0.805652916431427	▁c RT ▁; ▁di al ysis - dependent ▁patients
D-905	-0.805652916431427	cRT ; dialysis-dependent patients
P-905	-1.0712 -4.1626 -0.2705 -0.2619 -0.2220 -0.3249 -0.4474 -0.2445 -1.2165 -0.4039 -0.2367
S-865	General use of beta-blockers (93%) and adherence in this study was high.<unk>
T-865	beta-blockers
H-865	-0.459529310464859	▁beta - block ers
D-865	-0.459529310464859	beta-blockers
P-865	-0.6597 -0.1064 -0.3503 -0.1801 -1.2651 -0.1956
S-217	The mean age of the CHF patients was 76 ± 14 years, and 57% were female.<unk>
T-217	chf ; patients
H-217	-0.6902177333831787	▁CHF
D-217	-0.6902177333831787	CHF
P-217	-0.1953 -1.7297 -0.1456
S-163	Where 'usual' care is less good, the impact of RM is likely to be greater.<unk>
T-163	rm
H-163	-0.9307283759117126	▁care ▁; ▁RM
D-163	-0.9307283759117126	care ; RM
P-163	-3.6545 -0.3019 -0.2442 -0.1922 -0.2608
S-556	BACKGROUND: Few studies have focused on young and very young adults with HF.<unk>
T-556	hf
H-556	-0.822627067565918	▁ HF
D-556	-0.822627067565918	HF
P-556	-2.5515 -0.2810 -0.3019 -0.1561
S-1143	Cardiac function was assessed by means of the pressure-volume conductance catheter system.<unk>
T-1143	cardiac function ; catheter
H-1143	-0.4383615553379059	▁Card iac ▁function ▁; ▁pressure - volu me ▁conduct ance ▁; ▁cat heter ▁system
D-1143	-0.4383615553379059	Cardiac function ; pressure-volume conductance ; catheter system
P-1143	-0.3637 -0.3079 -0.3558 -0.2571 -0.0906 -0.2044 -0.1047 -0.2405 -0.1004 -0.3612 -2.4083 -1.0926 -0.0271 -0.2630 -0.6897 -0.1467
S-1741	However, limited evidence is available specifically on idiopathic dilated cardiomyopathy.<unk>
T-1741	evidence ; idiopathic dilated cardiomyopathy
H-1741	-0.3804178833961487	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1741	-0.3804178833961487	idiopathic dilated cardiomyopathy
P-1741	-1.0017 -0.0077 -0.0597 -0.3045 -0.5409 -0.0626 -0.2186 -1.3696 -0.3118 -0.0718 -0.4887 -0.1274
S-1079	Unfolded protein response regulates cardiac sodium current in systolic human heart failure.<unk>
T-1079	unfolded protein response ; cardiac sodium ; systolic ; heart failure
H-1079	-0.5247164368629456	▁un fold ed ▁protein ▁response ▁; ▁cardiac ▁so dium ▁current ▁; ▁sy sto lic ▁human ▁heart ▁failure
D-1079	-0.5247164368629456	unfolded protein response ; cardiac sodium current ; systolic human heart failure
P-1079	-0.5779 -0.0001 -0.0134 -0.9388 -0.6766 -1.1104 -1.2428 -0.1513 -0.2184 -0.8140 -0.2017 -0.5184 -0.0486 -0.1360 -1.4876 -0.7969 -0.1149 -0.6120 -0.3098
S-529	Hypoalbuminemia has been recognized as a prognostic indicator in patients with heart failure.<unk>
T-529	hypoalbuminemia ; prognostic ; patients ; heart failure
H-529	-0.3771812617778778	▁Hypo album in emia ▁; ▁heart ▁failure
D-529	-0.3771812617778778	Hypoalbuminemia ; heart failure
P-529	-0.1988 -0.4378 -0.2128 -0.1135 -0.3418 -1.3366 -0.1496 -0.3220 -0.2817
S-350	The patient was diagnosed as hypertensive LV dysfunction with mild MR and significant MS.<unk>
T-350	patient ; diagnosed ; hypertensive lv dysfunction
H-350	-0.31907472014427185	▁hyper tensi ve ▁LV ▁dys function ▁; ▁MR ▁; ▁MS
D-350	-0.31907472014427185	hypertensive LV dysfunction ; MR ; MS
P-350	-0.9365 -0.3416 -0.1910 -0.0683 -0.1513 -0.5962 -0.1305 -0.3910 -0.2194 -0.4477 -0.1920 -0.1635
S-1795	The prognosis of C'D HF is worse than for other etiologies.<unk>
T-1795	prognosis ; hf ; etiologies
H-1795	-0.7114636898040771	▁c d ▁ HF ▁; ▁et i ologie s
D-1795	-0.7114636898040771	cd HF ; etiologies
P-1795	-0.4975 -3.1789 -0.4734 -0.3079 -1.2044 -0.0502 -0.8292 -0.4948 -0.1385 -0.4129 -0.2384
S-1461	First-in-class angiotensin receptor neprilysin inhibitor in heart failure.<unk>
T-1461	angiotensin receptor neprilysin inhibitor ; heart failure
H-1461	-0.40026983618736267	▁ang io ten sin ▁receptor ▁nepri ly sin ▁inhibi tor ▁; ▁heart ▁failure
D-1461	-0.40026983618736267	angiotensin receptor neprilysin inhibitor ; heart failure
P-1461	-0.0793 -1.8298 -0.4833 -0.1698 -0.0041 -1.1649 -0.1530 -0.2786 -0.1047 -0.0598 -0.7826 -0.0655 -0.1565 -0.4764 -0.1955
S-1252	Western blot analysis, immunohistochemistry and electron microscopy were used.<unk>
T-1252	western blot ; immunohistochemistry ; electron microscopy
H-1252	-0.4432812035083771	▁western ▁blot ▁; ▁immun oh isto che mist ry ▁; ▁electro n ▁micro s copy
D-1252	-0.4432812035083771	western blot ; immunohistochemistry ; electron microscopy
P-1252	-0.9322 -0.0396 -1.0284 -0.0127 -0.0893 -1.0655 -0.3745 -2.0317 -0.0638 -0.2047 -0.0004 -0.0096 -0.5156 -0.3124 -0.3302 -0.3553 -0.1699
S-1566	Presence of diastolic dysfunction in patients with peripheral artery disease.<unk>
T-1566	diastolic dysfunction ; patients ; peripheral artery disease
H-1566	-0.5177444815635681	▁dia sto lic ▁dys function ▁; ▁per i pher al ▁arter y ▁disease
D-1566	-0.5177444815635681	diastolic dysfunction ; peripheral artery disease
P-1566	-0.4557 -0.3735 -1.2437 -0.4200 -1.1998 -0.2058 -0.0603 -0.2927 -0.0126 -0.2907 -0.3527 -0.6696 -1.3974 -0.5549 -0.2368
S-67	Ischemic cardiomyopathy and male sex were not independent predictors of mortality.<unk>
T-67	ischemic cardiomyopathy ; mortality
H-67	-0.5816118717193604	▁i sche mic ▁cardio my o pathy ▁; ▁male ▁sex ▁; ▁mortal ity
D-67	-0.5816118717193604	ischemic cardiomyopathy ; male sex ; mortality
P-67	-0.4185 -0.0034 -0.0468 -0.3647 -1.1727 -0.2631 -0.0587 -0.2150 -3.7588 -0.8369 -0.6496 -0.3293 -0.0392 -0.2865 -0.2809
S-943	BACKGROUND: AF is a precipitating factor for clinical deterioration of HFPEF.<unk>
T-943	clinical ; hfpef
H-943	-0.6683717966079712	▁AF ▁; ▁precipit ating ▁factor ▁; ▁clinic al ▁deteriora tion ▁; ▁h FP EF
D-943	-0.6683717966079712	AF ; precipitating factor ; clinical deterioration ; hFPEF
P-943	-0.8520 -0.2468 -0.8355 -0.1263 -0.0364 -0.3065 -2.2946 -0.0733 -0.2715 -0.1569 -0.9106 -1.3405 -1.9677 -0.7089 -0.3859 -0.1807
S-714	Among the 454 patients who underwent heart transplant, 84 (18.5%) were ECCT.<unk>
T-714	patients ; heart transplant ; ecct
H-714	-1.0198135375976562	▁heart ▁transplant ▁; ▁EC CT
D-714	-1.0198135375976562	heart transplant ; ECCT
P-714	-4.4760 -0.0539 -0.7657 -1.1163 -0.3003 -0.2074 -0.2191
S-254	The proteome of HDL particles was profiled by shotgun LC-MS/MS.<unk>
T-254	proteome ; hdl
H-254	-0.7302575707435608	▁prote ome ▁; ▁HD l ▁parti cles ▁; ▁shot gun ▁; LC - MS
D-254	-0.7302575707435608	proteome ; HDl particles ; shotgun ;LC-MS
P-254	-1.3664 -0.3696 -0.3603 -1.2209 -3.3425 -0.1966 -0.0730 -0.2501 -1.1629 -0.1941 -0.5534 -0.5282 -0.1213 -0.4758 -1.1905 -0.2785
S-632	CONCLUSIONS: Frailty is independently associated with risk of HF in older adults.<unk>
T-632	frailty ; hf
H-632	-0.465751588344574	▁Fra il ty ▁; ▁risk ▁; ▁ HF
D-632	-0.465751588344574	Frailty ; risk ; HF
P-632	-0.8167 -0.2641 -0.2659 -0.0774 -0.8476 -0.6781 -0.4888 -0.0712 -0.9670 -0.1806
S-1003	METHODS: Southeastern Minnesota residents with HF were recruited from 2007 to 2011.<unk>
T-1003	minnesota ; hf
H-1003	-0.5080515146255493	▁south e a stern ▁Minnesota ▁; ▁ HF
D-1003	-0.5080515146255493	southeastern Minnesota ; HF
P-1003	-3.0470 -0.0172 -0.0200 -0.0026 -0.1010 -0.5278 -0.3472 -0.3235 -0.3936 -0.3007
S-1153	A left bundle branch block electrical activation sequence was simulated in all models.<unk>
T-1153	left bundle branch block
H-1153	-0.5103229880332947	▁bund le ▁; ▁bran ch ▁block ▁electric al ▁activa tion ▁se que nce
D-1153	-0.5103229880332947	bundle ; branch block electrical activation sequence
P-1153	-0.2304 -0.8649 -1.7297 -0.3102 -0.1513 -0.0643 -0.9220 -0.0563 -0.7375 -0.1516 -0.3473 -0.1808 -1.0222 -0.6857 -0.2005
S-1834	The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.<unk>
T-1834	dpp-4 inhibitors ; drugs
H-1834	-0.3956586420536041	▁h HF ▁; ▁d p -4 ▁inhibi tors ▁; ▁drugs
D-1834	-0.3956586420536041	hHF ; dp-4 inhibitors ; drugs
P-1834	-0.0175 -1.2676 -0.1419 -0.3820 -1.0742 -0.2769 -0.3561 -0.0649 -0.5185 -0.1934 -0.2839 -0.1711
S-872	We found that 538 proteins significantly changed after TAC, which mapped to 53 pathways.<unk>
T-872	proteins ; tac
H-872	-0.6505961418151855	▁protein s ▁; ▁ TAC
D-872	-0.6505961418151855	proteins ; TAC
P-872	-2.1293 -0.0982 -0.2199 -0.3840 -0.1161 -1.3384 -0.2682
S-9	OBJECTIVES: Cardiac cachexia (CC) is associated with changes in body composition.<unk>
T-9	cardiac cachexia
H-9	-0.4802740216255188	▁Card iac ▁cache xia ▁; cc ▁; ▁body ▁composition
D-9	-0.4802740216255188	Cardiac cachexia ;cc ; body composition
P-9	-1.2645 -0.0319 -0.0228 -0.4264 -0.2972 -0.4502 -0.8419 -0.8795 -0.6535 -0.2359 -0.1793
S-992	Specific signalling pathways activating either adaptive or maladaptive cardiac remodelling have been identified.<unk>
T-992	signalling pathways ; cardiac remodelling
H-992	-0.30434364080429077	▁signal ling ▁path ways ▁; ▁mal adapt ive ▁cardiac ▁remodel ling
D-992	-0.30434364080429077	signalling pathways ; maladaptive cardiac remodelling
P-992	-0.7412 -0.0742 -0.1354 -0.1266 -0.3414 -1.2642 -0.0298 -0.0135 -0.4141 -0.1913 -0.0361 -0.3308 -0.2578
S-908	No periprocedural or long-term complications were observed among dialysis patients.<unk>
T-908	complications ; dialysis ; patients
H-908	-0.841545045375824	▁di al ysis
D-908	-0.841545045375824	dialysis
P-908	-2.0944 -0.2064 -0.3862 -1.2970 -0.2237
S-1872	The primary safety end point was system- and procedure-related major adverse neurological and cardiovascular events.<unk>
T-1872	end point ; neurological ; cardiovascular events
H-1872	-1.2136988639831543	▁safety ▁; ▁neurologi cal ▁; ▁cardiovascular
D-1872	-1.2136988639831543	safety ; neurological ; cardiovascular
P-1872	-2.2510 -0.7362 -3.0655 -0.1965 -0.5217 -0.0384 -2.6891 -0.2112
S-981	In children, where coronary disease is not the leading cause of heart failure, it is less common.<unk>
T-981	coronary disease ; leading ; heart failure
H-981	-0.5442726016044617	▁corona ry ▁disease ▁; ▁heart ▁failure
D-981	-0.5442726016044617	coronary disease ; heart failure
P-981	-0.6084 -0.1919 -1.1703 -0.1057 -1.7037 -0.0844 -0.3294 -0.1604
S-20	Prospectively, FFM decreased but FM increased, despite stable body weight in CC.<unk>
T-20	prospectively ; ffm ; stable
H-20	-0.6148502826690674	▁f f ▁; ▁FM ▁; ▁body ▁weight ▁; ▁CC
D-20	-0.6148502826690674	ff ; FM ; body weight ; CC
P-20	-0.6892 -0.8381 -0.7297 -1.7781 -0.2583 -0.6778 -0.1109 -0.5371 -0.5556 -0.3267 -0.2617
S-84	Participating in a multihospital study to promote adoption of heart failure guidelines: lessons for nurse leaders.<unk>
T-84	heart failure ; nurse
H-84	-1.1728503704071045	▁multi hospital ▁; ▁heart ▁failure ▁; ▁nurse ▁leaders
D-84	-1.1728503704071045	multihospital ; heart failure ; nurse leaders
P-84	-3.5571 -0.0243 -1.2996 -2.8332 -0.0625 -1.8090 -0.8438 -0.7446 -0.3379 -0.2167
S-248	Protective effects of exercise training (ET) on endothelial function have been demonstrated.<unk>
T-248	exercise ; training ; endothelial function
H-248	-0.5041117668151855	▁exercise ▁training ▁; ET ▁; ▁en dot heli al ▁function
D-248	-0.5041117668151855	exercise training ;ET ; endothelial function
P-248	-2.6044 -0.1829 -0.1864 -0.1594 -0.4679 -0.0469 -1.2992 -0.2336 -0.0321 -0.1930 -0.4210 -0.2226
S-361	However, the degree of MS early after surgery was not significant, with an MVA of 1.8 cm2.<unk>
T-361	surgery ; mva
H-361	-1.2720822095870972	▁MS
D-361	-1.2720822095870972	MS
P-361	-1.4648 -2.1617 -0.1897
S-1931	CONCLUSIONS: Poor social support and high barriers to exercise were associated with lower exercise time.<unk>
T-1931	exercise ; exercise
H-1931	-1.1116993427276611	▁social ▁support ▁; ▁exercise ▁; ▁exercise
D-1931	-1.1116993427276611	social support ; exercise ; exercise
P-1931	-0.6974 -2.0194 -0.1813 -1.8969 -1.7248 -0.8751 -1.2734 -0.2254
S-1446	This appears to be a genuine effect that is not solely a consequence of heart rate variation.<unk>
T-1446	heart rate
H-1446	-0.9925551414489746	▁heart ▁rate ▁variation
D-1446	-0.9925551414489746	heart rate variation
P-1446	-3.3448 -0.0736 -0.5889 -0.5704 -0.3851
S-1769	Participants were divided into age-specific low, moderate, and high CRF categories.<unk>
T-1769	crf
H-1769	-0.5034470558166504	▁c RF
D-1769	-0.5034470558166504	cRF
P-1769	-0.6453 -0.9283 -0.2745 -0.1657
S-688	Mediterranean and DASH diet scores were calculated from food-frequency questionnaires.<unk>
T-688	dash
H-688	-0.7682417035102844	▁Mediterrane an ▁; ▁DAS h
D-688	-0.7682417035102844	Mediterranean ; DASh
P-688	-0.3061 -0.0124 -0.1546 -0.0111 -0.3160 -4.3390 -0.2385
S-1711	OBJECTIVES: To analyze the relationship between length of stay and rehospitalization.<unk>
T-1711	rehospitalization
H-1711	-0.7631320953369141	▁length ▁; ▁re hospital ization
D-1711	-0.7631320953369141	length ; rehospitalization
P-1711	-1.2430 -2.8373 -0.4102 -0.0250 -0.1603 -0.3751 -0.2910
S-412	Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.<unk>
T-412	nitroxyl ; hno ; acute ; heart failure
H-412	-0.564959704875946	▁ni tro x yl ▁; ▁h no ▁; ▁a cute ▁treatment ▁; ▁heart ▁failure
D-412	-0.564959704875946	nitroxyl ; hno ; acute treatment ; heart failure
P-412	-0.2377 -0.1677 -0.5002 -0.5566 -0.1472 -1.8346 -0.3022 -0.3511 -0.5017 -0.0771 -2.1040 -1.3891 -0.2500 -0.1074 -0.3227 -0.1901
S-844	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.<unk>
T-844	cardiac-resynchronization therapy ; heart failure ; narrow qrs complex
H-844	-0.4200483560562134	▁Card iac - re syn chron ization ▁ therapy ▁; ▁heart ▁failure
D-844	-0.4200483560562134	Cardiac-resynchronization therapy ; heart failure
P-844	-0.6076 -0.6197 -0.0569 -0.0882 -0.0616 -0.0061 -0.4627 -1.7002 -0.0655 -0.2011 -0.3507 -0.1386 -1.3616 -0.1603
S-191	Multivariate models were used to compute odds ratios while accounting for hospital clustering.<unk>
T-191	multivariate models ; odds ratios ; accounting ; hospital
H-191	-0.843733012676239	▁odds ▁ratio s ▁; ▁account ing ▁; ▁hospital
D-191	-0.843733012676239	odds ratios ; accounting ; hospital
P-191	-0.9891 -0.0227 -0.0994 -0.2478 -0.0917 -0.0354 -0.5614 -0.1767 -5.9287 -0.2844
S-588	The change in LVET between admission and follow-up measurement was not associated with outcome.<unk>
T-588	change ; lvet ; admission ; follow-up ; outcome
H-588	-0.47725963592529297	▁change ▁; ▁l VET ▁; ▁follow - up ▁measure ment
D-588	-0.47725963592529297	change ; lVET ; follow-up measurement
P-588	-1.2319 -0.3189 -1.8820 -0.1742 -0.2498 -0.5520 -0.1851 -0.0298 -0.1223 -0.1074 -0.6354 -0.2384
S-1636	Blacks had shorter 6-minute walk distance and lower peak VO2 at baseline.<unk>
T-1636	6-minute walk distance ; peak vo2 ; baseline
H-1636	-0.8792460560798645	▁black s ▁; ▁base line
D-1636	-0.8792460560798645	blacks ; baseline
P-1636	-0.4280 -0.1178 -0.3730 -3.9537 -0.1010 -0.6123 -0.5691
S-1412	Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure.<unk>
T-1412	physician ; death ; readmission ; discharge ; patients ; heart failure
H-1412	-0.7943270802497864	▁physician ▁continu ity ▁; ▁death ▁; ▁urgent ▁read mission ▁; ▁dis charge ▁; ▁patients ▁; ▁heart ▁failure
D-1412	-0.7943270802497864	physician continuity ; death ; urgent readmission ; discharge ; patients ; heart failure
P-1412	-1.1871 -1.8397 -0.0149 -0.4093 -3.1423 -0.1546 -1.2205 -1.3949 -0.0745 -0.6217 -0.0345 -0.0683 -0.7586 -1.8883 -1.1280 -0.2860 -0.1751 -0.4132 -0.2809
S-497	HFrEF and HFpEF patients exhibited a similar distribution along the regression line.<unk>
T-497	hfref ; hfpef ; patients ; regression line
H-497	-0.7556705474853516	▁h Fr ef ▁; ▁ HF p EF ▁; ▁re gression ▁line
D-497	-0.7556705474853516	hFref ; HFpEF ; regression line
P-497	-2.2000 -1.7361 -1.8360 -0.0605 -0.1303 -0.6589 -0.0579 -0.8111 -1.2310 -0.4234 -0.0196 -0.3370 -0.6435 -0.4341
S-1573	Hospital-to-Home: a hospital readmission reduction program for congestive heart failure.<unk>
T-1573	hospital-to-home ; hospital ; readmission ; congestive heart failure
H-1573	-0.5429049134254456	▁hospital ▁; ▁read mission ▁re duction ▁program ▁; ▁con ges tive ▁heart ▁failure
D-1573	-0.5429049134254456	hospital ; readmission reduction program ; congestive heart failure
P-1573	-0.3733 -1.9339 -2.5024 -0.3391 -0.0225 -0.0186 -0.4277 -0.4963 -0.0198 -0.1487 -0.1088 -0.8138 -0.1596 -0.5578 -0.2215
S-377	Risk stratification for death and all-cause hospitalization in heart failure clinic outpatients.<unk>
T-377	risk stratification ; death ; all-cause hospitalization ; heart failure ; clinic ; outpatients
H-377	-0.9439604878425598	▁death ▁; ▁hospital ization ▁; ▁heart ▁failure ▁clinic ▁out patient s
D-377	-0.9439604878425598	death ; hospitalization ; heart failure clinic outpatients
P-377	-5.9240 -0.2448 -1.8724 -0.2181 -0.2551 -0.1121 -0.0966 -1.0765 -1.4521 -0.0131 -0.1749 -0.5129 -0.3189
S-132	In patients with diabetes, lower EO-CFUs were associated with improved functional capacity.<unk>
T-132	patients ; diabetes ; eo-cfus ; functional capacity
H-132	-0.7477772235870361	▁diabetes ▁; ▁ EO - C FU s
D-132	-0.7477772235870361	diabetes ; EO-CFUs
P-132	-0.1795 -0.2760 -1.7897 -0.0544 -0.1663 -2.7229 -0.3925 -0.3403 -1.3092 -0.2471
S-1	The effects of more than a decade of national efforts dedicated to improve patient safety remain largely unclear.<unk>
T-1	patient
H-1	-0.9021339416503906	▁patient ▁safety
D-1	-0.9021339416503906	patient safety
P-1	-2.6085 -0.4514 -0.2657 -0.2830
S-2000	At 6 months, 88% of patients continued on support, 4% received transplants, and 8% died.<unk>
T-2000	patients ; transplants
H-2000	-0.49129974842071533	▁transplant s
D-2000	-0.49129974842071533	transplants
P-2000	-0.8205 -0.1597 -0.8564 -0.1286
S-1903	Healthy individuals should engage in 150 minutes of moderate-intensity, aerobic exercise per week.<unk>
T-1903	healthy ; engage ; exercise
H-1903	-0.9331004023551941	▁aero bic ▁exercise
D-1903	-0.9331004023551941	aerobic exercise
P-1903	-2.0212 -0.7077 -1.2895 -0.3047 -0.3424
S-1690	However, individual quality measures are suboptimal in identifying superior and inferior hospitals based on outcome performance.<unk>
T-1690	hospitals ; outcome
H-1690	-1.2411460876464844	▁outcome ▁performance
D-1690	-1.2411460876464844	outcome performance
P-1690	-3.3017 -1.0815 -0.2642 -0.3172
S-671	The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown.<unk>
T-671	chf ; patients
H-671	-0.5085854530334473	▁tras tuz um ab - related ▁CHF
D-671	-0.5085854530334473	trastuzumab-related CHF
P-671	-1.5770 -0.0532 -0.1195 -0.0713 -0.8116 -0.1690 -0.6423 -0.7726 -0.3608
S-1694	We ranked hospitals on the basis of their July 2005 to June 2008 performance on the composite.<unk>
T-1694	hospitals
H-1694	-0.588034987449646	▁hospital s
D-1694	-0.588034987449646	hospitals
P-1694	-1.2947 -0.2277 -0.6840 -0.1457
S-1498	RESULTS: Peak VO2 was 1.9±0.1 L/min (66±3% of predicted values).<unk>
T-1498	peak vo2
H-1498	-0.5796131491661072	▁Peak ▁VO 2
D-1498	-0.5796131491661072	Peak VO2
P-1498	-0.1512 -0.5200 -0.3674 -1.6467 -0.2127
S-948	Multiple procedures and pharmaceutically assisted success rate was 73% (n = 54).<unk>
T-948	pharmaceutically
H-948	-0.7949586510658264	▁procedure s ▁; ▁ pharma ce ut ically
D-948	-0.7949586510658264	procedures ; pharmaceutically
P-948	-2.8374 -0.1127 -0.2969 -0.3957 -0.0079 -0.2045 -2.4340 -0.1207 -1.4066 -0.1332
S-1955	FINDINGS: Between Oct 10, 2013, and March 27, 2015, we enrolled ten patients.<unk>
T-1955	patients
H-1955	-1.0873546600341797	▁financial s
D-1955	-1.0873546600341797	financials
P-1955	-1.6865 -0.8321 -1.5984 -0.2324
S-1182	Coronary artery disease (CAD) is a major cause of systolic heart failure (HF).<unk>
T-1182	coronary artery disease ; cad ; systolic heart failure ; hf
H-1182	-0.2618039548397064	▁Corona ry ▁arter y ▁disease ▁; CAD ▁; ▁sy sto lic ▁heart ▁failure ▁; HF
D-1182	-0.2618039548397064	Coronary artery disease ;CAD ; systolic heart failure ;HF
P-1182	-0.0356 -0.0763 -0.1331 -0.0714 -0.9196 -0.1461 -0.1956 -0.1662 -0.3635 -0.0157 -0.6230 -0.6905 -0.0798 -0.4593 -0.0169 -0.3507 -0.1075
S-538	In conclusion, preoperative hypoalbuminemia is associated with poor prognosis after LVAD surgery.<unk>
T-538	preoperative ; hypoalbuminemia ; prognosis ; lvad ; surgery
H-538	-0.33399736881256104	▁pre operativ e ▁hypo album in emia ▁; ▁l VAD ▁surgery
D-538	-0.33399736881256104	preoperative hypoalbuminemia ; lVAD surgery
P-538	-0.2990 -0.0131 -0.0837 -0.3254 -0.2856 -0.1884 -0.2743 -0.1540 -1.6270 -0.1066 -0.5792 -0.2069 -0.1989
S-1554	Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.<unk>
T-1554	psoriasis ; atherosclerosis ; cardiovascular events ; rotterdam study
H-1554	-0.534359872341156	▁p sori asis ▁; ▁at hero sc ler osis ▁; ▁incident ▁cardiovascular ▁events ▁; ▁Rotterdam
D-1554	-0.534359872341156	psoriasis ; atherosclerosis ; incident cardiovascular events ; Rotterdam
P-1554	-1.2818 -0.1014 -0.1438 -0.0728 -0.1793 -0.7167 -0.3142 -2.6585 -0.1053 -0.1399 -0.3393 -0.4461 -0.0946 -0.7279 -0.0512 -1.5348 -0.1764
S-125	We recorded mortality, HF hospital admissions, transplant, and ventricular assist device.<unk>
T-125	mortality ; hf ; hospital ; admissions ; transplant ; ventricular assist device
H-125	-0.4923971891403198	▁mortal ity ▁; ▁ HF ▁hospital ▁ad missions ▁; ▁transplant ▁; ▁vent ri cular ▁assist ▁device
D-125	-0.4923971891403198	mortality ; HF hospital admissions ; transplant ; ventricular assist device
P-125	-1.2550 -0.0331 -0.3208 -1.1447 -0.0784 -1.1477 -0.1399 -0.0092 -0.1394 -0.0263 -0.4564 -1.1167 -0.8863 -0.1540 -0.8905 -0.3190 -0.5273 -0.2183
S-600	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.<unk>
T-600	heart failure ; patients ; rheumatoid arthritis ; tnf antagonist
H-600	-0.5488750338554382	▁Heart ▁failure ▁risk ▁; ▁rhe um ato id ▁ar thri tis ▁; ▁t NF ▁anta gon ist
D-600	-0.5488750338554382	Heart failure risk ; rheumatoid arthritis ; tNF antagonist
P-600	-0.2104 -0.0744 -1.2396 -0.3225 -1.3494 -0.0402 -0.8157 -1.6469 -0.2283 -0.6393 -0.5405 -0.5297 -0.3335 -0.1947 -0.7930 -0.3238 -0.2717 -0.6606 -0.2144
S-342	He had grade 4/6 holosystolic murmur and a third heart sound in the apex.<unk>
T-342	grade ; holosystolic murmur ; third heart sound ; apex
H-342	-0.39976227283477783	▁holo sy sto lic ▁mur mur ▁; ▁third ▁heart ▁sound
D-342	-0.39976227283477783	holosystolic murmur ; third heart sound
P-342	-0.0435 -0.9693 -0.2562 -0.5468 -0.7669 -0.0606 -0.1612 -0.0471 -1.1149 -0.1312 -0.4814 -0.2180
S-815	CV events were defined as CV death, non-fatal stroke and hospitalisation for heart failure.<unk>
T-815	death ; stroke ; hospitalisation ; heart failure
H-815	-0.5519946217536926	▁CV ▁; ▁death ▁; ▁non - fa tal ▁stroke ▁; ▁hospital isation ▁; ▁heart ▁failure
D-815	-0.5519946217536926	CV ; death ; non-fatal stroke ; hospitalisation ; heart failure
P-815	-1.1329 -0.8085 -4.2000 -0.1752 -0.1082 -0.0564 -0.3117 -0.0660 -0.8008 -0.1553 -0.3537 -0.0131 -0.4119 -0.0983 -0.0541 -0.3537 -0.2840
S-1039	The remodelling that precedes HF is induced by haemodynamic and neuronal stressors.<unk>
T-1039	remodelling ; hf ; haemodynamic ; neuronal stressors
H-1039	-0.3880501389503479	▁ HF ▁; ▁ha emo dynamic ▁; ▁neuron al ▁stress ors
D-1039	-0.3880501389503479	HF ; haemodynamic ; neuronal stressors
P-1039	-2.4196 -0.2390 -0.2558 -0.0085 -0.6451 -0.0279 -0.1482 -0.2311 -0.0663 -0.1398 -0.0791 -0.5850 -0.1991
S-1012	CONCLUSION: The deficit index and the biological phenotype equally predict mortality.<unk>
T-1012	deficit index ; biological phenotype ; mortality
H-1012	-0.7421382069587708	▁deficit ▁index ▁; ▁bi ological ▁; ▁mortal ity
D-1012	-0.7421382069587708	deficit index ; biological ; mortality
P-1012	-1.9006 -0.2872 -0.1669 -0.0740 -0.0662 -2.4519 -1.9641 -0.0734 -0.1769 -0.2602
S-1157	Relationships between right ventricular function, body composition, and prognosis in advanced heart failure.<unk>
T-1157	right ventricular function ; prognosis ; heart failure
H-1157	-0.8498123288154602	▁right ▁vent ri cular ▁function ▁; ▁body ▁composition ▁; ▁advanced ▁heart ▁failure
D-1157	-0.8498123288154602	right ventricular function ; body composition ; advanced heart failure
P-1157	-0.0612 -3.7374 -1.4122 -0.4279 -1.0795 -0.3421 -0.3023 -0.3425 -0.2084 -2.2926 -0.8536 -0.2416 -0.3637 -0.2323
S-1457	Fat, cachexia, and the right ventricle in heart failure: a web of complicity.<unk>
T-1457	cachexia ; right ventricle ; heart failure
H-1457	-0.6220239400863647	▁Fat ▁; ▁cache xia ▁; ▁right ▁vent ric le ▁; ▁heart ▁failure
D-1457	-0.6220239400863647	Fat ; cachexia ; right ventricle ; heart failure
P-1457	-0.8178 -0.6085 -0.0414 -0.4277 -0.1931 -0.0076 -1.7575 -2.7839 -0.6108 -0.3314 -0.1467 -0.1106 -0.6574 -0.2140
S-1231	BACKGROUND: Atrial fibrillation (AF) is common in patients with heart failure.<unk>
T-1231	atrial fibrillation ; patients ; heart failure
H-1231	-0.4149722158908844	▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure
D-1231	-0.4149722158908844	atrial fibrillation ;AF ; heart failure
P-1231	-1.0741 -0.0289 -0.5794 -0.0376 -0.8582 -0.5438 -0.2214 -0.5101 -0.3989 -0.0913 -0.4422 -0.1937
S-718	CONCLUSIONS: ECCT is an acceptable alternative for advanced heart failure therapy in select patients.<unk>
T-718	ecct ; heart failure ; therapy ; patients
H-718	-0.7126997709274292	▁ec CT ▁; ▁advanced ▁heart ▁failure ▁ therapy
D-718	-0.7126997709274292	ecCT ; advanced heart failure therapy
P-718	-0.5337 -3.1172 -0.2432 -0.5421 -1.2260 -0.0548 -0.5606 -0.0633 -0.6033 -0.1829
S-306	Should eligibility for heart transplantation be a requirement for left ventricular assist device use?<unk>
T-306	heart transplantation ; left ventricular assist device
H-306	-1.1593637466430664	▁e ligi bility ▁; ▁heart ▁transplant ation ▁; ▁left ▁vent ri cular ▁assist ▁device
D-306	-1.1593637466430664	eligibility ; heart transplantation ; left ventricular assist device
P-306	-4.3651 -0.0104 -0.0851 -0.2870 -0.9611 -0.3196 -0.7120 -0.2792 -0.5539 -2.6764 -2.2085 -0.4474 -2.6920 -0.9845 -1.7453 -0.2226
S-1273	Exercise intolerance is a hallmark feature of chronic heart failure and is associated with poor prognosis.<unk>
T-1273	exercise intolerance ; chronic heart failure ; prognosis
H-1273	-0.47850462794303894	▁exercise ▁in tolerance ▁; ▁chronic ▁heart ▁failure
D-1273	-0.47850462794303894	exercise intolerance ; chronic heart failure
P-1273	-0.4970 -0.0633 -0.0521 -0.2718 -0.5278 -1.5732 -0.1382 -0.9699 -0.2134
S-328	During AVD and VVD variations, CO was associated with free wall RS (P < 0.008).<unk>
T-328	avd ; vvd ; free wall rs
H-328	-0.4049198627471924	▁AV d ▁; ▁VVD ▁; ▁free ▁wall ▁RS
D-328	-0.4049198627471924	AVd ; VVD ; free wall RS
P-328	-0.3547 -0.6036 -0.0856 -0.3305 -0.3683 -0.1062 -0.6066 -1.0903 -0.3069 -0.1965
S-929	Recent clinical studies have connected elevated resistin levels with the development and severity of heart failure.<unk>
T-929	clinical ; connected ; elevated ; resistin ; heart failure
H-929	-1.1050785779953003	▁clinic al ▁; ▁resist in ▁levels ▁; ▁heart ▁failure
D-929	-1.1050785779953003	clinical ; resistin levels ; heart failure
P-929	-3.0091 -0.0609 -1.4281 -4.9499 -1.1726 -0.1842 -0.1727 -0.6082 -0.1550 -0.2661 -0.1490
S-884	All baseline ECGs were reviewed by a panel of 3 experienced electrocardiographers.<unk>
T-884	baseline ; ecgs ; electrocardiographers
H-884	-0.6259371042251587	▁base line ▁e CG s ▁; ▁electro car dio graph ers
D-884	-0.6259371042251587	baseline eCGs ; electrocardiographers
P-884	-0.0009 -0.0269 -2.5704 -0.6756 -0.1521 -0.3012 -0.0368 -0.6714 -1.7793 -0.9049 -0.2217 -0.6136 -0.1823
S-293	Survival after left ventricular assist device with and without temporary right ventricular support.<unk>
T-293	left ventricular assist device ; right ventricular support
H-293	-0.8997710943222046	▁Sur vi val ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁right ▁vent ri cular ▁support
D-293	-0.8997710943222046	Survival ; left ventricular assist device ; right ventricular support
P-293	-5.5479 -0.0485 -0.0278 -0.3338 -0.0383 -1.8155 -0.5606 -0.1409 -1.5877 -0.6892 -0.2278 -0.0367 -2.1211 -0.9683 -0.1617 -1.0807 -0.6338 -0.1754
S-388	Therefore, we examined incidence and predictors of ESRD in outpatients with HF.<unk>
T-388	incidence ; esrd ; outpatients ; hf
H-388	-0.5101244449615479	▁incide nce ▁; ▁ES RD ▁; ▁out patient s ▁; ▁ HF
D-388	-0.5101244449615479	incidence ; ESRD ; outpatients ; HF
P-388	-0.3999 -0.1800 -0.1699 -1.9341 -2.0837 -0.1852 -0.0444 -0.0154 -0.0712 -0.5621 -0.5038 -0.0971 -0.5471 -0.3478
S-923	Wilcoxon matched-pairs signed-rank tests were used for pre-post comparisons.<unk>
T-923	wilcoxon matched-pairs signed-rank tests
H-923	-0.4916321039199829	▁Wil co xon ▁; ▁signed - rank ▁tests
D-923	-0.4916321039199829	Wilcoxon ; signed-rank tests
P-923	-1.1736 -0.0050 -0.8227 -1.0685 -0.7522 -0.0730 -0.0267 -0.1153 -0.5848 -0.2945
S-1557	Adjusted means were calculated for subclinical atherosclerosis using general linear models.<unk>
T-1557	subclinical ; atherosclerosis ; linear models
H-1557	-0.8819575309753418	▁sub clin ical ▁at hero sc ler osis ▁; ▁general ▁linear ▁models
D-1557	-0.8819575309753418	subclinical atherosclerosis ; general linear models
P-1557	-2.6211 -0.1210 -0.0286 -0.7658 -1.9244 -0.4484 -4.1732 -0.1694 -0.7908 -0.0057 -0.0451 -0.3600 -0.5056 -0.3882
S-1593	Renal artery stenosis (RAS) is a common form of peripheral arterial disease.<unk>
T-1593	renal artery stenosis ; ras ; peripheral arterial disease
H-1593	-0.17740526795387268	▁Ren al ▁arter y ▁sten osis ▁; RAS ▁; ▁per i pher al ▁arterial ▁disease
D-1593	-0.17740526795387268	Renal artery stenosis ;RAS ; peripheral arterial disease
P-1593	-0.0655 -0.0284 -0.0752 -0.1047 -0.0613 -0.0704 -0.2215 -0.0303 -0.2926 -0.0241 -0.1498 -0.0063 -0.0806 -0.1786 -1.0470 -0.3450 -0.2345
S-711	Baseline characteristics and outcomes were compared between ECCT and standard criteria cardiac transplant recipients.<unk>
T-711	baseline ; outcomes ; ecct ; cardiac transplant
H-711	-0.8497267961502075	▁ec CT ▁; ▁cardiac ▁transplant ▁recipient s
D-711	-0.8497267961502075	ecCT ; cardiac transplant recipients
P-711	-1.6596 -4.1746 -0.1858 -0.3699 -0.1592 -0.1958 -0.2613 -0.3796 -0.2618
S-1227	Eplerenone was effective in reducing the primary composite endpoint in all subgroups.<unk>
T-1227	eplerenone ; primary composite endpoint
H-1227	-0.39627334475517273	▁e pler en one ▁; ▁primary ▁com posit e ▁end point
D-1227	-0.39627334475517273	eplerenone ; primary composite endpoint
P-1227	-0.6027 -0.0026 -0.2838 -0.0261 -0.6072 -0.9654 -0.8871 -0.0067 -0.0778 -0.2194 -0.3178 -0.8800 -0.2751
S-599	The patient had an uneventful recovery and was asymptomatic after 6 months of follow-up.<unk>
T-599	patient ; asymptomatic ; follow-up
H-599	-0.9618334174156189	▁recovery
D-599	-0.9618334174156189	recovery
P-599	-1.7417 -0.9805 -0.1634
S-777	The patients were extubated within 3 to 6 hours, and blood loss and transfusion requirements were nominal.<unk>
T-777	patients ; extubated ; blood ; transfusion
H-777	-0.4850313663482666	▁ex tuba ted ▁; ▁blood ▁loss ▁; ▁trans fusion
D-777	-0.4850313663482666	extubated ; blood loss ; transfusion
P-777	-0.2125 -0.0449 -0.3556 -0.3980 -2.1120 -0.0314 -0.3438 -0.0129 -0.1377 -1.4009 -0.2856
S-776	We have used this technique to exchange malfunctioning HeartMate II LVADs in 14 consecutive patients.<unk>
T-776	heartmate ii ; lvads ; patients
H-776	-0.9022727608680725	▁exchange ▁mal function ing ▁Heart Mate ▁II ▁l VAD s
D-776	-0.9022727608680725	exchange malfunctioning HeartMate II lVADs
P-776	-2.7979 -0.3746 -0.5062 -0.1384 -1.2815 -0.1171 -1.1419 -2.4448 -0.1719 -0.1856 -1.3432 -0.3243
S-1074	Heart failure (HF) is the most common cause of cardiovascular hospitalization, especially among the elderly.<unk>
T-1074	heart failure ; hf ; cardiovascular ; hospitalization
H-1074	-0.46950531005859375	▁Heart ▁failure ▁; HF ▁; ▁cardiovascular ▁hospital ization
D-1074	-0.46950531005859375	Heart failure ;HF ; cardiovascular hospitalization
P-1074	-0.6453 -0.0235 -0.2166 -0.0857 -0.4992 -0.7968 -0.7276 -0.2363 -1.2535 -0.2105
S-458	Moreover, VEGF inhibition counteracted the positive effects of B on cardiac function and remodeling.<unk>
T-458	vegf inhibition ; cardiac function ; remodeling
H-458	-0.5048221349716187	▁ve GF ▁inhibi tion ▁; ▁b ▁; ▁cardiac ▁function ▁; ▁remodel ing
D-458	-0.5048221349716187	veGF inhibition ; b ; cardiac function ; remodeling
P-458	-0.7346 -1.5896 -0.2486 -0.0567 -0.2886 -1.1313 -0.7262 -0.0710 -0.3434 -1.2896 -0.0805 -0.0462 -0.3340 -0.1273
S-400	We recently found changing doses of β-blocker (BB) may affect sST2 concentrations.<unk>
T-400	changing ; β-blocker ; sst2
H-400	-0.7178294062614441	▁β - block er ▁; BB ▁; ▁s st 2
D-400	-0.7178294062614441	β-blocker ;BB ; sst2
P-400	-1.4752 -0.0972 -0.4399 -0.4279 -0.3706 -0.2731 -0.5400 -0.0036 -3.2859 -0.3190 -1.0953 -0.2863
S-1484	Here, we give an overview of these miRNAs and their role in cardiac pathogenesis.<unk>
T-1484	mirnas ; cardiac ; pathogenesis
H-1484	-0.22396475076675415	▁mi RNA s ▁; ▁cardiac ▁path ogen es is
D-1484	-0.22396475076675415	miRNAs ; cardiac pathogenesis
P-1484	-0.3552 -0.0302 -0.0569 -0.1441 -0.1763 -0.1713 -0.1496 -0.1318 -0.9014 -0.1966 -0.1503
S-1884	CONCLUSION: The CPET guiding exercise rehabilitation is safe and effective for patients with CHF.<unk>
T-1884	cpet ; exercise rehabilitation ; patients ; chf
H-1884	-0.6229398846626282	▁c PET ▁gu iding ▁exercise ▁rehabilita tion ▁; ▁CHF
D-1884	-0.6229398846626282	cPET guiding exercise rehabilitation ; CHF
P-1884	-0.5451 -1.9765 -1.5143 -0.0110 -0.6018 -0.8808 -0.0903 -0.3510 -0.3420 -0.3667 -0.1729
S-1203	The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.<unk>
T-1203	patient ; heart failure with reduced ejection fraction
H-1203	-0.6711950302124023	▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1203	-0.6711950302124023	heart failure ; ejection fraction
P-1203	-3.4120 -0.0961 -0.3011 -0.6921 -0.1784 -0.1271 -0.7111 -0.0097 -0.9873 -0.1972
S-732	Patients with heart failure were complex and often had diagnostic testing and medication changes at follow-up visits.<unk>
T-732	patients ; heart failure ; diagnostic ; medication ; follow-up
H-732	-1.0223159790039062	▁heart ▁failure ▁; ▁medication
D-732	-1.0223159790039062	heart failure ; medication
P-732	-2.6639 -0.1887 -1.3664 -0.9829 -0.6206 -0.3114
S-199	Pediatric heart failure (HF) is an important cause of morbidity and mortality in childhood.<unk>
T-199	heart failure ; hf ; morbidity ; mortality
H-199	-0.33413785696029663	▁Pediatri c ▁heart ▁failure ▁; HF ▁; ▁morbi d ity ▁; ▁mortal ity
D-199	-0.33413785696029663	Pediatric heart failure ;HF ; morbidity ; mortality
P-199	-0.3216 -0.0498 -1.3811 -0.0428 -0.1911 -0.1169 -0.8922 -0.1820 -0.0826 -0.0598 -0.6551 -0.0119 -0.0209 -0.8041 -0.2001
S-1429	Further, the expression of type I regulatory subunit (RI) was increased in HF.<unk>
T-1429	expression ; type i regulatory subunit ; ri ; hf
H-1429	-0.8281139731407166	▁regulator y ▁; RI ▁; ▁ HF
D-1429	-0.8281139731407166	regulatory ;RI ; HF
P-1429	-1.0836 -0.0925 -2.8989 -1.9595 -0.3426 -0.3004 -0.2657 -0.2579 -0.2518
S-730	Only 13% of patients had no discrepancy between the discharge and follow-up medication lists.<unk>
T-730	patients ; discharge ; follow-up ; medication
H-730	-0.42973873019218445	▁dis charge ▁; ▁follow - up ▁medication
D-730	-0.42973873019218445	discharge ; follow-up medication
P-730	-0.4644 -0.1189 -0.2854 -0.1171 -0.2083 -0.0216 -0.3001 -2.0925 -0.2593
S-1042	However, the role of 'readers' (bromodomain proteins) was less well defined.<unk>
T-1042	bromodomain proteins
H-1042	-0.6967672109603882	bro modo main ▁protein s
D-1042	-0.6967672109603882	bromodomain proteins
P-1042	-2.9911 -0.4633 -0.1008 -0.5349 -0.0522 -0.4942 -0.2408
S-532	Preoperative clinical characteristics and laboratory variables associated with mortality were analyzed.<unk>
T-532	preoperative ; clinical ; mortality
H-532	-0.9581891298294067	▁pre operativ e ▁; ▁mortal ity
D-532	-0.9581891298294067	preoperative ; mortality
P-532	-2.2817 -0.0055 -0.5186 -1.8417 -2.4460 -0.0958 -0.1854 -0.2908
S-1030	Measuring heart failure care by 30-day readmission: Rethinking the quality of outcome measures.<unk>
T-1030	heart failure ; readmission ; outcome
H-1030	-0.8615483641624451	▁heart ▁failure ▁; ▁read mission
D-1030	-0.8615483641624451	heart failure ; readmission
P-1030	-0.6765 -0.0275 -1.0665 -2.5463 -0.0438 -1.4858 -0.1843
S-315	We found that BTT and DT as implantation strategies tend to be no longer mutually exclusive.<unk>
T-315	btt ; dt ; implantation
H-315	-0.6645711660385132	▁b t ▁; ▁ DT
D-315	-0.6645711660385132	bt ; DT
P-315	-0.9926 -0.6562 -0.3348 -0.0459 -0.7402 -1.6225 -0.2600
S-566	Fatal and nonfatal outcomes were discordant, with better survival despite higher hospitalization rates.<unk>
T-566	outcomes ; hospitalization
H-566	-0.8339658975601196	▁Fa tal ▁; ▁non fa tal ▁outcome s ▁; ▁hospital ization ▁rates
D-566	-0.8339658975601196	Fatal ; nonfatal outcomes ; hospitalization rates
P-566	-3.3973 -0.0917 -0.6718 -0.0891 -0.7494 -0.6545 -0.3706 -0.1100 -0.7649 -2.0009 -0.2254 -2.0311 -0.2661 -0.2529
S-1970	The treatment was safe, typical adverse event was hypotension, however without a need to interrupt the treatment.<unk>
T-1970	adverse event ; hypotension
H-1970	-1.2623214721679688	▁hypo tension
D-1970	-1.2623214721679688	hypotension
P-1970	-3.2968 -0.7462 -0.7912 -0.2151
S-1475	However, the use of biomarkers in the treatment of HF remains in its infancy.<unk>
T-1475	biomarkers ; hf
H-1475	-0.46166732907295227	▁bio mark ers ▁; ▁ HF
D-1475	-0.46166732907295227	biomarkers ; HF
P-1475	-0.9767 -0.0373 -0.1270 -0.1397 -1.7496 -0.1717 -0.2309 -0.2606
S-288	RESULTS: Over a mean follow-up of 10.4 years, 970 participants developed incident HF.<unk>
T-288	follow-up ; hf
H-288	-0.9404513239860535	▁incident ▁ HF
D-288	-0.9404513239860535	incident HF
P-288	-1.7595 -2.1941 -0.2960 -0.2553 -0.1973
S-699	ST2 was analyzed in a subset of 910 patients with evaluable plasma samples.<unk>
T-699	st2 ; patients ; plasma
H-699	-0.6825211644172668	▁ST 2 ▁; ▁plasma ▁sample s
D-699	-0.6825211644172668	ST2 ; plasma samples
P-699	-0.7705 -0.1064 -0.5320 -2.9431 -0.5173 -0.0904 -0.3083 -0.1921
S-1575	In addition to indicating possible suboptimal care of patients with this condition, there are significant economic considerations.<unk>
T-1575	patients ; condition ; economic
H-1575	-0.6055126786231995	▁economic
D-1575	-0.6055126786231995	economic
P-1575	-1.1256 -0.4008 -0.2901
S-1121	Reasons for not prescribing guideline-recommended medications to adults with heart failure.<unk>
T-1121	prescribing ; medications ; heart failure
H-1121	-0.8660841584205627	▁pre scribi ng ▁guide line - re com mend ed ▁medication s ▁; ▁heart ▁failure
D-1121	-0.8660841584205627	prescribing guideline-recommended medications ; heart failure
P-1121	-7.9335 -0.2745 -0.0296 -1.2557 -0.0261 -0.4372 -0.0567 -0.2287 -0.0100 -0.1052 -0.1631 -0.0693 -0.4929 -2.5829 -0.0719 -0.6447 -0.3414
S-1667	This patient population has a 1-year mortality rate of approximately 50% and requires special therapeutic interventions.<unk>
T-1667	patient ; mortality ; therapeutic
H-1667	-1.0165607929229736	▁mortal ity ▁rate
D-1667	-1.0165607929229736	mortality rate
P-1667	-2.2877 -0.0338 -0.2375 -2.3128 -0.2110
S-1564	The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately.<unk>
T-1564	coronary heart disease ; stroke ; heart failure
H-1564	-0.4300197958946228	▁corona ry ▁heart ▁disease ▁; ▁stroke ▁; ▁heart ▁failure
D-1564	-0.4300197958946228	coronary heart disease ; stroke ; heart failure
P-1564	-0.4733 -0.0887 -1.1253 -1.5197 -0.1683 -0.1769 -0.2100 -0.4349 -0.1063 -0.2384 -0.1885
S-1991	Neither intervention had a significant effect on quality of life as measured by the MLHF Questionnaire.<unk>
T-1991	quality of life ; mlhf questionnaire
H-1991	-1.2631548643112183	▁quality ▁of ▁life ▁; ML HF
D-1991	-1.2631548643112183	quality of life ;MLHF
P-1991	-4.2715 -0.1969 -0.2274 -0.1543 -2.0744 -1.2312 -1.5733 -0.3762
S-984	Most of these lesions, such as septal defects, are amenable to surgical intervention.<unk>
T-984	lesions ; septal ; surgical
H-984	-0.4954025149345398	▁sept al ▁defect s ▁; ▁sur g ical
D-984	-0.4954025149345398	septal defects ; surgical
P-984	-1.3279 -0.0796 -0.0602 -0.0467 -0.8349 -0.2274 -0.1000 -0.0284 -2.0639 -0.1851
S-61	We conducted a meta-analysis to identify factors associated with mortality in ICD-HF patients.<unk>
T-61	meta-analysis ; mortality ; patients
H-61	-0.9780864119529724	▁mortal ity ▁; ▁i CD - HF
D-61	-0.9780864119529724	mortality ; iCD-HF
P-61	-3.3732 -0.0773 -0.3287 -0.2260 -1.6960 -0.1651 -0.1881 -2.2052 -0.5431
S-1369	Unilateral renal denervation improves autonomic balance in conscious rabbits with chronic heart failure.<unk>
T-1369	unilateral renal denervation ; autonomic balance ; chronic heart failure
H-1369	-0.5513729453086853	▁Uni lateral ▁renal ▁den er va tion ▁; ▁autonomi c ▁balance ▁; ▁rabbi ts ▁; ▁chronic ▁heart ▁failure
D-1369	-0.5513729453086853	Unilateral renal denervation ; autonomic balance ; rabbits ; chronic heart failure
P-1369	-2.8039 -0.0023 -0.0636 -0.0903 -0.4011 -2.5575 -0.1160 -0.1566 -0.0653 -0.9422 -0.0144 -0.2131 -0.5405 -0.0101 -0.1246 -1.0968 -1.0275 -0.2286 -0.3443 -0.2289
S-1468	The treatment aims are to stabilize the patient, improve clinical symptoms, and increase long-term survival rates.<unk>
T-1468	patient ; clinical ; symptoms
H-1468	-1.580888271331787	
D-1468	-1.580888271331787	
P-1468	-3.0179 -0.1439
S-676	In total, 9,535 patients were included, of whom 2,203 (23.1%) received trastuzumab.<unk>
T-676	patients ; trastuzumab
H-676	-0.15425121784210205	▁tras tuz um ab
D-676	-0.15425121784210205	trastuzumab
P-676	-0.3264 -0.0519 -0.0292 -0.0151 -0.2865 -0.2164
S-1454	Seventy-seven cases with pre-HCT germline DNA and 178 controls were genotyped.<unk>
T-1454	dna ; genotyped
H-1454	-0.7011253833770752	▁pre - H CT ▁germ line ▁DNA ▁; ▁geno type d
D-1454	-0.7011253833770752	pre-HCT germline DNA ; genotyped
P-1454	-0.9148 -0.0166 -2.3967 -1.7447 -0.0532 -0.0537 -0.2498 -0.6978 -0.0981 -0.2015 -1.8433 -0.6098 -0.2346
S-2008	BACKGROUND: Heart failure disease management programs can influence medical resource use and quality-adjusted survival.<unk>
T-2008	heart failure ; disease ; medical
H-2008	-0.7446293830871582	▁Heart ▁failure ▁disease ▁; ▁medical ▁resource ▁; ▁survival
D-2008	-0.7446293830871582	Heart failure disease ; medical resource ; survival
P-2008	-0.6715 -0.0988 -1.6413 -1.2491 -0.3033 -0.4954 -1.0817 -1.6201 -0.1267 -0.1584
S-1381	Renal DNx also prevented the increase in circulating plasma NE seen in CHF-INV rabbits.<unk>
T-1381	renal dnx ; plasma
H-1381	-0.37831974029541016	▁Ren al ▁DN x ▁; ▁circula ting ▁plasma ▁NE ▁; ▁CHF - in v ▁rabbi ts
D-1381	-0.37831974029541016	Renal DNx ; circulating plasma NE ; CHF-inv rabbits
P-1381	-0.0895 -0.0091 -0.3641 -0.1831 -0.1965 -0.7604 -0.1636 -0.1687 -2.1684 -0.3115 -0.5011 -0.1396 -0.2346 -0.7386 -0.0699 -0.0438 -0.4493 -0.2181
S-627	During a median follow up of 11.4 (7.1-11.7) years, 466 participants developed HF.<unk>
T-627	follow up ; hf
H-627	-0.7242572903633118	▁ HF
D-627	-0.7242572903633118	HF
P-627	-2.0723 -0.3270 -0.2482 -0.2495
S-729	Fifty-one percent of patients had blood work drawn, and 26% had a medication dose changed.<unk>
T-729	patients ; blood ; medication
H-729	-1.0962214469909668	▁blood ▁work ▁draw n ▁; ▁medication
D-729	-1.0962214469909668	blood work drawn ; medication
P-729	-4.4611 -0.4011 -1.1145 -0.2386 -0.5524 -0.5519 -1.1307 -0.3195
S-1021	Studies and subsequent meta-analyses are mixed on the absolute value of routine NP assessment of ED patients.<unk>
T-1021	meta-analyses ; patients
H-1021	-0.5123853087425232	▁ NP ▁assessment ▁; ▁ED
D-1021	-0.5123853087425232	NP assessment ; ED
P-1021	-1.0543 -0.0781 -0.1600 -0.2954 -0.2810 -1.4787 -0.2392
S-1778	BACKGROUND: Cardiac hypertrophy is accompanied by significant alterations in energy metabolism.<unk>
T-1778	cardiac hypertrophy ; energy metabolism
H-1778	-0.3951701521873474	▁Card iac ▁hyper trop hy ▁; ▁energy ▁metabolism
D-1778	-0.3951701521873474	Cardiac hypertrophy ; energy metabolism
P-1778	-1.5095 -0.1415 -0.2796 -0.0841 -1.1523 -0.1625 -0.0282 -0.0865 -0.3571 -0.1503
S-531	We studied 272 consecutive patients undergoing LVAD implantation from 2000 to 2010 at our institution.<unk>
T-531	patients ; lvad ; implantation
H-531	-0.8116927742958069	▁l VAD ▁implant ation
D-531	-0.8116927742958069	lVAD implantation
P-531	-2.2478 -0.3721 -0.5375 -0.1207 -1.3621 -0.2299
S-252	HDL-bound malondialdehyde and HDL-induced NO production by EC were quantified.<unk>
T-252	malondialdehyde
H-252	-0.7877683043479919	▁HD l - bound ▁malo ndi alde hy de ▁; ▁HD l - indu ced ▁NO ▁production ▁; ▁ec
D-252	-0.7877683043479919	HDl-bound malondialdehyde ; HDl-induced NO production ; ec
P-252	-0.7870 -2.1121 -0.0549 -0.0248 -0.3301 -0.2264 -0.2641 -3.2956 -0.8519 -0.1309 -0.5829 -2.0827 -0.0522 -0.0214 -0.5624 -2.4777 -0.0274 -1.0370 -1.0478 -0.4120 -0.1618
S-719	Age and renal dysfunction are important determinants of long-term survival and post-transplant morbidity.<unk>
T-719	renal dysfunction ; morbidity
H-719	-0.39102327823638916	▁Age ▁; ▁renal ▁dys function ▁; ▁post - trans plant ▁morbi d ity
D-719	-0.39102327823638916	Age ; renal dysfunction ; post-transplant morbidity
P-719	-0.8333 -0.5893 -0.0096 -0.2690 -1.8053 -0.2865 -0.1980 -0.0323 -0.0315 -0.1394 -0.3961 -0.4274 -0.3398 -0.2970 -0.2109
S-1189	Of the 124 patients in the derivation cohort, 27% had CAD, including 15% with severe CAD.<unk>
T-1189	patients ; cad ; cad
H-1189	-0.5359840393066406	▁deriva tion ▁co hor t ▁; ▁CAD ▁; ▁severe ▁CAD
D-1189	-0.5359840393066406	derivation cohort ; CAD ; severe CAD
P-1189	-1.9496 -0.0345 -0.0543 -1.0699 -0.4309 -0.2297 -0.5520 -0.3828 -0.6364 -0.7279 -0.1684 -0.1953
S-154	DATA EXTRACTION: Data were extracted and validity was assessed independently by two reviewers.<unk>
T-154	
H-154	-0.7953721880912781	
D-154	-0.7953721880912781	
P-154	-1.4809 -0.1098
S-1874	RESULTS: One hundred forty-six patients were randomized, 70 to control and 76 to treatment.<unk>
T-1874	patients ; randomized
H-1874	-0.6739375591278076	
D-1874	-0.6739375591278076	
P-1874	-1.1570 -0.1908
S-302	Survival to hospital discharge was not different between groups (95.2 versus 88.2%; p = 0.2).<unk>
T-302	hospital ; discharge
H-302	-0.7455727458000183	▁Sur vi val ▁; ▁hospital ▁dis charge
D-302	-0.7455727458000183	Survival ; hospital discharge
P-302	-3.9197 -0.0505 -0.0862 -0.7325 -1.0216 -0.2508 -0.1038 -0.3618 -0.1832
S-1713	SETTING: Six thousand five hundred thirty-seven hospitals nationwide from January 1999 through September 2005.<unk>
T-1713	hospitals
H-1713	-0.6442713141441345	▁hospital s
D-1713	-0.6442713141441345	hospitals
P-1713	-1.5712 -0.5500 -0.2667 -0.1893
S-40	Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease.<unk>
T-40	anemia ; heart disease
H-40	-0.8518415093421936	▁an emia ▁; ▁heart ▁disease
D-40	-0.8518415093421936	anemia ; heart disease
P-40	-0.7544 -0.3899 -0.3057 -2.9491 -0.8557 -0.4007 -0.3074
S-592	Right atrial myxoma complicated by pulmonary embolism and revealed by right heart failure.<unk>
T-592	right atrial myxoma ; pulmonary embolism ; right heart failure
H-592	-0.3374635577201843	▁right ▁at rial ▁my xo ma ▁; ▁pulmonar y ▁e mbol ism ▁; ▁right ▁heart ▁failure
D-592	-0.3374635577201843	right atrial myxoma ; pulmonary embolism ; right heart failure
P-592	-0.1660 -0.0788 -0.0434 -2.4172 -0.1654 -0.1527 -0.4677 -0.0146 -0.0689 -0.0811 -0.0139 -0.3266 -0.4206 -0.0130 -0.6755 -0.2616 -0.5442 -0.1631
S-638	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure.<unk>
T-638	nfat ; mir-25 ; transcription factor ; hand2 ; heart failure
H-638	-0.4500003457069397	▁na fat ▁; ▁mi r -25 ▁; ▁tran scription ▁factor ▁; ▁hand 2 ▁; ▁heart ▁failure
D-638	-0.4500003457069397	nafat ; mir-25 ; transcription factor ; hand2 ; heart failure
P-638	-1.1264 -0.6747 -0.1027 -0.0398 -1.3021 -0.0688 -0.2223 -0.4531 -0.4995 -0.0476 -0.6050 -0.8702 -0.1932 -0.5101 -0.1801 -0.2546 -0.5409 -0.4089
S-938	Further, elevation in resistin correlated with decline in ejection fraction in these women.<unk>
T-938	elevation ; resistin ; correlated ; ejection fraction
H-938	-0.4126951992511749	▁resist in ▁cor related ▁; ▁decline ▁; ▁e je ction ▁ fraction
D-938	-0.4126951992511749	resistin correlated ; decline ; ejection fraction
P-938	-0.0343 -0.4677 -1.1568 -0.0701 -0.2676 -0.5336 -0.7607 -0.0237 -0.1901 -0.2113 -0.5478 -0.0135 -1.1536 -0.3470
S-1280	Orthotopic heart transplantation (OHT) is the optimal treatment for end-stage heart failure.<unk>
T-1280	orthotopic heart transplantation ; oht ; end-stage heart failure
H-1280	-0.5468580722808838	▁Ort ho topic ▁heart ▁transplant ation ▁; ▁o HT ▁; ▁end - s tage ▁heart ▁failure
D-1280	-0.5468580722808838	Orthotopic heart transplantation ; oHT ; end-stage heart failure
P-1280	-0.1269 -0.0724 -0.1488 -2.2068 -0.0746 -0.2176 -0.3569 -0.0169 -3.5055 -0.4599 -1.0158 -0.0858 -0.0236 -0.0030 -0.9101 -0.0756 -0.3900 -0.1534
S-594	Myxomas in the right atrium may rarely embolize to the pulmonary arterial vasculature.<unk>
T-594	myxomas ; right atrium ; embolize ; pulmonary arterial vasculature
H-594	-0.39058855175971985	▁My xo mas ▁; ▁right ▁at rium ▁; ▁pulmonar y ▁arterial ▁vas cula ture
D-594	-0.39058855175971985	Myxomas ; right atrium ; pulmonary arterial vasculature
P-594	-1.0121 -0.0291 -0.3819 -0.1967 -0.0081 -0.2488 -0.0317 -0.3087 -0.0153 -0.1219 -0.1657 -1.1329 -1.2965 -0.4094 -0.5749 -0.3158
S-720	Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative.<unk>
T-720	change ; readmissions ; follow-up ; heart failure ; readmission
H-720	-0.657588005065918	▁read missions ▁; ▁follow - up ▁visit s ▁; ▁heart ▁failure ▁; ▁read mission ▁quality
D-720	-0.657588005065918	readmissions ; follow-up visits ; heart failure ; readmission quality
P-720	-2.2556 -0.0258 -0.1409 -0.1122 -0.1132 -0.0099 -0.4595 -0.1014 -0.2301 -0.2537 -0.0529 -0.9816 -2.6801 -0.1564 -1.2100 -2.1209 -0.2748
S-1999	The indications for LVAS support were bridge to transplantation (54%) or destination therapy (46%).<unk>
T-1999	lvas ; bridge to transplantation ; destination therapy
H-1999	-0.5126912593841553	▁l VAS ▁; ▁ bridge ▁to ▁transplant ation ▁; ▁destination ▁ therapy
D-1999	-0.5126912593841553	lVAS ; bridge to transplantation ; destination therapy
P-1999	-1.4587 -0.7634 -0.5397 -1.3203 -0.0195 -0.6393 -0.0264 -0.1016 -0.7698 -0.4432 -0.4957 -0.0492 -0.3620 -0.1890
S-1809	Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice.<unk>
T-1809	cardiac overexpression ; mammalian enabled ; mena ; heart failure
H-1809	-0.43651968240737915	▁Card iac ▁; ▁Mamma lian ▁; Men a ▁; ▁heart ▁failure ▁; ▁mi ce
D-1809	-0.43651968240737915	Cardiac ; Mammalian ;Mena ; heart failure ; mice
P-1809	-0.2639 -0.2102 -0.5820 -0.1576 -0.3300 -0.2381 -1.1246 -0.0177 -0.2052 -2.0242 -0.1014 -1.1105 -0.0153 -0.0896 -0.3504 -0.1636
S-123	We evaluated CPCs and functional capacity (peak VO2) every 6 months for up to 2 years.<unk>
T-123	cpcs ; functional capacity ; peak vo2
H-123	-0.578159511089325	▁c p s ▁; ▁functional ▁capacity ▁; ▁pe ak ▁VO 2
D-123	-0.578159511089325	cps ; functional capacity ; peak VO2
P-123	-0.1142 -1.6329 -0.7020 -0.2045 -1.3829 -0.0866 -0.3571 -0.8609 -0.0093 -0.4056 -0.9786 -0.3607 -0.4209
S-774	When dysfunction is due to pump failure or driveline injury, isolated pump replacement can be curative.<unk>
T-774	dysfunction ; pump ; driveline ; pump ; curative
H-774	-0.546345055103302	▁pump ▁failure ▁; ▁drive line ▁injury ▁; ▁isola ted ▁pump ▁replace ment
D-774	-0.546345055103302	pump failure ; driveline injury ; isolated pump replacement
P-774	-3.2275 -0.4673 -0.1173 -0.0261 -0.0479 -0.9148 -0.5049 -0.4572 -0.0107 -0.9650 -0.1344 -0.0989 -0.4498 -0.2269
S-164	Investigation of apoptosis in a canine model of chronic heart failure induced by tachycardia.<unk>
T-164	apoptosis ; chronic heart failure ; tachycardia
H-164	-0.596102237701416	▁apo pto sis ▁; ▁can ine ▁model ▁; ▁chronic ▁heart ▁failure ▁induc ed ▁; ▁ta chy car dia
D-164	-0.596102237701416	apoptosis ; canine model ; chronic heart failure induced ; tachycardia
P-164	-2.8681 -0.2892 -1.3268 -0.1793 -0.1156 -0.0094 -0.1428 -0.5197 -0.1415 -1.3223 -0.1201 -0.2030 -0.0660 -1.4122 -0.3302 -0.7354 -0.4669 -0.9991 -0.4968 -0.1777
S-959	Nicorandil (3 mg/kg/day) was given orally with or without doxorubicin treatment.<unk>
T-959	nicorandil ; orally ; doxorubicin
H-959	-0.40806108713150024	▁Nico rand il ▁; ▁do xor ubi cin
D-959	-0.40806108713150024	Nicorandil ; doxorubicin
P-959	-0.0149 -0.0222 -0.1313 -0.1304 -1.0028 -0.3683 -0.1171 -1.0042 -1.1641 -0.1253
S-1525	However, clinical characteristics and outcomes of EH have not been well described in HFpEF.<unk>
T-1525	clinical ; outcomes ; hfpef
H-1525	-0.5180169939994812	▁EH ▁; ▁ HF p EF
D-1525	-0.5180169939994812	EH ; HFpEF
P-1525	-0.8451 -0.2650 -1.1070 -0.7467 -0.0181 -0.5564 -0.3353 -0.2706
S-1648	The EAST will test whether an early, modern rhythm control therapy can reduce cardiovascular complications in AF.<unk>
T-1648	east ; rhythm control therapy ; cardiovascular ; complications
H-1648	-0.4315338730812073	▁e ast ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁cardiovascular ▁complica tions ▁; ▁AF
D-1648	-0.4315338730812073	east ; rhythm control therapy ; cardiovascular complications ; AF
P-1648	-1.3656 -0.0299 -0.3229 -0.2254 -0.2372 -0.1304 -0.6047 -0.0691 -0.4815 -0.5109 -0.2564 -0.0984 -1.7388 -0.1862 -0.3185 -0.3286
S-560	The youngest patients were less likely to have clinical and radiological signs of HF during hospitalization.<unk>
T-560	patients ; clinical ; radiological ; hf ; hospitalization
H-560	-0.6427629590034485	▁radi ological ▁; ▁ HF
D-560	-0.6427629590034485	radiological ; HF
P-560	-1.1524 -0.2349 -1.2813 -0.8691 -0.0872 -0.5531 -0.3213
S-1199	Diuretics are frequently administered to relieve congestive symptoms in patients with heart failure (HF).<unk>
T-1199	diuretics ; symptoms ; patients ; heart failure ; hf
H-1199	-0.3832349479198456	▁di ure tics ▁; ▁con ges tive ▁symptoms ▁; ▁heart ▁failure ▁; HF
D-1199	-0.3832349479198456	diuretics ; congestive symptoms ; heart failure ;HF
P-1199	-0.1190 -0.0492 -0.8084 -0.3148 -1.0374 -0.0953 -0.0841 -1.0898 -0.1983 -0.5326 -0.0607 -0.7821 -0.0415 -0.3484 -0.1868
S-1333	Given the lack of effective evidence-based therapies in these patients, FES warrants further investigation.<unk>
T-1333	evidence-based ; therapies ; patients ; fes
H-1333	-0.8176457285881042	▁evidence - based ▁ therapie s
D-1333	-0.8176457285881042	evidence-based therapies
P-1333	-1.0476 -0.0605 -0.0119 -0.6836 -0.0749 -0.0670 -4.3805 -0.2152
S-399	BACKGROUND: Concentrations of soluble (s)ST2 predict prognosis in heart failure.<unk>
T-399	st2 ; prognosis ; heart failure
H-399	-0.9338001012802124	▁s 2 ▁; ▁heart ▁failure
D-399	-0.9338001012802124	s2 ; heart failure
P-399	-2.4604 -1.2071 -0.4882 -1.7316 -0.2421 -0.2489 -0.1583
S-1103	Framingham Heart Study criteria were used to define HF, which was further classified according to EF.<unk>
T-1103	framingham heart study ; hf ; ef
H-1103	-0.4136430323123932	▁Fram ing ham ▁Heart ▁study ▁criteri a ▁; ▁ HF ▁; ▁EF
D-1103	-0.4136430323123932	Framingham Heart study criteria ; HF ; EF
P-1103	-0.3438 -0.0481 -0.0376 -0.8895 -0.4386 -1.5415 -0.3108 -0.1748 -0.3497 -0.1668 -0.3291 -0.6642 -0.3447 -0.1519
S-1771	During a mean follow-up of 19.8±10.4 years, 153 HF deaths occurred.<unk>
T-1771	follow-up ; hf ; deaths
H-1771	-0.7902590036392212	▁ HF
D-1771	-0.7902590036392212	HF
P-1771	-0.5383 -0.3848 -1.9233 -0.3146
S-140	Correlations between the ACR and CMS metrics were highest (r = 0.67-0.84).<unk>
T-140	correlations ; acr ; cms
H-140	-0.7469713091850281	▁a CR ▁; ▁CMS
D-140	-0.7469713091850281	aCR ; CMS
P-140	-0.4875 -2.3118 -0.2357 -0.2856 -0.9122 -0.2490
S-171	No band of activated Caspase was found in the normal nor in the paced myocardium.<unk>
T-171	caspase ; myocardium
H-171	-0.7221957445144653	▁band ▁of ▁activa ted ▁Cas pas e ▁; ▁pace d ▁my o car dium
D-171	-0.7221957445144653	band of activated Caspase ; paced myocardium
P-171	-6.1559 -0.3387 -0.1545 -0.0785 -0.2768 -0.2055 -0.5350 -0.1379 -0.2114 -0.2017 -1.0634 -0.1190 -0.2574 -1.0865 -0.5182 -0.2149
S-621	Frailty and risk for heart failure in older adults: the health, aging, and body composition study.<unk>
T-621	frailty ; heart failure ; health
H-621	-0.5326434373855591	▁Fra il ty ▁; ▁risk ▁; ▁heart ▁failure ▁; ▁ aging ▁; ▁body ▁composition
D-621	-0.5326434373855591	Frailty ; risk ; heart failure ; aging ; body composition
P-621	-1.4570 -0.0420 -0.2682 -0.1182 -0.9729 -0.3724 -0.3276 -0.1610 -0.2830 -3.1673 -0.0202 -0.5167 -0.0351 -0.2631 -0.3629 -0.1547
S-1828	OBJECTIVE: To examine the associations of hHF with saxagliptin and sitagliptin.<unk>
T-1828	saxagliptin ; sitagliptin
H-1828	-0.6352227926254272	▁h f ▁; ▁sax ag lip tin ▁; ▁si tag lip tin
D-1828	-0.6352227926254272	hf ; saxagliptin ; sitagliptin
P-1828	-0.0155 -2.2881 -0.1349 -0.5765 -0.3023 -0.8797 -1.4223 -0.1301 -1.1886 -0.2999 -0.1183 -0.8071 -0.5441 -0.1858
S-747	Heart T2* was confirmed to be highly predictive over 1 year for heart failure and arrhythmias.<unk>
T-747	heart ; heart failure ; arrhythmias
H-747	-0.6534022688865662	▁Heart ▁t 2 ▁; ▁heart ▁failure ▁; ▁ar rhythm ias
D-747	-0.6534022688865662	Heart t2 ; heart failure ; arrhythmias
P-747	-0.5615 -1.1574 -0.0146 -0.5135 -3.5001 -0.2853 -0.4468 -0.0641 -0.3736 -0.4040 -0.3236 -0.1963
S-1285	All but one of the seven ischemic/inflammatory abdominal problems occurred in the MT group.<unk>
T-1285	ischemic ; inflammatory ; abdominal
H-1285	-0.9896994233131409	▁ ische mic ▁; ▁in flam ma tory ▁abdominal ▁; ▁MT ▁group
D-1285	-0.9896994233131409	ischemic ; inflammatory abdominal ; MT group
P-1285	-1.1549 -1.0715 -0.6937 -1.3011 -1.4175 -0.6275 -0.9264 -0.2102 -1.8624 -2.2218 -0.3000 -1.3126 -0.4060 -0.3502
S-208	Rates of ED visits and of intubations for congestive heart failure declined from 1996 to 2008.<unk>
T-208	intubations ; congestive heart failure
H-208	-0.21116302907466888	▁ED ▁; ▁in tuba tions ▁; ▁con ges tive ▁heart ▁failure
D-208	-0.21116302907466888	ED ; intubations ; congestive heart failure
P-208	-0.4183 -0.8469 -0.0547 -0.0510 -0.0476 -0.2366 -0.0111 -0.0675 -0.0569 -0.4630 -0.0950 -0.2015 -0.1949
S-62	METHODS: We searched in MedLine, EMBASE, and CINAHL in May 2012.<unk>
T-62	medline ; embase ; cinahl
H-62	-0.736458957195282	▁Med line ▁; ▁ EMBA se ▁; ▁c ina hl
D-62	-0.736458957195282	Medline ; EMBAse ; cinahl
P-62	-0.3582 -1.0933 -0.1601 -0.2744 -0.0838 -3.5865 -0.1886 -0.4564 -1.0941 -1.0557 -0.2935 -0.1929
S-35	This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system.<unk>
T-35	evidence ; acp ; clinical practice guidelines
H-35	-0.7193454504013062	▁evidence ▁; ▁a CP ▁; ▁clinic al ▁practice ▁guidelines
D-35	-0.7193454504013062	evidence ; aCP ; clinical practice guidelines
P-35	-1.9441 -0.1529 -1.1593 -0.3125 -0.3010 -0.9057 -0.1380 -0.0395 -1.1213 -1.5564 -0.2822
S-1899	Exercise is generally associated with a 50% reduction in adverse events from coronary artery disease (CAD).<unk>
T-1899	exercise ; adverse events ; coronary artery disease ; cad
H-1899	-0.5071095824241638	▁exercise ▁; ▁advers e ▁events ▁; ▁corona ry ▁arter y ▁disease ▁; CAD
D-1899	-0.5071095824241638	exercise ; adverse events ; coronary artery disease ;CAD
P-1899	-1.4979 -0.3153 -2.0384 -0.1367 -0.0638 -0.5021 -0.0923 -0.0842 -0.2513 -0.2362 -1.1805 -0.4903 -0.2430 -0.2887 -0.1860
S-1852	We will synthesise the results narratively and, if appropriate, will pool results for meta-analysis.<unk>
T-1852	meta-analysis
H-1852	-0.7643380761146545	
D-1852	-0.7643380761146545	
P-1852	-1.3506 -0.1781
S-792	Future studies should extend and replicate our findings, including the establishment of its responsiveness to clinical change.<unk>
T-792	clinical ; change
H-792	-0.6156328320503235	▁clinic al ▁change
D-792	-0.6156328320503235	clinical change
P-792	-2.7881 -0.0341 -0.0106 -0.1074 -0.1380
S-216	RESULTS: Of the 2,374,428 ED visits, 32,036 (1.3%) were for CHF.<unk>
T-216	chf
H-216	-0.7047505974769592	▁ED ▁; ▁CHF
D-216	-0.7047505974769592	ED ; CHF
P-216	-1.8167 -1.2897 -0.0875 -0.1650 -0.1649
S-892	There may be some delayed benefit when the QRS is ≥160 ms, but this needs further investigation.<unk>
T-892	qrs
H-892	-0.723183274269104	▁QR s
D-892	-0.723183274269104	QRs
P-892	-0.7374 -1.5576 -0.4710 -0.1267
S-1716	RESULTS: Medicare's post-acute care transfer policy led to immediate declines in length of stay.<unk>
T-1716	medicare ; policy
H-1716	-0.33228790760040283	▁Medica re ▁; ▁post - a cute ▁care ▁transfer ▁policy
D-1716	-0.33228790760040283	Medicare ; post-acute care transfer policy
P-1716	-0.2388 -0.0459 -0.1867 -0.1547 -0.0328 -0.0103 -0.0268 -0.7626 -0.1841 -0.0497 -2.0039 -0.2913
S-692	Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality.<unk>
T-692	mortality
H-692	-0.37085551023483276	▁Diet ▁score ▁; ▁vegetables ▁; ▁nu ts ▁; ▁whole ▁grain ▁in take ▁; ▁mortal ity
D-692	-0.37085551023483276	Diet score ; vegetables ; nuts ; whole grain intake ; mortality
P-692	-1.8144 -1.2721 -0.2432 -0.5755 -0.1392 -0.3176 -0.0143 -0.2207 -0.2360 -0.0468 -0.0903 -0.0820 -0.6144 -0.1839 -0.0314 -0.2007 -0.2219
S-1508	Contrasting groups validity, internal consistency, and test-retest reliability were supported as well.<unk>
T-1508	
H-1508	-1.4071332216262817	
D-1508	-1.4071332216262817	
P-1508	-2.5611 -0.2532
S-1611	Interactors of the DEGs were retrieved with Osprey and then networks were constructed.<unk>
T-1611	degs ; osprey
H-1611	-0.4075154662132263	▁de g s ▁; ▁o spre y
D-1611	-0.4075154662132263	degs ; osprey
P-1611	-0.9916 -1.4602 -0.0950 -0.3737 -0.0122 -0.0030 -0.2097 -0.3873 -0.1351
S-1467	It is a life-threatening situation in which diagnosis and initiation of therapy are crucial.<unk>
T-1467	diagnosis ; therapy
H-1467	-0.659385621547699	▁ therapy
D-1467	-0.659385621547699	therapy
P-1467	-1.9646 -0.1800 -0.1724 -0.3205
S-1791	A systematic search of the electronic databases and the World Health Organization website was undertaken for HF in LA.<unk>
T-1791	world health organization ; hf
H-1791	-0.6409004926681519	▁electronic ▁database s ▁; ▁world ▁health ▁organization ▁; ▁ HF
D-1791	-0.6409004926681519	electronic databases ; world health organization ; HF
P-1791	-1.7351 -0.8460 -0.0532 -0.0930 -0.1660 -0.2086 -0.9087 -0.2123 -0.4583 -0.4548 -2.3974 -0.1574
S-1008	The deficit index ranged from 0.02-0.75, with a mean (SD) of 0.25 (0.13).<unk>
T-1008	deficit index
H-1008	-0.6883724331855774	▁deficit ▁index
D-1008	-0.6883724331855774	deficit index
P-1008	-0.4481 -0.1939 -1.8603 -0.2511
S-848	All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off.<unk>
T-848	patients ; implantation ; crt
H-848	-1.140326976776123	▁device ▁implant ation ▁; ▁c RT
D-848	-1.140326976776123	device implantation ; cRT
P-848	-1.9115 -0.6567 -0.2704 -0.3042 -0.3531 -3.8540 -1.5217 -0.2509
S-619	CONCLUSIONS: Anecdotal evidence of perceived benefit was expressed in participant satisfaction responses.<unk>
T-619	evidence
H-619	-1.0292738676071167	
D-619	-1.0292738676071167	
P-619	-1.9167 -0.1419
S-49	Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown.<unk>
T-49	
H-49	-0.9460622072219849	▁ir on
D-49	-0.9460622072219849	iron
P-49	-0.2516 -0.1755 -3.1232 -0.2340
S-146	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis.<unk>
T-146	remote monitoring ; hospital ; discharge ; patients ; heart failure ; meta-analysis
H-146	-0.4994194209575653	▁remote ▁monitoring ▁; ▁hospital ▁dis charge ▁; ▁patients ▁; ▁heart ▁failure
D-146	-0.4994194209575653	remote monitoring ; hospital discharge ; patients ; heart failure
P-146	-0.1549 -0.0715 -0.4789 -1.5420 -0.1502 -0.0636 -0.3220 -1.7137 -1.1183 -0.2972 -0.0778 -0.3484 -0.1542
S-489	In conclusion, e' is useful for estimating LV filling pressure in stable severe systolic HF.<unk>
T-489	lv filling pressure ; stable ; severe systolic hf
H-489	-0.530943751335144	▁LV ▁; ▁fill ing ▁pressure ▁; ▁severe ▁sy sto lic ▁ HF
D-489	-0.530943751335144	LV ; filling pressure ; severe systolic HF
P-489	-0.7936 -1.2894 -0.3272 -0.0558 -0.1136 -0.1079 -2.7877 -0.6886 -0.1204 -0.1394 -0.3305 -0.0460 -0.4475 -0.1855
S-695	Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.<unk>
T-695	st2 ; ambulatory ; patients ; heart failure ; functional capacity ; outcomes
H-695	-0.43874937295913696	▁Solu ble ▁ST 2 ▁; ▁ambula tory ▁patients ▁; ▁heart ▁failure
D-695	-0.43874937295913696	Soluble ST2 ; ambulatory patients ; heart failure
P-695	-0.4323 -0.0486 -0.9466 -0.1719 -0.3360 -0.9212 -0.0213 -1.2494 -0.3515 -0.3446 -0.1137 -0.5689 -0.1977
S-907	Baseline and 6-month echocardiograms were assessed for evidence of reverse remodeling.<unk>
T-907	baseline ; echocardiograms ; evidence ; reverse remodeling
H-907	-0.5280596017837524	▁base line ▁; ▁e cho card i ogram s
D-907	-0.5280596017837524	baseline ; echocardiograms
P-907	-0.0775 -0.0059 -0.1198 -0.0915 -0.6360 -0.4741 -0.4545 -0.0694 -0.3138 -3.4019 -0.1644
S-771	Titin hypophosphorylation importantly contributed to the underlying myocardial DD.<unk>
T-771	titin hypophosphorylation ; myocardial dd
H-771	-0.4203028976917267	▁Tit in ▁hypo phos phor y lation ▁; ▁my o card ial ▁ DD
D-771	-0.4203028976917267	Titin hypophosphorylation ; myocardial DD
P-771	-0.0354 -0.3959 -0.4802 -0.2547 -0.8254 -0.8194 -1.0215 -0.1018 -0.5052 -0.1953 -0.5660 -0.0539 -0.6150 -0.1300 -0.4807 -0.2443
S-821	Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertension.<unk>
T-821	prognostic ; right ventricular contractile reserve ; patients ; pulmonary hypertension
H-821	-0.5941187739372253	▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁pulmonar y ▁hyper tension
D-821	-0.5941187739372253	right ventricular contractile reserve ; pulmonary hypertension
P-821	-0.0873 -1.6838 -0.6116 -0.2064 -0.1643 -3.6492 -0.0463 -0.2356 -0.5187 -0.0683 -0.4642 -0.1209 -0.2991 -0.1617
S-502	The bottleneck stent model for chronic myocardial ischemia and heart failure in pigs.<unk>
T-502	bottleneck stent ; chronic myocardial ischemia ; heart failure
H-502	-0.30008554458618164	▁bottle ne ck ▁sten t ▁model ▁; ▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure ▁; ▁pig s
D-502	-0.30008554458618164	bottleneck stent model ; chronic myocardial ischemia ; heart failure ; pigs
P-502	-0.0160 -0.0078 -0.0526 -0.4449 -0.2253 -0.0944 -0.4129 -0.0754 -0.8934 -0.1919 -0.7424 -0.0286 -0.1073 -0.6559 -0.8759 -0.1696 -0.1326 -0.0343 -0.9770 -0.0062 -0.0599 -0.5030 -0.1946
S-1439	Variability in QT intervals was expressed as the SD of all QT intervals (SDQT).<unk>
T-1439	qt intervals ; sd of all qt intervals ; sdqt
H-1439	-0.9323204159736633	▁ QT ▁interval s ▁; ▁SD ▁; ▁ QT ▁interval s
D-1439	-0.9323204159736633	QT intervals ; SD ; QT intervals
P-1439	-0.3645 -0.9163 -0.1375 -0.0749 -0.2292 -0.2201 -1.0063 -0.6229 -1.2614 -0.2407 -0.0735 -6.6333 -0.3395
S-1656	Gastrointestinal bleeding in patients with ventricular assist devices: what every cardiac nurse should know.<unk>
T-1656	gastrointestinal bleeding ; patients ; ventricular assist devices ; cardiac ; nurse
H-1656	-0.5464600920677185	▁Gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁nurse
D-1656	-0.5464600920677185	Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
P-1656	-0.2072 -0.1957 -1.1850 -0.1470 -0.6011 -0.3841 -0.2130 -0.2413 -1.9733 -0.6519 -0.2674 -1.9418 -0.1239 -0.8614 -0.0349 -0.3150 -0.3074 -0.1849
S-183	No benefit of RAS- or β-blocker uptitration was observed in HFpEF.<unk>
T-183	β-blocker ; uptitration ; hfpef
H-183	-0.5421813726425171	▁ RAS - ▁; ▁β - block er ▁up tit ration ▁; ▁ HF p EF
D-183	-0.5421813726425171	RAS- ; β-blocker uptitration ; HFpEF
P-183	-1.5107 -0.0316 -0.2441 -1.0309 -0.2617 -0.1337 -0.6747 -0.5707 -0.1103 -1.3040 -1.2666 -0.2202 -0.4110 -0.6667 -0.0127 -0.6551 -0.3668 -0.2879
S-1321	RESULTS: Attrition was 30% but with 100% compliance to exercise and injections in patients who completed the study.<unk>
T-1321	attrition ; compliance ; exercise ; injections ; patients
H-1321	-0.359860360622406	▁compliance ▁; ▁exercise ▁; ▁inject ions
D-1321	-0.359860360622406	compliance ; exercise ; injections
P-1321	-0.8777 -0.2239 -0.2941 -0.4018 -0.0173 -0.3257 -0.5464 -0.1921
S-2004	There were no pump exchanges, pump malfunctions, pump thrombosis, or hemolysis events.<unk>
T-2004	pump ; pump ; pump thrombosis ; hemolysis
H-2004	-0.47401344776153564	▁pump ▁exchange s ▁; ▁pump ▁mal function s ▁; ▁pump ▁ thro mbo sis ▁; ▁hem ol ysis ▁events
D-2004	-0.47401344776153564	pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis events
P-2004	-0.0588 -0.0683 -0.1044 -0.2835 -0.1514 -0.7575 -0.2943 -0.1091 -0.2515 -0.2998 -0.6050 -0.2469 -0.7493 -1.5080 -0.2554 -0.4294 -1.5132 -0.2525 -1.4480 -0.4207 -0.1474
S-903	Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure.<unk>
T-903	cardiac resynchronization therapy ; patients ; heart failure
H-903	-0.3656497299671173	▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁di al ysis - dependent ▁patients ▁; ▁heart ▁failure
D-903	-0.3656497299671173	cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
P-903	-0.4342 -0.0143 -0.0750 -0.0236 -0.6017 -1.6473 -0.0633 -0.1969 -0.0963 -0.1212 -0.3739 -0.3552 -0.2038 -1.2240 -0.5590 -0.1636 -0.1298 -0.3908 -0.2733
S-1401	All top 10 NOC outcomes demonstrated statistically significant improvement in outcome ratings from admission to discharge.<unk>
T-1401	noc ; outcomes ; outcome ; admission ; discharge
H-1401	-0.7591668367385864	▁NO c ▁; ▁ad mission ▁; ▁dis charge
D-1401	-0.7591668367385864	NOc ; admission ; discharge
P-1401	-1.1898 -1.9539 -0.8530 -1.0198 -0.0448 -1.5680 -0.0507 -0.0440 -0.4935 -0.3741
S-843	In addition, the beneficial effects of HRQoL from exercise training were not modulated by baseline Hgb.<unk>
T-843	hrqol ; exercise ; training ; baseline ; hgb
H-843	-0.5155060291290283	▁HR Qo L ▁; ▁exercise ▁training ▁; ▁base line ▁h gb
D-843	-0.5155060291290283	HRQoL ; exercise training ; baseline hgb
P-843	-1.4153 -0.0420 -1.2740 -0.1870 -0.2498 -0.3475 -0.2433 -0.0043 -0.0170 -2.1597 -0.0367 -0.5255 -0.1995
S-1400	Data were obtained from 268 inpatient records of patients discharged with HF during a 1-year period.<unk>
T-1400	inpatient ; patients ; discharged ; hf
H-1400	-0.6303934454917908	▁in patient ▁records ▁; ▁ HF
D-1400	-0.6303934454917908	inpatient records ; HF
P-1400	-0.4531 -0.3622 -0.0685 -0.2426 -2.8943 -0.4934 -0.2482 -0.2808
S-1500	Low skeletal muscle mass correlated with poorer VO2 max (r=0.67, p=0.004).<unk>
T-1500	skeletal muscle ; correlated ; vo2 max
H-1500	-0.654399573802948	▁skelet al ▁muscle ▁mass ▁cor related ▁; ▁poor er ▁VO 2
D-1500	-0.654399573802948	skeletal muscle mass correlated ; poorer VO2
P-1500	-1.0065 -0.0495 -0.6026 -0.1153 -2.3287 -0.0993 -0.2195 -2.5800 -0.1843 -0.3637 -0.2047 -0.6132 -0.1399
S-1297	Seven days after the emergency cardiac catheterization the patient was extubated and transferred to our intermediate care.<unk>
T-1297	cardiac catheterization ; patient ; extubated ; transferred
H-1297	-0.36341607570648193	▁emergency ▁cardiac ▁cat heter ization ▁; ▁ex tuba ted ▁; ▁intermedi ate
D-1297	-0.36341607570648193	emergency cardiac catheterization ; extubated ; intermediate
P-1297	-0.2563 -0.0469 -0.9975 -0.0314 -0.4806 -0.4875 -0.0225 -0.0059 -0.1214 -0.6983 -0.0179 -0.3294 -1.4770 -0.1151
S-1925	BACKGROUND: Psychosocial factors may influence adherence with exercise training for heart failure (HF) patients.<unk>
T-1925	psychosocial ; exercise ; training ; heart failure ; hf ; patients
H-1925	-0.4598012864589691	▁psycho social ▁factors ▁; ▁exercise ▁training ▁; ▁heart ▁failure ▁; HF
D-1925	-0.4598012864589691	psychosocial factors ; exercise training ; heart failure ;HF
P-1925	-1.3410 -0.8549 -0.0711 -0.3489 -0.1552 -0.3360 -0.3610 -0.3181 -0.0729 -0.4268 -0.0854 -1.3703 -0.2358
S-198	Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.<unk>
T-198	diagnosis ; medical ; heart failure ; canadian cardiovascular society
H-198	-0.8555638194084167	▁medical ▁management ▁; ▁heart ▁failure ▁; ▁Canadian ▁Card io vas cular ▁society
D-198	-0.8555638194084167	medical management ; heart failure ; Canadian Cardiovascular society
P-198	-0.7425 -1.3128 -0.3525 -0.2778 -0.0724 -0.1738 -1.8072 -2.2807 -2.1299 -0.6460 -0.3090 -0.3216 -1.3459 -0.2056
S-77	Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo.<unk>
T-77	randomized ; double-blind ; active ; placebo
H-77	-0.915941596031189	▁active ▁treatment ▁; ▁place bo
D-77	-0.915941596031189	active treatment ; placebo
P-77	-3.2404 -1.2533 -1.5139 -0.0208 -0.0474 -0.1274 -0.2084
S-290	Interestingly, the simpler laboratory report model was statistically no different than the ARIC HF model.<unk>
T-290	report ; aric ; hf
H-290	-0.4174351990222931	▁laborator y ▁report ▁model ▁; ▁a RIC ▁ HF ▁model
D-290	-0.4174351990222931	laboratory report model ; aRIC HF model
P-290	-1.0564 -0.2401 -0.1457 -0.3138 -0.2053 -0.4314 -0.4401 -0.2747 -0.4209 -0.6710 -0.5428 -0.2670
S-883	For this substudy, we excluded patients in atrial fibrillation and those with a previous pacemaker.<unk>
T-883	patients ; atrial fibrillation ; pacemaker
H-883	-0.59510737657547	▁at rial ▁fi bril lation ▁; ▁pace maker
D-883	-0.59510737657547	atrial fibrillation ; pacemaker
P-883	-1.6898 -0.1164 -0.7111 -0.0843 -1.2176 -0.3573 -1.0399 -0.2045 -0.3520 -0.1782
S-68	CONCLUSIONS: This meta-analysis identified strong reliable mortality predictors in ICD-HF patients.<unk>
T-68	meta-analysis ; mortality ; patients
H-68	-0.6805623769760132	▁mortal ity ▁predict ors ▁; ▁i CD - HF
D-68	-0.6805623769760132	mortality predictors ; iCD-HF
P-68	-2.5808 -0.0973 -0.1426 -0.1641 -0.2451 -0.1224 -1.6888 -0.0600 -0.1023 -2.0635 -0.2193
S-1223	Patients were receiving optimal therapy and most had been hospitalized for a cardiovascular reason within 180 days of inclusion.<unk>
T-1223	patients ; therapy ; hospitalized ; cardiovascular
H-1223	-1.3734999895095825	▁patients ▁; ▁cardiovascular
D-1223	-1.3734999895095825	patients ; cardiovascular
P-1223	-3.8766 -1.1711 -1.1478 -0.3801 -0.2918
S-945	AF-free probability after catheter ablation and factors relating to maintenance of sinus rhythm were investigated.<unk>
T-945	catheter ablation ; sinus rhythm
H-945	-0.6079126000404358	▁AF - free ▁probabil ity ▁; ▁cat heter ▁ab lation ▁; ▁factors ▁; ▁maintenance ▁; ▁sinus ▁ rhythm
D-945	-0.6079126000404358	AF-free probability ; catheter ablation ; factors ; maintenance ; sinus rhythm
P-945	-0.2746 -0.1224 -0.0449 -2.7977 -0.0977 -0.6174 -0.5601 -0.0262 -0.0228 -0.4253 -0.2402 -2.8823 -0.3163 -0.8906 -1.3362 -0.2109 -0.2437 -0.2846 -0.4621 -0.3024
S-1768	Measures included body mass index and CRF quantified as duration of maximal treadmill exercise testing.<unk>
T-1768	body mass index ; crf ; exercise
H-1768	-0.286185085773468	▁body ▁mass ▁index ▁; ▁c RF ▁; ▁tre ad m ill ▁exercise ▁testing
D-1768	-0.286185085773468	body mass index ; cRF ; treadmill exercise testing
P-1768	-0.1467 -0.1376 -0.0831 -0.1862 -0.0893 -0.2746 -0.1369 -0.4893 -0.2101 -0.0786 -0.0219 -1.4279 -0.2835 -0.4217 -0.3054
S-1426	In this study, human myocardial tissue was used to examine the state of PKA subunits.<unk>
T-1426	myocardial tissue ; pka
H-1426	-0.5990055799484253	▁human ▁my o card ial ▁tissu e ▁; ▁p KA
D-1426	-0.5990055799484253	human myocardial tissue ; pKA
P-1426	-1.1546 -1.2111 -0.1914 -0.5594 -0.0813 -0.4062 -0.5223 -0.1778 -0.5072 -1.5380 -0.6464 -0.1925
S-982	It is, however, an important disease, accounting for 10% of paediatric cardiac transplants in children.<unk>
T-982	disease ; accounting ; cardiac transplants
H-982	-0.6875283718109131	▁pa e dia tric ▁cardiac ▁transplant s ▁; ▁children
D-982	-0.6875283718109131	paediatric cardiac transplants ; children
P-982	-1.6042 -0.1128 -1.8472 -0.2535 -0.0927 -0.0694 -0.1920 -1.8873 -0.9549 -0.2956 -0.2533
S-526	Because Ees is unaltered, improved ventricular-arterial coupling is responsible for increased SV.<unk>
T-526	ees ; ventricular-arterial coupling
H-526	-0.3784562945365906	▁e es ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁SV
D-526	-0.3784562945365906	ees ; ventricular-arterial coupling ; SV
P-526	-0.5012 -0.0737 -0.1647 -1.9878 -0.8881 -0.1629 -0.2390 -0.0290 -0.1406 -0.0912 -0.1399 -0.5542 -0.1443 -0.2874 -0.2730
S-986	There is a small subgroup of children that have diastolic failure from cardiomyopathic restriction to flow.<unk>
T-986	diastolic failure ; cardiomyopathic
H-986	-0.4202134311199188	▁dia sto lic ▁failure ▁; ▁cardio my o pathi c ▁restriction ▁to ▁flow
D-986	-0.4202134311199188	diastolic failure ; cardiomyopathic restriction to flow
P-986	-1.3986 -0.1335 -0.5627 -0.0522 -0.1543 -0.1117 -1.1058 -0.4205 -0.0192 -0.4105 -0.2417 -1.2698 -0.0041 -0.2887 -0.1299
S-1436	The aim of the present study was to investigate the role of autonomic nervous system activity on QTV.<unk>
T-1436	autonomic nervous system ; activity ; qtv
H-1436	-0.7263991832733154	▁autonomi c ▁ner vous ▁system ▁activity ▁; ▁Q TV
D-1436	-0.7263991832733154	autonomic nervous system activity ; QTV
P-1436	-0.1559 -0.7690 -1.2795 -1.6653 -0.0870 -0.9645 -0.4331 -1.2839 -0.9060 -0.2533 -0.1928
S-5	However, there were no measurable overall improvements for patients admitted with pneumonia or surgical conditions.<unk>
T-5	patients ; pneumonia ; surgical ; conditions
H-5	-0.5031976699829102	▁pneu monia ▁; ▁sur g ical ▁conditions
D-5	-0.5031976699829102	pneumonia ; surgical conditions
P-5	-0.2355 -2.6215 -0.2487 -0.4980 -0.3736 -0.0263 -0.0503 -0.2375 -0.2373
S-1065	T1 mapping may be a useful technique for detecting early but clinically significant myocardial fibrosis.<unk>
T-1065	t1 mapping ; clinically ; myocardial fibrosis
H-1065	-0.8024343252182007	▁t 1 ▁ma pping ▁; ▁my o card ial ▁fibro sis
D-1065	-0.8024343252182007	t1 mapping ; myocardial fibrosis
P-1065	-0.3559 -0.2094 -3.4725 -0.0522 -0.2713 -1.7461 -0.3330 -1.9178 -0.1270 -0.0372 -1.4162 -0.3362 -0.1569
S-1862	RESULTS: The sample (n = 25) was predominately male (76%) with an average age of 62 years.<unk>
T-1862	
H-1862	-0.4717128872871399	
D-1862	-0.4717128872871399	
P-1862	-0.7682 -0.1752
S-1315	Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.<unk>
T-1315	patients ; prognosis
H-1315	-1.0970606803894043	▁high - risk ▁patients
D-1315	-1.0970606803894043	high-risk patients
P-1315	-2.7915 -0.0583 -0.3741 -1.0864 -2.0338 -0.2383
S-1983	Exercise attendance was 84% (SD, 14%) and diet adherence was 99% (SD, 1%).<unk>
T-1983	exercise
H-1983	-0.7244961857795715	▁exercise ▁; ▁die t ▁ad her ence
D-1983	-0.7244961857795715	exercise ; diet adherence
P-1983	-0.7096 -1.2236 -3.1278 -0.1594 -0.0387 -0.3790 -0.0406 -0.6950 -0.1467
S-626	RESULTS: Mean age of participants was 74 ± 3 years; 48% were men and 59% were white.<unk>
T-626	
H-626	-0.3885657787322998	▁white
D-626	-0.3885657787322998	white
P-626	-0.7777 -0.1122 -0.2759
S-1681	This month's "Ethics Rounds" presents a case in which these 2 complexities overlapped.<unk>
T-1681	ethics rounds
H-1681	-0.6787674427032471	▁e thi cs ▁Round s
D-1681	-0.6787674427032471	ethics Rounds
P-1681	-2.4025 -0.5595 -0.0825 -0.4468 -0.0979 -0.9809 -0.1813
S-2013	The model can be used to evaluate parallel-group and single-cohort study designs and hypothetical programs.<unk>
T-2013	
H-2013	-0.9896215200424194	
D-2013	-0.9896215200424194	
P-2013	-1.7356 -0.2436
S-13	Biomarkers of neurohormonal stimulation, inflammation, and endothelial dysfunction were measured.<unk>
T-13	biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
H-13	-0.2779489755630493	▁Bio mark ers ▁; ▁neuro hormon al ▁stimul ation ▁; ▁ inflammation ▁; ▁en dot heli al ▁dys function
D-13	-0.2779489755630493	Biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
P-13	-1.8230 -0.0221 -0.0716 -0.2756 -0.0472 -0.0312 -0.0546 -0.1107 -0.0869 -0.1902 -0.0188 -0.0530 -0.1602 -0.0215 -1.1201 -0.1692 -0.0144 -0.0716 -1.0596 -0.2627 -0.1728
S-2018	Heart Failure: Pathophysiology, Diagnosis, Medical Treatment Guidelines, and Nursing Management.<unk>
T-2018	heart failure ; pathophysiology ; diagnosis ; medical treatment ; nursing
H-2018	-0.4861491024494171	▁Heart ▁Fail ure ▁; ▁path o phy si ology ▁; ▁medical ▁Treatment ▁guide lines ▁; ▁Nur sing ▁management
D-2018	-0.4861491024494171	Heart Failure ; pathophysiology ; medical Treatment guidelines ; Nursing management
P-2018	-0.2130 -0.2294 -0.0215 -0.4055 -0.5523 -1.4648 -0.0142 -0.8462 -0.0290 -0.2132 -0.1253 -1.3001 -1.5834 -0.4501 -0.7750 -0.2503 -0.0077 -0.9730 -0.1341 -0.1349
S-29	Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians.<unk>
T-29	anemia ; patients ; heart disease ; clinical practice guideline ; american college of physicians
H-29	-0.5966737866401672	▁an emia ▁; ▁heart ▁disease ▁; ▁clinic al ▁practice ▁guide line ▁; ▁American ▁college ▁of ▁Physic ians
D-29	-0.5966737866401672	anemia ; heart disease ; clinical practice guideline ; American college of Physicians
P-29	-0.4237 -0.1270 -0.3643 -2.3815 -0.8775 -0.6847 -2.2130 -0.0609 -0.0286 -0.4473 -0.0165 -0.7133 -1.5819 -0.2741 -0.0668 -0.4005 -0.0480 -0.4162 -0.2109
S-515	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.<unk>
T-515	heart rate reduction ; ivabradine ; left ventricle ; heart failure ; patients
H-515	-0.9068807363510132	▁heart ▁rate ▁re duction ▁; ▁i va bra dine ▁un load s ▁; ▁left ▁vent ric le ▁; ▁heart ▁failure
D-515	-0.9068807363510132	heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
P-515	-3.0081 -0.0793 -0.4783 -0.0280 -0.5977 -0.0199 -1.8794 -0.5035 -0.1164 -0.4770 -0.0219 -0.4702 -0.7875 -0.0394 -3.1975 -3.7622 -1.5605 -0.4829 -0.3152 -0.2192 -1.4999 -0.4075
S-386	Incidence and predictors of end-stage renal disease in outpatients with systolic heart failure.<unk>
T-386	incidence ; end-stage renal disease ; outpatients ; systolic heart failure
H-386	-0.2688377797603607	▁end - s tage ▁renal ▁disease ▁; ▁out patient s ▁; ▁sy sto lic ▁heart ▁failure
D-386	-0.2688377797603607	end-stage renal disease ; outpatients ; systolic heart failure
P-386	-0.1459 -0.0681 -0.0241 -0.0068 -0.0326 -0.4448 -0.1472 -0.0974 -0.0072 -0.0686 -0.3259 -0.1880 -0.0667 -1.5826 -0.9127 -0.1144 -0.4017 -0.2044
S-327	During RVPO with BiVP, CO only correlated with RS synchrony and CS (P < 0.05).<unk>
T-327	rvpo ; bivp ; correlated ; rs synchrony
H-327	-0.6370140314102173	▁ rv po ▁; ▁bi VP ▁; ▁co ▁; ▁RS ▁synchron y ▁; ▁CS
D-327	-0.6370140314102173	rvpo ; biVP ; co ; RS synchrony ; CS
P-327	-0.2265 -1.4128 -0.8666 -0.0871 -0.5614 -1.7977 -0.2522 -2.2935 -0.4210 -0.7421 -0.0104 -0.2979 -0.6714 -0.0772 -0.1896 -0.2848
S-1382	These results suggest renal DNx improves cardiac autonomic balance in CHF by a reduction of sympathetic tone.<unk>
T-1382	renal dnx ; cardiac ; autonomic balance ; chf ; sympathetic tone
H-1382	-0.24015960097312927	▁renal ▁DN x ▁; ▁cardiac ▁autonomi c ▁balance ▁; ▁CHF ▁; ▁sympa the tic ▁tone
D-1382	-0.24015960097312927	renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
P-1382	-0.0123 -0.1615 -0.1496 -0.1783 -0.1192 -0.1772 -0.7402 -0.0317 -0.2003 -0.0059 -0.3605 -0.0310 -1.1342 -0.0967 -0.2931 -0.2769 -0.1142
S-931	Specifically, we explored whether resistin underlies acute anthracycline-induced cardiotoxicity.<unk>
T-931	resistin ; acute ; anthracycline-induced cardiotoxicity
H-931	-0.36506980657577515	▁resist in ▁; ▁a cute ▁an thra cycli ne - indu ced ▁cardio toxic ity
D-931	-0.36506980657577515	resistin ; acute anthracycline-induced cardiotoxicity
P-931	-0.1124 -0.5017 -0.1079 -0.0700 -0.0561 -0.1198 -0.2952 -0.6540 -0.2751 -0.5646 -0.0257 -1.0925 -0.1681 -0.8790 -0.4016 -0.6282 -0.2543
S-1447	The effect of acute autonomic nervous system modulation on QTV appears to be limited in HF patients.<unk>
T-1447	acute ; autonomic nervous system ; qtv ; hf ; patients
H-1447	-0.5938218832015991	▁a cute ▁autonomi c ▁ner vous ▁system ▁modul ation ▁; ▁Q TV ▁; ▁ HF
D-1447	-0.5938218832015991	acute autonomic nervous system modulation ; QTV ; HF
P-1447	-0.6517 -0.0128 -0.4668 -0.7068 -0.8731 -1.6943 -0.0692 -1.7258 -0.0992 -0.3043 -1.0646 -0.8118 -0.1335 -0.4429 -0.1110 -0.7345 -0.1927
S-960	Heart rate and aortic blood flow were recorded 24 h after receiving the last dose of doxorubicin.<unk>
T-960	heart rate ; aortic ; blood flow ; doxorubicin
H-960	-0.3556245267391205	▁Heart ▁rate ▁; ▁a or tic ▁blood ▁flow ▁; ▁do xor ubi cin
D-960	-0.3556245267391205	Heart rate ; aortic blood flow ; doxorubicin
P-960	-0.5355 -0.0085 -0.1930 -0.0261 -0.3106 -0.0697 -1.5052 -0.0206 -0.4959 -0.2856 -0.2833 -0.1793 -0.9465 -0.3225 -0.1520
S-1850	We will include clinical outcomes such as hospitalisations, readmissions and mortality, if data is available.<unk>
T-1850	clinical ; outcomes ; hospitalisations ; readmissions ; mortality
H-1850	-0.6607140898704529	▁hospital isation s ▁; ▁read missions ▁; ▁mortal ity
D-1850	-0.6607140898704529	hospitalisations ; readmissions ; mortality
P-1850	-4.7118 -0.0327 -0.1930 -0.4705 -0.2092 -0.0428 -1.0150 -0.0183 -0.0392 -0.2172 -0.3181
S-1213	RESULTS: Myocardial PDE2 expression and activity were ~2-fold higher in advanced human HF.<unk>
T-1213	myocardial ; pde2 ; expression ; activity ; hf
H-1213	-0.5866015553474426	▁my o card ial ▁p de 2 ▁expression ▁; ▁activity ▁; ▁ HF
D-1213	-0.5866015553474426	myocardial pde2 expression ; activity ; HF
P-1213	-1.5737 -0.1194 -0.3545 -0.0605 -1.1832 -1.5526 -0.0702 -0.4708 -0.1895 -0.2195 -0.2332 -1.6575 -0.4843 -0.3682 -0.2619
S-1869	BAT results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity.<unk>
T-1869	bat ; sympathetic outflow ; parasympathetic activity
H-1869	-0.5839962363243103	▁BAT ▁; ▁sympa the tic ▁out flow ▁; ▁para sy mpa the tic ▁activity
D-1869	-0.5839962363243103	BAT ; sympathetic outflow ; parasympathetic activity
P-1869	-0.0770 -0.7608 -0.7308 -1.4259 -0.1029 -0.0703 -0.0382 -0.2154 -0.6679 -0.6249 -0.2660 -3.4558 -0.2659 -0.0326 -0.3866 -0.2230
S-426	Echocardiographic predictors of reverse remodeling after cardiac resynchronization therapy and subsequent events.<unk>
T-426	echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
H-426	-0.5329835414886475	▁e cho car dio graphic ▁predict ors ▁; ▁rever se ▁remodel ing ▁; ▁cardiac ▁re syn chron ization ▁ therapy
D-426	-0.5329835414886475	echocardiographic predictors ; reverse remodeling ; cardiac resynchronization therapy
P-426	-0.6929 -0.2907 -2.2993 -2.7681 -0.5646 -0.8053 -0.0879 -0.3835 -0.0005 -0.0251 -0.0832 -0.1027 -0.4603 -0.0630 -0.0218 -0.0113 -0.0070 -0.3962 -1.6879 -0.1059 -0.6307 -0.2377
S-1933	However, for cardiovascular death or HF hospitalization, exercise training had a greater impact on patients with lower BTES.<unk>
T-1933	cardiovascular death ; hf ; hospitalization ; exercise ; training ; patients ; btes
H-1933	-0.5698221921920776	▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁exercise ▁training ▁; ▁b tes
D-1933	-0.5698221921920776	cardiovascular death ; HF hospitalization ; exercise training ; btes
P-1933	-1.2385 -1.3307 -0.0603 -0.1685 -0.0219 -1.0694 -0.3362 -0.2284 -0.0677 -0.1933 -0.3063 -2.6200 -0.3985 -0.3311 -0.1767
S-245	Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties.<unk>
T-245	exercise ; training ; patients ; chronic heart failure ; high-density lipoprotein
H-245	-0.6453714966773987	▁exercise ▁training ▁; ▁chronic ▁heart ▁failure ▁; ▁high - dens ity ▁lipo prote in
D-245	-0.6453714966773987	exercise training ; chronic heart failure ; high-density lipoprotein
P-245	-1.7687 -0.3469 -0.2605 -0.8454 -1.7399 -0.1366 -0.3036 -0.5223 -0.1368 -0.7023 -0.0202 -0.5380 -0.6922 -0.9263 -1.1762 -0.2099
S-634	Neurohormonal abnormalities contribute to the pathophysiology of congestive heart failure (CHF).<unk>
T-634	neurohormonal ; pathophysiology ; congestive heart failure ; chf
H-634	-0.35633015632629395	▁Neuro hormon al ▁ab normal ities ▁; ▁con ges tive ▁heart ▁failure ▁; CH f
D-634	-0.35633015632629395	Neurohormonal abnormalities ; congestive heart failure ;CHf
P-634	-0.3782 -0.0429 -0.0144 -0.0478 -0.0262 -0.0848 -0.1172 -1.7615 -0.1819 -0.1028 -1.3883 -0.0988 -0.5498 -0.1709 -0.6030 -0.3447 -0.1444
S-1135	The parasympathetic neurotransmission can be improved by acetylcholinesterase inhibition.<unk>
T-1135	parasympathetic neurotransmission ; acetylcholinesterase inhibition
H-1135	-0.6046727299690247	▁para sy mpa the tic ▁neuro trans mission ▁; ▁a ce tyl cho line ster ase ▁inhibi tion
D-1135	-0.6046727299690247	parasympathetic neurotransmission ; acetylcholinesterase inhibition
P-1135	-0.0847 -0.3501 -0.2090 -2.3647 -0.0672 -0.1689 -0.0279 -0.2654 -0.1409 -0.0390 -0.1372 -1.0500 -2.7380 -0.2605 -0.8519 -1.6106 -0.1510 -0.3512 -1.0278 -0.1976
S-118	The differential effect of LVEF on long-term mortality is significantly attenuated in the older age group.<unk>
T-118	differential effect ; lvef ; mortality
H-118	-0.6632489562034607	▁LV EF ▁; ▁long - term ▁mortal ity
D-118	-0.6632489562034607	LVEF ; long-term mortality
P-118	-2.1175 -0.7891 -0.3605 -0.6767 -0.2017 -0.1722 -0.5380 -0.0718 -1.4092 -0.2958
S-684	Mediterranean and DASH diet scores and mortality in women with heart failure: The Women's Health Initiative.<unk>
T-684	dash ; mortality ; heart failure ; health
H-684	-0.6162611246109009	▁Mediterrane an ▁; ▁DAS h ▁; ▁mortal ity ▁; ▁heart ▁failure ▁; ▁women ▁; ▁health ▁Initiative
D-684	-0.6162611246109009	Mediterranean ; DASh ; mortality ; heart failure ; women ; health Initiative
P-684	-0.2919 -0.0234 -0.2819 -0.0061 -0.4821 -0.4517 -1.1049 -0.0307 -0.1477 -1.1683 -0.1984 -0.3924 -1.5254 -1.9832 -0.5259 -2.0626 -0.2277 -0.1885
S-1682	An 18-year-old Jehovah's Witness with sickle cell disease has life-threatening anemia.<unk>
T-1682	witness ; sickle cell disease ; anemia
H-1682	-0.5406327247619629	▁Jehovah ' s ▁Wit ness ▁; ▁sick le ▁cell ▁disease ▁; ▁an emia
D-1682	-0.5406327247619629	Jehovah's Witness ; sickle cell disease ; anemia
P-1682	-0.0412 -3.4257 -0.1462 -0.1345 -0.1474 -0.1580 -0.0487 -0.4350 -0.8872 -0.8901 -0.2907 -0.4663 -0.3095 -0.3686 -0.3604
S-1485	In addition, we provide brief insight into the potential of miRNAs as novel therapeutic targets for heart failure.<unk>
T-1485	mirnas ; therapeutic ; heart failure
H-1485	-0.4592829644680023	▁mi RNA s ▁; ▁heart ▁failure
D-1485	-0.4592829644680023	miRNAs ; heart failure
P-1485	-0.3811 -0.0274 -0.0710 -0.2460 -2.4429 -0.0943 -0.2142 -0.1973
S-586	Dobutamine requirement, higher furosemide dose, and higher oxygen flow were associated with unfavorable outcome.<unk>
T-586	dobutamine ; furosemide ; outcome
H-586	-0.4806349575519562	▁do bu tamine ▁; ▁fur os em ide ▁; ▁oxygen ▁flow
D-586	-0.4806349575519562	dobutamine ; furosemide ; oxygen flow
P-586	-0.3552 -0.0959 -0.4551 -0.2991 -0.1325 -0.2507 -0.1126 -0.3190 -1.2495 -2.2258 -0.0408 -0.5362 -0.1760
S-1626	No relationship was found between the Health Buddy Program and ED use or number of hospital days for participants who were hospitalized.<unk>
T-1626	health buddy program ; hospital ; hospitalized
H-1626	-0.6429608464241028	▁health ▁Budd y ▁program ▁; ▁ED
D-1626	-0.6429608464241028	health Buddy program ; ED
P-1626	-0.5607 -0.0840 -0.1241 -1.3856 -0.1403 -0.1616 -2.4615 -0.2258
S-1670	Potent inhibition of L-type Ca2+ currents by a Rad variant associated with congestive heart failure.<unk>
T-1670	rad variant ; congestive heart failure
H-1670	-0.6759202480316162	▁l - type ▁ca 2 ▁; ▁current s ▁; ▁Rad ▁; ▁con ges tive ▁heart ▁failure
D-1670	-0.6759202480316162	l-type ca2 ; currents ; Rad ; congestive heart failure
P-1670	-3.2251 -0.1948 -0.1662 -0.6804 -0.1420 -1.7118 -1.2905 -0.2196 -0.2193 -0.3858 -1.4920 -0.2101 -0.1771 -0.1261 -0.8902 -0.3551 -0.4373 -0.2431
S-130	CONCLUSIONS: We noted differential relations between CPCs and outcomes in patients with vs without diabetes.<unk>
T-130	cpcs ; outcomes ; patients ; diabetes
H-130	-0.5297324657440186	▁c p s ▁; ▁outcome s ▁; ▁diabetes
D-130	-0.5297324657440186	cps ; outcomes ; diabetes
P-130	-0.4050 -1.2909 -0.6079 -0.3141 -0.9351 -0.0651 -0.6215 -0.4998 -0.1833 -0.3746
S-936	We also examined resistin levels in anthracycline-treated breast cancer patients with and without cardiotoxicity.<unk>
T-936	resistin ; breast cancer ; patients ; cardiotoxicity
H-936	-0.44287779927253723	▁resist in ▁levels ▁; ▁an thra cycli ne - tre ated ▁breast ▁cancer ▁; ▁cardio toxic ity
D-936	-0.44287779927253723	resistin levels ; anthracycline-treated breast cancer ; cardiotoxicity
P-936	-0.2092 -0.8048 -0.0962 -0.2159 -0.0173 -0.2205 -1.3625 -0.4155 -0.8819 -0.4504 -0.1624 -0.1745 -0.2695 -0.9142 -0.2649 -0.5562 -0.4443 -0.6954 -0.2591
S-597	The left pulmonary artery was completed occluded and the right pulmonary artery was partially obstructed.<unk>
T-597	left pulmonary artery ; right pulmonary artery
H-597	-0.28294166922569275	▁pulmonar y ▁arter y ▁; ▁right ▁pulmonar y ▁arter y
D-597	-0.28294166922569275	pulmonary artery ; right pulmonary artery
P-597	-0.6955 -0.1013 -0.1235 -0.3073 -0.5190 -0.0488 -0.0918 -0.1521 -0.1503 -0.2603 -0.6961 -0.2495
S-1057	Animals were scanned twice with a 1.5-T MRI scanner, once at baseline and once at heart failure.<unk>
T-1057	mri scanner ; baseline ; heart failure
H-1057	-0.8643548488616943	▁Animal s ▁; ▁m RI ▁scanner ▁; ▁base line ▁; ▁heart ▁failure
D-1057	-0.8643548488616943	Animals ; mRI scanner ; baseline ; heart failure
P-1057	-4.2442 -0.1500 -0.3616 -2.3207 -2.5691 -0.2951 -0.4209 -0.0037 -0.0193 -0.3592 -0.4841 -0.2815 -0.3340 -0.2574
S-1368	However, clinical and therapeutic implications are indistinct and need to be elucidated in further studies.<unk>
T-1368	clinical ; therapeutic
H-1368	-0.9187420010566711	
D-1368	-0.9187420010566711	
P-1368	-1.6734 -0.1641
S-209	OBJECTIVE: Many advances have been made recently in the treatment of congestive heart failure (CHF).<unk>
T-209	congestive heart failure ; chf
H-209	-0.27270960807800293	▁con ges tive ▁heart ▁failure ▁; CH f
D-209	-0.27270960807800293	congestive heart failure ;CHf
P-209	-0.4396 -0.0977 -0.0346 -0.6775 -0.0419 -0.3934 -0.1898 -0.4436 -0.2734 -0.1355
S-1493	A muscle-wasting syndrome exists in acquired heart failure but has not been assessed in Fontan subjects.<unk>
T-1493	syndrome ; heart failure ; fontan
H-1493	-0.28543978929519653	▁muscle - was ting ▁syndrome ▁; ▁acquire d ▁heart ▁failure ▁; ▁Font an
D-1493	-0.28543978929519653	muscle-wasting syndrome ; acquired heart failure ; Fontan
P-1493	-0.7349 -0.2078 -0.7716 -0.0107 -0.1264 -0.1229 -0.0254 -0.0344 -0.7547 -0.0866 -0.9086 -0.1280 -0.1185 -0.1083 -0.1427
S-623	BACKGROUND: Frailty is common in the elderly and is associated with adverse health outcomes.<unk>
T-623	frailty ; health ; outcomes
H-623	-0.7822672128677368	▁Fra il ty ▁; ▁el der ly ▁; ▁advers e ▁health
D-623	-0.7822672128677368	Frailty ; elderly ; adverse health
P-623	-0.7080 -0.2530 -0.5722 -0.1673 -2.8186 -0.0286 -0.0500 -0.2999 -0.6513 -0.0991 -0.2254 -4.0958 -0.2004
S-221	CONCLUSION: The rates of annual ED visits for CHF and intubation rates declined from 1996 to 2008.<unk>
T-221	chf ; intubation
H-221	-0.48655182123184204	▁ED ▁visit s ▁; ▁CHF ▁; ▁in tub ation ▁rates
D-221	-0.48655182123184204	ED visits ; CHF ; intubation rates
P-221	-2.4455 -1.4345 -0.0576 -0.1831 -0.0223 -0.2360 -0.0035 -0.0715 -0.0940 -0.6725 -0.4450 -0.1732
S-650	The effectiveness of bisoprolol in reducing mortality has also also been documented in a number of studies.<unk>
T-650	bisoprolol ; mortality
H-650	-0.4350633919239044	▁bis o pro lol ▁; ▁mortal ity
D-650	-0.4350633919239044	bisoprolol ; mortality
P-650	-0.2891 -0.1419 -0.1422 -1.0901 -0.6034 -1.1446 -0.0608 -0.2423 -0.2011
S-1622	INTERVENTION: The Health Buddy Program, which integrates a content-driven telehealth system with care management.<unk>
T-1622	health buddy program ; telehealth
H-1622	-0.4714786410331726	▁health ▁Budd y ▁program ▁; ▁tele health ▁system ▁; ▁care ▁management
D-1622	-0.4714786410331726	health Buddy program ; telehealth system ; care management
P-1622	-0.4833 -0.0999 -0.0671 -1.5516 -0.2905 -0.8874 -0.6783 -0.2299 -0.5327 -0.0373 -0.7660 -0.3020 -0.2032
S-1714	PARTICIPANTS: Medicare fee-for-service beneficiaries associated with 2,101,481 hospitalizations.<unk>
T-1714	medicare ; hospitalizations
H-1714	-0.5400856733322144	▁Medica re ▁fee - for - service ▁; ▁hospital ization
D-1714	-0.5400856733322144	Medicare fee-for-service ; hospitalization
P-1714	-0.2531 -0.0689 -1.0560 -0.1314 -0.1385 -0.0657 -0.0727 -1.2511 -0.6712 -0.2423 -2.3246 -0.2055
S-1422	Research is needed to explore whether physician continuity is important for other conditions and in settings other than recent hospital discharge.<unk>
T-1422	physician ; conditions ; hospital ; discharge
H-1422	-0.44056782126426697	▁physician ▁continu ity ▁; ▁conditions ▁; ▁hospital ▁dis charge
D-1422	-0.44056782126426697	physician continuity ; conditions ; hospital discharge
P-1422	-0.9241 -0.6973 -0.0404 -0.3770 -0.3572 -0.2497 -1.4945 -0.1890 -0.0698 -0.1859 -0.2614
S-1740	BACKGROUND: Contemporary therapeutic options have led to substantial improvement in survival of patients with heart failure.<unk>
T-1740	therapeutic ; patients ; heart failure
H-1740	-1.4269473552703857	▁ therapeut ic ▁; ▁heart ▁failure
D-1740	-1.4269473552703857	therapeutic ; heart failure
P-1740	-5.0648 -0.2104 -0.0451 -1.3595 -4.2704 -0.0543 -0.2403 -0.1708
S-1928	Higher PSSS indicated higher levels of social support, whereas higher BTES indicated more barriers to exercise.<unk>
T-1928	psss ; btes ; exercise
H-1928	-0.9996966123580933	▁PS SS ▁; ▁social ▁support ▁; ▁b tes
D-1928	-0.9996966123580933	PSSS ; social support ; btes
P-1928	-1.2968 -0.8101 -0.1871 -0.3743 -1.7881 -0.5249 -1.2405 -0.3321 -3.1753 -0.2679
S-1219	This may constitute an important defense mechanism during cardiac stress, for example, by antagonizing excessive β-AR drive.<unk>
T-1219	cardiac stress ; β-ar ; drive
H-1219	-0.8491207957267761	▁defense ▁mechanism ▁; ▁cardiac ▁stress ▁; ▁β - AR ▁drive
D-1219	-0.8491207957267761	defense mechanism ; cardiac stress ; β-AR drive
P-1219	-5.0573 -0.0030 -0.3091 -0.1452 -0.1392 -0.1693 -3.0120 -0.0777 -0.5941 -0.0204 -0.4659 -0.1961
S-99	This study reports the quantitative analysis of a new chromatin subproteome in the normal and diseased mouse heart.<unk>
T-99	chromatin subproteome ; diseased ; heart
H-99	-0.5767388939857483	▁chr omat in ▁sub prote ome ▁; ▁mouse ▁heart
D-99	-0.5767388939857483	chromatin subproteome ; mouse heart
P-99	-1.2819 -0.0607 -1.6897 -0.2709 -0.0518 -0.3680 -0.1277 -1.7218 -0.3807 -0.1925 -0.1984
S-329	CO correlated with septal wall CS during AVD variation and free wall CS during VVD variation (P < 0.008).<unk>
T-329	correlated ; septal ; wall ; avd ; free wall cs ; vvd
H-329	-0.7863231301307678	▁co ▁cor related ▁; ▁sept al ▁wall ▁CS ▁; ▁AV d ▁variation ▁; ▁free ▁wall ▁CS ▁; ▁VVD
D-329	-0.7863231301307678	co correlated ; septal wall CS ; AVd variation ; free wall CS ; VVD
P-329	-0.7579 -0.5315 -0.0484 -0.2875 -0.0977 -0.3202 -0.2210 -3.2489 -0.2302 -2.9793 -0.8760 -1.4404 -0.0968 -0.0021 -0.6359 -2.6831 -0.2206 -0.3899 -0.4746 -0.1846
S-946	LV strain and strain rate were assessed by echocardiography at baseline and over 12 months after ablation.<unk>
T-946	lv strain ; strain ; echocardiography ; baseline ; ablation
H-946	-0.49825239181518555	▁LV ▁; ▁strain ▁rate ▁; ▁e cho card i ography ▁; ▁base line
D-946	-0.49825239181518555	LV ; strain rate ; echocardiography ; baseline
P-946	-0.1689 -2.2271 -0.2314 -0.2335 -0.5794 -0.0933 -0.4192 -0.6989 -0.5264 -0.6482 -0.6162 -0.0011 -0.0431 -0.7968 -0.1905
S-1162	Subjects were followed up for adverse events (defined as death, transplantation, or circulatory assist device).<unk>
T-1162	followed up ; adverse events ; death ; transplantation ; circulatory assist device
H-1162	-0.8037140369415283	▁death ▁; ▁transplant ation ▁; ▁circula tory ▁assist ▁device
D-1162	-0.8037140369415283	death ; transplantation ; circulatory assist device
P-1162	-5.8670 -0.5215 -0.0488 -0.1027 -0.4553 -0.1729 -0.0124 -0.4671 -0.5901 -0.4230 -0.1800
S-318	Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure.<unk>
T-318	biventricular pacing ; left heart twist ; strain ; right heart failure
H-318	-0.39426368474960327	▁bi ven tri cular ▁pa cing ▁; ▁left ▁heart ▁twist ▁; ▁strain ▁; ▁por cine ▁model ▁; ▁right ▁heart ▁failure
D-318	-0.39426368474960327	biventricular pacing ; left heart twist ; strain ; porcine model ; right heart failure
P-318	-0.3975 -0.5889 -0.8203 -0.4743 -0.4936 -0.0179 -0.3667 -0.2245 -1.7008 -0.0256 -0.4870 -0.0553 -0.2380 -0.7124 -0.0392 -0.2153 -0.5168 -0.0042 -0.3994 -0.1001 -0.4629 -0.3330
S-1092	The etiologic causes of acute RV failure often differ from those encountered in left ventricular dysfunction.<unk>
T-1092	etiologic ; acute rv failure ; left ventricular dysfunction
H-1092	-0.794924795627594	▁et i ologic ▁; ▁a cute ▁ RV ▁failure ▁; ▁left ▁vent ri cular ▁dys function
D-1092	-0.794924795627594	etiologic ; acute RV failure ; left ventricular dysfunction
P-1092	-1.2795 -0.2746 -0.1794 -0.5384 -0.2079 -0.0235 -0.4506 -0.4235 -0.2349 -0.2672 -0.1904 -3.7850 -2.5290 -0.3969 -0.5529 -1.9305 -0.7525 -0.2919
S-121	We evaluated the association between serial measurements of CPCs and functional capacity and outcomes in heart failure (HF).<unk>
T-121	cpcs ; functional capacity ; outcomes ; heart failure ; hf
H-121	-0.5468075275421143	▁c PC s ▁; ▁functional ▁capacity ▁; ▁heart ▁failure ▁; HF
D-121	-0.5468075275421143	cPCs ; functional capacity ; heart failure ;HF
P-121	-0.1554 -1.7696 -0.1628 -0.1574 -2.4496 -0.0914 -0.2148 -0.5598 -0.0759 -0.6849 -0.0549 -0.4297 -0.3023
S-418	Neither inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.<unk>
T-418	protein kinase a ; guanylate cyclase ; contractile response
H-418	-0.7966310381889343	▁inhibi tion ▁of ▁protein ▁kina se ▁; ▁solu ble ▁gua ny late ▁cy cla se ▁; ▁contract ile ▁response
D-418	-0.7966310381889343	inhibition of protein kinase ; soluble guanylate cyclase ; contractile response
P-418	-1.1853 -0.0271 -0.5572 -0.1672 -0.0396 -0.6924 -0.4384 -1.2047 -0.3711 -0.1402 -0.7827 -1.7138 -0.1156 -0.3080 -2.2252 -0.4372 -0.0367 -3.9072 -1.5260 -0.5258 -0.3277
S-119	Changes in circulating progenitor cells are associated with outcome in heart failure patients: a longitudinal study.<unk>
T-119	circulating progenitor cells ; outcome ; heart failure ; patients ; longitudinal
H-119	-0.7072339057922363	▁circula ting ▁pro gen itor ▁cell s ▁; ▁outcome ▁; ▁heart ▁failure ▁patients
D-119	-0.7072339057922363	circulating progenitor cells ; outcome ; heart failure patients
P-119	-3.0063 -0.0749 -0.0966 -0.2206 -0.3251 -1.4453 -0.0609 -0.2914 -1.5409 -0.4096 -0.1391 -0.0873 -2.2783 -0.3978 -0.2344
S-832	Stress Doppler echocardiography may be a useful tool for prognostic assessment in pulmonary hypertension patients.<unk>
T-832	stress doppler echocardiography ; prognostic ; pulmonary hypertension ; patients
H-832	-0.4847179651260376	▁stress ▁do pp ler ▁e cho card i ography ▁; ▁pulmonar y ▁hyper tension
D-832	-0.4847179651260376	stress doppler echocardiography ; pulmonary hypertension
P-832	-0.4845 -0.6731 -0.0025 -0.3712 -0.1317 -1.3544 -0.9573 -0.7411 -0.6676 -0.2686 -0.0422 -0.0631 -0.3282 -0.3853 -1.0994 -0.1853
S-351	Both systolic and diastolic mitral leaflet motions were restricted without any clear organic lesion.<unk>
T-351	systolic ; diastolic mitral leaflet motions ; organic ; lesion
H-351	-0.5284814238548279	▁sy sto lic ▁; ▁dia sto lic ▁; ▁mit ral ▁le a flet ▁motion s ▁; ▁organic ▁les ion
D-351	-0.5284814238548279	systolic ; diastolic ; mitral leaflet motions ; organic lesion
P-351	-0.5233 -0.1778 -0.3780 -0.1865 -0.0747 -0.5023 -0.3898 -0.7257 -1.0506 -0.1079 -1.2407 -0.2061 -0.0094 -1.2913 -0.1563 -0.4587 -1.4888 -1.2763 -0.2080 -0.3406 -0.3053
S-2023	Such an understanding can ultimately reduce morbidity and mortality and optimize quality of life in patients with HF.<unk>
T-2023	morbidity ; mortality ; quality of life ; patients ; hf
H-2023	-0.772604763507843	▁morbi d ity ▁; ▁mortal ity ▁; HF
D-2023	-0.772604763507843	morbidity ; mortality ;HF
P-2023	-0.9336 -0.1908 -0.1225 -0.3502 -0.0332 -0.0502 -0.2742 -5.2792 -0.2452 -0.2469
S-291	CONCLUSIONS: cTnT and NT-proBNP have significant value in HF risk prediction.<unk>
T-291	ctnt ; nt-probnp ; hf
H-291	-0.30898812413215637	▁c t n t ▁; ▁NT - pro b NP ▁; ▁ HF ▁risk ▁predict ion
D-291	-0.30898812413215637	ctnt ; NT-probNP ; HF risk prediction
P-291	-0.0103 -0.2516 -0.0084 -0.2371 -0.0661 -0.1008 -0.0888 -0.0203 -0.5987 -0.1468 -0.1353 -0.2362 -0.5311 -2.1431 -0.1977 -0.0434 -0.4701 -0.2760
S-215	We used the Student t test, calculated 95% confidence intervals (CIs), and performed regression analyses.<unk>
T-215	student t test ; confidence intervals ; cis ; regression analyses
H-215	-0.6658373475074768	▁t ▁test ▁; ▁ci s ▁; ▁re gression
D-215	-0.6658373475074768	t test ; cis ; regression
P-215	-0.1441 -0.5523 -0.5107 -2.7144 -0.0926 -1.3341 -0.0513 -0.0154 -0.9745 -0.2689
S-565	Clinical and radiological signs of HF were less common, yet quality of life was more significantly impaired.<unk>
T-565	clinical ; radiological ; hf ; quality of life
H-565	-0.4867594242095947	▁radi ological ▁; ▁ HF
D-565	-0.4867594242095947	radiological ; HF
P-565	-0.2284 -0.3779 -1.1447 -0.7810 -0.0940 -0.5717 -0.2096
S-195	Inhospital mortality was 2.7%, and patients above the median BNP level had higher mortality than those below.<unk>
T-195	inhospital ; mortality ; patients ; bnp ; mortality
H-195	-0.6045982241630554	▁in hospital ▁mortal ity ▁; ▁b NP ▁level
D-195	-0.6045982241630554	inhospital mortality ; bNP level
P-195	-0.3738 -0.0117 -0.1938 -0.0328 -0.4491 -0.9169 -0.8463 -0.6814 -2.3201 -0.2200
S-1287	Mortality was 24 per cent with five deaths occurring within 30 days of ACS consultation and/or operation.<unk>
T-1287	mortality ; deaths ; acs ; consultation ; operation
H-1287	-0.8635357022285461	▁Mor t ality ▁; ▁a CS
D-1287	-0.8635357022285461	Mortality ; aCS
P-1287	-1.5425 -0.2784 -0.0127 -0.5100 -1.6149 -2.2082 -0.4831 -0.2586
S-1091	The right ventricle (RV) is integral to normal cardiac function, but receives little attention in the medical literature.<unk>
T-1091	right ventricle ; rv ; cardiac function ; medical
H-1091	-0.723395049571991	▁right ▁vent ric le ▁; RV ▁; ▁cardiac ▁function ▁; ▁medical
D-1091	-0.723395049571991	right ventricle ;RV ; cardiac function ; medical
P-1091	-0.0159 -1.8732 -1.5568 -0.8654 -0.3856 -0.4637 -0.5623 -0.3928 -0.9392 -0.7993 -0.0223 -1.3583 -0.1693
S-1721	BACKGROUND: There is an urgent need to improve outcomes and reduce costs for patients with heart failure (HF).<unk>
T-1721	outcomes ; costs ; patients ; heart failure ; hf
H-1721	-0.807377815246582	▁costs ▁; ▁heart ▁failure ▁; HF
D-1721	-0.807377815246582	costs ; heart failure ;HF
P-1721	-2.1890 -0.3691 -2.4259 -0.0825 -0.6873 -0.1465 -0.3792 -0.1795
S-1164	The extent of RV dysfunction correlated with greater antecedent weight loss and a lower fat/lean body mass ratio.<unk>
T-1164	rv dysfunction ; correlated ; lean body mass
H-1164	-0.7747668623924255	▁ RV ▁dys function ▁; ▁weight ▁loss ▁; ▁fat / lean ▁body ▁mass ▁ratio
D-1164	-0.7747668623924255	RV dysfunction ; weight loss ; fat/lean body mass ratio
P-1164	-0.3794 -0.6096 -0.7511 -1.4145 -0.2362 -0.9026 -0.1292 -0.3763 -1.0203 -4.7458 -0.2200 -0.5015 -0.1576 -0.0784 -0.5624 -0.3114
S-1937	This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF.<unk>
T-1937	hr reduction ; beta blockers ; exercise capacity ; hfref
H-1937	-0.4236500561237335	▁HR ▁re duction ▁; ▁beta ▁block ers ▁; ▁exercise ▁capacity ▁; ▁h Fr EF
D-1937	-0.4236500561237335	HR reduction ; beta blockers ; exercise capacity ; hFrEF
P-1937	-1.2072 -0.2703 -0.0185 -0.2197 -0.1225 -0.1229 -0.0582 -0.3010 -0.0470 -0.0486 -0.3485 -1.7671 -1.0228 -0.6199 -0.4033 -0.2009
S-1274	This review provides an update on cardiopulmonary exercise variables, proven to be prognostically important in heart failure.<unk>
T-1274	cardiopulmonary ; exercise ; prognostically ; heart failure
H-1274	-0.7073550224304199	▁cardio pul mon ary ▁exercise ▁variable s ▁; ▁heart ▁failure
D-1274	-0.7073550224304199	cardiopulmonary exercise variables ; heart failure
P-1274	-0.9060 -0.6083 -1.8193 -0.0636 -1.4028 -1.6768 -0.0871 -0.2347 -1.0624 -0.0983 -0.3184 -0.2104
S-1951	METHODS: We did this proof-of-principle cohort study at one centre in Canada.<unk>
T-1951	proof-of-principle cohort study ; canada
H-1951	-0.8029961585998535	▁ proof - of - princip le ▁co hor t ▁study
D-1951	-0.8029961585998535	proof-of-principle cohort study
P-1951	-3.4275 -0.1102 -0.0702 -1.1713 -0.0305 -0.0336 -0.9605 -0.0798 -0.9809 -0.5929 -0.8116 -2.0080 -0.1619
S-1115	Primary outcome was sympathetic activity as measured by (123)I-MIBG myocardial washout.<unk>
T-1115	primary outcome ; sympathetic activity ; myocardial washout
H-1115	-0.9810075163841248	▁i - mi b ▁; ▁my o card ial ▁was hout
D-1115	-0.9810075163841248	i-mib ; myocardial washout
P-1115	-0.6166 -0.2700 -0.2987 -3.2162 -0.6167 -2.9014 -0.2738 -1.8568 -0.0169 -1.4215 -0.3452 -0.5259 -0.3934
S-761	They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification.<unk>
T-761	myocardial diastolic dysfunction ; dd ; collagen deposition ; titin
H-761	-0.3606206178665161	▁my o card ial ▁dia sto lic ▁dys function ▁; DD ▁; ▁collage n ▁de position ▁; ▁titi n ▁modification
D-761	-0.3606206178665161	myocardial diastolic dysfunction ;DD ; collagen deposition ; titin modification
P-761	-0.2639 -0.1001 -0.2801 -0.0272 -0.6718 -0.1921 -0.7843 -0.1625 -1.7376 -0.2432 -0.5836 -0.6607 -0.0307 -0.0590 -0.1045 -0.0658 -0.3003 -0.0203 -0.0588 -0.9929 -0.4238 -0.1706
S-849	The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure.<unk>
T-849	outcome ; death ; hospitalization ; heart failure
H-849	-1.3603960275650024	▁death ▁; ▁hospital ization ▁; ▁heart ▁failure
D-849	-1.3603960275650024	death ; hospitalization ; heart failure
P-849	-5.9154 -0.2903 -2.8068 -0.1783 -0.3281 -2.2004 -0.1437 -0.1682 -0.2124
S-701	The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8).<unk>
T-701	baseline ; st2 ; interquartile range
H-701	-0.6524441838264465	▁base line ▁; ▁ST 2 ▁; inter quart ile ▁range
D-701	-0.6524441838264465	baseline ; ST2 ;interquartile range
P-701	-0.0119 -0.0279 -0.8953 -1.8323 -0.0722 -2.1504 -1.4117 -0.0088 -0.2012 -0.5002 -0.5252 -0.1924
S-1637	Over a median follow-up of 2.5 years, black race was associated with increased risk for all outcomes except mortality.<unk>
T-1637	follow-up ; outcomes ; mortality
H-1637	-0.2663561999797821	▁black ▁race ▁; ▁mortal ity
D-1637	-0.2663561999797821	black race ; mortality
P-1637	-0.0135 -0.3062 -0.3543 -0.7235 -0.0238 -0.1784 -0.2648
S-1395	Nursing-sensitive outcome change scores for hospitalized older adults with heart failure: a preliminary descriptive study.<unk>
T-1395	outcome ; change ; hospitalized ; heart failure
H-1395	-0.48715952038764954	▁Nur sing - sensitiv e ▁outcome ▁change ▁score s ▁; ▁hospital ized ▁older ▁adults ▁; ▁heart ▁failure
D-1395	-0.48715952038764954	Nursing-sensitive outcome change scores ; hospitalized older adults ; heart failure
P-1395	-1.2530 -0.0341 -0.0942 -0.0058 -0.5844 -0.1984 -0.0502 -0.9461 -0.0615 -0.3913 -1.2504 -0.1307 -1.9574 -0.5102 -0.6180 -0.3675 -0.1897 -0.3804 -0.2329
S-1071	Besides therapeutic functions, devices can have add-on diagnostic features such as early detection of fluid overload.<unk>
T-1071	therapeutic ; diagnostic ; fluid overload
H-1071	-0.8058324456214905	▁ therapeut ic ▁; ▁fluid ▁over load
D-1071	-0.8058324456214905	therapeutic ; fluid overload
P-1071	-2.6276 -0.0332 -0.0619 -1.3174 -1.7364 -0.2989 -0.6364 -0.3412 -0.1995
S-927	Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.<unk>
T-927	resistin ; heart failure ; breast cancer
H-927	-0.39237675070762634	▁Human ▁resist in ▁; ▁che mo therapy - indu ced ▁heart ▁failure ▁; ▁human ized ▁male ▁mi ce ▁; ▁breast ▁cancer
D-927	-0.39237675070762634	Human resistin ; chemotherapy-induced heart failure ; humanized male mice ; breast cancer
P-927	-1.1891 -0.0538 -0.2253 -0.3283 -0.3735 -0.2121 -0.1148 -0.4826 -0.0179 -0.3982 -0.7445 -0.0330 -0.3099 -0.6502 -0.0991 -0.9458 -0.0708 -0.0840 -0.1839 -1.4922 -0.3292 -0.4196 -0.2668
S-1926	We aimed to describe the association between social support and barriers to participation with exercise adherence and clinical outcomes.<unk>
T-1926	exercise ; clinical ; outcomes
H-1926	-0.800197184085846	▁social ▁support ▁; ▁exercise ▁ad her ence
D-1926	-0.800197184085846	social support ; exercise adherence
P-1926	-1.7076 -1.1596 -0.2084 -1.0442 -0.0402 -0.2500 -0.0362 -2.4847 -0.2709
S-6	Some events, such as pressure ulcers in surgical patients, actually increased despite considerable national attention to these problems.<unk>
T-6	pressure ulcers ; surgical ; patients
H-6	-0.4796968698501587	▁pressure ▁ul cer s ▁; ▁sur g ical ▁patients
D-6	-0.4796968698501587	pressure ulcers ; surgical patients
P-6	-0.4050 -0.4142 -0.7765 -0.1765 -0.3190 -1.0679 -0.1208 -0.0188 -0.8563 -0.8390 -0.2828
S-369	At the time of second HF 4 years after valve plasty, MS was significant with an MVA of 1.2 cm2.<unk>
T-369	hf ; valve plasty ; mva
H-369	-0.5622058510780334	▁ HF ▁; ▁val ve ▁plast y ▁; ▁MS ▁; ▁m VA
D-369	-0.5622058510780334	HF ; valve plasty ; MS ; mVA
P-369	-0.7241 -0.2210 -0.1019 -2.5473 -0.1439 -0.0438 -0.4915 -0.2312 -1.2873 -0.5319 -0.1870 -0.9093 -0.2785 -0.1722
S-902	PD appears to be a viable option in refractory, end-stage congestive heart failure (CHF).<unk>
T-902	pd ; congestive heart failure ; chf
H-902	-0.21438834071159363	▁PD ▁; ▁re frac tory ▁; ▁end - s tage ▁con ges tive ▁heart ▁failure ▁; CH f
D-902	-0.21438834071159363	PD ; refractory ; end-stage congestive heart failure ;CHf
P-902	-0.8579 -0.1380 -0.1380 -0.0107 -0.0124 -0.2039 -0.1100 -0.0401 -0.0133 -0.0013 -0.0443 -0.2488 -0.0458 -0.7249 -0.0467 -0.4271 -0.1312 -0.5569 -0.3853 -0.1512
S-662	Multivariable hierarchical regression models were adjusted for demographics, insurance status, and comorbidities.<unk>
T-662	regression models ; comorbidities
H-662	-1.0864644050598145	▁insurance ▁; ▁como rbi di ties
D-662	-1.0864644050598145	insurance ; comorbidities
P-662	-2.6100 -3.6651 -1.3877 -0.0209 -0.2936 -0.1912 -0.1971 -0.3261
S-649	However, during the past decades several studies have demonstrated that beta blockers decrease mortality in patients with heart failure.<unk>
T-649	beta blockers ; mortality ; patients ; heart failure
H-649	-0.6165607571601868	▁beta ▁block ers ▁; ▁mortal ity ▁; ▁heart ▁failure
D-649	-0.6165607571601868	beta blockers ; mortality ; heart failure
P-649	-1.4361 -0.5636 -0.2219 -0.3904 -1.5049 -0.0445 -0.2299 -1.7871 -0.2150 -0.2257 -0.1630
S-553	Various transcatheter approaches to these difficult problems are also available and offer less invasive alternatives to conventional surgery.<unk>
T-553	transcatheter ; invasive ; surgery
H-553	-0.33346858620643616	▁trans cat heter ▁; ▁surgery
D-553	-0.33346858620643616	transcatheter ; surgery
P-553	-0.0166 -0.1351 -0.0339 -0.5821 -1.2022 -0.1529 -0.2115
S-850	RESULTS: On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board.<unk>
T-850	
H-850	-0.5653201937675476	▁fut ility ▁; ▁data ▁; ▁monitoring ▁board
D-850	-0.5653201937675476	futility ; data ; monitoring board
P-850	-1.3699 -0.6009 -0.3501 -0.1510 -0.7709 -1.1401 -0.0139 -0.4137 -0.2774
S-1661	This article describes the possible causes of, the array of diagnostic procedures for, and treatments for this complication.<unk>
T-1661	diagnostic ; complication
H-1661	-0.8162156939506531	▁diagnostic ▁procedure s ▁; ▁complica tion
D-1661	-0.8162156939506531	diagnostic procedures ; complication
P-1661	-2.8453 -0.2461 -0.0323 -0.5575 -2.0038 -0.4842 -0.1477 -0.2129
S-748	The choice of chelation regimens known to remove heart iron efficiently was not sufficient by itself to influence the risk.<unk>
T-748	chelation ; heart iron
H-748	-0.85521000623703	▁che lation ▁regime ns ▁; ▁heart ▁ir on ▁; ▁risk
D-748	-0.85521000623703	chelation regimens ; heart iron ; risk
P-748	-1.5232 -0.5524 -0.1796 -1.1346 -0.1788 -3.9299 -0.0670 -0.0926 -1.4312 -0.8289 -0.1707 -0.1735
S-1284	Patients undergoing MT were more likely to require consultation for abdominal problems (88 vs 27%; P = 0.004).<unk>
T-1284	patients ; consultation ; abdominal
H-1284	-0.6622830629348755	▁MT ▁; ▁abdominal ▁problems
D-1284	-0.6622830629348755	MT ; abdominal problems
P-1284	-0.5574 -0.8304 -0.6075 -1.3682 -0.3130 -0.2973
S-793	Within-day test-retest reliability of the Timed Up & Go test in patients with advanced chronic organ failure.<unk>
T-793	patients ; chronic organ failure
H-793	-0.8950336575508118	▁test - re test ▁reli ability ▁; ▁Time d ▁up ▁& ▁go ▁test ▁; ▁chronic ▁organ ▁failure
D-793	-0.8950336575508118	test-retest reliability ; Timed up & go test ; chronic organ failure
P-793	-5.8819 -0.1829 -0.0529 -0.4691 -1.6813 -0.0094 -0.3205 -0.5281 -0.1163 -0.0663 -2.0505 -0.3827 -0.3585 -0.2011 -3.7529 -0.0695 -0.2608 -0.3620 -0.2591
S-1893	The duration and extent of the symptoms are relevant and it is useful to classify patients according to the NYHA functional assessment.<unk>
T-1893	symptoms ; patients ; nyha
H-1893	-1.1664170026779175	▁NY HA
D-1893	-1.1664170026779175	NYHA
P-1893	-2.7647 -0.8075 -0.8711 -0.2223
S-727	Frequency of 7-day follow-up visits increased from 19.6% to 46.9% (P < .01).<unk>
T-727	follow-up
H-727	-0.5649504661560059	▁follow - up
D-727	-0.5649504661560059	follow-up
P-727	-1.4916 -0.2041 -0.0727 -0.9306 -0.1258
S-2001	Thirty-day mortality was 2% and 6-month survival 92%, which exceeded the 88% performance goal.<unk>
T-2001	mortality
H-2001	-0.9479199647903442	▁mortal ity
D-2001	-0.9479199647903442	mortality
P-2001	-2.1294 -0.0440 -1.4620 -0.1563
S-576	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension.<unk>
T-576	left ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
H-576	-0.4474768340587616	▁Le ft ▁vent ri cular ▁e je ction ▁time ▁; ▁a cute ▁heart ▁failure ▁; ▁pre cap illa ry ▁pulmonar y ▁hyper tension
D-576	-0.4474768340587616	Left ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
P-576	-1.3380 -0.0013 -3.1456 -1.0523 -0.1725 -0.0924 -0.1503 -0.0557 -1.3316 -0.3144 -0.0348 -0.0215 -0.9853 -0.0814 -0.3115 -0.0515 -0.3150 -0.2283 -0.0122 -0.0640 -0.0608 -0.3638 -0.1399 -0.6118 -0.2509
S-541	Surgical correction of aortic valve insufficiency after left ventricular assist device implantation.<unk>
T-541	surgical ; aortic valve insufficiency ; left ventricular assist device ; implantation
H-541	-0.7366054654121399	▁a or tic ▁val ve ▁insu ffi cie ncy ▁; ▁left ▁vent ri cular ▁assist ▁device ▁implant ation
D-541	-0.7366054654121399	aortic valve insufficiency ; left ventricular assist device implantation
P-541	-0.9146 -0.2749 -0.0484 -1.5207 -0.1637 -1.3718 -0.1628 -2.3580 -0.0261 -0.3263 -0.0311 -2.0289 -0.6989 -0.1026 -2.2213 -0.5965 -0.8058 -0.3273 -0.5915 -0.1609
S-750	Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure.<unk>
T-750	ejection fraction ; clinical ; cardiac resynchronization therapy ; mild heart failure
H-750	-0.26635074615478516	▁e je ction ▁ fraction ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁mild ▁heart ▁failure
D-750	-0.26635074615478516	ejection fraction ; cardiac resynchronization therapy ; mild heart failure
P-750	-0.2677 -0.0394 -0.0278 -0.6082 -0.0024 -0.2202 -0.6308 -0.0172 -0.0748 -0.0112 -0.2891 -0.9935 -0.0506 -0.3213 -0.2547 -0.5003 -0.1153 -0.4175 -0.2188
S-571	The primary outcome, measured after 12 weeks, was functional capacity assessed by a 6-minute walk test (6MWT).<unk>
T-571	primary outcome ; functional capacity ; 6-minute walk test ; 6mwt
H-571	-1.2347805500030518	▁functional ▁capacity ▁; ▁walk ▁test
D-571	-1.2347805500030518	functional capacity ; walk test
P-571	-4.3477 -0.3596 -0.4200 -1.3453 -0.3734 -1.5081 -0.2894
S-917	In HFPEF animal models, dietary sodium restriction improves ventricular and vascular stiffness and function.<unk>
T-917	hfpef ; sodium ; ventricular ; vascular stiffness
H-917	-0.6735571026802063	▁H FP EF ▁; ▁dieta ry ▁so dium ▁restriction ▁; ▁vent ri cular ▁; ▁vas cular ▁sti ff ness
D-917	-0.6735571026802063	HFPEF ; dietary sodium restriction ; ventricular ; vascular stiffness
P-917	-2.6227 -0.8125 -1.2460 -0.3622 -1.5095 -0.0073 -0.0731 -0.9294 -0.4183 -0.1144 -0.6716 -0.7302 -0.2440 -0.2583 -0.6476 -0.3046 -0.1509 -1.2693 -0.5493 -1.0518 -0.1716
S-1992	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.<unk>
T-1992	fully magnetically levitated left ventricular assist system ; hf
H-1992	-0.5759942531585693	▁magnet ically ▁Lev itate d ▁Le ft ▁Vent ri cular ▁Assist ▁system ▁for ▁Tre ating ▁Advanced ▁ HF
D-1992	-0.5759942531585693	magnetically Levitated Left Ventricular Assist system for Treating Advanced HF
P-1992	-2.3110 -0.0179 -0.0590 -0.4566 -0.1434 -1.1513 -0.0078 -1.1355 -1.6390 -0.2365 -0.6900 -0.5365 -1.6477 -0.5112 -0.0012 -0.1690 -0.0717 -0.1867 -0.3809 -0.1671
S-1341	Here, we found that CHF atrial explants produced less c-Kit+ cells than sham explants.<unk>
T-1341	chf ; atrial explants ; cells ; explants
H-1341	-0.4707379639148712	▁CHF ▁at rial ▁ex plant s ▁; ▁c - K it ▁; ▁cell s ▁; ▁sham ▁ex plant s
D-1341	-0.4707379639148712	CHF atrial explants ; c-Kit ; cells ; sham explants
P-1341	-0.0189 -0.9350 -0.0862 -0.1669 -0.0643 -0.2195 -0.1927 -0.0055 -0.2136 -1.3206 -0.6961 -1.1126 -3.1392 -0.1222 -0.3221 -0.2306 -0.1996 -0.0320 -0.2418 -0.4072 -0.1591
S-1370	A hallmark of chronic heart failure (CHF) is an increased sympathetic tone resulting in autonomic imbalance.<unk>
T-1370	chronic heart failure ; chf ; sympathetic tone ; autonomic imbalance
H-1370	-0.4131747782230377	▁chronic ▁heart ▁failure ▁; CH f ▁; ▁sympa the tic ▁tone ▁; ▁autonomi c ▁im balance
D-1370	-0.4131747782230377	chronic heart failure ;CHf ; sympathetic tone ; autonomic imbalance
P-1370	-0.3577 -1.6816 -0.0612 -0.2503 -0.3285 -0.4628 -0.4681 -0.2248 -0.8441 -0.1070 -0.8252 -0.1573 -0.0121 -0.8239 -0.1206 -0.0195 -0.4625 -0.2302
S-1480	Heart failure is the leading cause of mortality in Western society and represents the fastest growing subclass of cardiovascular diseases.<unk>
T-1480	heart failure ; leading ; mortality ; western ; society ; cardiovascular diseases
H-1480	-0.6544961333274841	▁Heart ▁failure ▁; ▁western ▁society ▁; ▁cardiovascular ▁disease s
D-1480	-0.6544961333274841	Heart failure ; western society ; cardiovascular diseases
P-1480	-0.8132 -0.0566 -0.2304 -3.9825 -0.0052 -0.2414 -0.3347 -0.9037 -0.1281 -0.2992 -0.2044
S-1290	Extracorporeal membrane oxygenation as bridge to recovery in infarction-related refractory right heart failure.<unk>
T-1290	extracorporeal membrane oxygenation ; refractory right heart failure
H-1290	-0.3322296738624573	extra corp o real ▁membran e ▁oxygen ation ▁; ▁recovery ▁; ▁in far ction - related ▁re frac tory ▁right ▁heart ▁failure
D-1290	-0.3322296738624573	extracorporeal membrane oxygenation ; recovery ; infarction-related refractory right heart failure
P-1290	-2.0767 -0.0976 -0.3112 -0.1195 -0.0280 -0.0472 -0.3500 -0.1236 -0.2371 -1.7386 -0.5316 -0.0136 -0.1112 -0.0767 -0.3440 -0.0196 -0.0330 -0.0023 -0.0464 -0.1154 -0.6015 -0.2518 -0.5071 -0.1898
S-1527	We compared clinical, laboratory, echocardiographic, invasive hemodynamic, and outcome data among groups.<unk>
T-1527	clinical ; echocardiographic ; invasive ; hemodynamic ; outcome
H-1527	-0.5290104746818542	▁clinic al ▁; ▁laborator y ▁; ▁e cho car dio graphic ▁; ▁invasi ve ▁hem o dynamic
D-1527	-0.5290104746818542	clinical ; laboratory ; echocardiographic ; invasive hemodynamic
P-1527	-2.4940 -0.0933 -0.1526 -1.0164 -0.0966 -0.1350 -0.0230 -0.1729 -0.7550 -1.9960 -0.4565 -0.1542 -0.0060 -0.1400 -1.3679 -0.2782 -0.0097 -0.5553 -0.1486
S-1292	INVESTIGATIONS: The cardiac catheterization showed a thrombotic obstruction of the right coronary artery.<unk>
T-1292	cardiac catheterization ; thrombotic obstruction ; right coronary artery
H-1292	-0.26494452357292175	▁cardiac ▁cat heter ization ▁; ▁ thro mbo tic ▁ob struct ion ▁; ▁right ▁corona ry ▁arter y
D-1292	-0.26494452357292175	cardiac catheterization ; thrombotic obstruction ; right coronary artery
P-1292	-0.4626 -0.5459 -0.0149 -0.3233 -0.1545 -0.1765 -0.1155 -1.2981 -0.4074 -0.1110 -0.0214 -0.0222 -0.3245 -0.0082 -0.2541 -0.0609 -0.0679 -0.4735 -0.2956 -0.1610
S-136	DATA SOURCES: 2000-2009 California Office of Statewide Health Planning and Development Patient Discharge Data Nonpublic file.<unk>
T-136	california office of statewide health planning and development patient discharge data nonpublic file
H-136	-0.6986274719238281	▁California ▁office ▁of ▁state wide ▁health ▁plan ning ▁and ▁development ▁Patient ▁dis charge ▁data
D-136	-0.6986274719238281	California office of statewide health planning and development Patient discharge data
P-136	-3.1713 -0.6194 -0.4277 -0.3176 -0.0110 -0.2883 -0.4571 -0.0418 -0.3763 -0.0754 -1.8807 -1.1039 -0.0382 -1.2158 -0.9858 -0.1678
S-224	Fontan failure can occur even with normal systolic ventricular function and often in the context of significant liver disease.<unk>
T-224	fontan failure ; systolic ventricular function ; liver disease
H-224	-0.872957706451416	▁Font an ▁failure ▁; ▁sy sto lic ▁vent ri cular ▁function ▁; ▁ liver ▁disease
D-224	-0.872957706451416	Fontan failure ; systolic ventricular function ; liver disease
P-224	-0.2253 -1.3575 -0.1920 -0.1987 -1.8699 -0.0915 -1.8650 -3.8023 -1.0941 -0.2615 -0.9977 -0.1542 -0.1238 -0.2673 -1.8623 -0.2774 -0.1999
S-1402	Findings from this study provide insight on the possible contribution of nursing to outcomes of hospitalized older adults with HF.<unk>
T-1402	nursing ; outcomes ; hospitalized ; hf
H-1402	-1.3575714826583862	▁hospital ized ▁older ▁adults ▁; ▁ HF
D-1402	-1.3575714826583862	hospitalized older adults ; HF
P-1402	-7.2541 -0.1733 -2.5637 -0.2222 -0.6092 -0.7239 -0.0607 -0.2865 -0.3245
S-165	Participation of apoptosis during the development of pacing-induced dilated cardiomyopathy is not fully understood.<unk>
T-165	apoptosis ; pacing-induced dilated cardiomyopathy
H-165	-0.6487746834754944	▁apo pto sis ▁; ▁pa cing - indu ced ▁dil ated ▁cardio my o pathy
D-165	-0.6487746834754944	apoptosis ; pacing-induced dilated cardiomyopathy
P-165	-1.2573 -0.4137 -2.1233 -0.2380 -0.3853 -0.3496 -0.1296 -0.0229 -0.6584 -1.3404 -0.3274 -0.3381 -2.1176 -0.5766 -0.1848 -0.3340 -0.2323
S-1146	Mechanistic insight into prolonged electromechanical delay in dyssynchronous heart failure: a computational study.<unk>
T-1146	electromechanical delay ; dyssynchronous heart failure
H-1146	-0.4460192322731018	▁electro me chan ical ▁de lay ▁; ▁dys syn chron ous ▁heart ▁failure
D-1146	-0.4460192322731018	electromechanical delay ; dyssynchronous heart failure
P-1146	-3.3530 -0.0685 -0.0567 -0.0275 -0.1325 -0.0121 -0.3051 -0.0497 -0.0304 -0.0057 -0.1138 -1.0773 -0.0887 -1.0344 -0.3347
S-682	Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk.<unk>
T-682	patients ; trastuzumab ; cardiac ; comorbidities
H-682	-0.571031391620636	▁tras tuz um ab ▁; ▁cardiac
D-682	-0.571031391620636	trastuzumab ; cardiac
P-682	-0.9533 -0.0358 -0.0234 -0.0224 -0.3776 -0.0671 -2.7965 -0.2920
S-279	This phenotype was reproducible, and there were few perioperative or early deaths in the experimental procedures.<unk>
T-279	phenotype ; perioperative ; deaths
H-279	-0.8909847736358643	▁per i operativ e
D-279	-0.8909847736358643	perioperative
P-279	-0.9654 -0.1677 -0.0233 -0.4182 -3.5204 -0.2508
S-1233	We compared the economic impact of the 2 treatment strategies in patients with AF and heart failure from the province of Québec, Canada.<unk>
T-1233	economic ; patients ; heart failure ; québec ; canada
H-1233	-0.6462895274162292	▁economic ▁impact ▁; ▁af ▁; ▁heart ▁failure ▁; ▁province ▁of ▁Québec ▁; ▁Canada
D-1233	-0.6462895274162292	economic impact ; af ; heart failure ; province of Québec ; Canada
P-1233	-0.0700 -0.2665 -0.2432 -2.3361 -0.4424 -0.7398 -0.0977 -0.7434 -0.7547 -0.2823 -0.2102 -1.3739 -1.7067 -0.2683 -0.1590
S-1811	We have previously demonstrated that cardiac Mena deletion produced cardiac dysfunction with conduction abnormalities and hypertrophy.<unk>
T-1811	cardiac ; mena deletion ; cardiac dysfunction ; hypertrophy
H-1811	-0.36676254868507385	▁cardiac ▁Men a ▁dele tion ▁; ▁cardiac ▁dys function ▁; ▁con duction ▁ab normal ities ▁; ▁hyper trop hy
D-1811	-0.36676254868507385	cardiac Mena deletion ; cardiac dysfunction ; conduction abnormalities ; hypertrophy
P-1811	-0.1877 -0.2529 -0.1164 -0.0591 -0.0900 -0.2524 -0.1701 -0.5246 -1.4067 -0.2535 -0.3357 -0.0059 -0.0539 -0.0439 -0.0256 -0.6230 -0.1114 -0.0729 -2.5636 -0.3327 -0.2200
S-886	Of these, 1175 had left bundle-branch block (LBBB) and 308 had non-LBBB.<unk>
T-886	left bundle-branch block ; lbbb
H-886	-0.3979887068271637	▁bund le - bran ch ▁block ▁; LB BB ▁; ▁non - LB BB
D-886	-0.3979887068271637	bundle-branch block ;LBBB ; non-LBBB
P-886	-0.0723 -0.1261 -0.0622 -0.0032 -0.1177 -0.0975 -0.3186 -1.3474 -1.0304 -0.3966 -0.1053 -0.0887 -1.1389 -0.8730 -0.3466 -0.2434
S-167	We evaluated protein levels of these genes by Western blot and DNA fragmentation by TUNEL method from autopsy samples.<unk>
T-167	protein ; genes ; western blot ; dna fragmentation ; tunel
H-167	-0.4982874393463135	▁protein ▁levels ▁; ▁western ▁blot ▁; ▁DNA ▁fragment ation ▁; ▁TU NEL ▁; ▁auto psy ▁sample s
D-167	-0.4982874393463135	protein levels ; western blot ; DNA fragmentation ; TUNEL ; autopsy samples
P-167	-0.7560 -0.1526 -0.2614 -1.7127 -0.1217 -0.1540 -0.0632 -0.1576 -0.0362 -0.4485 -0.4001 -1.3062 -0.9774 -0.8140 -0.0569 -1.4023 -0.0933 -0.3382 -0.2153
S-1257	Effectiveness of Chinese herbal medicine as an adjunctive treatment for dilated cardiomyopathy in patients with heart failure.<unk>
T-1257	medicine ; dilated cardiomyopathy ; patients ; heart failure
H-1257	-0.459562748670578	▁Chinese ▁herbal ▁medicine ▁; ▁ad ju nc tive ▁treatment ▁; ▁dil ated ▁cardio my o pathy ▁; ▁heart ▁failure
D-1257	-0.459562748670578	Chinese herbal medicine ; adjunctive treatment ; dilated cardiomyopathy ; heart failure
P-1257	-2.1139 -0.2362 -0.4465 -0.1182 -1.1113 -0.0244 -0.0586 -0.0099 -0.7935 -0.2589 -0.0420 -0.0603 -0.3707 -1.9425 -0.3942 -0.1066 -0.2332 -0.5301 -0.0881 -0.4591 -0.2525
S-1856	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study.<unk>
T-1856	patient ; implantable cardioverter-defibrillator
H-1856	-0.7085070013999939	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1856	-0.7085070013999939	implantable cardioverter-defibrillator deactivation
P-1856	-3.0715 -0.0902 -0.6022 -0.0531 -0.5968 -0.0621 -0.0496 -0.5158 -3.1797 -0.8801 -0.1156 -0.2524 -0.0322 -0.2654 -1.2966 -0.2728
S-1532	Despite these differences, EH and CH had similarly elevated cardiac filling pressures and equivalent adverse outcomes.<unk>
T-1532	elevated ; cardiac filling pressures ; adverse outcomes
H-1532	-0.8578833341598511	▁EH ▁; ▁CH ▁; ▁cardiac ▁fill ing ▁pressure s
D-1532	-0.8578833341598511	EH ; CH ; cardiac filling pressures
P-1532	-0.2781 -0.1268 -2.4728 -0.4054 -0.9721 -2.3671 -0.0900 -0.6923 -0.2525 -1.5438 -0.2358
S-596	The right atrium mass presented with prolapse through the tricuspid valve causing a stenotic physiology.<unk>
T-596	right atrium ; prolapse ; tricuspid valve ; stenotic physiology
H-596	-0.4211342930793762	▁right ▁at rium ▁mass ▁; ▁pro lapse ▁; ▁tri cus pid ▁val ve ▁; ▁ste no tic ▁physio log y
D-596	-0.4211342930793762	right atrium mass ; prolapse ; tricuspid valve ; stenotic physiology
P-596	-0.0116 -0.2485 -0.0562 -0.0797 -0.1581 -0.0034 -0.2230 -0.2645 -1.0404 -1.4636 -0.0260 -2.0778 -0.3310 -0.4480 -0.0336 -0.0518 -0.0852 -0.6916 -0.5616 -0.7170 -0.5047 -0.1875
S-271	Furthermore, the optimal cutoff level of NT-proBNP used to predict 4-year survival had high sensitivity.<unk>
T-271	nt-probnp ; sensitivity
H-271	-0.3850072920322418	▁cut off ▁level ▁; ▁NT - pro b NP ▁; ▁survival
D-271	-0.3850072920322418	cutoff level ; NT-probNP ; survival
P-271	-0.1510 -0.5040 -0.4307 -0.3118 -0.1555 -0.0419 -0.0293 -0.4483 -0.2331 -0.5961 -1.4913 -0.3907 -0.2214
S-1423	Human heart failure is accompanied by altered protein kinase A subunit expression and post-translational state.<unk>
T-1423	heart failure ; protein kinase a ; expression
H-1423	-0.4863307774066925	▁human ▁heart ▁failure ▁; ▁protein ▁kina se ▁; ▁sub un it ▁expression ▁; ▁post - trans la tional ▁state
D-1423	-0.4863307774066925	human heart failure ; protein kinase ; subunit expression ; post-translational state
P-1423	-1.3205 -1.1511 -0.0862 -0.2360 -2.6643 -0.1056 -0.4009 -0.4766 -0.5108 -0.3961 -0.8974 -0.0174 -0.6335 -0.0311 -0.0394 -0.0118 -0.2405 -0.0071 -0.1947 -0.3834 -0.4087
S-1106	Over the 5-year follow-up period, 715 patients developed HF, 475 of whom developed it during the first week.<unk>
T-1106	follow-up ; patients ; hf
H-1106	-0.6808257102966309	▁ HF
D-1106	-0.6808257102966309	HF
P-1106	-1.5535 -0.2046 -0.7091 -0.2561
S-2012	Projections of resource use and quality of life are modeled using relationships with time-varying Seattle Heart Failure Model scores.<unk>
T-2012	quality of life ; seattle heart failure model
H-2012	-1.2608051300048828	▁Seattle ▁Heart ▁Fail ure ▁model
D-2012	-1.2608051300048828	Seattle Heart Failure model
P-2012	-3.8510 -0.9474 -0.3925 -0.0314 -1.0582 -2.3169 -0.2283
S-76	INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy.<unk>
T-76	randomized ; dopamine ; nesiritide
H-76	-0.5651735067367554	▁dop amine ▁; ▁nesi riti de ▁strategy
D-76	-0.5651735067367554	dopamine ; nesiritide strategy
P-76	-1.9381 -1.2611 -0.2305 -0.0126 -0.0211 -0.6404 -0.5083 -0.2931 -0.1814
S-414	Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects.<unk>
T-414	clinical ; nitrite ; vascular
H-414	-0.6286364793777466	▁chemical ▁in st ability ▁; ▁co genera tion ▁; ▁nit rite ▁; ▁vas cular ▁effects
D-414	-0.6286364793777466	chemical instability ; cogeneration ; nitrite ; vascular effects
P-414	-3.8811 -0.0961 -0.1468 -0.0165 -0.1492 -0.0304 -0.1171 -0.0929 -1.3860 -0.0440 -1.7096 -0.4979 -0.2136 -0.1159 -1.4610 -0.4846 -0.2442
S-1875	The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%).<unk>
T-1875	neurological ; cardiovascular ; bound
H-1875	-0.33549657464027405	▁neurologi cal ▁; ▁cardiovascular ▁event - free ▁rate
D-1875	-0.33549657464027405	neurological ; cardiovascular event-free rate
P-1875	-0.2649 -0.1302 -0.2627 -0.1844 -1.0880 -0.3803 -0.0388 -0.0380 -0.8431 -0.1245
S-1558	Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated.<unk>
T-1558	cox regression ; cardiovascular events ; psoriasis
H-1558	-0.25467348098754883	▁co x ▁re gression ▁; ▁cardiovascular ▁events ▁; ▁psoriasis
D-1558	-0.25467348098754883	cox regression ; cardiovascular events ; psoriasis
P-1558	-0.0748 -0.5107 -0.0287 -0.0787 -0.2496 -0.7649 -0.1668 -0.3342 -0.0064 -0.3261 -0.2605
S-1845	We will include prospective studies evaluating implementation interventions aimed at improving uptake of class I CPG recommendations in HF.<unk>
T-1845	prospective studies ; cpg ; hf
H-1845	-0.6593913435935974	▁c p ▁; ▁ HF
D-1845	-0.6593913435935974	cp ; HF
P-1845	-1.9036 -0.2209 -0.4766 -1.0823 -0.2913 -0.3017 -0.3394
S-259	A correlation between changes in HDL-induced NO production and flow-mediated dilatation improvement by ET was evident.<unk>
T-259	correlation ; flow-mediated dilatation
H-259	-0.49037495255470276	▁HD l - indu ced ▁NO ▁production ▁; ▁flow - media ted ▁di la tation ▁; ▁ET
D-259	-0.49037495255470276	HDl-induced NO production ; flow-mediated dilatation ; ET
P-259	-2.5897 -1.8559 -0.1761 -0.0143 -0.6418 -0.7659 -0.0518 -0.1197 -0.0107 -0.1380 -0.1892 -0.4921 -0.2372 -0.4437 -0.0185 -0.7953 -0.2382 -0.3036 -0.2354
S-58	However, patients with AHF are highly heterogeneous, and appropriate risk stratification is essential in conducting studies in this area.<unk>
T-58	patients ; ahf ; risk stratification
H-58	-1.3397291898727417	▁patients ▁; ▁a HF
D-58	-1.3397291898727417	patients ; aHF
P-58	-4.0050 -0.6109 -0.5507 -1.0776 -1.4673 -0.3269
S-1070	Data in patients with preserved systolic function are scarce, but interesting therapeutic concepts are evolving.<unk>
T-1070	patients ; systolic function ; therapeutic
H-1070	-0.7241772413253784	▁pres er ved ▁sy sto lic ▁function ▁; ▁ therapeut ic
D-1070	-0.7241772413253784	preserved systolic function ; therapeutic
P-1070	-3.9784 -0.1488 -0.0945 -1.2065 -0.1540 -0.8504 -0.4513 -0.8940 -0.5140 -0.0485 -0.0741 -0.7722 -0.2276
S-1050	Importantly, the targets of BETs in the mouse TAC model were also found to be relevant in human HF.<unk>
T-1050	bets ; tac ; hf
H-1050	-0.48018479347229004	▁bet s ▁; ▁mouse ▁ TAC ▁model ▁; ▁human ▁ HF
D-1050	-0.48018479347229004	bets ; mouse TAC model ; human HF
P-1050	-1.4657 -0.1060 -0.1472 -0.9397 -0.7959 -0.0296 -0.4138 -0.2305 -0.6736 -0.6669 -0.2020 -0.3020 -0.2696
S-614	The challenge is to deliver cost-effective, participatory, population-specific health interventions that result in measurable benefits.<unk>
T-614	health
H-614	-0.8310844898223877	▁cost - effect ive ▁; ▁health ▁intervention s
D-614	-0.8310844898223877	cost-effective ; health interventions
P-614	-0.1901 -0.1016 -0.0677 -0.0579 -0.5737 -3.4260 -2.7357 -0.1059 -0.8207 -0.2317
S-1662	It is critical to develop an understanding of this topic so cardiac nurses can partner with other subspecialty groups to manage this population.<unk>
T-1662	cardiac ; nurses
H-1662	-0.4166248142719269	▁cardiac ▁nurse s
D-1662	-0.4166248142719269	cardiac nurses
P-1662	-0.2822 -0.3047 -0.0603 -1.2585 -0.1774
S-1282	In total, 28 consultations were required in 21 patients (9%) and 16 procedures were performed in 11 patients (5%).<unk>
T-1282	consultations ; patients ; patients
H-1282	-0.4334460198879242	▁procedure s
D-1282	-0.4334460198879242	procedures
P-1282	-0.9781 -0.0625 -0.5214 -0.1718
S-50	Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed.<unk>
T-50	transfusion ; mortality
H-50	-0.7692856192588806	▁trans fusion ▁; ▁mortal ity ▁rates
D-50	-0.7692856192588806	transfusion ; mortality rates
P-50	-0.0568 -1.2428 -2.3588 -0.3887 -0.0667 -1.3552 -0.4418 -0.2434
S-1972	Czech Republic significantly contributed to this study and all study sites should be congratulated and thanked for their high-quality work provided.<unk>
T-1972	czech republic
H-1972	-0.7399083375930786	▁Czech ▁Republic
D-1972	-0.7399083375930786	Czech Republic
P-1972	-1.0363 -0.2677 -1.3955 -0.2602
S-858	METHODS: All patients in the MADIT-CRT study who received a device (N = 1,790) were identified.<unk>
T-858	patients ; madit-crt
H-858	-1.1050879955291748	▁MAD - c RT ▁; ▁device
D-858	-1.1050879955291748	MAD-cRT ; device
P-858	-0.3369 -2.2894 -2.0886 -2.0261 -1.4241 -0.3243 -0.1923 -0.1591
S-851	At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months.<unk>
T-851	patients ; randomization
H-851	-1.1473511457443237	▁study ▁ closure
D-851	-1.1473511457443237	study closure
P-851	-1.7557 -0.8389 -0.0034 -2.9202 -0.2186
S-383	The concordance c statistics in the UM/VA/VA-RT cohorts were 0.71/0.68/0.74.<unk>
T-383	c statistics
H-383	-1.2592283487319946	▁UM / VA ▁; VA - RT
D-383	-1.2592283487319946	UM/VA ;VA-RT
P-383	-1.0266 -1.6334 -1.5213 -1.1822 -3.5477 -0.3430 -1.2313 -0.5184 -0.3292
S-1539	The absolute risk of heart failure was 4.4% in the exposed group and 3.7% in the control group (P < 0.01).<unk>
T-1539	heart failure
H-1539	-1.1224725246429443	▁heart ▁failure ▁; ▁expose d ▁group
D-1539	-1.1224725246429443	heart failure ; exposed group
P-1539	-2.9617 -0.1703 -1.0842 -1.1056 -0.0486 -0.0675 -3.3469 -0.1949
S-1431	Western blots with site-specific monoclonal antibodies showed increased Ser83 phosphorylation in HF.<unk>
T-1431	western blots ; monoclonal antibodies ; ser83 ; phosphorylation ; hf
H-1431	-0.47221139073371887	▁Western ▁blot s ▁; ▁mono clo nal ▁anti bo dies ▁; ▁ser 83 ▁ phos phor y lation ▁; ▁ HF
D-1431	-0.47221139073371887	Western blots ; monoclonal antibodies ; ser83 phosphorylation ; HF
P-1431	-0.8669 -0.0273 -0.0864 -0.1391 -0.1283 -0.1135 -0.8250 -0.0182 -0.9035 -1.0048 -0.1467 -0.6787 -0.4885 -0.5945 -0.0915 -1.3528 -1.1537 -0.7804 -0.5355 -0.2346 -0.0586 -0.4204 -0.2118
S-528	Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation.<unk>
T-528	preoperative ; serum albumin ; patients ; left ventricular assist device ; implantation
H-528	-0.8619988560676575	▁pre operativ e ▁se rum ▁album in ▁levels ▁; ▁left ▁vent ri cular ▁assist ▁device ▁implant ation
D-528	-0.8619988560676575	preoperative serum albumin levels ; left ventricular assist device implantation
P-528	-1.6275 -0.0201 -0.2726 -0.0446 -0.6859 -0.4852 -0.3084 -0.4588 -0.2931 -2.3507 -2.5918 -2.0955 -0.1852 -2.2285 -0.6740 -0.8581 -0.3665 -0.6051 -0.2263
S-2005	New York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive and sustained improvement.<unk>
T-2005	new york heart association classification ; 6-min walk test ; quality-of-life
H-2005	-0.8194459080696106	▁New ▁York ▁Heart ▁association ▁; ▁walk ▁test ▁; ▁quality - of - life
D-2005	-0.8194459080696106	New York Heart association ; walk test ; quality-of-life
P-2005	-1.6157 -0.6877 -2.1735 -0.6937 -0.6226 -2.3200 -0.7912 -0.8926 -0.1252 -0.1283 -0.0258 -0.0663 -0.1539 -1.7432 -0.2519
S-366	There have been reports demonstrating development of functional MS following ring annuloplasty for ischemic MR with LV dilatation.<unk>
T-366	functional ms ; ring annuloplasty ; ischemic mr ; lv dilatation
H-366	-0.29368123412132263	▁MS ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁MR ▁; ▁LV ▁di la tation
D-366	-0.29368123412132263	MS ; ring annuloplasty ; ischemic MR ; LV dilatation
P-366	-2.7540 -0.1377 -0.0402 -0.1503 -0.3778 -0.1400 -0.3015 -0.1198 -0.2497 -0.1909 -0.0445 -0.0864 -0.1201 -0.0292 -0.1233 -0.0713 -0.0065 -0.4877 -0.1490
S-1350	This occurred despite a profound change in Paco2, cerebral blood flow, and perfusion of the carotid bodies.<unk>
T-1350	change ; paco2 ; cerebral ; blood flow ; perfusion ; carotid
H-1350	-0.37101510167121887	▁Paco 2 ▁; ▁cerebral ▁blood ▁flow ▁; ▁per fusion ▁; ▁caro tid ▁bo dies
D-1350	-0.37101510167121887	Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
P-1350	-0.1589 -0.0984 -0.3848 -0.0722 -2.2679 -0.0268 -0.2023 -0.0928 -0.0451 -0.6161 -0.5557 -0.2419 -0.2038 -0.3362 -0.3882 -0.2451
S-1194	Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.<unk>
T-1194	vasopressin receptor antagonist ; tolvaptan ; heart failure ; patients
H-1194	-0.459189772605896	▁vaso press in ▁receptor ▁anta gon ist ▁; ▁to lv ap tan ▁; ▁Japanese ▁heart ▁failure
D-1194	-0.459189772605896	vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure
P-1194	-0.0876 -0.1816 -0.8890 -0.0034 -0.7318 -0.3590 -1.0047 -0.2122 -0.0069 -0.1408 -0.5191 -0.2189 -0.1895 -1.4955 -0.9469 -0.0654 -1.0518 -0.1614
S-2021	This article describes the pathophysiology of HF, diagnosis, medical management, and nursing interventions.<unk>
T-2021	pathophysiology ; hf ; diagnosis ; medical ; nursing
H-2021	-0.7310925722122192	▁pat ho phy si ology ▁; ▁ HF ▁; ▁medical
D-2021	-0.7310925722122192	pathophysiology ; HF ; medical
P-2021	-1.6060 -0.6876 -0.0591 -1.6293 -0.0752 -0.2204 -0.2071 -0.1598 -0.4634 -0.0909 -3.4053 -0.1690
S-212	SETTING: consecutive patients seen by ED physicians in 4 suburban hospitals in New Jersey and New York from 1996 to 2008.<unk>
T-212	patients ; physicians ; hospitals ; new jersey ; new york
H-212	-0.806684672832489	▁ED ▁physician s ▁; ▁New ▁Jersey ▁; ▁New ▁York
D-212	-0.806684672832489	ED physicians ; New Jersey ; New York
P-212	-2.3183 -2.1738 -0.0934 -0.2838 -2.3496 -0.2637 -0.3776 -0.4178 -0.2128 -0.2386 -0.1441
S-1560	Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels.<unk>
T-1560	psoriasis ; patients ; diastolic blood pressure ; body mass index
H-1560	-0.6391403675079346	▁p sori asis ▁; ▁smo ked ▁; ▁dia sto lic ▁blood ▁pressure ▁; ▁body ▁mass ▁index
D-1560	-0.6391403675079346	psoriasis ; smoked ; diastolic blood pressure ; body mass index
P-1560	-0.7918 -0.0655 -0.6639 -0.7540 -1.6146 -0.4786 -0.3060 -0.9068 -0.1352 -1.1145 -2.4567 -0.5946 -0.2844 -0.0337 -0.0930 -0.2348 -0.7065 -0.2700
S-1272	Exercise intolerance in heart failure: update on exercise parameters for diagnosis, prognosis and therapeutic interventions.<unk>
T-1272	exercise intolerance ; heart failure ; exercise ; diagnosis ; prognosis ; therapeutic
H-1272	-0.3987070620059967	▁exercise ▁in tolerance ▁; ▁heart ▁failure
D-1272	-0.3987070620059967	exercise intolerance ; heart failure
P-1272	-0.3716 -0.0482 -0.0151 -0.5304 -0.3957 -0.0656 -1.5514 -0.2117
S-1954	Patients had clinical and echocardiography evaluations at baseline and months 1 and 3 after shunt implantation.<unk>
T-1954	patients ; clinical ; echocardiography ; baseline ; shunt ; implantation
H-1954	-0.42266738414764404	▁e cho card i ography ▁; ▁base line ▁; ▁shu nt ▁implant ation
D-1954	-0.42266738414764404	echocardiography ; baseline ; shunt implantation
P-1954	-1.1711 -0.3582 -0.6922 -0.6073 -0.7957 -0.9249 -0.0144 -0.0368 -0.5466 -0.0107 -0.2591 -0.0935 -0.1593 -0.3712 -0.2992
S-1383	Comparative effects of ventricular assist device and extracorporeal membrane oxygenation on renal function in pediatric heart failure.<unk>
T-1383	ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
H-1383	-0.3663887679576874	▁vent ri cular ▁assist ▁device ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁renal ▁function ▁; ▁pediatr ic ▁heart ▁failure
D-1383	-0.3663887679576874	ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; pediatric heart failure
P-1383	-0.5558 -0.6627 -0.1630 -1.3196 -0.7350 -0.2096 -0.3797 -0.0756 -0.4010 -0.0996 -0.0566 -0.0750 -0.7361 -0.3110 -0.3983 -0.0422 -0.2946 -0.3128 -0.2336 -0.0064 -0.8073 -0.2795 -0.4235 -0.2149
S-700	Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes.<unk>
T-700	correlations ; cox models ; st2 ; functional capacity ; outcomes
H-700	-0.46759429574012756	▁co x ▁models ▁; ▁ST 2 ▁; ▁functional ▁capacity
D-700	-0.46759429574012756	cox models ; ST2 ; functional capacity
P-700	-0.3942 -0.2812 -0.2785 -0.3255 -1.1047 -0.1338 -0.9641 -0.4052 -0.1460 -0.8535 -0.2567
S-160	Reductions were also observed in all-cause hospitalisations for TM interventions but not for STS interventions.<unk>
T-160	all-cause hospitalisations ; sts
H-160	-0.7897031903266907	▁TM ▁intervention s ▁; ▁s ts
D-160	-0.7897031903266907	TM interventions ; sts
P-160	-2.3083 -1.4181 -0.0739 -0.3596 -0.0982 -0.7810 -1.0443 -0.2342
S-838	Treatment group effects on HRQoL were estimated using linear mixed models according to the intention-to-treat principle.<unk>
T-838	hrqol ; linear mixed models ; intention-to-treat
H-838	-0.9882534146308899	▁treatment ▁group ▁effects ▁; ▁HR Qo L
D-838	-0.9882534146308899	treatment group effects ; HRQoL
P-838	-2.6519 -0.3180 -1.5113 -0.6655 -0.9594 -0.0223 -1.0981 -1.5174 -0.1504
S-1513	We aimed to characterize and quantify the various forms of NT-proBNP in the circulation of HF patients.<unk>
T-1513	nt-probnp ; circulation ; hf ; patients
H-1513	-0.3878856301307678	▁NT - pro b NP ▁; ▁circulation ▁; ▁ HF
D-1513	-0.3878856301307678	NT-probNP ; circulation ; HF
P-1513	-0.4868 -0.0931 -0.0390 -1.1084 -0.3431 -0.1901 -0.0785 -0.4307 -0.2504 -0.1451 -1.0429 -0.4464
S-1779	Whether these changes in energy metabolism precede and contribute to the development of heart failure in the hypertrophied heart is not clear.<unk>
T-1779	energy metabolism ; heart failure ; hypertrophied ; heart
H-1779	-0.21510884165763855	▁energy ▁metabolism ▁; ▁heart ▁failure ▁; ▁hyper trop hi ed ▁heart
D-1779	-0.21510884165763855	energy metabolism ; heart failure ; hypertrophied heart
P-1779	-0.0767 -0.1553 -0.1179 -0.6402 -0.2172 -0.1341 -0.1258 -0.0645 -0.0949 -0.1313 -0.6995 -0.1617 -0.1773
S-368	Because functional MS is dynamic and proportional to LV dilatation, the degree of functional MS can potentially vary considerably.<unk>
T-368	functional ms ; lv dilatation ; functional ms
H-368	-0.7453383803367615	▁MS ▁; ▁LV ▁di la tation ▁; ▁functional ▁MS
D-368	-0.7453383803367615	MS ; LV dilatation ; functional MS
P-368	-2.7444 -0.3404 -1.1004 -0.3001 -0.1869 -0.0043 -0.8421 -1.7620 -0.4462 -0.2146 -0.2575
S-1568	We investigated 120 consecutive patients with PAD, defined by an ankle-brachial index ≤ 0.9.<unk>
T-1568	patients ; pad ; ankle-brachial index
H-1568	-0.6930260062217712	▁ PAD ▁; ▁an kle - bra chi al ▁index
D-1568	-0.6930260062217712	PAD ; ankle-brachial index
P-1568	-2.0090 -0.1217 -0.3261 -0.0679 -0.5319 -0.3530 -0.5234 -3.4618 -0.1528 -0.0552 -0.4848 -0.2286
S-525	CONCLUSIONS: Isolated HR reduction by ivabradine improves TAC, thus reducing Ea.<unk>
T-525	hr reduction ; ivabradine ; tac ; ea
H-525	-0.5772072672843933	▁i sol ated ▁HR ▁re duction ▁; ▁i va bra dine ▁; ▁ TAC
D-525	-0.5772072672843933	isolated HR reduction ; ivabradine ; TAC
P-525	-1.6197 -0.9449 -0.0278 -0.5760 -0.1334 -0.0128 -0.1702 -0.0143 -2.6832 -0.3182 -0.0476 -0.0708 -0.2757 -0.0988 -1.9621 -0.2799
S-1388	Comparison of baseline characteristics, duration of mechanical cardiac support, and renal function was made between the three groups.<unk>
T-1388	baseline ; mechanical cardiac support ; renal function
H-1388	-0.32047146558761597	▁base line ▁; ▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function
D-1388	-0.32047146558761597	baseline ; mechanical cardiac support ; renal function
P-1388	-0.0146 -0.1079 -0.3704 -0.0286 -0.0275 -0.3867 -1.1294 -0.2527 -0.0365 -0.9149 -0.3715 -0.2049
S-1390	The patients in the ECMO group were significantly younger and smaller than the patients in the VAD and ECMO+VAD groups.<unk>
T-1390	patients ; ecmo ; patients ; vad ; ecmo ; vad
H-1390	-0.9530004858970642	▁ec mo ▁group ▁; ▁ VAD ▁; ▁ec mo + VAD ▁groups
D-1390	-0.9530004858970642	ecmo group ; VAD ; ecmo+VAD groups
P-1390	-1.4911 -0.7106 -1.3087 -0.2348 -0.3010 -0.1467 -0.2167 -1.1385 -1.1580 -4.3278 -0.6765 -0.7090 -0.5668 -0.3559
S-1075	It has a higher mortality and morbidity than several cancers and consumes a significant portion of the health-care budget.<unk>
T-1075	mortality ; morbidity ; health-care ; budget
H-1075	-0.29255959391593933	▁mortal ity ▁; ▁morbi d ity ▁; ▁cancer s ▁; ▁health - care ▁budget
D-1075	-0.29255959391593933	mortality ; morbidity ; cancers ; health-care budget
P-1075	-0.6243 -0.0276 -0.2554 -0.0410 -0.1119 -0.2533 -0.2850 -0.4045 -0.1680 -0.2435 -0.7504 -0.5217 -0.2081 -0.1462 -0.2764 -0.3636
S-1652	Usual care will consist of anticoagulation, therapy of underlying heart disease, and rate control as an initial approach.<unk>
T-1652	anticoagulation ; therapy ; heart disease ; rate control
H-1652	-0.40507400035858154	▁antico ag ulation ▁; ▁ therapy ▁; ▁under ly ing ▁heart ▁disease ▁; ▁rate ▁control
D-1652	-0.40507400035858154	anticoagulation ; therapy ; underlying heart disease ; rate control
P-1652	-1.0175 -1.7180 -0.1426 -0.1469 -0.8816 -0.0170 -0.2338 -0.5213 -0.0413 -0.0525 -0.3292 -0.7436 -0.3987 -0.0026 -0.1632 -0.2816 -0.1949
S-648	Because of their negative inotropic effect, beta blockers were neglected for a long time from the treatment of heart failure.<unk>
T-648	inotropic effect ; beta blockers ; heart failure
H-648	-0.4703878164291382	▁in o tropi c ▁effect ▁; ▁beta ▁block ers ▁; ▁heart ▁failure
D-648	-0.4703878164291382	inotropic effect ; beta blockers ; heart failure
P-648	-1.0555 -0.4028 -0.2382 -0.3971 -0.4952 -0.2991 -0.2674 -0.2846 -0.1762 -0.2989 -2.1083 -0.1346 -0.2444 -0.1829
S-398	Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure.<unk>
T-398	interleukin receptor ; st2 ; beta-blocker ; therapy ; chronic heart failure
H-398	-0.43959107995033264	▁inter le u kin ▁receptor ▁family ▁; ▁ST 2 ▁; ▁beta - block er ▁ therapy ▁; ▁chronic ▁heart ▁failure
D-398	-0.43959107995033264	interleukin receptor family ; ST2 ; beta-blocker therapy ; chronic heart failure
P-398	-0.2611 -0.8623 -0.0910 -2.5489 -0.0053 -1.0673 -0.4478 -0.1971 -0.0978 -0.1185 -0.3186 -0.1227 -0.4243 -0.1956 -0.4280 -0.0440 -0.2844 -0.2544 -1.1183 -0.2966 -0.3128 -0.1742
S-725	RESULTS: The average age of patients with heart failure was 79.9 years in 2011, with 45.9% having systolic heart failure.<unk>
T-725	patients ; heart failure ; systolic heart failure
H-725	-0.9559435248374939	▁heart ▁failure ▁; ▁sy sto lic ▁heart ▁failure
D-725	-0.9559435248374939	heart failure ; systolic heart failure
P-725	-4.5648 -0.1742 -0.3072 -0.4028 -0.0622 -1.2096 -2.2625 -0.1229 -0.2418 -0.2113
S-1237	Baseline characteristics were similar in rhythm-control (n = 149) and rate-control (n = 155) groups.<unk>
T-1237	baseline ; rhythm-control ; rate-control
H-1237	-0.21577009558677673	▁base line ▁; ▁ rhythm - control ▁; ▁rate - control
D-1237	-0.21577009558677673	baseline ; rhythm-control ; rate-control
P-1237	-0.0895 -0.0339 -0.3554 -0.2249 -0.2370 -0.2835 -0.0425 -0.2990 -0.0226 -0.3562 -0.0732 -0.5313 -0.2561
S-43	Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted.<unk>
T-43	hemoglobin ; health ; outcomes
H-43	-1.123648762702942	▁hem o glob in ▁levels
D-43	-1.123648762702942	hemoglobin levels
P-43	-2.2449 -0.1156 -1.2732 -1.1765 -0.2201 -2.5974 -0.2379
S-376	Functional MS can potentially be reversed by medical treatment and thus requires careful evaluation of the surgical indications.<unk>
T-376	functional ms ; medical treatment ; surgical
H-376	-0.6699457168579102	▁function al ▁MS ▁; ▁medical ▁; ▁sur g ical
D-376	-0.6699457168579102	functional MS ; medical ; surgical
P-376	-1.2752 -0.0236 -0.2344 -0.5603 -0.1156 -1.2509 -2.9109 -0.0835 -0.0064 -0.7845 -0.1239
S-1790	The HF epidemiology and the adequacy of relevant health service provision related to HF in LA are not well delineated.<unk>
T-1790	hf ; epidemiology ; health ; hf
H-1790	-0.5238437056541443	▁ HF ▁epidemi ology ▁; ▁health ▁service ▁; ▁ HF ▁; ▁LA
D-1790	-0.5238437056541443	HF epidemiology ; health service ; HF ; LA
P-1790	-1.1128 -0.2153 -1.2048 -0.1236 -0.1067 -0.7855 -0.1708 -0.8729 -0.2714 -0.4203 -0.5064 -0.7438 -0.5171 -0.2823
S-2019	Heart failure (HF) is a debilitating chronic disease and is expected to increase in upcoming years due to demographic changes.<unk>
T-2019	heart failure ; hf ; chronic ; disease
H-2019	-0.6115850210189819	▁Heart ▁failure ▁; HF
D-2019	-0.6115850210189819	Heart failure ;HF
P-2019	-0.4670 -0.0187 -0.2246 -0.1195 -2.6408 -0.1989
S-555	OBJECTIVES: This study sought to determine the characteristics and outcomes of young adults with heart failure (HF).<unk>
T-555	outcomes ; heart failure ; hf
H-555	-0.9458323121070862	▁heart ▁failure ▁; HF
D-555	-0.9458323121070862	heart failure ;HF
P-555	-4.0053 -0.0801 -0.7610 -0.1677 -0.3723 -0.2887
S-548	RESULTS: During follow-up, 6 CF LVAD patients developed new, severe AI that was accompanied by heart failure.<unk>
T-548	follow-up ; lvad ; patients ; heart failure
H-548	-0.801600456237793	▁CF ▁l VAD ▁; ▁AI ▁; ▁heart ▁failure
D-548	-0.801600456237793	CF lVAD ; AI ; heart failure
P-548	-0.4965 -2.7618 -0.3223 -0.4971 -2.2282 -0.2294 -0.8591 -0.2111 -0.2183 -0.1921
S-38	(Grade: strong recommendation; moderate-quality evidence) Treatment of anemia in patients with heart disease: a systematic review.<unk>
T-38	grade ; evidence ; anemia ; patients ; heart disease
H-38	-0.46851569414138794	▁an emia ▁; ▁heart ▁disease
D-38	-0.46851569414138794	anemia ; heart disease
P-38	-0.6044 -0.1480 -0.2330 -1.2367 -0.6966 -0.1574 -0.2035
S-1746	There was a trend toward enrollment of older patients with less severe left ventricular dilatation and dysfunction during the years.<unk>
T-1746	patients ; left ventricular dilatation ; dysfunction
H-1746	-1.5489145517349243	▁left ▁vent ri cular ▁di la tation
D-1746	-1.5489145517349243	left ventricular dilatation
P-1746	-3.3997 -4.1402 -1.6297 -0.5300 -0.6022 -0.9434 -0.0427 -2.4029 -0.2495
S-203	This work does not include Recommendations for advanced management involving ventricular assist devices, or other device therapies.<unk>
T-203	ventricular assist devices ; therapies
H-203	-1.1141858100891113	▁vent ri cular ▁assist ▁devices ▁; ▁device ▁ therapie
D-203	-1.1141858100891113	ventricular assist devices ; device therapie
P-203	-2.3106 -0.8073 -0.1288 -1.8432 -0.1420 -0.7845 -0.2569 -0.2456 -0.0397 -5.4755 -0.2219
S-1956	The device was successfully implanted in all patients; no device-related or procedural adverse events occurred during follow-up.<unk>
T-1956	implanted ; patients ; adverse events ; follow-up
H-1956	-1.082037091255188	▁device
D-1956	-1.082037091255188	device
P-1956	-1.5578 -1.5439 -0.1445
S-1394	CONCLUSIONS: On the basis of these data, we demonstrate that renal dysfunction improves early after mechanical cardiac support.<unk>
T-1394	renal dysfunction ; mechanical cardiac support
H-1394	-0.44878506660461426	▁renal ▁dys function ▁; ▁mechanic al ▁cardiac
D-1394	-0.44878506660461426	renal dysfunction ; mechanical cardiac
P-1394	-0.2398 -0.5472 -1.2472 -0.1083 -0.0175 -0.0210 -0.2679 -1.4852 -0.1049
S-1002	Each method has strengths and limitations, but their utility has never been evaluated in the same community HF cohort.<unk>
T-1002	hf
H-1002	-1.0638127326965332	▁ HF
D-1002	-1.0638127326965332	HF
P-1002	-1.4582 -0.3913 -2.0844 -0.3214
S-144	CONCLUSIONS: Different approaches to computing readmissions can produce different hospital rankings and impact pay-for-performance.<unk>
T-144	readmissions ; hospital
H-144	-0.5795275568962097	▁computing ▁read missions ▁; ▁hospital ▁ranking s ▁; ▁pay - for - per form ance
D-144	-0.5795275568962097	computing readmissions ; hospital rankings ; pay-for-performance
P-144	-1.8264 -2.7612 -0.0490 -0.1660 -1.9928 -0.5701 -0.0777 -0.1280 -0.1780 -0.1050 -0.2729 -0.1510 -0.1513 -0.6979 -0.0545 -0.4095 -0.2607
S-1506	We then used exploratory factor analysis to determine the presence of separate scale dimensions, followed by CFA in a separate sub-sample.<unk>
T-1506	exploratory factor analysis ; cfa
H-1506	-1.0380682945251465	▁c f
D-1506	-1.0380682945251465	cf
P-1506	-1.7086 -1.4929 -0.5524 -0.3983
S-1351	It is concluded that PB in patients with HF could be produced by primary oscillations originating from the central pattern generator.<unk>
T-1351	pb ; patients ; hf
H-1351	-0.7289700508117676	PB ▁; ▁ HF ▁; ▁central ▁pattern ▁generator
D-1351	-0.7289700508117676	PB ; HF ; central pattern generator
P-1351	-0.3574 -0.2015 -1.1358 -2.0950 -0.4594 -1.4020 -0.5581 -0.0141 -0.7092 -0.3572
S-1124	Reasons for nontreatment were identified from clinic notes and from interviews with 62 primary care clinicians caring for these patients.<unk>
T-1124	clinic ; clinicians ; patients
H-1124	-0.9591763615608215	▁non tre at ment ▁; ▁primary ▁care ▁clinic ians
D-1124	-0.9591763615608215	nontreatment ; primary care clinicians
P-1124	-3.9254 -1.3529 -0.4944 -0.0406 -0.9244 -1.7657 -0.4985 -0.6109 -0.1100 -0.6003 -0.2279
S-1113	Second, we assessed whether that response correlates with levels of various serum factors that serve as markers for coagulability.<unk>
T-1113	correlates ; coagulability
H-1113	-0.4139215052127838	▁se rum ▁factors ▁; ▁coa gul ability
D-1113	-0.4139215052127838	serum factors ; coagulability
P-1113	-0.4290 -0.3857 -0.0288 -0.4854 -0.3882 -0.9078 -0.5497 -0.2778 -0.2727
S-65	RESULTS: Of 10,420 studies reviewed, 72 studies evaluating 63 predictors on 257,692 ICD patients proved eligible.<unk>
T-65	icd ; patients
H-65	-1.1296042203903198	▁i cd
D-65	-1.1296042203903198	icd
P-65	-0.2552 -2.6515 -1.3431 -0.2687
S-267	RESULTS: The mean age of the patients in this study was 71.1 ± 10.3 years; 50 of these patients were female.<unk>
T-267	patients ; patients
H-267	-0.7795790433883667	
D-267	-0.7795790433883667	
P-267	-1.3442 -0.2149
S-1365	Both BNP and NT-proBNP have proven to be reliable diagnostic and prognostic biomarkers in patients with heart failure.<unk>
T-1365	bnp ; nt-probnp ; diagnostic ; prognostic ; biomarkers ; patients ; heart failure
H-1365	-0.6582356095314026	▁b NP ▁; ▁NT - pro b NP ▁; ▁heart ▁failure
D-1365	-0.6582356095314026	bNP ; NT-probNP ; heart failure
P-1365	-0.5493 -0.7784 -0.1206 -0.1915 -0.0918 -0.0135 -0.3548 -0.2648 -0.3657 -5.1440 -0.1841 -0.2491 -0.2494
S-1765	Cardiorespiratory fitness, body mass index, and heart failure mortality in men: Cooper Center Longitudinal Study.<unk>
T-1765	cardiorespiratory fitness ; body mass index ; heart failure ; mortality ; cooper center longitudinal study
H-1765	-0.7381387948989868	▁Card ore spira tory ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁mortal ity ▁; ▁Cooper ▁center
D-1765	-0.7381387948989868	Cardorespiratory ; body mass index ; heart failure mortality ; Cooper center
P-1765	-1.4350 -2.3933 -0.1392 -0.0489 -1.2032 -0.2944 -0.2627 -0.2073 -0.2270 -0.9138 -0.2242 -0.8417 -0.0265 -0.7036 -1.3852 -1.4046 -1.3819 -0.1941
S-15	An inverse correlation was observed between pro-adrenomedullin (MR-proADM) and FFM.<unk>
T-15	inverse correlation ; pro-adrenomedullin ; mr-proadm ; ffm
H-15	-0.3523575961589813	▁pro - ad re nom edu llin ▁; MR - pro AD m ▁; ▁f m
D-15	-0.3523575961589813	pro-adrenomedullin ;MR-proADm ; fm
P-15	-0.0892 -0.0436 -0.0887 -0.1927 -0.4238 -0.6005 -0.5539 -0.2283 -0.0828 -0.0157 -0.0276 -1.3138 -0.1223 -0.2978 -0.4706 -0.9813 -0.5999 -0.2099
S-1979	INTERVENTIONS: Twenty weeks of diet, exercise, or both; attention control consisted of telephone calls every 2 weeks.<unk>
T-1979	exercise
H-1979	-1.4071002006530762	
D-1979	-1.4071002006530762	
P-1979	-2.6698 -0.1444
S-1133	Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart.<unk>
T-1133	heart failure ; hf ; elevated ; sympathetic activity ; parasympathetic control ; heart
H-1133	-0.5717105269432068	▁Heart ▁failure ▁; HF ▁; ▁sympa the tic ▁activity ▁; ▁para sy mpa the tic ▁control ▁; ▁heart
D-1133	-0.5717105269432068	Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
P-1133	-0.4308 -0.0208 -0.2491 -0.0937 -0.5340 -1.0681 -1.4966 -0.1764 -0.1280 -0.0818 -0.8937 -0.3437 -0.0963 -3.2561 -0.0992 -0.4087 -0.4366 -1.1376 -0.3012 -0.1818
S-59	Predictors of mortality in patients with an implantable cardiac defibrillator: a systematic review and meta-analysis.<unk>
T-59	mortality ; patients ; implantable cardiac defibrillator ; meta-analysis
H-59	-0.4747997522354126	▁pred ic tors ▁of ▁mortal ity ▁; ▁implant able ▁cardiac ▁de fi br illa tor
D-59	-0.4747997522354126	predictors of mortality ; implantable cardiac defibrillator
P-59	-3.2718 -0.0315 -0.0714 -0.2392 -0.0402 -0.0629 -0.2970 -0.9295 -0.0379 -0.1124 -0.1497 -0.2063 -1.0020 -0.7399 -0.2080 -0.5136 -0.1581
S-471	In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function.<unk>
T-471	atp ; xo-mediated ros ; mitochondrial respiration ; contractile function
H-471	-0.36551812291145325	▁ATP ▁demand ▁; ▁ XO - media ted ▁ ROS ▁; ▁mito cho ndri al ▁respira tion ▁; ▁contract ile ▁function
D-471	-0.36551812291145325	ATP demand ; XO-mediated ROS ; mitochondrial respiration ; contractile function
P-471	-0.1968 -0.4316 -0.1505 -0.5482 -0.0459 -0.0418 -0.0978 -0.0458 -0.1465 -0.1238 -0.3487 -0.0782 -1.5643 -1.0480 -0.0788 -0.3969 -0.0804 -0.2844 -0.0235 -1.3367 -0.6815 -0.4855 -0.1714
S-1898	Regular physical activity controls acquired cardiovascular risk factors such as obesity, diabetes mellitus, hypertension and hyperlipidaemia.<unk>
T-1898	physical ; activity ; cardiovascular ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
H-1898	-0.2859593331813812	▁physical ▁activity ▁; ▁cardiovascular ▁risk ▁factors ▁; ▁obes ity ▁; ▁diabetes ▁mell itus ▁; ▁hyper tension ▁; ▁hyper li pida emia
D-1898	-0.2859593331813812	physical activity ; cardiovascular risk factors ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
P-1898	-0.1462 -0.3238 -0.3753 -0.5611 -1.0485 -0.1090 -0.2973 -0.4214 -0.1767 -0.1881 -0.0462 -0.0245 -0.0615 -0.2831 -0.1120 -0.1825 -0.2162 -0.2033 -0.6772 -0.3066 -0.1953 -0.3714 -0.2498
S-1184	Whether all patients with systolic HF of unclear etiology should undergo coronary angiography has been controversial.<unk>
T-1184	patients ; systolic hf ; etiology ; coronary angiography
H-1184	-0.24939222633838654	▁sy sto lic ▁ HF ▁; ▁un clear ▁et i ology ▁; ▁corona ry ▁ang i ography
D-1184	-0.24939222633838654	systolic HF ; unclear etiology ; coronary angiography
P-1184	-0.9134 -0.0960 -0.2178 -0.5796 -0.0341 -0.1327 -0.2285 -0.0223 -0.0279 -0.1697 -0.0257 -0.1174 -0.4594 -0.0682 -0.0594 -0.8044 -0.2399 -0.3860 -0.1561
S-1230	Atrial fibrillation and congestive heart failure: a cost analysis of rhythm-control vs. rate-control strategies.<unk>
T-1230	atrial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
H-1230	-0.37058189511299133	▁at rial ▁fi bril lation ▁; ▁con ges tive ▁heart ▁failure ▁; ▁cost ▁; ▁ rhythm - control ▁; ▁rate - control ▁strategie s
D-1230	-0.37058189511299133	atrial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control strategies
P-1230	-1.3100 -0.0090 -0.4480 -0.0321 -0.5074 -0.2501 -0.0077 -0.1560 -0.0603 -0.5865 -0.0646 -0.8453 -0.1516 -0.8009 -0.1706 -0.4328 -0.3158 -0.0454 -0.5986 -0.0186 -0.5932 -0.0563 -1.3318 -0.0722 -0.5874 -0.1829
S-506	Ejection fraction (EF), infarct size, collateral growth, and myocardial perfusion were assessed.<unk>
T-506	ejection fraction ; ef ; infarct ; collateral growth ; myocardial perfusion
H-506	-0.2777099907398224	▁e je ction ▁ fraction ▁; EF ▁; ▁in far ct ▁; ▁col lateral ▁growth ▁; ▁my o card ial ▁per fusion
D-506	-0.2777099907398224	ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
P-506	-0.4749 -0.0667 -0.0215 -0.5217 -0.0031 -0.3303 -0.2408 -0.2077 -0.0784 -0.2015 -0.2257 -1.1881 -0.0326 -0.0006 -0.2563 -0.3482 -0.5228 -0.3499 -0.6579 -0.0746 -0.0869 -0.2181 -0.3152 -0.2414
S-1510	Circulating fragments of N-terminal pro-B-type natriuretic peptides in plasma of heart failure patients.<unk>
T-1510	n-terminal pro-b-type natriuretic peptides ; plasma ; heart failure ; patients
H-1510	-0.4805511236190796	▁Circula ting ▁fragment s ▁; ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti des ▁; ▁plasma ▁; ▁heart ▁failure
D-1510	-0.4805511236190796	Circulating fragments ; N-terminal pro-B-type natriuretic peptides ; plasma ; heart failure
P-1510	-0.1159 -0.0195 -0.5954 -0.0711 -0.5408 -1.6462 -0.0604 -0.0397 -0.0074 -0.0241 -0.0284 -1.0483 -0.0764 -0.6408 -0.0060 -0.4174 -0.1423 -1.0040 -0.0452 -0.8780 -2.5518 -0.2464 -0.0620 -1.1707 -0.5119 -0.1047 -1.1083 -0.2923
S-1300	Half of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF).<unk>
T-1300	patients ; heart failure ; hf ; preserved left ventricular ejection fraction ; hfpef
H-1300	-0.5435194373130798	▁heart ▁failure ▁; HF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; HF p EF
D-1300	-0.5435194373130798	heart failure ;HF ; left ventricular ejection fraction ;HFpEF
P-1300	-1.8228 -0.0723 -0.1573 -0.2008 -0.2136 -0.8884 -2.9040 -1.1586 -0.4250 -0.1582 -0.1966 -0.2652 -0.7138 -0.0178 -0.4388 -0.3736 -0.0138 -0.1939 -0.4983 -0.1575
S-1657	Patients with end-stage heart failure are increasingly being treated with implantation of a long-term ventricular assist device.<unk>
T-1657	patients ; end-stage heart failure ; implantation ; ventricular assist device
H-1657	-0.7797248959541321	▁end - s tage ▁heart ▁failure ▁; ▁implant ation ▁; ▁long - term ▁vent ri cular ▁assist ▁device
D-1657	-0.7797248959541321	end-stage heart failure ; implantation ; long-term ventricular assist device
P-1657	-1.5039 -0.0886 -0.0646 -0.0096 -1.9585 -0.1847 -0.4265 -1.2274 -0.0673 -0.6326 -0.1057 -0.1750 -0.0467 -3.5387 -2.3388 -0.3826 -0.9566 -0.8223 -0.7069 -0.3577
S-356	His HF symptom as well as cardiac murmurs disappeared with a reduction in blood pressure to 140/80 mm Hg.<unk>
T-356	hf ; symptom ; cardiac murmurs ; blood pressure
H-356	-0.8101512789726257	▁ HF ▁; ▁cardiac ▁mur mur s ▁; ▁re duction ▁; ▁blood ▁pressure
D-356	-0.8101512789726257	HF ; cardiac murmurs ; reduction ; blood pressure
P-356	-1.5476 -0.3437 -0.5554 -1.2029 -0.1899 -0.0397 -0.2899 -0.2737 -3.6712 -0.0087 -0.5531 -1.1834 -0.3878 -1.5018 -0.4033
S-1406	These 2 receptors have opposing actions on adenylyl cyclase because of differential G-protein coupling.<unk>
T-1406	receptors ; adenylyl cyclase ; g-protein coupling
H-1406	-0.5143478512763977	▁receptor s ▁; ▁a den yl ▁cy cla se ▁; ▁differenti al ▁g - prote in ▁coup ling
D-1406	-0.5143478512763977	receptors ; adenyl cyclase ; differential g-protein coupling
P-1406	-0.3181 -0.1256 -0.2623 -0.0363 -0.0253 -1.1248 -1.8612 -0.1024 -1.6497 -0.2422 -0.0263 -0.0091 -1.1117 -0.3674 -0.4854 -1.2391 -0.0493 -0.2141 -0.7962 -0.2405
S-1445	In conclusion, patients with HF and spontaneous VT have larger fluctuations in beat-to-beat QT intervals.<unk>
T-1445	patients ; hf ; spontaneous vt ; qt intervals
H-1445	-0.30107739567756653	▁ HF ▁; ▁spontane ous ▁ VT ▁; ▁beat - to - beat ▁ QT ▁interval s
D-1445	-0.30107739567756653	HF ; spontaneous VT ; beat-to-beat QT intervals
P-1445	-0.9596 -0.2155 -0.0868 -0.5265 -0.0186 -0.1519 -0.0839 -0.3659 -0.0172 -0.1188 -0.1302 -0.0827 -0.2379 -0.4327 -0.8093 -0.5048 -0.0554 -0.6466 -0.2764
S-305	However biventricular dysfunction does not have a favorable outcome at 1 year when compared with patients requiring isolated HeartMate II.<unk>
T-305	biventricular dysfunction ; outcome ; patients ; heartmate ii
H-305	-0.8353155255317688	▁bi ven tri cular ▁dys function ▁; ▁isola ted ▁Heart Mate ▁II
D-305	-0.8353155255317688	biventricular dysfunction ; isolated HeartMate II
P-305	-0.1672 -0.9521 -1.8904 -1.5056 -0.8604 -3.2384 -0.1550 -0.1549 -0.0228 -0.8911 -0.1247 -1.0771 -0.4102 -0.2444
S-806	CONCLUSIONS: The TUG test is reliable in patients with advanced COPD, CHF, or CRF after 2 trials.<unk>
T-806	tug test ; patients ; copd ; chf ; crf
H-806	-0.856145977973938	▁TU g ▁test ▁; ▁advanced ▁COP d ▁; ▁CHF ▁; ▁c RF
D-806	-0.856145977973938	TUg test ; advanced COPd ; CHF ; cRF
P-806	-1.5760 -1.2910 -0.3500 -0.1296 -3.1740 -1.8190 -2.0334 -0.1070 -0.0392 -0.1295 -0.2443 -0.6423 -0.2998 -0.1507
S-877	CONCLUSIONS: This study elucidates the signaling pathways significantly changed in pressure-overload-induced heart failure.<unk>
T-877	signaling pathways ; pressure-overload-induced heart failure
H-877	-0.5049460530281067	▁signal ing ▁path ways ▁; ▁pressure - over load - indu ced ▁heart ▁failure
D-877	-0.5049460530281067	signaling pathways ; pressure-overload-induced heart failure
P-877	-3.1892 -0.2109 -0.0360 -0.0728 -0.2031 -0.0608 -0.1575 -0.0652 -0.3675 -0.4143 -0.0627 -1.3655 -0.9570 -0.1889 -0.4472 -0.2805
S-1396	Nursing has a social mandate to ensure effective practice within its domain and to be accountable for the outcomes of nursing care.<unk>
T-1396	nursing ; mandate ; accountable ; outcomes ; nursing
H-1396	-0.5454645156860352	▁Nur sing ▁; ▁social ▁mandat e ▁; ▁account able ▁; ▁outcome s ▁; ▁nur sing ▁care
D-1396	-0.5454645156860352	Nursing ; social mandate ; accountable ; outcomes ; nursing care
P-1396	-1.9259 -0.0183 -0.2354 -0.3565 -0.0226 -0.2309 -0.4230 -0.3637 -0.0744 -0.3128 -1.6552 -0.0393 -1.4619 -1.2010 -0.0679 -0.9331 -0.2180 -0.2786
S-1294	TREATMENT AND CLINICAL COURSE: The patient became again hemodynamically unstable and a CPR was required.<unk>
T-1294	clinical ; patient ; hemodynamically ; cpr
H-1294	-0.8648890256881714	▁TRE AT MENT ▁; ▁hem o dynamic ally ▁uns table ▁; ▁c PR
D-1294	-0.8648890256881714	TREATMENT ; hemodynamically unstable ; cPR
P-1294	-4.6181 -1.6670 -0.5435 -0.2064 -1.9977 -0.1459 -0.0122 -0.0706 -1.2048 -0.2114 -0.2059 -0.2925 -1.5005 -0.1795 -0.1174
S-419	Unlike isoproterenol, CXL-1020 was equally effective in myocytes from normal or failing hearts.<unk>
T-419	isoproterenol ; cxl-1020 ; myocytes ; hearts
H-419	-0.8049771785736084	▁iso prot eren ol ▁; ▁c XL -10 20 ▁; ▁my o cy tes ▁; ▁heart s
D-419	-0.8049771785736084	isoproterenol ; cXL-1020 ; myocytes ; hearts
P-419	-0.0075 -1.1532 -2.7151 -2.4202 -0.4106 -0.3650 -0.4447 -0.1114 -0.0876 -0.7300 -0.3482 -0.1922 -0.1133 -0.1265 -0.5719 -4.4001 -0.1929 -0.5751 -0.3292
S-454	Moreover, B treatment was associated with increased cardiac angiogenesis and in vivo coronary perfusion and reduced cardiac fibrosis.<unk>
T-454	cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
H-454	-0.5488804578781128	▁b ▁; ▁cardiac ▁ang io gene sis ▁; ▁in ▁vivo ▁corona ry ▁per fusion ▁; ▁cardiac ▁fibro sis
D-454	-0.5488804578781128	b ; cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
P-454	-1.2068 -1.7677 -1.4851 -0.0786 -1.9725 -0.2766 -0.9526 -0.1292 -0.5020 -0.0056 -0.7520 -0.0358 -0.1040 -0.0530 -0.2299 -0.3967 -0.0225 -0.4813 -0.3990 -0.1266
S-1434	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia.<unk>
T-1434	repolarization ; patients ; heart failure ; ventricular tachycardia
H-1434	-0.8257099986076355	▁auto no mic ▁modul ation ▁; ▁repo lar ization ▁in st ability ▁; ▁heart ▁failure ▁pro ne ▁; ▁vent ri cular ▁ta chy car dia
D-1434	-0.8257099986076355	autonomic modulation ; repolarization instability ; heart failure prone ; ventricular tachycardia
P-1434	-6.5857 -0.0139 -1.0582 -1.6590 -0.0262 -0.9255 -0.1235 -1.3564 -0.0954 -0.0987 -0.2236 -0.0350 -0.3471 -1.2720 -0.1018 -0.2688 -0.0784 -0.4542 -0.5794 -0.8405 -0.2144 -1.2330 -1.1691 -0.8584 -1.5171 -0.9171 -0.2416
S-1141	Pyridostigmine reduced the myocyte diameter and collagen density of the surviving left ventricle.<unk>
T-1141	pyridostigmine ; myocyte ; collagen ; left ventricle
H-1141	-0.37765854597091675	▁Pyr ido stig mine ▁; ▁my o cy te ▁diameter ▁; ▁collage n ▁den s ity ▁; ▁left ▁vent ric le
D-1141	-0.37765854597091675	Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
P-1141	-0.0061 -0.1025 -0.0007 -0.0886 -0.0916 -0.1556 -0.0996 -0.1065 -0.2846 -0.0152 -0.1145 -0.0358 -0.1543 -0.0234 -0.1882 -0.0577 -0.2435 -0.8365 -1.9858 -1.9077 -1.5427 -0.4493 -0.1960
S-1975	Exercise intolerance is the primary symptom of chronic HFPEF and a major determinant of reduced quality of life (QOL).<unk>
T-1975	exercise intolerance ; symptom ; chronic hfpef ; quality of life ; qol
H-1975	-0.8770924210548401	▁exercise ▁in tolerance ▁; ▁chronic ▁H FP EF ▁; ▁quality ▁of ▁life ▁; Q OL
D-1975	-0.8770924210548401	exercise intolerance ; chronic HFPEF ; quality of life ;QOL
P-1975	-0.5139 -0.0583 -0.0241 -0.1918 -0.7944 -3.3346 -2.1855 -0.5096 -0.2471 -2.7842 -0.2272 -0.5928 -0.7318 -2.0681 -0.2119 -0.2394 -0.1960
S-1781	The rates of energy substrate metabolism were assessed in isolated working hearts obtained 1, 2, and 3 weeks after AAC.<unk>
T-1781	energy substrate metabolism ; hearts ; aac
H-1781	-0.22781400382518768	▁energy ▁substrat e ▁metabolism ▁; ▁working ▁heart s ▁; ▁a ac
D-1781	-0.22781400382518768	energy substrate metabolism ; working hearts ; aac
P-1781	-0.0556 -0.0330 -0.0753 -0.2265 -0.4141 -0.1477 -0.2575 -0.0651 -0.7114 -0.1500 -0.5996 -0.0719 -0.1538
S-1509	This evidence provides a new understanding of the structure of the SCHFI v.6.2 and supports its use in clinical practice and research.<unk>
T-1509	evidence ; schfi v.6.2 ; clinical
H-1509	-0.8723315000534058	▁ SCH fi ▁; ▁clinic al ▁practice
D-1509	-0.8723315000534058	SCHfi ; clinical practice
P-1509	-2.8843 -0.6326 -1.6318 -0.5944 -1.0377 -0.0852 -0.0743 -0.6921 -0.2186
S-1191	A prediction rule of having ≥1 independent predictor identified 97% of the patients with CAD and 100% of the patients with severe CAD.<unk>
T-1191	rule ; patients ; cad ; patients ; cad
H-1191	-1.3715951442718506	▁rule ▁; ▁CAD ▁; ▁severe ▁CAD
D-1191	-1.3715951442718506	rule ; CAD ; severe CAD
P-1191	-3.4131 -0.2301 -3.1939 -0.4917 -2.2744 -0.9583 -0.1662 -0.2451
S-630	Results were comparable across age, sex, and race, and in sub-groups based on diabetes mellitus or cardiovascular disease at baseline.<unk>
T-630	diabetes mellitus ; cardiovascular disease ; baseline
H-630	-0.403899222612381	▁diabetes ▁mell itus ▁; ▁cardiovascular ▁disease
D-630	-0.403899222612381	diabetes mellitus ; cardiovascular disease
P-630	-0.6170 -0.0147 -0.1352 -0.2525 -0.0364 -1.6622 -0.2643 -0.2489
S-1563	The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06).<unk>
T-1563	cvd ; psoriasis ; hazard ratio ; confidence interval
H-1563	-0.8136537075042725	▁cv d ▁; ▁psoriasis
D-1563	-0.8136537075042725	cvd ; psoriasis
P-1563	-2.8468 -0.3250 -0.1933 -0.1191 -1.1097 -0.2881
S-1277	Different mechanisms underlie these exercise variables with an important contribution of haemodynamic, pulmonary and peripheral abnormalities.<unk>
T-1277	exercise ; haemodynamic ; pulmonary
H-1277	-0.17078115046024323	▁ha emo dynamic ▁; ▁pulmonar y ▁; ▁per i pher al ▁ab normal ities
D-1277	-0.17078115046024323	haemodynamic ; pulmonary ; peripheral abnormalities
P-1277	-0.2128 -0.4294 -0.0267 -0.1487 -0.0168 -0.0830 -0.3330 -0.0127 -0.3621 -0.0107 -0.0825 -0.0838 -0.1161 -0.0955 -0.3879 -0.3309
S-1188	The diagnostic performance of the defined prediction rule was prospectively validated in a separate cohort recruited from 2 institutions.<unk>
T-1188	diagnostic ; rule ; prospectively
H-1188	-0.6236629486083984	▁predict ion ▁rule
D-1188	-0.6236629486083984	prediction rule
P-1188	-2.0188 -0.0431 -0.0625 -0.8281 -0.1658
S-1556	In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes.<unk>
T-1556	rotterdam study ; psoriasis ; cardiovascular ; outcomes
H-1556	-0.5802584290504456	▁Rotterdam ▁study ▁; ▁psoriasis ▁; ▁cardiovascular ▁outcome s
D-1556	-0.5802584290504456	Rotterdam study ; psoriasis ; cardiovascular outcomes
P-1556	-3.7392 -1.1288 -0.0910 -0.0637 -0.2245 -0.0586 -0.1852 -0.0291 -0.1855 -0.0968
S-607	The HR for the TNF antagonists compared with nbDMARD was 0.85 (95% CI 0.63 to 1.14).<unk>
T-607	tnf antagonists ; nbdmard
H-607	-0.4758032262325287	▁HR ▁; ▁t NF ▁anta gon ists ▁; ▁n b DM ARD
D-607	-0.4758032262325287	HR ; tNF antagonists ; nbDMARD
P-607	-0.1427 -0.1128 -0.1714 -0.5344 -1.3824 -0.3832 -0.4026 -0.1058 -0.1183 -0.0162 -1.7908 -0.2979 -1.0407 -0.1619
S-1286	Complications occurred after five ACS procedures (31%) in two patients undergoing MT and three patients undergoing VAD.<unk>
T-1286	complications ; acs ; patients ; patients ; vad
H-1286	-0.6528269648551941	▁a CS ▁procedure s ▁; ▁MT ▁; ▁ VAD
D-1286	-0.6528269648551941	aCS procedures ; MT ; VAD
P-1286	-0.5102 -2.6322 -1.0983 -0.1238 -0.1289 -0.9322 -0.1396 -0.8359 -0.1061 -0.3401 -0.3336
S-1577	SETTING: General hospital and cardiac specialty hospital, both located in a community of 150,000 population in predominantly rural South Dakota.<unk>
T-1577	hospital ; cardiac ; hospital ; south dakota
H-1577	-0.4364265203475952	▁general ▁hospital ▁; ▁cardiac ▁special ty ▁hospital ▁; ▁south ▁da kota
D-1577	-0.4364265203475952	general hospital ; cardiac specialty hospital ; south dakota
P-1577	-0.3058 -0.3431 -0.1146 -0.0595 -0.2008 -0.0607 -0.8672 -0.3753 -2.5080 -0.4754 -0.0250 -0.1651 -0.1732
S-1131	The structure of medical records should be improved to facilitate documentation of contextual reasons for not providing guideline-recommended care.<unk>
T-1131	medical
H-1131	-0.6349425315856934	▁medical ▁records
D-1131	-0.6349425315856934	medical records
P-1131	-0.1913 -0.1148 -2.0232 -0.2105
S-1392	In the ECMO group, the improvement in eGFR continued until day 28 after which there was a steady decline in eGFR.<unk>
T-1392	ecmo ; egfr ; egfr
H-1392	-0.6851738691329956	▁ec mo ▁group ▁; ▁e g FR ▁; ▁e g FR
D-1392	-0.6851738691329956	ecmo group ; egFR ; egFR
P-1392	-0.2973 -0.6284 -0.6506 -0.2131 -0.0926 -0.5468 -2.0689 -0.5422 -0.1971 -0.6177 -2.3341 -0.4655 -0.2529
S-683	Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.<unk>
T-683	administration ; chf
H-683	-0.42647555470466614	▁administration ▁; ▁tras tuz um ab ▁; ▁CHF
D-683	-0.42647555470466614	administration ; trastuzumab ; CHF
P-683	-0.7268 -0.1132 -0.2935 -0.0346 -0.0500 -0.0202 -1.7245 -0.8434 -0.2832 -0.1753
S-1018	We describe lessons learned from recent trials in acute HF and outline strategies to improve the potential for success in future trials.<unk>
T-1018	acute hf
H-1018	-0.7653290629386902	▁a cute ▁ HF ▁; ▁out line
D-1018	-0.7653290629386902	acute HF ; outline
P-1018	-1.9279 -0.0335 -0.6147 -0.2429 -0.5649 -0.0285 -0.0080 -3.0542 -0.4134
S-1476	This is partly a result of shortcomings in research studies and a dearth of biomarker-guided clinical trials.<unk>
T-1476	clinical
H-1476	-0.45746511220932007	▁research ▁; ▁bio mark er - guide d ▁clinic al ▁trial s
D-1476	-0.45746511220932007	research ; biomarker-guided clinical trials
P-1476	-1.1610 -2.4524 -0.5584 -0.0376 -0.1102 -0.2691 -0.0025 -0.0896 -0.6815 -0.2800 -0.1328 -0.0918 -0.2561 -0.2815
S-142	Between 47 and 75 percent of hospitals in an extreme decile according to one metric remained when using a different metric.<unk>
T-142	hospitals
H-142	-0.9901541471481323	▁hospital s ▁; ▁ metric
D-142	-0.9901541471481323	hospitals ; metric
P-142	-1.7228 -0.1663 -0.5404 -3.6177 -0.0089 -0.4354 -0.4396
S-272	However, especially in the case of long-term survival, additional prospective, large, and multicenter studies are required to confirm our results.<unk>
T-272	prospective
H-272	-0.8367583751678467	
D-272	-0.8367583751678467	
P-272	-1.5094 -0.1642
S-1905	Sudden cardiac death in athletes under 35 is rare with.estimates ranging from 1 in 50,000 to 1 in 200,000.<unk>
T-1905	cardiac death
H-1905	-0.4716039299964905	▁sud den ▁cardiac ▁death ▁; ▁ath letes
D-1905	-0.4716039299964905	sudden cardiac death ; athletes
P-1905	-0.9053 -0.0015 -0.1430 -1.1882 -0.6218 -0.2612 -0.3390 -0.6032 -0.1813
S-1159	BACKGROUND: Previous studies investigating HF-related cachexia have not examined the impact of RV function on body composition.<unk>
T-1159	cachexia ; rv function
H-1159	-0.3790644109249115	▁ HF - related ▁cache xia ▁; ▁ RV ▁function ▁; ▁body ▁composition
D-1159	-0.3790644109249115	HF-related cachexia ; RV function ; body composition
P-1159	-0.9978 -0.3733 -0.1841 -0.0636 -0.2724 -0.8971 -0.2094 -0.1870 -0.1728 -0.6858 -0.7239 -0.0525 -0.3599 -0.3650 -0.1412
S-1692	To assess how well the composite measure predicts future high and low performers, and explains variance in future hospital mortality.<unk>
T-1692	hospital ; mortality
H-1692	-0.5861973166465759	▁hospital ▁mortal ity
D-1692	-0.5861973166465759	hospital mortality
P-1692	-1.6248 -0.5270 -0.1114 -0.2417 -0.4261
S-1719	CONCLUSION: A 1-day reduction in hospital length of stay was not consistently associated with a higher rate of rehospitalization.<unk>
T-1719	hospital ; rehospitalization
H-1719	-0.5271128416061401	▁hospital ▁length ▁of ▁stay ▁; ▁re hospital ization
D-1719	-0.5271128416061401	hospital length of stay ; rehospitalization
P-1719	-2.5280 -0.1532 -0.9270 -0.0673 -0.3597 -0.5587 -0.0449 -0.2069 -0.1761 -0.2494
S-207	Subsequently, the authors analyzed the association of cognitive impairment with 6-month mortality or readmission.<unk>
T-207	mortality ; readmission
H-207	-0.6110377311706543	▁cognitive ▁im pair ment ▁; ▁mortal ity
D-207	-0.6110377311706543	cognitive impairment ; mortality
P-207	-0.6371 -0.0252 -0.1619 -0.1646 -0.2480 -1.8172 -0.0733 -2.1710 -0.2011
S-1359	This review provides an overview of the sonographic, histological, and functional abnormalities of different gastrointestinal regions.<unk>
T-1359	sonographic ; histological ; gastrointestinal
H-1359	-1.394836664199829	▁sono graphic ▁; ▁his t ological ▁; ▁functional ▁ab normal ities
D-1359	-1.394836664199829	sonographic ; histological ; functional abnormalities
P-1359	-6.7477 -2.1252 -0.3896 -0.5342 -0.8187 -0.1220 -0.2396 -1.1064 -0.2822 -0.0435 -0.0826 -5.2863 -0.3548
S-1023	Natriuretic peptide levels, like other biomarkers, can now be measured at the point of care (POC).<unk>
T-1023	natriuretic peptide ; biomarkers ; point of care ; poc
H-1023	-0.6356111168861389	▁na tri ure tic ▁pe pti de ▁levels ▁; ▁bio mark ers
D-1023	-0.6356111168861389	natriuretic peptide levels ; biomarkers
P-1023	-0.1328 -0.1205 -0.0661 -0.4789 -0.0587 -0.3665 -1.0886 -0.3257 -0.4042 -2.0145 -0.0782 -0.1390 -3.4525 -0.1725
S-1352	Do anticoagulants or antiplatelet drugs have a role in treating heart failure in the absence of atrial fibrillation?<unk>
T-1352	anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
H-1352	-0.4374226927757263	▁antico a gul ants ▁; ▁anti plate let ▁drugs ▁; ▁heart ▁failure ▁; ▁at rial ▁fi bril lation
D-1352	-0.4374226927757263	anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
P-1352	-1.5328 -0.2954 -0.4863 -0.0411 -0.1254 -0.0061 -0.2412 -0.9764 -0.1253 -0.2495 -1.7855 -0.1221 -0.1457 -0.2827 -0.1789 -0.6647 -0.0599 -0.9284 -0.3562 -0.1449
S-445	Spironolactone was independently associated with a 3.5-fold increased risk of hyperkalemia but not with acute kidney injury.<unk>
T-445	spironolactone ; hyperkalemia ; acute kidney injury
H-445	-0.4189085066318512	▁Spir ono lac tone ▁; ▁hyper kal emia ▁; ▁a cute ▁ki dne y ▁injury
D-445	-0.4189085066318512	Spironolactone ; hyperkalemia ; acute kidney injury
P-445	-0.3343 -0.2441 -0.1045 -0.1104 -0.0961 -0.8781 -1.5440 -0.5601 -0.1007 -0.0531 -0.0554 -0.1870 -1.6184 -0.1042 -0.6691 -0.2723 -0.1896
S-1572	The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.<unk>
T-1572	prevalence ; bnp ; patients ; pad ; bnp ; hf
H-1572	-0.6771125793457031	▁b NP ▁levels ▁; ▁ PAD ▁; ▁b NP ▁; ▁ HF
D-1572	-0.6771125793457031	bNP levels ; PAD ; bNP ; HF
P-1572	-2.1286 -0.5886 -0.4277 -0.1094 -0.6956 -0.0414 -0.1164 -1.6903 -0.5389 -0.9769 -1.1062 -0.5215 -0.3317 -0.2063
S-1868	BACKGROUND: Increased sympathetic and decreased parasympathetic activity contribute to HF symptoms and disease progression.<unk>
T-1868	sympathetic ; parasympathetic activity ; hf ; symptoms ; disease
H-1868	-0.832654595375061	▁sympa the tic ▁; ▁para sy mpa tic ▁activity ▁; ▁ HF
D-1868	-0.832654595375061	sympathetic ; parasympatic activity ; HF
P-1868	-1.4256 -1.2662 -0.1520 -0.0724 -1.4272 -0.8203 -0.1379 -3.1674 -0.2925 -0.1332 -0.1121 -0.1626 -2.3387 -0.1491
S-1529	Compared with CH, patients with EH had lower systolic blood pressure and less renal impairment despite similar rates of hypertension.<unk>
T-1529	patients ; systolic blood pressure ; renal impairment ; hypertension
H-1529	-0.9233537912368774	▁EH ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁renal ▁im pair ment ▁; ▁hyper tension
D-1529	-0.9233537912368774	EH ; systolic blood pressure ; renal impairment ; hypertension
P-1529	-1.8105 -0.2083 -4.1480 -0.1601 -1.8546 -2.6771 -0.6144 -0.1537 -0.0417 -0.0098 -0.0151 -0.0708 -0.3716 -2.7621 -0.3478 -0.2383 -0.2131
S-1631	We aimed to investigate the association between race and outcomes and to explore interactions with exercise training in patients with ambulatory HF.<unk>
T-1631	outcomes ; exercise ; training ; patients ; ambulatory ; hf
H-1631	-0.31725427508354187	▁race ▁; ▁outcome s ▁; ▁exercise ▁training ▁; ▁ambula tory ▁ HF
D-1631	-0.31725427508354187	race ; outcomes ; exercise training ; ambulatory HF
P-1631	-1.2244 -0.1740 -0.9292 -0.0372 -0.2459 -0.0637 -0.0838 -0.2156 -0.4996 -0.0216 -0.3312 -0.0822 -0.2302 -0.3030
S-283	This might be a novel and useful mouse HF model to study the transition from compensated LV hypertrophy to HF in HHD.<unk>
T-283	hf ; transition ; compensated lv hypertrophy ; hf ; hhd
H-283	-0.7426251173019409	▁mouse ▁; ▁ HF ▁model ▁; ▁transition ▁; ▁compensa ted ▁LV ▁hyper trop hy ▁; ▁ HF ▁; ▁h h
D-283	-0.7426251173019409	mouse ; HF model ; transition ; compensated LV hypertrophy ; HF ; hh
P-283	-1.6745 -1.2068 -1.2719 -0.3327 -0.7963 -0.2315 -1.8224 -0.4861 -0.8576 -0.0699 -0.3968 -1.0143 -0.1356 -1.7549 -0.1371 -0.1147 -0.1622 -0.1599 -0.7545 -1.9028 -0.8884 -0.1670
S-808	Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation.<unk>
T-808	global left ventricular longitudinal systolic strain ; cardiovascular events ; patients ; atrial fibrillation
H-808	-0.8053756356239319	▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁cardiovascular ▁events ▁; ▁at rial ▁fi bril lation
D-808	-0.8053756356239319	left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
P-808	-1.5655 -4.0970 -0.5310 -0.1507 -0.0506 -0.1997 -0.0287 -2.6921 -0.1884 -0.8376 -2.1909 -0.2967 -0.2305 -0.3622 -0.2357 -0.4154 -0.2009 -1.1677 -0.1169 -1.4300 -0.4630 -0.2669
S-434	During follow-up, there were 134 deaths, 18 heart transplantations/LV assist device implantations, and 93 heart failure admissions.<unk>
T-434	follow-up ; deaths ; heart transplantations ; lv assist device implantations ; heart failure ; admissions
H-434	-0.6233552098274231	▁heart ▁transplant ations ▁; LV ▁assist ▁device ▁implant ations ▁; ▁heart ▁failure ▁ad missions
D-434	-0.6233552098274231	heart transplantations ;LV assist device implantations ; heart failure admissions
P-434	-3.7828 -0.1846 -0.2620 -0.2285 -0.9812 -1.6444 -0.2727 -0.3102 -0.1088 -0.4555 -0.8120 -0.1618 -0.2565 -0.0126 -0.3019 -0.1982
S-503	A large animal model of chronic myocardial ischemia and heart failure is crucial for the development of novel therapeutic approaches.<unk>
T-503	chronic myocardial ischemia ; heart failure ; therapeutic
H-503	-0.8464343547821045	▁chronic ▁my o card ial ▁ ische mia ▁; ▁heart ▁failure ▁; ▁ therapeut ic
D-503	-0.8464343547821045	chronic myocardial ischemia ; heart failure ; therapeutic
P-503	-4.5878 -3.0488 -0.1833 -0.5973 -0.0508 -0.1645 -0.8710 -1.0944 -0.2425 -0.1468 -0.0240 -1.9137 -0.5301 -0.0683 -0.0794 -0.6058 -0.1808
S-237	An ability to identify patients with HFpEF who are at increased risk for adverse outcomes can facilitate their more careful management.<unk>
T-237	patients ; hfpef ; adverse outcomes
H-237	-0.537604570388794	▁ HF p EF ▁; ▁advers e ▁outcome s
D-237	-0.537604570388794	HFpEF ; adverse outcomes
P-237	-1.7110 -0.4656 -0.0222 -0.3359 -0.6967 -1.1724 -0.3684 -0.0804 -0.0557 -0.6419 -0.3634
S-1384	BACKGROUND: Effects of mechanical cardiac support on renal function in children with end-stage heart failure are unknown.<unk>
T-1384	mechanical cardiac support ; renal function ; end-stage heart failure
H-1384	-0.40309447050094604	▁mechanic al ▁cardiac ▁support ▁; ▁renal ▁function ▁; ▁end - s tage ▁heart ▁failure
D-1384	-0.40309447050094604	mechanical cardiac support ; renal function ; end-stage heart failure
P-1384	-0.0206 -0.0431 -0.8271 -1.9806 -0.4128 -0.0507 -0.2597 -0.2236 -0.8154 -0.1068 -0.0252 -0.0037 -0.9668 -0.2429 -0.2587 -0.2118
S-1603	Surgical revascularization is considered only if catheter-based revascularization is unsuitable or unsuccessful.<unk>
T-1603	surgical ; revascularization ; revascularization
H-1603	-0.5730160474777222	▁re vas cular ization ▁; ▁cat heter - based ▁re vas cular ization
D-1603	-0.5730160474777222	revascularization ; catheter-based revascularization
P-1603	-5.4881 -0.3102 -0.1354 -0.1636 -0.8445 -0.3187 -0.0032 -0.1060 -0.0386 -0.1128 -0.1277 -0.1699 -0.2125 -0.3492 -0.2149
S-841	Baseline Hgb did not moderate the beneficial effect of exercise training on KCCQ overall or subscales relative to usual care.<unk>
T-841	baseline ; hgb ; exercise ; training ; kccq
H-841	-0.7010130882263184	▁base line ▁h gb ▁; ▁exercise ▁training ▁; ▁k cc q
D-841	-0.7010130882263184	baseline hgb ; exercise training ; kccq
P-841	-0.0609 -0.0154 -2.5379 -0.0379 -0.2122 -0.7035 -0.6181 -0.3178 -0.8061 -0.0563 -2.6693 -0.8049 -0.2730
S-96	Morpholino-based knockdown of nucleolin nearly abolished protein expression but surprisingly had little impact on gross morphological development.<unk>
T-96	morpholino-based ; nucleolin ; protein expression
H-96	-0.7472944259643555	▁Mor pho lino - based ▁knock down ▁; ▁nucleo lin ▁; ▁protein ▁expression ▁; ▁ morph ological
D-96	-0.7472944259643555	Morpholino-based knockdown ; nucleolin ; protein expression ; morphological
P-96	-0.4354 -0.5257 -0.9458 -0.3567 -0.0785 -0.3850 -0.0894 -0.9452 -0.3616 -4.5622 -0.4600 -0.7126 -0.0542 -1.4945 -1.7437 -0.0781 -0.1950 -0.6114 -0.1635
S-1185	We sought to derive and validate a clinical prediction rule to exclude CAD as a cause of systolic HF.<unk>
T-1185	clinical ; rule ; cad ; systolic hf
H-1185	-0.32863855361938477	▁clinic al ▁predict ion ▁rule ▁; ▁CAD ▁; ▁sy sto lic ▁ HF
D-1185	-0.32863855361938477	clinical prediction rule ; CAD ; systolic HF
P-1185	-1.4738 -0.0322 -0.0893 -0.0255 -0.0470 -0.1141 -0.1912 -0.0791 -1.4951 -0.1404 -0.1902 -0.3528 -0.0380 -0.4790 -0.1819
S-775	We have developed a quick, safe pump-exchange technique that avoids a redo sternotomy and cardiopulmonary bypass.<unk>
T-775	redo sternotomy ; cardiopulmonary bypass
H-775	-0.6148465275764465	▁pump - ex change ▁technique ▁; ▁redo ▁ster no to my ▁; ▁cardio pul mon ary ▁by pass
D-775	-0.6148465275764465	pump-exchange technique ; redo sternotomy ; cardiopulmonary bypass
P-775	-1.9057 -0.1870 -0.0461 -0.0117 -2.4535 -0.2422 -1.2008 -0.9597 -0.0076 -0.1935 -1.7225 -0.1669 -0.0590 -0.2862 -0.8104 -0.0296 -0.8423 -0.1865 -0.6878 -0.2980
S-354	The possibility of MS to improve after medical treatment for HF was considered because functional MS is highly dynamic and can potentially respond to medical treatment.<unk>
T-354	medical treatment ; hf ; functional ms ; medical treatment
H-354	-0.6132187843322754	▁MS ▁; ▁medical ▁treatment ▁; ▁ HF ▁; ▁MS ▁; ▁medical ▁treatment
D-354	-0.6132187843322754	MS ; medical treatment ; HF ; MS ; medical treatment
P-354	-0.8101 -0.1898 -0.3633 -1.2417 -0.1767 -0.4927 -0.0351 -0.3804 -1.7705 -0.4263 -0.6808 -1.7330 -0.1704 -0.1142
S-1134	Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution.<unk>
T-1134	evidence ; parasympathetic ; therapeutic ; hf
H-1134	-0.7713285088539124	▁para sy mpa the tic ▁function ▁; ▁ HF ▁e volution
D-1134	-0.7713285088539124	parasympathetic function ; HF evolution
P-1134	-3.2961 -1.2180 -0.2611 -2.4487 -0.1373 -0.6427 -0.1269 -0.3353 -0.6637 -0.4285 -0.0027 -0.3378 -0.1285
S-371	After aggressive medical treatment for HF, the HF symptom disappeared and the MS was reversed to an MVA of 1.7 cm2.<unk>
T-371	medical treatment ; hf ; hf ; symptom ; mva
H-371	-0.8363485932350159	▁medical ▁; ▁ HF ▁; ▁ HF ▁; ▁ms ▁; ▁m VA
D-371	-0.8363485932350159	medical ; HF ; HF ; ms ; mVA
P-371	-3.1674 -0.7931 -0.8632 -0.1788 -0.2680 -0.9147 -0.3008 -0.3930 -1.3177 -0.9486 -0.4002 -1.6379 -0.2893 -0.2362
S-1895	Estimating the jugular venous pressure and the presence of peripheral oedema allows assessment of the patient's volume status.<unk>
T-1895	jugular venous pressure ; peripheral oedema ; patient
H-1895	-0.3145098388195038	▁jugu lar ▁ve nous ▁pressure ▁; ▁per i pher al ▁oed ema ▁; ▁volume
D-1895	-0.3145098388195038	jugular venous pressure ; peripheral oedema ; volume
P-1895	-0.0253 -0.3765 -0.0322 -0.5813 -0.3506 -0.0735 -0.0162 -0.0774 -0.0035 -0.0489 -0.4169 -0.0248 -0.8577 -0.1208 -1.8600 -0.1665
S-1487	Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality.<unk>
T-1487	heart failure ; hf ; condition ; morbidity ; mortality
H-1487	-0.6828200221061707	▁Heart ▁failure ▁; HF
D-1487	-0.6828200221061707	Heart failure ;HF
P-1487	-0.7831 -0.0232 -0.2219 -0.1479 -2.7577 -0.1630
S-333	It is reported that functional mitral stenosis frequently develops after ring annuloplasty for ischemic mitral regurgitation.<unk>
T-333	reported ; functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
H-333	-0.3131963610649109	▁functional ▁mit ral ▁sten osis ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation
D-333	-0.3131963610649109	functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
P-333	-1.3752 -1.0319 -0.1194 -0.0869 -0.0647 -0.1922 -0.0559 -0.1191 -0.3214 -0.2460 -0.2076 -0.2339 -0.5174 -0.1316 -0.0754 -0.5744 -0.4411 -0.0197 -0.0313 -0.3552 -0.0343 -0.7517 -0.2172
S-232	In conclusion, adult patients with failing Fontan circulation had a lower SVR index and similar cardiac index compared with the pediatric cohort.<unk>
T-232	patients ; fontan circulation ; svr ; cardiac index
H-232	-0.5247165560722351	▁Font an ▁circulation ▁; ▁s VR ▁index ▁; ▁cardiac ▁index
D-232	-0.5247165560722351	Fontan circulation ; sVR index ; cardiac index
P-232	-3.1045 -0.4284 -0.0138 -0.1273 -0.1844 -0.4304 -0.1824 -0.0903 -0.0817 -0.2668 -1.2246 -0.1620
S-297	The purpose of this study was to determine the 1-year survival in patients requiring isolated LVAD and patients requiring biventricular support.<unk>
T-297	patients ; lvad ; patients ; biventricular support
H-297	-0.7014393210411072	▁isola ted ▁l VAD ▁; ▁bi ven tri cular
D-297	-0.7014393210411072	isolated lVAD ; biventricular
P-297	-1.3681 -0.0293 -2.0747 -0.1614 -0.2115 -1.0791 -0.4624 -0.4802 -0.2841 -1.3270 -0.2381
S-1709	These hypothesis-generating findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race.<unk>
T-1709	mineralocorticoid receptor antagonists
H-1709	-0.9646786451339722	▁mineral o cor tico id ▁receptor ▁anta gon ists
D-1709	-0.9646786451339722	mineralocorticoid receptor antagonists
P-1709	-1.9554 -0.1388 -2.0839 -1.9238 -1.4470 -0.0050 -0.5852 -0.5559 -0.4975 -1.1957 -0.2232
S-1906	Hereditary and congenital abnormalities of the heart are the most common cause of nontraumatic death during sport in young athletes.<unk>
T-1906	hereditary ; congenital ; heart ; death
H-1906	-0.43735936284065247	▁her edit ary ▁; ▁con geni tal ▁ab normal ities ▁; ▁heart ▁; ▁non trau matic ▁death ▁; ▁sport
D-1906	-0.43735936284065247	hereditary ; congenital abnormalities ; heart ; nontraumatic death ; sport
P-1906	-0.9139 -0.2903 -0.0153 -0.3822 -0.0458 -0.0243 -0.0962 -0.1872 -0.1089 -0.1727 -0.3791 -0.8483 -0.3349 -0.1156 -0.1946 -0.4232 -1.7929 -0.7160 -0.5181 -1.1712 -0.4540
S-1494	We sought to investigate whether adults with the Fontan circulation exhibit reduced skeletal muscle mass and/or metabolic abnormalities.<unk>
T-1494	fontan circulation ; skeletal muscle ; metabolic
H-1494	-0.3145289421081543	▁Font an ▁circulation ▁; ▁skelet al ▁muscle ▁mass ▁; ▁metabol ic ▁ab normal ities
D-1494	-0.3145289421081543	Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
P-1494	-0.5889 -0.4328 -0.0175 -0.1717 -0.9322 -0.1857 -0.8947 -0.1057 -0.5528 -0.0641 -0.0329 -0.3236 -0.1818 -0.1145 -0.2728 -0.1607
S-303	However, 1-year survival was significantly greater in patients who required isolated HeartMate II LVAD (87% versus 77%; p = 0.03).<unk>
T-303	patients ; heartmate ii ; lvad
H-303	-0.8154847025871277	▁isola ted ▁Heart Mate ▁II ▁l VAD
D-303	-0.8154847025871277	isolated HeartMate II lVAD
P-303	-1.3270 -0.0331 -1.2673 -0.1949 -0.8149 -2.4813 -0.1546 -0.8731 -0.1932
S-85	Many multisite studies in practice settings focus on improving processes of care, adopting evidence-based practices, and improving patient outcomes.<unk>
T-85	evidence-based ; patient ; outcomes
H-85	-0.785486102104187	▁practice ▁; ▁evidence - based ▁practice s
D-85	-0.785486102104187	practice ; evidence-based practices
P-85	-0.5516 -1.3904 -3.2195 -0.0920 -0.0160 -0.0132 -0.0430 -1.5209 -0.2228
S-1830	SETTING: 18 health insurance and health system data partners in the U.S. Food and Drug Administration's Mini-Sentinel program.<unk>
T-1830	health ; health ; u.s. ; drug ; administration
H-1830	-0.5381894111633301	▁health ▁insurance ▁; ▁health ▁system ▁; ▁u . s . ▁Food ▁and ▁drug ▁administration
D-1830	-0.5381894111633301	health insurance ; health system ; u.s. Food and drug administration
P-1830	-0.4268 -0.6272 -0.1339 -0.2213 -0.1090 -0.5786 -0.1758 -0.0596 -0.1261 -0.0309 -0.7046 -0.5293 -2.0313 -0.3319 -2.1753 -0.3495
S-262	Determination of a predictive cutoff value of NT-proBNP testing for long-term survival in ED patients with acute heart failure.<unk>
T-262	nt-probnp ; patients ; acute heart failure
H-262	-0.43249568343162537	▁cut off ▁value ▁; ▁NT - pro b NP ▁testing ▁; ▁ED ▁; ▁a cute ▁heart ▁failure
D-262	-0.43249568343162537	cutoff value ; NT-probNP testing ; ED ; acute heart failure
P-262	-1.5965 -0.2323 -0.2675 -0.3361 -0.0820 -0.0526 -0.0216 -0.6015 -0.1848 -0.3492 -0.1364 -0.8673 -0.9060 -0.1051 -0.1719 -1.4358 -0.1495 -0.4477 -0.2736
S-1635	Blacks were younger with significantly more hypertension and diabetes, less ischemic etiology, and lower socioeconomic status versus whites.<unk>
T-1635	hypertension ; diabetes ; ischemic ; etiology
H-1635	-0.28736263513565063	▁black s ▁; ▁hyper tension ▁; ▁diabetes ▁; ▁ ische mic ▁et i ology ▁; ▁socio economic ▁status
D-1635	-0.28736263513565063	blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status
P-1635	-0.2336 -0.1380 -0.1286 -0.1703 -0.1037 -0.0999 -0.0412 -0.1272 -0.1056 -0.1164 -0.1040 -0.0179 -0.2612 -0.0322 -0.3229 -0.0821 -0.4655 -0.4129 -2.5587 -0.2255
S-536	Furthermore, the impact of normalization of albumin levels during LVAD support on postoperative survival was analyzed in both groups.<unk>
T-536	albumin ; lvad ; postoperative
H-536	-0.7223752737045288	▁album in ▁levels ▁; ▁l VAD ▁; ▁post operativ e ▁survival
D-536	-0.7223752737045288	albumin levels ; lVAD ; postoperative survival
P-536	-4.2878 -1.0194 -0.1335 -0.4947 -0.7707 -0.2600 -0.7918 -0.0620 -0.0354 -0.5241 -0.5849 -0.1567 -0.2699
S-1612	The overlapping part of the network was selected out using Cytoscape, for which functional enrichment analysis was applied with DAVID tools.<unk>
T-1612	cytoscape ; functional enrichment analysis ; david
H-1612	-0.7196399569511414	▁cy to scape ▁; ▁da VID
D-1612	-0.7196399569511414	cytoscape ; daVID
P-1612	-0.9645 -0.0321 -0.0993 -0.2531 -3.0764 -0.3128 -0.7881 -0.2307
S-694	These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF.<unk>
T-694	cardiovascular ; conditions ; patients ; hf
H-694	-0.7986374497413635	▁cardiovascular ▁conditions ▁; ▁ HF
D-694	-0.7986374497413635	cardiovascular conditions ; HF
P-694	-3.3382 -0.2070 -0.2019 -1.3738 -0.0896 -0.1639 -0.2162
S-7	This study suggests that national patient safety initiatives have led to real progress in some areas but have not created across-the-board improvements.<unk>
T-7	patient
H-7	-1.2352513074874878	▁patient ▁safety
D-7	-1.2352513074874878	patient safety
P-7	-1.5612 -0.8853 -2.2673 -0.2272
S-1151	The goal of this study was to determine the individual and combined contributions of HF-induced remodeling aspects to EMD prolongation.<unk>
T-1151	remodeling ; emd
H-1151	-0.49093741178512573	▁ HF - indu ced ▁remodel ing ▁; ▁EM d ▁prolong ation
D-1151	-0.49093741178512573	HF-induced remodeling ; EMd prolongation
P-1151	-1.1026 -0.4541 -0.2208 -0.0380 -1.3323 -0.5796 -0.0828 -0.8016 -0.4656 -0.4209 -0.7060 -0.1512 -0.3283 -0.1893
S-1459	We first propose fundamental definitions of the distinctive components of the right heart circulation and provide consensus on a universal definition of right heart failure.<unk>
T-1459	right heart circulation ; right heart failure
H-1459	-0.3556501865386963	▁right ▁heart ▁circulation ▁; ▁right ▁heart ▁failure
D-1459	-0.3556501865386963	right heart circulation ; right heart failure
P-1459	-0.3114 -0.8759 -0.0418 -0.3056 -0.3836 -0.5651 -0.1837 -0.3088 -0.2249
S-994	A notable example is the Raf-MEK1/2-ERK1/2 signalling pathway that can control both adaptive and maladaptive remodelling.<unk>
T-994	signalling pathway ; remodelling
H-994	-0.5282039046287537	▁Raf - MEK 1/2 - ER k 1/2 ▁signal ling ▁path way ▁; ▁remodel ling
D-994	-0.5282039046287537	Raf-MEK1/2-ERk1/2 signalling pathway ; remodelling
P-994	-0.0116 -0.0810 -0.0111 -0.2460 -0.0682 -1.1097 -0.2837 -0.3689 -0.4050 -0.0680 -0.1987 -0.6463 -0.5630 -4.3386 -0.1249 -0.2383 -0.2166
S-1104	Both early-onset (0-7 days after MI) and late-onset (8 days to 5 years after MI) HF were examined.<unk>
T-1104	mi ; mi ; hf
H-1104	-0.7875236868858337	▁mi ▁; ▁late - ons et ▁; ▁MI ▁; ▁ HF
D-1104	-0.7875236868858337	mi ; late-onset ; MI ; HF
P-1104	-1.8258 -0.7590 -2.4804 -0.0901 -0.0328 -0.5480 -0.2306 -2.3049 -0.4191 -0.5455 -0.3563 -0.2905 -0.3548
S-1544	CONCLUSIONS: Bisphosphonate users were at increased risk of heart failure compared to age- and gender-matched control subjects.<unk>
T-1544	bisphosphonate ; heart failure
H-1544	-0.7411554455757141	▁bis phos phon ate ▁; ▁heart ▁failure
D-1544	-0.7411554455757141	bisphosphonate ; heart failure
P-1544	-0.7650 -0.0369 -0.5380 -2.2228 -0.3272 -1.1838 -0.2610 -1.1689 -0.1668
S-2009	Because projecting long-term costs and survival is challenging, a consistent and valid approach to extrapolating short-term outcomes would be valuable.<unk>
T-2009	costs ; outcomes
H-2009	-0.7308124303817749	▁costs ▁; ▁survival
D-2009	-0.7308124303817749	costs ; survival
P-2009	-0.4405 -0.4650 -1.3615 -1.0654 -0.3217
S-620	Secondary outcomes were met in relation to sustainability with commissioning of hospital- and community-based programmes on completion of the study.<unk>
T-620	secondary outcomes
H-620	-0.8080818057060242	▁commission ing ▁; ▁hospital ▁; ▁community - based ▁programme s
D-620	-0.8080818057060242	commissioning ; hospital ; community-based programmes
P-620	-4.1248 -0.2709 -0.5094 -0.1936 -2.9682 -0.0336 -0.5043 -0.0348 -0.4019 -0.1622 -0.2238 -0.2696
S-1473	As a result, the focus of research investigations and clinical care has shifted to measurement and modification of maladaptive molecular processes.<unk>
T-1473	clinical
H-1473	-0.7446761131286621	▁clinic al ▁care ▁; ▁mal adapt ive ▁molecular
D-1473	-0.7446761131286621	clinical care ; maladaptive molecular
P-1473	-2.2816 -0.0336 -1.0014 -0.4030 -0.0534 -0.0564 -0.0209 -0.5523 -2.8625 -0.1817
S-469	Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.<unk>
T-469	xanthine oxidase inhibition ; left ventricular ; systolic ; diastolic function ; cardiac volume overload
H-469	-0.7818190455436707	▁Xan thi ne ▁oxid ase ▁inhibi tion ▁; ▁left ▁vent ri cular ▁sy sto lic ▁; ▁dia sto lic ▁function ▁; ▁cardiac ▁volume ▁over load
D-469	-0.7818190455436707	Xanthine oxidase inhibition ; left ventricular systolic ; diastolic function ; cardiac volume overload
P-469	-0.0024 -2.0114 -0.0714 -0.1379 -3.2972 -0.4180 -0.1267 -0.1839 -0.4399 -1.4447 -1.8503 -0.5417 -2.5272 -0.3454 -1.4069 -0.1712 -0.6982 -0.2650 -0.6495 -0.9608 -0.3971 -0.0586 -0.8811 -0.9366 -0.0557 -0.9907 -0.2394
S-21	Diagnosis of heart failure with preserved ejection fraction: role of clinical Doppler echocardiography.<unk>
T-21	diagnosis ; heart failure with preserved ejection fraction ; clinical ; doppler echocardiography
H-21	-0.4253680408000946	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁clinic al ▁do pp ler ▁e cho card i ography
D-21	-0.4253680408000946	heart failure ; preserved ejection fraction ; clinical doppler echocardiography
P-21	-2.4369 -0.0715 -0.1839 -0.0865 -0.1095 -0.1000 -0.0378 -0.1560 -0.0691 -0.6683 -0.0022 -0.2422 -1.0371 -0.0287 -0.5840 -0.0025 -0.8613 -0.1180 -1.1085 -0.6432 -0.7060 -0.4468 -0.3802 -0.1285
S-238	We studied the patients having heart failure (HF) using data from the Heart Failure Adherence and Retention Trial (HART).<unk>
T-238	patients ; heart failure ; hf ; heart failure adherence and retention trial ; hart
H-238	-0.4778042137622833	▁heart ▁failure ▁; HF ▁; ▁Heart ▁Fail ure ▁ad her ence ▁; ▁re tention ▁Tri al ▁; HAR t
D-238	-0.4778042137622833	heart failure ;HF ; Heart Failure adherence ; retention Trial ;HARt
P-238	-2.2230 -0.0744 -0.2682 -0.1051 -0.3571 -1.0182 -0.6792 -0.0625 -0.2988 -0.1744 -0.0126 -1.1684 -0.1519 -0.0176 -0.9937 -0.0270 -0.5631 -0.0205 -1.3338 -0.3079 -0.1767
S-1076	HF with preserved ejection fraction (HFpEF) is commoner among women who may have underlying hypertension.<unk>
T-1076	hf with preserved ejection fraction ; hfpef ; hypertension
H-1076	-0.3929879665374756	HF ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁hyper tension
D-1076	-0.3929879665374756	HF ; preserved ejection fraction ;HFpEF ; hypertension
P-1076	-0.8575 -0.4541 -1.8838 -0.1647 -0.2529 -0.0911 -0.2188 -0.0968 -0.7193 -0.0131 -0.2036 -0.2971 -0.0322 -0.1934 -0.2757 -1.0714 -0.1476 -0.2167 -0.2770
S-1873	The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance.<unk>
T-1873	end points ; nyha functional class ; quality-of-life ; 6-minute hall walk
H-1873	-0.9829569458961487	▁NY ha ▁; ▁quality - of - life ▁score
D-1873	-0.9829569458961487	NYha ; quality-of-life score
P-1873	-2.6905 -0.8899 -0.3800 -1.8947 -0.0834 -0.0308 -0.0846 -0.3935 -1.0826 -2.9209 -0.3615
S-1338	METHODS AND RESULTS: Myocardial infarction was created by left anterior descending coronary artery occlusion.<unk>
T-1338	myocardial infarction ; left anterior descending coronary artery occlusion
H-1338	-0.4491804540157318	▁my o card ial ▁in far ction ▁; ▁left ▁anterior ▁descend ing ▁corona ry ▁arter y ▁oc clusi on
D-1338	-0.4491804540157318	myocardial infarction ; left anterior descending coronary artery occlusion
P-1338	-1.8806 -0.4174 -0.5573 -0.0913 -0.0626 -0.7613 -0.1147 -0.3894 -0.8583 -0.8360 -0.2316 -0.0246 -1.3967 -0.0628 -0.0602 -0.5924 -0.0168 -0.0489 -0.2428 -0.5752 -0.2118
S-1891	Clinical symptoms and signs in HFpEF are often nonspecific although the primary symptoms are breathlessness, fatigue and fluid retention.<unk>
T-1891	clinical ; symptoms ; hfpef ; symptoms ; breathlessness ; fluid retention
H-1891	-0.9191358685493469	▁ha p EF ▁; ▁breath less ness ▁; ▁fatigue ▁; ▁fluid ▁re tention
D-1891	-0.9191358685493469	hapEF ; breathlessness ; fatigue ; fluid retention
P-1891	-5.9191 -0.0195 -2.2328 -0.3258 -2.9866 -0.0436 -0.6679 -0.4232 -0.0051 -0.2498 -0.0315 -0.0876 -0.0995 -0.4209 -0.2742
S-1521	Immunodetection of NT-proBNP was significantly improved with the use of antibodies that did not target these terminal regions.<unk>
T-1521	immunodetection ; nt-probnp ; antibodies ; terminal
H-1521	-0.32319432497024536	▁immun o det ection ▁; ▁NT - pro b NP ▁; ▁anti bo dies
D-1521	-0.32319432497024536	immunodetection ; NT-probNP ; antibodies
P-1521	-0.2008 -0.1289 -0.2117 -0.0393 -0.4691 -0.1095 -0.0845 -0.0266 -0.8399 -0.2199 -0.6649 -0.0127 -0.3705 -0.5393 -1.0811 -0.1724
S-574	CONCLUSIONS: Nordic walking was superior to standard cardiac rehabilitation care in improving functional capacity and other important outcomes in patients with heart failure.<unk>
T-574	walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; heart failure
H-574	-0.9924044609069824	▁Nordic ▁walking ▁; ▁cardiac ▁rehabilita tion ▁; ▁functional ▁capacity ▁; ▁heart ▁failure
D-574	-0.9924044609069824	Nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
P-574	-0.1787 -3.1359 -0.2588 -0.5428 -0.2688 -0.0740 -0.8238 -5.3505 -0.2437 -0.3788 -2.0147 -0.1046 -0.3191 -0.1995
S-1132	Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure.<unk>
T-1132	parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
H-1132	-0.7319608330726624	▁para sy mpa the tic ▁tone ▁; ▁py rido stig mine ▁; ▁vent ri cular ▁dys function ▁; ▁ons et ▁of ▁heart ▁failure
D-1132	-0.7319608330726624	parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; onset of heart failure
P-1132	-0.4461 -1.5879 -0.1784 -2.6614 -0.1103 -1.1676 -0.1227 -0.2956 -0.0287 -0.0009 -0.0753 -0.1460 -0.8318 -1.6550 -0.7850 -0.6768 -1.3219 -0.3218 -3.9792 -0.3163 -0.1619 -0.5268 -0.1713 -0.5069 -0.2231
S-459	CONCLUSIONS: β-Blockade promotes cardiac angiogenesis in heart failure via activation of VEGF signaling pathway.<unk>
T-459	β-blockade ; cardiac angiogenesis ; heart failure ; vegf signaling pathway
H-459	-0.5689574480056763	▁β - Block ade ▁; ▁cardiac ▁ang io gene sis ▁; ▁heart ▁failure ▁; ▁ve GF ▁signal ing ▁path way
D-459	-0.5689574480056763	β-Blockade ; cardiac angiogenesis ; heart failure ; veGF signaling pathway
P-459	-0.4253 -0.1091 -0.2613 -1.3360 -0.3925 -0.1826 -0.0425 -3.3854 -0.6754 -1.6424 -0.3385 -0.2038 -0.1636 -0.2524 -0.4612 -0.6210 -0.2907 -0.3198 -0.0291 -0.6925 -0.4977 -0.1942
S-101	Risk factors and outcomes associated with the development of myocardial ischemic events in patients who receive cardiac resynchronization therapy.<unk>
T-101	outcomes ; myocardial ischemic events ; patients ; cardiac resynchronization therapy
H-101	-0.41867542266845703	▁my o card ial ▁ ische mic ▁events ▁; ▁cardiac ▁re syn chron ization ▁ therapy
D-101	-0.41867542266845703	myocardial ischemic events ; cardiac resynchronization therapy
P-101	-2.4744 -0.2527 -0.5764 -0.0903 -0.2422 -0.3892 -0.3822 -0.3733 -0.2199 -0.1108 -0.0243 -0.0189 -0.0085 -0.4699 -1.2456 -0.0698 -0.3068 -0.2809
S-544	In the present report, we have described 6 patients who underwent aortic valve surgery for new-onset post-LVAD AI.<unk>
T-544	report ; patients ; aortic valve ; surgery ; post-lvad ai
H-544	-0.43640604615211487	▁report ▁; ▁a or tic ▁val ve ▁surgery ▁; ▁new - ons et ▁post - L VAD ▁AI
D-544	-0.43640604615211487	report ; aortic valve surgery ; new-onset post-LVAD AI
P-544	-0.0712 -0.1795 -0.2244 -0.1559 -0.0486 -1.4834 -0.0778 -0.6292 -0.1497 -0.7990 -0.1641 -0.0193 -0.3996 -0.0472 -0.0379 -3.0285 -0.0622 -0.6481 -0.3232 -0.1793
S-527	Therefore, unloading of the heart may contribute to the beneficial effect of isolated HR reduction in patients with systolic heart failure.<unk>
T-527	heart ; hr reduction ; patients ; systolic heart failure
H-527	-0.5737709403038025	▁un load ing ▁of ▁the ▁heart ▁; ▁isola ted ▁HR ▁re duction ▁; ▁sy sto lic ▁heart ▁failure
D-527	-0.5737709403038025	unloading of the heart ; isolated HR reduction ; systolic heart failure
P-527	-0.3370 -0.0587 -0.0387 -1.9714 -0.1555 -1.7270 -0.3604 -0.1031 -0.0078 -1.4328 -0.0648 -0.0053 -0.3212 -1.0683 -0.1565 -1.2650 -1.6613 -0.1127 -0.4024 -0.2255
S-439	We studied the effectiveness and safety of spironolactone in adults with newly diagnosed systolic heart failure in clinical practice.<unk>
T-439	spironolactone ; diagnosed ; systolic heart failure ; clinical
H-439	-0.5909490585327148	▁spi rono lac tone ▁; ▁sy sto lic ▁heart ▁failure
D-439	-0.5909490585327148	spironolactone ; systolic heart failure
P-439	-1.7108 -0.0424 -0.1615 -0.1233 -0.1521 -1.3246 -0.1226 -0.9206 -1.5899 -0.1117 -0.6602 -0.1717
S-980	Heart failure is an enormous clinical burden in adult medicine, largely because of the prevalence of atheromatous coronary disease.<unk>
T-980	heart failure ; clinical ; medicine ; prevalence ; coronary disease
H-980	-0.534558117389679	▁Heart ▁failure ▁; ▁a ther omat ous ▁corona ry ▁disease
D-980	-0.534558117389679	Heart failure ; atheromatous coronary disease
P-980	-0.6750 -0.0308 -0.2469 -2.6210 -0.0776 -0.0403 -0.1810 -0.7402 -0.1738 -1.1020 -0.3409 -0.1853
S-1789	Heart failure (HF) data in Latin America (LA) were reviewed to guide health service planning in the prevention and treatment of HF.<unk>
T-1789	heart failure ; hf ; latin america ; health ; hf
H-1789	-0.45444878935813904	▁Heart ▁failure ▁; HF ▁; ▁Latin ▁America ▁; LA ▁; ▁health ▁service ▁planning ▁; ▁ HF
D-1789	-0.45444878935813904	Heart failure ;HF ; Latin America ;LA ; health service planning ; HF
P-1789	-1.0278 -0.0360 -0.2115 -0.3826 -0.4547 -2.0842 -0.2698 -0.1720 -0.4796 -0.4920 -0.4965 -0.2474 -0.6535 -0.1453 -0.4155 -0.1399 -0.2732 -0.1985
S-1710	Does reducing length of stay increase rehospitalization of medicare fee-for-service beneficiaries discharged to skilled nursing facilities?<unk>
T-1710	rehospitalization ; medicare ; discharged ; nursing
H-1710	-0.28788238763809204	▁re hospital ization ▁; ▁medica re ▁fee - for - service ▁; ▁dis charge d ▁; ▁skille d ▁nur sing ▁facilities
D-1710	-0.28788238763809204	rehospitalization ; medicare fee-for-service ; discharged ; skilled nursing facilities
P-1710	-0.6935 -0.0143 -0.0706 -0.3808 -0.0599 -0.1040 -0.5044 -0.1199 -0.1433 -0.0468 -0.0230 -0.6261 -0.3861 -0.0061 -0.4775 -0.6030 -0.4165 -0.0756 -0.7689 -0.1083 -0.4772 -0.3068 -0.2087
S-755	The time to death or first HF hospitalization was significantly prolonged with CRT (hazard ratio, 0.26; P=0.012).<unk>
T-755	death ; hf ; hospitalization ; crt ; hazard ratio
H-755	-0.9079146981239319	▁ HF ▁hospital ization ▁; ▁c RT ▁; haz ard ▁ratio
D-755	-0.9079146981239319	HF hospitalization ; cRT ;hazard ratio
P-755	-1.4094 -0.4966 -3.2083 -0.5236 -0.2211 -0.2532 -3.2973 -0.8398 -0.2286 -0.2972 -0.0187 -0.6993 -0.3097
S-1820	In addition to palliative care of patients in the terminal phase, accurate recognition of advanced disease is vital in the determination of therapeutic options.<unk>
T-1820	palliative care ; patients ; terminal ; disease ; therapeutic
H-1820	-0.7513026595115662	▁palli ative ▁; ▁patients ▁; ▁advanced ▁disease ▁; ▁ therapeut ic
D-1820	-0.7513026595115662	palliative ; patients ; advanced disease ; therapeutic
P-1820	-0.0564 -0.0838 -1.9660 -3.1964 -0.2946 -1.0864 -0.4770 -1.2636 -0.5183 -0.0224 -0.1013 -0.5811 -0.1196
S-1892	There is still no single diagnostic test for HFpEF and the cornerstone in the assessment remains a thorough medical history and physical examination.<unk>
T-1892	diagnostic ; hfpef ; medical history ; physical examination
H-1892	-0.5639685392379761	▁diagnostic ▁test ▁; ▁ HF p EF ▁; ▁medical ▁history ▁; ▁physical
D-1892	-0.5639685392379761	diagnostic test ; HFpEF ; medical history ; physical
P-1892	-1.1753 -1.3884 -0.1700 -0.4917 -0.4442 -0.0475 -0.6626 -0.2122 -0.2362 -1.0730 -0.3142 -0.0038 -1.4712 -0.2052
S-281	Oxidative stress was enhanced and small GTPase Rac1 activity was upregulated in the hearts of ANS mice.<unk>
T-281	oxidative stress ; gtpase ; rac1 ; activity ; hearts
H-281	-0.4745166003704071	▁o xi da tive ▁stress ▁; ▁GT Pas e ▁Rac 1 ▁; ▁heart s ▁; ▁ ANS ▁mi ce
D-281	-0.4745166003704071	oxidative stress ; GTPase Rac1 ; hearts ; ANS mice
P-281	-0.1527 -0.0695 -0.1916 -0.1605 -0.2563 -0.1418 -1.6399 -0.3196 -0.0309 -0.2426 -1.8532 -0.7271 -1.0819 -0.0579 -0.5325 -0.8402 -0.1762 -0.3015 -0.5199 -0.4370 -0.2321
S-928	Resistin is a circulating mediator of insulin resistance mainly expressed in human monocytes and responsive to inflammatory stimuli.<unk>
T-928	resistin ; insulin resistance ; monocytes ; inflammatory
H-928	-0.32693159580230713	▁Res istin ▁; ▁circula ting ▁media tor ▁of ▁insulin ▁resist ance ▁; ▁mono cy tes ▁; ▁infla mma tory ▁stimul i
D-928	-0.32693159580230713	Resistin ; circulating mediator of insulin resistance ; monocytes ; inflammatory stimuli
P-928	-1.6191 -0.0031 -0.2104 -0.2926 -0.0379 -0.0153 -0.1881 -0.9153 -0.2764 -0.0777 -0.0303 -0.2347 -0.1481 -0.0182 -0.0239 -0.2062 -0.3166 -0.5843 -0.0387 -0.5162 -1.1159 -0.3590 -0.2914
S-1757	Primary study end point was a composite of cardiovascular death and urgent cardiac transplant, and secondary end point was all-cause death.<unk>
T-1757	end point ; cardiovascular death ; cardiac transplant ; secondary end point ; death
H-1757	-0.7931181788444519	▁cardiovascular ▁death ▁; ▁urgent ▁cardiac ▁transplant
D-1757	-0.7931181788444519	cardiovascular death ; urgent cardiac transplant
P-1757	-1.8374 -2.1911 -0.1529 -0.1983 -0.0489 -0.0312 -1.6768 -0.2084
S-658	Practice-level variation in use of recommended medications among outpatients with heart failure: Insights from the NCDR PINNACLE program.<unk>
T-658	medications ; outpatients ; heart failure ; ncdr pinnacle
H-658	-0.9274808168411255	▁medication s ▁; ▁out patient s ▁; ▁heart ▁failure ▁; ▁NC d ▁PIN na CLE
D-658	-0.9274808168411255	medications ; outpatients ; heart failure ; NCd PINnaCLE
P-658	-3.5855 -0.0997 -0.5657 -1.5650 -0.0064 -0.1550 -0.8184 -0.1941 -0.0787 -0.6988 -0.3168 -2.6119 -0.8560 -0.5435 -2.6079 -0.8164 -0.2475
S-1110	Differential effects of nonselective versus selective beta-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.<unk>
T-1110	selective beta-blockers ; cardiac sympathetic activity ; hemostasis ; patients ; heart failure
H-1110	-0.6786783337593079	▁non sel ective ▁; ▁beta - block ers ▁; ▁cardiac ▁sympa the tic ▁activity ▁; ▁hemos tas is ▁; ▁heart ▁failure
D-1110	-0.6786783337593079	nonselective ; beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
P-1110	-3.6310 -0.1001 -0.1577 -0.8099 -1.2058 -0.1119 -0.3352 -0.3581 -0.5459 -0.0457 -0.7168 -1.8957 -1.2557 -0.1025 -0.4149 -0.0950 -0.0810 -1.3734 -0.5061 -0.9648 -0.1199 -0.5003 -0.2821
S-1581	RESULTS: A statistically significant 42 percent relative reduction in 30-day readmission rate was documented for those patients participating in the pilot program.<unk>
T-1581	readmission ; patients
H-1581	-1.6356010437011719	
D-1581	-1.6356010437011719	
P-1581	-2.9631 -0.3081
S-86	While specific research questions may be the focus, it is the implementation issues and strategies that reveal how individuals and organizations are profoundly transformed.<unk>
T-86	
H-86	-0.7244367599487305	
D-86	-0.7244367599487305	
P-86	-1.2287 -0.2202
S-51	Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study.<unk>
T-51	intravenous ; symptoms ; patients ; heart failure
H-51	-0.5868064165115356	▁Intra ven ous ▁ir on ▁; ▁heart ▁failure ▁; ▁ir on
D-51	-0.5868064165115356	Intravenous iron ; heart failure ; iron
P-51	-0.1847 -0.0154 -0.3926 -0.0817 -0.2296 -0.3889 -1.5149 -0.1473 -0.2784 -0.0266 -0.1596 -3.9717 -0.2371
S-462	Background—Heart failure is a common Emergency Department (ED) presentation but whether ED volume influences patient outcomes is unknown.<unk>
T-462	heart failure ; emergency department ; patient ; outcomes
H-462	-0.7307910919189453	▁he art ▁failure ▁; ▁Emer gen cy ▁department ▁; ED ▁; ▁ED ▁volume ▁; ▁patient ▁outcome s
D-462	-0.7307910919189453	heart failure ; Emergency department ;ED ; ED volume ; patient outcomes
P-462	-5.4377 -0.3302 -0.0462 -0.2154 -0.4301 -0.2800 -0.0103 -0.3926 -0.3361 -0.4134 -0.4234 -0.7652 -1.7110 -0.6483 -1.7420 -0.2229 -0.0733 -0.2044 -0.2024
S-991	While certain stimuli mediate a beneficial adaptation to stress conditions, others result in maladaptive remodelling, ultimately leading to heart failure.<unk>
T-991	conditions ; remodelling ; leading ; heart failure
H-991	-0.7600248456001282	▁conditions ▁; ▁mal adapt ive ▁remodel ling ▁; ▁heart ▁failure
D-991	-0.7600248456001282	conditions ; maladaptive remodelling ; heart failure
P-991	-4.4075 -0.2646 -2.7947 -0.0542 -0.0096 -0.1270 -0.0253 -0.2816 -0.6569 -0.1180 -0.1880 -0.1929
S-1613	RESULTS: A total of 293 and 133 DEGs were obtained for non-ischemic and ischemic heart failure, respectively.<unk>
T-1613	degs ; ischemic heart failure
H-1613	-0.5630203485488892	▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure
D-1613	-0.5630203485488892	non-ischemic ; ischemic heart failure
P-1613	-1.9850 -0.0770 -1.0313 -0.3169 -0.7154 -0.0978 -0.2899 -0.2264 -1.3517 -0.1568 -0.2979 -0.2101
S-1559	A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years.<unk>
T-1559	psoriasis ; systemic ; followed up
H-1559	-0.7348897457122803	▁psoriasis ▁; ▁system ic ▁; UV
D-1559	-0.7348897457122803	psoriasis ; systemic ;UV
P-1559	-0.0481 -0.4661 -0.0666 -0.0417 -2.5918 -0.4430 -2.0589 -0.1629
S-1160	We hypothesized that RV dysfunction is linked to weight loss, abnormal body composition, and worsened prognosis in advanced HF.<unk>
T-1160	rv dysfunction ; prognosis ; hf
H-1160	-0.6346559524536133	▁ RV ▁dys function ▁; ▁weight ▁loss ▁; ▁ab normal ▁body ▁composition ▁; ▁ HF
D-1160	-0.6346559524536133	RV dysfunction ; weight loss ; abnormal body composition ; HF
P-1160	-0.7735 -0.7226 -1.0270 -1.7264 -0.1652 -0.4844 -0.0795 -0.2879 -2.1674 -0.0454 -0.1450 -0.2249 -0.3056 -1.8525 -0.2328 -0.2110 -0.3382
S-609	But, it was elevated prior to 2002 (HR 2.17, 95% CI 0.45 to 10.50, test for interaction p=0.036).<unk>
T-609	elevated
H-609	-0.9726862907409668	
D-609	-0.9726862907409668	
P-609	-1.7132 -0.2321
S-158	Exclusion of one trial that provided better-than-usual support to the control group rendered each of the above comparisons statistically significant.<unk>
T-158	
H-158	-0.6325755715370178	▁trial
D-158	-0.6325755715370178	trial
P-158	-0.7027 -0.9780 -0.2171
S-26	Hence, the diagnosis of clinical (prognostic) diastolic dysfunction leading to HFPEF is of critical importance.<unk>
T-26	diagnosis ; clinical ; prognostic ; diastolic dysfunction ; leading ; hfpef
H-26	-0.9701274037361145	▁clinic al ▁; prog nosti c ▁; ▁dia sto lic ▁dys function ▁; ▁H FP EF
D-26	-0.9701274037361145	clinical ;prognostic ; diastolic dysfunction ; HFPEF
P-26	-2.8394 -0.0322 -0.2917 -5.8712 -0.2819 -0.1615 -0.6267 -0.3668 -0.3524 -1.4622 -0.3557 -0.8598 -0.2414 -2.2738 -0.6859 -0.2685 -0.2440 -0.2473
S-1424	β-Adrenergic receptor blockade reduces total mortality and all-cause hospitalizations in patients with heart failure (HF).<unk>
T-1424	β-adrenergic receptor blockade ; mortality ; all-cause hospitalizations ; patients ; heart failure ; hf
H-1424	-0.4954843819141388	▁β - Ad r energi c ▁receptor ▁block ade ▁; ▁hospital ization s ▁; ▁heart ▁failure ▁; HF
D-1424	-0.4954843819141388	β-Adrenergic receptor blockade ; hospitalizations ; heart failure ;HF
P-1424	-0.2562 -0.0464 -0.4398 -0.5679 -0.6527 -0.2544 -0.0047 -0.1710 -0.3777 -0.2824 -2.9704 -0.4542 -0.4605 -0.2898 -0.8114 -0.1617 -1.1421 -0.0456 -0.3169 -0.2039
S-578	Major right ventricle overload leads to decreased stroke volume, which shortens left ventricular ejection time (LVET).<unk>
T-578	right ventricle ; leads ; stroke volume ; shortens ; left ventricular ejection time ; lvet
H-578	-0.8321588635444641	▁right ▁vent ric le ▁over load ▁lead s ▁; ▁stroke ▁volume ▁; ▁left ▁vent ri cular ▁e je ction ▁time ▁; ▁l VET
D-578	-0.8321588635444641	right ventricle overload leads ; stroke volume ; left ventricular ejection time ; lVET
P-578	-0.1608 -3.7793 -1.6308 -0.9964 -0.5529 -0.1318 -0.4080 -0.0582 -0.3416 -2.3262 -0.1835 -0.3051 -0.7507 -2.9926 -1.5760 -0.1361 -0.1383 -0.4260 -0.1512 -0.7938 -1.4610 -0.5215 -0.0667 -0.7126 -0.2031
S-1515	NT-proBNP was enriched from HF patient plasma by use of immunoprecipitation followed by mass spectrometric analysis.<unk>
T-1515	nt-probnp ; hf ; patient ; plasma ; immunoprecipitation ; mass spectrometric analysis
H-1515	-0.4559328258037567	▁NT - pro b NP ▁; ▁ HF ▁; ▁immun o preci pit ation ▁; ▁mass ▁spec tro metric
D-1515	-0.4559328258037567	NT-probNP ; HF ; immunoprecipitation ; mass spectrometric
P-1515	-0.0725 -0.0971 -0.0249 -0.5427 -0.4508 -0.2327 -0.8140 -0.3205 -1.0143 -1.2913 -0.2183 -0.1791 -0.0520 -0.2114 -0.5595 -0.0118 -0.5820 -0.8205 -0.2086 -1.6232 -0.2472
S-90	Chromatin-associated proteins alter chromatin structure by changing their association with DNA, thereby altering the gene expression profile.<unk>
T-90	chromatin-associated proteins ; chromatin structure ; changing ; dna ; gene expression profile
H-90	-0.4590678811073303	▁Chro mat in - as soci ated ▁protein s ▁; ▁chr omat in ▁structure ▁; ▁DNA ▁; ▁gene ▁expression ▁profile
D-90	-0.4590678811073303	Chromatin-associated proteins ; chromatin structure ; DNA ; gene expression profile
P-90	-0.1099 -0.0556 -1.3006 -0.3203 -0.0488 -0.0292 -0.1048 -1.2861 -0.1507 -0.4145 -0.0841 -0.0997 -2.1078 -1.7115 -0.1910 -0.0740 -0.5954 -0.6834 -0.1494 -0.0364 -0.3007 -0.2457
S-895	We examined the impact of PD on clinical status hospitalizations, and complications of therapy in severe end-stage HF.<unk>
T-895	pd ; clinical ; hospitalizations ; complications ; therapy ; end-stage hf
H-895	-0.5336241126060486	▁PD ▁; ▁hospital ization s ▁; ▁ therapy ▁; ▁severe ▁end - s tage ▁ HF
D-895	-0.5336241126060486	PD ; hospitalizations ; therapy ; severe end-stage HF
P-895	-1.2153 -0.3134 -2.1518 -0.2186 -0.3260 -0.2172 -1.1429 -0.1594 -0.1742 -2.7302 -0.1148 -0.1509 -0.0340 -0.0039 -0.1791 -0.0397 -0.2148 -0.2192
S-577	BACKGROUND: Novel noninvasive tools may improve the management of patients with pulmonary hypertension (PH) experiencing heart failure.<unk>
T-577	noninvasive ; patients ; pulmonary hypertension ; heart failure
H-577	-0.2903802692890167	▁pulmonar y ▁hyper tension ▁; PH ▁; ▁heart ▁failure
D-577	-0.2903802692890167	pulmonary hypertension ;PH ; heart failure
P-577	-0.6418 -0.0554 -0.3245 -0.2086 -0.2544 -0.1329 -0.3522 -0.7069 -0.0534 -0.2485 -0.2156
S-1912	OBJECTIVE: The objective of this study was assess robot-assisted gait therapy with the Lokomat® system in heart failure patients.<unk>
T-1912	gait ; therapy ; lokomat ; heart failure ; patients
H-1912	-0.7247303128242493	▁robot - assist ed ▁ga it ▁ therapy ▁; ▁Lok omat ® ▁system ▁; ▁heart ▁failure
D-1912	-0.7247303128242493	robot-assisted gait therapy ; Lokomat® system ; heart failure
P-1912	-2.2186 -0.2101 -0.0136 -0.1077 -0.1886 -4.1946 -0.4372 -0.0441 -0.1409 -0.0899 -0.0214 -3.2702 -0.1231 -0.3265 -0.1511 -0.0613 -1.2652 -0.1811
S-1647	Furthermore, catheter ablation and new antiarrhythmic drugs have enhanced the potential effectiveness and safety of rhythm control therapy.<unk>
T-1647	catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
H-1647	-0.20772810280323029	▁cat heter ▁ab lation ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁ rhythm ▁control ▁ therapy
D-1647	-0.20772810280323029	catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
P-1647	-0.5348 -0.0097 -0.0135 -0.2640 -0.0878 -0.0309 -0.3743 -0.2418 -0.0826 -0.0221 -0.2969 -0.1718 -0.2870 -0.1324 -0.5189 -0.0512 -0.3768 -0.2426
S-258	In healthy individuals, ET had no effect on HDL function, whereas ET of CHF-NYHA-IIIb significantly improved HDL function.<unk>
T-258	healthy ; hdl ; chf-nyha-iiib ; hdl
H-258	-1.1398485898971558	▁ET ▁; ▁HD L ▁function ▁; ▁CHF - NY ha - III b ▁; ▁HD L ▁function
D-258	-1.1398485898971558	ET ; HDL function ; CHF-NYha-IIIb ; HDL function
P-258	-2.2541 -0.3825 -3.1912 -3.2471 -0.3572 -0.3405 -2.6513 -0.2288 -0.3213 -0.9426 -0.3254 -0.0939 -0.0549 -0.2855 -2.7763 -3.3211 -0.4457 -0.2960 -0.1420
S-652	Cardiac failure is a major cause of death in patients with type 2 diabetes, but the molecular mechanism that links diabetes to heart failure remains unclear.<unk>
T-652	cardiac failure ; death ; patients ; type 2 diabetes ; diabetes ; heart failure
H-652	-0.8822278380393982	▁Card iac ▁failure ▁; ▁diabetes ▁; ▁diabetes ▁; ▁heart ▁failure
D-652	-0.8822278380393982	Cardiac failure ; diabetes ; diabetes ; heart failure
P-652	-1.8833 -0.7510 -0.0299 -0.1576 -2.3102 -0.1485 -3.7987 -0.1556 -0.9185 -0.1575 -0.1113 -0.1648
S-1179	Because this patient population is symptomatic on exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful.<unk>
T-1179	patient ; symptomatic ; therapeutic ; exercise ; hemodynamic
H-1179	-0.7322238683700562	▁ex er tion ▁; ▁exercise ▁; ▁hem o dynamic ▁status
D-1179	-0.7322238683700562	exertion ; exercise ; hemodynamic status
P-1179	-2.3154 -0.1232 -0.0787 -0.2791 -2.4141 -1.4634 -0.7406 -0.2430 -0.0149 -0.5801 -0.3031 -0.2310
S-584	The LVET at entry (237 milliseconds) had 73% sensitivity and 89% specificity for identifying death in the ICU.<unk>
T-584	lvet ; sensitivity ; specificity ; death ; icu
H-584	-0.9752549529075623	▁l VET ▁; ▁death ▁; ▁ ICU
D-584	-0.9752549529075623	lVET ; death ; ICU
P-584	-2.2104 -0.4390 -0.3224 -4.8310 -0.3310 -0.1708 -0.0799 -0.1365 -0.2563
S-1578	PARTICIPANTS: All patients admitted between June 7, 2010 and June 6, 2011 with a diagnosis of congestive heart failure.<unk>
T-1578	patients ; diagnosis ; congestive heart failure
H-1578	-0.31657305359840393	▁con ges tive ▁heart ▁failure
D-1578	-0.31657305359840393	congestive heart failure
P-1578	-0.5193 -0.1360 -0.0877 -0.9422 -0.1058 -0.2158 -0.2092
S-1859	AIM: To determine patient awareness, preferences and timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1859	patient ; implantable cardioverter-defibrillator
H-1859	-0.7168238759040833	▁a IM ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1859	-0.7168238759040833	aIM ; implantable cardioverter-defibrillator deactivation
P-1859	-0.4373 -0.3013 -0.6147 -2.8341 -0.0459 -0.7971 -0.1380 -0.7076 -0.1032 -0.0700 -1.2770 -2.9797 -1.4315 -0.1165 -0.5150 -0.0395 -0.2221 -0.7378 -0.2511
S-1250	We hypothesized that an improved mitochondrial structure may facilitate the reversal of detrimental alterations in sarcomeric microstructure.<unk>
T-1250	mitochondrial structure ; sarcomeric microstructure
H-1250	-0.9766411185264587	▁mito cho ndri al ▁structure ▁; ▁sar come ric ▁micro structure
D-1250	-0.9766411185264587	mitochondrial structure ; sarcomeric microstructure
P-1250	-0.2366 -2.4286 -0.8755 -0.0957 -1.0497 -0.2066 -1.2518 -1.5876 -2.1896 -1.7208 -0.6460 -0.1989 -0.2089
S-668	Addressing practice-level differences may be an important component of improving quality of care for patients with heart failure and reduced ejection fraction.<unk>
T-668	patients ; heart failure and reduced ejection fraction
H-668	-0.8105730414390564	▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-668	-0.8105730414390564	heart failure ; ejection fraction
P-668	-5.6691 -0.0565 -0.2102 -0.5873 -0.3548 -0.1242 -0.3802 -0.0122 -0.4014 -0.3098
S-1363	SUMMARY: The gut and its role for inflammation and dietary interventions in heart failure patients are a crucial target of further heart failure research.<unk>
T-1363	gut ; inflammation ; heart failure ; patients ; heart failure
H-1363	-0.6443952918052673	▁gut ▁; ▁ inflammation ▁; ▁dieta ry ▁intervention s ▁; ▁heart ▁failure
D-1363	-0.6443952918052673	gut ; inflammation ; dietary interventions ; heart failure
P-1363	-0.6422 -0.0964 -0.2000 -0.0843 -0.1221 -1.9352 -0.0713 -1.8749 -0.1480 -0.2637 -0.1467 -0.0595 -3.1756 -0.2016
S-141	Rates calculated using the PPR and either ACR or CMS metrics were moderately correlated (r = 0.50-0.67).<unk>
T-141	ppr ; acr ; cms ; correlated
H-141	-0.7142500281333923	▁p p ▁; ▁a CR ▁; ▁CMS
D-141	-0.7142500281333923	pp ; aCR ; CMS
P-141	-0.5760 -0.7829 -0.1202 -0.1772 -2.7749 -0.1647 -0.5226 -1.0237 -0.2860
S-513	The mortality was 32 and 37% in the LCX and LAD models but very (71%) high in the two-vessel disease model.<unk>
T-513	mortality ; lcx ; lad ; disease
H-513	-0.4467043876647949	▁mortal ity ▁; ▁ LC x ▁; ▁ LAD ▁; ▁two - ves sel ▁disease ▁model
D-513	-0.4467043876647949	mortality ; LCx ; LAD ; two-vessel disease model
P-513	-0.8834 -0.0236 -0.1252 -0.9815 -0.0402 -2.1476 -0.1555 -0.0164 -0.0333 -1.0751 -0.0332 -0.1844 -0.1570 -0.0389 -1.2126 -0.3827 -0.3515 -0.1988
S-210	We hypothesize that this should have resulted in fewer CHF patients presenting to the emergency department (ED) and fewer being intubated.<unk>
T-210	chf ; patients ; emergency department ; intubated
H-210	-0.3870669901371002	▁CHF ▁; ▁emergency ▁department ▁; ED ▁; ▁in tuba ted
D-210	-0.3870669901371002	CHF ; emergency department ;ED ; intubated
P-210	-0.1018 -1.2704 -0.4548 -0.0179 -0.1780 -0.9793 -0.5462 -0.0783 -0.0743 -0.2943 -0.3923 -0.2574
S-635	Successful approaches to improving the prognosis of patients with CHF are based largely on therapeutic interruption of activated neurohormonal systems.<unk>
T-635	prognosis ; patients ; chf ; therapeutic ; neurohormonal systems
H-635	-0.29162952303886414	▁CHF ▁; ▁ therapeut ic ▁interrupt ion ▁; ▁activa ted ▁neuro hormon al ▁systems
D-635	-0.29162952303886414	CHF ; therapeutic interruption ; activated neurohormonal systems
P-635	-0.8576 -0.5359 -1.3946 -0.0533 -0.0298 -0.0120 -0.0175 -0.7245 -0.1298 -0.0245 -0.2390 -0.0889 -0.0501 -0.0328 -0.3556 -0.1202
S-770	CONCLUSIONS: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span.<unk>
T-770	obese ; zsf1 ; heart failure with preserved ejection fraction
H-770	-0.40764927864074707	▁z f 1 ▁rat s ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-770	-0.40764927864074707	zf1 rats ; heart failure ; preserved ejection fraction
P-770	-0.2954 -2.0484 -0.6505 -0.4080 -0.0981 -0.3197 -0.6366 -0.1843 -0.1951 -0.5430 -0.1290 -0.2999 -0.0660 -0.4173 -0.1846 -0.5559 -0.0340 -0.4395 -0.2402
S-1413	BACKGROUND: Early physician follow-up after discharge is associated with lower rates of death and readmission among patients with heart failure.<unk>
T-1413	physician ; follow-up ; discharge ; death ; readmission ; patients ; heart failure
H-1413	-0.8498514890670776	▁physician ▁; ▁follow - up ▁; ▁dis charge ▁; ▁death ▁; ▁read mission ▁; ▁heart ▁failure
D-1413	-0.8498514890670776	physician ; follow-up ; discharge ; death ; readmission ; heart failure
P-1413	-2.5432 -0.6498 -3.1265 -0.0960 -0.0300 -1.0524 -0.0329 -0.0781 -0.3597 -2.7232 -0.4253 -0.6384 -0.0559 -0.5538 -2.3614 -0.1214 -0.2696 -0.1798
S-744	Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.<unk>
T-744	heart magnetic resonance imaging ; chelation ; compliance ; heart disease ; patients ; thalassaemia major
H-744	-0.608040988445282	▁impact ▁of ▁heart ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁choice s ▁; ▁heart ▁disease ▁; ▁tha lassa emia
D-744	-0.608040988445282	impact of heart magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia
P-744	-1.6115 -0.6474 -1.5451 -0.0544 -0.2203 -0.2246 -0.2570 -0.7431 -0.1805 -0.4174 -0.6905 -0.3239 -0.8003 -0.1793 -0.2868 -2.5698 -0.9897 -0.2717 -0.0509 -0.6394 -0.6500 -0.4397 -0.1918
S-579	Our arterial tonometry study tested the hypothesis that LVET carries prognostic value in patients with precapillary PH with heart failure.<unk>
T-579	arterial tonometry ; lvet ; prognostic ; patients ; precapillary ph ; heart failure
H-579	-0.4438525140285492	▁arterial ▁ton ometr y ▁; ▁l VET ▁; ▁pre cap illa ry ▁PH ▁; ▁heart ▁failure
D-579	-0.4438525140285492	arterial tonometry ; lVET ; precapillary PH ; heart failure
P-579	-0.7080 -1.6374 -0.0178 -0.1105 -0.5771 -1.6982 -0.2883 -0.1959 -0.5071 -0.2698 -0.3420 -0.0118 -0.2539 -0.1664 -0.4766 -0.1004 -0.3777 -0.2503
S-8	Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.<unk>
T-8	cross-talk ; heart ; adipose tissue ; cachectic heart failure ; patients ; prospective study
H-8	-0.5335240364074707	▁cross - talk ▁; ▁heart ▁; ▁adi pose ▁tissu e ▁; ▁cache ctic ▁heart ▁failure ▁; ▁body ▁composition
D-8	-0.5335240364074707	cross-talk ; heart ; adipose tissue ; cachectic heart failure ; body composition
P-8	-0.7919 -0.2117 -0.0875 -0.8918 -1.0000 -0.3417 -0.0399 -0.1527 -0.3463 -0.1602 -0.2355 -0.0497 -1.4349 -0.9932 -0.0421 -1.6259 -0.8761 -0.9699 -0.2289 -0.1907
S-641	In line, mutant mice overexpressing Hand2 in otherwise healthy heart muscle cells developed a phenotype of pathological hypertrophy.<unk>
T-641	hand2 ; healthy ; heart muscle ; cells ; phenotype ; pathological ; hypertrophy
H-641	-0.6164757013320923	▁mu tant ▁mi ce ▁; ▁hand 2 ▁; ▁heart ▁muscle ▁cell s ▁; ▁path ological ▁hyper trop hy
D-641	-0.6164757013320923	mutant mice ; hand2 ; heart muscle cells ; pathological hypertrophy
P-641	-1.3348 -0.6340 -0.0271 -0.2635 -0.4568 -1.0284 -0.1132 -0.1886 -2.4419 -0.5866 -1.5321 -0.1515 -0.5753 -0.0673 -0.0965 -0.5621 -0.0258 -1.6598 -0.3158 -0.2682
S-1957	Transoesophageal echocardiography at 1 month showed that all shunts were patent, with no thrombosis or migration.<unk>
T-1957	transoesophageal echocardiography ; shunts ; thrombosis
H-1957	-0.5095103979110718	▁trans o es op hage al ▁e cho card i ography ▁; ▁shu nts ▁; ▁ thro mbo sis ▁; ▁migration
D-1957	-0.5095103979110718	transoesophageal echocardiography ; shunts ; thrombosis ; migration
P-1957	-0.0489 -0.3991 -0.3234 -0.4304 -0.3189 -0.2885 -0.1588 -0.4588 -0.5713 -0.5990 -0.7062 -0.2156 -0.8651 -0.0283 -0.1701 -0.4185 -0.5892 -0.7968 -2.6283 -1.1968 -0.0117 -0.3219 -0.1729
S-180	Patients who received uptitration were significantly younger, with a higher heart rate and better renal function, and received spironolactone more often.<unk>
T-180	patients ; uptitration ; heart rate ; renal function ; spironolactone
H-180	-0.5340701937675476	▁up tit ration ▁; ▁heart ▁rate ▁; ▁renal ▁function ▁; ▁spi rono lac tone
D-180	-0.5340701937675476	uptitration ; heart rate ; renal function ; spironolactone
P-180	-0.6862 -0.9839 -0.7684 -0.3451 -2.3376 -0.0362 -0.1182 -0.1192 -0.4513 -0.7645 -0.9505 -0.0728 -0.1846 -0.1301 -0.2561 -0.3403
S-914	Compared with matched controls, dialysis patients were at increased risk for adverse events and worsened echocardiographic outcomes.<unk>
T-914	dialysis ; patients ; adverse events ; echocardiographic ; outcomes
H-914	-0.9554789066314697	▁di al ysis ▁patients ▁; ▁e cho car dio graphic ▁outcome s
D-914	-0.9554789066314697	dialysis patients ; echocardiographic outcomes
P-914	-0.1670 -0.1325 -0.5039 -2.1501 -0.3574 -1.2844 -1.7740 -1.7620 -1.8194 -2.0360 -0.7743 -0.0758 -0.3285 -0.2113
S-1481	An increasing body of evidence indicates an important role for microRNAs (miRNAs) in the pathogenesis and progression of heart failure.<unk>
T-1481	evidence ; micrornas ; mirnas ; pathogenesis ; heart failure
H-1481	-0.43296465277671814	▁micro RNA s ▁; mi RNA s ▁; ▁path ogen es is ▁; ▁heart ▁failure
D-1481	-0.43296465277671814	microRNAs ;miRNAs ; pathogenesis ; heart failure
P-1481	-2.2592 -0.0516 -0.0452 -0.2150 -0.1872 -0.0161 -0.0369 -0.3098 -1.2514 -0.0948 -0.0714 -0.7013 -0.1444 -1.4855 -0.1091 -0.2180 -0.1636
S-1964	Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure Chronic heart failure is a crucial problem of current cardiology.<unk>
T-1964	paradigm-hf ; shift ; chronic heart failure ; chronic heart failure ; cardiology
H-1964	-0.7735884189605713	▁PARA DIG m - HF ▁; ▁chronic ▁heart ▁failure ▁; ▁Chro nic ▁heart ▁failure ▁; ▁card i ology
D-1964	-0.7735884189605713	PARADIGm-HF ; chronic heart failure ; Chronic heart failure ; cardiology
P-1964	-3.8515 -0.2853 -0.3210 -0.0628 -0.0420 -0.1760 -2.7088 -1.5207 -0.0761 -0.5994 -1.8196 -0.0083 -0.7871 -0.0347 -0.3023 -1.9417 -0.4813 -0.0477 -0.2007 -0.2048
S-122	METHODS: We included 156 consecutive consenting ambulatory HF patients (left ventricular ejection fraction < 40%).<unk>
T-122	ambulatory ; hf ; patients ; left ventricular ejection fraction
H-122	-0.8178830742835999	▁ambula tory ▁ HF ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction
D-122	-0.8178830742835999	ambulatory HF ; left ventricular ejection fraction
P-122	-1.8671 -0.0096 -0.6787 -0.1733 -1.1510 -2.0833 -0.0932 -2.8870 -1.3192 -0.4270 -0.1974 -0.2887 -0.4335 -1.2746 -0.0280 -0.7993 -0.1931
S-1373	The present study used conscious, chronically instrumented New Zealand White rabbits undergoing renal DNx prior to pacing-induced CHF.<unk>
T-1373	new zealand ; renal dnx ; pacing-induced chf
H-1373	-0.2629780173301697	▁white ▁rabbi ts ▁; ▁renal ▁DN x ▁; ▁pa cing - indu ced ▁CHF
D-1373	-0.2629780173301697	white rabbits ; renal DNx ; pacing-induced CHF
P-1373	-1.6593 -0.1140 -0.0166 -0.2405 -0.1328 -0.1389 -0.1328 -0.3652 -0.2517 -0.0283 -0.1053 -0.0075 -0.4066 -0.1036 -0.3065 -0.1982
S-1435	QT variability (QTV) signifies repolarization lability, and increased QTV is a risk predictor for sudden cardiac death.<unk>
T-1435	qt variability ; qtv ; repolarization ; qtv ; cardiac death
H-1435	-0.763194739818573	▁ QT ▁variabil ity ▁; Q TV ▁; ▁repo lar ization ▁la bility ▁; ▁Q TV ▁; ▁risk ▁predict or ▁; ▁sud den ▁cardiac ▁death
D-1435	-0.763194739818573	QT variability ;QTV ; repolarization lability ; QTV ; risk predictor ; sudden cardiac death
P-1435	-2.0147 -1.2523 -0.4943 -0.1034 -0.2798 -2.4570 -2.7143 -0.4780 -1.1610 -0.9537 -0.0744 -0.0357 -0.0145 -0.3177 -1.2151 -2.0214 -0.1773 -2.2467 -0.1998 -0.4512 -0.3381 -0.1109 -0.0014 -0.0558 -0.9097 -0.2643 -0.2636
S-1941	Beta-blocker dose after 12 months was comparable in patients with resting HR<70 versus ≥70 bpm (P value=0.631).<unk>
T-1941	beta-blocker ; patients ; resting hr ; bpm ; p value
H-1941	-0.9772223234176636	▁Beta - block er ▁dose ▁; ▁rest ing ▁HR
D-1941	-0.9772223234176636	Beta-blocker dose ; resting HR
P-1941	-0.1280 -0.0824 -0.1871 -0.6107 -1.5959 -0.2869 -3.8335 -0.0434 -1.1293 -2.7282 -0.1241
S-1054	Multiacquisition T1-mapping MRI during tidal respiration for quantification of myocardial T1 in swine with heart failure.<unk>
T-1054	t1-mapping ; mri ; tidal respiration ; myocardial t1 ; heart failure
H-1054	-0.41426509618759155	▁t 1- ma pping ▁m RI ▁; ▁tid al ▁respira tion ▁; ▁my o card ial ▁t 1 ▁; ▁s win e ▁; ▁heart ▁failure
D-1054	-0.41426509618759155	t1-mapping mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
P-1054	-0.3489 -0.0883 -0.0618 -0.0251 -1.7798 -3.6583 -0.3187 -0.4806 -0.0412 -0.2853 -0.0486 -0.1703 -0.2065 -0.2747 -0.5422 -0.0153 -0.6663 -0.1928 -0.2357 -0.0066 -0.4015 -0.2702 -0.2231 -0.1671 -0.0812 -0.4038 -0.1914
S-1767	METHODS AND RESULTS: A total of 44 674 men without a history of cardiovascular disease underwent a baseline examination between 1971 and 2010.<unk>
T-1767	cardiovascular disease ; baseline
H-1767	-1.3426436185836792	▁cardiovascular ▁; ▁base line
D-1767	-1.3426436185836792	cardiovascular ; baseline
P-1767	-2.2470 -4.6009 -0.0370 -0.0346 -0.8189 -0.3176
S-1029	It is also important that processes of care delivery are redesigned to take full advantage of the faster turnaround times provided by POC technology.<unk>
T-1029	advantage ; poc
H-1029	-1.8626185655593872	▁process es ▁of ▁care ▁delivery
D-1029	-1.8626185655593872	processes of care delivery
P-1029	-4.4001 -0.7126 -0.4970 -0.2049 -0.9136 -5.9542 -0.3559
S-1555	Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results.<unk>
T-1555	psoriasis ; cardiovascular disease ; cvd
H-1555	-0.6288552284240723	▁p sori asis ▁; ▁cardiovascular ▁disease ▁; CV d
D-1555	-0.6288552284240723	psoriasis ; cardiovascular disease ;CVd
P-1555	-1.6774 -0.2118 -0.3392 -0.1684 -0.7391 -2.3786 -0.2604 -0.1177 -0.3360 -0.5074 -0.1814
S-1697	RESULTS: The composite (vs. Hospital Compare) explained 68% (vs. 39%) of variation in future AMI mortality rates.<unk>
T-1697	hospital compare ; ami ; mortality
H-1697	-0.9029778838157654	▁ AMI ▁mortal ity ▁rates
D-1697	-0.9029778838157654	AMI mortality rates
P-1697	-1.3954 -0.4203 -2.2108 -0.0432 -1.6205 -0.3327 -0.2979
S-726	Thirty-day all-cause readmissions decreased from 27.5% to 19.1% after our quality improvement initiative (P = .024).<unk>
T-726	all-cause readmissions
H-726	-1.0737875699996948	
D-726	-1.0737875699996948	
P-726	-2.0388 -0.1088
S-94	Our study identified 321 proteins in this subproteome, demonstrating it to have modest conservation (37%) with that revealed using strong acid.<unk>
T-94	proteins ; subproteome
H-94	-0.990774393081665	▁protein s ▁; ▁strong ▁acid
D-94	-0.990774393081665	proteins ; strong acid
P-94	-1.8122 -0.1260 -0.2326 -4.2135 -0.2511 -0.1467 -0.1533
S-1645	Rhythm control therapy has been only moderately effective in published trials, and its potential benefit was offset by side effects of repeated interventions.<unk>
T-1645	rhythm control therapy
H-1645	-0.6364859342575073	▁ Rhythm ▁control ▁ therapy
D-1645	-0.6364859342575073	Rhythm control therapy
P-1645	-0.8799 -0.0837 -0.0611 -0.7065 -0.0818 -2.4828 -0.1596
S-487	Using a cutoff of 8, negative predictive value of E/e'septal was 89% and negative likelihood ratio of 0.15.<unk>
T-487	septal ; likelihood ratio
H-487	-1.0280531644821167	▁cut off ▁; ▁e / e ' sept al ▁; ▁negative ▁like li hood ▁ratio
D-487	-1.0280531644821167	cutoff ; e/e'septal ; negative likelihood ratio
P-487	-0.5046 -0.3095 -0.1968 -0.8358 -4.1379 -0.0874 -5.5940 -0.0384 -0.0294 -0.6594 -1.2213 -2.7620 -0.0750 -0.1015 -0.0820 -0.5743 -0.2675
S-2015	RESULTS: The model demonstrated acceptable internal and external validity in replicating resource use, costs, and survival estimates from 3 clinical trials.<unk>
T-2015	costs ; clinical
H-2015	-1.0285521745681763	▁costs ▁; ▁clinic al ▁trial s
D-2015	-1.0285521745681763	costs ; clinical trials
P-2015	-3.8284 -0.5415 -2.7546 -0.0887 -0.4624 -0.1407 -0.1251 -0.2872
S-1546	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction.<unk>
T-1546	cardiac dysfunction ; subcellular ; metoprolol ; heart failure ; myocardial infarction
H-1546	-0.3878733217716217	▁cardiac ▁dys function ▁; ▁sub cel lular ▁altera tions ▁; ▁met o pro lol ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
D-1546	-0.3878733217716217	cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
P-1546	-0.3866 -0.2635 -1.7157 -0.1918 -0.0163 -0.2764 -0.0812 -0.9386 -0.0306 -0.5610 -0.0761 -0.1505 -0.0825 -0.4118 -0.3661 -0.1853 -0.0581 -0.3121 -0.7744 -0.2191 -1.5951 -0.0861 -0.0651 -0.3881 -0.4606 -0.5209 -0.2589
S-28	LV diastolic dysfunction and filling pressures can be assessed non-invasively using Doppler echocardiography.<unk>
T-28	lv diastolic dysfunction ; filling pressures ; non-invasively ; doppler echocardiography
H-28	-0.5739012956619263	▁LV ▁dia sto lic ▁dys function ▁; ▁fill ing ▁pressure s ▁; ▁do pp ler ▁e cho card i ography
D-28	-0.5739012956619263	LV diastolic dysfunction ; filling pressures ; doppler echocardiography
P-28	-0.3684 -1.9443 -0.3801 -0.8548 -0.3965 -1.2701 -0.1281 -0.0739 -0.0380 -0.2232 -0.1371 -0.4291 -0.7345 -0.0059 -0.8490 -0.1853 -1.3470 -1.0510 -0.7700 -0.7549 -0.4306 -0.2540
S-733	Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction.<unk>
T-733	cardiac magnetic resonance postcontrast t1 time ; outcome ; patients ; heart failure ; preserved ejection fraction
H-733	-0.44172757863998413	▁Card iac ▁magnetic ▁res on ance ▁post contra st ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-733	-0.44172757863998413	Cardiac magnetic resonance postcontrast ; heart failure ; preserved ejection fraction
P-733	-0.5044 -0.2394 -0.0256 -0.1003 -0.1508 -0.1328 -0.5121 -0.0303 -0.0504 -0.9788 -4.1388 -0.1019 -0.2087 -0.9819 -0.1375 -0.2404 -0.0415 -0.2550 -0.1616 -0.5545 -0.0231 -0.4229 -0.1670
S-764	Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined.<unk>
T-764	myocardial collagen ; collagen cross-linking ; titin ; isoforms ; phosphorylation
H-764	-0.2891881763935089	▁my o card ial ▁collage n ▁; ▁collage n ▁cross - link ing ▁; ▁titi n ▁iso form s ▁; ▁ phos phor y lation
D-764	-0.2891881763935089	myocardial collagen ; collagen cross-linking ; titin isoforms ; phosphorylation
P-764	-1.3275 -0.0711 -0.4162 -0.0899 -0.0263 -0.2691 -0.3164 -0.1211 -0.0910 -1.3399 -0.0183 -0.0497 -0.0285 -0.3321 -0.0339 -0.0537 -0.0124 -0.3624 -0.0710 -0.4931 -0.0735 -0.0406 -0.4564 -0.3958 -0.8161 -0.3074 -0.1949
S-185	RAS-blocker uptitration independently predicts clinical outcome in patients with HFrEF but not in those with HFpEF.<unk>
T-185	ras-blocker ; uptitration ; clinical ; outcome ; patients ; hfref ; hfpef
H-185	-0.5564430952072144	RAS - block er ▁up tit ration ▁; ▁h Fr EF ▁; ▁ HF p EF
D-185	-0.5564430952072144	RAS-blocker uptitration ; hFrEF ; HFpEF
P-185	-0.3403 -0.1140 -0.3501 -0.6758 -0.2113 -0.9294 -0.6009 -0.1872 -2.4411 -1.0040 -0.8049 -0.1547 -0.5594 -0.4625 -0.0414 -0.4623 -0.4232 -0.2534
S-833	Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial).<unk>
T-833	hemoglobin ; exercise ; training ; health ; patients ; chronic heart failure ; hf-action ; randomized
H-833	-0.5407347083091736	▁Hem o glob in ▁; ▁exercise ▁training ▁; ▁health ▁status ▁; ▁chronic ▁heart ▁failure ▁; ▁ HF - ac tion
D-833	-0.5407347083091736	Hemoglobin ; exercise training ; health status ; chronic heart failure ; HF-action
P-833	-0.2153 -0.0624 -0.3235 -0.6658 -0.3767 -0.6656 -0.4412 -0.2818 -0.5558 -0.0769 -0.2059 -1.5694 -1.0618 -0.4399 -0.4943 -0.5067 -0.0826 -0.0709 -1.3078 -1.3717 -0.8894 -0.2307
S-88	Systems proteomics of cardiac chromatin identifies nucleolin as a regulator of growth and cellular plasticity in cardiomyocytes.<unk>
T-88	systems proteomics ; cardiac chromatin ; nucleolin ; cellular plasticity ; cardiomyocytes
H-88	-0.5960502028465271	▁systems ▁prote o mics ▁; ▁cardiac ▁chr omat in ▁; ▁nucleo lin ▁; ▁regulator ▁of ▁growth ▁; ▁cel lular ▁plastic ity ▁; ▁cardio my o cy tes
D-88	-0.5960502028465271	systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
P-88	-0.3443 -1.2987 -1.2384 -0.0327 -0.3407 -0.0690 -0.1006 -0.0492 -1.5112 -0.2015 -0.1972 -2.7884 -0.1563 -2.3965 -0.7494 -0.1831 -0.2799 -2.2490 -0.0420 -0.0396 -0.0271 -0.4914 -0.0415 -0.7511 -0.7193 -0.0970 -0.3022 -0.3922 -0.1959
S-1514	METHODS: Plasma samples were collected from HF patients (n = 20) at rest and stored at -80 °C.<unk>
T-1514	plasma ; collected ; hf ; patients
H-1514	-0.5398375391960144	▁Plas ma ▁sample s ▁; ▁ HF
D-1514	-0.5398375391960144	Plasma samples ; HF
P-1514	-0.6508 -0.3356 -0.3085 -0.0567 -0.3339 -0.2368 -0.2270 -2.5414 -0.1679
S-1217	Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses.<unk>
T-1217	cardiomyocytes ; hypertrophic
H-1217	-0.4654364287853241	▁p de 2- over express ing ▁cardio my o cy tes ▁; ▁no re pine ph rine - indu ced ▁hyper trop hic ▁response s
D-1217	-0.4654364287853241	pde2-overexpressing cardiomyocytes ; norepinephrine-induced hypertrophic responses
P-1217	-0.3018 -1.1327 -0.9126 -0.1532 -0.4197 -0.0819 -0.9671 -1.3820 -0.7128 -0.4070 -0.3901 -0.2296 -0.1544 -0.2475 -0.1138 -1.0564 -0.0191 -0.3239 -0.0603 -1.3253 -0.2741 -0.0281 -0.0397 -0.8882 -0.1311 -0.6107 -0.2035
S-1804	This novel finding could partly explain the reported greater risk of heart failure linked to the CLCNKA SNP, but requires confirmation on other populations.<unk>
T-1804	reported ; heart failure ; clcnka ; snp
H-1804	-1.5032516717910767	▁risk ▁; ▁heart ▁failure ▁; ▁CL CN KA ▁s NP
D-1804	-1.5032516717910767	risk ; heart failure ; CLCNKA sNP
P-1804	-7.1275 -0.9608 -2.0168 -0.4051 -0.2006 -2.1977 -2.8178 -0.9388 -0.4729 -0.0429 -0.5762 -0.2817
S-1871	They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months.<unk>
T-1871	gdmt ; gdmt ; bat
H-1871	-0.673213005065918	▁GD MT ▁; ▁control ▁group ▁; ▁GD MT ▁; ▁BAT
D-1871	-0.673213005065918	GDMT ; control group ; GDMT ; BAT
P-1871	-0.8257 -0.8676 -0.2908 -2.6605 -0.0372 -0.3464 -0.9237 -0.7098 -0.1621 -0.4338 -0.6810 -0.1400
S-1940	At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR<70 bpm.<unk>
T-1940	baseline ; patients ; resting hr ; bpm
H-1940	-0.9435152411460876	▁base line ▁; ▁rest ing ▁HR
D-1940	-0.9435152411460876	baseline ; resting HR
P-1940	-0.0210 -0.0411 -0.3555 -5.2095 -0.0322 -1.1088 -0.6232 -0.1568
S-993	Paradoxically, however, in a number of cases, the transduction pathways involved in such opposing responses engage the same signalling proteins.<unk>
T-993	transduction pathways ; engage ; signalling proteins
H-993	-0.27277490496635437	▁trans duction ▁path ways ▁; ▁signal ling ▁protein s
D-993	-0.27277490496635437	transduction pathways ; signalling proteins
P-993	-0.0225 -0.6545 -0.1182 -0.1052 -0.2052 -0.4314 -0.0698 -0.9180 -0.0679 -0.2529 -0.1549
S-1545	However, users of alendronate showed a dose-dependent reduction in this risk, suggesting that alendronate may reduce the risk of heart failure.<unk>
T-1545	alendronate ; alendronate ; heart failure
H-1545	-1.0384808778762817	▁ale ndr onate ▁; ▁ale ndr onate ▁; ▁heart ▁failure
D-1545	-1.0384808778762817	alendronate ; alendronate ; heart failure
P-1545	-0.9615 -0.3105 -0.7555 -0.2304 -4.2188 -0.6018 -1.2010 -0.3454 -2.9583 -0.3593 -0.2849 -0.2343
S-1838	Results were also similar in subgroups of patients with and without prior cardiovascular disease and in a subgroup defined by the 2 highest DRS deciles.<unk>
T-1838	patients ; cardiovascular disease ; drs
H-1838	-0.8036021590232849	▁cardiovascular ▁disease ▁; ▁d RS
D-1838	-0.8036021590232849	cardiovascular disease ; dRS
P-1838	-1.0804 -1.0067 -0.3128 -0.1634 -0.5820 -2.3153 -0.1646
S-1417	A familiar physician was defined as one who had seen the patient at least twice in the year before the index admission or once during the index admission.<unk>
T-1417	physician ; patient ; admission ; admission
H-1417	-0.4297510087490082	▁index ▁ad mission ▁; ▁index ▁ad mission
D-1417	-0.4297510087490082	index admission ; index admission
P-1417	-1.7001 -0.0068 -0.0305 -1.1293 -0.0672 -0.0113 -0.0539 -0.2612 -0.6074
S-861	RESULTS: Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4 ± 1.1 years.<unk>
T-861	therapy ; patients ; follow-up
H-861	-0.8002238869667053	▁in appropria te ▁ therapy
D-861	-0.8002238869667053	inappropriate therapy
P-861	-3.2625 -0.0134 -0.4899 -0.3955 -0.0665 -1.1793 -0.1944
S-1939	Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy.<unk>
T-1939	patients ; beta-blocker ; therapy
H-1939	-0.8795480728149414	▁beta - block er ▁ therapy
D-1939	-0.8795480728149414	beta-blocker therapy
P-1939	-4.6753 -0.0589 -0.4009 -0.2491 -0.7408 -0.1249 -0.2783 -0.5081
S-1535	OBJECTIVES: The aim of this study was to investigate the occurrence of heart failure in patients treated with bisphosphonates.<unk>
T-1535	heart failure ; patients ; bisphosphonates
H-1535	-0.7311903238296509	▁heart ▁failure ▁; ▁bis phos phon ates
D-1535	-0.7311903238296509	heart failure ; bisphosphonates
P-1535	-3.6855 -0.0977 -0.2495 -0.5078 -0.0971 -0.8407 -0.3908 -0.4562 -0.2555
S-622	OBJECTIVE: The aim of this study was to assess the association between frailty and risk for heart failure (HF) in older adults.<unk>
T-622	frailty ; heart failure ; hf
H-622	-0.4465341567993164	▁fra il ty ▁; ▁risk ▁; ▁heart ▁failure ▁; HF
D-622	-0.4465341567993164	frailty ; risk ; heart failure ;HF
P-622	-1.9697 -0.2835 -0.5069 -0.1026 -0.2709 -0.5805 -0.2353 -0.0770 -0.3774 -0.1717 -0.5923 -0.1907
S-1483	To date, many miRNAs (and their targets) that play a role in diverse aspects of cardiac remodeling and heart failure development have been identified.<unk>
T-1483	mirnas ; cardiac remodeling ; heart failure
H-1483	-0.1627013087272644	▁mi RNA s ▁; ▁cardiac ▁remodel ing ▁; ▁heart ▁failure
D-1483	-0.1627013087272644	miRNAs ; cardiac remodeling ; heart failure
P-1483	-0.3235 -0.0104 -0.0414 -0.1163 -0.1137 -0.1465 -0.0525 -0.1262 -0.3938 -0.1135 -0.3953 -0.1191
S-200	This article presents guidelines for the recognition, diagnosis, and early medical management of HF in infancy, childhood, and adolescence.<unk>
T-200	diagnosis ; medical ; hf
H-200	-0.9270275831222534	▁medical ▁management ▁; ▁ HF ▁; ▁in fan cy
D-200	-0.9270275831222534	medical management ; HF ; infancy
P-200	-2.5945 -1.4082 -0.2313 -0.6072 -0.1566 -1.0581 -1.1392 -0.1028 -0.0116 -2.6148 -0.2729
S-25	In the general population, the presence of even mild clinical diastolic dysfunction has been associated with pronounced increases in all cause mortality.<unk>
T-25	clinical ; diastolic dysfunction ; mortality
H-25	-0.741591215133667	▁clinic al ▁dia sto lic ▁dys function ▁; ▁cause ▁mortal ity
D-25	-0.741591215133667	clinical diastolic dysfunction ; cause mortality
P-25	-1.4786 -0.0114 -0.7998 -0.2134 -1.6959 -0.2823 -1.4808 -0.3260 -2.8284 -0.1570 -0.0514 -0.1610 -0.1548
S-1516	Customized homogeneous sandwich AlphaLISA® immunoassays were developed and validated to quantify 6 fragments of NT-proBNP.<unk>
T-1516	alphalisa ; immunoassays ; nt-probnp
H-1516	-0.5947360992431641	▁Alpha lis a ▁; ▁immun o assa ys ▁; ▁NT - pro b NP
D-1516	-0.5947360992431641	Alphalisa ; immunoassays ; NT-probNP
P-1516	-3.2590 -1.3963 -0.4911 -0.5126 -0.0143 -0.2237 -0.2419 -1.2296 -0.3214 -0.3821 -0.0598 -0.0241 -0.6591 -0.0790 -0.3694 -0.2523
S-226	Twenty-seven symptomatic adult Fontan (SAF) patients who underwent catheterization from 2001 to 2011 constituted our study group.<unk>
T-226	symptomatic adult fontan ; saf ; patients ; catheterization
H-226	-0.7628572583198547	▁Font an ▁; SAF
D-226	-0.7628572583198547	Fontan ;SAF
P-226	-1.6904 -0.3783 -0.7371 -0.0998 -1.3863 -0.2853
S-1011	Both measures predicted death equally (C-statistics: 0.687 for biological phenotype and 0.700 for deficit index).<unk>
T-1011	death ; c-statistics ; biological phenotype ; deficit index
H-1011	-0.4337398111820221	▁c - stat istic s ▁; ▁bi ological ▁ph eno type ▁; ▁deficit ▁index
D-1011	-0.4337398111820221	c-statistics ; biological phenotype ; deficit index
P-1011	-3.2177 -0.3370 -0.0700 -0.0752 -0.0483 -0.2460 -0.0499 -0.0844 -0.6978 -0.1297 -0.9236 -0.2094 -0.1675 -0.1003 -0.3358 -0.2472
S-1354	Patients in sinus rhythm may benefit from antiplatelet agents or anticoagulants, but much work remains to establish efficacy and safety.<unk>
T-1354	patients ; sinus rhythm ; antiplatelet agents ; anticoagulants
H-1354	-0.38741156458854675	▁sinus ▁ rhythm ▁; ▁anti plate let ▁agents ▁; ▁antico a gul ants
D-1354	-0.38741156458854675	sinus rhythm ; antiplatelet agents ; anticoagulants
P-1354	-0.9703 -0.1432 -0.1408 -0.2715 -0.0169 -0.2658 -2.0434 -0.0747 -0.2502 -0.0536 -0.3487 -0.5167 -0.0557 -0.4660 -0.1936
S-1858	Few studies have reported the patient's perspective on the timing of implantable cardioverter-defibrillator deactivation discussions.<unk>
T-1858	reported ; patient ; implantable cardioverter-defibrillator
H-1858	-0.8059056401252747	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1858	-0.8059056401252747	implantable cardioverter-defibrillator deactivation
P-1858	-5.2737 -0.0524 -0.6315 -0.0876 -0.5000 -0.0658 -0.0485 -0.7026 -2.8074 -0.9188 -0.1329 -0.3925 -0.0422 -0.3954 -0.6544 -0.1888
S-22	In developed countries, at least 38–54% of patients with heart failure show preserved left ventricular (LV) ejection fraction.<unk>
T-22	patients ; heart failure ; left ventricular ; ejection fraction
H-22	-0.8149571418762207	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction
D-22	-0.8149571418762207	heart failure ; left ventricular ;LV ; ejection fraction
P-22	-3.8215 -0.1337 -0.1307 -1.6250 -3.3338 -1.1189 -0.1954 -0.2123 -0.1259 -1.2977 -0.0475 -0.1578 -0.1274 -0.6627 -0.0128 -0.5676 -0.2837
S-955	Despite of its known cardiotoxicity, doxorubicin is still a highly effective anti-neoplastic agent in the treatment of several cancers.<unk>
T-955	cardiotoxicity ; doxorubicin ; anti-neoplastic agent
H-955	-0.440794974565506	▁cardio toxic ity ▁; ▁do xor ubi cin ▁; ▁anti - neo plast ic ▁; ▁cancer s
D-955	-0.440794974565506	cardiotoxicity ; doxorubicin ; anti-neoplastic ; cancers
P-955	-0.2051 -1.2325 -0.3490 -0.2305 -0.0439 -0.1674 -0.0586 -0.6382 -0.2054 -0.0126 -0.0879 -0.0430 -0.5285 -0.0327 -2.7762 -0.8370 -0.4393 -0.3186 -0.1686
S-1288	In summary, this is one of the largest series of ACS problems in patients undergoing OHT bridged to transplant with MT or VAD.<unk>
T-1288	acs ; patients ; oht ; transplant ; vad
H-1288	-0.7707839012145996	▁a CS ▁; ▁o HT ▁ bridge d ▁; ▁transplant ▁; ▁MT ▁; ▁ VAD
D-1288	-0.7707839012145996	aCS ; oHT bridged ; transplant ; MT ; VAD
P-1288	-0.5882 -2.6593 -0.4853 -0.2449 -5.2831 -1.1970 -0.0008 -0.3632 -0.7062 -0.0489 -0.3965 -0.1113 -0.3054 -0.0608 -0.0181 -0.3935 -0.2409
S-1019	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives.<unk>
T-1019	natriuretic peptides ; point of care ; ambulatory
H-1019	-0.4028915464878082	▁na tri ure tic ▁pe pti des ▁; ▁emergency ▁; ▁ambula tory
D-1019	-0.4028915464878082	natriuretic peptides ; emergency ; ambulatory
P-1019	-0.0201 -0.3434 -0.0678 -0.4908 -0.0529 -0.1102 -1.9377 -0.2889 -1.0769 -0.4159 -0.0136 -0.0091 -0.5938 -0.2193
S-179	Patients with a RAS- and β-blocker dose increase of ≥10% of the recommended target dose were compared with patients without uptitration.<unk>
T-179	patients ; β-blocker ; patients ; uptitration
H-179	-0.9480800628662109	▁ RAS - ▁; ▁β - block er ▁; ▁up tit ration
D-179	-0.9480800628662109	RAS- ; β-blocker ; uptitration
P-179	-0.5699 -0.0342 -0.1889 -2.2033 -0.3854 -0.1509 -0.7210 -0.6401 -2.4781 -3.2178 -0.7512 -1.1760 -0.4045 -0.3518
S-460	β-Blocker-induced enhancement of cardiac angiogenesis is essential for the favorable effects of this therapy on cardiac function and remodeling.<unk>
T-460	cardiac angiogenesis ; therapy ; cardiac function ; remodeling
H-460	-0.5680834650993347	▁β - Block er - indu ced ▁enhance ment ▁; ▁cardiac ▁ang io gene sis ▁; ▁ therapy ▁; ▁cardiac ▁function
D-460	-0.5680834650993347	β-Blocker-induced enhancement ; cardiac angiogenesis ; therapy ; cardiac function
P-460	-0.1361 -0.0679 -0.3586 -0.2280 -0.1012 -0.0384 -2.4412 -0.9556 -0.0374 -0.7793 -0.0378 -0.0441 -2.7419 -0.4159 -0.7466 -0.2656 -1.4232 -0.0804 -0.3473 -0.0855 -0.3736 -1.1932 -0.1672
S-602	We studied the risk of new or recurrent HF among a group of patients receiving these agents to treat rheumatoid arthritis (RA).<unk>
T-602	hf ; patients ; rheumatoid arthritis ; ra
H-602	-0.8018768429756165	▁ HF ▁; ▁rhe um ato id ▁ar thri tis ▁; RA
D-602	-0.8018768429756165	HF ; rheumatoid arthritis ;RA
P-602	-2.0104 -0.2400 -0.3962 -3.7682 -0.0345 -1.0698 -1.7038 -0.0678 -0.2063 -0.2791 -0.4960 -0.0675 -0.6063 -0.2806
S-170	Compared to the control group, expression of Bax and Bcl-2 proteins and their ratio were increased in dogs only after 4 weeks of pacing.<unk>
T-170	expression ; bax ; bcl-2 ; proteins ; pacing
H-170	-0.47614797949790955	▁expression ▁; ▁Bax ▁; ▁b cl -2 ▁protein s ▁; ▁dog s
D-170	-0.47614797949790955	expression ; Bax ; bcl-2 proteins ; dogs
P-170	-0.3050 -0.3253 -0.0090 -0.1127 -0.2484 -0.0880 -0.3419 -1.3792 -0.0984 -0.2717 -2.1906 -0.1214 -0.9314 -0.2430
S-139	PRINCIPAL FINDINGS: Average hospital rates for HF patients and the CMS metric were generally higher than for other conditions and metrics.<unk>
T-139	principal ; hospital ; hf ; patients ; cms ; conditions
H-139	-1.2482291460037231	▁ HF ▁; ▁CMS ▁ metric ▁; ▁conditions
D-139	-1.2482291460037231	HF ; CMS metric ; conditions
P-139	-4.3594 -0.5248 -1.3601 -2.5042 -1.2216 -0.0047 -1.5002 -0.0101 -0.6730 -0.3243
S-1362	The regulation of feeding is discussed, as are nutritional strategies with potentially anti-inflammatory effects in the treatment of CHF.<unk>
T-1362	regulation ; anti-inflammatory ; chf
H-1362	-0.4184127151966095	▁regula tion ▁of ▁feed ing ▁; ▁anti - in flam ma tory ▁effects ▁; ▁CHF
D-1362	-0.4184127151966095	regulation of feeding ; anti-inflammatory effects ; CHF
P-1362	-0.0760 -0.0119 -0.2034 -0.0045 -0.0426 -0.2333 -1.8260 -0.0535 -0.6367 -0.1577 -1.4628 -0.2403 -0.6417 -0.2890 -0.8324 -0.2548 -0.1464
S-1077	Significant progress has been achieved in the development of lifesaving drugs for HF with reduced ejection fraction (HFrEF).<unk>
T-1077	drugs ; hf with reduced ejection fraction ; hfref
H-1077	-0.5248804092407227	▁drugs ▁; ▁ HF ▁; ▁e je ction ▁ fraction ▁; HF r EF
D-1077	-0.5248804092407227	drugs ; HF ; ejection fraction ;HFrEF
P-1077	-2.6327 -0.0971 -1.2507 -0.1221 -0.1440 -0.9891 -0.2922 -0.0661 -0.4267 -0.0178 -0.3105 -0.7991 -0.1382 -0.4714 -0.5022 -0.1381
S-444	Crude rates of severe hyperkalemia and acute kidney injury during spironolactone use were similar to that seen in clinical trials.<unk>
T-444	hyperkalemia ; acute kidney injury ; spironolactone ; clinical
H-444	-0.4711626470088959	▁Cru de ▁rates ▁of ▁severe ▁hyper kal emia ▁; ▁a cute ▁ki dne y ▁injury ▁; ▁spi rono lac tone
D-444	-0.4711626470088959	Crude rates of severe hyperkalemia ; acute kidney injury ; spironolactone
P-444	-0.9262 -0.0556 -0.6060 -1.7964 -0.4198 -0.4134 -0.6457 -0.1035 -0.1307 -0.0441 -0.0254 -0.1107 -1.4326 -0.0957 -0.8743 -0.2820 -0.1614 -0.0620 -0.2493 -0.0933 -1.6728 -0.1646
S-1371	Renal denervation (DNx) in CHF patients has resulted in symptomatic improvement, but the protective mechanisms remain unclear.<unk>
T-1371	renal denervation ; dnx ; chf ; patients ; symptomatic
H-1371	-0.8402153849601746	▁Ren al ▁den er va tion ▁; DN x ▁; ▁CHF ▁; ▁protect ive ▁mechanism s
D-1371	-0.8402153849601746	Renal denervation ;DNx ; CHF ; protective mechanisms
P-1371	-0.2696 -0.0580 -0.0592 -1.2375 -3.4673 -0.2625 -0.3567 -2.1431 -0.3545 -0.2995 -0.0571 -2.1131 -3.9087 -0.0197 -0.0059 -0.0726 -0.2925 -0.1467
S-1289	With similar incidence in MT and VAD groups, ACS consultations and operations are infrequent with high mortality and morbidity.<unk>
T-1289	incidence ; vad ; acs ; consultations ; operations ; mortality ; morbidity
H-1289	-0.5830054879188538	▁MT ▁; ▁ VAD ▁groups ▁; ▁a CS ▁; ▁operation s
D-1289	-0.5830054879188538	MT ; VAD groups ; aCS ; operations
P-1289	-0.2210 -0.2741 -0.0453 -0.1283 -0.3654 -0.3572 -0.3106 -1.6533 -0.5868 -0.5247 -0.0499 -2.8367 -0.2258
S-893	Reduced hospitalizations in severe, refractory congestive heart failure with peritoneal dialysis: a consecutive case series.<unk>
T-893	hospitalizations ; refractory congestive heart failure ; peritoneal dialysis
H-893	-0.3706998825073242	▁hospital ization s ▁; ▁re frac tory ▁con ges tive ▁heart ▁failure ▁; ▁per ito ne al ▁di al ysis
D-893	-0.3706998825073242	hospitalizations ; refractory congestive heart failure ; peritoneal dialysis
P-893	-2.0771 -0.3409 -0.2021 -0.3735 -0.5158 -0.0118 -0.0552 -0.2294 -0.4666 -0.1150 -0.8981 -0.0560 -0.2002 -0.0139 -1.1126 -0.1335 -0.0500 -0.4596 -0.1857 -0.2718 -0.2234 -0.1629
S-1810	Mammalian enabled (Mena) is a key regulator of cytoskeletal actin dynamics, which has been implicated in heart failure (HF).<unk>
T-1810	mammalian enabled ; mena ; cytoskeletal actin dynamics ; heart failure ; hf
H-1810	-0.32241854071617126	▁Mamma lian ▁enabled ▁; Men a ▁; ▁cy tos kelet al ▁act in ▁dynamic s ▁; ▁heart ▁failure ▁; HF
D-1810	-0.32241854071617126	Mammalian enabled ;Mena ; cytoskeletal actin dynamics ; heart failure ;HF
P-1810	-0.5940 -0.1174 -0.9207 -0.2444 -0.4208 -0.0109 -0.2632 -0.2303 -1.1982 -0.2991 -0.0628 -0.1060 -1.1076 -0.0572 -0.0371 -0.1579 -0.2148 -0.1680 -0.5030 -0.0162 -0.2382 -0.1255
S-1949	BACKGROUND: In patients with heart failure, interventions to reduce elevated left atrial pressure improve symptoms and reduce the risk of hospital admission.<unk>
T-1949	patients ; heart failure ; elevated ; left atrial pressure ; symptoms ; hospital ; admission
H-1949	-0.9239393472671509	▁heart ▁failure ▁; ▁left ▁at rial ▁pressure ▁; ▁hospital ▁ad mission
D-1949	-0.9239393472671509	heart failure ; left atrial pressure ; hospital admission
P-1949	-1.7104 -0.0915 -0.4001 -4.7223 -1.0814 -1.2669 -0.3479 -0.7050 -1.2014 -0.0384 -0.0427 -0.1905 -0.2128
S-916	BACKGROUND: Heart failure with preserved ejection fraction (HFPEF) involves failure of cardiovascular reserve in multiple domains.<unk>
T-916	heart failure with preserved ejection fraction ; hfpef ; cardiovascular reserve
H-916	-0.3956286609172821	▁Heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f f ▁; ▁failure ▁of ▁cardiovascular ▁reserve
D-916	-0.3956286609172821	Heart failure ; preserved ejection fraction ; hff ; failure of cardiovascular reserve
P-916	-0.7978 -0.0946 -0.1673 -0.0497 -0.1485 -0.0860 -0.0423 -0.2937 -0.0701 -0.4454 -0.0065 -0.2821 -1.0516 -1.5480 -1.0271 -0.6781 -0.3337 -0.9984 -0.1641 -0.0252 -0.2692 -0.1243
S-24	LV diastolic dysfunction, either alone or in combination with other factors (figure 1), is the major underlying mechanism of HFPEF.<unk>
T-24	lv diastolic dysfunction ; combination ; figure ; hfpef
H-24	-0.8869580030441284	▁LV ▁dia sto lic ▁dys function ▁; ▁mechanism ▁; ▁h f f
D-24	-0.8869580030441284	LV diastolic dysfunction ; mechanism ; hff
P-24	-0.6755 -2.3444 -0.1969 -0.8602 -0.2156 -1.2285 -0.1470 -1.9261 -0.4892 -1.3278 -1.8052 -0.5439 -0.4380 -0.2192
S-1421	INTERPRETATION: Early physician follow-up after discharge and physician continuity were both associated with better outcomes among patients with heart failure.<unk>
T-1421	physician ; follow-up ; discharge ; physician ; outcomes ; patients ; heart failure
H-1421	-0.6789029240608215	▁physician ▁follow - up ▁; ▁dis charge ▁; ▁physician ▁continu ity ▁; ▁heart ▁failure
D-1421	-0.6789029240608215	physician follow-up ; discharge ; physician continuity ; heart failure
P-1421	-2.1493 -2.8494 -0.0917 -0.0294 -0.9011 -0.0446 -0.0885 -0.2579 -0.1216 -0.3629 -0.0159 -0.5606 -2.8644 -0.1040 -0.2242 -0.1970
S-63	Two reviewers selected citations that included ambulatory ICD patients and addressed the association between any predictor and mortality using multivariable regression.<unk>
T-63	ambulatory ; icd ; patients ; mortality ; multivariable regression
H-63	-0.5054787397384644	▁ambula tory ▁i CD ▁patients ▁; ▁predict or ▁; ▁mortal ity ▁; ▁multi vari able ▁re gression
D-63	-0.5054787397384644	ambulatory iCD patients ; predictor ; mortality ; multivariable regression
P-63	-0.3532 -0.0257 -0.6502 -2.4839 -1.2904 -0.3224 -0.2051 -0.1639 -0.8000 -0.0396 -0.0388 -2.2752 -0.0431 -0.1668 -0.1599 -0.0479 -0.0142 -0.1920 -0.3317
S-1966	In this regard, first results of studies with ARNI inhibitors (angiotensin-receptor neprilysin inhibitors) may be considered hopeful.<unk>
T-1966	arni inhibitors ; angiotensin-receptor neprilysin inhibitors
H-1966	-0.6118884682655334	▁AR NI ▁inhibi tors ▁; angi oten sin - recept or ▁nepri ly sin ▁inhibi tors
D-1966	-0.6118884682655334	ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
P-1966	-1.3834 -1.5954 -0.6041 -0.0436 -0.2888 -0.0142 -3.0058 -1.6601 -0.4764 -0.0333 -0.1804 -0.2724 -0.2135 -0.1918 -0.3648 -0.0942 -0.4164 -0.1752
S-1659	Gastrointestinal bleeding is not uncommon and is reported to occur in 13% to 44% of patients treated with ventricular assist devices.<unk>
T-1659	gastrointestinal bleeding ; reported ; patients ; ventricular assist devices
H-1659	-0.6484529972076416	▁Gastro inte stin al ▁ble ed ing ▁; ▁vent ri cular ▁assist ▁devices
D-1659	-0.6484529972076416	Gastrointestinal bleeding ; ventricular assist devices
P-1659	-0.5134 -0.3762 -1.0150 -0.1268 -0.7945 -0.5195 -0.2480 -0.2181 -2.4095 -0.9341 -0.2688 -1.5126 -0.1594 -0.3959 -0.2352
S-966	Interestingly, nicorandil did not interfere with cytotoxic effect of doxorubicin against the growth of solid Ehrlich carcinoma.<unk>
T-966	nicorandil ; cytotoxic ; doxorubicin ; ehrlich carcinoma
H-966	-0.3932395875453949	▁nic oran dil ▁; ▁cy to toxic ▁effect ▁; ▁do xor ubi cin ▁; ▁solid ▁Eh r lich ▁car cino ma
D-966	-0.3932395875453949	nicorandil ; cytotoxic effect ; doxorubicin ; solid Ehrlich carcinoma
P-966	-0.0682 -0.0285 -0.2187 -0.2089 -0.0508 -0.0454 -0.3856 -0.2649 -0.4833 -0.0687 -0.4129 -0.0506 -0.7097 -0.5725 -2.5833 -0.3560 -0.0227 -0.3183 -0.8787 -0.2310 -0.3202 -0.5856 -0.1802
S-593	Myxomas are the most common type of cardiac benign tumors and most of them are located in the left atrium, followed by the right atrium.<unk>
T-593	myxomas ; cardiac ; benign tumors ; left atrium ; right atrium
H-593	-0.4618370532989502	▁my xo mas ▁; ▁cardiac ▁benign ▁tumor s ▁; ▁left ▁at rium
D-593	-0.4618370532989502	myxomas ; cardiac benign tumors ; left atrium
P-593	-1.4505 -0.0299 -0.1538 -0.2648 -0.4928 -0.1170 -0.1083 -0.0940 -0.6402 -0.2892 -0.1638 -0.0066 -2.4077 -0.2471
S-1328	We sought to investigate the effects of FES on the above parameters in patients with preserved ejection fraction (HFpEF).<unk>
T-1328	fes ; patients ; preserved ejection fraction ; hfpef
H-1328	-0.43417006731033325	▁f es ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1328	-0.43417006731033325	fes ; preserved ejection fraction ;HFpEF
P-1328	-2.0814 -0.8931 -0.1503 -0.7011 -0.2095 -0.2272 -0.0924 -0.4988 -0.1746 -0.4187 -0.0234 -0.4252 -0.3472 -0.0122 -0.2673 -0.5897 -0.2688
S-1366	Recently, the diagnostic roles of BNP and NT-proBNP in patients with coronary artery disease (CAD) have been investigated.<unk>
T-1366	diagnostic ; bnp ; nt-probnp ; patients ; coronary artery disease ; cad
H-1366	-0.4303114712238312	▁b NP ▁; ▁NT - pro b NP ▁; ▁corona ry ▁arter y ▁disease ▁; CAD
D-1366	-0.4303114712238312	bNP ; NT-probNP ; coronary artery disease ;CAD
P-1366	-0.9229 -1.8161 -0.1047 -0.1010 -0.0598 -0.0166 -0.5589 -0.3051 -0.1148 -0.3824 -0.1220 -0.3202 -0.4241 -1.4455 -0.2891 -0.3060 -0.2362 -0.2200
S-1883	However, there were nosignificant changes in control group (P>0.05) and their changes were smaller than those in exercise group (P < 0.01).<unk>
T-1883	nosignificant ; exercise
H-1883	-0.5601949691772461	▁exercise ▁group
D-1883	-0.5601949691772461	exercise group
P-1883	-1.5622 -0.3779 -0.1303 -0.1704
S-1512	Moreover, there is yet to be established a common consensus regarding the circulating forms of NT-proBNP being used in current assays.<unk>
T-1512	nt-probnp
H-1512	-0.556181013584137	▁NT - pro b NP ▁; ▁as say s
D-1512	-0.556181013584137	NT-probNP ; assays
P-1512	-2.3463 -0.0699 -0.0206 -0.6293 -0.2012 -1.3010 -0.7719 -0.0691 -0.1244 -0.2716 -0.3128
S-713	The first to identify clinical variables contributing to survival between the 2 groups, and the second to determine the additional risk associated with assignment to ECCT.<unk>
T-713	clinical ; ecct
H-713	-1.040798544883728	▁clinic al ▁variable s ▁; ▁ec CT
D-713	-1.040798544883728	clinical variables ; ecCT
P-713	-3.7238 -0.0477 -0.8802 -0.1728 -0.2119 -2.0066 -1.8010 -0.2412 -0.2820
S-573	No significant differences were found for peak aerobic capacity, left-hand grip strength, body weight, waist circumference, or symptoms of anxiety.<unk>
T-573	symptoms
H-573	-0.3346852958202362	▁pe ak ▁aero bic ▁capacity ▁; ▁left - hand ▁grip ▁; ▁body ▁weight ▁; ▁wa ist ▁circum ferenc e ▁; ▁anxiety
D-573	-0.3346852958202362	peak aerobic capacity ; left-hand grip ; body weight ; waist circumference ; anxiety
P-573	-0.9034 -0.0291 -0.0819 -0.8672 -0.1854 -0.2764 -0.0684 -0.0460 -0.0517 -0.4340 -1.6416 -0.2811 -0.1662 -0.2664 -0.0382 -0.1055 -0.0164 -0.0423 -0.1454 -0.7700 -0.8660 -0.1875 -0.2278
S-1851	We will identify the common elements of successful and failing interventions, and examine the context in which they were applied, using the Process Redesign contextual framework.<unk>
T-1851	
H-1851	-0.8153017163276672	▁process ▁re design
D-1851	-0.8153017163276672	process redesign
P-1851	-1.2291 -1.6297 -0.0148 -0.9312 -0.2717
S-651	Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38alpha MAPK during insulin resistance.<unk>
T-651	myocardial ; irs1 ; irs2 ; heart failure ; p38alpha ; mapk ; insulin resistance
H-651	-0.27731776237487793	▁my o card ial ▁loss ▁; ▁i RS 1 ▁; ▁i RS 2 ▁; ▁heart ▁failure ▁; ▁p 38 al pha ▁MA PK ▁; ▁insulin ▁resist ance
D-651	-0.27731776237487793	myocardial loss ; iRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
P-651	-1.1692 -0.1919 -0.5785 -0.0503 -0.0144 -0.4726 -0.5692 -0.3661 -0.6745 -0.1902 -0.3417 -0.6861 -0.0927 -0.2181 -0.2748 -0.1142 -0.1372 -0.0136 -0.3103 -0.0820 -0.0145 -0.1853 -0.0559 -0.2778 -0.0252 -0.1362 -0.0155 -0.4456 -0.3388
S-273	A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.<unk>
T-273	heart failure ; hypertensive heart disease ; angiotensin ii ; infusion ; nephrectomy ; salt loading
H-273	-0.4766908884048462	▁heart ▁failure ▁mi ce ▁model ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁ang io ten sin ▁II ▁in fusion ▁; ▁nep hr ecto my ▁; ▁salt ▁load ing
D-273	-0.4766908884048462	heart failure mice model ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
P-273	-0.4540 -0.0333 -0.1850 -0.0202 -0.3394 -0.7127 -0.0743 -0.7081 -0.3764 -2.8108 -1.5372 -0.2415 -0.0045 -1.2355 -0.4947 -0.0677 -0.3023 -0.0199 -0.0214 -0.3130 -0.0597 -1.2623 -0.3503 -0.9649 -0.5963 -0.0129 -0.0019 -0.0203 -0.8467 -0.2332
S-337	Functional mitral stenosis (MS) frequently develops after ring annuloplasty for ischemic mitral regurgitation (MR).<unk>
T-337	functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
H-337	-0.3550665080547333	▁function al ▁mit ral ▁sten osis ▁; MS ▁; ▁ring ▁ann ulo plast y ▁; ▁ ische mic ▁mit ral ▁re gur gi tation ▁; MR
D-337	-0.3550665080547333	functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation ;MR
P-337	-1.1218 -0.1232 -1.3749 -0.0751 -0.1601 -0.1437 -0.2837 -0.8733 -0.3695 -0.0657 -0.1091 -0.3607 -0.1623 -0.1392 -0.2411 -0.2690 -0.1232 -0.0636 -0.6655 -0.3161 -0.0167 -0.0518 -0.3588 -0.0181 -1.8856 -0.0040 -0.4094 -0.1564
S-590	CONCLUSIONS: Shortened LVET at ICU admission was a prognostic factor in patients with precapillary PH with heart failure.<unk>
T-590	shortened ; lvet ; icu ; admission ; prognostic ; patients ; precapillary ph ; heart failure
H-590	-0.3345912992954254	▁short en ed ▁l VET ▁; ▁ ICU ▁ad mission ▁; ▁pre cap illa ry ▁PH ▁; ▁heart ▁failure
D-590	-0.3345912992954254	shortened lVET ; ICU admission ; precapillary PH ; heart failure
P-590	-1.4178 -0.0444 -0.0695 -1.7674 -0.1486 -0.2170 -0.1420 -0.0460 -0.0487 -0.0228 -0.1778 -0.5127 -0.3043 -0.3348 -0.0152 -0.2539 -0.1915 -0.5385 -0.0733 -0.4438 -0.2563
S-235	Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.<unk>
T-235	heart ; hospitalization ; death ; patients ; preserved left ventricular ejection fraction
H-235	-1.0860517024993896	▁heart ▁failure - related ▁hospital ization ▁; ▁death ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-235	-1.0860517024993896	heart failure-related hospitalization ; death ; left ventricular ejection fraction
P-235	-3.3667 -0.4653 -0.8547 -0.0408 -0.4397 -0.4559 -0.3109 -1.5189 -0.3715 -0.9870 -4.4973 -2.7115 -1.0959 -0.4137 -0.8392 -0.7052 -1.4643 -0.0434 -0.6707 -0.4685
S-236	Heart failure with preserved ejection fraction (HFpEF) is recognized as a major cause of cardiovascular morbidity and mortality.<unk>
T-236	heart failure with preserved ejection fraction ; hfpef ; cardiovascular morbidity ; mortality
H-236	-0.2876470983028412	▁Heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁cardiovascular ▁morbi d ity
D-236	-0.2876470983028412	Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbidity
P-236	-0.5697 -0.0303 -0.2090 -0.1297 -0.1855 -0.1292 -0.0337 -0.2614 -0.0527 -0.5347 -0.0132 -0.2699 -0.1405 -0.0114 -0.3542 -0.3762 -0.1604 -0.0778 -0.1467 -0.1327 -2.3022 -0.2070
S-479	Usefulness of tissue Doppler imaging for assessing left ventricular filling pressure in patients with stable severe systolic heart failure.<unk>
T-479	tissue doppler ; left ventricular filling pressure ; patients ; stable ; severe systolic heart failure
H-479	-0.940358579158783	▁tissu e ▁do pp ler ▁imagin g ▁; ▁left ▁vent ri cular ▁; ▁fill ing ▁pressure ▁; ▁sy sto lic ▁heart ▁failure
D-479	-0.940358579158783	tissue doppler imaging ; left ventricular ; filling pressure ; systolic heart failure
P-479	-2.0403 -0.1822 -0.6121 -0.0032 -0.8886 -0.6614 -0.0712 -0.2258 -0.3446 -3.6109 -2.0517 -0.4098 -2.9048 -0.7439 -0.0848 -0.7147 -0.2742 -2.8769 -0.1490 -1.2521 -1.6798 -0.1630 -0.4558 -0.1678
S-766	At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic.<unk>
T-766	zsf1 ; hypertensive ; obese ; zsf1 ; hypertensive ; diabetic
H-766	-0.7198356986045837	▁z SF 1 ▁group ▁; ▁obes e ▁; ▁z SF 1 ▁groups ▁; ▁hyper tensi ve ▁; ▁diabet ic
D-766	-0.7198356986045837	zSF1 group ; obese ; zSF1 groups ; hypertensive ; diabetic
P-766	-1.8794 -2.2639 -0.8066 -0.7586 -0.1879 -0.7031 -0.1486 -2.2208 -0.7748 -1.3326 -0.8555 -0.5137 -0.3997 -0.8648 -0.4489 -0.2422 -0.3054 -0.0283 -0.0232 -0.2224 -0.1361
S-23	The prevalence of heart failure with preserved ejection fraction (HFPEF) is steadily increasing and its prognosis is poor.<unk>
T-23	prevalence ; heart failure with preserved ejection fraction ; hfpef ; prognosis
H-23	-0.49517059326171875	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f f
D-23	-0.49517059326171875	heart failure ; preserved ejection fraction ; hff
P-23	-1.3819 -0.0743 -0.1191 -0.0859 -0.1248 -0.1517 -0.0601 -0.2528 -0.0871 -0.4616 -0.0150 -0.2345 -1.1187 -1.2806 -0.9468 -1.8485 -0.1745
S-779	Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.<unk>
T-779	kansas city cardiomyopathy questionnaire ; patients ; heart failure ; reduced ejection fraction
H-779	-0.5850786566734314	▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-779	-0.5850786566734314	Kansas City Cardiomyopathy Questionnaire ; heart failure ; ejection fraction
P-779	-0.0966 -0.1883 -3.0988 -0.0909 -0.3295 -2.2933 -0.6626 -2.0418 -0.0206 -0.0949 -0.7747 -0.0545 -0.2263 -0.2890 -0.1669 -0.1428 -0.5522 -0.0186 -0.3003 -0.2590
S-1220	Thus, activating myocardial PDE2 may represent a novel intracellular antiadrenergic therapeutic strategy in HF.<unk>
T-1220	myocardial ; pde2 ; intracellular ; antiadrenergic ; therapeutic ; hf
H-1220	-0.585848867893219	▁my o card ial ▁p de 2 ▁; ▁intra cel lular ▁anti ad r energi c ▁; ▁strategy ▁; ▁ HF
D-1220	-0.585848867893219	myocardial pde2 ; intracellular antiadrenergic ; strategy ; HF
P-1220	-1.1548 -0.1018 -0.2135 -0.0687 -1.3434 -1.3564 -0.0517 -0.1765 -0.5954 -0.3335 -0.0255 -0.0355 -1.4466 -0.2821 -0.5698 -0.4201 -1.4752 -2.3941 -0.5383 -0.2393 -0.1447 -0.2438 -0.2637
S-447	Our findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications.<unk>
T-447	spironolactone ; clinical ; medications
H-447	-0.8337386846542358	▁spi rono lac tone ▁; ▁medication s
D-447	-0.8337386846542358	spironolactone ; medications
P-447	-2.1545 -0.0384 -0.1219 -0.1610 -0.3691 -3.8328 -0.2364 -0.3275 -0.2621
S-690	For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died.<unk>
T-690	follow-up ; hf ; hospitalization
H-690	-1.088472843170166	▁ HF ▁hospital ization ▁; ▁die d
D-690	-1.088472843170166	HF hospitalization ; died
P-690	-1.3331 -0.2384 -2.3412 -0.3224 -1.5573 -3.3751 -0.1040 -0.2795 -0.2453
S-105	Time-dependent analysis was performed to identify the effect of IE on the risk for subsequent heart failure (HF) or death in CRT-D recipients.<unk>
T-105	heart failure ; hf ; death ; crt-d
H-105	-0.9433948993682861	▁i p ▁; ▁heart ▁failure ▁; HF ▁; ▁death ▁; ▁c RT - d
D-105	-0.9433948993682861	ip ; heart failure ;HF ; death ; cRT-d
P-105	-1.2139 -4.7407 -0.2341 -1.4022 -0.0471 -0.1463 -0.2508 -0.1620 -3.4809 -0.1353 -0.2107 -1.2191 -0.0952 -0.7936 -0.6930 -0.2694
S-1470	This review summarizes the principles of pharmacologic treatment, the underlying clinical trials, and new pharmacologic targets.<unk>
T-1470	pharmacologic ; clinical ; pharmacologic
H-1470	-0.4283769130706787	▁ pharma c ologic ▁; ▁clinic al ▁trial s ▁; ▁ pharma c ologic
D-1470	-0.4283769130706787	pharmacologic ; clinical trials ; pharmacologic
P-1470	-0.5472 -0.0437 -0.3119 -0.2071 -1.2401 -1.1264 -0.1611 -0.3951 -0.0468 -0.4028 -0.4595 -0.0401 -0.2095 -0.1765 -1.2474 -0.2387
S-846	Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients.<unk>
T-846	patients ; narrow qrs complex ; crt ; patients
H-846	-0.5275954008102417	▁mechanic al ▁dys syn chron y ▁; ▁QR s ▁complex ▁; ▁c RT
D-846	-0.5275954008102417	mechanical dyssynchrony ; QRs complex ; cRT
P-846	-0.0659 -0.0184 -0.2309 -0.0261 -0.0047 -0.4101 -0.2123 -1.4232 -1.9813 -0.6951 -0.2287 -0.3298 -1.7168 -0.3265 -0.2442
S-510	Complete coronary occlusion was necessary for significant collateral growth, which mostly had occurred already during the first wk after the stent occlusion.<unk>
T-510	coronary occlusion ; collateral growth ; stent
H-510	-0.6625015139579773	▁corona ry ▁oc clusi on ▁; ▁col lateral ▁growth
D-510	-0.6625015139579773	coronary occlusion ; collateral growth
P-510	-0.7094 -0.0740 -0.0064 -0.2006 -0.1269 -0.2218 -0.1083 -0.0017 -0.3655 -5.2981 -0.1748
S-1561	The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects.<unk>
T-1561	carotid intima-media thickness ; psoriasis
H-1561	-0.3864586353302002	▁caro tid ▁intim a - media ▁thi ck ness ▁; ▁psoriasis
D-1561	-0.3864586353302002	carotid intima-media thickness ; psoriasis
P-1561	-1.3753 -0.2285 -0.3965 -0.0579 -0.1079 -0.0892 -0.9260 -0.2509 -0.8419 -0.2678 -0.0140 -0.2689 -0.1992
S-48	Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication.<unk>
T-48	transfusions ; patients ; heart disease
H-48	-0.39506784081459045	▁trans fusion s ▁; ▁heart ▁disease
D-48	-0.39506784081459045	transfusions ; heart disease
P-48	-0.0837 -0.2327 -0.1824 -0.3847 -0.6897 -0.7887 -0.5378 -0.2609
S-1985	The combination of exercise + diet was additive (complementary) for peak VO2 (joint effect, 2.5 mL/kg/min).<unk>
T-1985	combination ; exercise ; peak vo2 ; joint
H-1985	-0.8211020827293396	▁exercise ▁; ▁pe ak ▁VO 2 ▁; jo int ▁effect
D-1985	-0.8211020827293396	exercise ; peak VO2 ;joint effect
P-1985	-0.9319 -0.1269 -5.5960 -0.0252 -0.6270 -0.1221 -0.7916 -0.3870 -0.1338 -0.0367 -0.8301 -0.2449
S-1348	The 8- to 9-s PVF was incidentally produced during the ascending phase of a PB cycle, followed by another 12-s recovery period of low BP.<unk>
T-1348	pvf ; pb ; bp
H-1348	-0.3703260123729706	▁PV f ▁; ▁ PB ▁cycle ▁; ▁recovery ▁period ▁; ▁low ▁BP
D-1348	-0.3703260123729706	PVf ; PB cycle ; recovery period ; low BP
P-1348	-0.5705 -0.6148 -0.1365 -0.4322 -0.0935 -0.7413 -0.2632 -0.2480 -0.5914 -0.5504 -0.2884 -0.2362 -0.2456 -0.1725
S-646	The prevalence of chronic heart failure in Hungary is 1.6% in the adult population, but it occurs in 15-20% of subjects over 80 years of age.<unk>
T-646	prevalence ; chronic heart failure ; hungary
H-646	-1.1601345539093018	▁chronic ▁heart ▁failure ▁; ▁Hungary
D-646	-1.1601345539093018	chronic heart failure ; Hungary
P-646	-1.9445 -2.8925 -0.1704 -0.5856 -1.1013 -1.1831 -0.2435
S-1168	CONCLUSIONS: RV dysfunction and cardiac cachexia often coexist, have additive adverse impact, and might be mechanistically interrelated.<unk>
T-1168	rv dysfunction ; cardiac cachexia
H-1168	-0.5903244614601135	▁ RV ▁dys function ▁; ▁cardiac ▁cache xia
D-1168	-0.5903244614601135	RV dysfunction ; cardiac cachexia
P-1168	-0.4509 -0.9515 -0.2090 -0.7522 -0.0783 -0.0536 -0.0715 -0.9667 -2.1224 -0.2471
S-148	Remote monitoring (RM) strategies have the potential to deliver specialised care and management and may be one way to meet the growing needs of the heart failure population.<unk>
T-148	remote monitoring ; rm ; heart failure
H-148	-0.6381341218948364	▁remote ▁monitoring ▁; RM ▁; ▁heart ▁failure
D-148	-0.6381341218948364	remote monitoring ;RM ; heart failure
P-148	-0.1010 -0.0208 -0.2480 -0.0102 -0.6436 -3.9025 -0.0619 -0.6356 -0.1195
S-881	The interaction between these 2 simple ECG parameters and their effect on CRT has not been systematically assessed in a large-scale clinical trial.<unk>
T-881	ecg ; crt ; clinical
H-881	-0.9145930409431458	▁ec g ▁parameter s ▁; ▁c RT
D-881	-0.9145930409431458	ecg parameters ; cRT
P-881	-0.9101 -0.9286 -1.8423 -0.0840 -0.1204 -0.6133 -2.4934 -1.0801 -0.1593
S-407	Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard.<unk>
T-407	patients ; sst2 ; cardiovascular event
H-407	-0.7165723443031311	▁s st 2 ▁; ▁low - dos e ▁BB ▁; ▁cardiovascular ▁event ▁rate
D-407	-0.7165723443031311	sst2 ; low-dose BB ; cardiovascular event rate
P-407	-0.0180 -3.2556 -0.2211 -0.2918 -0.2600 -0.0305 -0.7281 -0.1388 -1.0471 -0.2916 -0.5254 -0.5227 -0.1454 -3.0015 -0.2709
S-681	In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials.<unk>
T-681	breast cancer ; patients ; chf ; reported ; clinical
H-681	-0.606294572353363	▁breast ▁cancer ▁; ▁tras tuz um b - related ▁CHF
D-681	-0.606294572353363	breast cancer ; trastuzumb-related CHF
P-681	-1.8597 -0.2728 -1.2240 -1.1010 -0.0194 -0.0408 -0.0695 -0.9138 -0.0278 -0.3457 -1.2290 -0.1721
S-1150	However, the contributions of the four major HF remodeling aspects in extending EMD in the dyssynchronous failing heart remain unknown.<unk>
T-1150	hf ; remodeling ; emd ; dyssynchronous failing heart
H-1150	-0.4031592011451721	▁ HF ▁remodel ing ▁; ▁EM d ▁; ▁dys syn chron ous ▁fail ing ▁heart
D-1150	-0.4031592011451721	HF remodeling ; EMd ; dyssynchronous failing heart
P-1150	-0.8025 -0.3921 -0.7383 -0.0413 -0.7980 -1.6412 -0.6264 -0.1251 -0.0801 -0.0308 -0.0203 -0.0992 -0.0667 -0.0513 -0.8055 -0.2940 -0.2408
S-1466	Acute heart failure (AHF) is defined as the rapid onset of, or changes in, the symptoms and signs of heart failure (HF).<unk>
T-1466	acute heart failure ; ahf ; symptoms ; heart failure ; hf
H-1466	-0.8116438984870911	▁a cute ▁heart ▁failure ▁; ▁a HF ▁; ▁symptoms ▁; ▁heart ▁failure ▁; HF
D-1466	-0.8116438984870911	acute heart failure ; aHF ; symptoms ; heart failure ;HF
P-1466	-0.6407 -0.0343 -1.1255 -0.0500 -0.2503 -0.8139 -1.8067 -0.4320 -4.5486 -0.1593 -1.1702 -0.1272 -0.6726 -0.6886 -0.2438 -0.2227
S-449	BACKGROUND: Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure.<unk>
T-449	angiogenesis ; post-myocardial infarction ; heart ; heart failure
H-449	-0.8340052366256714	▁ang io gene sis ▁; ▁post - my o card ial ▁in far ction ▁heart ▁; ▁progression ▁; ▁heart ▁failure
D-449	-0.8340052366256714	angiogenesis ; post-myocardial infarction heart ; progression ; heart failure
P-449	-0.3833 -4.1763 -0.4461 -2.8130 -0.1883 -0.0194 -0.0616 -2.4928 -1.2656 -1.5367 -0.1018 -0.1642 -0.3622 -0.1824 -1.2355 -0.2722 -0.3347 -1.4361 -0.1792 -0.0875 -0.4016 -0.2075
S-1734	Major clinical trials designed to analyze clinical outcomes using an aldosterone antagonist have been done in two groups with heart failure.<unk>
T-1734	clinical ; clinical ; outcomes ; aldosterone antagonist ; heart failure
H-1734	-0.561435878276825	▁clinic al ▁; ▁al do ster one ▁anta gon ist ▁; ▁heart ▁failure
D-1734	-0.561435878276825	clinical ; aldosterone antagonist ; heart failure
P-1734	-2.0279 -0.0481 -1.0819 -1.4493 -0.4493 -0.4429 -0.0396 -0.2334 -0.3060 -0.5690 -0.3389 -0.8753 -0.1104 -0.2968 -0.1528
S-355	Consequently, surgery was not performed and aggressive medical treatment for HF and hypertension with vasodilators and diuretics was started.<unk>
T-355	surgery ; medical treatment ; hf ; hypertension ; vasodilators ; diuretics
H-355	-0.3795742094516754	▁surgery ▁; ▁ HF ▁; ▁hyper tension ▁; ▁vaso dila tors ▁; ▁di ure tics
D-355	-0.3795742094516754	surgery ; HF ; hypertension ; vasodilators ; diuretics
P-355	-1.5267 -0.1255 -1.6839 -0.0636 -0.1539 -0.4330 -0.1040 -0.1760 -0.0390 -0.0267 -0.0306 -0.3834 -0.0916 -0.1207 -0.9730 -0.3955 -0.1256
S-1448	Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.<unk>
T-1448	genetic ; congestive heart failure ; haematopoietic cell transplantation
H-1448	-0.5114619731903076	▁Gene tic ▁; ▁an thra cycli ne - related ▁con ges tive ▁heart ▁failure ▁; ▁ha e mato po ie tic ▁cell ▁transplant ation
D-1448	-0.5114619731903076	Genetic ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
P-1448	-0.6098 -0.0116 -1.4642 -0.0266 -0.3494 -2.0903 -0.2080 -0.8544 -0.0363 -0.1563 -0.1523 -0.1169 -1.3096 -0.1343 -0.2772 -0.0103 -0.0912 -0.1147 -0.1558 -2.1843 -0.1006 -1.6523 -0.0599 -0.3494 -0.5432 -0.2392
S-1947	However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.<unk>
T-1947	uptitration ; patients ; hr reduction ; beta-blocker ; therapy
H-1947	-0.5166260004043579	▁HR ▁re duction ▁; ▁beta - block er ▁ therapy
D-1947	-0.5166260004043579	HR reduction ; beta-blocker therapy
P-1947	-3.7274 -0.1252 -0.0053 -0.2365 -0.2389 -0.0992 -0.3609 -0.1698 -0.6670 -0.0991 -0.2227 -0.2475
S-1218	CONCLUSIONS: PDE2 is markedly up-regulated in failing hearts and desensitizes against acute β-AR stimulation.<unk>
T-1218	pde2 ; hearts ; acute ; β-ar
H-1218	-0.5089439749717712	▁p de 2 ▁; ▁fail ing ▁heart s ▁; ▁a cute ▁β - AR ▁stimul ation
D-1218	-0.5089439749717712	pde2 ; failing hearts ; acute β-AR stimulation
P-1218	-0.4577 -0.7962 -0.0816 -0.5605 -0.1566 -0.0526 -0.6267 -0.0455 -0.3073 -2.2185 -0.0390 -0.5321 -0.0344 -0.6920 -1.0302 -0.5322 -0.6367 -0.3612
S-1565	Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.<unk>
T-1565	psoriasis ; patients ; disease ; atherosclerosis ; cardiovascular events ; psoriasis
H-1565	-1.0183508396148682	▁p sori asis ▁; ▁at hero sc ler osis ▁; ▁cardiovascular ▁; ▁psoriasis
D-1565	-1.0183508396148682	psoriasis ; atherosclerosis ; cardiovascular ; psoriasis
P-1565	-2.8388 -0.0722 -0.3765 -0.7493 -4.2492 -0.7265 -0.1924 -1.7282 -0.1417 -0.1570 -0.1037 -3.1478 -0.2530 -0.2176 -0.3214
S-34	The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease.<unk>
T-34	clinicians ; patient ; anemic ; patients ; heart disease
H-34	-0.803821861743927	▁a ne mic ▁; ▁ir on - d eficient ▁adult ▁patients ▁; ▁heart ▁disease
D-34	-0.803821861743927	anemic ; iron-deficient adult patients ; heart disease
P-34	-3.8255 -0.1177 -0.4265 -0.3570 -0.0193 -0.0259 -0.1470 -0.1427 -1.0703 -2.3403 -1.4833 -0.4783 -0.8284 -1.0474 -0.2357 -0.3158
S-1664	Because of its age-dependent increase in incidence and prevalence, heart failure is one of the leading causes of death and hospitalisation among the elderly.<unk>
T-1664	incidence ; prevalence ; heart failure ; leading ; death ; hospitalisation
H-1664	-0.93845134973526	▁heart ▁failure ▁; ▁hospital isation
D-1664	-0.93845134973526	heart failure ; hospitalisation
P-1664	-1.4002 -0.1667 -0.3931 -2.8669 -0.0391 -1.4193 -0.2838
S-397	A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD.<unk>
T-397	egfr ; diuretics ; hypertension ; patients ; esrd
H-397	-0.5255239605903625	▁e g FR ▁; ▁di ure tics ▁; ▁un control led ▁hyper tension ▁; ▁ES RD
D-397	-0.5255239605903625	egFR ; diuretics ; uncontrolled hypertension ; ESRD
P-397	-0.4393 -0.4380 -1.1732 -0.2678 -1.1857 -0.0645 -1.1895 -0.2847 -0.2714 -0.0143 -0.0233 -0.2042 -0.1451 -0.2158 -2.1047 -0.8680 -0.3068 -0.2632
S-678	Among trastuzumab users, the rate of CHF was 29.4% compared with 18.9% in nontrastuzumab users (P < .001).<unk>
T-678	trastuzumab ; chf ; nontrastuzumab users
H-678	-0.24423205852508545	▁tras tuz um ab ▁; ▁CHF ▁; ▁non tras tuz um ab
D-678	-0.24423205852508545	trastuzumab ; CHF ; nontrastuzumab
P-678	-0.2631 -0.0381 -0.0400 -0.0162 -0.2493 -0.1115 -0.1241 -0.2801 -0.1108 -0.0524 -0.0827 -0.0519 -1.8536 -0.1455
S-129	Higher EO-CFUs were associated with reduced mortality (hazard ratio, 0.25; 95% confidence interval, 0.09-0.69).<unk>
T-129	eo-cfus ; mortality ; hazard ratio ; confidence interval
H-129	-0.9761315584182739	▁ EO - C FU s ▁; ▁mortal ity ▁; haz ard ▁ratio
D-129	-0.9761315584182739	EO-CFUs ; mortality ;hazard ratio
P-129	-2.5743 -0.2625 -0.1224 -3.3740 -1.5839 -0.3671 -0.3887 -3.5981 -0.0631 -1.2245 -0.0244 -0.0711 -0.0507 -0.7199 -0.2172
S-1026	Point-of-care systems could be used to assess NP levels in the ED and community outpatient settings to monitor the risk of acute heart failure.<unk>
T-1026	point-of-care ; outpatient ; acute heart failure
H-1026	-0.4299430251121521	▁Point - of - care ▁systems ▁; ▁ NP ▁levels ▁; ▁ED ▁; ▁out patient ▁setting s ▁; ▁a cute ▁heart ▁failure
D-1026	-0.4299430251121521	Point-of-care systems ; NP levels ; ED ; outpatient settings ; acute heart failure
P-1026	-3.0066 -0.2216 -0.0512 -0.1635 -0.0716 -0.1899 -0.3779 -1.1223 -0.0218 -0.1250 -0.1311 -1.0539 -0.1281 -0.8702 -0.0221 -0.5304 -0.0499 -0.2727 -0.0596 -0.0553 -0.9331 -0.0879 -0.4854 -0.2876
S-1098	Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study.<unk>
T-1098	heart failure ; preserved ejection fraction ; myocardial infarction
H-1098	-0.36787891387939453	▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁my o card ial ▁in far ction
D-1098	-0.36787891387939453	heart failure ; ejection fraction ; myocardial infarction
P-1098	-1.8302 -0.1023 -0.1759 -0.2168 -0.1243 -0.0742 -0.4449 -0.0049 -0.5959 -0.4438 -0.3041 -0.9328 -0.0792 -0.0450 -0.2997 -0.2487 -0.4991 -0.1999
S-1995	OBJECTIVES: The aim of this single-arm, prospective, multicenter study was to evaluate the performance and safety of this LVAS.<unk>
T-1995	prospective ; lvas
H-1995	-1.5017060041427612	▁l VAS
D-1995	-1.5017060041427612	lVAS
P-1995	-4.3410 -1.2658 -0.1817 -0.2184
S-1639	The hazard associated with black race was largely caused by increased HF hospitalization (HR 1.58, 95% CI 1.27-1.96), given similar cardiovascular mortality.<unk>
T-1639	hf ; hospitalization ; cardiovascular mortality
H-1639	-0.44856253266334534	▁black ▁race ▁; ▁ HF ▁hospital ization ▁; ▁cardiovascular ▁mortal ity
D-1639	-0.44856253266334534	black race ; HF hospitalization ; cardiovascular mortality
P-1639	-0.0242 -0.1175 -0.1649 -0.5053 -0.0614 -1.1945 -0.1998 -0.2201 -2.6136 -0.1474 -0.0599 -0.2735 -0.2492
S-1904	Recent studies have demonstrated that even lower volumes of exercise below these recommendations confer health benefits, which is highly relevant to individuals with established cardiac disease including heart failure.<unk>
T-1904	exercise ; health ; cardiac disease ; heart failure
H-1904	-1.0453858375549316	▁exercise ▁; ▁cardiac ▁disease ▁; ▁heart ▁failure
D-1904	-1.0453858375549316	exercise ; cardiac disease ; heart failure
P-1904	-4.4649 -0.3586 -1.2966 -1.9223 -0.1667 -0.4985 -0.1543 -0.3027 -0.2440
S-736	METHODS AND RESULTS: Patients with suspected HFPEF (n=100) were enrolled in this prospective, observational study.<unk>
T-736	patients ; hfpef ; prospective
H-736	-1.1541221141815186	▁h f f f
D-736	-1.1541221141815186	hfff
P-736	-2.1371 -0.4970 -0.5444 -1.8440 -1.6983 -0.2039
S-1853	Discussion and dissemination In this review, we will assess the impact of implementation strategies and contextual factors on physician adherence to HF CPGs.<unk>
T-1853	physician ; hf ; cpgs
H-1853	-0.6567618250846863	▁physician ▁ad her ence ▁; ▁ HF ▁c PG s
D-1853	-0.6567618250846863	physician adherence ; HF cPGs
P-1853	-2.9613 -0.0196 -0.3887 -0.0481 -0.2744 -0.3555 -0.0993 -2.3992 -0.3843 -0.1058 -0.4003 -0.4446
S-1774	Within men matched for the same number of HF risk factors, fit men had significantly lower HF mortality than unfit men (P≤0.02).<unk>
T-1774	hf ; hf ; mortality
H-1774	-0.7753132581710815	▁ HF ▁; ▁ HF ▁; ▁ HF ▁mortal ity
D-1774	-0.7753132581710815	HF ; HF ; HF mortality
P-1774	-0.7961 -0.1925 -0.7406 -1.0584 -0.3212 -1.1676 -1.3464 -0.4603 -0.7008 -0.0695 -2.1924 -0.2579
S-260	CONCLUSIONS: These results demonstrate that HDL function is impaired in CHF and that ET improved the HDL-mediated vascular effects.<unk>
T-260	hdl ; chf ; vascular
H-260	-0.6984796524047852	▁HD L ▁function ▁; ▁CHF ▁; ▁ET ▁; ▁HD L - media ted ▁vas cular ▁effects
D-260	-0.6984796524047852	HDL function ; CHF ; ET ; HDL-mediated vascular effects
P-260	-1.4279 -2.7093 -0.2297 -0.1453 -0.0617 -0.0813 -0.9752 -0.1561 -1.1635 -3.1344 -0.1993 -0.0710 -0.0406 -1.1796 -0.0656 -0.4622 -0.3476 -0.1223
S-1181	A simple validated clinical tool to predict the absence of coronary artery disease in patients with systolic heart failure of unclear etiology.<unk>
T-1181	clinical ; coronary artery disease ; patients ; systolic heart failure ; etiology
H-1181	-0.42938992381095886	▁corona ry ▁arter y ▁disease ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁un clear ▁et i ology
D-1181	-0.42938992381095886	coronary artery disease ; systolic heart failure ; unclear etiology
P-1181	-1.6884 -0.1087 -0.2500 -0.2006 -1.6238 -0.0997 -0.2037 -0.0451 -1.0046 -1.1866 -0.0530 -0.5597 -0.0290 -0.0123 -0.0310 -0.6282 -0.0535 -0.2256 -0.1549
S-1953	Shunt implants were done after transseptal catheterisation with transoesophageal echocardiographic guidance under general anaesthesia.<unk>
T-1953	shunt ; implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
H-1953	-0.5075649619102478	▁Shu nt ▁implant s ▁; ▁trans sept al ▁cat heter isation ▁; ▁trans o es op hage al ▁e cho car dio graphic ▁; ▁general ▁ana es the sia
D-1953	-0.5075649619102478	Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
P-1953	-0.3419 -0.1192 -0.1767 -0.0355 -0.3333 -0.0054 -0.1574 -0.4341 -0.6203 -0.0119 -0.1379 -0.2047 -0.0028 -1.5765 -0.4410 -0.2656 -0.3030 -0.4513 -0.1071 -0.8111 -1.4970 -2.2108 -1.9952 -1.0188 -0.0243 -0.0908 -0.0622 -1.1031 -0.4848 -0.5264 -0.1842
S-520	Ea, total arterial compliance (TAC), and end-systolic elastance (Ees) were calculated at baseline and after 8 months of treatment.<unk>
T-520	ea ; total arterial compliance ; tac ; end-systolic elastance ; ees ; baseline
H-520	-0.5454513430595398	▁ea ▁; ▁arterial ▁compliance ▁; TAC ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁e es
D-520	-0.5454513430595398	ea ; arterial compliance ;TAC ; end-systolic elastance ; ees
P-520	-2.8903 -0.2089 -1.6468 -0.0206 -0.1331 -0.1530 -0.1074 -0.5790 -0.0802 -1.1279 -0.3282 -0.5335 -0.0758 -0.1441 -0.2373 -0.6217 -0.0190 -1.2936 -0.1631
S-304	CONCLUSIONS: Biventricular support using a HeartMate II LVAD and CentriMag RVAD resulted in limited mortality at hospital discharge.<unk>
T-304	biventricular support ; heartmate ii ; lvad ; centrimag ; rvad ; mortality ; hospital ; discharge
H-304	-0.9310517311096191	▁bi ven tri cular ▁support ▁; ▁Heart Mate ▁; ▁l VAD ▁; ▁centri Mag ▁R VAD ▁; ▁mortal ity ▁; ▁hospital ▁dis charge
D-304	-0.9310517311096191	biventricular support ; HeartMate ; lVAD ; centriMag RVAD ; mortality ; hospital discharge
P-304	-0.8711 -0.4732 -1.5507 -0.8358 -1.8412 -0.2602 -1.7546 -0.0978 -2.0692 -1.9696 -0.1535 -0.1275 -0.3290 -0.4011 -4.7473 -0.2286 -0.6731 -1.9935 -0.0403 -1.0767 -0.4623 -0.4904 -0.1702 -0.3372 -0.3222
S-969	Renal dysfunction is related to long-term mortality and myocardial infarction after coronary artery bypass grafting (CABG).<unk>
T-969	renal dysfunction ; mortality ; myocardial infarction ; coronary artery bypass grafting ; cabg
H-969	-0.41599220037460327	▁Ren al ▁dys function ▁; ▁my o card ial ▁in far ction ▁; ▁corona ry ▁arter y ▁by pass ▁graf ting ▁; CA BG
D-969	-0.41599220037460327	Renal dysfunction ; myocardial infarction ; coronary artery bypass grafting ;CABG
P-969	-0.1471 -0.0607 -0.2090 -0.8680 -0.2314 -2.3593 -0.2189 -0.5831 -0.0345 -0.0392 -0.2289 -0.1147 -0.3730 -0.1175 -0.0307 -0.1014 -0.4928 -0.7465 -0.5021 -0.2912 -0.1894 -1.1587 -0.7001 -0.3947 -0.4260 -0.1969
S-1890	Other cardiovascular risk factors, such as diabetes mellitus, atrial fibrillation and coronary artery disease are prevalent in the HFpEF population.<unk>
T-1890	cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; hfpef
H-1890	-0.3297465443611145	▁cardiovascular ▁risk ▁factors ▁; ▁diabetes ▁mell itus ▁; ▁at rial ▁fi bril lation ▁; ▁corona ry ▁arter y ▁disease ▁; ▁ HF p EF
D-1890	-0.3297465443611145	cardiovascular risk factors ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
P-1890	-0.1666 -1.4710 -0.0477 -0.1375 -0.0605 -0.0347 -0.1441 -0.1393 -0.0868 -0.0313 -0.3357 -0.0335 -0.2541 -0.1373 -0.1837 -0.0931 -0.2046 -0.4654 -2.6064 -0.4117 -0.4005 -0.1890 -0.0191 -0.3634 -0.3495 -0.2067
S-1443	Compared with baseline, isoprenaline infusion increased SDQT in HNorm subjects (P = 0.02) but not in HF patients.<unk>
T-1443	baseline ; isoprenaline ; infusion ; sdqt ; hf ; patients
H-1443	-0.34903189539909363	▁base line ▁; ▁iso pren a line ▁in fusion ▁; ▁SD QT ▁; ▁h Nor m ▁; ▁ HF
D-1443	-0.34903189539909363	baseline ; isoprenaline infusion ; SDQT ; hNorm ; HF
P-1443	-0.0100 -0.0647 -0.1990 -0.0080 -0.0538 -0.2080 -0.0454 -0.2301 -0.0548 -0.0987 -0.0596 -2.4400 -0.1422 -1.3705 -0.9427 -0.0209 -0.1427 -0.2741 -0.1036 -0.6211 -0.2396
S-978	Renal dysfunction was associated with all-cause mortality but not with cardiovascular events during the first 3 postoperative months after primary isolated CABG.<unk>
T-978	renal dysfunction ; all-cause mortality ; cardiovascular events ; postoperative ; cabg
H-978	-0.6056296229362488	▁Ren al ▁dys function ▁; ▁cardiovascular ▁events ▁; ▁post operativ e ▁months ▁; ▁primary ▁isola ted ▁ca BG
D-978	-0.6056296229362488	Renal dysfunction ; cardiovascular events ; postoperative months ; primary isolated caBG
P-978	-0.2595 -0.0534 -0.1598 -1.1081 -0.1806 -2.1461 -0.3306 -0.4665 -1.9377 -0.0706 -0.3899 -1.2745 -0.4493 -0.3882 -0.0458 -0.0283 -1.6321 -0.7866 -0.2232 -0.1817
S-1142	Pyridostigmine also increased vascular endothelial growth factor protein in the left ventricle, suggesting myocardial angiogenesis.<unk>
T-1142	pyridostigmine ; vascular endothelial growth factor ; protein ; left ventricle ; myocardial angiogenesis
H-1142	-0.5752449631690979	▁Pyr ido stig mine ▁; ▁vas cular ▁en dot heli al ▁growth ▁factor ▁; ▁left ▁vent ric le ▁; ▁my o card ial ▁ang io gene sis
D-1142	-0.5752449631690979	Pyridostigmine ; vascular endothelial growth factor ; left ventricle ; myocardial angiogenesis
P-1142	-0.0076 -0.0633 -0.0003 -0.0888 -0.1741 -0.1391 -0.0604 -0.0550 -1.6717 -0.2169 -0.0417 -0.3088 -0.0459 -0.8873 -0.2850 -2.0629 -2.0378 -0.8725 -0.2762 -0.4532 -0.1054 -1.0985 -0.0675 -0.1569 -3.2726 -0.4476 -1.1207 -0.4770 -0.1871
S-1393	Improvement in eGFR in the VAD group and the ECMO+VAD group was much higher than in the ECMO group in the first 7 days.<unk>
T-1393	egfr ; vad ; ecmo ; vad ; ecmo
H-1393	-0.7993639707565308	▁e g f ▁; ▁ VAD ▁group ▁; ▁ec mo ▁; ▁ VAD ▁group ▁; ▁ec mo
D-1393	-0.7993639707565308	egf ; VAD group ; ecmo ; VAD group ; ecmo
P-1393	-0.1448 -0.3456 -1.4790 -0.0864 -0.3222 -0.1890 -0.6232 -0.1326 -0.7002 -0.9420 -1.3343 -2.1214 -2.1683 -0.7361 -0.4033 -0.9512 -0.6561 -1.6328 -0.2196
S-213	OBJECTIVE: PROTOCOL: We classified patients as having CHF based on International Classification of Diseases, Ninth Revision, codes.<unk>
T-213	patients ; chf ; international classification of diseases
H-213	-0.4184877574443817	▁CHF ▁; ▁international ▁classifica tion ▁of ▁Disease s ▁; ▁Nin th ▁re vision
D-213	-0.4184877574443817	CHF ; international classification of Diseases ; Ninth revision
P-213	-0.9839 -0.4949 -0.6324 -0.6022 -0.0236 -0.0372 -0.2336 -0.0131 -1.0781 -0.0230 -0.0155 -0.6547 -0.0446 -1.2032 -0.2372
S-1163	RESULTS: Subjects with RV dysfunction (51%) had lower body mass index, lower fat mass index, and were more likely to display cachexia (19%).<unk>
T-1163	rv dysfunction ; body mass index ; fat mass ; cachexia
H-1163	-0.4977889955043793	▁ RV ▁dys function ▁; ▁body ▁mass ▁index ▁; ▁fat ▁mass ▁index ▁; ▁cache xia
D-1163	-0.4977889955043793	RV dysfunction ; body mass index ; fat mass index ; cachexia
P-1163	-0.1586 -0.7945 -0.8838 -1.4852 -0.2025 -0.9622 -0.1161 -0.1197 -0.2669 -1.0178 -0.0395 -0.0537 -0.5393 -0.3967 -0.8850 -0.3014 -0.2394
S-1775	CONCLUSIONS: Higher baseline CRF is associated with lower HF mortality risk in men, regardless of the number of HF risk factors present.<unk>
T-1775	baseline ; crf ; hf ; mortality ; hf
H-1775	-0.5674945116043091	▁base line ▁; ▁c RF ▁; ▁ HF ▁mortal ity ▁risk ▁; ▁ HF ▁risk ▁factors
D-1775	-0.5674945116043091	baseline ; cRF ; HF mortality risk ; HF risk factors
P-1775	-0.0183 -0.0287 -1.2772 -1.1584 -1.2767 -0.0943 -0.2427 -0.2648 -0.5504 -0.0215 -1.0751 -0.2610 -0.5927 -0.4221 -2.2767 -0.0784 -0.3785 -0.1972
S-1921	CONCLUSIONS: Robot-assisted gait therapy with the Lokomat® System is feasible in heart failure patients and was safe in this trial.<unk>
T-1921	gait ; therapy ; lokomat ; heart failure ; patients
H-1921	-0.5791478753089905	▁Robot - assist ed ▁ga it ▁ therapy ▁; ▁Lok omat ® ▁system ▁; ▁heart ▁failure
D-1921	-0.5791478753089905	Robot-assisted gait therapy ; Lokomat® system ; heart failure
P-1921	-0.5164 -0.1402 -0.0096 -0.1507 -0.1270 -3.7789 -0.3144 -0.0481 -0.1377 -0.1074 -0.0366 -2.6088 -0.3735 -0.2701 -0.2105 -0.0649 -1.3720 -0.1580
S-92	The present study tests the fundamental hypothesis that cardiac growth and plasticity in the setting of disease recapitulates conserved developmental chromatin remodeling events.<unk>
T-92	tests ; cardiac growth ; disease ; chromatin ; remodeling
H-92	-0.39126142859458923	▁cardiac ▁growth ▁; ▁plastic ity ▁; ▁disease ▁recap it ulat es ▁; ▁development al ▁chr omat in ▁remodel ing
D-92	-0.39126142859458923	cardiac growth ; plasticity ; disease recapitulates ; developmental chromatin remodeling
P-92	-0.3786 -0.7395 -0.3305 -0.0374 -0.0613 -0.1968 -0.3590 -0.0086 -0.8041 -0.0035 -0.8760 -0.1853 -0.6974 -0.0336 -0.1891 -0.0274 -0.9231 -0.2087 -0.1195 -1.8729 -0.1642
S-1742	We thus examined changes in prognosis of a large idiopathic dilated cardiomyopathy cohort systematically followed during the past 30 years.<unk>
T-1742	prognosis ; idiopathic dilated cardiomyopathy
H-1742	-0.7472726702690125	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1742	-0.7472726702690125	idiopathic dilated cardiomyopathy
P-1742	-1.2074 -0.0293 -0.3022 -0.6477 -0.5593 -0.0778 -0.3447 -2.4880 -0.3753 -0.2081 -2.5268 -0.2006
S-78	The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).<unk>
T-78	dopamine ; nesiritide ; placebo
H-78	-0.388561487197876	▁dop amine ▁; ▁nesi riti de
D-78	-0.388561487197876	dopamine ; nesiritide
P-78	-0.0205 -0.2337 -0.0538 -0.0265 -0.0148 -0.4467 -2.2034 -0.1091
S-41	Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors.<unk>
T-41	medline ; embase ; cochrane ; clinical
H-41	-0.3369165062904358	▁MED line ▁; ▁ EMBA se ▁; ▁co ch rane ▁; ▁clinic al ▁trial ▁registri es ▁; ▁technical ▁ad visor s
D-41	-0.3369165062904358	MEDline ; EMBAse ; cochrane ; clinical trial registries ; technical advisors
P-41	-0.2205 -0.6872 -0.1386 -0.0452 -0.0375 -1.6886 -0.1471 -0.1065 -0.1612 -0.0056 -0.7451 -1.0849 -0.1010 -0.7015 -0.2083 -0.0812 -0.3143 -0.0668 -0.2298 -0.0011 -0.3609 -0.3388 -0.2774
S-1127	Clinician interviews identified twice as many reasons for nonprescribing as chart review (mean 1.6 vs. 0.8 reasons per patient, P<0.001).<unk>
T-1127	clinician ; nonprescribing ; patient
H-1127	-0.5489801168441772	▁Clinic ▁; ▁non pre scribi ng ▁; ▁chart ▁review
D-1127	-0.5489801168441772	Clinic ; nonprescribing ; chart review
P-1127	-0.9618 -1.7115 -2.3779 -0.0210 -0.0870 -0.0200 -0.2459 -0.0804 -0.0773 -0.2900 -0.1660
S-1764	CONCLUSIONS: The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF.<unk>
T-1764	patients ; severe hf ; prognostic ; hf
H-1764	-0.9360432624816895	▁ HF ▁; ▁ HF
D-1764	-0.9360432624816895	HF ; HF
P-1764	-1.5976 -0.4734 -1.2127 -1.7376 -0.3417 -0.7419 -0.4475
S-522	RESULTS: At baseline Ea, TAC, HR, and Ees did not differ significantly between ivabradine- and placebo-treated patients.<unk>
T-522	baseline ; ea ; tac ; ees ; patients
H-522	-0.4921186864376068	▁base line ▁Ea ▁; ▁ TAC ▁; ▁HR ▁; ▁e es ▁; ▁i va bra dine ▁; ▁place bo - tre ated ▁patients
D-522	-0.4921186864376068	baseline Ea ; TAC ; HR ; ees ; ivabradine ; placebo-treated patients
P-522	-0.2333 -0.0102 -1.7467 -0.3372 -0.1303 -0.1130 -0.2179 -0.3463 -0.4312 -0.5698 -0.0338 -0.3342 -0.0309 -1.6881 -0.2723 -0.0841 -1.5040 -0.4761 -0.0846 -0.2952 -0.2631 -0.3947 -2.1038 -0.3582 -0.2438
S-1628	CONCLUSION: Care management coupled with content-driven telehealth technology has potential to improve health outcomes in high-cost Medicare beneficiaries.<unk>
T-1628	telehealth ; health ; outcomes ; medicare
H-1628	-0.3687964975833893	▁care ▁management ▁; ▁content - driv en ▁tele health ▁technology ▁; ▁health ▁outcome s ▁; ▁high - co st ▁Medica re
D-1628	-0.3687964975833893	care management ; content-driven telehealth technology ; health outcomes ; high-cost Medicare
P-1628	-1.8829 -0.4524 -0.0805 -1.7467 -0.0575 -0.0223 -0.1255 -0.3322 -0.8167 -0.0834 -0.2161 -0.1963 -0.1440 -0.0379 -0.1252 -0.3549 -0.0680 -0.0463 -0.1695 -0.0800 -0.0472 -1.2074 -0.1894
S-1256	These initial results warrant further rigorous investigation, since the use of ERC (or pure epicatechin) may represent a safe and novel means of improving muscle function.<unk>
T-1256	warrant ; erc ; epicatechin ; muscle
H-1256	-0.6143767833709717	▁ ERC ▁; ▁pure ▁epi cate chin ▁; ▁muscle ▁function
D-1256	-0.6143767833709717	ERC ; pure epicatechin ; muscle function
P-1256	-1.0441 -0.0732 -0.1046 -0.0603 -0.6064 -0.0165 -0.5477 -0.7066 -3.0038 -0.6395 -0.3334 -0.2363
S-1128	In these interviews, biomedical reasons for nonprescribing were cited in 50%-70% of patients, and contextual reasons in 64%-70%.<unk>
T-1128	biomedical ; nonprescribing ; patients
H-1128	-0.3619720935821533	▁bio medic al ▁reasons ▁; ▁non pre scribi ng
D-1128	-0.3619720935821533	biomedical reasons ; nonprescribing
P-1128	-0.5542 -0.0756 -0.0048 -0.9668 -0.4132 -0.0830 -0.0153 -0.1483 -0.0734 -1.4219 -0.2252
S-1433	Therefore, failing myocardium displays altered expression and post-translational modification of PKA subunits that may impact downstream signaling.<unk>
T-1433	myocardium ; expression ; pka ; downstream signaling
H-1433	-0.6676582098007202	▁my o car dium ▁; ▁post - trans la tional ▁; ▁p KA ▁; ▁down stream ▁signal ing
D-1433	-0.6676582098007202	myocardium ; post-translational ; pKA ; downstream signaling
P-1433	-0.7829 -0.0784 -0.4720 -0.8006 -0.8478 -4.3832 -0.0124 -0.0132 -0.3368 -0.0037 -0.4908 -0.8404 -1.2587 -0.8916 -0.1891 -0.0192 -0.6397 -0.3978 -0.5336 -0.3612
S-867	Inappropriate therapy due to atrial fibrillation was associated with a 50% lower rate in patients receiving carvedilol compared with those receiving metoprolol.<unk>
T-867	therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
H-867	-0.634277880191803	▁at rial ▁fi bril lation ▁; ▁car vedi lol ▁; ▁met o pro lol
D-867	-0.634277880191803	atrial fibrillation ; carvedilol ; metoprolol
P-867	-3.3588 -0.1662 -0.8164 -0.0641 -0.9943 -0.3921 -1.4973 -0.1241 -0.1609 -0.6298 -0.4228 -0.2634 -0.0974 -0.2011 -0.7251 -0.2345
S-1860	DESIGN: Grounded theory was used to collect and analyze interview data from 25 heart failure patients with an implantable cardioverter-defibrillator.<unk>
T-1860	collect ; heart failure ; patients ; implantable cardioverter-defibrillator
H-1860	-0.6086330413818359	▁ground ed ▁theory ▁; ▁heart ▁failure ▁; ▁implant able ▁cardio ver ter - de fi br illa tor
D-1860	-0.6086330413818359	grounded theory ; heart failure ; implantable cardioverter-defibrillator
P-1860	-1.8311 -0.2362 -0.0192 -0.3349 -2.4564 -0.0513 -1.3225 -0.3958 -0.0244 -0.3421 -0.0649 -0.3546 -0.1261 -0.0877 -0.3699 -1.7235 -1.2520 -0.2355 -0.7497 -0.1947
S-367	This patient showed that functional MS could develop even in a patient with successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-367	patient ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
H-367	-0.48640885949134827	▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁LV
D-367	-0.48640885949134827	functional MS ; valve plasty ; degenerative MR ; LV
P-367	-1.4610 -0.1984 -0.1537 -2.9829 -0.0381 -0.0598 -0.4572 -0.1474 -0.0427 -0.0090 -0.0170 -0.1291 -0.1998 -0.1322 -1.6022 -0.1520
S-300	RESULTS: A total of 139 patients required HeartMate II insertion; 34 (24%) required biventricular support at the time of HeartMate II implantation.<unk>
T-300	patients ; heartmate ii ; biventricular support ; heartmate ii ; implantation
H-300	-0.779982328414917	▁Heart Mate ▁II ▁ insertion ▁; ▁bi ven tri cular ▁; ▁Heart Mate ▁II ▁implant ation
D-300	-0.779982328414917	HeartMate II insertion ; biventricular ; HeartMate II implantation
P-300	-2.2397 -0.2400 -0.7741 -1.0857 -0.0200 -0.1506 -0.1651 -0.6187 -1.2077 -0.2915 -2.1737 -2.2835 -0.2007 -0.7422 -0.7817 -0.3713 -0.4210 -0.2726
S-1663	Management of end stage heart failure Heart failure is a major public health problem, with a patient population of at least 10 million in Europe and approximately 5 million in North America.<unk>
T-1663	end stage heart failure ; heart failure ; public ; health ; patient ; europe ; north america
H-1663	-0.8176169395446777	▁end ▁stage ▁heart ▁failure ▁; ▁public ▁health ▁; ▁ europe ▁; ▁North ▁America
D-1663	-0.8176169395446777	end stage heart failure ; public health ; europe ; North America
P-1663	-2.9136 -0.0879 -2.1100 -0.0552 -0.6955 -0.9743 -0.4039 -0.7916 -1.2474 -0.0787 -0.2479 -1.7056 -0.3670 -0.3200 -0.2656
S-1105	Changes in patient presentation were noted, including fewer ST-segment-elevation MIs, lower Killip class, and more comorbid conditions.<unk>
T-1105	patient ; st-segment-elevation mis ; killip class ; comorbid ; conditions
H-1105	-0.456159770488739	▁ST - seg ment - elevat ion ▁MI s ▁; ▁Kill ip ▁class
D-1105	-0.456159770488739	ST-segment-elevation MIs ; Killip class
P-1105	-4.1981 -0.0528 -0.0031 -0.0760 -0.0482 -0.0208 -0.0229 -0.4977 -0.0402 -0.2346 -0.9015 -0.0211 -0.1368 -0.3902 -0.1984
S-1818	Future of advanced heart failure and mechanical support devices: A Cardiology-Cardiovascular Surgery Consensus Report Heart failure is a progressive disease.<unk>
T-1818	heart failure ; cardiology-cardiovascular surgery consensus report ; heart failure ; disease
H-1818	-0.6094529628753662	▁heart ▁failure ▁; ▁mechanic al ▁support ▁devices ▁; ▁Card i ology - Car dio vas cular ▁Sur ger y ▁; ▁report ▁; ▁Heart ▁failure
D-1818	-0.6094529628753662	heart failure ; mechanical support devices ; Cardiology-Cardiovascular Surgery ; report ; Heart failure
P-1818	-1.2875 -0.0798 -0.1457 -0.0053 -0.0150 -0.4765 -0.0896 -0.3192 -0.7605 -0.2245 -0.1052 -0.0742 -0.9420 -3.1215 -0.9954 -0.1449 -1.1791 -0.2942 -0.0355 -0.8844 -0.6916 -1.0075 -1.5610 -0.0678 -1.1702 -0.1678
S-769	The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment.<unk>
T-769	s3991 ; n2bus ; s12884 ; pevk
H-769	-0.8116468191146851	▁s 39 91 ▁; ▁elastic ▁N 2 Bu s ▁segment ▁; ▁s 12 884 ▁; ▁pe v k ▁segment
D-769	-0.8116468191146851	s3991 ; elastic N2Bus segment ; s12884 ; pevk segment
P-769	-1.6365 -0.1320 -0.2441 -0.2047 -0.0949 -3.2281 -0.3523 -1.1997 -0.2386 -1.5726 -0.1474 -0.4291 -0.0208 -0.4214 -0.1584 -1.3817 -2.1430 -0.9240 -1.6892 -0.5056 -0.3204
S-1504	The Self-Care of Heart Failure Index Version 6.2 (SCHFI v.6.2) is widely used, but its psychometric profile is still questioned.<unk>
T-1504	self-care of heart failure index version 6.2 ; schfi v.6.2 ; psychometric
H-1504	-0.42074355483055115	▁self - Car e ▁of ▁Heart ▁Fail ure ▁index ▁; SCH fi ▁; ▁psycho metric ▁profile
D-1504	-0.42074355483055115	self-Care of Heart Failure index ;SCHfi ; psychometric profile
P-1504	-0.6136 -0.0504 -0.5858 -0.0840 -0.1945 -0.6884 -0.4448 -0.0705 -0.8651 -0.2928 -0.7047 -2.1436 -0.3855 -0.1107 -0.0310 -0.0165 -0.1534 -0.1380
S-93	We used quantitative proteomics to identify chromatin-associated proteins extracted via detergent and to quantify changes in their abundance during disease.<unk>
T-93	proteomics ; chromatin-associated proteins ; disease
H-93	-0.5480856895446777	▁prote o mics ▁; ▁chr omat in - as soci ated ▁protein s ▁; ▁detergent
D-93	-0.5480856895446777	proteomics ; chromatin-associated proteins ; detergent
P-93	-1.4417 -1.0792 -0.0738 -0.2839 -0.2477 -0.0295 -1.1391 -0.2289 -0.0684 -0.0224 -0.2094 -0.7701 -0.0736 -1.2398 -0.3762 -1.8231 -0.2106
S-1993	BACKGROUND: The HeartMate 3 left ventricular assist system (LVAS) is intended to provide long-term support to patients with advanced heart failure.<unk>
T-1993	heartmate ; left ventricular assist system ; lvas ; patients ; heart failure
H-1993	-0.9005555510520935	▁Heart Mate ▁; ▁left ▁vent ri cular ▁assist ▁system ▁; ▁l VAS ▁; ▁advanced ▁heart ▁failure
D-1993	-0.9005555510520935	HeartMate ; left ventricular assist system ; lVAS ; advanced heart failure
P-1993	-0.6142 -0.3388 -0.3836 -0.1928 -3.7865 -1.7452 -0.3937 -1.5440 -0.1464 -0.6168 -0.2750 -0.4732 -0.5381 -3.2341 -1.2669 -0.1894 -0.3093 -0.1620
S-954	Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.<unk>
T-954	nicorandil ; mitochondrial dysfunction ; heart failure ; cardioprotection
H-954	-0.46673399209976196	▁Nico rand il ▁a meli orat es ▁mito cho ndri al ▁dys function ▁; ▁do xor ubi cin - indu ced ▁heart ▁failure ▁; ▁rat s ▁; ▁mechanism ▁of ▁cardio protec tion
D-954	-0.46673399209976196	Nicorandil ameliorates mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats ; mechanism of cardioprotection
P-954	-0.0011 -0.0503 -0.0651 -0.5846 -0.0011 -0.0519 -0.1775 -0.1735 -3.2857 -0.9285 -0.0883 -0.3504 -1.2723 -0.2576 -0.0369 -0.5786 -0.0763 -2.1596 -0.1726 -0.1167 -1.0461 -0.8017 -0.1325 -0.3971 -0.2836 -0.0258 -0.9559 -0.0437 -0.3360 -0.3827 -0.3990 -0.1236 -0.3579 -0.1548
S-1016	As a result, pharmacologic management for acute HF has changed little in recent years, and adverse event rates remain higher than in chronic HF.<unk>
T-1016	pharmacologic ; acute hf ; adverse event ; chronic hf
H-1016	-0.44072631001472473	▁ pharma c ologic ▁; ▁a cute ▁ HF ▁; ▁advers e ▁event ▁rates ▁; ▁chronic ▁ HF
D-1016	-0.44072631001472473	pharmacologic ; acute HF ; adverse event rates ; chronic HF
P-1016	-1.4554 -0.1432 -0.1663 -0.2128 -0.4193 -0.0665 -0.0144 -0.3081 -0.0885 -0.4335 -0.8916 -0.1187 -0.3166 -1.8919 -0.4282 -0.8241 -0.3548 -0.1212 -0.3746 -0.1849
S-517	BACKGROUND: The effective arterial elastance (Ea) represents resistive and pulsatile afterload of the heart derived from the pressure volume relation.<unk>
T-517	arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
H-517	-0.5049906969070435	▁arterial ▁elastan ce ▁; ▁e a ▁; ▁pulsa tile ▁after load ▁; ▁heart ▁; ▁pressure ▁volume ▁relation
D-517	-0.5049906969070435	arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
P-517	-0.6795 -0.2201 -0.5203 -0.2087 -0.4805 -0.0116 -0.4212 -1.3969 -0.1505 -1.1918 -0.0637 -0.3423 -0.5688 -0.3463 -0.1578 -0.8301 -1.1591 -0.6813 -0.1642
S-416	METHODS AND RESULTS: CXL-1020 converts solely to HNO and inactive CXL-1051 with a t1/2 of 2 minutes.<unk>
T-416	cxl-1020 ; hno ; cxl-1051 ; t1
H-416	-0.609969437122345	▁c XL -10 20 ▁convert s ▁; ▁h no ▁; ▁in active ▁; ▁c XL -10 51
D-416	-0.609969437122345	cXL-1020 converts ; hno ; inactive ; cXL-1051
P-416	-0.6887 -1.0064 -0.0821 -0.2148 -1.5870 -0.7260 -0.2138 -2.0791 -0.3104 -0.0722 -0.0311 -0.0356 -2.1173 -0.6261 -0.7908 -0.1361 -0.0797 -0.4905 -0.3017
S-611	CONCLUSIONS: TNF antagonists were not associated with a risk of HF hospital admissions compared with nbDMARDs in this RA population.<unk>
T-611	tnf antagonists ; hf ; hospital ; admissions ; nbdmards ; ra
H-611	-0.31954360008239746	▁t NF ▁anta gon ists ▁; ▁ HF ▁hospital ▁ad missions ▁; ▁n b DM ARD s ▁; ▁RA
D-611	-0.31954360008239746	tNF antagonists ; HF hospital admissions ; nbDMARDs ; RA
P-611	-0.1029 -0.4708 -0.5496 -0.6766 -0.6018 -0.1135 -0.5015 -0.1203 -1.6205 -0.0099 -0.0159 -0.1108 -0.0884 -0.0144 -0.6471 -0.1530 -0.1222 -0.2213 -0.1582 -0.2497 -0.1619
S-1236	RESULTS: In all, 304 patients were included, aged 68 ± 9 years; 86% male; ejection fraction, 26% ± 6%.<unk>
T-1236	patients ; ejection fraction
H-1236	-0.47313931584358215	▁e je ction ▁ fraction
D-1236	-0.47313931584358215	ejection fraction
P-1236	-1.1947 -0.2618 -0.1685 -0.8085 -0.0107 -0.5763 -0.2915
S-817	Multivariate analysis showed worsening GLS (HR 1.121; 95% CI 1.023 to 1.228, p=0.014) was independently associated with increased CV events.<unk>
T-817	multivariate analysis ; gls
H-817	-1.3009047508239746	▁g ls ▁; HR ▁; ▁cv ▁events
D-817	-1.3009047508239746	gls ;HR ; cv events
P-817	-0.6347 -2.4185 -0.1373 -3.0696 -0.2923 -2.7210 -1.8353 -0.2550 -0.3445
S-1981	RESULTS: Of the 100 enrolled participants, 26 participants were randomized to exercise; 24 to diet; 25 to exercise + diet; 25 to control.<unk>
T-1981	randomized ; exercise ; exercise
H-1981	-0.6594507098197937	▁exercise ▁; ▁die t
D-1981	-0.6594507098197937	exercise ; diet
P-1981	-1.1265 -0.1769 -0.9132 -0.2341 -1.2688 -0.2373
S-1695	We then estimated the odds of future (July to December 2009) 30-day, risk-adjusted mortality at the worst versus best quintile of hospitals.<unk>
T-1695	mortality ; hospitals
H-1695	-0.4189821481704712	▁risk - ad just ed ▁mortal ity ▁; ▁hospital s
D-1695	-0.4189821481704712	risk-adjusted mortality ; hospitals
P-1695	-0.7400 -0.1125 -0.0757 -0.0119 -0.0287 -0.1939 -0.0567 -0.9225 -2.2814 -0.1494 -0.1719 -0.2831
S-87	Utilizing voluntary testimonies and conversations with participating nurses, the benefits of involvement in a multisite study extend beyond meeting Magnet(®) research requirements.<unk>
T-87	nurses ; magnet
H-87	-1.3880455493927002	▁magnetic ▁; ▁research
D-87	-1.3880455493927002	magnetic ; research
P-87	-3.2543 -2.2767 -0.8251 -0.3339 -0.2503
S-1842	We will conduct a systematic review to identify implementation strategies that improve physician adherence to class I recommendations, those with clear evidence that benefits outweigh the risks.<unk>
T-1842	physician ; evidence
H-1842	-0.5300422310829163	▁physician ▁ad her ence ▁; ▁class ▁I ▁recommendations
D-1842	-0.5300422310829163	physician adherence ; class I recommendations
P-1842	-0.6404 -0.0100 -0.2993 -0.0723 -0.4080 -0.7617 -1.4517 -0.3121 -1.1188 -0.2261
S-1271	Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.<unk>
T-1271	diagnosed ; patients ; hf ; drug treatment ; paf ; biosynthetic enzymes ; lyso-paf-at
H-1271	-0.7567276358604431	▁ HF ▁; ▁drug ▁treatment ▁; ▁PA f ▁bio syn the tic ▁enzym es ▁; ▁lys o - PA f - AT
D-1271	-0.7567276358604431	HF ; drug treatment ; PAf biosynthetic enzymes ; lyso-PAf-AT
P-1271	-0.8196 -0.2596 -0.2677 -4.3148 -1.6241 -0.1834 -1.6827 -1.8601 -1.0467 -0.1006 -1.6678 -0.2585 -0.0831 -0.1274 -0.2014 -0.0635 -0.0472 -0.0672 -1.1327 -1.0301 -0.1785 -0.1143 -0.7575 -0.2730
S-1099	Major changes have recently occurred in the epidemiology of myocardial infarction (MI) that could possibly affect outcomes such as heart failure (HF).<unk>
T-1099	epidemiology ; myocardial infarction ; mi ; outcomes ; heart failure ; hf
H-1099	-0.37494462728500366	▁epidemi ology ▁; ▁my o card ial ▁in far ction ▁; MI ▁; ▁heart ▁failure ▁; HF
D-1099	-0.37494462728500366	epidemiology ; myocardial infarction ;MI ; heart failure ;HF
P-1099	-0.4931 -0.1067 -0.2370 -0.1991 -0.2227 -0.9119 -0.0679 -0.0890 -0.2595 -0.1823 -0.2707 -1.6154 -0.2308 -0.9866 -0.0691 -0.5646 -0.0218 -0.3847 -0.2111
S-737	Confirmatory diagnostic tests, cardiac magnetic resonance imaging including T1 mapping, and invasive hemodynamic assessments were performed at baseline.<unk>
T-737	diagnostic ; tests ; cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments ; baseline
H-737	-0.39829832315444946	▁cardiac ▁magnetic ▁res on ance ▁imagin g ▁; ▁t 1 ▁ma pping ▁; ▁invasi ve ▁hem o dynamic ▁assessment s
D-737	-0.39829832315444946	cardiac magnetic resonance imaging ; t1 mapping ; invasive hemodynamic assessments
P-737	-0.2286 -0.0862 -0.1744 -0.1513 -0.0995 -0.9823 -0.1408 -0.1398 -0.2626 -0.3482 -1.3281 -0.0222 -0.2254 -0.3681 -0.2564 -1.1144 -0.4625 -0.0148 -0.2252 -0.4412 -1.5094 -0.1812
S-1935	Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response.<unk>
T-1935	heart rate reduction ; exercise ; heart failure with reduced ejection fraction ; beta-blocker
H-1935	-0.4704848527908325	▁Heart ▁rate ▁re duction ▁; ▁exercise ▁performance ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁beta - block er ▁hypo - respons e
D-1935	-0.4704848527908325	Heart rate reduction ; exercise performance ; heart failure ; ejection fraction ; beta-blocker hypo-response
P-1935	-0.6171 -0.0430 -0.1416 -0.0485 -0.2945 -0.0215 -0.2737 -0.2975 -5.6311 -0.1249 -0.2450 -0.3198 -0.0680 -0.0534 -0.3216 -0.0034 -0.4412 -1.3058 -0.0639 -0.4383 -0.1363 -0.8123 -0.1537 -0.0067 -0.2102 -0.4555 -0.1746
S-1597	Even though the majority of patients with RAS are asymptomatic, it can clinically present with hypertension, nephropathy and congestive heart failure.<unk>
T-1597	patients ; ras ; asymptomatic ; clinically ; hypertension ; nephropathy ; congestive heart failure
H-1597	-0.2505039572715759	▁ RAS ▁; ▁hyper tension ▁; ▁nep hro pathy ▁; ▁con ges tive ▁heart ▁failure
D-1597	-0.2505039572715759	RAS ; hypertension ; nephropathy ; congestive heart failure
P-1597	-1.9372 -0.0307 -0.2429 -0.3176 -0.0738 -0.1559 -0.0363 -0.0434 -0.1973 -0.0917 -0.0075 -0.0919 -0.0954 -0.3752 -0.0399 -0.2964 -0.2254
S-585	Other prognostic factors at admission were higher serum levels of brain natriuretic peptide (BNP) and creatinine and lower natremia.<unk>
T-585	prognostic ; admission ; brain natriuretic peptide ; bnp ; creatinine ; natremia
H-585	-0.4689648151397705	▁ad mission ▁; ▁se rum ▁levels ▁; ▁brain ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁creati nine ▁; ▁na trem ia
D-585	-0.4689648151397705	admission ; serum levels ; brain natriuretic peptide ; bNP ; creatinine ; natremia
P-585	-2.1553 -0.0565 -0.3203 -0.8642 -0.4843 -0.1006 -0.5358 -0.3874 -0.0122 -0.2664 -0.0271 -0.4019 -0.0187 -0.4885 -1.6964 -0.4782 -1.0021 -0.4984 -0.3944 -0.0886 -0.0989 -0.3229 -0.0329 -0.3161 -0.8085 -0.5326 -0.2729
S-868	(MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy; NCT00180271).<unk>
T-868	madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-868	-0.5554414391517639	▁bem - c RT ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy ▁; ▁N CT 001 80 2 71)
D-868	-0.5554414391517639	bem-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy ; NCT00180271)
P-868	-3.3250 -0.1168 -1.8678 -1.2964 -0.3603 -0.2999 -0.0131 -0.3747 -0.0060 -1.1093 -0.7355 -0.3337 -0.3035 -0.1300 -0.2130 -0.2924 -0.3870 -0.0424 -0.4923 -0.0625 -0.0121 -0.4055 -0.4471 -0.5550 -1.7221 -0.3295 -0.9158 -0.1416 -0.0560 -0.9118 -0.4179 -0.0984
S-17	The latter correlated inversely to baseline NT-proBNP, MR-proANP, and MR-proADM (p<0.05).<unk>
T-17	correlated ; baseline ; nt-probnp ; mr-proanp ; mr-proadm
H-17	-0.4559260308742523	▁base line ▁; ▁NT - pro b NP ▁; ▁MR - pro an p ▁; ▁MR - pro ad m
D-17	-0.4559260308742523	baseline ; NT-probNP ; MR-proanp ; MR-proadm
P-17	-0.0149 -0.0559 -0.8337 -0.6756 -0.0634 -0.0177 -0.9245 -0.3288 -0.1224 -0.0879 -0.0547 -0.0286 -2.4520 -0.1881 -0.1742 -0.1726 -0.0773 -0.0870 -3.0073 -0.0506 -0.3071 -0.3057
S-1430	Isoelectric focusing of RIα demonstrated up to three variants, consistent with reports that Ser77 and Ser83 are in vivo phosphorylation sites.<unk>
T-1430	isoelectric focusing ; riα ; ser77 ; ser83 ; in vivo ; phosphorylation
H-1430	-0.5599490404129028	▁iso electric ▁focus ing ▁; ▁RI α ▁; ▁ser 77 ▁; ▁ser 83 ▁; ▁vivo ▁ phos phor y lation ▁sites
D-1430	-0.5599490404129028	isoelectric focusing ; RIα ; ser77 ; ser83 ; vivo phosphorylation sites
P-1430	-0.6023 -1.0062 -2.0156 -0.0747 -0.3875 -0.5597 -1.2734 -0.2282 -0.3267 -0.1188 -0.1525 -0.1104 -0.5489 -0.3347 -0.1369 -0.3658 -0.0869 -1.0312 -1.0473 -1.4676 -0.3456 -0.4641 -0.1938
S-1440	The ratio of the SDQT to SD of RR intervals (SDRR) was calculated as an index of QTV normalized to heart rate variability.<unk>
T-1440	sdqt ; sd of rr intervals ; sdrr ; qtv ; heart rate variability
H-1440	-0.9989383220672607	▁ratio ▁; ▁SD QT ▁; ▁SD ▁; ▁ RR ▁interval s ▁; SD r ▁; ▁Q TV ▁; ▁heart ▁rate ▁variabil ity
D-1440	-0.9989383220672607	ratio ; SDQT ; SD ; RR intervals ;SDr ; QTV ; heart rate variability
P-1440	-2.0599 -0.2142 -0.1147 -1.0731 -0.1503 -0.2024 -1.0295 -0.2871 -2.2978 -1.2267 -0.0560 -0.1941 -1.2658 -2.8555 -0.2423 -3.9286 -2.2186 -0.1270 -2.4771 -0.0947 -0.6550 -0.1333 -0.6279 -0.4429
S-486	AUCs of E/eseptal and E/emean did not vary with s'septal, QRS width, or resynchronization.<unk>
T-486	aucs ; septal ; qrs ; resynchronization
H-486	-1.1070215702056885	▁a UC s ▁; ▁e / e sept al ▁; ▁e / eme an ▁; ▁s ' sept al ▁; ▁QR s
D-486	-1.1070215702056885	aUCs ; e/eseptal ; e/emean ; s'septal ; QRs
P-486	-2.8044 -1.6518 -0.2158 -0.3773 -0.7441 -4.0666 -0.1983 -0.6692 -0.0609 -0.1259 -0.6822 -4.5569 -0.0089 -0.1274 -0.3349 -0.5414 -4.7211 -0.3777 -0.0794 -0.4604 -0.3192 -1.6803 -1.3117 -0.4528
S-973	Logistic regression models were used to estimate the risk for the primary outcome and the secondary outcome of death from any cause, while adjusting for confounders.<unk>
T-973	logistic regression ; primary outcome ; secondary outcome ; death
H-973	-0.4320189654827118	▁Log istic ▁re gression ▁models ▁; ▁seconda ry ▁outcome ▁; ▁death ▁; ▁con found ers
D-973	-0.4320189654827118	Logistic regression models ; secondary outcome ; death ; confounders
P-973	-0.4269 -0.0336 -0.0873 -0.0123 -0.4089 -0.4122 -1.2789 -0.0274 -0.0516 -1.0537 -1.3733 -1.3177 -0.4083 -0.0508 -0.0436 -0.1743 -0.1837
S-326	RESULTS: During IVC occlusion, CO correlated with twist, apical rotation, RS, RS synchrony, and CS (P < 0.05).<unk>
T-326	ivc occlusion ; correlated ; rs ; rs synchrony
H-326	-0.3230699896812439	▁IV c ▁oc clusi on ▁; ▁co ▁cor related ▁; ▁twist ▁; ▁ap ical ▁ro tation ▁; ▁RS ▁; ▁synchron y
D-326	-0.3230699896812439	IVc occlusion ; co correlated ; twist ; apical rotation ; RS ; synchrony
P-326	-0.0878 -1.6457 -0.0030 -0.1252 -0.2434 -0.2724 -0.9732 -0.3484 -0.0823 -0.1899 -0.0033 -0.2581 -0.0908 -0.0161 -0.0214 -0.0230 -0.3088 -0.0226 -0.6581 -0.8048 -0.0941 -0.9368 -0.2214
S-1574	OBJECTIVE: To decrease the 30-day readmission rate following hospital stay for congestive heart failure, which in the United States approaches 30 percent nationally.<unk>
T-1574	readmission ; hospital ; congestive heart failure ; united states
H-1574	-0.6957067251205444	▁read mission ▁rate ▁; ▁hospital ▁; ▁con ges tive ▁heart ▁failure
D-1574	-0.6957067251205444	readmission rate ; hospital ; congestive heart failure
P-1574	-3.9293 -0.1063 -0.0226 -0.1822 -0.3222 -1.4795 -0.0360 -0.1040 -0.0562 -0.5731 -0.0949 -1.9361 -0.2018
S-1200	Despite their widespread use, prospective data on the potential of diuretics to modulate HF-related morbidity and mortality are scarce.<unk>
T-1200	prospective ; diuretics ; morbidity ; mortality
H-1200	-0.4237573444843292	▁di ure tics ▁; ▁ HF - related ▁morbi d ity
D-1200	-0.4237573444843292	diuretics ; HF-related morbidity
P-1200	-0.1965 -0.0714 -1.0341 -0.2139 -0.4916 -0.0849 -0.2577 -0.0294 -0.4070 -0.2648 -0.1688 -2.1108 -0.1780
S-731	CONCLUSIONS: Our hospital's 30-day readmission rate for patients with heart failure decreased in parallel with an increase in 7-day follow-up visits.<unk>
T-731	hospital ; readmission ; patients ; heart failure ; follow-up
H-731	-1.0361238718032837	▁hospital ▁; ▁read mission ▁rate ▁; ▁heart ▁failure
D-731	-1.0361238718032837	hospital ; readmission rate ; heart failure
P-731	-2.8058 -0.1877 -4.1431 -0.1074 -0.0225 -0.1448 -1.6046 -0.0745 -1.1036 -0.1671
S-1658	As the use of these devices has grown, health care providers have been faced with managing clinically significant gastrointestinal bleeding in this population.<unk>
T-1658	health care ; clinically ; gastrointestinal bleeding
H-1658	-0.8864272236824036	▁devices ▁; ▁gastro inte stin al ▁ble ed ing
D-1658	-0.8864272236824036	devices ; gastrointestinal bleeding
P-1658	-4.1125 -0.2734 -1.6383 -0.4793 -0.7900 -0.0860 -0.6584 -0.5413 -0.2632 -0.7376 -0.1707
S-740	Patients with T1 times below the median (<388.3 ms) were at greater risk of cardiac events than the rest of the group (P<0.01).<unk>
T-740	patients ; t1 times ; cardiac events
H-740	-0.5928713083267212	▁cardiac ▁events
D-740	-0.5928713083267212	cardiac events
P-740	-1.2601 -0.4833 -0.4090 -0.2191
S-1391	There was a steady improvement in eGFR in the VAD group and the ECMO+VAD group until day 7 after which there was a decline in renal function.<unk>
T-1391	egfr ; vad ; ecmo ; vad ; renal function
H-1391	-0.5848376154899597	▁e g f ▁; ▁ VAD ▁group ▁; ▁ec mo + VAD ▁group ▁; ▁renal ▁function
D-1391	-0.5848376154899597	egf ; VAD group ; ecmo+VAD group ; renal function
P-1391	-0.1467 -0.2707 -1.6036 -0.1073 -0.4112 -0.0417 -0.3723 -0.1682 -0.3785 -1.1547 -3.2488 -0.1811 -0.4294 -0.3593 -0.2337 -0.9534 -0.2734 -0.1932
S-406	Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events).<unk>
T-406	sst2 ; sst2 ; outcomes
H-406	-0.7964715957641602	▁s st 2/ low - dos e ▁BB ▁; ▁s st 2/ high - dos e ▁BB
D-406	-0.7964715957641602	sst2/low-dose BB ; sst2/high-dose BB
P-406	-0.0199 -2.1809 -0.7082 -0.8848 -0.0575 -1.4113 -0.1427 -0.8854 -0.3469 -0.1274 -2.4161 -0.7847 -1.4443 -0.0999 -1.7408 -0.0787 -0.9602 -0.5625 -0.2806
S-214	For each year of the study, we determined CHF visit rates (as a percentage of total ED visits) and calculated the percentage of CHF patients intubated.<unk>
T-214	chf ; chf ; patients ; intubated
H-214	-0.8648619651794434	▁CHF ▁visit ▁rates ▁; ▁ED ▁visit s ▁; ▁CHF ▁patients ▁in tuba ted
D-214	-0.8648619651794434	CHF visit rates ; ED visits ; CHF patients intubated
P-214	-0.3305 -3.1860 -1.6755 -0.1673 -2.0254 -1.6859 -0.1645 -0.3349 -0.5460 -1.9900 -0.1489 -0.0065 -0.0772 -0.4604 -0.1741
S-1731	CONCLUSIONS: Physician volume is associated with lower mortality for HF, particularly in low-volume institutions and among noncardiologist physicians.<unk>
T-1731	physician ; mortality ; hf ; physicians
H-1731	-0.5992075800895691	▁physical ▁volume ▁; ▁mortal ity ▁; ▁ HF ▁; ▁non car dio logist
D-1731	-0.5992075800895691	physical volume ; mortality ; HF ; noncardiologist
P-1731	-0.3884 -1.1225 -0.1765 -2.3316 -0.0613 -0.2013 -0.4541 -0.0488 -0.3493 -0.1580 -0.5261 -0.8052 -0.3136 -1.9128 -0.1387
S-100	Validation studies in the complementary model system of zebrafish examine the role of Nucleolin to orchestrate genomic reprogramming events shared between development and disease.<unk>
T-100	nucleolin ; genomic reprogramming ; disease
H-100	-0.35617759823799133	▁zebra fish ▁; ▁Nu cle olin ▁; ▁genom ic ▁re programm ing ▁events ▁; ▁disease
D-100	-0.35617759823799133	zebrafish ; Nucleolin ; genomic reprogramming events ; disease
P-100	-0.4876 -0.0466 -0.1402 -0.7436 -0.0151 -0.1626 -0.3202 -0.1249 -0.0346 -0.0541 -0.1863 -0.0775 -1.1501 -0.7801 -1.4390 -0.1449 -0.1476
S-483	Mean age was 56 ± 11 years and mean LV ejection fraction was 28 ± 8%; 48% had PCWP of >15 mm Hg.<unk>
T-483	lv ejection fraction ; pcwp
H-483	-0.5356782078742981	▁LV ▁e je ction ▁ fraction ▁; ▁PC WP
D-483	-0.5356782078742981	LV ejection fraction ; PCWP
P-483	-0.6438 -0.5271 -0.1500 -0.1062 -1.5370 -0.0232 -0.1755 -1.0541 -0.6228 -0.8825 -0.1703
S-1314	CONCLUSIONS: Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high mortality.<unk>
T-1314	incidence ; hf ; ami ; mortality
H-1314	-0.41093212366104126	▁ HF ▁; ▁ AMI ▁; ▁high ▁mortal ity
D-1314	-0.41093212366104126	HF ; AMI ; high mortality
P-1314	-1.6007 -0.2149 -0.1858 -0.7682 -0.2904 -0.3503 -0.4905 -0.2148 -0.0306 -0.1921 -0.1818
S-56	Comments on "the role of the emergency department in acute heart failure clinical trials-Enriching patient identification and enrollment" by Collins et al.<unk>
T-56	emergency department ; acute heart failure ; clinical ; patient ; collins
H-56	-0.6887167096138	▁emergency ▁department ▁; ▁a cute ▁heart ▁failure ▁; ▁trial s
D-56	-0.6887167096138	emergency department ; acute heart failure ; trials
P-56	-0.6350 -0.0145 -0.0630 -0.0280 -0.0168 -1.8764 -0.0948 -0.7133 -1.3423 -0.0712 -3.1946 -0.2148
S-1915	A cardiopulmonary exercise test, a quality of life score and an evaluation of the muscular strength by measuring the peak quadriceps force was performed.<unk>
T-1915	cardiopulmonary exercise test ; quality of life ; muscular ; peak quadriceps force
H-1915	-0.6762539148330688	▁cardio pul mon ary ▁exercise ▁test ▁; ▁quality ▁of ▁life ▁score ▁; ▁muscular ▁strength ▁; ▁pe ak ▁quadri cep s ▁force
D-1915	-0.6762539148330688	cardiopulmonary exercise test ; quality of life score ; muscular strength ; peak quadriceps force
P-1915	-0.1489 -0.6024 -1.3817 -0.2813 -1.8311 -2.2321 -0.2200 -4.3502 -0.0166 -0.0511 -1.5009 -0.1125 -0.3236 -0.6698 -0.1342 -0.0141 -0.0391 -0.5648 -0.2936 -0.0457 -0.1253 -0.3312 -0.2837
S-1808	Physicians and professionals in public health should be aware that the air pollution experienced in most urban and industrial areas can aggravate cardiovascular health and lead to hospitalisation and death.<unk>
T-1808	physicians ; public ; health ; air ; cardiovascular ; health ; lead ; hospitalisation ; death
H-1808	-0.5311985015869141	▁public ▁health ▁; ▁air ▁pollution ▁; ▁industrial ▁areas ▁; ▁cardiovascular ▁health ▁; ▁hospital isation ▁; ▁death
D-1808	-0.5311985015869141	public health ; air pollution ; industrial areas ; cardiovascular health ; hospitalisation ; death
P-1808	-0.1191 -0.4908 -0.1657 -0.0585 -0.3752 -0.1743 -1.7867 -0.3697 -0.4409 -1.6987 -0.3702 -0.3992 -0.6507 -0.0281 -1.2381 -0.6027 -0.2992 -0.2938
S-1909	The ECG has the ability to detect congenital accessory pathways and ion channelopathies, and is frequently abnormal in individuals with cardiomyopathy.<unk>
T-1909	ecg ; congenital ; accessory ; ion channelopathies ; cardiomyopathy
H-1909	-0.55527263879776	▁ec g ▁; ▁con geni tal ▁accesso ry ▁path ways ▁; ▁ion ▁channel o pathi es ▁; ▁cardio my o pathy
D-1909	-0.55527263879776	ecg ; congenital accessory pathways ; ion channelopathies ; cardiomyopathy
P-1909	-0.8469 -0.8035 -0.3227 -3.8286 -0.0774 -0.1732 -0.6124 -0.0245 -0.0939 -0.0398 -0.1843 -0.4815 -0.3078 -1.6764 -0.0529 -0.2758 -0.2512 -0.4721 -1.3515 -0.1907 -0.2159 -0.2696 -0.2188
S-1739	Improving survival rates of patients with idiopathic dilated cardiomyopathy in Tuscany over 3 decades: impact of evidence-based management.<unk>
T-1739	patients ; idiopathic dilated cardiomyopathy ; tuscany ; evidence-based
H-1739	-0.5206132531166077	▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁Tu sca ny
D-1739	-0.5206132531166077	idiopathic dilated cardiomyopathy ; Tuscany
P-1739	-1.1604 -0.0295 -0.3564 -0.4421 -0.5740 -0.1151 -0.3978 -2.3714 -0.4291 -0.2331 -0.3277 -0.7899 -0.0062 -0.1289 -0.8405 -0.1276
S-1140	In conscious HF rats, pyridostigmine reduced the basal heart rate, increased vagal, and reduced sympathetic control of heart rate.<unk>
T-1140	hf ; pyridostigmine ; basal heart rate ; sympathetic control of heart rate
H-1140	-0.3446524143218994	▁ HF ▁rat s ▁; ▁py rido stig mine ▁; ▁bas al ▁heart ▁rate ▁; ▁va gal ▁; ▁sympa the tic ▁control ▁; ▁heart ▁rate
D-1140	-0.3446524143218994	HF rats ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
P-1140	-0.8190 -1.2624 -0.2675 -0.0631 -0.1775 -0.0498 -0.0167 -0.0009 -0.0837 -0.0926 -0.0144 -0.0504 -1.6043 -0.0408 -0.2299 -0.0064 -0.0069 -0.3795 -0.1467 -0.8382 -0.0373 -0.4384 -0.6966 -1.1616 -0.0620 -0.4910 -0.2680
S-1301	Morbidity and mortality in HFpEF are similar to values observed in patients with HF and reduced EF, yet no effective treatment has been identified.<unk>
T-1301	morbidity ; mortality ; hfpef ; patients ; hf ; reduced ef
H-1301	-0.30719447135925293	▁Morbi d ity ▁; ▁mortal ity ▁; ▁ HF p EF ▁; ▁ HF ▁; ▁EF
D-1301	-0.30719447135925293	Morbidity ; mortality ; HFpEF ; HF ; EF
P-1301	-0.0596 -0.1790 -0.0689 -0.6666 -0.0183 -0.0270 -0.2189 -0.6232 -0.1176 -0.0568 -0.2009 -0.2511 -0.9882 -0.2011 -0.1917 -0.6563 -0.8323 -0.1720
S-1244	HF (heart failure) and T2D (Type 2 diabetes) associate with detrimental alterations in SkM (skeletal muscle) structure/function.<unk>
T-1244	hf ; heart failure ; t2d ; type 2 diabetes ; skm ; skeletal muscle
H-1244	-0.29871106147766113	HF ▁; heart ▁failure ▁; ▁t 2 d ▁; ▁type ▁2 ▁diabetes ▁; ▁Sk m ▁; s kelet al ▁muscle
D-1244	-0.29871106147766113	HF ;heart failure ; t2d ; type 2 diabetes ; Skm ;skeletal muscle
P-1244	-0.2827 -0.4015 -0.2974 -0.0186 -0.1773 -0.1276 -0.0475 -0.4218 -0.1119 -1.3696 -0.3252 -0.0541 -0.3674 -0.0953 -0.1077 -0.1939 -1.3770 -0.0432 -0.0515 -0.1941 -0.3336 -0.1730
S-378	BACKGROUND: Most heart failure (HF) risk stratification models were developed for inpatient use, and available outpatient models use a complex set of variables.<unk>
T-378	heart failure ; hf ; risk stratification ; inpatient ; outpatient
H-378	-0.6557126641273499	▁heart ▁failure ▁; HF ▁; ▁in patient ▁; ▁out patient ▁models
D-378	-0.6557126641273499	heart failure ;HF ; inpatient ; outpatient models
P-378	-0.6084 -0.1045 -0.3469 -0.0966 -0.7199 -4.7377 -0.0703 -0.6932 -0.0248 -0.0428 -0.5744 -0.3041 -0.2008
S-1474	Accumulating evidence shows that molecular biomarkers provide a window into the pathophysiology of chronic HF and therefore have important therapeutic implications.<unk>
T-1474	evidence ; biomarkers ; pathophysiology ; chronic hf ; therapeutic
H-1474	-0.41558486223220825	▁molecular ▁bio mark ers ▁; ▁pat ho phy si ology ▁; ▁chronic ▁ HF
D-1474	-0.41558486223220825	molecular biomarkers ; pathophysiology ; chronic HF
P-1474	-1.3547 -0.3358 -0.0875 -0.1430 -0.1324 -1.0172 -0.4804 -0.1556 -1.4923 -0.0388 -0.1762 -0.1031 -0.1303 -0.0809 -0.7535 -0.1674
S-857	BACKGROUND: The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated.<unk>
T-857	carvedilol ; metoprolol ; therapy ; heart failure ; patients
H-857	-0.5299694538116455	▁car vedi lol ▁; ▁met o pro lol ▁; ▁heart ▁failure ▁; ▁devices
D-857	-0.5299694538116455	carvedilol ; metoprolol ; heart failure ; devices
P-857	-1.0700 -0.0897 -0.2704 -0.4035 -0.1445 -0.1880 -0.0848 -0.3508 -0.5493 -1.8221 -0.0667 -2.3714 -0.0883 -0.1905 -0.2595
S-52	Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms.<unk>
T-52	erythropoiesis-stimulating agents ; patients ; anemia ; heart disease
H-52	-0.4443359673023224	▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁heart ▁disease
D-52	-0.4443359673023224	erythropoiesis-stimulating agents ; anemia ; heart disease
P-52	-0.2253 -0.1137 -0.6685 -0.1838 -2.4779 -0.4134 -0.5520 -0.0259 -0.1839 -0.2149 -0.2582 -0.2077 -0.1427 -0.1697 -0.4147 -1.2440 -0.2633 -0.2383
S-46	Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure.<unk>
T-46	evidence ; intravenous ; exercise tolerance ; quality of life ; patients ; heart failure
H-46	-0.5267173051834106	▁intra ven ous ▁ir on ▁; ▁exercise ▁ tolerance ▁; ▁heart ▁failure
D-46	-0.5267173051834106	intravenous iron ; exercise tolerance ; heart failure
P-46	-2.3342 -0.0273 -0.3316 -0.0669 -0.0626 -0.2011 -0.7053 -0.1388 -0.0076 -0.2395 -2.6715 -0.0894 -0.3232 -0.1752
S-335	We report the case of a 57-year-old man who had a history of successful mitral valve plasty for degenerative mitral regurgitation.<unk>
T-335	report ; mitral valve plasty ; degenerative mitral regurgitation
H-335	-0.29742762446403503	▁report ▁; ▁mit ral ▁val ve ▁plast y ▁; ▁de genera tive ▁mit ral ▁re gur gi tation
D-335	-0.29742762446403503	report ; mitral valve plasty ; degenerative mitral regurgitation
P-335	-0.0074 -0.0870 -1.5965 -0.1244 -0.9781 -0.1357 -0.0634 -0.3448 -0.1645 -0.4152 -0.0135 -0.0375 -0.3800 -0.4841 -0.0201 -0.0476 -0.2947 -0.0518 -0.5186 -0.1836
S-1235	In-trial resource utilization and unit costs were estimated from Québec Health Insurance Board databases supplemented by disease-specific costs from the Ontario Case Costing Initiative.<unk>
T-1235	costs ; québec health insurance board ; costs ; ontario case costing initiative
H-1235	-0.7002512216567993	▁in - t rial ▁resource ▁; ▁unit ▁costs ▁; ▁Québec ▁; ▁health ▁insurance ▁board ▁; ▁costs ▁; ▁Ontario ▁case ▁cost ing ▁Initiative
D-1235	-0.7002512216567993	in-trial resource ; unit costs ; Québec ; health insurance board ; costs ; Ontario case costing Initiative
P-1235	-1.0938 -0.5967 -0.1845 -0.0537 -0.5636 -0.8117 -0.2135 -0.1088 -0.2714 -0.5571 -2.5237 -0.3854 -0.8285 -0.1650 -0.3230 -1.6071 -0.2566 -1.5606 -1.1313 -0.9616 -0.0609 -1.6605 -0.6599 -0.2271
S-1045	Similar results were achieved through knockdown of the BET bromodomain-containing protein 4 (BRD4), which is highly expressed in cardiac tissues.<unk>
T-1045	bet ; bromodomain-containing protein 4 ; brd4 ; cardiac
H-1045	-0.578865110874176	▁ BET ▁; ▁bro modo main - conta ining ▁protein ▁4 ▁; BR d 4 ▁; ▁cardiac ▁tissu es
D-1045	-0.578865110874176	BET ; bromodomain-containing protein 4 ;BRd4 ; cardiac tissues
P-1045	-2.6100 -0.2547 -1.5187 -0.2723 -0.1100 -0.1634 -1.2174 -0.5831 -0.1371 -0.1954 -0.4760 -0.3747 -0.3021 -0.8468 -0.8712 -0.4751 -0.0973 -0.7639 -0.3694 -0.2890 -0.2283
S-1971	Dual RAS and neprilysin inhibition might thus after long time become a change in stable chronic heart failure with systolic dysfunction treatment "paradigm".<unk>
T-1971	ras ; neprilysin inhibition ; change ; stable ; chronic heart failure ; systolic dysfunction
H-1971	-0.5502269864082336	▁ RAS ▁; ▁nepri ly sin ▁inhibi tion ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function
D-1971	-0.5502269864082336	RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction
P-1971	-1.5464 -0.0263 -0.2698 -0.2019 -0.1138 -0.2073 -0.1618 -0.0756 -0.4128 -1.6855 -1.1116 -0.1188 -0.1577 -0.3620 -0.1117 -1.4848 -0.3667 -0.5918 -1.7529 -0.2451
S-724	We quantified the change in 30-day readmission rate after the initiative, frequency of 7-day follow-up visits, and events at follow-up visits.<unk>
T-724	change ; readmission ; follow-up ; follow-up
H-724	-0.6088030338287354	▁read mission ▁rate ▁; ▁follow - up
D-724	-0.6088030338287354	readmission rate ; follow-up
P-724	-2.1011 -0.2699 -0.0644 -0.6054 -0.0707 -0.1827 -0.0304 -1.9466 -0.2080
S-1386	METHODS: We performed a single center retrospective observational study in children with end-stage heart failure supported on pediatric mechanical cardiac support.<unk>
T-1386	end-stage heart failure ; mechanical cardiac support
H-1386	-0.7378191351890564	▁end - s tage ▁heart ▁failure ▁; ▁pediatr ic ▁mechanic al ▁cardiac
D-1386	-0.7378191351890564	end-stage heart failure ; pediatric mechanical cardiac
P-1386	-4.9302 -0.0592 -0.0218 -0.0078 -1.1375 -0.0866 -0.4004 -0.5004 -0.0489 -0.0158 -0.0264 -0.2610 -2.6207 -0.2125
S-317	However, evidence gaps, limitations in economic models, and the lack of Canadian data point to the importance of mandatory, systematic monitoring of LVAD use and outcomes.<unk>
T-317	evidence ; economic ; lvad ; outcomes
H-317	-0.8507567048072815	▁economic ▁models ▁; ▁l VAD ▁; ▁outcome s
D-317	-0.8507567048072815	economic models ; lVAD ; outcomes
P-317	-0.0660 -0.2736 -0.1590 -3.8382 -0.2051 -1.5880 -1.9313 -0.0484 -0.2427 -0.1552
S-428	We hypothesized that combining parameters would be more robust and sought to develop a multiparametric echocardiographic score for predicting CRT response.<unk>
T-428	echocardiographic ; crt
H-428	-1.014455795288086	▁e cho car dio graphic ▁score ▁; ▁c RT ▁response
D-428	-1.014455795288086	echocardiographic score ; cRT response
P-428	-1.1730 -1.1770 -1.1864 -1.1121 -0.7024 -1.7143 -0.1342 -0.3397 -3.1312 -0.9169 -0.2596 -0.3268
S-909	Heterogenous improvement in ejection fraction (+3.1 ± 9.2%) was noted and 2 patients derived absolute improvements of 8% and 22%, respectively.<unk>
T-909	ejection fraction ; patients
H-909	-0.7502316236495972	▁e je ction ▁ fraction
D-909	-0.7502316236495972	ejection fraction
P-909	-1.6114 -0.3702 -0.2747 -0.6029 -0.0071 -2.1964 -0.1889
S-953	However, the current study was a single-arm analysis; therefore, larger randomized control studies are needed to verify the benefit of AF ablation in this cohort.<unk>
T-953	randomized ; af ablation
H-953	-0.6283185482025146	▁AF ▁ab lation
D-953	-0.6283185482025146	AF ablation
P-953	-1.7400 -0.0382 -0.4330 -0.6311 -0.2994
S-1170	Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.<unk>
T-1170	if-channel inhibition ; hemodynamic ; exercise tolerance ; heart failure with preserved ejection fraction ; randomized
H-1170	-0.3816349506378174	▁If - chan nel ▁inhibi tion ▁; ▁hem o dynamic ▁status ▁; ▁exercise ▁ tolerance ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-1170	-0.3816349506378174	If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; preserved ejection fraction
P-1170	-4.5050 -0.0992 -0.0081 -0.5922 -0.4533 -0.1879 -0.7436 -0.5763 -0.3288 -0.0149 -0.1212 -0.1766 -0.0498 -0.0971 -0.0051 -0.2810 -0.0943 -0.0677 -0.2773 -0.0510 -0.2304 -0.4099 -0.0571 -0.2404 -0.1654 -0.5566 -0.0150 -0.4678 -0.1944
S-1058	A T1-mapping sequence was performed during tidal respiration before and 5 minutes after the administration of a gadolinium-chelate contrast agent.<unk>
T-1058	t1-mapping ; tidal respiration ; administration ; gadolinium-chelate contrast agent
H-1058	-0.42750871181488037	▁t 1- ma pping ▁se que nce ▁; ▁tid al ▁respira tion ▁; ▁ gado lini um - che late ▁contrast ▁agent
D-1058	-0.42750871181488037	t1-mapping sequence ; tidal respiration ; gadolinium-chelate contrast agent
P-1058	-0.2798 -0.0630 -0.1271 -0.0364 -0.1835 -0.1293 -0.6074 -0.3898 -0.0971 -0.0450 -0.3618 -0.0684 -0.2177 -1.2696 -0.0477 -0.6543 -0.0988 -0.1883 -0.0561 -2.8807 -0.9026 -0.6463 -0.6627 -0.2464
S-1777	Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.<unk>
T-1777	cardiac ; insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
H-1777	-0.29771459102630615	▁Card iac ▁insulin - re si stance ▁; ▁mito cho ndri al ▁energy ▁production ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁pressure - over load ▁hyper trop hy
D-1777	-0.29771459102630615	Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
P-1777	-0.3573 -0.0481 -0.2330 -0.1015 -0.1173 -0.7572 -0.0054 -0.0910 -0.0889 -1.6609 -0.4278 -0.0348 -0.0354 -0.0681 -0.1492 -0.3131 -0.0318 -0.5817 -1.0935 -0.1403 -0.2637 -0.0099 -0.1698 -0.0760 -0.1568 -0.3056 -0.0088 -0.9392 -0.4556 -0.2099
S-1723	METHODS AND RESULTS: We used Medicare inpatient data in 2009 to examine all HF admissions to acute care hospitals in the United States.<unk>
T-1723	medicare ; inpatient ; hf ; admissions ; acute ; hospitals ; united states
H-1723	-0.38782384991645813	▁Medica re ▁in patient ▁data ▁; ▁ HF ▁ad missions ▁; ▁a cute ▁care ▁hospital s
D-1723	-0.38782384991645813	Medicare inpatient data ; HF admissions ; acute care hospitals
P-1723	-0.1374 -0.0620 -0.2972 -0.0410 -0.9493 -0.1329 -0.6931 -0.2722 -0.0319 -0.0110 -0.2440 -0.0346 -0.1386 -1.1651 -0.4751 -0.0850 -1.9804 -0.2299
S-941	Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.<unk>
T-941	outcomes ; catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction
H-941	-0.39868003129959106	▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-941	-0.39868003129959106	catheter ablation ; atrial fibrillation ; heart failure ; preserved ejection fraction
P-941	-2.3761 -0.0800 -0.0300 -0.1828 -0.7459 -0.0890 -0.3833 -1.1750 -0.0985 -0.3476 -0.1971 -0.3805 -0.0708 -0.3217 -0.1655 -0.1938 -0.3791 -0.0921 -0.4102 -0.2592 -0.6355 -0.0093 -0.6674 -0.2779
S-71	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.<unk>
T-71	dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; rose ; acute heart failure ; randomized
H-71	-0.38924527168273926	▁low - dos e ▁dop amine ▁; ▁low - dos e ▁nesi riti de ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁RO SE ▁a cute ▁heart ▁failure
D-71	-0.38924527168273926	low-dose dopamine ; low-dose nesiritide ; acute heart failure ; renal dysfunction ; ROSE acute heart failure
P-71	-0.3907 -0.0732 -1.0240 -0.1750 -0.0262 -0.2050 -0.0735 -0.1511 -0.0174 -0.3941 -0.0376 -0.1854 -0.0694 -0.5943 -0.2223 -0.0115 -0.0131 -0.7374 -0.0654 -0.2145 -0.0313 -0.2078 -0.6715 -0.4541 -1.6992 -1.7592 -0.2625 -0.0620 -1.6309 -0.0898 -0.7459 -0.1607
S-1253	We report severe perturbations in components of the DAPC (dystrophin-associated protein complex) as well as sarcomeric microstructure at baseline.<unk>
T-1253	report ; dapc ; dystrophin-associated protein complex ; sarcomeric microstructure ; baseline
H-1253	-0.5238437056541443	▁report ▁; ▁DAP c ▁; dys trop hin - as soci ated ▁protein ▁complex ▁; ▁sar come ric ▁; ▁base line
D-1253	-0.5238437056541443	report ; DAPc ;dystrophin-associated protein complex ; sarcomeric ; baseline
P-1253	-0.4192 -0.1451 -0.1012 -1.8703 -0.1741 -0.2042 -0.4265 -1.1773 -0.1761 -0.1157 -0.0081 -0.3086 -0.2374 -0.1467 -0.3448 -0.2144 -1.1713 -2.1928 -1.9546 -0.0623 -0.0806 -0.3007 -0.2165
S-275	This study aimed to develop a novel mouse HF model of HHD by combining salt loading and uninephrectomy with ANG II infusion.<unk>
T-275	hf ; hhd ; salt loading ; uninephrectomy ; ang ii infusion
H-275	-0.4737832248210907	▁mouse ▁ HF ▁model ▁; ▁h h ▁; ▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ANG ▁II ▁in fusion
D-275	-0.4737832248210907	mouse HF model ; hh ; salt loading ; uninephrectomy ; ANG II infusion
P-275	-0.2716 -1.6290 -0.1312 -0.5147 -0.3282 -0.8540 -1.6679 -0.2176 -1.2103 -0.0067 -0.0520 -0.1694 -0.0810 -0.0534 -0.6726 -0.1392 -0.3905 -1.9172 -0.1292 -0.3288 -0.3088 -0.0197 -0.0441 -0.5042 -0.2033
S-176	Benefits in HF with preserved ejection fraction (pEF), as well as uptitration after a hospitalization, remain uncertain.<unk>
T-176	hf with preserved ejection fraction ; pef ; uptitration ; hospitalization
H-176	-0.4102325737476349	▁ HF ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁p EF ▁; ▁up tit ration ▁; ▁hospital ization
D-176	-0.4102325737476349	HF ; preserved ejection fraction ; pEF ; uptitration ; hospitalization
P-176	-1.5294 -0.4257 -0.1326 -0.8071 -0.1851 -0.2161 -0.1039 -0.7473 -0.3219 -0.4792 -0.0161 -0.2363 -0.7927 -0.4637 -0.4920 -0.0174 -0.7212 -0.0981 -0.5534 -0.1865 -0.4539 -0.2111 -0.2449
S-759	Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model.<unk>
T-759	myocardial ; titin hypophosphorylation ; heart failure with preserved ejection fraction ; metabolic
H-759	-0.3961901366710663	▁My o card ial ▁titi n ▁hypo phos phor y lation ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁rat ▁metabol ic ▁risk ▁model
D-759	-0.3961901366710663	Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat metabolic risk model
P-759	-1.1069 -0.0450 -0.1743 -0.0219 -0.4365 -0.0872 -1.1280 -0.3461 -1.3963 -1.0441 -0.6623 -0.1641 -0.2413 -0.0845 -0.1869 -0.2184 -0.0588 -0.0298 -0.4072 -0.0097 -0.2389 -0.0314 -0.2226 -0.0159 -0.8207 -1.0415 -0.6271 -0.2460
S-427	BACKGROUND: Studies of echocardiographic predictors of response after cardiac resynchronization therapy (CRT) have largely involved single parameters.<unk>
T-427	echocardiographic ; cardiac resynchronization therapy ; crt
H-427	-0.5062653422355652	▁e cho car dio graphic ▁predict ors ▁; ▁response ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-427	-0.5062653422355652	echocardiographic predictors ; response ; cardiac resynchronization therapy ; cRT
P-427	-0.0694 -0.2139 -1.3518 -2.3367 -0.3685 -0.7889 -0.1092 -0.3355 -0.0613 -0.7546 -0.0779 -0.0170 -0.0328 -0.0119 -0.3605 -0.7439 -0.0654 -0.3488 -0.7914 -1.8051 -0.3324 -0.1611
S-441	We excluded patients with baseline serum creatinine level of >2.5 mg/dl or a serum potassium level of >5.0 mEq/L.<unk>
T-441	patients ; baseline ; serum creatinine ; serum potassium
H-441	-0.5411292910575867	▁base line ▁se rum ▁creati nine ▁level ▁; ▁se rum ▁po tas s ium ▁level
D-441	-0.5411292910575867	baseline serum creatinine level ; serum potassium level
P-441	-0.0150 -0.0203 -0.8366 -0.4626 -1.4237 -0.4781 -1.0861 -0.2008 -0.0793 -0.2113 -0.3211 -0.2980 -0.5622 -1.1546 -0.7825 -1.1089 -0.1580
S-91	Little is known about the global changes in chromatin subproteomes that accompany heart failure, and the mechanisms by which these proteins alter chromatin structure.<unk>
T-91	chromatin subproteomes ; heart failure ; proteins ; chromatin structure
H-91	-0.6685706973075867	▁chr omat in ▁sub prote om es ▁; ▁heart ▁failure ▁; ▁mechanism s ▁; ▁protein s ▁; ▁chr omat in ▁structure
D-91	-0.6685706973075867	chromatin subproteomes ; heart failure ; mechanisms ; proteins ; chromatin structure
P-91	-2.3195 -0.0756 -1.2671 -0.8671 -0.1002 -1.1095 -0.9032 -0.2466 -0.3295 -0.1411 -0.3845 -0.5286 -0.0402 -0.3521 -3.2804 -0.0689 -0.5024 -0.4184 -0.0797 -0.9723 -0.7921 -0.3652 -0.2331
S-934	Hum-Retn mice showed increased cardiac mRNA levels of inflammatory and cell adhesion genes compared with Retn(-/-) mice.<unk>
T-934	cardiac mrna ; inflammatory ; cell adhesion genes ; retn
H-934	-0.4277667701244354	▁Hum - ▁re t n ▁mi ce ▁; ▁cardiac ▁m RNA ▁levels ▁; ▁infla mma tory ▁; ▁cell ▁a dhe sion ▁gene s ▁; ▁Ret n
D-934	-0.4277667701244354	Hum- retn mice ; cardiac mRNA levels ; inflammatory ; cell adhesion genes ; Retn
P-934	-0.0529 -0.2231 -1.9945 -0.2008 -0.0113 -0.1821 -0.1707 -0.2741 -0.2731 -0.0480 -0.0480 -0.2643 -0.3708 -0.4868 -0.8697 -0.0513 -0.4917 -1.4030 -0.1398 -0.0362 -0.0400 -0.9944 -0.1156 -0.5806 -0.0305 -0.0238 -2.2917 -0.3086
S-834	Anemia is common in patients with chronic heart failure (HF), with a prevalence ranging from 10% to 56%, and may be a risk factor for poor outcomes.<unk>
T-834	anemia ; patients ; chronic heart failure ; hf ; prevalence ; outcomes
H-834	-0.6173962354660034	▁an emia ▁; ▁chronic ▁heart ▁failure ▁; HF
D-834	-0.6173962354660034	anemia ; chronic heart failure ;HF
P-834	-0.2511 -0.0166 -0.3007 -0.9602 -1.9818 -0.1314 -0.4208 -0.0641 -1.8141 -0.2333
S-728	Eighty-one percent of 7-day visits occurred in the University of Connecticut Heart Failure Center with a cardiologist or heart failure nurse practitioner.<unk>
T-728	university of connecticut heart failure center ; heart failure ; nurse practitioner
H-728	-0.5580149292945862	▁university ▁of ▁connect i cut ▁Heart ▁Fail ure ▁center ▁; ▁cardio logist ▁; ▁heart ▁failure
D-728	-0.5580149292945862	university of connecticut Heart Failure center ; cardiologist ; heart failure
P-728	-0.8850 -0.0184 -2.4965 -0.0556 -0.4102 -1.3399 -0.7517 -0.0728 -1.1917 -0.1432 -0.0393 -0.1118 -0.0699 -0.3750 -0.0678 -1.2696 -0.1876
S-1519	The apparent circulating NT-proBNP concentration was increased with antibodies targeting nonglycosylated and nonterminal epitopes (P < 0.05).<unk>
T-1519	nt-probnp ; antibodies ; nonterminal epitopes
H-1519	-0.45798686146736145	▁NT - pro b NP ▁; ▁anti bo dies ▁; ▁non gly cos yla ted ▁; ▁non termin al ▁e pito pes
D-1519	-0.45798686146736145	NT-probNP ; antibodies ; nonglycosylated ; nonterminal epitopes
P-1519	-2.8215 -0.0736 -0.0295 -0.9074 -0.3905 -0.9674 -0.0152 -0.4614 -0.6357 -0.2895 -0.0152 -1.5422 -0.1179 -0.6682 -0.1025 -0.4208 -0.0643 -0.6842 -0.0047 -0.0602 -0.2028 -0.0593 -0.2629 -0.1948
S-1093	Thus, RV failure frequently requires diagnostic procedures and management strategies that differ from those routinely used in the management of intrinsic left ventricular dysfunction.<unk>
T-1093	rv failure ; diagnostic ; left ventricular dysfunction
H-1093	-0.8253278136253357	▁ RV ▁failure ▁; ▁management ▁strategie s ▁; ▁intr in sic ▁left ▁vent ri cular ▁dys function
D-1093	-0.8253278136253357	RV failure ; management strategies ; intrinsic left ventricular dysfunction
P-1093	-0.2838 -1.0420 -0.3405 -0.2932 -3.9878 -1.2687 -0.0639 -0.2132 -0.4598 -0.0609 -0.0080 -0.3087 -2.8437 -1.8614 -0.3697 -0.2183 -1.4396 -0.3775 -0.2407
S-899	After PD initiation, average weight loss was almost 7 kg (p = 0.016) with improvement in diuretic response, peripheral edema, and functional class.<unk>
T-899	pd ; diuretic ; peripheral edema ; functional class
H-899	-0.2932589650154114	▁PD ▁; ▁weight ▁loss ▁; ▁di ure tic ▁response ▁; ▁per i pher al ▁ed ema
D-899	-0.2932589650154114	PD ; weight loss ; diuretic response ; peripheral edema
P-899	-0.6625 -0.6591 -0.9171 -0.0691 -0.3754 -0.0377 -0.0421 -0.1659 -0.6713 -0.1926 -0.0029 -0.0948 -0.0094 -0.0365 -0.0328 -0.0045 -1.1777 -0.1271
S-1334	Chronic heart failure is associated with transforming growth factor beta-dependent yield and functional decline in atrial explant-derived c-Kit+ cells.<unk>
T-1334	chronic heart failure ; yield ; atrial ; cells
H-1334	-0.5734755992889404	▁Chro nic ▁heart ▁failure ▁; ▁transform ing ▁growth ▁factor ▁; ▁beta - dependent ▁yi eld ▁; ▁functional ▁decline ▁; ▁at rial ▁ex plant - der i ved ▁c - K it
D-1334	-0.5734755992889404	Chronic heart failure ; transforming growth factor ; beta-dependent yield ; functional decline ; atrial explant-derived c-Kit
P-1334	-0.0220 -0.0040 -1.3897 -0.0569 -0.1561 -0.0894 -0.0163 -0.4346 -0.0307 -0.6937 -3.1869 -0.0245 -0.2732 -0.0544 -0.0025 -0.1014 -4.2044 -1.1419 -0.2057 -0.2201 -0.0706 -0.4613 -0.0170 -0.1096 -0.1842 -0.2073 -0.3215 -0.0227 -0.0879 -2.0351 -0.4494 -2.4646 -0.1852
S-791	CONCLUSIONS: Among patients with HFpEF, the KCCQ seems to be a valid and reliable measure of health status and offers excellent prognostic ability.<unk>
T-791	patients ; hfpef ; kccq ; health ; prognostic
H-791	-0.6217838525772095	▁ HF p EF ▁; ▁k cc q ▁; ▁health ▁status ▁; ▁prognos tic
D-791	-0.6217838525772095	HFpEF ; kccq ; health status ; prognostic
P-791	-1.3142 -0.4954 -0.0407 -0.7552 -0.1269 -1.0363 -0.0423 -1.9111 -0.3811 -0.9026 -0.1824 -1.0561 -0.0966 -0.3095 -1.1055 -0.1927
S-298	METHODS: All patients who underwent HeartMate II LVAD alone or in conjunction with a temporary CentriMag RVAD were examined from 2006 to 2011.<unk>
T-298	patients ; heartmate ii ; lvad ; centrimag ; rvad
H-298	-0.9427785873413086	▁Heart Mate ▁II ▁l VAD ▁; ▁temporar y ▁centri Mag ▁R VAD
D-298	-0.9427785873413086	HeartMate II lVAD ; temporary centriMag RVAD
P-298	-1.1835 -0.1970 -0.9862 -2.5528 -0.1155 -0.1902 -2.0140 -0.0831 -0.5766 -0.4106 -4.3896 -0.0602 -0.2394 -0.2000
S-615	METHODOLOGY: A mixed-methods study was undertaken to assess the benefits of participation in a structured exercise programme for patients with heart failure.<unk>
T-615	mixed-methods study ; exercise ; patients ; heart failure
H-615	-1.3895494937896729	▁exercise ▁; ▁heart ▁failure
D-615	-1.3895494937896729	exercise ; heart failure
P-615	-4.1985 -1.7805 -1.7685 -0.0574 -0.2746 -0.2578
S-1100	Data describing trends in HF after MI are scarce and conflicting and do not distinguish between preserved and reduced ejection fraction (EF).<unk>
T-1100	hf ; mi ; reduced ejection fraction ; ef
H-1100	-0.6911200284957886	▁ HF ▁; ▁MI ▁; ▁pres er ved ▁; ▁e je ction ▁ fraction ▁; EF
D-1100	-0.6911200284957886	HF ; MI ; preserved ; ejection fraction ;EF
P-1100	-2.1625 -0.2565 -0.1873 -1.5746 -0.2714 -2.3198 -0.1097 -0.2999 -0.1993 -1.6828 -0.4847 -0.2429 -0.6638 -0.0233 -0.9030 -0.0784 -0.5984 -0.3818
S-1623	MEASUREMENTS: Mortality, inpatient admissions, hospital days, and emergency department (ED) visits during the 2-year study period were measured.<unk>
T-1623	mortality ; inpatient ; admissions ; hospital ; emergency department
H-1623	-0.33361557126045227	▁Mor t ality ▁; ▁in patient ▁ad missions ▁; ▁hospital ▁days ▁; ▁emergency ▁department ▁; ED
D-1623	-0.33361557126045227	Mortality ; inpatient admissions ; hospital days ; emergency department ;ED
P-1623	-1.0606 -0.1909 -0.0445 -0.3034 -0.3506 -0.2595 -0.0128 -0.0166 -0.2970 -0.3372 -0.7738 -0.2530 -0.1057 -0.0096 -0.4412 -0.9226 -0.4151 -0.2111
S-606	RESULTS: We compared 8656 new users of a nbDMARD with 11 587 new users of a TNF antagonist with similar baseline covariates.<unk>
T-606	nbdmard ; tnf antagonist ; baseline ; covariates
H-606	-0.5224255323410034	▁n b DM ARD ▁; ▁t NF ▁anta gon ist ▁; ▁base line
D-606	-0.5224255323410034	nbDMARD ; tNF antagonist ; baseline
P-606	-0.2171 -0.0226 -1.5209 -0.3421 -0.0940 -0.3731 -0.6359 -0.3385 -0.8449 -0.2913 -0.4912 -0.0011 -0.0623 -2.3362 -0.2651
S-670	The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF).<unk>
T-670	trastuzumab ; adjuvant ; outcomes ; cardiotoxicity ; congestive heart failure ; chf
H-670	-0.25230324268341064	▁tras tuz um ab ▁; ▁cardio toxic ity ▁; ▁con ges tive ▁heart ▁failure ▁; CH f
D-670	-0.25230324268341064	trastuzumab ; cardiotoxicity ; congestive heart failure ;CHf
P-670	-0.0814 -0.0228 -0.0234 -0.0231 -0.1001 -0.3338 -0.8972 -0.2055 -0.0943 -0.0157 -0.0643 -0.1418 -0.6668 -0.0832 -0.6439 -0.1859 -0.6080 -0.4005 -0.2022
S-1138	After 4 wk of pyridostigmine administration, per os, methylatropine and propranolol were used to evaluate the cardiac sympathovagal balance.<unk>
T-1138	pyridostigmine ; administration ; methylatropine ; propranolol ; cardiac ; sympathovagal balance
H-1138	-0.3284083306789398	▁py rido stig mine ▁administration ▁; ▁met hy la tropi ne ▁; ▁propra no lol ▁; ▁cardiac ▁sympa t hova gal ▁balance
D-1138	-0.3284083306789398	pyridostigmine administration ; methylatropine ; propranolol ; cardiac sympathovagal balance
P-1138	-0.1561 -0.0469 -0.0014 -0.1173 -0.8995 -0.1662 -0.3347 -0.7107 -1.0853 -0.0597 -0.6036 -0.2810 -0.0212 -0.0019 -0.0627 -0.4938 -0.0920 -0.7234 -0.8437 -0.0645 -0.1332 -0.0973 -0.6551 -0.2303
S-1084	UPR effectors, protein kinase R-like ER kinase (PERK), calreticulin, and CHOP, were increased in human HF tissues.<unk>
T-1084	upr ; protein kinase r-like er kinase ; perk ; calreticulin ; chop ; hf
H-1084	-0.48389631509780884	▁u PR ▁effect ors ▁; ▁protein ▁kina se ▁; ▁er ▁kina se ▁; per k ▁; ▁cal ret icul in ▁; ▁CHO p ▁; ▁ HF ▁tissu es
D-1084	-0.48389631509780884	uPR effectors ; protein kinase ; er kinase ;perk ; calreticulin ; CHOp ; HF tissues
P-1084	-0.0788 -0.2894 -0.6331 -0.0349 -0.3622 -0.1061 -0.0726 -0.4242 -0.7386 -3.4946 -0.2650 -0.1187 -0.3269 -0.4668 -0.7736 -0.1596 -0.0274 -0.0525 -0.0027 -0.5757 -0.3346 -1.0217 -0.1786 -0.4308 -0.7610 -0.4322 -1.6293 -0.1546 -0.3860 -0.1849
S-1427	As expected, total myosin binding protein-C phosphorylation and Ser23/24 troponin I phosphorylation significantly decreased in HF.<unk>
T-1427	myosin ; protein-c ; phosphorylation ; troponin i ; phosphorylation ; hf
H-1427	-0.5923354029655457	▁my os in ▁ binding ▁protein - C ▁ phos phor y lation ▁; ▁ser 23 /24 ▁trop onin ▁I ▁ phos phor y lation ▁; ▁ HF
D-1427	-0.5923354029655457	myosin binding protein-C phosphorylation ; ser23/24 troponin I phosphorylation ; HF
P-1427	-1.0311 -0.0235 -0.8214 -0.4096 -0.0018 -0.5921 -0.1829 -1.5530 -0.4317 -0.0743 -1.0114 -1.4362 -0.5820 -0.2291 -0.4370 -0.0921 -0.0209 -0.9693 -0.2340 -3.0724 -0.2090 -0.0757 -1.0270 -1.2682 -0.7725 -0.4013 -0.1980 -0.1158 -0.2647 -0.2321
S-1324	Echocardiographic measures, N-terminal pro-brain natriuretic peptide, and inflammatory markers were mostly unchanged.<unk>
T-1324	echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory
H-1324	-0.726992130279541	▁electro car dio graphic ▁measure s ▁; ▁N - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory
D-1324	-0.726992130279541	electrocardiographic measures ; N-terminal pro-brain natriuretic peptide ; inflammatory
P-1324	-4.0646 -2.9596 -1.4120 -0.7102 -0.8938 -0.0447 -0.1505 -1.4159 -0.0380 -0.0988 -0.0039 -0.0295 -0.0617 -0.1115 -0.2335 -0.0140 -0.2189 -0.0599 -0.3595 -0.0509 -0.4031 -1.4595 -0.3450 -0.0503 -0.5738 -0.1700 -4.1300 -0.2925
S-1207	Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes.<unk>
T-1207	phosphodiesterase-2 ; hearts ; beta-adrenergic responses ; cardiomyocytes
H-1207	-0.6386939287185669	▁Pho s pho dies tera se -2 ▁; ▁fail ing ▁heart s ▁; ▁blu nts ▁; ▁beta - ad r energi c ▁response s ▁; ▁cardio my o cy tes
D-1207	-0.6386939287185669	Phosphodiesterase-2 ; failing hearts ; blunts ; beta-adrenergic responses ; cardiomyocytes
P-1207	-0.2515 -0.2644 -2.2195 -1.6771 -0.1297 -1.8056 -0.2405 -0.4927 -2.2804 -0.0360 -0.7750 -0.0521 -0.2255 -0.3022 -0.0082 -1.0797 -0.5172 -0.0582 -0.7583 -0.8191 -1.9485 -0.6551 -0.5410 -0.1060 -0.4441 -0.0475 -0.8823 -0.2699 -0.1171 -0.4942 -0.5789 -0.3606
S-1120	Therefore, carvedilol may reduce the risk of thromboembolic events in patients with heart failure, irrespective of β2-receptor haplotype status.<unk>
T-1120	carvedilol ; thromboembolic events ; patients ; heart failure ; β2-receptor haplotype
H-1120	-0.5743202567100525	▁car vedi lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁heart ▁failure ▁; ▁β 2- recept or ▁ha plo type ▁status
D-1120	-0.5743202567100525	carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype status
P-1120	-0.3466 -0.0502 -0.4915 -0.3933 -0.3572 -0.1853 -2.4175 -1.1417 -0.2022 -0.4379 -0.6984 -0.1873 -0.6846 -0.1155 -0.3246 -0.2705 -1.2418 -0.1225 -0.0866 -0.0450 -0.2175 -2.8063 -0.6912 -0.6750 -0.1676
S-1946	CONCLUSIONS: In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy.<unk>
T-1946	hfref ; exercise ; resting hr ; bpm ; beta-blocker ; therapy
H-1946	-0.5737077593803406	▁h f f ▁; ▁exercise ▁performance ▁; ▁rest ing ▁HR ▁; ▁beta - block er ▁ therapy
D-1946	-0.5737077593803406	hff ; exercise performance ; resting HR ; beta-blocker therapy
P-1946	-1.3715 -2.1116 -0.6713 -0.1820 -0.2421 -0.3277 -0.1701 -2.3857 -0.0205 -0.4466 -0.1811 -1.1471 -0.0962 -0.2747 -0.1033 -0.4741 -0.0415 -0.4527 -0.2006
S-1266	Baseline and 6-Week follow-up levels of PAF and activity of its metabolic enzymes in patients with heart failure and healthy volunteers--a pilot study.<unk>
T-1266	baseline ; follow-up ; paf ; activity ; metabolic ; enzymes ; patients ; heart failure ; healthy
H-1266	-0.5935359597206116	▁base line ▁; ▁p f ▁; ▁activity ▁; ▁metabol ic ▁enzym es ▁; ▁heart ▁failure
D-1266	-0.5935359597206116	baseline ; pf ; activity ; metabolic enzymes ; heart failure
P-1266	-0.3281 -0.0103 -0.1335 -3.8481 -0.4262 -0.1748 -1.8560 -0.4324 -0.0599 -0.0301 -0.0865 -0.0684 -0.2580 -0.5220 -0.0697 -1.5313 -0.2546
S-472	Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat.<unk>
T-472	xo inhibition ; cardiomyocyte bioenergetics ; lv function ; chronic acf
H-472	-0.41245073080062866	▁ XO ▁inhibi tion ▁; ▁cardio my o cy te ▁bio ener ge tics ▁; ▁LV ▁function ▁; ▁chronic ▁a CF ▁; ▁rat
D-472	-0.41245073080062866	XO inhibition ; cardiomyocyte bioenergetics ; LV function ; chronic aCF ; rat
P-472	-0.8976 -0.1126 -0.4352 -0.1871 -0.0704 -0.0267 -0.9985 -0.2807 -0.2925 -0.7510 -0.3425 -0.7040 -0.7067 -1.2036 -0.0856 -0.0675 -0.4818 -0.0721 -0.0369 -0.6064 -0.5812 -0.7309 -0.0087 -0.4550 -0.1761
S-152	STUDY SELECTION: All randomised-controlled trials (RCTs) or observational cohort studies with a contemporaneous control group were included.<unk>
T-152	randomised-controlled trials ; rcts ; observational cohort studies ; contemporaneous control group
H-152	-0.43211933970451355	▁random ised - control led ▁trial s ▁; RC t s
D-152	-0.43211933970451355	randomised-controlled trials ;RCts
P-152	-0.6241 -0.2816 -0.0828 -0.0223 -0.1016 -0.0867 -0.0508 -0.4009 -0.0354 -1.3545 -0.1516 -2.2482 -0.1769
S-391	Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified.<unk>
T-391	cox hazard models ; esrd ; death ; composite end point ; esrd ; death ; esrd
H-391	-1.4458916187286377	▁co x ▁hazard ▁models ▁; ▁ES RD ▁; ▁to ▁death ▁; ▁ES RD ▁; ▁death ▁; ▁predict ors ▁; ▁ES RD
D-391	-1.4458916187286377	cox hazard models ; ESRD ; to death ; ESRD ; death ; predictors ; ESRD
P-391	-0.2266 -0.0523 -4.2266 -0.3311 -0.1142 -3.4385 -2.3081 -0.2107 -6.0026 -0.9097 -0.4688 -2.6877 -1.9352 -0.2962 -2.6131 -0.6181 -2.0630 -0.1060 -0.6722 -1.3368 -2.1505 -0.2099 -0.2775
S-970	We aimed to investigate the association between preoperative renal dysfunction and early risk of stroke, myocardial infarction, or heart failure after CABG.<unk>
T-970	preoperative ; renal dysfunction ; stroke ; myocardial infarction ; heart failure ; cabg
H-970	-0.4515037536621094	▁pre operativ e ▁renal ▁dys function ▁; ▁early ▁risk ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁ca BG
D-970	-0.4515037536621094	preoperative renal dysfunction ; early risk ; stroke ; myocardial infarction ; heart failure ; caBG
P-970	-2.3751 -0.0141 -0.1825 -0.0314 -0.1276 -0.8435 -0.1042 -0.8122 -0.3644 -0.9747 -0.3075 -0.1370 -0.6154 -0.3595 -0.7910 -0.0577 -0.0660 -0.3260 -0.2974 -0.1587 -0.3530 -0.0438 -0.5785 -0.8740 -0.9500 -0.2324 -0.2130
S-1753	BACKGROUND: In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT) is not always identified.<unk>
T-1753	patients ; heart failure ; hf ; cardiopulmonary exercise test ; anaerobic threshold
H-1753	-0.5625088214874268	▁heart ▁failure ▁; HF ▁; ▁cardio pul mon ary ▁exercise ▁test ▁; ▁ana ero bic ▁thre s hold ▁; AT
D-1753	-0.5625088214874268	heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold ;AT
P-1753	-1.1746 -0.0851 -0.2583 -0.0654 -0.2051 -0.7405 -0.2815 -0.8312 -0.0901 -1.5670 -1.3396 -0.2604 -0.0406 -0.0563 -1.4177 -0.6829 -0.1775 -1.5851 -1.0623 -0.0198 -0.2919 -0.1424
S-1896	Patients with heart failure should be referred to heart failure nurses and have follow-up with local cardiology services as these have both been shown to reduce mortality.<unk>
T-1896	patients ; heart failure ; heart failure ; nurses ; follow-up ; cardiology ; mortality
H-1896	-0.7711684107780457	▁heart ▁failure ▁; ▁heart ▁failure ▁nurse s ▁; ▁card i ology ▁; ▁mortal ity
D-1896	-0.7711684107780457	heart failure ; heart failure nurses ; cardiology ; mortality
P-1896	-1.6959 -0.0940 -0.3649 -3.4734 -0.0923 -0.8839 -0.0492 -0.2316 -2.4010 -0.5224 -0.0669 -1.4725 -0.5012 -0.0311 -0.2110 -0.2471
S-1144	HF rats treated with pyridostigmine exhibited a higher stroke volume, ejection fraction, cardiac output, and contractility of the left ventricle.<unk>
T-1144	hf ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
H-1144	-0.5880494117736816	▁ HF ▁rat s ▁; ▁py rido stig mine ▁; ▁stroke ▁volume ▁; ▁e je ction ▁ fraction ▁; ▁cardiac ▁output ▁; ▁contract ility ▁; ▁left ▁vent ric le
D-1144	-0.5880494117736816	HF rats ; pyridostigmine ; stroke volume ; ejection fraction ; cardiac output ; contractility ; left ventricle
P-1144	-2.1175 -0.2422 -1.7830 -0.1021 -0.2897 -0.4746 -0.0175 -0.0010 -0.2240 -0.1074 -2.3526 -0.6588 -0.1485 -0.0268 -0.1499 -0.0996 -0.4451 -0.0057 -0.1843 -0.0510 -0.0101 -0.2145 -0.0773 -0.2753 -0.3907 -0.1177 -3.0740 -2.1346 -1.7015 -0.5318 -0.2208
S-1907	In middle-aged recreational athletes more than 90% of sudden cardiac deaths occur in males and more than 90% are caused by atherosclerotic CAD.<unk>
T-1907	cardiac deaths ; atherosclerotic cad
H-1907	-0.7004045248031616	▁recrea tional ▁ath letes ▁; ▁sud den ▁cardiac ▁death s ▁; ▁a ther os cle ro tic ▁CAD
D-1907	-0.7004045248031616	recreational athletes ; sudden cardiac deaths ; atherosclerotic CAD
P-1907	-4.5789 -0.0855 -3.4189 -0.0641 -0.3831 -0.2120 -0.0013 -0.0748 -0.7988 -0.0938 -0.4733 -1.3584 -0.1556 -0.1802 -0.8463 -0.2663 -0.0843 -0.1733 -0.4308 -0.3284
S-359	Direct observation at the time of surgery also confirmed no findings of rheumatic or other causes of MS. After the surgery, MVA was reduced but only modestly.<unk>
T-359	surgery ; rheumatic ; surgery ; mva
H-359	-0.7967922687530518	▁direct ▁observation ▁; ▁rhe u matic ▁; ▁MS ▁; ▁m VA
D-359	-0.7967922687530518	direct observation ; rheumatic ; MS ; mVA
P-359	-0.0893 -0.7666 -0.1005 -4.3742 -0.0176 -0.0215 -0.0754 -1.7596 -1.7809 -0.2220 -0.8870 -0.1028 -0.1610
S-687	METHODS AND RESULTS: Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009.<unk>
T-687	health ; followed up ; hf ; hospitalization ; death ; contact
H-687	-1.3591961860656738	▁women ▁; ▁health ▁initiative ▁; ▁ HF
D-687	-1.3591961860656738	women ; health initiative ; HF
P-687	-3.3107 -4.0052 -0.1445 -1.7046 -0.4573 -0.2277 -0.2591 -1.8256 -0.2980
S-1340	CHF-developed infarcted animals were selected on the basis of left ventricle end-diastolic pressure ≥ 20 mm Hg and scar size ≥ 30%.<unk>
T-1340	infarcted ; left ventricle end-diastolic pressure
H-1340	-0.7286147475242615	▁CHF - develop ed ▁in far cted ▁animals ▁; ▁left ▁vent ric le ▁; ▁end - dia sto lic ▁pressure
D-1340	-0.7286147475242615	CHF-developed infarcted animals ; left ventricle ; end-diastolic pressure
P-1340	-0.0134 -0.7052 -0.1886 -0.0451 -0.0197 -0.0284 -0.9053 -1.0842 -0.2849 -0.1250 -2.4083 -1.6071 -1.1637 -1.3532 -0.6033 -0.1442 -0.7441 -0.6755 -0.7821 -0.6915 -2.3498 -0.1069
S-1094	In this summary, the structure and function of the RV will be reviewed, concentrating on the pathophysiologic mechanisms behind the development of RV dysfunction.<unk>
T-1094	rv ; pathophysiologic ; rv dysfunction
H-1094	-0.5694785118103027	▁ RV ▁; ▁pat ho phy si ologic ▁mechanism s ▁; ▁ RV ▁dys function
D-1094	-0.5694785118103027	RV ; pathophysiologic mechanisms ; RV dysfunction
P-1094	-0.8918 -0.8886 -0.2891 -1.5157 -0.8559 -0.4639 -1.6451 -0.2528 -0.0376 -0.1166 -0.2400 -0.1374 -0.3375 -0.3563 -1.1374 -0.2847 -0.2307
S-912	In conclusion, at our center, the dialysis-dependent patients with HF who underwent CRT implantation did so safely and no serious complications were observed.<unk>
T-912	patients ; hf ; crt ; implantation ; complications
H-912	-0.4241345226764679	▁di al ysis - dependent ▁patients ▁; ▁ HF ▁; ▁c RT ▁implant ation
D-912	-0.4241345226764679	dialysis-dependent patients ; HF ; cRT implantation
P-912	-0.3596 -0.0459 -0.2496 -0.1824 -0.1132 -1.3450 -0.1967 -0.1651 -0.0804 -0.1116 -0.6713 -1.7671 -0.5046 -0.1917 -0.6803 -0.1218
S-1918	Peak oxygen consumption (range: –3% to + 61%) increased in three, and oxygen pulse (range: –7% to + 44%) in four of five patients.<unk>
T-1918	peak oxygen consumption ; pulse ; patients
H-1918	-0.849945068359375	▁Peak ▁; ▁oxygen ▁; ▁puls e
D-1918	-0.849945068359375	Peak ; oxygen ; pulse
P-1918	-0.0478 -2.4084 -0.4352 -2.3660 -0.8018 -0.1880 -0.3887 -0.1637
S-613	Abstract In the current economic climate within the NHS, behavioural-change interventions in chronic disease such as exercise programmes will be time-limited within acute hospital facilities.<unk>
T-613	economic ; nhs ; chronic ; disease ; exercise ; acute ; hospital
H-613	-0.46029970049858093	▁economic ▁climate ▁; ▁NH s ▁; ▁behaviour al - change ▁; ▁chronic ▁disease ▁; ▁exercise ▁programme s ▁; ▁a cute ▁hospital
D-613	-0.46029970049858093	economic climate ; NHs ; behavioural-change ; chronic disease ; exercise programmes ; acute hospital
P-613	-0.0243 -1.2718 -0.1310 -0.9074 -1.2793 -0.2475 -0.1077 -0.1965 -0.2039 -0.0171 -0.5714 -0.4380 -0.6768 -0.2332 -0.0478 -1.0638 -0.1093 -0.6030 -0.0952 -0.0199 -0.5397 -1.4770 -0.3256
S-1452	Cases (post-HCT CHF) were identified from 2950 patients who underwent HCT between 1988 and 2007 at City of Hope and had survived ≥1 year.<unk>
T-1452	chf ; patients ; hct ; city of hope
H-1452	-0.9824827909469604	▁post - h ct ▁CHF ▁; ▁h CT ▁; ▁City ▁of ▁Hope
D-1452	-0.9824827909469604	post-hct CHF ; hCT ; City of Hope
P-1452	-1.1916 -0.0160 -1.2161 -1.7616 -0.2768 -0.4520 -3.5601 -2.2833 -0.2892 -1.1909 -0.0256 -1.0943 -0.2486 -0.1487
S-557	METHODS: Patients were categorized into 5 age groups: 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years.<unk>
T-557	patients
H-557	-0.5913760662078857	
D-557	-0.5913760662078857	
P-557	-1.0319 -0.1508
S-321	MATERIALS AND METHODS: In nine pigs, the inferior vena cava (IVC) was snared to decrease CO and establish a control model.<unk>
T-321	inferior vena cava ; ivc
H-321	-0.701801061630249	▁pig s ▁; ▁ve na ▁ca va ▁; IV c ▁; ▁snar ed ▁; ▁co
D-321	-0.701801061630249	pigs ; vena cava ;IVc ; snared ; co
P-321	-3.9051 -0.0569 -0.1946 -0.2079 -0.0645 -0.0100 -1.9254 -0.2714 -0.1733 -0.9575 -0.3409 -1.6553 -0.0809 -0.2497 -0.8612 -0.7735 -0.2025
S-932	Remarkably, doxorubicin (25mg/kg ip) led to a 4-fold induction of serum resistin levels in Hum-Retn mice.<unk>
T-932	doxorubicin ; resistin
H-932	-0.468880295753479	▁do xor ubi cin ▁; ▁i p ▁; ▁se rum ▁resist in ▁levels ▁; ▁Hum - re t n ▁mi ce
D-932	-0.468880295753479	doxorubicin ; ip ; serum resistin levels ; Hum-retn mice
P-932	-0.0161 -0.3197 -0.0611 -0.4419 -0.1358 -0.5008 -0.0042 -0.3440 -0.4597 -0.6928 -0.1080 -0.8675 -0.3702 -0.3673 -0.0835 -0.3226 -3.1215 -0.3964 -0.0628 -0.3512 -0.7549 -0.6835 -0.3188
S-1729	Finally, costs were higher for the high-volume physicians ($8982 versus $8731; P=0.002, a difference that was consistent across hospital volume groups).<unk>
T-1729	costs ; physicians ; hospital
H-1729	-0.6444555521011353	▁costs ▁; ▁high - volu me ▁physician s
D-1729	-0.6444555521011353	costs ; high-volume physicians
P-1729	-0.1757 -0.2731 -0.8069 -0.0775 -0.1583 -0.0832 -1.1497 -0.0594 -3.4785 -0.1823
S-1361	This review highlights the current knowledge of nutritional abnormalities that may occur in CHF, including fat, carbohydrates, proteins, water, and micronutrients.<unk>
T-1361	chf ; proteins
H-1361	-0.4749436676502228	▁nutrition al ▁ab normal ities ▁; ▁CHF ▁; ▁fat ▁; ▁car bo hydrat es ▁; ▁protein s ▁; ▁water
D-1361	-0.4749436676502228	nutritional abnormalities ; CHF ; fat ; carbohydrates ; proteins ; water
P-1361	-3.2851 -0.0452 -0.0458 -0.0185 -0.0290 -0.2894 -0.1204 -0.3218 -1.2571 -0.2625 -0.3338 -0.5530 -0.5398 -0.1472 -0.2536 -0.2166 -0.0293 -0.4181 -0.1691 -1.4762 -0.1623
S-1864	Most patients (n = 17, 68%) said they would consider deactivation, six (24%) were undecided and two (8%) were adamant they would never turn it off.<unk>
T-1864	patients
H-1864	-0.65496826171875	▁de activa tion
D-1864	-0.65496826171875	deactivation
P-1864	-1.5804 -0.0330 -0.0669 -1.4292 -0.1654
S-438	Aldosterone receptor antagonists have been shown in randomized trials to reduce morbidity and mortality in adults with symptomatic systolic heart failure.<unk>
T-438	aldosterone receptor antagonists ; randomized ; morbidity ; mortality ; symptomatic systolic heart failure
H-438	-0.49544981122016907	▁al do ster one ▁receptor ▁anta gon ists ▁; ▁morbi d ity ▁; ▁mortal ity ▁; ▁symptom a tic ▁sy sto lic ▁heart ▁failure
D-438	-0.49544981122016907	aldosterone receptor antagonists ; morbidity ; mortality ; symptomatic systolic heart failure
P-438	-0.4558 -0.2067 -0.5066 -0.0231 -0.0017 -0.4999 -0.5885 -1.3042 -0.3181 -0.5989 -0.0822 -0.1313 -0.6739 -0.0183 -0.0130 -0.3408 -1.5256 -0.1071 -0.0176 -0.9992 -0.1909 -1.7462 -1.7327 -0.1507 -0.4854 -0.1633
S-1089	Because the effect is not entirely specific to the SCN5A transcript, the UPR may play an important role in downregulation of multiple cardiac genes in HF.<unk>
T-1089	scn5a ; upr ; downregulation ; cardiac ; genes ; hf
H-1089	-0.44899386167526245	▁s cn 5 a ▁tran script ▁; ▁u PR ▁; ▁down regul ation ▁; ▁cardiac ▁gene s ▁; ▁ HF
D-1089	-0.44899386167526245	scn5a transcript ; uPR ; downregulation ; cardiac genes ; HF
P-1089	-0.5889 -1.1631 -0.1700 -0.2900 -0.9079 -0.0573 -0.1443 -0.0968 -1.4840 -0.2729 -0.1460 -0.1081 -0.0643 -0.4526 -1.0821 -1.4748 -0.0948 -0.2944 -0.1225 -0.1952 -0.3962 -0.2716
S-1655	CONCLUSION: EAST will determine whether rhythm control therapy, when applied early after the initial diagnosis of AF, can prevent cardiovascular complications associated with AF.<unk>
T-1655	east ; rhythm control therapy ; diagnosis ; cardiovascular ; complications
H-1655	-0.3965429365634918	▁e ast ▁; ▁ rhythm ▁control ▁ therapy ▁; ▁AF ▁; ▁cardiovascular ▁complica tions ▁; ▁AF
D-1655	-0.3965429365634918	east ; rhythm control therapy ; AF ; cardiovascular complications ; AF
P-1655	-1.5874 -0.0560 -0.2923 -0.1579 -0.1007 -0.0600 -0.4713 -0.0356 -0.2933 -1.5410 -0.4196 -0.1247 -0.1415 -0.1009 -0.7230 -0.6127 -0.2011 -0.2186
S-540	Attention to albumin levels by correcting nutrition, inflammation, and hepatic function could be an effective way to improve prognosis in patients evaluated for LVAD implantation.<unk>
T-540	albumin ; inflammation ; hepatic ; prognosis ; patients ; lvad ; implantation
H-540	-0.5023179054260254	▁album in ▁levels ▁; ▁ inflammation ▁; ▁he pati c ▁function ▁; ▁l VAD ▁implant ation
D-540	-0.5023179054260254	albumin levels ; inflammation ; hepatic function ; lVAD implantation
P-540	-0.3384 -0.4363 -0.1271 -0.2150 -0.7534 -0.1724 -0.2859 -0.9959 -0.4776 -0.5148 -0.3014 -0.3389 -2.5777 -0.1738 -0.5063 -0.2693 -0.3392 -0.2183
S-294	BACKGROUND: Right ventricular (RV) failure after the insertion of a left ventricular assist device (LVAD) historically results in poor outcomes.<unk>
T-294	right ventricular ; rv ; left ventricular assist device ; lvad ; outcomes
H-294	-0.6581864356994629	▁right ▁vent ri cular ▁; RV ▁; ▁ insertion ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l VAD
D-294	-0.6581864356994629	right ventricular ;RV ; insertion ; left ventricular assist device ; lVAD
P-294	-0.1008 -1.7550 -0.4945 -0.1396 -0.6693 -0.6351 -0.5853 -2.1315 -0.0299 -0.4661 -0.0970 -2.0956 -1.1811 -0.1425 -1.0541 -0.6768 -0.4602 -0.3490 -0.0440 -0.5770 -0.1373
S-496	TAPSE vs. PASP relationship showed a downward regression line shift in nonsurvivors who were more frequently presenting with higher PASP and lower TAPSE.<unk>
T-496	tapse ; pasp ; downward ; regression line ; shift ; pasp ; tapse
H-496	-0.818396806716919	▁t AP se ▁; ▁PAS p ▁relationship ▁; ▁down ward ▁re gression ▁line ▁shift ▁; ▁non sur viv ors ▁; ▁PAS p ▁; ▁t AP se
D-496	-0.818396806716919	tAPse ; PASp relationship ; downward regression line shift ; nonsurvivors ; PASp ; tAPse
P-496	-1.7561 -1.9592 -3.4536 -0.2897 -0.9290 -0.8466 -1.2593 -0.3768 -0.6357 -0.2894 -0.0339 -0.0121 -0.0898 -0.1251 -0.4445 -0.9042 -0.2223 -0.0611 -0.1340 -0.3358 -1.7808 -0.9187 -0.2751 -2.5566 -0.9985 -1.7653 -0.2309 -0.2310
S-689	Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI).<unk>
T-689	cox proportional hazards models ; health ; health ; hazard ratios ; confidence intervals
H-689	-0.7021471261978149	▁co x ▁proportion al ▁hazard s ▁models ▁; ▁health ▁behavior s ▁; ▁health ▁status ▁; ▁hazard ▁ratio s
D-689	-0.7021471261978149	cox proportional hazards models ; health behaviors ; health status ; hazard ratios
P-689	-0.0310 -0.0996 -0.1934 -0.0162 -2.8531 -0.3877 -1.3779 -0.4079 -0.3711 -1.3970 -0.0700 -0.3091 -0.7055 -0.1895 -0.5924 -2.1201 -0.0338 -0.1174 -2.5325 -0.2379
S-10	Lipolysis and increased energy expenditure caused by A- and B natriuretic peptides (NPs) have been suggested to play a role in CC.<unk>
T-10	lipolysis ; expenditure ; b natriuretic peptides ; nps
H-10	-0.4874177575111389	▁li poly sis ▁; ▁energy ▁ex pendi ture ▁; ▁na tri ure tic ▁pe pti des ▁; NP s ▁; cc
D-10	-0.4874177575111389	lipolysis ; energy expenditure ; natriuretic peptides ;NPs ;cc
P-10	-0.1622 -0.1032 -1.1746 -0.0949 -0.0826 -0.1272 -0.0140 -0.2285 -0.3839 -1.4032 -0.7728 -0.1021 -0.4726 -0.0188 -0.4332 -1.9069 -0.3798 -0.0107 -0.0132 -0.8187 -1.8167 -0.3983 -0.2925
S-816	RESULTS: There were 19 CV deaths, 12 non-fatal stroke and 28 hospitalisations for heart failure during an average follow-up of 21 ± 10 months.<unk>
T-816	deaths ; stroke ; hospitalisations ; heart failure ; follow-up
H-816	-0.5330042243003845	▁CV ▁death s ▁; ▁non - fa tal ▁stroke ▁; ▁hospital isation s ▁; ▁heart ▁failure
D-816	-0.5330042243003845	CV deaths ; non-fatal stroke ; hospitalisations ; heart failure
P-816	-3.5696 -2.4225 -0.0450 -0.2180 -0.0430 -0.0592 -0.2173 -0.1092 -0.9049 -0.1610 -0.5930 -0.0145 -0.0907 -0.5391 -0.2505 -0.0700 -0.1341 -0.1526
S-1817	These findings indicate that hearts with increased levels of Mena fare worse when subjected to cardiac injury and suggest that Mena contributes to HF pathophysiology.<unk>
T-1817	hearts ; mena ; cardiac injury ; mena ; hf ; pathophysiology
H-1817	-0.5779153108596802	▁heart s ▁; ▁Men a ▁; ▁cardiac ▁injury ▁; ▁Men a ▁; ▁ HF
D-1817	-0.5779153108596802	hearts ; Mena ; cardiac injury ; Mena ; HF
P-1817	-1.2756 -0.0678 -0.1794 -1.2795 -0.1562 -0.3162 -0.6520 -1.8289 -0.1505 -0.5323 -0.1541 -0.1942 -0.2248 -0.1193 -1.8746 -0.2411
S-1477	In this review, we summarize the potential therapeutic implications of promising biomarkers that uniquely capture the molecular dysfunction that occurs in chronic HF.<unk>
T-1477	therapeutic ; biomarkers ; molecular dysfunction ; chronic hf
H-1477	-0.3498670160770416	▁ therapeut ic ▁; ▁bio mark ers ▁; ▁molecular ▁dys function ▁; ▁chronic ▁ HF
D-1477	-0.3498670160770416	therapeutic ; biomarkers ; molecular dysfunction ; chronic HF
P-1477	-2.1314 -0.3141 -0.0963 -0.5852 -0.6225 -0.0506 -0.0994 -0.1620 -0.0349 -0.0496 -0.6520 -0.1090 -0.1703 -0.2077 -0.1249 -0.3255 -0.2123
S-705	However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.<unk>
T-705	st2 ; c statistic ; net reclassification improvement ; integrated discrimination improvement
H-705	-0.5781703591346741	▁ST 2 ▁; ▁re class ification ▁; ▁risk ▁; ▁c ▁statistic ▁; ▁net ▁re class ification ▁; ▁discrimina tion
D-705	-0.5781703591346741	ST2 ; reclassification ; risk ; c statistic ; net reclassification ; discrimination
P-705	-1.8368 -0.0691 -0.3473 -1.7690 -0.0624 -0.3381 -0.8376 -1.2205 -0.1760 -0.6355 -0.8798 -0.2356 -0.1093 -0.0527 -0.1047 -0.1981 -0.6079 -0.7713 -0.2911 -1.2949 -0.3039
S-814	MAIN OUTCOME MEASURES: The risk of GLS measured by index beat method for CV events was assessed by Cox proportional hazards analyses.<unk>
T-814	outcome ; gls ; beat ; cox proportional hazards analyses
H-814	-0.4482688903808594	▁g ls ▁; ▁index ▁beat ▁method ▁; ▁cv ▁; ▁co x ▁proportion al ▁hazard s
D-814	-0.4482688903808594	gls ; index beat method ; cv ; cox proportional hazards
P-814	-0.5107 -1.7914 -0.1388 -0.2159 -0.0122 -0.2291 -0.2600 -0.7220 -0.7532 -0.1523 -0.2887 -0.1768 -0.0151 -1.3470 -0.2986 -0.4526 -0.2562
S-1615	CONCLUSIONS: Genes differentially expressed in non-ischemic and ischemic heart failure can be biomarkers to distinguish the two types of heart failure.<unk>
T-1615	genes ; ischemic heart failure ; biomarkers ; heart failure
H-1615	-0.5350090861320496	▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure ▁; ▁bio mark ers ▁; ▁heart ▁failure
D-1615	-0.5350090861320496	non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
P-1615	-1.7366 -0.0473 -0.7904 -0.3529 -0.5745 -0.1293 -0.1891 -0.2803 -2.1857 -0.0904 -0.4036 -0.3812 -0.0231 -0.1036 -0.2240 -2.1563 -0.0929 -0.1929 -0.2110
S-1389	RESULTS: During the study period, there were 23 patients in the VAD group, 16 patients in the ECMO+VAD group, and 37 patients in the ECMO group.<unk>
T-1389	patients ; vad ; patients ; ecmo ; vad ; patients ; ecmo
H-1389	-0.8947699069976807	▁ VAD ▁group ▁; ▁ec mo + VAD ▁group ▁; ▁ec mo ▁group
D-1389	-0.8947699069976807	VAD group ; ecmo+VAD group ; ecmo group
P-1389	-0.7819 -0.1873 -1.2064 -0.1242 -0.9023 -0.8230 -3.8812 -0.1558 -0.6807 -0.3739 -1.6045 -0.7878 -1.2535 -0.3871 -0.2720
S-1806	Ambient air pollution is a well-recognised risk factor for cardiovascular health, and it has been shown to be an important trigger of acute myocardial infarction.<unk>
T-1806	air ; cardiovascular ; health ; acute myocardial infarction
H-1806	-0.6803590059280396	▁Ambient ▁air ▁pollution ▁; ▁cardiovascular ▁health ▁; ▁a cute ▁my o card ial ▁in far ction
D-1806	-0.6803590059280396	Ambient air pollution ; cardiovascular health ; acute myocardial infarction
P-1806	-0.1442 -0.2010 -0.2141 -0.1936 -1.8619 -0.4115 -0.2797 -0.3995 -0.0620 -3.7714 -1.0668 -1.5427 -0.0710 -0.0676 -0.4849 -0.8685 -0.3853 -0.2208
S-784	Predictive validity of the KCCQ Overall Summary scores was assessed with Kaplan-Meier curves for death and all-cause hospitalization.<unk>
T-784	kccq ; kaplan-meier curves ; death ; all-cause hospitalization
H-784	-0.7187419533729553	▁k cc q ▁; ▁Ka plan - Me ier ▁cur ves ▁; ▁death ▁; ▁all - ca use ▁hospital ization
D-784	-0.7187419533729553	kccq ; Kaplan-Meier curves ; death ; all-cause hospitalization
P-784	-1.6999 -0.0711 -1.5654 -0.3798 -0.3938 -0.2043 -0.0475 -1.2230 -0.4876 -0.1618 -0.6770 -0.3255 -2.4772 -0.5592 -2.6453 -0.0593 -0.0082 -0.7703 -0.8019 -0.6207 -0.3099 -0.3236
S-1599	Screening patients for RAS with either Doppler ultrasonography, computed tomographic angiography, or magnetic resonance angiography is preferred.<unk>
T-1599	patients ; ras ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
H-1599	-0.310515433549881	▁ RAS ▁; ▁do pp ler ▁ultra son ography ▁; ▁com put ed ▁to mo graphic ▁ang i ography ▁; ▁magnetic ▁res on ance ▁ang i ography
D-1599	-0.310515433549881	RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
P-1599	-1.5745 -0.0096 -0.2271 -0.9487 -0.0084 -0.8413 -0.1589 -0.1024 -0.6029 -0.1257 -0.7240 -0.0568 -0.0571 -0.0124 -0.2313 -0.4198 -0.0546 -0.3692 -0.3069 -0.3574 -0.0108 -0.0687 -0.1035 -0.1104 -0.0432 -0.4899 -0.2960 -0.4478 -0.2455
S-1316	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study.<unk>
T-1316	testosterone therapy ; exercise rehabilitation ; patients ; chronic heart failure ; testosterone ; double-blind ; randomized
H-1316	-0.5645812153816223	▁test o ster one ▁ therapy ▁; ▁exercise ▁rehabilita tion ▁; ▁chronic ▁heart ▁failure ▁; ▁low ▁testosteron e ▁status
D-1316	-0.5645812153816223	testosterone therapy ; exercise rehabilitation ; chronic heart failure ; low testosterone status
P-1316	-3.1156 -0.3801 -0.1593 -0.0224 -1.5121 -0.0646 -0.4063 -0.4136 -0.1953 -0.0829 -0.3159 -2.1482 -1.3985 -0.1138 -0.2899 -0.3475 -0.0745 -0.0498 -0.1045 -0.5262 -0.1353
S-1596	The pathophysiologic mechanism stems from renal underperfusion resulting in the activation of the renin- angiotensin-aldosterone pathway.<unk>
T-1596	pathophysiologic ; renal underperfusion ; renin- angiotensin-aldosterone pathway
H-1596	-0.52095627784729	▁pat ho phy si ologic ▁mechanism ▁; ▁renal ▁under per fusion ▁; ▁re nin - ▁ang io ten sin - al do ster one ▁path way
D-1596	-0.52095627784729	pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone pathway
P-1596	-2.1482 -1.2265 -0.3035 -2.0378 -0.3687 -0.0281 -0.3400 -0.0487 -0.1957 -0.1638 -0.2885 -0.1340 -0.0376 -0.1739 -0.0688 -0.0431 -2.0126 -0.3377 -0.3237 -0.2620 -0.0933 -1.5587 -0.5219 -0.0597 -0.0848 -0.6904 -0.6896 -0.3455
S-1718	Individuals hospitalized for AMI without major complications, heart failure, or kidney infection or UTI with major complications had no increase in 30-day rehospitalization.<unk>
T-1718	hospitalized ; ami ; complications ; heart failure ; kidney infection ; uti ; complications ; rehospitalization
H-1718	-0.4662097990512848	▁ AMI ▁; ▁heart ▁failure ▁; ▁ki dne y ▁infection ▁; ▁ UTI
D-1718	-0.4662097990512848	AMI ; heart failure ; kidney infection ; UTI
P-1718	-2.0923 -0.1388 -0.2930 -1.6297 -0.0583 -0.2374 -0.1168 -0.3889 -0.0654 -1.1130 -0.1008 -0.0981 -0.0114 -0.3945 -0.2547
S-869	Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides.<unk>
T-869	proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
H-869	-0.47580787539482117	▁global ▁prote o mics ▁; ▁path way ▁analysis ▁; ▁pressure - over load - indu ced ▁heart ▁failure ▁; ▁mito cho ndri al - tar get ed ▁pe pti des
D-869	-0.47580787539482117	global proteomics ; pathway analysis ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
P-869	-0.7613 -0.1494 -0.9182 -0.0363 -0.1617 -0.7846 -0.1049 -1.0901 -0.7284 -0.0094 -0.0932 -0.0481 -0.2682 -0.2399 -0.1108 -0.9747 -1.3153 -0.1227 -0.2721 -0.0998 -2.3244 -1.1939 -0.0397 -0.0962 -0.0949 -0.4234 -0.0300 -0.0109 -0.1672 -1.9892 -0.3436 -0.2231
S-965	Moreover, nicorandil provided a significant cardioprotection via inhibition of apoptotic signaling pathway, DNA fragmentation and mitochondrial ultrastructural changes.<unk>
T-965	nicorandil ; cardioprotection ; apoptotic signaling pathway ; dna fragmentation ; mitochondrial
H-965	-0.32263442873954773	▁nic oran dil ▁; ▁cardio protec tion ▁; ▁apo pto tic ▁signal ing ▁path way ▁; ▁DNA ▁fragment ation ▁; ▁mito cho ndri al ▁ultra struct ural ▁changes
D-965	-0.32263442873954773	nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
P-965	-0.1646 -0.0309 -0.3194 -0.1988 -0.2667 -0.3064 -0.0963 -0.2757 -0.1711 -0.1612 -0.1082 -0.0489 -0.4080 -0.0239 -0.5553 -0.4791 -0.0124 -0.1380 -0.0610 -0.2705 -0.0194 -2.1432 -0.5551 -0.0506 -0.7393 -0.1554 -0.0062 -1.3153 -0.4088 -0.1892
S-103	The present study population comprised 1,045 patients with IC enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy.<unk>
T-103	patients ; ic ; multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy
H-103	-0.37841910123825073	▁IC ▁; ▁multi center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁; ▁Tri al - Card iac ▁re syn chron ization ▁Therapy
D-103	-0.37841910123825073	IC ; multicenter Automatic Defibrillator Implantation ; Trial-Cardiac resynchronization Therapy
P-103	-1.9761 -0.3663 -0.3338 -0.0334 -0.4534 -0.0039 -1.3480 -0.9057 -0.3993 -0.1836 -0.1053 -0.1140 -0.7747 -0.7874 -0.0443 -0.0215 -0.1430 -0.1730 -0.4623 -0.0102 -0.0027 -0.2182 -0.2285 -0.2227 -0.1490
S-1102	All residents of Olmsted County, Minnesota (n = 2,596) who had a first-ever MI diagnosed in 1990-2010 and no prior HF were followed-up through 2012.<unk>
T-1102	olmsted county ; minnesota ; mi ; diagnosed ; hf ; followed-up
H-1102	-0.511584997177124	▁Ol m sted ▁County ▁; ▁Minnesota ▁; ▁MI ▁; ▁ HF
D-1102	-0.511584997177124	Olmsted County ; Minnesota ; MI ; HF
P-1102	-1.2428 -0.0051 -0.0337 -1.4592 -0.3542 -0.0888 -0.2455 -1.2642 -0.5485 -0.7406 -0.3204 -0.1427 -0.2050
S-1627	The Health Buddy Program was most strongly associated with fewer admissions for individuals with chronic obstructive pulmonary disease and mortality for those with congestive heart failure.<unk>
T-1627	health buddy program ; admissions ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
H-1627	-0.34277063608169556	▁health ▁Budd y ▁program ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁mortal ity ▁; ▁con ges tive ▁heart ▁failure
D-1627	-0.34277063608169556	health Buddy program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
P-1627	-0.3523 -0.0689 -0.0363 -1.1825 -0.2659 -0.8043 -0.1985 -0.1767 -0.0461 -0.0570 -0.1297 -1.9443 -0.2074 -0.1378 -0.0215 -0.2631 -0.0349 -0.1036 -0.0973 -1.0607 -0.1336 -0.3693 -0.1921
S-379	We hypothesized that routinely collected clinical data could predict the 6-month risk of death and all-cause medical hospitalization in HF clinic outpatients.<unk>
T-379	collected ; clinical ; death ; medical ; hospitalization ; hf ; clinic ; outpatients
H-379	-1.010553002357483	▁medical ▁hospital ization ▁; ▁ HF
D-379	-1.010553002357483	medical hospitalization ; HF
P-379	-4.3842 -1.0800 -0.1313 -0.2440 -0.3993 -0.1852 -1.2822 -0.3782
S-1308	We assessed the temporal incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year after discharge.<unk>
T-1308	incidence ; adjusted odds ratio ; hazard ratio ; death ; hf ; ami ; admission ; discharge
H-1308	-1.0417674779891968	▁ HF ▁; ▁ad mission ▁; ▁dis charge
D-1308	-1.0417674779891968	HF ; admission ; discharge
P-1308	-4.4702 -0.7378 -0.2404 -2.2596 -0.0607 -0.8526 -0.6839 -0.3320 -0.4293 -0.3511
S-184	In conclusion, uptitration of neurohumoral blockers after an HF hospitalization is more frequently performed in younger patients with low co-morbidity burden.<unk>
T-184	uptitration ; neurohumoral blockers ; hf ; hospitalization ; patients ; co-morbidity
H-184	-0.48056066036224365	▁neuro hu moral ▁block ers ▁; ▁ HF ▁; ▁co - mor bid ity ▁burde n
D-184	-0.48056066036224365	neurohumoral blockers ; HF ; co-morbidity burden
P-184	-0.3669 -0.1876 -1.9856 -0.2246 -0.3135 -0.1965 -0.1786 -0.0347 -1.5543 -1.1689 -0.1867 -0.5057 -0.5162 -0.0277 -0.3844 -0.3259 -0.3137 -0.1785
S-110	Age-dependent effect of left ventricular ejection fraction on long-term mortality in patients with heart failure (from the Heart Failure Survey in ISrael).<unk>
T-110	left ventricular ejection fraction ; mortality ; patients ; heart failure ; heart failure survey ; israel
H-110	-0.7681013345718384	▁Age - dependent ▁effect ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁long - term ▁mortal ity ▁; ▁heart ▁failure ▁; ▁Heart ▁Fail ure ▁Survey ▁; ▁IS ra el
D-110	-0.7681013345718384	Age-dependent effect ; left ventricular ejection fraction ; long-term mortality ; heart failure ; Heart Failure Survey ; ISrael
P-110	-2.4264 -0.1952 -0.2971 -0.2613 -1.0249 -0.0621 -3.1822 -1.8726 -0.8469 -0.1887 -0.1904 -0.2442 -1.6218 -0.0430 -0.3252 -2.8269 -0.1667 -0.1174 -0.1895 -0.0395 -0.2944 -1.3239 -0.1664 -0.4264 -2.2003 -0.6686 -0.0817 -1.1777 -0.9027 -1.9280 -0.0158 -0.0064 -0.5184 -0.2827
S-450	The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure.<unk>
T-450	vascular endothelial growth factor ; vegf ; transition ; compensatory hypertrophy ; cardiac failure
H-450	-0.6108299493789673	▁inhibi tion ▁of ▁vas cular ▁en dot heli al ▁growth ▁factor ▁; VE GF ▁; ▁transition ▁; ▁compensa tory ▁hyper trop hy ▁; ▁cardiac ▁failure
D-450	-0.6108299493789673	inhibition of vascular endothelial growth factor ;VEGF ; transition ; compensatory hypertrophy ; cardiac failure
P-450	-3.2568 -0.0227 -0.5766 -0.2309 -0.1438 -0.0513 -2.3100 -0.2539 -0.0332 -0.4825 -0.0472 -0.9893 -0.5943 -1.4873 -0.9514 -1.7842 -0.6293 -0.0059 -0.0196 -0.2989 -0.0437 -1.2922 -0.3409 -0.0187 -0.1516 -0.3298 -0.1463
S-1192	In the prospective validation cohort of 143 patients, the prediction rule had 98% sensitivity and 18% specificity for CAD but 100% sensitivity for severe CAD.<unk>
T-1192	prospective ; patients ; rule ; sensitivity ; specificity ; cad ; sensitivity ; cad
H-1192	-0.8106023073196411	▁predict ion ▁rule ▁; ▁CAD ▁; ▁severe ▁CAD
D-1192	-0.8106023073196411	prediction rule ; CAD ; severe CAD
P-1192	-3.7413 -0.0248 -0.0885 -0.1306 -0.6561 -0.4070 -2.2854 -0.4714 -0.1512 -0.1497
S-530	We aimed to investigate the association of hypoalbuminemia with postoperative mortality in patients undergoing left ventricular assist device (LVAD) implantation.<unk>
T-530	hypoalbuminemia ; postoperative ; mortality ; patients ; left ventricular assist device ; lvad ; implantation
H-530	-0.6202763915061951	▁hypo album in emia ▁; ▁post operativ e ▁mortal ity ▁; ▁left ▁vent ri cular ▁assist ▁device ▁; ▁l VAD
D-530	-0.6202763915061951	hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
P-530	-0.1250 -0.5206 -0.2693 -0.2631 -0.1766 -0.0155 -0.0771 -1.0162 -0.0787 -0.0374 -0.2984 -0.2226 -3.2710 -2.4764 -0.3305 -1.2865 -0.6902 -0.5680 -0.4066 -0.0622 -1.2122 -0.2419
S-173	Our results are not in favour of apoptosis in the pathogenesis of heart failure in this model and may be it could be attributed to activation of other systems.<unk>
T-173	apoptosis ; pathogenesis ; heart failure
H-173	-0.5545293688774109	▁apo pto sis ▁; ▁path ogen es is ▁; ▁heart ▁failure
D-173	-0.5545293688774109	apoptosis ; pathogenesis ; heart failure
P-173	-0.8572 -0.3336 -1.3568 -0.1772 -0.1139 -0.2061 -0.0773 -0.8666 -0.9512 -0.3944 -0.0548 -1.5884 -0.2312
S-1819	A considerable number of patients eventually reach an advanced or terminal phase, in spite of developments in diagnostic procedure, alternative treatments that can slow progression, management, and follow-up.<unk>
T-1819	patients ; terminal ; diagnostic ; follow-up
H-1819	-1.0974270105361938	▁diagnostic ▁procedure ▁; ▁treatment s
D-1819	-1.0974270105361938	diagnostic procedure ; treatments
P-1819	-2.4801 -0.3632 -0.6575 -2.9064 -0.6923 -0.3941 -0.1883
S-1201	Diuretic efficacy may be limited by adverse neurohormonal activation and by "congestion-like" symptoms that may occur in the absence of fluid overload.<unk>
T-1201	diuretic ; neurohormonal ; symptoms ; fluid overload
H-1201	-0.43249499797821045	▁di ure tic ▁ef fica cy ▁; ▁neuro hormon al ▁activa tion ▁; con gestion - like ▁; ▁fluid ▁over load
D-1201	-0.43249499797821045	diuretic efficacy ; neurohormonal activation ;congestion-like ; fluid overload
P-1201	-0.0993 -0.0345 -0.2765 -0.5013 -0.0684 -0.1947 -0.2372 -1.4441 -0.1020 -0.0677 -0.7087 -0.0726 -0.3582 -1.1964 -0.0085 -0.1841 -0.6349 -1.5969 -1.2781 -0.2376 -0.1940 -0.2811 -0.1706
S-1088	CONCLUSIONS: UPR can be initiated by Na+ channel mRNA splice variants and is involved in the reduction of cardiac Na+ current during human HF.<unk>
T-1088	upr ; mrna splice ; cardiac ; hf
H-1088	-0.9692569971084595	▁u PR ▁; ▁na + ▁channel ▁m RNA ▁sp lice ▁; ▁re duction ▁; ▁cardiac ▁na + ▁current ▁; ▁human ▁ HF
D-1088	-0.9692569971084595	uPR ; na+ channel mRNA splice ; reduction ; cardiac na+ current ; human HF
P-1088	-0.0943 -2.6727 -0.2899 -0.1507 -4.7667 -0.1990 -0.2294 -0.3686 -0.7967 -0.1841 -0.5781 -1.9696 -0.0057 -1.1409 -0.0830 -0.2564 -4.1365 -1.4573 -0.3350 -2.4635 -0.2173 -0.2319 -0.4112 -0.2235
S-114	Among the study patients, 30% had preserved LVEF and 20%, 25%, and 25%, had mild, moderate, and severe reductions in LVEF, respectively.<unk>
T-114	patients ; preserved lvef ; lvef
H-114	-0.5216102004051208	▁LV EF ▁; ▁LV EF
D-114	-0.5216102004051208	LVEF ; LVEF
P-114	-0.8200 -0.5530 -0.5339 -0.8148 -0.4387 -0.3029 -0.1880
S-316	We conclude that evidence is sufficient to support LVAD use, regardless of transplantation eligibility status, as long as patients are carefully selected and program infrastructure and budget are adequate.<unk>
T-316	evidence ; lvad ; transplantation ; patients ; budget
H-316	-0.6271119117736816	▁l VAD ▁; ▁transplant ation ▁e ligi bility ▁status ▁; ▁budget
D-316	-0.6271119117736816	lVAD ; transplantation eligibility status ; budget
P-316	-2.1627 -0.4734 -0.5484 -0.3195 -0.1902 -0.1615 -0.0355 -0.1248 -0.0681 -0.8509 -2.7971 -0.2816 -0.1387
S-1052	Moreover, BETs were found to function, in part, by promoting transcriptional pause release (and thereby re-activating transcription) during pathological stress.<unk>
T-1052	bets ; transcriptional pause release ; pathological
H-1052	-0.39299875497817993	BET s ▁; ▁tran scription al ▁pause ▁release ▁; ▁tran scription ▁; ▁path ological ▁stress
D-1052	-0.39299875497817993	BETs ; transcriptional pause release ; transcription ; pathological stress
P-1052	-1.1364 -0.4198 -0.3913 -0.3281 -0.4731 -0.2424 -0.1410 -0.2159 -0.2010 -1.2891 -0.3313 -0.7771 -0.0266 -0.0933 -0.1236 -0.2880 -0.2030
S-1910	Screening with a 12-lead ECG in older athletes is of limited value given the overwhelming contribution of atherosclerotic CAD to sudden cardiac death.<unk>
T-1910	ecg ; atherosclerotic cad ; cardiac death
H-1910	-0.45314401388168335	▁ec g ▁; ▁a ther os cle ro tic ▁CAD ▁; ▁sud den ▁cardiac ▁death
D-1910	-0.45314401388168335	ecg ; atherosclerotic CAD ; sudden cardiac death
P-1910	-3.0917 -1.0442 -0.1365 -0.5112 -0.0936 -0.1272 -0.6594 -0.1411 -0.0349 -0.2296 -0.2301 -0.0538 -0.0021 -0.0271 -0.7661 -0.3477 -0.2074
S-1313	Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day survivors.<unk>
T-1313	hf ; ami ; hazard ratio ; mortality
H-1313	-1.0092142820358276	▁ HF ▁; ▁index ▁ AMI ▁; ▁adjust ed ▁hazard ▁ratio ▁; ▁1- year ▁mortal ity
D-1313	-1.0092142820358276	HF ; index AMI ; adjusted hazard ratio ; 1-year mortality
P-1313	-1.6837 -0.9157 -0.2214 -0.6024 -1.4741 -0.0786 -0.2400 -3.1409 -0.0475 -0.7986 -0.0070 -0.4195 -6.1892 -0.1229 -0.0963 -0.1065 -1.7261 -0.2952
S-107	Treatment with CRT-D did not have a significant effect on IE risk compared with defibrillator-only therapy (HR 0.87, p = 0.51).<unk>
T-107	crt-d ; therapy
H-107	-0.6793859601020813	▁c RT - d ▁; ▁IE ▁; ▁de fi br illa tor - on ly ▁ therapy
D-107	-0.6793859601020813	cRT-d ; IE ; defibrillator-only therapy
P-107	-0.5658 -2.3929 -0.0953 -0.7210 -0.2391 -1.3665 -0.7933 -0.9676 -0.1406 -1.1027 -1.7076 -0.0600 -0.1650 -0.1056 -0.4202 -0.4546 -0.2340 -1.1530 -0.2235
S-1587	Various measures of HR dynamics, such as time-domain, spectral, and non-linear measures of HR variability have been used in risk stratification.<unk>
T-1587	hr variability ; risk stratification
H-1587	-0.6564456224441528	▁HR ▁dynamic s ▁; ▁HR ▁variabil ity ▁; ▁risk ▁strat ification
D-1587	-0.6564456224441528	HR dynamics ; HR variability ; risk stratification
P-1587	-0.6033 -0.0865 -0.0806 -0.3053 -2.3002 -0.3398 -0.1362 -0.7880 -0.4897 -1.6784 -0.9587 -0.3833 -0.3841
S-1174	Cardiopulmonary exercise testing with echocardiographic assessment of myocardial function and left ventricular filling were undertaken at rest and after exercise.<unk>
T-1174	cardiopulmonary exercise testing ; echocardiographic ; myocardial function ; left ventricular filling ; exercise
H-1174	-0.6939998865127563	▁cardio pul mon ary ▁exercise ▁testing ▁; ▁e cho car dio graphic ▁assessment ▁; ▁my o card ial ▁function ▁; ▁left ▁vent ri cular ▁fill ing
D-1174	-0.6939998865127563	cardiopulmonary exercise testing ; echocardiographic assessment ; myocardial function ; left ventricular filling
P-1174	-3.7116 -0.1948 -1.1093 -0.1129 -0.6206 -0.7426 -0.1768 -0.0143 -0.0723 -1.2056 -1.3548 -0.7712 -1.0141 -0.2735 -0.1434 -0.1271 -1.1024 -0.1107 -1.1662 -0.1908 -0.0468 -1.9708 -0.9273 -0.2976 -0.8915 -0.0636 -0.8575 -0.1620
S-320	Accordingly, we used speckle tracking echocardiography (STE) to analyze BiVP during acute right ventricular pressure overload (RVPO).<unk>
T-320	speckle tracking echocardiography ; ste ; bivp ; acute ; right ventricular pressure overload ; rvpo
H-320	-0.5448995232582092	▁spec kle ▁track ing ▁e cho card i ography ▁; STE ▁; ▁bi VP ▁; ▁right ▁vent ri cular ▁pressure ▁over load ▁; RV PO
D-320	-0.5448995232582092	speckle tracking echocardiography ;STE ; biVP ; right ventricular pressure overload ;RVPO
P-320	-0.0738 -1.1213 -0.0636 -0.0235 -0.1772 -0.2603 -0.5981 -0.3346 -0.5884 -0.2443 -2.3323 -0.3316 -0.5106 -0.6867 -0.2281 -0.6997 -2.7016 -0.7610 -0.4716 -0.1996 -0.2761 -0.0886 -0.7312 -0.0561 -0.5199 -0.4389 -0.1931
S-860	Secondary endpoints were inappropriate therapy due to atrial fibrillation and atrial tachyarrhythmias, also evaluated as ATP or shock therapy.<unk>
T-860	secondary endpoints ; therapy ; atrial fibrillation ; atrial tachyarrhythmias ; atp ; shock therapy
H-860	-0.43376678228378296	▁at rial ▁fi bril lation ▁; ▁at rial ▁ta chy ar rhythm ias ▁; ▁ATP ▁; ▁shock ▁ therapy
D-860	-0.43376678228378296	atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
P-860	-2.2584 -0.0336 -0.3030 -0.0225 -0.7507 -0.2304 -0.0702 -0.0738 -0.8166 -1.1403 -0.0812 -0.1800 -0.9324 -0.4853 -0.0740 -0.2063 -0.1311 -0.6219 -0.0326 -0.4281 -0.2366
S-1293	After percutaneous coronary revascularization a hemodynamically stable situation could be achieved and the patient was admitted to the intensive care unit (ICU).<unk>
T-1293	percutaneous ; coronary revascularization ; hemodynamically ; stable ; patient ; intensive care unit ; icu
H-1293	-0.3450263440608978	▁per cuta ne ous ▁corona ry ▁re vas cular ization ▁; ▁hem o dynamic ally ▁; ICU
D-1293	-0.3450263440608978	percutaneous coronary revascularization ; hemodynamically ;ICU
P-1293	-0.1749 -0.0008 -0.0532 -0.1033 -0.3312 -0.0608 -0.0269 -0.1930 -0.3097 -0.2855 -0.3036 -0.3359 -0.0850 -0.0056 -0.0936 -1.1347 -2.8308 -0.1129 -0.1142
S-760	BACKGROUND: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction.<unk>
T-760	obesity ; diabetes mellitus ; metabolic ; comorbidities ; heart failure with preserved ejection fraction
H-760	-0.3859352469444275	▁ob es ity ▁; ▁diabetes ▁mell itus ▁; ▁metabol ic ▁risk ▁factors ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-760	-0.3859352469444275	obesity ; diabetes mellitus ; metabolic risk factors ; heart failure ; preserved ejection fraction
P-760	-2.3668 -0.1078 -0.3236 -0.2410 -0.0522 -0.0382 -0.1445 -0.4292 -0.1324 -0.0118 -0.5076 -0.0364 -0.1956 -2.9401 -0.1236 -0.3236 -0.0756 -0.2037 -0.2488 -0.0505 -0.2000 -0.1685 -0.3978 -0.0128 -0.4457 -0.2567
S-188	We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF.<unk>
T-188	ef ; bnp ; hf ; patients ; prognostic ; significance ; bnp ; ef
H-188	-1.0381709337234497	▁sex ▁; ▁EF ▁; ▁b NP ▁; ▁ HF ▁; ▁bem ▁; ▁b NP ▁; ▁b NP ▁; ▁sex ▁; ▁EF
D-188	-1.0381709337234497	sex ; EF ; bNP ; HF ; bem ; bNP ; bNP ; sex ; EF
P-188	-4.2645 -0.1751 -0.7620 -0.2160 -0.8373 -1.0773 -0.1166 -0.2555 -0.2210 -0.4598 -3.0978 -0.3053 -1.7622 -0.7950 -0.2005 -3.4202 -0.9990 -0.2394 -2.7290 -0.3612 -0.7880 -0.4230 -0.3722
S-1087	PERK inhibition prevented the loss of full-length SCN5A and Kv4.3 mRNA levels resulting from expressing Na+ channel mRNA splice variants.<unk>
T-1087	perk ; scn5a ; kv4.3 ; mrna ; mrna splice
H-1087	-0.7502381205558777	▁per k ▁inhibi tion ▁; ▁full - leng th ▁s CN 5 a ▁; ▁kv 4.3 ▁m RNA ▁levels ▁; ▁na + ▁channel ▁m RNA ▁sp lice
D-1087	-0.7502381205558777	perk inhibition ; full-length sCN5a ; kv4.3 mRNA levels ; na+ channel mRNA splice
P-1087	-0.9232 -0.4807 -0.4970 -0.0863 -0.3154 -2.3075 -0.0359 -0.0060 -0.1447 -0.2388 -2.2974 -0.5428 -0.7638 -0.1999 -0.4258 -1.5732 -0.0645 -0.1695 -0.3434 -0.2565 -0.0867 -5.2119 -0.1374 -0.1187 -0.3390 -1.7984 -0.2537 -1.8186 -0.3202
S-112	We sought to evaluate the differential effect of LVEF on long-term mortality after hospitalization for acute decompensated HF in a real-world setting.<unk>
T-112	differential effect ; lvef ; mortality ; hospitalization ; acute ; decompensated hf
H-112	-0.3694910407066345	▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁hospital ization ▁; ▁a cute ▁de com pensa ted ▁ HF
D-112	-0.3694910407066345	LVEF ; long-term mortality ; hospitalization ; acute decompensated HF
P-112	-1.7551 -1.1035 -0.4071 -1.3164 -0.1491 -0.0969 -0.3184 -0.0717 -0.4818 -0.4670 -0.1623 -0.2219 -0.0162 -0.0303 -0.0999 -0.3577 -0.0144 -0.1172 -0.2641 -0.0884 -0.3182 -0.2712
S-1812	Moreover, elevated Mena expression correlates with HF in human and animal models, yet the precise role of Mena in cardiac pathophysiology is unclear.<unk>
T-1812	elevated ; mena expression ; correlates ; hf ; mena ; cardiac ; pathophysiology
H-1812	-0.6275734901428223	▁Men a ▁expression ▁; ▁ HF ▁; ▁Men a ▁; ▁cardiac ▁pat ho phy si ology
D-1812	-0.6275734901428223	Mena expression ; HF ; Mena ; cardiac pathophysiology
P-1812	-0.2527 -0.0765 -0.0334 -0.1111 -0.2779 -0.2287 -0.1233 -4.5058 -0.0896 -0.1650 -0.1162 -1.5974 -0.9498 -0.2838 -1.9986 -0.0970 -0.2047 -0.1848
S-282	After the addition of salt loading and uninephrectomy to the ANG II infusion mouse model, cardiac function was significantly impaired, and mice developed HF.<unk>
T-282	salt loading ; uninephrectomy ; ang ii infusion ; cardiac function ; hf
H-282	-0.39885178208351135	▁salt ▁load ing ▁; ▁un ine ph r ecto my ▁; ▁ang ▁II ▁in fusion ▁mouse ▁model ▁; ▁cardiac ▁function ▁; ▁mi ce ▁; ▁ HF
D-282	-0.39885178208351135	salt loading ; uninephrectomy ; ang II infusion mouse model ; cardiac function ; mice ; HF
P-282	-0.2524 -0.0057 -0.0316 -0.1666 -0.0120 -0.0428 -0.6106 -0.0900 -0.1672 -2.3953 -0.1214 -0.9366 -0.3500 -0.0370 -0.0324 -1.6273 -0.5166 -0.2094 -0.0428 -0.5983 -0.2991 -1.1599 -0.1005 -0.4739 -0.4531 -0.0815 -0.2096 -0.1441
S-433	Combination of these into an echocardiographic score allowed prediction of LV reverse remodeling with a sensitivity of 84% and a specificity of 79%.<unk>
T-433	combination ; echocardiographic ; lv reverse remodeling ; sensitivity ; specificity
H-433	-0.6365557909011841	▁e cho car dio graphic ▁score ▁; ▁LV ▁rever se ▁remodel ing
D-433	-0.6365557909011841	echocardiographic score ; LV reverse remodeling
P-433	-0.1993 -0.4487 -1.7042 -1.6440 -1.2817 -1.7018 -0.1111 -0.0653 -0.0247 -0.0784 -0.1382 -0.0972 -1.1802 -0.2371
S-1353	Patients with atrial fibrillation (AF) and heart failure (HF) are at risk for stroke, and progress in anticoagulation has led to new options for these patients.<unk>
T-1353	patients ; atrial fibrillation ; heart failure ; hf ; stroke ; anticoagulation ; patients
H-1353	-0.5867281556129456	▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure ▁; HF ▁; ▁stroke ▁; ▁antico ag ulation
D-1353	-0.5867281556129456	atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
P-1353	-0.6865 -0.0411 -0.7992 -0.0304 -0.9236 -0.5906 -0.3125 -0.3501 -0.7094 -0.1311 -0.3697 -0.2139 -0.4853 -1.5756 -0.5082 -1.4640 -1.5410 -0.0770 -0.6776 -0.2477
S-1942	However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17±22 versus 4±15 bpm; P value=0.027).<unk>
T-1942	uptitration ; hr reduction ; bpm ; p value
H-1942	-0.8577102422714233	▁dose ▁up tit ration ▁; ▁HR ▁re duction
D-1942	-0.8577102422714233	dose uptitration ; HR reduction
P-1942	-2.6904 -0.0977 -0.6088 -0.5231 -0.2552 -1.9535 -0.2200 -0.0432 -1.9028 -0.2825
S-508	The occlusion time of the bottleneck stent and the timing of myocardial infarction could be modulated by the duration of antiplatelet medication.<unk>
T-508	bottleneck stent ; myocardial infarction ; antiplatelet medication
H-508	-0.436774343252182	▁bottle ne ck ▁sten t ▁; ▁my o card ial ▁in far ction ▁; ▁anti plate let ▁medication
D-508	-0.436774343252182	bottleneck stent ; myocardial infarction ; antiplatelet medication
P-508	-0.3818 -0.0513 -0.0656 -0.3619 -0.4829 -0.2105 -2.0549 -0.3542 -1.0407 -0.0642 -0.0586 -0.2280 -0.0949 -0.3113 -0.0206 -0.3529 -1.1207 -0.6126 -0.5570 -0.3110
S-278	At 6 wk after the procedures, only ANS mice showed significant decreases in LV fractional shortening and increases in lung weight with a high incidence.<unk>
T-278	lv fractional shortening ; lung ; incidence
H-278	-0.48841312527656555	▁ ANS ▁mi ce ▁; ▁LV ▁ fraction al ▁short en ing ▁; ▁lung ▁weight
D-278	-0.48841312527656555	ANS mice ; LV fractional shortening ; lung weight
P-278	-2.7446 -0.2642 -0.2577 -0.3508 -0.1973 -0.3652 -1.5867 -0.0059 -0.0430 -0.1373 -0.2035 -0.1160 -0.1625 -0.5423 -0.2788 -0.8047 -0.2427
S-234	Our data suggest that Fontan failure is a distinct circulatory derangement with hemodynamic features similar to portal hypertension, albeit with limited ability to augment cardiac output.<unk>
T-234	fontan failure ; circulatory ; hemodynamic ; portal hypertension ; cardiac output
H-234	-0.3409441113471985	▁Font an ▁failure ▁; ▁circula tory ▁de rang ement ▁; ▁hem o dynamic ▁; ▁portal ▁hyper tension ▁; ▁aug ment ▁cardiac ▁output
D-234	-0.3409441113471985	Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; augment cardiac output
P-234	-0.1958 -0.1493 -0.0378 -0.1564 -1.3278 -0.0359 -0.4275 -0.0264 -0.0790 -0.2144 -0.5545 -0.2163 -0.0133 -0.2253 -0.0250 -0.2132 -0.1506 -0.3425 -2.9771 -0.0241 -0.1723 -0.0160 -0.4560 -0.1464
S-679	Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95% CI, 1.75 to 2.17).<unk>
T-679	trastuzumab ; chf ; nontrastuzumab users ; hazard ratio
H-679	-0.21384957432746887	▁Tras tuz um ab ▁; ▁CHF ▁; ▁non tras tuz um ab ▁; haz ard ▁ratio ▁; HR
D-679	-0.21384957432746887	Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio ;HR
P-679	-0.3763 -0.0618 -0.0429 -0.0178 -0.2120 -0.1038 -0.1658 -0.5773 -0.0393 -0.0298 -0.0905 -0.0757 -0.4686 -0.2527 -0.1303 -0.0141 -0.4202 -0.2831 -0.6502 -0.2648
S-446	Within a diverse community-based cohort with incident systolic heart failure, use of spironolactone was not independently associated with risks of hospitalization or death.<unk>
T-446	systolic heart failure ; spironolactone ; hospitalization ; death
H-446	-0.845209002494812	▁incident ▁sy sto lic ▁heart ▁failure ▁; ▁spi rono lac tone ▁; ▁hospital ization
D-446	-0.845209002494812	incident systolic heart failure ; spironolactone ; hospitalization
P-446	-2.5371 -2.1302 -0.0616 -1.3962 -1.3703 -0.0948 -0.2863 -0.5258 -0.0187 -0.0765 -0.1061 -0.8748 -1.3733 -0.1843 -2.2282 -0.2592
S-1673	In this study, we have investigated the potential dysfunction of a naturally occurring Rad variant (Q66P) that has been associated with congestive heart failure in humans.<unk>
T-1673	dysfunction ; rad variant ; q66p ; congestive heart failure
H-1673	-0.6617308259010315	▁Rad ▁variant ▁; Q 66 p ▁; ▁con ges tive ▁heart ▁failure ▁; ▁humans
D-1673	-0.6617308259010315	Rad variant ;Q66p ; congestive heart failure ; humans
P-1673	-2.4813 -0.7918 -0.2537 -3.0308 -0.1263 -0.1654 -0.1566 -0.0159 -0.1449 -0.0978 -0.7977 -0.0751 -1.4749 -0.5808 -0.2289 -0.1658
S-1614	Two networks were established and then functional enrichment analysis revealed that "regulation of programmed cell death" was most significantly over-represented in common DEGs.<unk>
T-1614	functional enrichment analysis ; regulation ; cell death ; degs
H-1614	-0.7842798233032227	▁regula tion ▁of ▁programme d ▁cell ▁death ▁; ▁de g s
D-1614	-0.7842798233032227	regulation of programmed cell death ; degs
P-1614	-3.7266 -0.3089 -1.1271 -0.0329 -0.0597 -0.7352 -0.7970 -0.6765 -1.0190 -1.1831 -0.0572 -0.2583 -0.2140
S-1642	Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.<unk>
T-1642	outcomes ; patients ; atrial fibrillation ; early treatment of atrial fibrillation for stroke prevention trial
H-1642	-0.5979218482971191	▁at rial ▁fi bril lation ▁; ▁at rial ▁fi bril lation ▁; ▁Stro ke ▁pre vention ▁Tri al
D-1642	-0.5979218482971191	atrial fibrillation ; atrial fibrillation ; Stroke prevention Trial
P-1642	-1.4489 -0.1126 -0.8590 -0.0926 -1.0390 -0.3473 -3.2513 -0.2698 -0.5793 -0.0777 -1.1110 -0.3179 -1.1360 -0.0694 -0.1356 -0.0038 -0.6260 -0.0350 -0.2627 -0.1834
S-564	CONCLUSIONS: Beyond divergent etiology and comorbidities, younger patients exhibited striking differences in presentation and outcomes compared with older counterparts.<unk>
T-564	etiology ; comorbidities ; patients ; outcomes
H-564	-0.5656548142433167	▁et i ology ▁; ▁como rbi di ties
D-564	-0.5656548142433167	etiology ; comorbidities
P-564	-0.2188 -0.4310 -0.0656 -0.1989 -1.0551 -0.1417 -0.6934 -0.2235 -2.4555 -0.1730
S-1358	RECENT FINDINGS: Apart from these perturbations, increasing evidence points to alterations in intestinal morphology, permeability, and absorption function in patients with CHF.<unk>
T-1358	evidence ; intestinal ; patients ; chf
H-1358	-0.56622314453125	▁intestinal ▁ morph ology ▁; ▁per me ability ▁; ▁ab sor p tion ▁function ▁; ▁CHF
D-1358	-0.56622314453125	intestinal morphology ; permeability ; absorption function ; CHF
P-1358	-5.7807 -0.3128 -0.0457 -0.1872 -0.2198 -0.1600 -0.0317 -0.0480 -0.3915 -0.0063 -0.2062 -0.3589 -0.4112 -0.1277 -0.6812 -0.6181 -0.3590 -0.2459
S-1756	We excluded 921 patients who did not perform a maximal exercise, based on lack of achievement of anaerobic metabolism (peak respiratory quotient ≤1.05).<unk>
T-1756	patients ; exercise ; anaerobic metabolism ; peak respiratory quotient
H-1756	-0.6649565696716309	▁exercise ▁; ▁ana ero bic ▁metabolism ▁; ▁pe ak ▁respirator y
D-1756	-0.6649565696716309	exercise ; anaerobic metabolism ; peak respiratory
P-1756	-3.4188 -0.4081 -0.4678 -0.1526 -0.8793 -0.4844 -0.3243 -0.5837 -0.0156 -0.3943 -0.1198 -1.1829 -0.2128
S-1969	Beneficial effect of ARNI was consistent also for total and cardiovascular mortality, for hospitalization for heart failure and in other pre-specified subgroup analyses, including quality of life.<unk>
T-1969	arni ; cardiovascular mortality ; hospitalization ; heart failure ; quality of life
H-1969	-0.566586971282959	▁AR NI ▁; ▁cardiovascular ▁mortal ity ▁; ▁hospital ization ▁; ▁heart ▁failure
D-1969	-0.566586971282959	ARNI ; cardiovascular mortality ; hospitalization ; heart failure
P-1969	-1.9149 -2.0487 -0.3348 -0.3507 -0.2657 -0.0643 -0.3963 -0.4315 -0.1248 -0.6335 -0.2146 -0.1447 -0.7208 -0.2868
S-768	The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation.<unk>
T-768	myocardial dd ; muscle ; titin hypophosphorylation
H-768	-0.4835949242115021	▁my o card ial ▁ DD ▁; ▁muscle ▁strip ▁sti ff ness ▁; ▁titi n ▁hypo phos phor y lation
D-768	-0.4835949242115021	myocardial DD ; muscle strip stiffness ; titin hypophosphorylation
P-768	-0.6458 -0.0786 -0.1569 -0.0355 -0.6645 -0.2339 -0.2298 -2.1764 -0.0946 -0.3835 -0.3654 -0.6639 -0.2608 -0.5267 -0.0782 -0.5795 -0.3760 -0.6759 -0.7286 -1.0663 -0.4379 -0.1804
S-1917	The combined training resulted in an improvement in peak work rate (range: 6% to 36%) and peak quadriceps force (range: 3% to 80%) in all participants.<unk>
T-1917	combined training ; peak work rate ; peak quadriceps force
H-1917	-0.2168215811252594	▁pe ak ▁work ▁rate ▁; ▁pe ak ▁quadri cep s ▁force
D-1917	-0.2168215811252594	peak work rate ; peak quadriceps force
P-1917	-0.4148 -0.0240 -0.4181 -0.0381 -0.1858 -0.0154 -0.0265 -0.7063 -0.1386 -0.0652 -0.1474 -0.3692 -0.2693
S-95	Of these proteins, 176 exhibited altered expression during cardiac hypertrophy and failure; we conducted extensive functional characterization of one of these proteins, Nucleolin.<unk>
T-95	proteins ; expression ; cardiac hypertrophy ; proteins ; nucleolin
H-95	-0.8186643123626709	▁protein s ▁; ▁cardiac ▁hyper trop hy ▁; ▁failure ▁; ▁protein s ▁; ▁Nu cle olin
D-95	-0.8186643123626709	proteins ; cardiac hypertrophy ; failure ; proteins ; Nucleolin
P-95	-3.7675 -0.0649 -0.3192 -0.4950 -0.4687 -0.0972 -0.8138 -0.3378 -1.5501 -0.3659 -2.7825 -0.1033 -0.7461 -2.0423 -0.0334 -0.1882 -0.2121 -0.3479
S-1750	CONCLUSIONS: Evidence-based treatment has led to dramatic improvement in the prognosis of idiopathic dilated cardiomyopathy during the past 3 decades.<unk>
T-1750	evidence-based ; prognosis ; idiopathic dilated cardiomyopathy
H-1750	-0.4548298716545105	▁ idio pathi c ▁dil ated ▁cardio my o pathy
D-1750	-0.4548298716545105	idiopathic dilated cardiomyopathy
P-1750	-1.1596 -0.0613 -0.1510 -0.3375 -0.4806 -0.0805 -0.4550 -1.7517 -0.3919 -0.1548 -0.3120 -0.1221
S-1728	In contrast, patients cared for by high-volume physicians had higher readmission rates (25.8% versus 21.5%; P<0001); this relationship was similar across hospital volume groups.<unk>
T-1728	patients ; physicians ; readmission ; hospital
H-1728	-0.90101158618927	▁patients ▁; ▁high - volu me ▁physician s ▁; ▁read mission ▁rates
D-1728	-0.90101158618927	patients ; high-volume physicians ; readmission rates
P-1728	-4.4432 -0.2223 -0.7516 -0.0492 -0.2072 -0.1230 -1.2566 -0.0709 -0.3681 -0.6581 -0.2460 -0.8618 -3.1817 -0.1745
S-1024	We have reviewed the current status of NP measurement together with the potential contribution of POC measurement of NPs to clinical care delivery in the emergency and other settings.<unk>
T-1024	poc ; nps ; clinical
H-1024	-0.5705240368843079	▁ NP ▁measure ment ▁; ▁PO C ▁measure ment ▁; ▁ NP s ▁; ▁clinic al ▁care ▁delivery ▁; ▁emergency
D-1024	-0.5705240368843079	NP measurement ; POC measurement ; NPs ; clinical care delivery ; emergency
P-1024	-1.5621 -0.0867 -0.6133 -0.0321 -0.1238 -2.2612 -2.5105 -0.7644 -0.0256 -0.2033 -0.7782 -0.0164 -0.1018 -0.2913 -0.2875 -0.0726 -0.8014 -0.7098 -0.7615 -0.1140 -0.2099 -0.2242
S-1751	The benefits of controlled randomized trials can be replicated in the real world, emphasizing the importance of tailored follow-up and long-term continuity of care.<unk>
T-1751	randomized ; follow-up
H-1751	-0.7771995067596436	▁random ized ▁trial s ▁; ▁follow - up
D-1751	-0.7771995067596436	randomized trials ; follow-up
P-1751	-3.3360 -0.2905 -0.3156 -0.0370 -0.7112 -0.5185 -0.1289 -0.0457 -2.1833 -0.2052
S-781	We evaluated the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated measure of HF with reduced EF, in patients with HFpEF.<unk>
T-781	kansas city cardiomyopathy questionnaire ; kccq ; hf with reduced ef ; patients ; hfpef
H-781	-0.5673050880432129	▁Kansas ▁City ▁; ▁card i om yo pathy ▁Question naire ▁; ▁k cc q ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF
D-781	-0.5673050880432129	Kansas City ; cardiomyopathy Questionnaire ; kccq ; HF ; EF ; HFpEF
P-781	-0.0342 -0.1935 -1.4991 -1.9114 -0.1291 -0.2006 -1.7022 -0.8959 -1.4807 -0.0112 -0.1656 -0.9596 -0.0508 -1.4641 -0.0774 -0.2013 -0.2120 -0.0976 -1.3383 -0.1370 -0.6405 -0.4744 -0.0263 -0.2980 -0.3255 -0.2234
S-491	Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis.<unk>
T-491	tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; right ventricular contractile function ; prognosis
H-491	-0.6212741136550903	▁Tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; ▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁relationship ▁; ▁heart ▁failure ▁; ▁right ▁vent ri cular ▁contract ile
D-491	-0.6212741136550903	Tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure relationship ; heart failure ; right ventricular contractile
P-491	-1.0189 -0.2801 -0.0245 -0.4504 -0.0022 -0.0057 -1.5446 -0.3285 -2.2198 -0.4776 -0.0374 -0.1926 -0.0070 -0.0227 -0.1183 -1.2665 -0.1008 -1.4395 -1.3312 -0.5707 -0.1680 -0.2005 -0.1210 -0.4067 -0.2100 -2.6543 -0.8351 -0.2042 -0.2746 -2.1064 -1.0527 -0.2085
S-296	For patients requiring biventricular support, we have used a hybrid system consisting of a HeartMate II LVAD and CentriMag right ventricular assist device (RVAD).<unk>
T-296	patients ; biventricular support ; heartmate ii ; lvad ; centrimag ; right ventricular assist device ; rvad
H-296	-0.7919635772705078	▁bi ven tri cular ▁support ▁; ▁Heart Mate ▁II ▁; ▁l VAD ▁; ▁centri Mag ▁right ▁vent ri cular ▁assist ▁device ▁; ▁r VAD
D-296	-0.7919635772705078	biventricular support ; HeartMate II ; lVAD ; centriMag right ventricular assist device ; rVAD
P-296	-0.4511 -0.6978 -1.1774 -0.7448 -2.2358 -0.3242 -2.5891 -0.1159 -0.7665 -1.0182 -1.0680 -0.0471 -0.0786 -0.4460 -0.0679 -0.2549 -1.5325 -0.7586 -0.1917 -0.8477 -0.5263 -0.4072 -3.5150 -0.1250 -0.4183 -0.1853
S-521	Blood pressure was measured by arm cuff; stroke volume (SV), ejection fraction, and end-diastolic volume were assessed by echocardiography.<unk>
T-521	blood pressure ; arm cuff ; stroke volume ; ejection fraction ; end-diastolic volume ; echocardiography
H-521	-0.38484442234039307	▁Blood ▁pressure ▁; ▁arm ▁cu ff ▁; ▁stroke ▁volume ▁; ▁sv ▁; ▁e je ction ▁ fraction ▁; ▁end - dia sto lic ▁volume ▁; ▁e cho card i ography
D-521	-0.38484442234039307	Blood pressure ; arm cuff ; stroke volume ; sv ; ejection fraction ; end-diastolic volume ; echocardiography
P-521	-0.2008 -0.1102 -0.1637 -0.9407 -0.0644 -0.2467 -0.0596 -0.7460 -0.2950 -0.2241 -2.0996 -0.4033 -0.0674 -0.1042 -0.0296 -0.2231 -0.0017 -0.2989 -0.1480 -0.1040 -0.9649 -0.5524 -0.6800 -0.3354 -0.3050 -0.1002 -0.7284 -0.5262 -0.4230 -0.7283 -0.2837 -0.1564
S-1060	The percentage of fibrosis of heart failure myocardial tissue was compared with similar left ventricular tissue from control animals using trichrome blue histologic analysis.<unk>
T-1060	fibrosis ; heart failure ; myocardial tissue ; left ventricular ; trichrome blue histologic analysis
H-1060	-0.560896098613739	▁fibro sis ▁; ▁heart ▁failure ▁; ▁my o card ial ▁tissu e ▁; ▁left ▁vent ri cular ▁tissu e ▁; ▁tri ch rom e ▁blue ▁his t ologic
D-1060	-0.560896098613739	fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue histologic
P-1060	-0.0046 -0.7350 -0.7279 -0.2770 -0.0389 -0.5951 -1.3862 -0.3261 -0.9780 -0.1484 -0.6878 -0.3643 -0.2865 -0.1411 -2.9747 -1.2882 -0.4181 -0.7943 -0.2913 -0.3002 -0.4379 -0.0375 -0.0466 -0.0770 -0.2042 -1.6973 -0.4437 -0.1977 -0.7355 -0.1855
S-1802	A total of 569 individuals aged 55-85 and Caucasian were genotyped for SNP rs10927887 in the Ka renal chloride channel gene (CLCNKA).<unk>
T-1802	genotyped ; snp ; rs10927887 ; ka renal chloride channel gene ; clcnka
H-1802	-0.7563156485557556	▁Cau ca sian ▁; ▁s NP ▁rs 109 27 887 ▁; ▁Ka ▁renal ▁chlor ide ▁channel ▁gene ▁; CL n KA
D-1802	-0.7563156485557556	Caucasian ; sNP rs10927887 ; Ka renal chloride channel gene ;CLnKA
P-1802	-5.4075 -0.0044 -0.0798 -0.1186 -0.4962 -0.1027 -1.5988 -0.0313 -0.0732 -0.0796 -0.1416 -1.1485 -0.0238 -0.3509 -0.7644 -0.1668 -2.5722 -0.4003 -0.9360 -1.5211 -0.4288 -0.6046 -0.3443
S-1934	Given that exercise training improves outcomes in HF patients, assessment of perceived barriers may facilitate individualized approaches to implement exercise training therapy in clinical practice.<unk>
T-1934	exercise ; training ; outcomes ; hf ; patients ; exercise ; training ; therapy ; clinical
H-1934	-0.6432761549949646	▁exercise ▁training ▁; ▁ HF ▁patients ▁; ▁exercise ▁training ▁ therapy
D-1934	-0.6432761549949646	exercise training ; HF patients ; exercise training therapy
P-1934	-0.4185 -0.1706 -0.1845 -0.8647 -0.0519 -2.4163 -0.6133 -1.0271 -0.1877 -0.9390 -0.0666 -1.1893 -0.2331
S-476	However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight.<unk>
T-476	contractile function ; lv dilatation ; lv end-diastolic pressure ; wall stress ; lung
H-476	-0.43678608536720276	▁contract ile ▁function ▁; ▁LV ▁di la tation ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; wall ▁stress ▁; ▁lung ▁weight
D-476	-0.43678608536720276	contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
P-476	-0.0446 -2.3392 -0.6467 -0.1504 -0.1799 -0.1967 -0.2409 -0.0089 -0.1792 -0.9248 -0.8231 -0.4445 -0.0441 -0.9358 -0.5122 -0.5817 -0.3431 -0.3343 -0.4451 -0.1661 -0.1999 -0.2856 -0.1214 -0.5575 -0.2139
S-265	METHODS: NT-proBNP levels were measured in plasma obtained from 99 patients with dyspnea and left ventricular dysfunction upon admission to the ED.<unk>
T-265	nt-probnp ; plasma ; patients ; dyspnea ; left ventricular dysfunction ; admission
H-265	-0.6755626797676086	▁NT - pro b NP ▁levels ▁; ▁plasma ▁; ▁dys pne a ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁ad mission ▁; ▁ED
D-265	-0.6755626797676086	NT-probNP levels ; plasma ; dyspnea ; left ventricular dysfunction ; admission ; ED
P-265	-0.2741 -0.0782 -0.0404 -1.1321 -0.8720 -0.3218 -0.2518 -2.4146 -0.1956 -0.5992 -0.1222 -0.2969 -0.1473 -0.0532 -3.6925 -1.9406 -0.5626 -0.5195 -1.5246 -0.5466 -0.0106 -0.0110 -1.0305 -0.4164 -0.3040 -0.2066
S-1035	It is a consequence of pathological remodelling of the heart, which involves cardiac hypertrophy (a robust predictor of subsequent HF and death), fibrosis and inflammation.<unk>
T-1035	pathological ; remodelling ; heart ; cardiac hypertrophy ; hf ; death ; fibrosis ; inflammation
H-1035	-0.3593541979789734	▁path ological ▁remodel ling ▁; ▁heart ▁; ▁cardiac ▁hyper trop hy ▁; ▁ HF ▁; ▁death ▁; ▁fibro sis ▁; ▁ inflammation
D-1035	-0.3593541979789734	pathological remodelling ; heart ; cardiac hypertrophy ; HF ; death ; fibrosis ; inflammation
P-1035	-0.2656 -0.1328 -0.1982 -0.1058 -0.4567 -1.0856 -0.2896 -0.1608 -0.2735 -0.0715 -0.9181 -0.1109 -0.0828 -0.0482 -0.1633 -2.3092 -0.2689 -0.0115 -0.5147 -0.2759 -0.0316 -0.0314 -0.5851 -0.2329
S-842	In conclusion, in the HF-ACTION cohort, there was no correlation with baseline Hgb and baseline HRQoL as measured by the KCCQ.<unk>
T-842	hf-action ; correlation ; baseline ; hgb ; baseline ; hrqol ; kccq
H-842	-0.5016264319419861	▁ HF - ac tion ▁co hor t ▁; ▁base line ▁h gb ▁; ▁base line ▁HR Qo L ▁; ▁k cc q
D-842	-0.5016264319419861	HF-action cohort ; baseline hgb ; baseline HRQoL ; kccq
P-842	-1.3732 -0.2502 -0.0427 -1.4139 -0.7470 -0.1076 -1.0118 -0.4471 -0.1548 -0.0014 -0.0102 -1.8608 -0.0239 -0.0447 -0.0022 -0.0069 -1.3965 -0.0283 -0.8820 -0.0943 -0.6829 -0.0703 -1.2966 -0.4186 -0.1729
S-120	BACKGROUND: Circulating progenitor cells (CPCs) are involved in the process of endothelial repair and are a prognostic factor in cardiovascular diseases.<unk>
T-120	circulating progenitor cells ; cpcs ; endothelial ; prognostic ; cardiovascular diseases
H-120	-0.3989301025867462	▁Circula ting ▁pro gen itor ▁cell s ▁; ▁c PC s ▁; ▁en dot heli al ▁repair ▁; ▁cardiovascular
D-120	-0.3989301025867462	Circulating progenitor cells ; cPCs ; endothelial repair ; cardiovascular
P-120	-0.2784 -0.0727 -0.0357 -0.1839 -0.1860 -0.7308 -0.0332 -0.2899 -0.1884 -0.9623 -0.0571 -0.2034 -0.0324 -0.9172 -0.1919 -0.0153 -0.1285 -0.2602 -0.2667 -3.1907 -0.1528
S-1158	OBJECTIVES: This study sought to examine the relationships between right ventricular (RV) function, body composition, and prognosis in patients with advanced heart failure (HF).<unk>
T-1158	right ventricular ; rv ; prognosis ; patients ; heart failure ; hf
H-1158	-0.6132788062095642	▁right ▁vent ri cular ▁; RV ▁; ▁body ▁composition ▁; ▁advanced ▁heart ▁failure ▁; HF
D-1158	-0.6132788062095642	right ventricular ;RV ; body composition ; advanced heart failure ;HF
P-1158	-0.1252 -2.2265 -0.6621 -0.1589 -0.6117 -0.2372 -0.6608 -0.6349 -0.4827 -0.2058 -2.5266 -0.6970 -0.0764 -0.6220 -0.0212 -0.2896 -0.1873
S-1385	The objective of this study was to investigate the impact of ventricular assist device (VAD) and extracorporeal membrane oxygenation (ECMO) on renal function in children.<unk>
T-1385	ventricular assist device ; vad ; extracorporeal membrane oxygenation ; ecmo ; renal function
H-1385	-0.4193575382232666	▁vent ri cular ▁assist ▁device ▁; VAD ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁; ▁ec mo ▁; ▁renal ▁function
D-1385	-0.4193575382232666	ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function
P-1385	-0.9992 -0.5177 -0.1419 -1.0136 -0.8223 -0.3381 -0.0158 -0.2073 -0.4130 -0.1746 -0.7969 -0.1468 -0.0398 -0.0845 -0.3314 -0.2457 -0.3459 -0.5264 -0.6919 -0.4428 -0.0188 -0.5467 -0.9860 -0.2177
S-1604	The American College of Cardiology/American Heart Association guidelines on evaluation and management of patients with RAS provide the framework for determining individualized assessment and treatment plans for patients with RAS.<unk>
T-1604	american college of cardiology ; american heart association ; patients ; ras ; patients ; ras
H-1604	-0.6702433228492737	▁American ▁college ▁of ▁Card i ology ▁; American ▁Heart ▁association ▁; ▁ RAS
D-1604	-0.6702433228492737	American college of Cardiology ;American Heart association ; RAS
P-1604	-2.7139 -0.2500 -0.0362 -2.0822 -0.2964 -0.0350 -0.2244 -0.2962 -0.9348 -0.3914 -0.4974 -1.0522 -0.0274 -0.9975 -0.2185
S-375	This case report demonstrates that functional MS could develop even in a patient with a history of successful valve plasty for degenerative MR, if the LV is dilated by another disease.<unk>
T-375	report ; functional ms ; patient ; valve plasty ; degenerative mr ; dilated ; disease
H-375	-0.5705640316009521	▁case ▁report ▁; ▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁LV
D-375	-0.5705640316009521	case report ; functional MS ; valve plasty ; degenerative MR ; LV
P-375	-1.9249 -0.0215 -0.0957 -0.4400 -0.2958 -0.1424 -4.2760 -0.0424 -0.0579 -0.4373 -0.1478 -0.0443 -0.0226 -0.0170 -0.1324 -0.2630 -0.1164 -2.2217 -0.1414
S-131	Higher EO-CFUs and lower CD34+VEGFR2+ cells were associated with improved functional capacity and reduced mortality in nondiabetic patients.<unk>
T-131	eo-cfus ; cells ; functional capacity ; mortality ; nondiabetic ; patients
H-131	-1.2917968034744263	▁ EO - C FU s ▁; ▁cd 34 ▁; ▁ve g f 2 ▁; ▁cell s ▁; ▁non dia be tic ▁patients
D-131	-1.2917968034744263	EO-CFUs ; cd34 ; vegf2 ; cells ; nondiabetic patients
P-131	-2.0811 -0.4426 -0.2084 -3.9552 -1.9987 -0.4234 -0.1155 -2.8430 -0.3554 -2.3260 -2.3509 -0.7079 -2.5395 -0.4970 -1.2084 -2.2286 -0.1202 -0.5229 -2.4316 -0.6380 -0.3416 -0.5809 -2.6824 -0.4569 -0.2387
S-1857	BACKGROUND: There is a class I recommendation for implantable cardioverter-defibrillator deactivation discussions to occur between physicians and heart failure patients.<unk>
T-1857	implantable cardioverter-defibrillator ; physicians ; heart failure ; patients
H-1857	-0.7014625668525696	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁physician s ▁; ▁heart ▁failure
D-1857	-0.7014625668525696	implantable cardioverter-defibrillator deactivation ; physicians ; heart failure
P-1857	-2.4090 -0.0322 -0.5223 -0.0920 -0.6853 -0.0951 -0.0525 -0.8591 -3.1543 -1.4062 -0.1509 -0.2403 -0.0541 -0.5961 -0.4943 -1.5101 -0.0755 -0.4274 -0.1866 -0.0506 -2.0517 -0.2866
S-340	However, functional MS could develop even in patients with a history of successful valve plasty and annular size reduction for degenerative MR if the LV were dilated by another disease.<unk>
T-340	functional ms ; patients ; valve plasty ; degenerative mr ; dilated ; disease
H-340	-0.3678193688392639	▁functional ▁MS ▁; ▁val ve ▁plast y ▁; ▁ann ular ▁size ▁re duction ▁; ▁de genera tive ▁MR ▁; ▁LV
D-340	-0.3678193688392639	functional MS ; valve plasty ; annular size reduction ; degenerative MR ; LV
P-340	-0.6995 -0.0692 -0.2493 -3.6103 -0.0428 -0.0482 -0.4448 -0.1377 -0.0033 -0.0010 -0.2467 -0.0880 -0.0062 -0.3211 -0.0366 -0.0216 -0.0220 -0.0831 -0.1324 -0.0908 -1.6157 -0.1216
S-1001	BACKGROUND: Frailty, an important prognostic indicator in heart failure (HF), may be defined as a biological phenotype or an accumulation of deficits.<unk>
T-1001	frailty ; prognostic ; heart failure ; hf ; biological phenotype
H-1001	-0.5849015712738037	▁Fra il ty ▁; ▁heart ▁failure ▁; HF ▁; ▁bi ological
D-1001	-0.5849015712738037	Frailty ; heart failure ;HF ; biological
P-1001	-0.9628 -0.2631 -0.2649 -0.1769 -1.8667 -0.0699 -0.2516 -0.2176 -0.5726 -0.1400 -0.0890 -2.5589 -0.1695
S-478	However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure.<unk>
T-478	lv remodeling ; diastolic ; xo inhibition ; symptoms ; hospitalizations ; patients ; severe heart failure
H-478	-0.5688022971153259	▁LV ▁remodel ing ▁; ▁dia sto lic ▁; ▁ XO ▁inhibi tion ▁; ▁hospital ization s ▁; ▁severe ▁heart ▁failure
D-478	-0.5688022971153259	LV remodeling ; diastolic ; XO inhibition ; hospitalizations ; severe heart failure
P-478	-0.0645 -0.3624 -0.0357 -0.1655 -0.9641 -0.6990 -0.4933 -2.9481 -0.3782 -0.1082 -0.2230 -0.0716 -0.3043 -2.6817 -0.1996 -0.2684 -0.1989 -1.1668 -0.6305 -0.1745 -0.1889 -0.1864
S-1442	SDQT increased significantly in the HFVT(+) and HFVT(-) groups compared with the HNorm group during fixed-rate atrial pacing (P = 0.008).<unk>
T-1442	sdqt ; atrial pacing
H-1442	-0.5728785395622253	▁SD QT ▁; ▁ HF VT ▁; ▁ HF VT ▁; ▁h Nor m ▁group ▁; ▁fixed - rate ▁at rial ▁pa cing
D-1442	-0.5728785395622253	SDQT ; HFVT ; HFVT ; hNorm group ; fixed-rate atrial pacing
P-1442	-0.0189 -1.3535 -0.0922 -0.4347 -0.5311 -1.5045 -0.2061 -0.2409 -0.9443 -1.9817 -0.2091 -1.8157 -1.7302 -0.0057 -0.4609 -0.2116 -0.0034 -0.2105 -0.2554 -0.6943 -0.2042 -0.2763 -0.1561 -0.5555 -0.2255
S-192	RESULTS: There were 47,025 patients with reduced (37% female), 13,950 with borderline (48% female), and 38,955 with preserved (65% female) EF.<unk>
T-192	patients ; ef
H-192	-1.3373678922653198	▁border line ▁; ▁EF
D-192	-1.3373678922653198	borderline ; EF
P-192	-1.4599 -0.0268 -0.1924 -5.7717 -0.3185 -0.2550
S-1063	CONCLUSION: The proposed T1-mapping technique can quantify diffuse myocardial changes associated with heart failure without the use of a contrast agent and without breath-holding.<unk>
T-1063	t1-mapping ; myocardial ; heart failure
H-1063	-0.4776588976383209	▁t 1- ma pping ▁technique ▁; ▁diffuse ▁my o card ial ▁changes ▁; ▁heart ▁failure ▁; ▁contrast ▁agent ▁; ▁breath - hold ing
D-1063	-0.4776588976383209	t1-mapping technique ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
P-1063	-0.5179 -0.0791 -0.1885 -0.2016 -2.8684 -0.3375 -0.2298 -0.8496 -0.3660 -1.1230 -0.0906 -1.8044 -0.2420 -0.2958 -0.1387 -0.2713 -0.1763 -0.1569 -0.4849 -0.3972 -0.2169 -0.1004 -0.0660 -0.4688 -0.2699
S-196	After adjusting for over 20 clinical variables, the ability of BNP to predict inhospital mortality was similar among all subgroups (P for heterogeneity = .47).<unk>
T-196	clinical ; bnp ; inhospital ; mortality
H-196	-0.4822096824645996	▁b p ▁; ▁in hospital ▁mortal ity
D-196	-0.4822096824645996	bp ; inhospital mortality
P-196	-0.8153 -1.9092 -0.2319 -0.0704 -0.0304 -0.3783 -0.0476 -0.6914 -0.1653
S-108	Time-dependent analysis showed that the development of IEs among CRT-D recipients was associated with more than twofold (p = 0.01) increased risk for subsequent heart failure or death.<unk>
T-108	ies ; crt-d ; heart failure ; death
H-108	-0.7760584354400635	▁i s ▁; ▁c RT - d ▁recipient s ▁; ▁heart ▁failure ▁; ▁death
D-108	-0.7760584354400635	is ; cRT-d recipients ; heart failure ; death
P-108	-2.6606 -0.5369 -0.1540 -0.1995 -1.7352 -0.1339 -0.7857 -1.5982 -0.1001 -0.1246 -2.1904 -0.1668 -0.7150 -0.8783 -0.2372 -0.2004
S-1800	Overall, in the scenario of lower total expenditure on health per capita and lower gross national income per capita, new strategies are essential for prevention and treatment of HF in LA.<unk>
T-1800	expenditure ; health ; income ; hf
H-1800	-0.5095267295837402	▁ex pendi ture ▁; ▁health ▁per ▁capita ▁; ▁gross ▁national ▁income ▁per ▁capita ▁; ▁ HF ▁; ▁LA
D-1800	-0.5095267295837402	expenditure ; health per capita ; gross national income per capita ; HF ; LA
P-1800	-0.9710 -0.0213 -0.1314 -0.3210 -0.4719 -0.4590 -0.0277 -0.1499 -1.6596 -1.8415 -0.0101 -0.3175 -0.0089 -0.5967 -0.5966 -0.2323 -0.8940 -0.7982 -0.5295 -0.1526
S-314	Neither BTT nor DT currently meet traditional cost-effectiveness limits in models using historical data, although BTT is standard practice for a limited number of patients in many regions.<unk>
T-314	btt ; dt ; btt ; patients
H-314	-0.6109383702278137	▁b t ▁; ▁ DT ▁; ▁cost - effect ive ness ▁limit s ▁; ▁b t ▁; ▁standard ▁practice ▁; ▁patients
D-314	-0.6109383702278137	bt ; DT ; cost-effectiveness limits ; bt ; standard practice ; patients
P-314	-0.6942 -0.7114 -0.1276 -0.0756 -0.3835 -0.3714 -0.1745 -0.2309 -0.1386 -0.2935 -0.5737 -1.4353 -0.0908 -0.2271 -0.9448 -0.8176 -0.2703 -4.0879 -0.0723 -0.5256 -1.3190 -0.2591 -0.2271
S-952	CONCLUSIONS: Our results suggest that AF can be effectively and safely treated with a composite of repeat procedures and pharmaceuticals in patients with HFPEF.<unk>
T-952	pharmaceuticals ; patients ; hfpef
H-952	-0.653740644454956	▁AF ▁; ▁ pharma ce u tical s ▁; ▁h FP EF
D-952	-0.653740644454956	AF ; pharmaceuticals ; hFPEF
P-952	-0.9159 -0.3781 -2.2770 -0.0487 -0.1081 -0.1259 -0.1213 -0.1257 -0.2356 -1.4290 -1.7848 -1.0213 -0.3169 -0.2641
S-1600	Adequate blood pressure control, goal-directed lipid-lowering therapy, smoking cessation, and other preventive measures form the foundation of management of patients with RAS.<unk>
T-1600	blood pressure ; therapy ; patients ; ras
H-1600	-0.42716148495674133	▁blood ▁pressure ▁control ▁; ▁lipid - lo wering ▁ therapy ▁; ▁smoking ▁ces s ation ▁; ▁ RAS
D-1600	-0.42716148495674133	blood pressure control ; lipid-lowering therapy ; smoking cessation ; RAS
P-1600	-2.0112 -0.1204 -0.3547 -0.1192 -2.1968 -0.1221 -0.1047 -0.0554 -0.5905 -0.1242 -0.1909 -0.0829 -0.3876 -0.0193 -0.1435 -0.5227 -1.0528 -0.0178 -0.1126 -0.2138
S-2014	Simulations consist of 10,000 pairs of virtual cohorts used to generate estimates of resource use, costs, survival, and incremental cost-effectiveness ratios from user inputs.<unk>
T-2014	costs
H-2014	-1.5689994096755981	▁cost - effect ive
D-2014	-1.5689994096755981	cost-effective
P-2014	-2.4347 -0.6193 -0.1605 -0.1805 -5.7565 -0.2625
S-999	However, after cardiac magnetic resonance, the typical amyloidotic pattern is found and the final diagnosis of multiple myeloma is made at osteomedullary biopsy.<unk>
T-999	cardiac magnetic resonance ; amyloidotic ; diagnosis ; multiple myeloma ; osteomedullary biopsy
H-999	-0.21330754458904266	▁cardiac ▁magnetic ▁res on ance ▁; ▁a my lo ido tic ▁pattern ▁; ▁multiple ▁mye loma ▁; ▁osteo me dulla ry ▁bio psy
D-999	-0.21330754458904266	cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
P-999	-0.0155 -0.0168 -0.0422 -0.0907 -0.0900 -0.1614 -0.0317 -1.0651 -0.6566 -0.4387 -0.7995 -0.1000 -0.1810 -0.1216 -0.0745 -0.2906 -0.2150 -0.0249 -0.0619 -0.1246 -0.1063 -0.0684 -0.0785 -0.3638 -0.1130
S-1068	Implantable cardioverter-defibrillators (ICDs) decrease mortality, and cardiac resynchronization therapy (CRT) improves symptoms and mortality.<unk>
T-1068	implantable cardioverter-defibrillators ; icds ; mortality ; cardiac resynchronization therapy ; crt ; symptoms ; mortality
H-1068	-0.5165538787841797	▁Implant able ▁cardio ver ter - de fi br illa tors ▁; IC d s ▁; ▁mortal ity ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-1068	-0.5165538787841797	Implantable cardioverter-defibrillators ;ICds ; mortality ; cardiac resynchronization therapy ; cRT
P-1068	-0.8416 -0.0053 -0.3532 -0.0448 -0.9842 -0.0581 -0.0720 -0.4416 -2.8251 -1.3853 -0.1306 -0.4652 -0.2405 -0.3606 -0.1030 -0.4232 -2.0530 -0.0513 -0.4752 -0.0646 -0.0142 -0.0224 -0.0100 -0.3528 -0.6681 -0.0635 -0.3152 -0.9067 -1.2601 -0.8081 -0.2138
S-448	Vascular endothelial growth factor blockade prevents the beneficial effects of beta-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.<unk>
T-448	vascular endothelial growth factor blockade ; beta-blocker ; therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
H-448	-0.45153528451919556	▁Vas cular ▁en dot heli al ▁growth ▁factor ▁block ade ▁; ▁beta - block er ▁ therapy ▁; ▁cardiac ▁function ▁; ▁ang io gene sis ▁; ▁remodel ing ▁; ▁heart ▁failure
D-448	-0.45153528451919556	Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling ; heart failure
P-448	-0.1652 -0.0146 -0.0823 -1.8715 -0.2510 -0.0209 -0.3285 -0.0712 -1.0667 -0.6126 -0.2274 -0.4275 -0.0398 -0.2309 -0.3640 -0.7080 -0.0444 -0.2889 -0.0317 -0.1936 -0.3810 -0.0173 -2.6449 -0.2470 -1.1195 -0.3605 -1.5936 -0.0209 -0.5726 -0.1273 -0.1072 -0.4547 -0.2135
S-915	Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction.<unk>
T-915	dash ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure with preserved ejection fraction
H-915	-0.3782843351364136	▁low - so dium ▁DAS h ▁die t ▁; ▁dia sto lic ▁function ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-915	-0.3782843351364136	low-sodium DASh diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; preserved ejection fraction
P-915	-0.1935 -0.0488 -0.1323 -0.4449 -0.1580 -0.7487 -3.1459 -0.2390 -0.1975 -0.5976 -0.2452 -1.3397 -0.8809 -0.1258 -0.5590 -0.7650 -0.2095 -0.1576 -0.1260 -0.2105 -0.0127 -0.0530 -0.1656 -0.1378 -0.3559 -0.2668 -0.6301 -0.0929 -0.2843 -0.1135 -0.2926 -0.2209 -0.0315 -0.2220 -0.1715 -0.4218 -0.0105 -0.5616 -0.1826
S-1303	Diagnosis of HFpEF is frequently challenging and relies upon careful clinical evaluation, echo-Doppler cardiography, and invasive haemodynamic assessment.<unk>
T-1303	diagnosis ; hfpef ; clinical ; echo-doppler cardiography ; invasive haemodynamic assessment
H-1303	-0.4974878132343292	▁ HF p EF ▁; ▁e cho - d opp ler ▁card i ography ▁; ▁invasi ve ▁ha emo dynamic ▁assessment
D-1303	-0.4974878132343292	HFpEF ; echo-doppler cardiography ; invasive haemodynamic assessment
P-1303	-1.4115 -0.6951 -0.0230 -0.8570 -0.1472 -0.3461 -0.1847 -0.0865 -2.3186 -0.0644 -0.7040 -1.0288 -0.3105 -0.5887 -0.2453 -0.3881 -0.2956 -0.0128 -1.1711 -0.0171 -0.1021 -0.3127 -0.1314
S-177	This study assesses the impact of RAS- and β-blocker uptitrations in patients with HFrEF versus HFpEF during and immediately after a hospital admission.<unk>
T-177	β-blocker ; uptitrations ; patients ; hfref ; hfpef ; hospital ; admission
H-177	-0.6507635712623596	▁ RAS - ▁; ▁β - block er ▁up ti tra tions ▁; ▁h Fr EF ▁; ▁ HF p EF
D-177	-0.6507635712623596	RAS- ; β-blocker uptitrations ; hFrEF ; HFpEF
P-177	-1.5529 -0.0511 -0.2962 -2.3732 -0.4235 -0.1626 -1.1958 -0.4229 -0.2484 -0.1529 -0.2634 -0.3178 -0.2704 -1.7544 -0.6309 -1.7084 -0.1790 -0.4016 -0.5728 -0.0708 -0.6368 -0.8441 -0.4380
S-827	Of 124 patients, 66 were below the median exercise-induced PASP increase of 30 mm Hg (low PASP), and 58 patients were above the median (high PASP).<unk>
T-827	patients ; exercise-induced pasp ; pasp ; patients ; pasp
H-827	-0.7558176517486572	▁exercise - indu ced ▁PAS p ▁; ▁low ▁PAS p
D-827	-0.7558176517486572	exercise-induced PASp ; low PASp
P-827	-1.1249 -0.1092 -0.0235 -0.5372 -0.3592 -0.4306 -0.4155 -4.1681 -0.4007 -0.3619 -0.9664 -0.1726
S-1243	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.<unk>
T-1243	skeletal muscle ; sarcomere ; patients ; heart failure ; type 2 diabetes
H-1243	-0.3907947838306427	▁skelet al ▁muscle ▁sar com ere ▁structure ▁; ▁heart ▁failure ▁; ▁type ▁2 ▁diabetes ▁; ▁e pica tech in - rich ▁coco a
D-1243	-0.3907947838306427	skeletal muscle sarcomere structure ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
P-1243	-0.9316 -0.0880 -0.3346 -0.3262 -0.9376 -1.1126 -1.8027 -0.2453 -0.3171 -0.0802 -0.1408 -0.1843 -0.2436 -0.0331 -0.4924 -0.5119 -0.0365 -0.3355 -0.1716 -0.2517 -0.0033 -0.6081 -0.0858 -0.2830 -0.2121
S-1722	Physician volume is associated with better outcomes for patients undergoing procedures, but its association with outcomes for medically managed diseases, such as HF, is not well understood.<unk>
T-1722	physician ; outcomes ; patients ; outcomes ; medically ; diseases ; hf
H-1722	-0.9260400533676147	▁physical ▁volume ▁; ▁patients ▁; ▁procedure s ▁; ▁ HF
D-1722	-0.9260400533676147	physical volume ; patients ; procedures ; HF
P-1722	-0.5745 -0.5923 -0.3005 -3.1480 -0.2678 -2.0536 -0.0524 -0.2532 -3.0102 -0.2262 -0.4684 -0.1654
S-1994	The centrifugal flow pump is designed for enhanced hemocompatibility by incorporating a magnetically levitated rotor with wide blood-flow paths and an artificial pulse.<unk>
T-1994	centrifugal flow pump ; hemocompatibility ; blood-flow ; pulse
H-1994	-0.36902543902397156	▁centri fu gal ▁flow ▁pump ▁; ▁hem o com pati bility ▁; ▁magnet ically ▁le vita ted ▁ro tor ▁; ▁blood - flow ▁path s ▁; ▁artificial ▁puls e
D-1994	-0.36902543902397156	centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
P-1994	-0.0031 -0.0780 -0.0253 -0.1189 -0.3779 -0.2094 -1.0089 -0.1134 -1.4729 -0.1680 -0.0871 -0.1422 -0.1900 -0.0498 -0.1908 -0.0216 -0.0416 -0.0443 -0.0595 -0.2282 -4.7568 -0.1622 -0.0525 -0.0667 -0.0462 -0.2613 -0.1788 -0.4532 -0.3086 -0.2800 -0.2425
S-1224	BACKGROUND: Underuse of eplerenone in patients with HF-REF may be due to fear of inducing hyperkalemia or WRF in high-risk patients.<unk>
T-1224	eplerenone ; patients ; hf-ref ; hyperkalemia ; patients
H-1224	-0.4252159595489502	▁e pler en one ▁; ▁ HF - re f ▁; ▁induc ing ▁hyper kal emia ▁; ▁w RF
D-1224	-0.4252159595489502	eplerenone ; HF-ref ; inducing hyperkalemia ; wRF
P-1224	-0.2714 -0.2178 -0.9713 -0.0967 -0.2587 -0.4696 -0.4029 -0.0744 -0.7314 -1.0224 -0.3434 -0.2482 -0.0660 -0.4146 -0.8579 -0.3897 -0.2449 -0.5351 -0.5905 -0.4462 -0.2766
S-1786	Reduced mitochondrial complex V activity was evident at 3 weeks post-AAC, concomitant with a reduction in the ratio of phosphocreatine to ATP.<unk>
T-1786	mitochondrial complex v activity ; phosphocreatine ; atp
H-1786	-0.6790735125541687	▁mito cho ndri al ▁complex ▁; ▁activity ▁; ▁post - a ac ▁; ▁ratio ▁of ▁ phos pho creati ne ▁; ▁ATP
D-1786	-0.6790735125541687	mitochondrial complex ; activity ; post-aac ; ratio of phosphocreatine ; ATP
P-1786	-0.8068 -2.5126 -0.6212 -0.0395 -0.1659 -1.7282 -0.7604 -0.1956 -1.4480 -0.0150 -0.3616 -0.3514 -0.1797 -0.3142 -0.7460 -0.1927 -0.0385 -2.3934 -1.7505 -0.3739 -0.5790 -0.0710 -0.4791 -0.1736
S-409	Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02).<unk>
T-409	patients ; sst2 ; sst2 ; odds ratios ; cardiovascular events
H-409	-0.7089968919754028	▁s st 2/ low - dos e ▁BB ▁; ▁s st 2/ high - dos e ▁BB ▁; ▁cardiovascular ▁events
D-409	-0.7089968919754028	sst2/low-dose BB ; sst2/high-dose BB ; cardiovascular events
P-409	-0.0190 -1.8172 -0.7254 -1.0153 -0.0598 -1.1427 -0.1530 -1.2364 -0.1316 -0.0715 -2.0079 -0.6716 -1.1660 -0.0706 -1.2969 -0.0669 -1.2277 -0.3239 -0.9696 -0.8598 -0.2817 -0.2832
S-1007	RESULTS: Among 223 patients (mean age 71 ± 14, 61% male), 21% were frail and 48% intermediate frail according to the biological phenotype.<unk>
T-1007	patients ; frail ; frail ; biological phenotype
H-1007	-0.4362180233001709	▁fra il ▁; ▁intermedi ate ▁fra il ▁; ▁bi ological
D-1007	-0.4362180233001709	frail ; intermediate frail ; biological
P-1007	-1.7336 -0.0676 -0.2036 -0.0035 -0.5768 -0.4571 -0.0693 -0.7398 -0.0472 -0.1846 -1.0019 -0.1497
S-880	BACKGROUND: The impact of QRS morphology and duration on the effectiveness of cardiac resynchronization therapy (CRT) has been usually assessed separately.<unk>
T-880	qrs morphology ; cardiac resynchronization therapy ; crt
H-880	-0.4107922911643982	▁QR s ▁ morph ology ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT
D-880	-0.4107922911643982	QRs morphology ; cardiac resynchronization therapy ; cRT
P-880	-0.5002 -0.8565 -0.5808 -0.0315 -0.1459 -0.1207 -0.6383 -0.0159 -0.0868 -0.0170 -0.4128 -0.9887 -0.0928 -0.3121 -0.7630 -1.3428 -0.3089 -0.1793
S-738	Sixty-one patients with confirmed HFPEF entered a longitudinal outcome-monitoring phase (mean, 22.9±5.0 months), during which 16 had a cardiac event.<unk>
T-738	patients ; hfpef ; longitudinal ; cardiac event
H-738	-0.7735461592674255	▁h f f ▁; ▁outcome - monitor ing ▁phase ▁; ▁cardiac ▁event
D-738	-0.7735461592674255	hff ; outcome-monitoring phase ; cardiac event
P-738	-2.2556 -0.4146 -0.3440 -0.4265 -3.3677 -0.2524 -0.2609 -0.0378 -1.6083 -0.3599 -0.3438 -0.7381 -0.2402 -0.1797
S-149	OBJECTIVE: To determine whether RM strategies improve outcomes for adults who have been recently discharged (<28 days) following an unplanned admission due to heart failure.<unk>
T-149	rm ; outcomes ; discharged ; admission ; heart failure
H-149	-0.453012615442276	▁RM ▁; ▁dis charge d ▁; ▁un plan ned ▁ad mission ▁; ▁heart ▁failure
D-149	-0.453012615442276	RM ; discharged ; unplanned admission ; heart failure
P-149	-2.0813 -1.1672 -0.3846 -0.0168 -0.2337 -0.2200 -0.4302 -0.0493 -0.1395 -0.0021 -0.0400 -0.4860 -1.4578 -0.0543 -0.2726 -0.2128
S-57	As the authors suggest, patient categorization in the emergency department is perhaps the single most important component that is not focused on in modern acute heart failure (AHF) clinical studies.<unk>
T-57	patient ; emergency department ; acute heart failure ; ahf ; clinical
H-57	-0.6694101095199585	▁emergency ▁department ▁; ▁a cute ▁heart ▁failure ▁; ▁a HF
D-57	-0.6694101095199585	emergency department ; acute heart failure ; aHF
P-57	-2.5231 -0.0386 -0.1317 -0.0270 -0.0735 -1.1549 -0.0750 -0.2514 -0.4619 -1.8721 -1.2379 -0.1858
S-639	Although aberrant reactivation of embryonic gene programs is intricately linked to pathological heart disease, the transcription factors driving these gene programs remain ill-defined.<unk>
T-639	gene ; pathological ; heart disease ; transcription factors ; driving ; gene
H-639	-0.7343609929084778	▁em bry o nic ▁gene ▁programs ▁; ▁path ological ▁heart ▁disease ▁; ▁tran scription ▁factors ▁; ▁gene ▁programs
D-639	-0.7343609929084778	embryonic gene programs ; pathological heart disease ; transcription factors ; gene programs
P-639	-0.9229 -0.4477 -0.1896 -0.3796 -3.1751 -0.6594 -0.2788 -0.0184 -0.1087 -1.8748 -1.1400 -0.7000 -0.0796 -0.1929 -0.0553 -0.8131 -1.9669 -1.0529 -0.3078 -0.3238
S-807	Values of standard error of measurement and MDC may be used in daily clinical practice with these populations to define what is expected and what represents true change in repeated measures.<unk>
T-807	standard error of measurement ; mdc ; clinical ; change
H-807	-0.5280640125274658	▁standard ▁error ▁of ▁measure ment ▁; ▁m DC
D-807	-0.5280640125274658	standard error of measurement ; mDC
P-807	-0.1290 -0.8410 -0.6401 -0.0200 -0.0719 -0.1882 -0.2153 -1.0440 -1.8537 -0.2775
S-887	In patients with LBBB receiving implantable cardioverter defibrillator-CRT, there was a reduction in the primary outcome and in each individual component of the primary outcome.<unk>
T-887	patients ; lbbb ; implantable ; primary outcome ; primary outcome
H-887	-0.5458192825317383	▁ LB BB ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT ▁; ▁primary ▁outcome
D-887	-0.5458192825317383	LBBB ; implantable cardioverter defibrillator-CRT ; primary outcome
P-887	-1.2041 -0.7241 -1.4909 -0.2485 -0.5802 -0.0180 -0.4880 -0.0548 -0.1623 -0.2493 -0.3000 -1.6094 -1.0341 -0.0422 -0.1894 -1.1028 -0.4520 -1.2637 -0.1110 -0.1078 -0.4035 -0.1718
S-516	OBJECTIVES: The study aimed to determine whether isolated heart rate (HR) reduction with ivabradine reduces afterload of patients with systolic heart failure.<unk>
T-516	heart rate ; ivabradine ; afterload ; patients ; systolic heart failure
H-516	-0.6443924307823181	▁isola ted ▁heart ▁rate ▁; HR ▁; ▁i va bra dine ▁; ▁after load ▁; ▁patients ▁; ▁sy sto lic ▁heart ▁failure
D-516	-0.6443924307823181	isolated heart rate ;HR ; ivabradine ; afterload ; patients ; systolic heart failure
P-516	-0.2175 -0.0184 -1.6424 -0.0261 -0.5019 -0.5431 -0.6909 -0.4643 -1.8052 -0.2776 -0.0898 -0.1769 -1.8045 -0.0791 -0.4184 -2.5533 -0.4816 -0.2983 -0.0886 -0.9669 -1.5272 -0.0995 -0.4851 -0.2091
S-1650	All patients will be followed up until the end of the trial for the composite primary outcome of cardiovascular death, stroke, worsening of heart failure, and myocardial infarction.<unk>
T-1650	patients ; followed up ; composite primary outcome ; cardiovascular death ; stroke ; heart failure ; myocardial infarction
H-1650	-0.4554365873336792	▁cardiovascular ▁death ▁; ▁stroke ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction
D-1650	-0.4554365873336792	cardiovascular death ; stroke ; heart failure ; myocardial infarction
P-1650	-1.9528 -1.8023 -0.1461 -0.4585 -0.1194 -0.4980 -0.0617 -0.2580 -0.4918 -0.1627 -0.5546 -0.0564 -0.0427 -0.1527 -0.3455 -0.3710 -0.2682
S-336	Four years later he developed heart failure, severe hypertension, mild mitral regurgitation, and significant mitral stenosis, which were reversed by aggressive medical treatment for heart failure.<unk>
T-336	heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; medical treatment ; heart failure
H-336	-0.4623476266860962	▁heart ▁failure ▁; ▁severe ▁hyper tension ▁; ▁mit ral ▁re gur gi tation ▁; ▁mit ral ▁sten osis
D-336	-0.4623476266860962	heart failure ; severe hypertension ; mitral regurgitation ; mitral stenosis
P-336	-1.1436 -0.0722 -0.2228 -2.4821 -0.4197 -0.1822 -0.1650 -0.0949 -0.0634 -0.0110 -0.0411 -0.2185 -0.0242 -0.3251 -0.0614 -0.0637 -0.0781 -0.0192 -3.3839 -0.1748
S-845	BACKGROUND: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.<unk>
T-845	cardiac-resynchronization therapy ; crt ; morbidity ; mortality ; chronic systolic heart failure ; wide qrs complex
H-845	-0.5545212030410767	▁Card iac - re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁morbi d ity ▁; ▁mortal ity ▁; ▁chronic ▁sy sto lic ▁heart ▁failure ▁; ▁QR s
D-845	-0.5545212030410767	Cardiac-resynchronization therapy ; cRT ; morbidity ; mortality ; chronic systolic heart failure ; QRs
P-845	-1.5403 -0.4645 -0.0287 -0.0942 -0.0557 -0.0139 -0.6620 -0.8719 -0.1161 -0.2441 -1.1096 -1.5431 -0.2713 -2.0939 -0.0618 -0.0790 -0.6114 -0.0169 -0.0130 -0.1817 -0.0789 -0.5740 -0.0737 -1.3290 -1.7574 -0.2654 -1.7020 -0.0416 -0.7507 -0.3597 -0.1848
S-1086	PERK activation destabilized SCN5A and, surprisingly, Kv4.3 channel mRNAs but not transient receptor potential cation channel M7 (TRPM7) channel mRNA.<unk>
T-1086	perk ; scn5a ; kv4.3 ; mrnas ; transient receptor potential cation channel m7 ; trpm7 ; mrna
H-1086	-0.5868837237358093	▁per k ▁activa tion ▁; ▁s cn 5 a ▁; ▁kv 4.3 ▁channel ▁m RNA s ▁; ▁trans ient ▁receptor ▁potential ▁ cation ▁channel ▁; ▁m 7 ▁; TR p 7) ▁channel ▁m RNA
D-1086	-0.5868837237358093	perk activation ; scn5a ; kv4.3 channel mRNAs ; transient receptor potential cation channel ; m7 ;TRp7) channel mRNA
P-1086	-1.0028 -0.5293 -1.4828 -0.0353 -1.2697 -0.2456 -1.5886 -0.4575 -0.3494 -0.1731 -0.3181 -1.0587 -0.7666 -0.1075 -0.0719 -0.2640 -0.2394 -0.0198 -0.1283 -0.0385 -0.0404 -0.3057 -0.0265 -0.4485 -1.5899 -2.5829 -0.1543 -0.2634 -1.1314 -1.6912 -1.2582 -0.5184 -0.0602 -0.0801 -0.5771 -0.2529
S-1861	SETTING AND PARTICIPANTS: Patients with an implantable cardioverter-defibrillator, from the Heart Function Clinic at University Health Network (Toronto, Canada).<unk>
T-1861	patients ; implantable cardioverter-defibrillator ; heart function clinic ; university health network ; toronto ; canada
H-1861	-0.5955629944801331	▁implant able ▁cardio ver ter - de fi br illa tor ▁; ▁Heart ▁Fun ction ▁Clinic ▁; ▁university ▁health ▁network ▁; ▁tor onto
D-1861	-0.5955629944801331	implantable cardioverter-defibrillator ; Heart Function Clinic ; university health network ; toronto
P-1861	-1.3162 -0.0136 -0.2882 -0.1122 -0.7047 -0.0444 -0.0750 -0.5656 -2.5424 -0.8903 -0.0833 -0.3383 -1.2658 -1.7377 -0.0036 -0.7203 -0.2753 -0.2406 -0.4372 -0.0325 -1.1398 -0.2662 -0.0066 -1.6446 -0.1446
S-831	CONCLUSIONS: Exercise-induced PASP increase is of high clinical and prognostic relevance in pulmonary hypertension patients and may indicate right ventricular contractile reserve.<unk>
T-831	exercise-induced pasp ; clinical ; prognostic ; pulmonary hypertension ; patients ; right ventricular contractile reserve
H-831	-0.5518901944160461	▁exercise - indu ced ▁PAS p ▁; ▁pulmonar y ▁hyper tension ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve
D-831	-0.5518901944160461	exercise-induced PASp ; pulmonary hypertension ; right ventricular contractile reserve
P-831	-1.1415 -0.0961 -0.0383 -0.6546 -0.2958 -0.5136 -0.8762 -0.0210 -0.1208 -0.3064 -0.1263 -1.0853 -0.0461 -1.1365 -1.0444 -0.3844 -0.1683 -2.8016 -0.1054 -0.4648 -0.1622
S-1550	Treatment of MI animals with metoprolol partially reversed the elevated levels of plasma norepinephrine and dopamine without affecting the elevated levels of epinephrine.<unk>
T-1550	mi ; metoprolol ; elevated ; plasma norepinephrine ; dopamine ; elevated ; epinephrine
H-1550	-0.6057159900665283	▁mi ania ▁; ▁met o pro lol ▁; ▁plasma ▁no re pine ph rine ▁; ▁dop amine ▁; ▁e pine ph rine
D-1550	-0.6057159900665283	miania ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
P-1550	-0.9667 -4.2321 -0.2048 -0.6249 -0.1085 -0.2429 -1.1701 -0.1200 -1.3788 -0.7063 -0.7842 -0.2400 -1.3269 -0.0812 -0.2396 -0.0099 -0.2953 -0.2136 -0.0402 -0.1048 -0.7816 -0.1631 -0.2945 -0.2074
S-1264	CONCLUSIONS: This meta-analysis indicated that biomedical treatment plus CHM is more effective than biomedical treatment alone in treating patients with DCM and heart failure.<unk>
T-1264	meta-analysis ; biomedical ; biomedical ; patients ; dcm ; heart failure
H-1264	-0.6088431477546692	▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁bio medic al ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure
D-1264	-0.6088431477546692	biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
P-1264	-0.9241 -0.3313 -0.0141 -2.3226 -0.1657 -2.8571 -0.1223 -0.1774 -0.6043 -0.0771 -0.0125 -1.3518 -0.2525 -0.4314 -1.2208 -0.1089 -0.4424 -0.0869 -0.4548 -0.2189
S-696	BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF).<unk>
T-696	st2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ; hf
H-696	-0.3263157904148102	▁ST 2 ▁; ▁cardio protec tive ▁signal ing ▁; ▁my o car dium ▁; ▁bio mark er ▁; ▁heart ▁failure ▁; HF
D-696	-0.3263157904148102	ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure ;HF
P-696	-1.6110 -0.1061 -0.1821 -0.2356 -0.4668 -0.0932 -0.3212 -0.2489 -0.2724 -0.3168 -0.0503 -0.2433 -0.5640 -0.1514 -0.7915 -0.0230 -0.5638 -0.2248 -0.2001 -0.0605 -0.5723 -0.0615 -0.3337 -0.1372
S-1602	The current ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial may provide more concrete data regarding the role of stenting in RAS.<unk>
T-1602	cardiovascular outcomes in renal atherosclerotic lesions ; coral ; stenting ; ras
H-1602	-0.5518745183944702	▁Card io vas cular ▁out com es ▁; ▁Ren al ▁Ath eros cle ro tic ▁Les ions ▁; co RAL ▁; ▁sten ting ▁; ▁ RAS
D-1602	-0.5518745183944702	Cardiovascular outcomes ; Renal Atherosclerotic Lesions ;coRAL ; stenting ; RAS
P-1602	-0.5811 -1.7873 -0.1046 -0.1646 -1.6384 -0.2114 -0.2353 -0.2300 -0.0209 -0.0655 -0.1290 -0.1715 -0.3380 -4.4359 -0.0953 -0.3075 -0.2737 -0.2157 -0.7752 -0.2243 -0.2203 -2.3445 -0.0506 -0.2587 -0.1233 -0.0135 -0.2908 -0.1455
S-60	BACKGROUND: Many current predictors of mortality in heart failure (HF) were evaluated before the use of implantable cardioverter defibrillators (ICDs).<unk>
T-60	mortality ; heart failure ; hf ; implantable cardioverter defibrillators ; icds
H-60	-0.4865197241306305	▁mortal ity ▁; ▁heart ▁failure ▁; HF ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tors ▁; IC d s
D-60	-0.4865197241306305	mortality ; heart failure ;HF ; implantable cardioverter defibrillators ;ICds
P-60	-2.5439 -0.1115 -0.3438 -0.7503 -0.1505 -0.2539 -0.1195 -0.3192 -0.5919 -0.0210 -0.5567 -0.0352 -0.2286 -0.1705 -0.2987 -2.4761 -1.1290 -0.0573 -0.4395 -0.0966 -0.2119 -0.0383 -0.5761 -0.1564
S-1950	We aimed to assess the safety and potential efficacy of therapeutic left-to-right interatrial shunting in patients with heart failure with reduced ejection fraction.<unk>
T-1950	therapeutic ; interatrial shunting ; patients ; heart failure with reduced ejection fraction
H-1950	-0.5405396819114685	▁left - to - right ▁inter at rial ▁sh unting ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1950	-0.5405396819114685	left-to-right interatrial shunting ; heart failure ; ejection fraction
P-1950	-4.7815 -0.0508 -0.2561 -0.1418 -0.1008 -0.0925 -0.4433 -0.1692 -0.8293 -0.9068 -0.2779 -0.7929 -0.0552 -0.3612 -0.3989 -0.2263 -0.1742 -0.4887 -0.0147 -0.5424 -0.2469
S-686	We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF.<unk>
T-686	dietary approaches to stop hypertension ; dash ; mortality ; postmenopausal ; hf
H-686	-0.4251268804073334	▁Mediterrane an ▁and ▁Diet ary ▁App ro ach es ▁; ▁stop ▁Hyper tension ▁; DAS h ▁; ▁die t ▁score s ▁; ▁mortal ity ▁; ▁post meno paus al ▁women ▁; ▁ HF
D-686	-0.4251268804073334	Mediterranean and Dietary Approaches ; stop Hypertension ;DASh ; diet scores ; mortality ; postmenopausal women ; HF
P-686	-0.2977 -0.0254 -1.1273 -0.1420 -0.0145 -1.3141 -0.4088 -0.4194 -0.0615 -1.3362 -0.6402 -0.5213 -0.2980 -0.3675 -0.1006 -0.5052 -0.2040 -2.3174 -0.1282 -0.1718 -0.0485 -0.1407 -0.1719 -0.0359 -0.2609 -0.0700 -0.0819 -0.0199 -0.0499 -2.0234 -0.3772 -0.6942 -0.0304 -0.2681 -0.2053
S-436	CONCLUSIONS: A multiparametric echocardiographic score is helpful in selecting patients likely to undergo reverse remodeling after CRT and predicts clinical outcomes.<unk>
T-436	echocardiographic ; patients ; reverse remodeling ; crt ; clinical ; outcomes
H-436	-0.5743259787559509	▁multi para metric ▁e cho car dio graphic ▁score ▁; ▁rever se ▁remodel ing ▁; ▁c RT
D-436	-0.5743259787559509	multiparametric echocardiographic score ; reverse remodeling ; cRT
P-436	-1.9746 -0.0716 -0.0246 -0.1800 -0.6000 -0.9847 -1.5761 -0.9302 -1.1806 -0.1772 -0.0140 -0.0269 -0.0838 -0.0290 -0.4306 -0.5549 -1.3867 -0.5236 -0.1632
S-1056	MATERIALS AND METHODS: Yorkshire swine were implanted with pacemakers and were ventricularly paced at 200 beats/min to induce heart failure.<unk>
T-1056	yorkshire ; implanted ; pacemakers ; ventricularly ; beats ; heart failure
H-1056	-0.34042689204216003	▁York shire ▁s win e ▁; ▁pace makers ▁; ▁vent ri cular ly ▁pace d ▁; ▁induc e ▁heart ▁failure
D-1056	-0.34042689204216003	Yorkshire swine ; pacemakers ; ventricularly paced ; induce heart failure
P-1056	-0.6399 -0.0504 -0.0110 -1.6385 -0.5472 -0.2346 -0.1955 -0.0427 -0.2353 -1.2906 -0.3100 -0.0399 -0.0399 -0.0901 -0.3125 -0.3163 -0.0630 -0.0561 -0.6555 -0.0568 -0.4612 -0.2022
S-636	The use of antagonists and inhibitors of the renin-angiotensin-aldosterone and sympathetic nervous systems has significantly improved clinical outcomes in CHF.<unk>
T-636	antagonists ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; clinical ; outcomes ; chf
H-636	-0.40661099553108215	▁re nin - angi oten sin - al do ster one ▁; ▁sympa the tic ▁ner vous ▁systems ▁; ▁CHF
D-636	-0.40661099553108215	renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
P-636	-0.4179 -0.1880 -0.0637 -0.0308 -0.7319 -0.7576 -0.2209 -0.0750 -1.1779 -0.6386 -0.0412 -0.2060 -0.0100 -0.9074 -0.0482 -0.9093 -1.3521 -0.0433 -0.8319 -0.0351 -0.1003 -0.1582
S-1799	LA is under the awful paradox of having the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, and rheumatic fever.<unk>
T-1799	hf ; hf ; epidemiology ; rheumatic fever
H-1799	-0.7176526188850403	▁ HF ▁; ▁ HF ▁; ▁epidemi ology ▁; ▁SH ▁; ▁c d ▁; ▁rhe u matic ▁fe ver
D-1799	-0.7176526188850403	HF ; HF ; epidemiology ; SH ; cd ; rheumatic fever
P-1799	-2.1437 -0.8242 -0.4667 -0.9160 -0.5971 -0.2922 -1.0769 -0.0913 -0.1357 -3.0411 -0.1862 -0.2912 -3.0643 -0.1511 -0.6412 -0.0566 -0.1169 -0.0163 -0.0349 -0.6097 -0.3173
S-1725	We used patient-level regression to compare 30-day risk-adjusted mortality, readmissions, and costs across volume groups, controlling for patient, physician, and hospital characteristics.<unk>
T-1725	mortality ; readmissions ; costs ; patient ; physician ; hospital
H-1725	-0.4762575626373291	▁patient - level ▁re gression ▁; ▁risk - ad just ed ▁mortal ity ▁; ▁read missions ▁; ▁costs
D-1725	-0.4762575626373291	patient-level regression ; risk-adjusted mortality ; readmissions ; costs
P-1725	-2.1374 -0.0560 -0.2038 -0.0443 -0.0030 -0.2376 -2.1031 -0.0631 -0.0343 -0.0199 -0.0319 -0.2773 -0.0393 -0.4019 -0.2268 -0.0324 -0.4342 -0.0407 -2.9263 -0.2118
S-1976	OBJECTIVE: To determine whether caloric restriction (diet) or aerobic exercise training (exercise) improves exercise capacity and QOL in obese older patients with HFPEF.<unk>
T-1976	exercise ; training ; exercise ; exercise capacity ; qol ; obese ; patients ; hfpef
H-1976	-0.5753607153892517	▁calor ic ▁restriction ▁; diet ▁; ▁aero bic ▁exercise ▁training ▁; exe rci se ▁; ▁exercise ▁capacity ▁; ▁Q OL ▁; ▁obes e ▁; ▁h FP EF
D-1976	-0.5753607153892517	caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; obese ; hFPEF
P-1976	-0.2213 -0.0439 -0.1523 -0.0911 -0.2292 -0.1128 -0.0135 -0.3275 -0.3723 -0.2111 -0.1635 -0.3472 -0.0875 -0.3073 -0.1327 -0.5140 -0.0943 -0.1258 -4.1695 -0.4949 -0.1479 -2.3644 -0.1770 -0.5362 -2.5931 -1.6050 -0.5080 -0.3373 -0.2048
S-1472	Understanding of chronic heart failure (HF) has progressed from the concept of a purely hemodynamic disorder to that of a syndrome that results from dysfunction in interconnected molecular pathways.<unk>
T-1472	chronic heart failure ; hf ; hemodynamic ; syndrome ; dysfunction ; molecular pathways
H-1472	-0.5105870366096497	▁chronic ▁heart ▁failure ▁; HF ▁; ▁hem o dynamic ▁disorder ▁; ▁syndrome ▁; ▁dys function ▁; ▁molecular ▁path ways
D-1472	-0.5105870366096497	chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; dysfunction ; molecular pathways
P-1472	-0.5728 -2.2947 -0.0729 -0.3150 -0.1839 -0.4469 -1.4843 -0.1818 -0.0111 -1.0981 -0.2218 -0.0374 -0.3560 -0.4685 -0.6392 -0.4520 -1.3840 -0.0129 -0.0603 -0.2431 -0.1856
S-667	CONCLUSIONS: Variation in the use of guideline-recommended medications for patients with heart failure and reduced ejection fraction exists in the outpatient setting.<unk>
T-667	medications ; patients ; heart failure and reduced ejection fraction ; outpatient
H-667	-0.45525500178337097	▁guide line - re com mend ed ▁medication s ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-667	-0.45525500178337097	guideline-recommended medications ; heart failure ; reduced ejection fraction
P-667	-3.5457 -0.0197 -0.2973 -0.0234 -0.2549 -0.0183 -0.1382 -0.1664 -0.0854 -0.2985 -0.4798 -0.0370 -0.1593 -0.8346 -0.0435 -0.0383 -0.4150 -0.1024 -0.4615 -0.0185 -2.2645 -0.3135
S-1172	BACKGROUND: Because symptoms of HFpEF are typically exertional, optimization of diastolic filling time by controlling heart rate may delay the onset of symptoms.<unk>
T-1172	symptoms ; hfpef ; diastolic filling time ; heart rate ; symptoms
H-1172	-0.7967475652694702	▁ HF p EF ▁; ▁dia sto lic ▁; ▁fill ing ▁time ▁; ▁heart ▁rate
D-1172	-0.7967475652694702	HFpEF ; diastolic ; filling time ; heart rate
P-1172	-1.2515 -0.9790 -0.0846 -1.3711 -0.2302 -2.4218 -0.4516 -0.9434 -2.1739 -0.2484 -0.0251 -0.3539 -0.1547 -2.2735 -0.0444 -0.3324 -0.2053
S-1813	In these studies, we evaluated mice with cardiac myocyte-specific Mena overexpression (TTA/TgTetMena) comparable to that observed in cardiac pathology.<unk>
T-1813	cardiac ; myocyte-specific mena overexpression ; cardiac ; pathology
H-1813	-0.3982921540737152	▁mi ce ▁; ▁cardiac ▁my o cy te - specific ▁Men a ▁over expression ▁; TTA ▁; ▁t g t t t Men a ▁; ▁cardiac ▁path ology
D-1813	-0.3982921540737152	mice ; cardiac myocyte-specific Mena overexpression ;TTA ; tgtttMena ; cardiac pathology
P-1813	-0.6704 -0.1383 -0.1518 -0.0530 -1.0446 -0.1832 -0.0772 -0.2453 -1.6482 -0.3374 -0.3720 -0.1130 -0.2217 -0.2842 -0.2038 -0.3620 -0.5700 -0.3289 -0.0161 -0.0746 -0.7420 -1.0235 -1.7221 -0.0237 -0.6924 -0.0817 -0.0779 -0.0669 -0.2555 -0.1673
S-1355	Additional progress is needed, including better tools for risk stratification and clarity regarding the need for antiplatelet agents in combination with anticoagulants for those with other vascular diseases.<unk>
T-1355	risk stratification ; antiplatelet agents ; combination ; anticoagulants ; vascular diseases
H-1355	-0.6089795231819153	▁anti plate let ▁agents ▁; ▁antico a gul ants ▁; ▁vas cular ▁disease s
D-1355	-0.6089795231819153	antiplatelet agents ; anticoagulants ; vascular diseases
P-1355	-0.4273 -0.6355 -2.1145 -0.1033 -0.3294 -0.3725 -0.6238 -0.6580 -0.1222 -0.4839 -2.2451 -0.1303 -0.8895 -0.0538 -0.3528 -0.2018
S-1458	In this guideline, the International Right Heart Foundation Working Group moves a step forward to develop a common language to describe the development and defects that exemplify the common syndrome of right heart failure.<unk>
T-1458	international right heart foundation working group ; step ; syndrome ; right heart failure
H-1458	-0.9284026622772217	▁right ▁Heart ▁foundation ▁; ▁right ▁heart ▁failure
D-1458	-0.9284026622772217	right Heart foundation ; right heart failure
P-1458	-0.8894 -1.0467 -0.4887 -1.0579 -2.0955 -0.6848 -1.4880 -0.3598 -0.2448
S-1025	Several POC systems for measuring NP levels are now available: these produce test results within 15 minutes and appear sufficiently sensitive and robust to be used routinely in diagnostic evaluations.<unk>
T-1025	poc ; diagnostic
H-1025	-0.7864475250244141	▁ NP ▁levels ▁; ▁diagnostic ▁evaluation s
D-1025	-0.7864475250244141	NP levels ; diagnostic evaluations
P-1025	-2.3575 -0.1092 -0.2190 -1.9419 -1.2630 -0.3779 -0.3156 -0.2496 -0.2443
S-890	CONCLUSIONS: In patients with LBBB, there was a continuous relationship between broader QRS and greater benefit from implantable cardioverter defibrillator-CRT.<unk>
T-890	patients ; lbbb ; qrs ; implantable
H-890	-0.6090958714485168	▁ LB BB ▁; ▁QR s ▁; ▁implant able ▁cardio ver ter ▁; ▁de fi br illa tor - C RT
D-890	-0.6090958714485168	LBBB ; QRs ; implantable cardioverter ; defibrillator-CRT
P-890	-1.5219 -1.0630 -1.1711 -0.1647 -0.8657 -1.2139 -0.0747 -1.1161 -0.0195 -0.4846 -0.0231 -0.1329 -1.7927 -0.2920 -0.1396 -0.9288 -0.6772 -0.0309 -0.1430 -1.2075 -0.2818 -0.5331 -0.1312
S-453	At the end of a 10-week treatment period, echocardiography revealed reduced cardiac diameters and improved cardiac function in B-treated compared with vehicle-treated rats.<unk>
T-453	echocardiography ; cardiac ; cardiac function
H-453	-0.3122168779373169	▁e cho card i ography ▁; ▁cardiac ▁diameter s ▁; ▁cardiac ▁function ▁; ▁b - tre ated ▁; ▁vehicle - tre ated ▁rat s
D-453	-0.3122168779373169	echocardiography ; cardiac diameters ; cardiac function ; b-treated ; vehicle-treated rats
P-453	-0.1574 -0.2738 -0.5686 -0.8323 -1.0767 -0.2234 -0.2429 -0.0188 -0.1539 -0.1314 -0.6767 -0.6667 -0.2654 -0.6132 -0.0814 -0.2169 -0.0498 -0.2679 -0.2636 -0.1206 -0.2941 -0.1042 -0.1195 -0.0486 -0.4965 -0.1532
S-151	DATA SOURCES: Fourteen electronic databases (including MEDLINE, EMBASE and PsycINFO) were searched to January 2012, and supplemented by hand-searching relevant articles.<unk>
T-151	medline ; embase ; psycinfo
H-151	-0.38351204991340637	▁electronic ▁database s ▁; ▁MED line ▁; ▁ EMBA se ▁; ▁Psy c INFO
D-151	-0.38351204991340637	electronic databases ; MEDline ; EMBAse ; PsycINFO
P-151	-0.4615 -0.6078 -0.0999 -0.1299 -0.3962 -1.0828 -0.1696 -0.1164 -0.0241 -1.8463 -0.0971 -0.5176 -0.1422 -0.0224 -0.2977 -0.1247
S-618	RESULTS: Overall significant improvements were not found in quality of life or functional capacity; some participants demonstrated significant improvements with others showing minor improvement or no improvement in one or both domains.<unk>
T-618	quality of life ; functional capacity
H-618	-1.3320798873901367	
D-618	-1.3320798873901367	
P-618	-2.4609 -0.2032
S-1977	DESIGN, SETTING, AND PARTICIPANTS: Randomized, attention-controlled, 2 × 2 factorial trial conducted from February 2009 through November 2014 in an urban academic medical center.<unk>
T-1977	randomized ; medical
H-1977	-0.9299404621124268	▁factor ial ▁trial
D-1977	-0.9299404621124268	factorial trial
P-1977	-0.7701 -0.0334 -0.7594 -2.9639 -0.1229
S-423	In patients with systolic HF, CXL-1020 reduced both left and right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke volume index.<unk>
T-423	patients ; systolic hf ; cxl-1020 ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke volume index
H-423	-0.5656615495681763	▁sy sto lic ▁ HF ▁; ▁c XL -10 20 ▁; ▁left ▁; ▁right ▁heart ▁fill ing ▁pressure s ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁cardiac ▁; ▁stroke
D-423	-0.5656615495681763	systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke
P-423	-1.7561 -0.1550 -0.1527 -1.0740 -0.1702 -0.1433 -0.6910 -0.1833 -0.2021 -0.0626 -0.5009 -1.2771 -1.1489 -0.0723 -2.7276 -1.3007 -0.0493 -0.6542 -0.2025 -0.2682 -0.0630 -0.0635 -0.6153 -0.3755 -0.1343 -0.0419 -0.5536 -0.1461 -0.4523 -0.8209 -1.7887 -0.2541
S-1242	CONCLUSION: In the study population, the therapeutic strategy used to manage AF in patients with severe heart failure appears to have little influence on the overall financial burden, which remains substantial.<unk>
T-1242	therapeutic ; patients ; severe heart failure ; financial
H-1242	-0.8081567883491516	▁af ▁; ▁severe ▁heart ▁failure ▁; ▁financial ▁burde n
D-1242	-0.8081567883491516	af ; severe heart failure ; financial burden
P-1242	-3.2017 -0.3067 -3.0505 -0.4432 -0.0515 -0.4228 -0.0318 -0.7788 -0.1700 -0.2929 -0.1400
S-16	During follow up body weight was unaltered in all groups even though FM increased by 1.35 kg (p<0.05) and FFM decreased by 0.5 kg (p<0.05) in CC patients.<unk>
T-16	follow up ; ffm ; patients
H-16	-0.7925581336021423	▁body ▁weight ▁; ▁FM ▁; ▁f m ▁; cc
D-16	-0.7925581336021423	body weight ; FM ; fm ;cc
P-16	-2.0538 -0.9353 -0.2206 -0.9496 -0.1633 -0.4741 -1.3080 -0.3857 -1.2928 -0.6571 -0.2779
S-1610	Data processing and differential analysis were carried out with packages of R. Cluster analysis was also performed for all the samples to globally observe the difference among the three groups of samples.<unk>
T-1610	differential analysis ; cluster analysis
H-1610	-1.3645521402359009	▁r . ▁Clu ster
D-1610	-1.3645521402359009	r. Cluster
P-1610	-3.6103 -1.4447 -0.3095 -0.0468 -2.6149 -0.1611
S-1260	Meta-analysis was performed on the overall effects on effective rate, left ventricular ejection fraction, left ventricular diastolic end diameter, and other outcome measures.<unk>
T-1260	meta-analysis ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
H-1260	-0.7590880990028381	▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter
D-1260	-0.7590880990028381	ventricular ejection fraction ; left ventricular diastolic end diameter
P-1260	-6.8299 -0.8537 -0.2199 -0.2411 -0.2601 -0.0976 -0.5679 -0.0070 -0.2086 -0.0652 -2.1122 -0.8875 -0.1641 -0.9240 -0.1225 -0.2834 -0.5367 -0.0037 -0.5454 -0.2512
S-1523	Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction.<unk>
T-1523	prevalence ; clinical ; outcomes ; concentric left ventricular hypertrophy ; heart failure with preserved ejection fraction
H-1523	-0.6280080080032349	▁ecce n tric ▁; ▁concentr ic ▁left ▁vent ri cular ▁hyper trop hy ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-1523	-0.6280080080032349	eccentric ; concentric left ventricular hypertrophy ; heart failure ; preserved ejection fraction
P-1523	-4.0039 -0.0101 -0.2076 -0.4450 -0.6761 -0.0195 -0.4646 -3.3277 -1.6768 -0.7925 -0.9281 -0.1089 -1.3463 -0.1924 -0.1755 -0.0779 -0.2794 -0.1537 -0.1715 -0.2696 -0.0658 -0.2166 -0.1861 -0.4236 -0.0055 -0.5030 -0.2285
S-1887	Half of these patients have normal, or near normal, left ventricular ejection fraction and are classified as heart failure with preserved ejection fraction (HFpEF).<unk>
T-1887	patients ; left ventricular ejection fraction ; heart failure with preserved ejection fraction ; hfpef
H-1887	-0.49111250042915344	▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1887	-0.49111250042915344	left ventricular ejection fraction ; heart failure ; preserved ejection fraction ;HFpEF
P-1887	-1.2363 -3.8237 -0.9008 -0.4251 -0.3647 -0.2162 -0.1925 -0.7088 -0.0148 -0.2729 -0.7323 -0.1699 -0.2195 -0.1801 -0.2282 -0.1279 -0.0987 -0.3332 -0.2029 -0.4259 -0.0181 -0.6302 -0.4658 -0.0115 -0.2219 -0.6966 -0.3415
S-451	Importantly, β-adrenergic receptor blocker therapy has been also shown to improve myocardial perfusion by enhancing neoangiogenesis in the failing heart.<unk>
T-451	β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
H-451	-0.27967071533203125	▁β - ad r energi c ▁receptor ▁block er ▁ therapy ▁; ▁my o card ial ▁per fusion ▁; ▁neo angi ogen es is ▁; ▁fail ing ▁heart
D-451	-0.27967071533203125	β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
P-451	-0.0302 -0.0470 -0.3583 -0.4119 -0.9020 -0.1499 -0.0030 -0.1550 -0.5215 -1.1942 -0.0435 -0.1774 -0.5662 -0.1511 -1.0927 -0.1513 -0.0910 -0.0955 -0.1122 -0.0502 -0.1580 -0.2150 -0.1179 -0.3904 -0.1911 -0.0463 -0.0305 -0.4086 -0.3446 -0.1835
S-1780	METHODS AND RESULTS: Mice were subjected to cardiac hypertrophy secondary to pressure-overload as a result of an abdominal aortic constriction (AAC).<unk>
T-1780	cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; aac
H-1780	-0.39674243330955505	▁mi ce ▁; ▁cardiac ▁hyper trop hy ▁seconda ry ▁to ▁pressure - over load ▁; ▁abdominal ▁a or tic ▁con stri ction ▁; ▁a ac
D-1780	-0.39674243330955505	mice ; cardiac hypertrophy secondary to pressure-overload ; abdominal aortic constriction ; aac
P-1780	-1.8483 -0.2307 -0.2789 -0.0620 -0.6075 -0.0775 -0.6433 -0.6279 -0.0069 -0.5003 -0.0684 -0.1383 -0.0645 -0.1429 -0.3259 -0.3598 -0.0454 -1.5471 -0.1386 -0.0879 -0.4615 -0.1387 -1.1071 -0.2388 -0.5324 -0.2427 -0.1887
S-839	It was hypothesized that baseline Hgb would be correlated with baseline KCCQ scales and that Hgb would moderate the beneficial effect of exercise training on HRQoL.<unk>
T-839	baseline ; hgb ; correlated ; baseline ; kccq ; hgb ; exercise ; training ; hrqol
H-839	-0.5050879120826721	▁base line ▁; ▁h gb ▁; ▁base line ▁; ▁k cc q ▁scale s ▁; ▁h gb ▁; ▁exercise ▁training ▁; ▁HR Qo L
D-839	-0.5050879120826721	baseline ; hgb ; baseline ; kccq scales ; hgb ; exercise training ; HRQoL
P-839	-0.0030 -0.0189 -0.9364 -1.3832 -0.0941 -0.0529 -0.0166 -0.0448 -0.3597 -1.8691 -0.0517 -1.5563 -0.8678 -0.0537 -0.0982 -0.5390 -0.0920 -0.0811 -0.3908 -0.7373 -0.4268 -1.1635 -0.0275 -1.7102 -0.3175 -0.2405
S-722	Some data suggest that outpatient assessments of patients with heart failure within 7 days of hospital discharge may prevent readmissions, although little is known about patient needs at 7-day follow-up visits.<unk>
T-722	outpatient ; patients ; heart failure ; hospital ; discharge ; readmissions ; patient ; follow-up
H-722	-0.5978171229362488	▁out patient ▁assessment s ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁hospital ▁dis charge ▁; ▁read missions
D-722	-0.5978171229362488	outpatient assessments ; patients ; heart failure ; hospital discharge ; readmissions
P-722	-1.4194 -0.0425 -0.1855 -0.0892 -0.3926 -2.5470 -0.7295 -0.6258 -0.0931 -0.2447 -1.7416 -0.5116 -0.0831 -0.4357 -0.2847 -0.0298 -1.0839 -0.2210
S-225	We hypothesized that Fontan failure is hemodynamically distinct from traditional heart failure and characterized by low systemic vascular resistance (SVR) index and preserved cardiac index.<unk>
T-225	fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; svr ; cardiac index
H-225	-0.39239251613616943	▁Font an ▁failure ▁; ▁hem o dynamic ally ▁; ▁heart ▁failure ▁; ▁system ic ▁vas cular ▁resist ance ▁; ▁s VR ▁; ▁pres er ved ▁cardiac ▁index
D-225	-0.39239251613616943	Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; preserved cardiac index
P-225	-0.1195 -0.2838 -0.1069 -0.1176 -1.2954 -0.0988 -0.0123 -0.0532 -0.1030 -0.7189 -0.0942 -0.1218 -0.0898 -0.0830 -0.6731 -0.9064 -0.0569 -0.0396 -0.2926 -0.3147 -0.9729 -0.4205 -3.2924 -0.0969 -0.1519 -0.1787 -0.0587 -0.4534 -0.1724
S-1156	These changes in myofiber dynamics delay the onset of myofiber shortening, thus giving rise to prolonged EMD in dyssynchronous HF.<unk>
T-1156	myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous hf
H-1156	-0.3309009075164795	▁my o fi ber ▁dynamic s ▁; ▁my o fi ber ▁short en ing ▁; ▁EM d ▁; ▁dys syn chron ous ▁ HF
D-1156	-0.3309009075164795	myofiber dynamics ; myofiber shortening ; EMd ; dyssynchronous HF
P-1156	-1.3546 -0.2698 -0.2959 -0.0580 -0.0695 -0.0571 -0.2099 -0.6989 -0.1200 -0.3241 -0.0407 -0.3332 -0.1438 -0.0728 -0.2567 -1.7028 -0.6730 -0.1142 -0.3991 -0.0214 -0.0069 -0.0752 -0.2239 -0.0777 -0.7389 -0.2654
S-1562	Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups.<unk>
T-1562	ankle-brachial index ; pulse-wave ; coronary artery calcium scores
H-1562	-0.3385014235973358	▁cru de ▁; ▁adjust ed ▁an kle - bra chi al ▁index ▁; ▁puls e - wa ve ▁veloci ty ▁; ▁corona ry ▁arter y ▁calci um ▁score s
D-1562	-0.3385014235973358	crude ; adjusted ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
P-1562	-0.5452 -0.1176 -0.1335 -0.3169 -0.0235 -0.0844 -0.5350 -0.1884 -0.2852 -3.3625 -0.2445 -0.3403 -0.1988 -0.2622 -0.1121 -0.1135 -0.0792 -0.2205 -0.0567 -0.1433 -0.2923 -0.1954 -0.0379 -0.1591 -0.2912 -0.1225 -0.0399 -1.1436 -0.1999 -0.4724 -0.1762
S-1081	In this work, we tested whether truncated Na+ channels activate the unfolded protein response (UPR), contributing to SCN5A electric remodeling in HF.<unk>
T-1081	activate ; unfolded protein response ; upr ; scn5a ; remodeling ; hf
H-1081	-0.4780125617980957	▁tru nca ted ▁na + ▁channel s ▁; ▁un fold ed ▁protein ▁response ▁; ▁u PR ▁; ▁s cn 5 a ▁; ▁electric ▁remodel ing ▁; ▁ HF
D-1081	-0.4780125617980957	truncated na+ channels ; unfolded protein response ; uPR ; scn5a ; electric remodeling ; HF
P-1081	-2.2917 -0.0329 -0.0148 -0.0554 -3.4629 -0.2690 -0.1976 -0.3954 -0.0232 -0.0108 -0.0246 -0.4420 -0.3911 -0.2285 -0.0584 -0.8767 -0.1289 -0.1109 -1.2353 -0.0911 -0.4279 -1.2176 -0.0634 -0.5031 -0.0549 -0.2534 -0.1710 -0.4735 -0.5903 -0.2443
S-1996	METHODS: The primary endpoint was 6-month survival compared with INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)-derived performance goal.<unk>
T-1996	primary endpoint ; intermacs ; interagency registry for mechanically assisted circulatory support
H-1996	-0.7756137251853943	▁inter ma cs ▁; ▁inter age ncy ▁Registr y ▁for ▁mechanic ally ▁assist ed ▁Circula tory ▁support
D-1996	-0.7756137251853943	intermacs ; interagency Registry for mechanically assisted Circulatory support
P-1996	-2.1709 -1.9852 -1.5374 -0.2272 -2.5264 -0.2948 -0.0030 -0.3188 -0.0546 -0.5362 -0.1688 -0.0387 -1.4222 -0.0223 -1.3970 -0.1113 -1.0108 -0.6878 -0.2232
S-477	In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca(2+) sensitivity.<unk>
T-477	allopurinol ; lv contractile function ; xo-mediated ros ; myofilament ; sensitivity
H-477	-0.5004620552062988	▁allo puri nol ▁; ▁LV ▁contract ile ▁function ▁; ▁efficiency ▁; ▁ XO - media ted ▁ ROS ▁; ▁my o fila ment ▁ca (2 +) ▁ sensitiv ity
D-477	-0.5004620552062988	allopurinol ; LV contractile function ; efficiency ; XO-mediated ROS ; myofilament ca(2+) sensitivity
P-477	-0.1619 -0.0980 -0.2715 -0.0697 -1.3697 -0.0656 -2.5356 -1.0261 -0.2324 -1.0490 -0.1412 -0.2786 -0.0497 -0.0258 -0.1175 -0.0366 -0.1347 -0.1869 -0.6516 -2.4485 -0.0578 -0.0619 -0.1413 -1.2730 -1.9609 -0.0436 -0.3334 -0.0072 -0.0240 -0.5125 -0.1482
S-1888	Newer imaging techniques have confirmed that systolic function in HFpEF patients is not completely normal, with reduced long axis function and extensive but subtle changes on exercise.<unk>
T-1888	systolic function ; hfpef ; patients ; long axis function ; exercise
H-1888	-0.8898730278015137	▁imagin g ▁; ▁sy sto lic ▁function ▁; ▁ HF p EF ▁; ▁long ▁a xis ▁function ▁; ▁exercise
D-1888	-0.8898730278015137	imaging ; systolic function ; HFpEF ; long axis function ; exercise
P-1888	-4.9785 -0.1192 -2.0394 -3.0188 -0.3426 -2.3788 -0.4378 -0.1512 -0.5832 -0.2178 -0.0522 -0.2945 -0.4986 -1.6496 -0.0720 -0.0629 -0.2700 -0.4537 -0.4779 -0.3280 -0.2605
S-1823	While our country has physicians experienced in the management of patients with advanced heart failure, these professionals are not distributed evenly across the country, and equitable access to therapeutic options is not provided.<unk>
T-1823	physicians ; patients ; heart failure ; equitable ; therapeutic
H-1823	-0.8934123516082764	▁physician s ▁; ▁advanced ▁heart ▁failure
D-1823	-0.8934123516082764	physicians ; advanced heart failure
P-1823	-1.9933 -0.0557 -0.3364 -1.7832 -0.7682 -0.0663 -1.9550 -0.1892
S-1312	Concurrent HF was associated with a multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.<unk>
T-1312	hf ; multivariate-adjusted odds ratio ; mortality ; hazard ratio ; mortality
H-1312	-0.6634419560432434	▁con current ▁ HF ▁; ▁28- day ▁mortal ity ▁; ▁hazard ▁ratio ▁; ▁28- day ▁sur viv ors
D-1312	-0.6634419560432434	concurrent HF ; 28-day mortality ; hazard ratio ; 28-day survivors
P-1312	-1.5723 -0.0329 -0.4689 -0.0728 -0.3087 -2.8981 -0.2146 -0.0478 -0.0435 -0.2355 -0.3796 -0.0100 -0.4595 -3.4278 -0.7123 -0.9889 -0.0330 -0.7810 -0.3553 -0.2263
S-1708	CONCLUSIONS: AAs with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit.<unk>
T-1708	aas ; hf ; hyperkalemia ; hypokalemia ; spironolactone ; clinical
H-1708	-0.482339471578598	▁AA s ▁; ▁ HF ▁; ▁hyper kal emia ▁; ▁hypo kal emia ▁; ▁spi rono lac tone ▁; ▁non - AA s
D-1708	-0.482339471578598	AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone ; non-AAs
P-1708	-1.8607 -0.3084 -0.1452 -0.4862 -0.2378 -0.1290 -0.5818 -0.7857 -0.1420 -0.0967 -0.0967 -1.4038 -0.2058 -0.0921 -0.2002 -0.0358 -0.0964 -0.0696 -0.2271 -2.6239 -0.0349 -0.1358 -0.0228 -1.8738 -0.1662
S-1407	Importantly, both of these receptors can be regulated by the actions of G-protein-coupled receptor kinase-2, which triggers desensitization and downregulation processes.<unk>
T-1407	receptors ; g-protein-coupled receptor ; kinase-2 ; downregulation
H-1407	-0.43950414657592773	▁g - prote in - co up led ▁receptor ▁kina se -2 ▁; ▁desen sit ization ▁; ▁down regul ation
D-1407	-0.43950414657592773	g-protein-coupled receptor kinase-2 ; desensitization ; downregulation
P-1407	-1.8969 -0.2359 -0.0638 -0.3909 -0.0769 -0.0130 -0.2134 -0.0225 -0.0044 -0.1267 -0.3169 -0.1957 -0.9476 -0.6391 -1.0769 -0.1523 -0.7366 -0.0192 -0.1085 -0.1213 -2.0733 -0.2375
S-1522	These findings support the development of a next generation NT-proBNP assay targeting nonterminal epitopes as well as avoiding the central glycosylated region of this molecule.<unk>
T-1522	nt-probnp ; nonterminal epitopes ; central glycosylated region
H-1522	-0.5308326482772827	▁NT - pro b NP ▁as say ▁; ▁non termin al ▁e pito pes ▁; ▁central ▁gly cos yla ted
D-1522	-0.5308326482772827	NT-probNP assay ; nonterminal epitopes ; central glycosylated
P-1522	-0.1695 -0.0688 -0.0292 -0.7312 -0.5707 -1.9478 -0.2912 -0.3092 -0.1763 -0.9329 -0.0049 -0.0772 -0.2720 -0.3185 -0.3048 -0.0729 -0.1032 -0.2345 -1.3698 -0.1541 -3.2063 -0.3333
S-1085	Induction of SCN5A variants with AngII or hypoxia or the expression of exogenous variants induced the UPR with concomitant downregulation of Na+ current.<unk>
T-1085	scn5a ; angii ; hypoxia ; expression ; upr ; downregulation
H-1085	-0.6753994822502136	▁s cn 5 a ▁; ▁ang II ▁; ▁hypo xia ▁; ▁ex ogen ous ▁variant s ▁induc ed ▁; ▁u PR ▁; ▁down regul ation ▁; ▁na + ▁current
D-1085	-0.6753994822502136	scn5a ; angII ; hypoxia ; exogenous variants induced ; uPR ; downregulation ; na+ current
P-1085	-0.6372 -1.5537 -0.2927 -0.4096 -0.2758 -0.1167 -1.2744 -0.1939 -0.1625 -0.5643 -0.3439 -2.0465 -0.0512 -0.0774 -0.8209 -0.3526 -0.0716 -0.3435 -1.1452 -0.1929 -1.0300 -0.3485 -0.1808 -0.1821 -0.1430 -0.7008 -0.0785 -5.5031 -0.7777 -0.6915 -0.3748
S-710	METHODS AND RESULTS: Between January 2000 and December 2009, adult patients undergoing isolated heart transplant were prospectively classified as ECCT based on prespecified criteria.<unk>
T-710	patients ; heart transplant ; prospectively ; ecct
H-710	-0.817416250705719	▁isola ted ▁heart ▁transplant
D-710	-0.817416250705719	isolated heart transplant
P-710	-0.3296 -0.0731 -2.2785 -0.0475 -1.9857 -0.1901
S-1571	Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e', highlighting these patients' diastolic dysfunction.<unk>
T-1571	multivariate logistic regression analysis ; bnp ; patients ; diastolic dysfunction
H-1571	-0.8958747386932373	▁b p ▁; ▁quart ile ▁of ▁e / e ▁; ▁dia sto lic ▁dys function
D-1571	-0.8958747386932373	bp ; quartile of e/e ; diastolic dysfunction
P-1571	-0.8202 -1.6352 -0.1041 -1.5741 -1.1514 -1.3895 -0.7753 -2.2150 -0.0418 -0.3025 -0.4174 -0.1704 -1.8458 -0.1880 -2.1621 -0.2251 -0.2119
S-663	A median rate ratio was calculated for each therapy, which describes the likelihood that the treatment of a patient with given comorbidities would differ at 2 randomly selected practices.<unk>
T-663	rate ratio ; therapy ; patient ; comorbidities
H-663	-0.8973432779312134	▁rate ▁ratio ▁; ▁ therapy ▁; ▁como rbi di ties
D-663	-0.8973432779312134	rate ratio ; therapy ; comorbidities
P-663	-2.5670 -0.0281 -0.3253 -1.4522 -0.0584 -0.2824 -4.4685 -0.0806 -0.5011 -0.3111 -0.4822 -0.2111
S-1715	MEASUREMENTS: Thirty-day rehospitalization derived from Medicare hospital claims using the implementation of Medicare's post-acute care transfer policy as a quasi-experiment.<unk>
T-1715	rehospitalization ; medicare ; hospital ; medicare ; policy
H-1715	-0.21498119831085205	▁re hospital ization ▁; ▁Medica re ▁; ▁claims ▁; ▁Medica re ▁; ▁post - a cute ▁care ▁transfer ▁policy
D-1715	-0.21498119831085205	rehospitalization ; Medicare ; claims ; Medicare ; post-acute care transfer policy
P-1715	-0.1400 -0.0275 -0.0977 -0.3116 -0.0591 -0.0196 -0.5406 -1.1073 -0.1297 -0.1244 -0.0198 -0.0950 -0.0959 -0.0362 -0.0162 -0.0445 -0.8342 -0.1124 -0.0176 -0.4400 -0.2455
S-1543	The risk of heart failure increased significantly with increasing refill compliance for etidronate (P for trend < 0.01), whereas it decreased for alendronate (P for trend < 0.01).<unk>
T-1543	heart failure ; compliance ; etidronate ; alendronate
H-1543	-0.4443346858024597	▁heart ▁failure ▁; ▁re fill ▁compliance ▁; ▁et id rona te ▁; ▁ale ndr onate
D-1543	-0.4443346858024597	heart failure ; refill compliance ; etidronate ; alendronate
P-1543	-1.9258 -0.2621 -0.1442 -0.2855 -0.0347 -0.2065 -0.1333 -0.0222 -1.2600 -0.0279 -0.0509 -0.1426 -2.0059 -0.0464 -0.3927 -0.4202 -0.1929
S-1762	Nonidentification of AT remained associated to prognosis also when compared with metabolic exercise and cardiac and kidney index score (P<0.01; HR=1.459; CI=1.09-1.10).<unk>
T-1762	prognosis ; metabolic exercise ; cardiac ; kidney
H-1762	-0.41050392389297485	▁AT ▁; ▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y ▁index ▁score
D-1762	-0.41050392389297485	AT ; metabolic exercise ; cardiac ; kidney index score
P-1762	-2.6110 -0.5890 -0.1252 -0.0158 -0.2344 -0.1059 -0.0370 -0.6100 -0.0663 -0.2875 -0.0648 -0.0805 -0.4423 -0.6733 -0.2146
S-1776	Men should be counseled on physical activity with the goal of achieving at least a moderate level of CRF, thereby presumably decreasing their risk of HF mortality.<unk>
T-1776	physical ; activity ; crf ; hf ; mortality
H-1776	-0.2820814549922943	▁physical ▁activity ▁; ▁c RF ▁; ▁ HF ▁mortal ity
D-1776	-0.2820814549922943	physical activity ; cRF ; HF mortality
P-1776	-0.2279 -0.1857 -0.1243 -0.2271 -0.7569 -0.1713 -0.6504 -0.1872 -0.3267 -0.0502 -0.2605 -0.2167
S-249	OBJECTIVE: This study was performed to evaluate the impact of ET on HDL-mediated protective effects and the respective molecular pathways in patients with chronic heart failure (CHF).<unk>
T-249	molecular pathways ; patients ; chronic heart failure ; chf
H-249	-0.6454245448112488	▁et ▁; ▁HD l - media ted ▁protect ive ▁effects ▁; ▁molecular ▁path ways ▁; ▁chronic ▁heart ▁failure ▁; CH f
D-249	-0.6454245448112488	et ; HDl-mediated protective effects ; molecular pathways ; chronic heart failure ;CHf
P-249	-1.9205 -0.8108 -2.7089 -2.5157 -0.2646 -0.1218 -0.0507 -0.8957 -0.0249 -0.4734 -0.2244 -0.6861 -0.0309 -0.0923 -0.2243 -0.4539 -1.2798 -0.1442 -0.5183 -0.3011 -0.5239 -0.3938 -0.1845
S-82	Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.<unk>
T-82	placebo ; dopamine ; nesiritide ; secondary end points ; renal function ; clinical ; outcomes
H-82	-0.4284689426422119	▁low - dos e ▁dop amine ▁; ▁nesi riti de ▁; ▁de con gestion ▁; ▁renal ▁function
D-82	-0.4284689426422119	low-dose dopamine ; nesiritide ; decongestion ; renal function
P-82	-2.0999 -0.0464 -1.2373 -0.2022 -0.2148 -0.6952 -0.1222 -0.0316 -0.0550 -0.6740 -0.2593 -0.7923 -0.0135 -0.0210 -0.2070 -0.0019 -0.5535 -0.7661 -0.1477
S-31	Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library.<unk>
T-31	anemia ; medline ; cochrane library
H-31	-0.46614784002304077	▁guide line ▁; ▁an emia ▁; ▁ir on ▁de fici en cy ▁; ▁MED line ▁; ▁co ch rane ▁Library
D-31	-0.46614784002304077	guideline ; anemia ; iron deficiency ; MEDline ; cochrane Library
P-31	-2.8116 -0.0246 -0.3180 -1.6480 -0.2136 -0.4568 -0.0073 -0.0629 -0.0891 -0.0091 -1.7345 -0.0420 -0.5458 -0.2021 -0.6710 -0.1641 -0.1098 -0.0827 -0.0115 -0.3090 -0.4485 -0.2931
S-790	The KCCQ domains demonstrated high internal consistency among patients with HFpEF (Cronbach's α=0.96 for overall summary and ≥0.69 in all subdomains).<unk>
T-790	kccq ; patients ; hfpef
H-790	-0.647540271282196	▁k cc q ▁; ▁internal ▁consiste ncy ▁; ▁ HF p EF ▁; ▁c ron bach
D-790	-0.647540271282196	kccq ; internal consistency ; HFpEF ; cronbach
P-790	-1.2715 -0.0246 -1.7457 -0.2462 -0.2466 -1.3785 -0.0363 -0.1777 -0.7230 -0.5959 -0.0362 -0.5666 -0.2047 -2.7445 -0.0180 -0.0174 -1.4354 -0.1870
S-891	However, our data do not support the use of implantable cardioverter defibrillator-CRT in patients with non-LBBB, especially when the QRS duration is <160 ms.<unk>
T-891	implantable ; patients ; qrs duration
H-891	-0.5469426512718201	▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT ▁; ▁non - LB BB ▁; ▁QR s ▁du ration
D-891	-0.5469426512718201	implantable cardioverter defibrillator-CRT ; non-LBBB ; QRs duration
P-891	-2.1098 -0.0176 -0.3237 -0.0472 -0.1524 -0.5067 -0.1581 -1.9808 -0.8768 -0.0515 -0.1673 -1.7064 -0.4957 -0.1447 -0.2274 -0.0989 -0.4018 -1.0583 -0.6639 -0.1812 -1.1996 -0.0956 -0.1769 -0.6418 -0.1895
S-1304	In this review, the principal mechanisms, diagnostic approaches, and clinical trials are reviewed, along with a discussion of novel treatment strategies that are currently under investigation or hold promise for the future.<unk>
T-1304	principal ; diagnostic ; clinical
H-1304	-0.9079210758209229	▁clinic al ▁trial s ▁; ▁treatment ▁strategie s
D-1304	-0.9079210758209229	clinical trials ; treatment strategies
P-1304	-4.2966 -0.0578 -0.2251 -0.0410 -0.7128 -1.9996 -1.0457 -0.0870 -0.4576 -0.1559
S-1538	RESULTS: The mean follow-up times were 2.8, 5.5 and 4.9 years for alendronate-, etidronate- and raloxifene-treated patients, respectively.<unk>
T-1538	follow-up ; patients
H-1538	-0.6227018237113953	▁ale ndr onate ▁; ▁et id rona te ▁; ▁ra lo xi fen e
D-1538	-0.6227018237113953	alendronate ; etidronate ; raloxifene
P-1538	-2.0580 -0.0866 -0.1814 -1.3406 -0.0095 -0.7466 -0.0156 -0.0232 -1.3543 -0.0153 -0.3233 -0.0911 -1.5702 -0.1515 -1.7550 -0.2410
S-674	Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes.<unk>
T-674	chemotherapy ; trastuzumab ; comorbidities ; chf ; international classification of diseases ; healthcare common procedure coding system codes
H-674	-0.2785085439682007	▁Che mo therapy ▁; ▁tras tuz um ab ▁; ▁CHF ▁; ▁international ▁classifica tion ▁of ▁Disease s ▁; ▁health care ▁Common ▁procedure ▁code s
D-674	-0.2785085439682007	Chemotherapy ; trastuzumab ; CHF ; international classification of Diseases ; healthcare Common procedure codes
P-674	-0.2931 -0.2361 -0.0464 -0.1056 -0.0311 -0.0156 -0.0245 -0.0093 -0.2540 -0.3442 -0.2078 -0.4152 -0.5823 -0.0090 -0.0363 -0.2656 -0.0111 -0.1847 -0.4437 -0.0322 -1.0893 -0.1516 -1.8311 -0.0801 -0.3643 -0.1770
S-111	Contemporary heart failure (HF) therapies have not resulted in improved outcomes among patients with HF and preserved left ventricular ejection fraction (LVEF).<unk>
T-111	heart failure ; hf ; therapies ; outcomes ; patients ; hf ; preserved left ventricular ejection fraction ; lvef
H-111	-0.48897406458854675	▁con tempor ary ▁heart ▁failure ▁; HF ▁; ▁ therapie s ▁; ▁ HF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; LV EF
D-111	-0.48897406458854675	contemporary heart failure ;HF ; therapies ; HF ; left ventricular ejection fraction ;LVEF
P-111	-0.9757 -0.0006 -0.0053 -0.7780 -0.0456 -0.2382 -0.1335 -0.2900 -1.1065 -1.5058 -0.0694 -0.1764 -0.3928 -0.1421 -0.0626 -1.2416 -2.1777 -1.3786 -0.3786 -0.1855 -0.4279 -0.3092 -0.6498 -0.0208 -0.5311 -0.1689 -0.0933 -0.4903 -0.2044
S-240	In HART, 208 patients had HFpEF and 692 had HF with reduced ejection fraction (HFrEF) and were followed for a median of 1,080 days.<unk>
T-240	hart ; patients ; hfpef ; hf with reduced ejection fraction ; hfref
H-240	-0.5125129222869873	▁h ART ▁; ▁ HF p EF ▁; ▁ HF ▁; ▁reduce d ▁e je ction ▁ fraction ▁; HF r EF
D-240	-0.5125129222869873	hART ; HFpEF ; HF ; reduced ejection fraction ;HFrEF
P-240	-1.3494 -0.0604 -0.1486 -0.9488 -0.3804 -0.5643 -0.6736 -0.0825 -0.7036 -0.3515 -0.2819 -3.2116 -0.1660 -0.0550 -0.3050 -0.0999 -0.4163 -0.0269 -0.2996 -0.9182 -0.2009 -0.3734 -0.4103 -0.2725
S-421	In conscious dogs with tachypacing-induced HF, CXL-1020 increased contractility assessed by end-systolic elastance and provided venoarterial dilation.<unk>
T-421	tachypacing-induced hf ; cxl-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
H-421	-0.370739221572876	▁ conscious ▁dog s ▁; ▁ta chy pac ing - indu ced ▁ HF ▁; ▁c XL -10 20 ▁; ▁contract ility ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁ve no arte rial ▁di lation
D-421	-0.370739221572876	conscious dogs ; tachypacing-induced HF ; cXL-1020 ; contractility ; end-systolic elastance ; venoarterial dilation
P-421	-1.9595 -0.1421 -1.1418 -0.0660 -0.2227 -0.5983 -0.6998 -0.0030 -0.0860 -0.0962 -0.0160 -0.9402 -0.5409 -0.2014 -0.1183 -0.5600 -0.3438 -0.2393 -0.0462 -0.5476 -0.0095 -0.0797 -0.1621 -0.3656 -0.0927 -1.2821 -0.4727 -0.6195 -0.0742 -0.4592 -0.2529 -0.0335 -0.0775 -0.1973 -0.1147 -0.1911 -0.4326 -0.7191 -0.2536
S-98	The mechanisms underlying these defects involve perturbed bone morphogenetic protein 4 expression, decreased rRNA transcription, and a shift to more heterochromatic chromatin.<unk>
T-98	bone morphogenetic protein 4 ; expression ; rrna transcription ; shift ; heterochromatic chromatin
H-98	-0.5936921834945679	▁mechanism s ▁; ▁bone ▁mor pho gene tic ▁protein ▁; ▁expression ▁; ▁r RNA ▁tran scription ▁; ▁shift ▁; ▁hetero ch ro matic ▁chr omat in
D-98	-0.5936921834945679	mechanisms ; bone morphogenetic protein ; expression ; rRNA transcription ; shift ; heterochromatic chromatin
P-98	-2.3748 -0.0610 -0.2643 -2.9489 -0.3862 -2.2479 -1.0666 -0.5293 -0.5539 -0.8255 -0.0655 -0.1754 -0.0273 -0.0681 -0.1454 -0.1009 -0.3795 -1.0068 -0.6312 -0.2177 -0.2491 -0.1036 -0.2191 -0.0980 -0.0340 -1.1473 -0.4641 -0.2318
S-873	The top pathways were in the categories of actin cytoskeleton, mitochondrial function, intermediate metabolism, glycolysis/gluconeogenesis, and citrate cycle.<unk>
T-873	actin cytoskeleton ; mitochondrial function ; metabolism ; glycolysis ; gluconeogenesis ; citrate cycle
H-873	-0.29142770171165466	▁act in ▁cy tos kelet on ▁; ▁mito cho ndri al ▁function ▁; ▁intermedi ate ▁metabolism ▁; ▁gly col ysis ▁; glu cone ogen es is ▁; ▁cit rate ▁cycle
D-873	-0.29142770171165466	actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
P-873	-0.0128 -0.2876 -0.0962 -1.0173 -0.1175 -0.1803 -0.2185 -0.0277 -1.6173 -0.6742 -0.0712 -0.3454 -0.1581 -0.0137 -0.0942 -0.1423 -0.1063 -0.0562 -0.0597 -0.6757 -0.4004 -0.5116 -0.1656 -0.6307 -0.0741 -0.4847 -0.2138 -0.0295 -0.2091 -0.2503 -0.2455 -0.1382
S-939	These results suggest that elevated resistin is a biomarker of anthracycline-induced cardiotoxicity and may contribute in the development of heart failure via its direct effects on macrophages.<unk>
T-939	elevated ; resistin ; biomarker ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
H-939	-0.2551393210887909	▁eleva ted ▁resist in ▁; ▁an thra cycli ne - indu ced ▁cardio toxic ity ▁; ▁heart ▁failure ▁; ▁macro pha ges
D-939	-0.2551393210887909	elevated resistin ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
P-939	-0.1499 -0.0287 -0.0228 -0.3604 -0.1927 -0.0313 -0.0784 -0.4649 -0.1493 -0.3874 -0.0226 -0.5405 -0.1259 -0.6194 -0.1708 -0.2089 -0.5578 -0.0981 -0.7238 -0.4022 -0.0860 -0.2503 -0.2813 -0.1701
S-741	Extracellular matrix of left ventricular biopsies (n=9), quantified by TissueFAXS technology correlated with T1 time (R=0.98; P<0.01).<unk>
T-741	extracellular matrix ; left ventricular ; biopsies ; tissuefaxs ; correlated ; t1 time
H-741	-0.7144190669059753	▁extra cel lular ▁matri x ▁; ▁left ▁vent ri cular ▁bio psi es ▁; ▁t issue FAX s ▁technology
D-741	-0.7144190669059753	extracellular matrix ; left ventricular biopsies ; tissueFAXs technology
P-741	-4.4346 -0.2376 -0.2545 -0.1493 -0.5135 -0.5385 -0.0192 -2.3940 -1.0146 -0.3767 -0.8571 -0.7752 -0.2371 -0.1466 -0.2522 -0.0363 -0.3882 -1.0421 -0.1257 -1.0817 -0.1281
S-389	METHODS AND RESULTS: Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis.<unk>
T-389	patients ; systolic hf ; the danish heart failure database ; esrd ; danish registry on dialysis
H-389	-0.5809276103973389	▁sy sto lic ▁ HF ▁; ▁Danish ▁Heart ▁Fail ure ▁database ▁; ▁new - ons et ▁ES RD ▁; ▁Danish ▁Registr y ▁on ▁Dia lys is
D-389	-0.5809276103973389	systolic HF ; Danish Heart Failure database ; new-onset ESRD ; Danish Registry on Dialysis
P-389	-1.5766 -0.0909 -0.2719 -0.2245 -0.1163 -0.1933 -1.0253 -0.6071 -0.1695 -0.0404 -0.3716 -0.0865 -3.3062 -0.0641 -0.0070 -0.2492 -0.2448 -2.1501 -0.1205 -1.4727 -0.6588 -0.0721 -0.0633 -1.2580 -0.6210 -0.4497 -0.5432 -0.2113
S-773	As left ventricular assist devices (LVADs) have become more widely used for treating patients with advanced heart failure, the incidence of pump dysfunction requiring pump replacement has increased.<unk>
T-773	left ventricular assist devices ; lvads ; patients ; heart failure ; incidence ; pump dysfunction ; pump
H-773	-0.5381893515586853	▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁advanced ▁heart ▁failure ▁; ▁pump ▁dys function ▁; ▁pump ▁replace ment
D-773	-0.5381893515586853	left ventricular assist devices ; lVADs ; advanced heart failure ; pump dysfunction ; pump replacement
P-773	-0.1013 -2.2662 -0.9591 -0.1273 -1.1271 -0.1517 -0.4741 -0.5165 -0.0895 -0.0793 -0.3525 -2.4254 -0.8650 -0.1659 -0.3819 -0.5090 -0.4180 -0.4940 -0.2164 -0.3379 -0.2647 -0.0725 -0.3093 -0.2119
S-704	In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide.<unk>
T-704	multivariable models ; st2 ; outcomes ; clinical ; amino-terminal pro-b-type natriuretic peptide
H-704	-0.4890957474708557	▁ST 2 ▁; ▁amino - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de
D-704	-0.4890957474708557	ST2 ; amino-terminal pro-b-type natriuretic peptide
P-704	-0.9099 -0.0817 -0.3361 -2.4413 -0.1341 -0.0592 -0.0053 -0.0677 -0.0607 -1.5108 -0.0994 -0.5675 -0.0169 -0.2835 -0.1569 -0.5596 -0.0442 -0.3152 -1.8433 -0.5971 -0.1804
S-319	BACKGROUND: Biventricular pacing (BiVP) improves cardiac output (CO) in selected cardiac surgery patients, but response remains variable, necessitating a better understanding of the mechanism.<unk>
T-319	biventricular pacing ; bivp ; cardiac output ; cardiac ; surgery ; patients
H-319	-0.48671701550483704	▁bi ven tri cular ▁pa cing ▁; ▁bi VP ▁; ▁cardiac ▁output ▁; co ▁; ▁cardiac ▁surgery
D-319	-0.48671701550483704	biventricular pacing ; biVP ; cardiac output ;co ; cardiac surgery
P-319	-0.2259 -0.3693 -1.5781 -0.5257 -0.5105 -0.2074 -0.4017 -0.2779 -0.6946 -0.3175 -0.1123 -0.0311 -0.3333 -1.2880 -0.5778 -0.1836 -0.2947 -1.1117 -0.2066
S-2002	Support with the fully magnetically levitated LVAS significantly reduced mortality risk by 66% compared with the Seattle Heart Failure Model-predicted survival of 78% (p = 0.0093).<unk>
T-2002	fully magnetically levitated lvas ; mortality ; seattle ; heart failure
H-2002	-0.4094527065753937	▁fully ▁magnet ically ▁le vita ted ▁l VAS ▁; ▁mortal ity ▁risk ▁; ▁Seattle ▁Heart ▁Fail ure ▁model - pred i cted ▁survival
D-2002	-0.4094527065753937	fully magnetically levitated lVAS ; mortality risk ; Seattle Heart Failure model-predicted survival
P-2002	-3.5453 -0.6699 -0.0237 -0.1213 -0.0146 -0.0602 -1.2030 -0.4391 -0.2021 -0.5098 -0.0197 -0.6075 -0.1346 -0.0129 -0.7248 -0.1879 -0.0228 -0.3430 -0.2558 -0.0150 -0.2667 -0.0425 -0.3205 -0.3445 -0.1493
S-1952	Patients (aged ≥18 years) with New York Heart Association (NYHA) class III chronic heart failure with reduced ejection fraction were enrolled under the Canadian special access programme.<unk>
T-1952	patients ; new york heart association ; nyha ; chronic heart failure ; reduced ejection fraction
H-1952	-0.7469014525413513	▁New ▁York ▁Heart ▁association ▁; NY HA ▁; ▁chronic ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-1952	-0.7469014525413513	New York Heart association ;NYHA ; chronic heart failure ; reduced ejection fraction
P-1952	-2.1868 -0.6937 -2.7879 -0.2998 -0.1924 -0.6068 -1.4061 -0.2476 -1.6743 -1.3005 -0.2906 -0.2554 -0.3851 -0.0465 -0.0323 -0.1597 -0.1163 -0.3327 -0.0166 -2.4277 -0.2259
S-1518	Consistent with this result, AlphaLISA immunoassays demonstrated that antibodies targeting the extreme N or C termini measured a low apparent concentration of circulating NT-proBNP.<unk>
T-1518	alphalisa ; immunoassays ; antibodies ; c termini ; nt-probnp
H-1518	-0.5957988500595093	▁Alpha LIS a ▁immun o assa ys ▁; ▁anti bo dies ▁; ▁N ▁; ▁c ▁termini ▁; ▁circula ting ▁NT - pro b NP
D-1518	-0.5957988500595093	AlphaLISa immunoassays ; antibodies ; N ; c termini ; circulating NT-probNP
P-1518	-0.0290 -1.0750 -0.8598 -0.1022 -0.2869 -0.4484 -1.8902 -0.0808 -0.0518 -0.3019 -0.5791 -0.1311 -2.9704 -0.8655 -0.4091 -0.5904 -0.0481 -2.7903 -0.0464 -0.5876 -0.0704 -0.0443 -0.6028 -0.0863 -0.3536 -0.1892
S-587	At the second evaluation, higher serum levels of creatinine and BNP, higher furosemide dose and oxygen flow, and dobutamine or norepinephrine requirement were associated with poor outcome.<unk>
T-587	creatinine ; bnp ; furosemide ; dobutamine ; norepinephrine ; outcome
H-587	-0.333680659532547	▁se rum ▁levels ▁; ▁creati nine ▁; ▁b NP ▁; ▁fur os em ide ▁dose ▁; ▁oxygen ▁flow ▁; ▁dobu tamine ▁; ▁no re pine ph rine
D-587	-0.333680659532547	serum levels ; creatinine ; bNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
P-587	-0.9586 -0.2700 -0.1129 -0.4912 -0.0721 -0.1664 -0.1243 -0.8601 -0.8060 -0.1433 -0.0351 -0.1348 -0.0698 -0.4656 -1.4817 -0.0898 -0.2610 -0.0139 -0.1439 -0.2469 -0.1340 -0.0848 -0.1897 -0.1622 -0.0714 -0.7564 -0.0152 -1.1854 -0.1301
S-1678	However, our results do not rule out the possibility that decreased expression, mistargeting or altered regulation of Rad Q66P may reduce the RGK protein's efficacy in vivo.<unk>
T-1678	rule ; expression ; regulation ; rad ; q66p ; rgk protein ; in vivo
H-1678	-0.5306187272071838	▁expression ▁; ▁mis tar ge ting ▁; ▁regula tion ▁; ▁Rad ▁Q 66 p ▁; ▁r GK ▁protein
D-1678	-0.5306187272071838	expression ; mistargeting ; regulation ; Rad Q66p ; rGK protein
P-1678	-0.3667 -0.0890 -0.4498 -0.0981 -0.0475 -0.0573 -0.0834 -0.4736 -0.0263 -0.1915 -0.3887 -2.2662 -0.1372 -0.1980 -0.0996 -1.9015 -0.9345 -0.6461 -2.0102 -0.1471
S-89	Myocyte hypertrophy antecedent to heart failure involves changes in global gene expression, although the preceding mechanisms to coordinate DNA accessibility on a genomic scale are unknown.<unk>
T-89	myocyte hypertrophy ; heart failure ; global gene expression ; dna ; genomic
H-89	-0.5475702285766602	▁my o cy te ▁hyper trop hy ▁; ▁heart ▁failure ▁; ▁global ▁gene ▁expression ▁; ▁DNA ▁access i bility ▁; ▁genom ic ▁scale
D-89	-0.5475702285766602	myocyte hypertrophy ; heart failure ; global gene expression ; DNA accessibility ; genomic scale
P-89	-1.5248 -0.0485 -0.1310 -0.3345 -0.3945 -0.0615 -1.0064 -0.5747 -1.3873 -0.2152 -0.4316 -2.1284 -0.7020 -0.1585 -0.6200 -0.6650 -1.4654 -0.1059 -0.0109 -0.6956 -0.1725 -0.0433 -0.3937 -0.1900 -0.2279
S-138	Using each metric, we calculated the absolute change and correlation between performance; the percent of hospitals remaining in extreme deciles and level of agreement; and differences in longitudinal performance.<unk>
T-138	change ; correlation ; hospitals ; longitudinal
H-138	-0.8218681216239929	▁performance ▁; ▁hospital s ▁; ▁extreme ▁deci les ▁; ▁longitud in al ▁performance
D-138	-0.8218681216239929	performance ; hospitals ; extreme deciles ; longitudinal performance
P-138	-6.8076 -0.2414 -0.8224 -0.0813 -0.2801 -0.8857 -0.2078 -0.0574 -0.4226 -1.6584 -0.1343 -0.0206 -0.2679 -0.1697 -0.2708
S-1259	DESIGN: Studies on biomedical treatment plus CHM versus biomedical treatment alone in treating patients with DCM and heart failure were retrieved from PubMed and other major databases (1980-2011).<unk>
T-1259	biomedical ; biomedical ; patients ; dcm ; heart failure ; pubmed
H-1259	-0.630050539970398	▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁bio medic al ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure ▁; ▁Pub Med
D-1259	-0.630050539970398	biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure ; PubMed
P-1259	-0.6759 -0.1887 -0.0071 -2.7347 -0.1607 -2.1142 -0.1388 -0.2523 -0.6392 -0.0560 -0.0081 -1.3782 -0.3608 -0.5140 -1.4401 -0.0894 -1.0120 -0.1053 -1.8839 -0.1320 -0.2202 -0.2098 -0.1698
S-408	Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event.<unk>
T-408	sst2 ; sst2 ; odds ratio ; cardiovascular event
H-408	-0.8036149144172668	▁s st 2/ high - dos e ▁BB ▁; ▁s st 2 ▁; ▁low - dos e ▁BB ▁; ▁cardiovascular ▁event
D-408	-0.8036149144172668	sst2/high-dose BB ; sst2 ; low-dose BB ; cardiovascular event
P-408	-0.0165 -2.5304 -2.7093 -1.3395 -0.0877 -1.0238 -0.1335 -1.6621 -0.4369 -0.2958 -2.8456 -0.1221 -0.2663 -0.4200 -0.0541 -0.9448 -0.0565 -0.9615 -0.4991 -0.7991 -0.8267 -0.2320 -0.2200
S-11	We tested the hypothesis that neurohormones and adipokines are associated with body composition in CC and that a progressive loss of fat free mass (FFM) and fat mass (FM) takes place.<unk>
T-11	neurohormones ; adipokines ; fat free mass ; ffm ; fat mass
H-11	-0.3944190442562103	▁neuro hormon es ▁; ▁adi pok ines ▁; ▁body ▁composition ▁; ▁CC ▁; ▁fat ▁free ▁mass ▁; FF m ▁; ▁fat ▁mass ▁; FM
D-11	-0.3944190442562103	neurohormones ; adipokines ; body composition ; CC ; fat free mass ;FFm ; fat mass ;FM
P-11	-0.2412 -0.0392 -0.2796 -0.1382 -0.0192 -0.1892 -0.1744 -0.1383 -0.4178 -0.7875 -0.1032 -0.9587 -0.1225 -2.5545 -0.0242 -0.0891 -0.3333 -0.6202 -0.2076 -0.3583 -0.6344 -0.0589 -0.8902 -0.0057 -0.6065 -0.2632
S-1411	CONCLUSIONS: We demonstrate that restoration of cardiac plasma membrane levels of S1PR1 produces beneficial effects that counterbalance the deleterious β1AR overstimulation in heart failure.<unk>
T-1411	cardiac plasma membrane ; s1pr1 ; β1ar ; heart failure
H-1411	-0.7345567345619202	▁cardiac ▁plasma ▁membran e ▁levels ▁; ▁s 1 PR 1 ▁; ▁counter balance ▁; ▁β 1 AR ▁over stimul ation ▁; ▁heart ▁failure
D-1411	-0.7345567345619202	cardiac plasma membrane levels ; s1PR1 ; counterbalance ; β1AR overstimulation ; heart failure
P-1411	-1.8707 -0.3409 -0.0187 -0.1032 -0.8808 -0.4309 -0.4536 -0.5411 -0.8379 -2.0672 -0.2757 -4.2470 -0.2013 -0.3878 -1.3896 -1.2738 -1.3997 -0.1408 -0.0849 -0.1506 -0.4506 -0.0831 -0.0927 -0.4498 -0.1916
S-473	Sprague-Dawley rats were randomized to either sham or ACF ± allopurinol (100 mg·kg(-1)·day(-1), n ≥7 rats/group).<unk>
T-473	sprague-dawley ; randomized ; acf ; allopurinol
H-473	-0.38069796562194824	▁Spr a gue - Da w ley ▁rat s ▁; ▁sham ▁; ▁a CF ▁; ▁allo puri nol
D-473	-0.38069796562194824	Sprague-Dawley rats ; sham ; aCF ; allopurinol
P-473	-0.0954 -0.1906 -0.0960 -0.0592 -1.5286 -0.0303 -0.3821 -0.5749 -0.0654 -0.2601 -0.3426 -0.1442 -1.1644 -0.3428 -0.2244 -0.1024 -0.0460 -0.2981 -1.4432 -0.2231
S-1064	These T1 changes appear to be associated with increases in the percentage of myocardial collagen that in this study were not detected by traditional myocardial delayed enhancement imaging.<unk>
T-1064	t1 ; myocardial collagen ; myocardial
H-1064	-0.37516018748283386	▁t 1 ▁changes ▁; ▁my o card ial ▁collage n ▁; ▁my o card ial ▁de lay ed ▁enhance ment ▁imagin g
D-1064	-0.37516018748283386	t1 changes ; myocardial collagen ; myocardial delayed enhancement imaging
P-1064	-0.3491 -0.1890 -1.7512 -0.1360 -0.2399 -0.2193 -1.0426 -0.1628 -0.0974 -0.3332 -0.1386 -1.6959 -0.1449 -1.3539 -0.1044 -0.0612 -0.0065 -0.0664 -0.2172 -0.0236 -0.1642 -0.0206 -0.3589 -0.1270
S-1833	RESULTS: 78 553 saxagliptin users and 298 124 sitagliptin users contributed an average of 7 to 9 months of follow-up data to 1 or more pairwise comparisons.<unk>
T-1833	saxagliptin ; sitagliptin ; follow-up
H-1833	-1.1509000062942505	▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁follow - up
D-1833	-1.1509000062942505	saxagliptin ; sitagliptin ; follow-up
P-1833	-0.0993 -0.3691 -0.6357 -4.1476 -0.2378 -2.2885 -0.7764 -0.3193 -3.3181 -0.9031 -1.2968 -0.2018 -0.0494 -2.4171 -0.2034
S-944	METHODS: Catheter ablation for AF was performed in a consecutive 74 patients with compensated HFPEF (left ventricular [LV] ejection fraction >50%).<unk>
T-944	catheter ablation ; patients ; compensated hfpef ; left ventricular ; ejection fraction
H-944	-0.5489464402198792	▁Cat heter ▁ab lation ▁; ▁AF ▁; ▁compensa ted ▁H FP EF ▁; ▁le ft ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction
D-944	-0.5489464402198792	Catheter ablation ; AF ; compensated HFPEF ; left ventricular ;LV ; ejection fraction
P-944	-1.0035 -0.0312 -0.0111 -0.3040 -1.0449 -0.2145 -0.2135 -0.0703 -0.0155 -1.4958 -1.6279 -0.4714 -0.1509 -1.5237 -0.0217 -2.3873 -1.2137 -0.2059 -0.1200 -0.3234 -0.9147 -0.0302 -0.2450 -0.1331 -0.6972 -0.0100 -0.6945 -0.1959
S-411	CONCLUSIONS: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.<unk>
T-411	therapy ; sst2 ; patients ; chronic heart failure
H-411	-0.5665228366851807	▁BB ▁ therapy ▁; ▁s st 2 ▁measure ment ▁; ▁chronic ▁heart ▁failure
D-411	-0.5665228366851807	BB therapy ; sst2 measurement ; chronic heart failure
P-411	-0.5951 -0.9449 -0.1040 -0.1916 -0.0180 -1.5024 -0.0453 -0.6599 -0.1021 -0.1718 -0.3257 -1.0061 -0.1273 -2.5263 -0.1774
S-853	There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02).<unk>
T-853	deaths ; crt ; hazard ratio
H-853	-0.9368525147438049	▁c RT ▁group ▁; ▁control ▁group ▁; ▁hazard ▁ratio
D-853	-0.9368525147438049	cRT group ; control group ; hazard ratio
P-853	-0.9480 -3.5520 -1.5789 -0.1557 -1.1241 -0.1979 -0.2572 -0.5691 -0.0148 -1.6409 -0.2668
S-396	CONCLUSIONS: ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m(2).<unk>
T-396	esrd ; outpatients ; systolic hf ; patients ; egfr
H-396	-0.5869976282119751	▁ES RD ▁; ▁out patient s ▁; ▁sy sto lic ▁ HF ▁; ▁e g f
D-396	-0.5869976282119751	ESRD ; outpatients ; systolic HF ; egf
P-396	-1.8195 -1.5830 -0.1506 -0.9117 -0.0237 -0.0826 -0.3353 -0.2209 -0.0635 -0.5620 -0.6318 -0.1518 -0.1542 -0.2029 -0.7683 -1.7195 -0.8785 -0.3060
S-501	The TAPSE vs. PASP relationship as a possible index of the length-force relationship may be a step forward for a more efficient RV function evaluation and is not affected by the quality of LV dysfunction.<unk>
T-501	tapse ; pasp ; step ; rv function ; lv dysfunction
H-501	-0.6766438484191895	▁t AP se ▁; ▁PAS p ▁relationship ▁; ▁length - force ▁relationship ▁; ▁ RV ▁function ▁; ▁LV ▁dys function
D-501	-0.6766438484191895	tAPse ; PASp relationship ; length-force relationship ; RV function ; LV dysfunction
P-501	-3.2462 -1.2793 -2.8003 -0.5087 -0.4991 -0.2226 -0.2278 -0.1832 -0.0019 -0.3047 -0.0675 -0.0728 -0.1804 -0.1657 -0.2107 -0.7742 -1.2513 -0.7112 -0.9494 -0.6750 -0.3219 -0.2324
S-172	In the TUNEL assay there was no significant difference between numbers of apoptotic cells in any of the groups, although a few TUNEL-positive cells were detected in the paced groups.<unk>
T-172	tunel ; apoptotic cells ; tunel-positive cells
H-172	-0.8059648871421814	▁TU el ▁as say ▁; ▁apo pto tic ▁cell s ▁; ▁TU NEL - posi tive ▁cell s ▁; ▁pace d ▁groups
D-172	-0.8059648871421814	TUel assay ; apoptotic cells ; TUNEL-positive cells ; paced groups
P-172	-1.4909 -3.6634 -2.1585 -0.1858 -0.2070 -0.9870 -0.3504 -0.1772 -1.1145 -0.0582 -0.3029 -1.8140 -3.6573 -0.1484 -0.0339 -0.1066 -0.9282 -0.0600 -1.0375 -0.0488 -0.2360 -0.1867 -0.2167 -0.1732
S-425	CONCLUSIONS: These data show the functional efficacy of a novel pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.<unk>
T-425	hno donor ; myocardial function ; evidence ; hf
H-425	-0.6857489347457886	▁ha no ▁donor ▁; ▁my o card ial ▁function ▁; ▁ HF
D-425	-0.6857489347457886	hano donor ; myocardial function ; HF
P-425	-3.9248 -0.8956 -0.6605 -0.1382 -0.9256 -0.1735 -0.4744 -0.1483 -0.6247 -0.2178 -0.8194 -0.1522 -0.2407 -0.2049
S-301	The mean duration of biventricular support was 17 ± 11.9 days (range, 6 to 56 days) with 91.8% (n = 31) of RVADs successfully explanted.<unk>
T-301	biventricular support ; rvads ; explanted
H-301	-0.8757824301719666	▁bi ven tri cular ▁support ▁; ▁r VAD s
D-301	-0.8757824301719666	biventricular support ; rVADs
P-301	-0.3924 -0.6353 -0.6431 -0.3727 -1.7317 -0.3313 -3.1508 -0.9011 -0.1878 -1.0642 -0.2233
S-1583	CONCLUSIONS: An intensive transitions of care program decreases the 30-day readmission rate for patients with congestive heart failure in a non-urbanized Midwestern state like South Dakota.<unk>
T-1583	transitions ; readmission ; patients ; congestive heart failure ; south dakota
H-1583	-0.6114967465400696	▁con ges tive ▁heart ▁failure ▁; ▁mid we stern ▁state ▁; ▁South ▁da kota
D-1583	-0.6114967465400696	congestive heart failure ; midwestern state ; South dakota
P-1583	-2.7706 -0.2417 -0.0332 -0.7459 -0.0846 -0.3965 -3.7443 -0.0703 -0.0056 -0.0477 -0.2222 -0.3539 -0.2647 -0.0082 -0.4772 -0.3172
S-990	The ability of cardiomyocytes to detect mechanical and humoral stimuli is critical for adaptation of the myocardium in response to new conditions and for sustaining the increased workload during stress.<unk>
T-990	cardiomyocytes ; myocardium ; conditions
H-990	-0.47745805978775024	▁cardio my o cy tes ▁; ▁mechanic al ▁; ▁humor al ▁stimul i ▁; ▁my o car dium ▁; ▁conditions ▁; ▁work load
D-990	-0.47745805978775024	cardiomyocytes ; mechanical ; humoral stimuli ; myocardium ; conditions ; workload
P-990	-0.1692 -0.5473 -0.2607 -0.2048 -0.2801 -0.2791 -0.0619 -0.0172 -0.4003 -0.1011 -0.1050 -0.4644 -0.7578 -0.3014 -0.8277 -0.0646 -0.4217 -2.1941 -0.4540 -0.4045 -0.3545 -0.4206 -0.2465 -2.2986 -0.2995
S-1283	The interval from transplantation to consultation was shorter for the MT group (50 vs 82 days; P = 0.015), whereas the interval from consultation to operation was longer (5 vs 1 day; P = 0.03).<unk>
T-1283	transplantation ; consultation ; consultation ; operation
H-1283	-1.135607123374939	▁MT ▁group ▁; ▁operation
D-1283	-1.135607123374939	MT group ; operation
P-1283	-3.5564 -1.0885 -0.7029 -0.9683 -0.3282 -0.1693
S-431	Cox proportional hazards models were used to identify the association of the score with death, transplantation or LV assist device implantation, and heart failure hospitalization during 57±22 months of follow-up.<unk>
T-431	cox proportional hazards models ; death ; transplantation ; lv assist device implantation ; heart failure ; hospitalization ; follow-up
H-431	-0.5080111622810364	▁co x ▁proportion al ▁hazard s ▁models ▁; ▁death ▁; ▁transplant ation ▁; ▁LV ▁assist ▁device ▁implant ation ▁; ▁heart ▁failure
D-431	-0.5080111622810364	cox proportional hazards models ; death ; transplantation ; LV assist device implantation ; heart failure
P-431	-0.0487 -0.0673 -0.1808 -0.0124 -0.9488 -0.2335 -1.7278 -0.3104 -3.0392 -0.2159 -0.2348 -0.2030 -0.1037 -0.3067 -0.4612 -0.2589 -0.7262 -0.1894 -0.2717 -0.5679 -0.1915 -1.2034 -0.1810
S-964	Nicorandil also preserved phosphocreatine and adenine nucleotides contents by restoring mitochondrial oxidative phosphorylation capacity and creatine kinase activity.<unk>
T-964	nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity
H-964	-0.431523859500885	▁Nico rand il ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity ▁; ▁creati ne ▁kina se ▁activity
D-964	-0.431523859500885	Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase activity
P-964	-0.0021 -0.0986 -0.0743 -0.1660 -0.3111 -0.0479 -1.8230 -1.4299 -0.3832 -0.2542 -0.0087 -0.0039 -0.0359 -0.1448 -0.0495 -0.9667 -0.3623 -0.0373 -1.2866 -0.4721 -0.0584 -0.2375 -0.3813 -0.3970 -0.0849 -2.1360 -1.4736 -1.4630 -0.2271 -0.3800 -0.0860 -0.0317 -0.0147 -0.1354 -0.3420 -0.4076 -0.1522
S-801	The intraclass correlation coefficient (ICC), kappa coefficient, standard error of measurement, and absolute and relative minimal detectable change (MDC) values were calculated.<unk>
T-801	intraclass correlation coefficient ; icc ; kappa coefficient ; standard error of measurement ; minimal detectable change ; mdc
H-801	-0.5025107860565186	▁corre lation ▁co e ffi cient ▁; IC c ▁; ▁ka ppa ▁co e ffi cient ▁; ▁standard ▁error ▁of ▁measure ment ▁; ▁m d
D-801	-0.5025107860565186	correlation coefficient ;ICc ; kappa coefficient ; standard error of measurement ; md
P-801	-1.9192 -2.0365 -0.0357 -0.1003 -0.0419 -0.0932 -0.4039 -0.5651 -1.7390 -0.2044 -0.1767 -0.0668 -0.0345 -0.0416 -0.0463 -0.0723 -0.5593 -0.4786 -0.2761 -1.0041 -0.0198 -0.0609 -0.2906 -1.6464 -0.4701 -0.9724 -0.2121
S-1826	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.<unk>
T-1826	hospitalized ; heart failure ; saxagliptin ; sitagliptin ; antihyperglycemic drugs ; retrospective cohort study
H-1826	-0.831854522228241	▁Hospital ized ▁Heart ▁Fail ure ▁; ▁Sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁drug s
D-1826	-0.831854522228241	Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic drugs
P-1826	-2.5153 -0.0300 -0.4709 -0.1251 -0.0292 -0.2892 -0.1602 -0.3739 -0.9067 -3.1557 -0.2542 -2.0731 -0.4219 -0.1821 -2.0079 -0.3162 -0.0634 -1.5576 -0.3459 -2.8374 -0.1512 -0.8128 -1.7059 -0.3634 -0.3100 -0.1690
S-1629	Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).<unk>
T-1629	exercise ; training ; outcomes ; chronic heart failure ; heart failure - a controlled trial investigating outcomes in exercise training ; hf-action
H-1629	-0.5334179401397705	▁race ▁; ▁exercise ▁training ▁; ▁chronic ▁heart ▁failure ▁; ▁Heart ▁Fail ure ▁; ▁control led ▁Tri al ▁Investiga ting ▁out com es ▁; ▁exercise ▁Tra i N ing ▁; HF - ac tion
D-1629	-0.5334179401397705	race ; exercise training ; chronic heart failure ; Heart Failure ; controlled Trial Investigating outcomes ; exercise TraiNing ;HF-action
P-1629	-0.6575 -0.2228 -0.1483 -0.0931 -0.1667 -1.0163 -0.4200 -0.0986 -0.3555 -1.5094 -0.5586 -0.0419 -0.1195 -1.3028 -0.0148 -1.2647 -0.0248 -0.9609 -0.0718 -0.8244 -0.6976 -0.0596 -0.3521 -0.2181 -1.8787 -0.3906 -1.5263 -0.0522 -0.5077 -0.1674 -0.0378 -1.0920 -1.1974 -0.4210 -0.1987
S-972	The Swedish National Inpatient Registry was used to obtain the primary end point, which was rehospitalization for stroke, myocardial infarction, or heart failure ≤90 days after CABG.<unk>
T-972	inpatient ; primary end point ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; cabg
H-972	-0.2847389578819275	▁stockholm ▁national ▁in patient ▁Registr y ▁; ▁re hospital ization ▁; ▁stroke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁ca BG
D-972	-0.2847389578819275	stockholm national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
P-972	-1.1349 -0.3761 -0.1122 -0.1666 -0.6713 -0.1339 -0.2169 -0.0651 -0.0045 -0.1206 -0.2654 -0.3458 -0.1085 -0.2222 -0.2776 -0.4183 -0.0298 -0.0289 -0.1903 -0.2306 -0.1366 -0.3002 -0.0299 -0.7531 -0.3689 -0.9035 -0.2036 -0.1574
S-1974	IMPORTANCE: More than 80% of patients with heart failure with preserved ejection fraction (HFPEF), the most common form of heart failure among older persons, are overweight or obese.<unk>
T-1974	patients ; heart failure with preserved ejection fraction ; hfpef ; heart failure ; obese
H-1974	-0.48098263144493103	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h FP EF ▁; ▁heart ▁failure ▁; ▁over weight ▁; ▁obes e
D-1974	-0.48098263144493103	heart failure ; preserved ejection fraction ; hFPEF ; heart failure ; overweight ; obese
P-1974	-2.0878 -0.1402 -0.2490 -0.2382 -0.2125 -0.1626 -0.0565 -0.4067 -0.1269 -0.4761 -0.0206 -0.3740 -1.1538 -2.2898 -0.6398 -0.2108 -1.2395 -0.2209 -0.3036 -0.2526 -0.2501 -0.7335 -0.0121 -0.1049 -0.3254 -0.2178
S-894	BACKGROUND: Peritoneal dialysis (PD) for long-term management of diuretic resistant volume overload in heart failure (HF) may provide potential benefit with few adverse consequences.<unk>
T-894	peritoneal dialysis ; pd ; diuretic ; volume overload ; heart failure ; hf
H-894	-0.18832534551620483	▁Peri tone al ▁di al ysis ▁; PD ▁; ▁di ure tic ▁resist ant ▁volume ▁over load ▁; ▁heart ▁failure ▁; HF
D-894	-0.18832534551620483	Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
P-894	-0.1285 -0.2485 -0.0289 -0.1224 -0.0909 -0.3259 -0.2305 -0.1117 -0.3342 -0.1684 -0.0387 -0.1707 -0.2099 -0.1172 -0.2651 -0.1332 -0.1197 -0.3199 -0.2742 -0.0604 -0.4419 -0.1597 -0.2975 -0.1219
S-387	BACKGROUND: Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown.<unk>
T-387	renal dysfunction ; prognostic ; heart failure ; hf ; dysfunction ; end-stage renal disease ; esrd
H-387	-0.4994855523109436	▁Ren al ▁dys function ▁; ▁heart ▁failure ▁; HF ▁; ▁dys function ▁; ▁end - s tage ▁renal ▁disease ▁; ES RD
D-387	-0.4994855523109436	Renal dysfunction ; heart failure ;HF ; dysfunction ; end-stage renal disease ;ESRD
P-387	-0.6409 -0.1104 -0.2226 -1.1957 -0.1153 -1.8420 -0.1175 -0.2800 -0.0915 -0.2299 -3.0940 -0.3851 -0.1826 -0.0464 -0.0701 -0.0169 -0.0020 -0.0190 -0.5481 -0.2580 -1.3541 -0.7381 -0.2748 -0.1528
S-430	Regression analysis was performed to create an echocardiographic score for prediction of LV reverse remodeling (defined as ≥15% reduction in the LV end-systolic volume).<unk>
T-430	regression analysis ; echocardiographic ; lv reverse remodeling ; lv end-systolic volume
H-430	-0.5408654808998108	▁re gression ▁analysis ▁; ▁e cho car dio graphic ▁score ▁; ▁LV ▁rever se ▁remodel ing ▁; ▁LV ▁; ▁end - sy sto lic ▁volume
D-430	-0.5408654808998108	regression analysis ; echocardiographic score ; LV reverse remodeling ; LV ; end-systolic volume
P-430	-1.2453 -0.0032 -0.9247 -0.2335 -0.0446 -0.4329 -0.9729 -2.0155 -0.8834 -1.3623 -0.0905 -0.2590 -0.0227 -0.0576 -0.1563 -0.0894 -0.1732 -1.4226 -1.3124 -0.2727 -0.0617 -0.8839 -0.3086 -0.3779 -0.4550 -0.4104 -0.1308
S-1567	Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined.<unk>
T-1567	peripheral artery disease ; pad ; heart failure ; hf ; prevalence ; hf ; patients ; pad
H-1567	-0.38237911462783813	▁Peri pher al ▁arter y ▁disease ▁; PAD ▁; ▁heart ▁failure ▁; HF ▁; ▁ HF ▁; ▁ PAD
D-1567	-0.38237911462783813	Peripheral artery disease ;PAD ; heart failure ;HF ; HF ; PAD
P-1567	-0.1090 -0.0135 -0.2390 -0.2586 -0.5412 -1.6937 -0.1166 -0.0578 -0.1038 -0.9847 -0.1433 -0.2487 -0.3120 -0.2800 -0.2008 -0.2735 -0.2231 -1.4459 -0.3294 -0.2353 -0.2200
S-137	STUDY DESIGN: We calculated 30-day readmission rates using three metrics, for three disease groups: heart failure (HF), acute myocardial infarction (AMI), and pneumonia.<unk>
T-137	readmission ; disease ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia
H-137	-0.7242241501808167	▁read mission ▁rates ▁; ▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁pneu monia
D-137	-0.7242241501808167	readmission rates ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
P-137	-7.0567 -0.2806 -0.8183 -0.4689 -1.9789 -0.1477 -0.3169 -0.1453 -0.1011 -0.0294 -0.0257 -2.0128 -0.7226 -0.7730 -0.0614 -0.0181 -0.3021 -0.2218 -0.3217 -0.4032 -0.2281 -0.0076 -1.0159 -0.4804 -0.1674
S-1492	OBJECTIVES: The peripheral muscle pump is key in promoting cardiac filling during exercise, especially in subjects who lack a subpulmonary ventricle (the Fontan circulation).<unk>
T-1492	peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; fontan circulation
H-1492	-0.38180187344551086	▁per i pher al ▁muscle ▁pump ▁; ▁cardiac ▁fill ing ▁; ▁exercise ▁; ▁sub pul mon ary ▁vent ric le ▁; ▁Font an ▁circulation
D-1492	-0.38180187344551086	peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; Fontan circulation
P-1492	-0.0478 -0.0850 -0.0092 -0.0516 -0.6090 -0.2548 -0.1747 -0.5860 -0.4467 -0.0241 -0.5176 -0.3340 -0.2781 -0.0188 -0.3903 -0.6746 -0.0085 -1.6212 -1.9743 -0.6883 -0.2013 -0.0826 -0.1125 -0.0070 -0.5455 -0.1833
S-1013	As the biological phenotype is not routinely assessed clinically, the deficit index, which can be ascertained from medical records, is a feasible alternative to ascertain frailty.<unk>
T-1013	biological phenotype ; clinically ; deficit index ; medical ; frailty
H-1013	-0.7021800875663757	▁bi ological ▁ph eno type ▁; ▁medical ▁records ▁; ▁fra il ty
D-1013	-0.7021800875663757	biological phenotype ; medical records ; frailty
P-1013	-0.1794 -0.1832 -2.0936 -0.7464 -0.5008 -0.1667 -1.9923 -0.2785 -0.9301 -1.8802 -0.1164 -0.4579 -0.1465 -0.1584
S-1444	SDQT remained elevated in the HFVT(+) group relative to the HNorm group despite acute β-adrenoceptor blockade with esmolol (P = 0.02).<unk>
T-1444	sdqt ; elevated ; acute ; β-adrenoceptor blockade ; esmolol
H-1444	-0.5960474610328674	▁SD QT ▁; ▁ HF VT ▁; ▁h Nor m ▁group ▁; ▁a cute ▁β - ad re no cept or ▁block ade ▁; ▁es mol ol
D-1444	-0.5960474610328674	SDQT ; HFVT ; hNorm group ; acute β-adrenoceptor blockade ; esmolol
P-1444	-0.0236 -1.2051 -0.0585 -0.8534 -0.4012 -2.5551 -0.1173 -1.5571 -1.2100 -0.0079 -0.3209 -0.1088 -0.5524 -0.0698 -0.3862 -0.0798 -0.3727 -0.4805 -0.1428 -1.5918 -0.8668 -0.1330 -1.2298 -0.2218 -0.8699 -0.1676 -1.0980 -0.4356 -0.1680
S-660	METHODS AND RESULTS: Cardiology practices participating in the National Cardiovascular Disease Registry Practice Innovation and Clinical Excellence registry from July 2008 to December 2010 were evaluated.<unk>
T-660	cardiology ; national cardiovascular disease registry practice innovation and clinical excellence registry
H-660	-0.6986927390098572	▁Card i ology ▁practice s ▁; ▁national ▁Card io vas cular ▁Disease ▁Registr y ▁; ▁practice ▁innovation ▁; ▁Clinic al ▁Excellence
D-660	-0.6986927390098572	Cardiology practices ; national Cardiovascular Disease Registry ; practice innovation ; Clinical Excellence
P-660	-2.4756 -0.8907 -0.2548 -0.3929 -0.0393 -0.1411 -0.6163 -1.6675 -2.6764 -0.2734 -0.3018 -0.6188 -0.5527 -0.0395 -0.4976 -0.7374 -1.0997 -0.8503 -0.6125 -0.0317 -0.1556 -0.9398 -0.2048
S-162	CONCLUSIONS: STS HH and TM with medical support provided during office hours showed beneficial trends, particularly in reducing all-cause mortality for recently discharged patients with heart failure.<unk>
T-162	sts ; hh ; medical ; all-cause mortality ; discharged ; patients ; heart failure
H-162	-0.5493496656417847	▁s ts ▁ HH ▁; ▁medical ▁; ▁office ▁hours ▁; ▁all - ca use ▁mortal ity ▁; ▁dis charge d ▁patients ▁; ▁heart ▁failure
D-162	-0.5493496656417847	sts HH ; medical ; office hours ; all-cause mortality ; discharged patients ; heart failure
P-162	-0.4481 -0.4140 -0.5223 -0.0438 -0.1607 -2.5795 -1.8295 -0.9069 -0.5776 -0.3491 -1.3425 -0.0599 -0.0116 -0.1746 -0.0670 -0.0372 -0.2061 -0.5670 -0.0649 -0.2308 -1.4931 -0.7269 -0.6679 -0.1407 -0.3922 -0.2691
S-452	METHODS AND RESULTS: Eight weeks from surgically induced myocardial infarction, heart failure rats were randomized to receive bisoprolol (B) or vehicle.<unk>
T-452	surgically ; myocardial infarction ; heart failure ; randomized ; bisoprolol
H-452	-0.3366835415363312	▁induc ed ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁rat s ▁; ▁bis o pro lol ▁; ▁vehicle
D-452	-0.3366835415363312	induced myocardial infarction ; heart failure rats ; bisoprolol ; vehicle
P-452	-2.0201 -0.0563 -0.9485 -0.2193 -0.6175 -0.0836 -0.0429 -0.1996 -0.1304 -0.3275 -0.1375 -0.0352 -0.2536 -0.0402 -0.3580 -0.1338 -0.0946 -0.1546 -0.2456 -0.6957 -0.2972 -0.4412 -0.2107
S-1579	INTERVENTION: An intensive transitions of care program was implemented to ensure adequate self-management training of patients and appropriate out-patient follow-up and monitoring of the patient by the health care system.<unk>
T-1579	transitions ; training ; patients ; out-patient ; follow-up ; patient ; health care
H-1579	-0.4621843695640564	▁transition s ▁of ▁care ▁; ▁self - management ▁training ▁; ▁out - patient ▁follow - up ▁; ▁health ▁care ▁system
D-1579	-0.4621843695640564	transitions of care ; self-management training ; out-patient follow-up ; health care system
P-1579	-0.2952 -0.1423 -0.2017 -0.2951 -1.6893 -0.4077 -0.0899 -0.0076 -0.4274 -0.3853 -0.4970 -0.2349 -0.0734 -0.5138 -0.5478 -0.0414 -0.2804 -1.6542 -1.6113 -0.1866 -0.2658 -0.3198
S-1337	Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.<unk>
T-1337	chf ; phenotype ; cardiac ; explant ; progenitors ; regulation
H-1337	-0.5078182220458984	▁CHF ▁; ▁cardiac ▁ex plant ▁c - K it ▁; ▁pro geni tors ▁; ▁regula tion
D-1337	-0.5078182220458984	CHF ; cardiac explant c-Kit ; progenitors ; regulation
P-1337	-0.5573 -0.2409 -0.9318 -0.0481 -0.0389 -0.6646 -0.1806 -1.7500 -0.7617 -1.1110 -0.6357 -0.0611 -0.1151 -0.4419 -1.1866 -0.0594 -0.2379 -0.1181
S-1380	Conversely, the tachycardia in response to intravenous atropine (indicative of cardiac vagal tone) was not improved in CHF-DNx vs. CHF-INV animals.<unk>
T-1380	tachycardia ; intravenous ; atropine ; cardiac ; vagal tone
H-1380	-0.3970557451248169	▁ta chy car dia ▁; ▁intra ven ous ▁a tropi ne ▁; ▁cardiac ▁va gal ▁tone ▁; ▁CHF - DN x ▁; ▁CHF - in v
D-1380	-0.3970557451248169	tachycardia ; intravenous atropine ; cardiac vagal tone ; CHF-DNx ; CHF-inv
P-1380	-0.4010 -0.5891 -0.3959 -1.1941 -0.1423 -0.2820 -0.0348 -0.5529 -0.0367 -0.4029 -0.4333 -0.2120 -0.0738 -0.2056 -0.0357 -0.5544 -0.5926 -0.1064 -0.0912 -1.5452 -0.3292 -0.4303 -0.3346 -0.0854 -0.3664 -0.3674 -1.1609 -0.1613
S-415	Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experimental models and in patients with heart failure (HF).<unk>
T-415	report ; stable ; hno donor ; cxl-1020 ; myoctyes ; hearts ; patients ; heart failure ; hf
H-415	-0.5753943920135498	▁report ▁; ▁h no ▁donor ▁; ▁c XL -10 20 ▁; ▁isola ted ▁my oc ty es ▁; ▁intact ▁heart s ▁; ▁heart ▁failure ▁; HF
D-415	-0.5753943920135498	report ; hno donor ; cXL-1020 ; isolated myoctyes ; intact hearts ; heart failure ;HF
P-415	-0.3151 -0.1574 -4.0072 -0.3415 -1.1925 -0.1058 -0.6540 -0.3774 -0.1697 -1.3608 -0.2431 -1.1234 -0.0120 -0.3652 -0.0892 -0.0774 -0.7865 -0.1875 -0.0667 -0.3445 -0.0314 -0.1760 -2.7461 -0.0436 -0.3757 -0.1350 -0.4174 -0.2091
S-947	RESULTS: During a 34 ± 16-month follow-up period, single- and multiple-procedure drug-free success rates were 27% (n = 20) and 45% (n = 33), respectively.<unk>
T-947	follow-up
H-947	-0.8170093297958374	▁drug - free
D-947	-0.8170093297958374	drug-free
P-947	-2.2706 -0.4074 -0.0533 -1.1804 -0.1734
S-374	In addition to the leaflet configurations, the serial evaluation strongly suggested that the MS in this patient was subvalvular and therefore dynamic, as opposed to annular MS with a fixed ring size.<unk>
T-374	leaflet ; patient ; subvalvular ; annular ms
H-374	-0.4582534432411194	▁le a flet ▁; ▁serial ▁evaluation ▁; ▁MS ▁; ▁sub val vu lar ▁; ▁dynamic ▁; ▁ann ular ▁MS ▁; ▁fixed ▁ring
D-374	-0.4582534432411194	leaflet ; serial evaluation ; MS ; subvalvular ; dynamic ; annular MS ; fixed ring
P-374	-3.2773 -0.0212 -0.0043 -0.3409 -0.1829 -0.0865 -0.1116 -0.4962 -0.1535 -0.0464 -0.5717 -0.2523 -0.7718 -0.0899 -0.0133 -0.1362 -0.0290 -0.0024 -0.6887 -0.2670 -0.0020 -0.0621 -3.1804 -0.2106
S-1630	BACKGROUND: The strength of race as an independent predictor of long-term outcomes in a contemporary chronic heart failure (HF) population and its association with exercise training response have not been well established.<unk>
T-1630	outcomes ; chronic heart failure ; hf ; exercise ; training
H-1630	-0.7427749037742615	▁race ▁; ▁chronic ▁heart ▁failure ▁; HF ▁; ▁exercise ▁training ▁response
D-1630	-0.7427749037742615	race ; chronic heart failure ;HF ; exercise training response
P-1630	-0.8084 -0.1656 -3.0374 -1.3926 -0.0917 -0.3287 -0.1692 -1.1494 -0.3709 -0.4705 -1.2852 -0.2321 -0.1544
S-457	After 10 weeks, histological analysis revealed reduced capillary and coronary perfusion in B-treated plus Ad-Flk rats compared with B-treated plus Ad-C rats.<unk>
T-457	histological ; capillary ; coronary perfusion
H-457	-0.5462641716003418	▁his t ological ▁; ▁cap illa ry ▁; ▁corona ry ▁per fusion ▁; ▁b - tre ated ▁; ▁ad - f lk ▁rat s ▁; ▁b - tre ated ▁; ▁ad - c ▁rat s
D-457	-0.5462641716003418	histological ; capillary ; coronary perfusion ; b-treated ; ad-flk rats ; b-treated ; ad-c rats
P-457	-1.9379 -1.4093 -0.2293 -0.7333 -2.2836 -0.4457 -0.1559 -0.4800 -0.8264 -0.1215 -0.1969 -0.1088 -0.2133 -1.3164 -0.1358 -0.0996 -0.0840 -0.1704 -0.0599 -0.2631 -1.4168 -0.2602 -0.4884 -0.0444 -0.3887 -1.2035 -0.1098 -0.1493 -0.1262 -0.1854 -0.1031 -0.1755 -2.4566 -0.8150 -0.0460 -0.6696 -0.3024
S-1730	The relationship between physician volume and mortality was strongest for internists (9.2% versus 10.6%; P<0.001) and weakest for cardiologists (6.4% versus 6.7%; P=0.485).<unk>
T-1730	physician ; mortality ; internists ; cardiologists
H-1730	-0.35230934619903564	▁physician ▁volume ▁; ▁mortal ity ▁; ▁intern ists ▁; ▁cardio logist s
D-1730	-0.35230934619903564	physician volume ; mortality ; internists ; cardiologists
P-1730	-0.6797 -0.7122 -0.4377 -0.0635 -0.0697 -0.3845 -0.0296 -0.9045 -0.2430 -0.5783 -0.2916 -0.1907 -0.2119 -0.1354
S-1322	Similar improvements in shuttle walk test (18% vs 19%), body mass (-1.3 kg vs -1.0 kg), and hand grip strength (2.1 kg vs 2.5 kg) from baseline were observed in both groups.<unk>
T-1322	shuttle walk test ; hand ; baseline
H-1322	-0.34286022186279297	▁shu ttle ▁walk ▁test ▁; ▁body ▁mass ▁; ▁hand ▁grip ▁strength ▁; ▁base line
D-1322	-0.34286022186279297	shuttle walk test ; body mass ; hand grip strength ; baseline
P-1322	-0.1178 -0.0334 -0.1513 -0.7578 -0.2413 -0.1304 -0.1517 -0.2029 -0.4618 -1.1696 -0.9524 -0.4464 -0.0222 -0.0671 -0.2931 -0.2865
S-1027	Furthermore, the use of protocol-driven POC testing of NP within the time frame of a patient consultation in the ED may facilitate and accelerate the throughput and disposition of at-risk patients.<unk>
T-1027	poc ; frame ; patient ; consultation ; patients
H-1027	-0.9324526786804199	▁protocol - driv en ▁PO C ▁testing ▁; ▁ NP ▁; ▁patient ▁consultation ▁; ▁ED
D-1027	-0.9324526786804199	protocol-driven POC testing ; NP ; patient consultation ; ED
P-1027	-0.8739 -0.2124 -0.0136 -0.1948 -2.9056 -3.2383 -0.2380 -0.3755 -0.3701 -0.0247 -0.2390 -2.7475 -1.7795 -0.1342 -0.9487 -1.2634 -0.2925
S-554	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).<unk>
T-554	clinical ; outcomes ; heart failure ; charm ; candesartan in heart failure assessment of reduction in mortality and morbidity
H-554	-0.5606229305267334	▁heart ▁failure ▁; ▁CHA RM ▁programme ▁; Can des ar tan ▁in ▁Heart ▁Fail ure ▁assessment ▁of ▁re duction ▁in ▁Mor t ality ▁and ▁Morbi d ity
D-554	-0.5606229305267334	heart failure ; CHARM programme ;Candesartan in Heart Failure assessment of reduction in Mortality and Morbidity
P-554	-4.9725 -0.1209 -0.3594 -2.0012 -1.0347 -0.1570 -0.2890 -0.4518 -0.0447 -0.0092 -0.0188 -0.4892 -0.8162 -0.4068 -0.0234 -0.3017 -1.1266 -0.4876 -0.0009 -0.4859 -0.2166 -0.1509 -0.0103 -1.1116 -0.0063 -0.1028 -0.0423 -0.7793 -0.2408
S-284	Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study.<unk>
T-284	troponin t ; n-terminal pro-b-type natriuretic peptide ; biomarker ; heart failure ; atherosclerosis risk in communities
H-284	-0.6588260531425476	▁Tro ponin ▁t ▁; ▁N - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; ▁heart ▁failure ▁risk ▁; ▁at hero sc ler osis
D-284	-0.6588260531425476	Troponin t ; N-terminal pro-b-type natriuretic peptide ; heart failure risk ; atherosclerosis
P-284	-0.0916 -0.0044 -1.1587 -0.3167 -2.5884 -0.0628 -0.0194 -0.0021 -0.0438 -0.0415 -1.4953 -0.0771 -0.7170 -0.0071 -0.4021 -0.0662 -0.3982 -0.0839 -0.3786 -1.3891 -0.4153 -2.2541 -0.0732 -1.0527 -0.3238 -0.9037 -0.8628 -0.4457 -3.3127 -0.1777 -1.7209 -0.1960
S-1948	Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study.<unk>
T-1948	interatrial shunting ; patients ; heart failure with reduced ejection fraction ; proof-of-principle cohort study
H-1948	-0.8359649777412415	▁left - to - right ▁inter at rial ▁sh unting ▁; ▁patients ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1948	-0.8359649777412415	left-to-right interatrial shunting ; patients ; heart failure ; ejection fraction
P-1948	-6.0887 -0.0308 -0.1197 -0.0813 -0.0422 -0.4716 -0.3701 -0.1527 -1.9067 -0.9606 -0.4881 -2.8867 -1.0933 -0.4542 -0.0592 -0.3478 -0.8608 -0.2870 -0.2125 -0.5313 -0.0193 -1.5356 -0.2272
S-1894	Physical examination should include the patient's BMI and weight, heart rate and rhythm, lying and standing blood pressure and auscultation to rule out valvular disease and pulmonary congestion.<unk>
T-1894	physical examination ; patient ; bmi ; heart rate ; rhythm ; blood pressure ; auscultation ; rule ; valvular disease ; pulmonary congestion
H-1894	-0.5814337134361267	▁physical ▁; ▁b mi ▁; ▁weight ▁; ▁heart ▁rate ▁; ▁ rhythm ▁; ▁ly ing ▁; ▁standing ▁blood ▁pressure ▁; ▁aus cul tation ▁; ▁val vu lar ▁disease ▁; ▁pulmonar y ▁con gestion
D-1894	-0.5814337134361267	physical ; bmi ; weight ; heart rate ; rhythm ; lying ; standing blood pressure ; auscultation ; valvular disease ; pulmonary congestion
P-1894	-0.2932 -1.0626 -0.8160 -2.4424 -0.1072 -1.0725 -0.1984 -1.2838 -0.0255 -0.2823 -0.2610 -0.1014 -0.1448 -0.0468 -0.0576 -0.1821 -0.0518 -2.6357 -0.2070 -0.2139 -1.3296 -0.0367 -0.0080 -0.2267 -1.7174 -1.3145 -1.1921 -1.8516 -0.2028 -0.0109 -0.0938 -0.0633 -0.0338 -0.4958 -0.2870
S-735	Our aims were to estimate myocardial extracellular matrix using cardiac magnetic resonance T1 mapping and to assess the relationship between pathobiology/pathophysiology and prognosis.<unk>
T-735	myocardial extracellular matrix ; cardiac magnetic resonance ; t1 mapping ; pathobiology ; pathophysiology ; prognosis
H-735	-0.4329514801502228	▁my o card ial ▁extra cel lular ▁matri x ▁; ▁cardiac ▁magnetic ▁res on ance ▁t 1 ▁; ▁path obi ology ▁; pat ho phy si ology
D-735	-0.4329514801502228	myocardial extracellular matrix ; cardiac magnetic resonance t1 ; pathobiology ;pathophysiology
P-735	-0.4794 -0.1678 -0.3754 -0.0509 -2.0433 -0.4756 -0.0816 -0.2111 -1.9018 -0.3512 -0.0172 -0.0579 -0.2504 -0.0791 -0.0608 -1.3173 -0.1529 -0.9518 -0.0623 -0.1549 -0.0857 -0.6120 -0.1258 -0.5231 -0.1034 -1.2501 -0.0617 -0.3217 -0.2295
S-1738	These trial results provide the background for aldosterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial infarction heart failure patients with reduced ejection.<unk>
T-1738	aldosterone antagonist ; therapy ; chronic advanced heart failure ; patients ; post-myocardial infarction ; heart failure ; patients
H-1738	-0.6541317701339722	▁al do ster one ▁anta gon ist ▁ therapy ▁; ▁chronic ▁advanced ▁heart ▁failure ▁patients ▁; ▁post - my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction
D-1738	-0.6541317701339722	aldosterone antagonist therapy ; chronic advanced heart failure patients ; post-myocardial infarction ; heart failure ; reduced ejection
P-1738	-1.1345 -0.2581 -0.3424 -0.0347 -0.1846 -0.3078 -0.8344 -1.0576 -0.0586 -0.1631 -2.2822 -1.7475 -1.4316 -0.0755 -1.9395 -0.2123 -0.0222 -0.0527 -1.4729 -0.8591 -1.0550 -0.0523 -0.1069 -0.3478 -0.1519 -1.5083 -1.8683 -0.0426 -2.2225 -0.3179 -0.0233 -0.0254 -0.2407 -0.4388 -0.3949 -0.2808
S-963	Nicorandil was effective in alleviating the decrement of heart rate and aortic blood flow and the state of mitochondrial oxidative stress induced by doxorubicin cardiotoxicity.<unk>
T-963	nicorandil ; heart rate ; aortic ; blood flow ; mitochondrial ; oxidative stress ; doxorubicin ; cardiotoxicity
H-963	-0.4951762557029724	▁Nico rand il ▁; ▁heart ▁rate ▁; ▁a or tic ▁blood ▁flow ▁; ▁mito cho ndri al ▁oxid ative ▁stress ▁induc ed ▁; ▁do xor ubi cin ▁cardio toxic ity
D-963	-0.4951762557029724	Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress induced ; doxorubicin cardiotoxicity
P-963	-0.0064 -0.0328 -0.0417 -0.1994 -3.2979 -0.0655 -0.1475 -0.0185 -0.4299 -0.0390 -1.9869 -0.0251 -0.1441 -0.1585 -1.7158 -0.9680 -0.0398 -0.3909 -0.1654 -0.1392 -0.3378 -0.1141 -0.8127 -0.0151 -0.0976 -0.0524 -1.3113 -1.1659 -1.1040 -0.1840 -0.4842 -0.1544
S-440	We identified all adults with newly diagnosed heart failure, left ventricular ejection fraction of <40%, and no previous spironolactone use from 2006 to 2008 in Kaiser Permanente Northern California.<unk>
T-440	diagnosed ; heart failure ; left ventricular ejection fraction ; spironolactone ; kaiser permanente ; northern california
H-440	-0.5372166633605957	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁spi rono lac tone ▁; ▁Kaiser ▁Permanent e ▁Northern ▁California
D-440	-0.5372166633605957	heart failure ; left ventricular ejection fraction ; spironolactone ; Kaiser Permanente Northern California
P-440	-2.6307 -0.1336 -0.1993 -0.0475 -2.7759 -1.4970 -0.4890 -0.0744 -0.1451 -0.0972 -1.9022 -0.0517 -0.2812 -0.6804 -0.0197 -0.0716 -0.0481 -0.3678 -0.2914 -0.0160 -0.4544 -0.4652 -0.0716 -0.3952 -0.2243
S-968	Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.<unk>
T-968	preoperative ; renal dysfunction ; cardiovascular events ; stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass grafting
H-968	-0.5789779424667358	▁renal ▁dys function ▁; ▁cardiovascular ▁events ▁; stro ke ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁death ▁; ▁isola ted ▁corona ry ▁arter y ▁by pass
D-968	-0.5789779424667358	renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; death ; isolated coronary artery bypass
P-968	-0.8708 -0.0969 -0.7345 -0.1382 -0.0672 -0.1365 -0.2045 -3.7597 -0.0547 -0.4941 -0.3932 -0.3418 -0.5081 -0.0388 -0.0570 -0.2911 -0.1317 -0.1869 -0.1667 -0.0313 -0.4150 -2.6460 -0.7824 -0.0074 -0.0162 -0.1592 -0.0418 -0.1055 -0.2226 -0.6391 -0.3826 -4.7546 -0.2302
S-1549	MI-induced decreases in septum (systolic) thickness as well as increase in LV posterior wall thickness and LV internal diameter were partially or fully reversible by metoprolol.<unk>
T-1549	septum ; systolic ; lv posterior wall ; lv internal diameter ; metoprolol
H-1549	-0.5842916369438171	▁MI - indu ced ▁decrease s ▁; ▁sept um ▁; sy sto lic ▁; ▁thi ck ness ▁; ▁LV ▁; ▁posterior ▁wall ▁thi ck ness ▁; ▁LV ▁internal ▁diameter ▁; ▁met o pro lol
D-1549	-0.5842916369438171	MI-induced decreases ; septum ;systolic ; thickness ; LV ; posterior wall thickness ; LV internal diameter ; metoprolol
P-1549	-1.0887 -0.1992 -0.1136 -1.0328 -0.3813 -0.2421 -0.3935 -0.1078 -0.0436 -0.9372 -1.0028 -1.2604 -1.1584 -0.8832 -2.1698 -0.2609 -0.5062 -0.1034 -0.6125 -1.3179 -0.8890 -1.5330 -1.6209 -0.2136 -0.2590 -0.1424 -0.7119 -0.0610 -0.0043 -0.5740 -0.0776 -0.0720 -0.0875 -0.4363 -0.3491 -0.1874
S-30	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease.<unk>
T-30	american college of physicians ; acp ; evidence ; clinical ; anemia ; patients ; heart disease
H-30	-0.5192698240280151	▁American ▁college ▁of ▁Physic ians ▁; ▁a CP ▁; ▁an emia ▁; ▁ir on ▁de fici en cy ▁; ▁heart ▁disease
D-30	-0.5192698240280151	American college of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
P-30	-1.9708 -0.3759 -0.0289 -0.6280 -0.0944 -0.3204 -0.5576 -0.3618 -0.4089 -0.8679 -0.1381 -0.1637 -0.0148 -0.0559 -0.1013 -0.0266 -1.9837 -0.0338 -0.3173 -1.7554 -1.0335 -0.4348 -0.2698
S-1990	CONCLUSIONS AND RELEVANCE: Among obese older patients with clinically stable HFPEF, caloric restriction or aerobic exercise training increased peak VO2, and the effects may be additive.<unk>
T-1990	obese ; patients ; clinically ; stable ; hfpef ; exercise ; training ; peak vo2
H-1990	-0.5639737248420715	▁h f ef ▁; ▁calor ic ▁restriction ▁; ▁aero bic ▁exercise ▁training ▁; ▁pe ak ▁VO 2
D-1990	-0.5639737248420715	hfef ; caloric restriction ; aerobic exercise training ; peak VO2
P-1990	-3.4119 -0.6211 -2.6073 -0.1764 -0.1736 -0.0604 -0.1437 -0.0725 -0.0264 -0.3961 -0.5576 -0.6391 -0.2831 -0.0055 -0.0506 -0.8198 -0.1065 -0.3076 -0.2562
S-2007	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure.<unk>
T-2007	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
H-2007	-0.6848723888397217	▁economic ▁analysis ▁; ▁Patient ▁management ▁Interven tions ▁; ▁Heart ▁Fail ure ▁cost - ef ective ness ▁model ▁; ▁cost - effect ive ness ▁; ▁disease ▁management ▁programs ▁; ▁heart ▁failure
D-2007	-0.6848723888397217	economic analysis ; Patient management Interventions ; Heart Failure cost-efectiveness model ; cost-effectiveness ; disease management programs ; heart failure
P-2007	-0.1761 -1.1957 -0.6156 -1.6860 -0.5573 -1.9214 -0.0408 -0.9105 -0.3616 -0.4757 -0.0325 -1.2618 -0.1759 -3.1714 -0.7141 -0.4549 -0.7811 -0.6299 -1.4205 -0.1410 -0.1746 -0.1147 -0.4914 -0.4248 -0.9684 -0.2611 -0.8844 -0.6449 -0.5688 -0.0956 -0.2861 -0.2775
S-782	METHODS AND RESULTS: Using a prospective HF registry, we dichotomized patients into HF with reduced EF (EF≤ 40) and HFpEF (EF≥50).<unk>
T-782	prospective ; hf ; patients ; hf with reduced ef ; ef ; hfpef ; ef
H-782	-0.6953967809677124	▁ HF ▁registr y ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF ▁; EF
D-782	-0.6953967809677124	HF registry ; HF ; EF ; HFpEF ;EF
P-782	-0.7390 -0.6566 -1.5258 -0.3446 -0.3840 -0.3960 -0.6563 -0.2045 -1.8833 -0.2088 -1.0397 -0.7286 -0.1125 -0.5944 -1.1905 -0.4226 -1.1538 -0.2762
S-1877	BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08).<unk>
T-1877	bat ; n-terminal pro-brain natriuretic peptide ; hospitalized ; hf
H-1877	-0.3776741027832031	▁BAT ▁; ▁N - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁ HF
D-1877	-0.3776741027832031	BAT ; N-terminal pro-brain natriuretic peptide ; HF
P-1877	-0.1847 -0.4834 -3.0840 -0.1012 -0.0580 -0.0059 -0.0315 -0.0810 -0.1098 -0.2383 -0.0145 -0.2512 -0.0632 -0.2443 -0.0541 -0.1962 -1.0663 -0.2913 -1.1459 -0.2853 -0.1852 -0.1336
S-1586	The majority of studies have shown that patients with reduced or abnormal HR variability have an increased risk of mortality within a few years after an AMI or after a diagnosis of CHF/LV dysfunction.<unk>
T-1586	patients ; hr variability ; mortality ; ami ; diagnosis ; chf ; lv dysfunction
H-1586	-0.6422396898269653	▁HR ▁variabil ity ▁; ▁mortal ity ▁; ▁ AMI ▁; ▁CHF ▁; LV ▁dys function
D-1586	-0.6422396898269653	HR variability ; mortality ; AMI ; CHF ;LV dysfunction
P-1586	-1.7165 -0.3175 -0.0366 -0.2525 -0.2077 -0.0159 -0.3011 -0.2576 -0.0690 -0.1136 -0.8527 -2.2678 -1.5783 -0.9626 -1.4119 -0.3494 -0.2072
S-1901	Recent evidence suggests that exercise prevents cell senescence, and active individuals are at lower risk of developing certain malignancies including cancer of the prostate and the colon, osteoporosis, depression and dementia.<unk>
T-1901	evidence ; exercise ; cell senescence ; active ; osteoporosis
H-1901	-0.45814117789268494	▁exercise ▁; ▁cell ▁se nesc ence ▁; ▁active ▁individuals ▁; ▁malign a ncies ▁; ▁cancer ▁; ▁prostat e ▁; ▁colon ▁; ▁osteo por osis ▁; ▁depression ▁; ▁dem entia
D-1901	-0.45814117789268494	exercise ; cell senescence ; active individuals ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
P-1901	-1.8947 -0.3714 -1.7990 -0.0173 -0.0330 -0.0107 -0.3953 -1.1189 -1.7753 -0.3470 -0.2502 -0.8548 -0.0481 -0.1871 -0.2348 -0.6910 -0.0582 -0.0781 -0.1011 -1.7154 -0.3349 -0.0185 -0.1456 -0.0398 -0.1899 -0.2437 -0.5876 -0.2267 -0.0062 -0.2351 -0.1931
S-708	BACKGROUND: Extended criteria cardiac transplant (ECCT) programs expand the transplant pool by matching donors and recipients typically excluded from the transplant process because of age or comorbidity.<unk>
T-708	extended criteria cardiac transplant ; ecct ; transplant ; donors ; transplant ; comorbidity
H-708	-0.6984791159629822	▁cardiac ▁transplant ▁; ▁ec CT ▁; ▁transplant ▁pool ▁; ▁donor s ▁; ▁recipient s ▁; ▁transplant
D-708	-0.6984791159629822	cardiac transplant ; ecCT ; transplant pool ; donors ; recipients ; transplant
P-708	-0.3082 -0.1535 -0.6777 -0.5621 -2.4959 -0.6838 -0.3034 -1.3343 -0.5295 -1.1106 -0.1223 -0.3980 -0.7893 -0.1193 -0.6289 -0.1396 -2.0568 -0.1593
S-227	Fifty-four predominantly asymptomatic pediatric Fontan (PF) patients who underwent catheterization during the same period were randomly selected to perform a control:case cohort analysis.<unk>
T-227	asymptomatic ; pediatric fontan ; patients ; catheterization
H-227	-0.70799320936203	▁Font an ▁; PF ▁; ▁cat heter ization
D-227	-0.70799320936203	Fontan ;PF ; catheterization
P-227	-2.0107 -0.3766 -0.5664 -0.1609 -1.6259 -0.7072 -0.0255 -0.4970 -0.8481 -0.2616
S-1660	Interestingly, because patients with ventricular assist devices are housed on units accustomed to managing the device, cardiac nurses are often asked about the management of gastrointestinal bleeding.<unk>
T-1660	patients ; ventricular assist devices ; cardiac ; nurses ; gastrointestinal bleeding
H-1660	-0.4582720696926117	▁vent ri cular ▁assist ▁devices ▁; ▁cardiac ▁nurse s ▁; ▁gastro inte stin al ▁ble ed ing
D-1660	-0.4582720696926117	ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
P-1660	-0.7844 -1.2503 -0.2518 -1.4109 -0.1697 -0.3705 -1.4249 -0.1270 -0.0380 -0.2180 -0.3693 -0.1842 -0.4040 -0.0595 -0.5237 -0.3914 -0.2051 -0.3204 -0.2041
S-1807	In The Lancet, Anoop Shah and colleagues provide a new systematic review of the effects of air pollution on heart failure, a common disorder associated with high morbidity and mortality, especially in elderly people.<unk>
T-1807	the lancet ; anoop shah ; air ; heart failure ; morbidity ; mortality
H-1807	-0.31101590394973755	▁Lance t ▁; ▁Ano op ▁Shah ▁; ▁air ▁pollution ▁; ▁heart ▁failure ▁; ▁morbi d ity ▁; ▁mortal ity
D-1807	-0.31101590394973755	Lancet ; Anoop Shah ; air pollution ; heart failure ; morbidity ; mortality
P-1807	-0.2140 -0.0865 -0.1813 -0.4727 -0.0425 -0.1484 -0.2576 -0.0889 -0.4535 -0.2407 -0.4180 -0.0878 -0.4424 -1.8099 -0.1368 -0.0604 -0.3833 -0.0119 -0.0193 -0.7875 -0.1878
S-835	Anemia in HF remains poorly understood, with significant gaps in its impact on health-related quality of life (HRQoL), with most studies in HF being retrospective or from registries.<unk>
T-835	anemia ; hf ; health-related quality of life ; hrqol ; hf
H-835	-0.33278992772102356	▁an emia ▁; ▁ HF ▁; ▁health - related ▁quality ▁of ▁life ▁; HR Qo L ▁; ▁ HF
D-835	-0.33278992772102356	anemia ; HF ; health-related quality of life ;HRQoL ; HF
P-835	-0.1806 -0.0234 -0.2686 -0.4528 -0.2303 -0.3216 -0.5452 -0.3283 -0.0193 -0.2223 -0.1096 -0.2805 -0.1972 -0.7252 -0.0445 -0.8148 -0.7312 -0.5021 -0.4344 -0.3870 -0.1696
S-1336	For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells.<unk>
T-1336	cell therapy ; chronic heart failure ; chf ; disease ; progenitor cells
H-1336	-0.42752349376678467	▁cell ▁ therapy ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁ex plant - der i ved ▁pro gen itor ▁cell s
D-1336	-0.42752349376678467	cell therapy ; chronic heart failure ;CHf ; explant-derived progenitor cells
P-1336	-2.1671 -0.4246 -0.0547 -0.1611 -0.1306 -1.1696 -0.1225 -0.2373 -0.3820 -0.6839 -0.2698 -0.9364 -0.0265 -0.0749 -0.0535 -0.1639 -0.4391 -0.2081 -0.0985 -0.1561 -1.5787 -0.0562 -0.4789 -0.1866
S-1152	We used MRI-based models of dyssynchronous nonfailing and HF canine electromechanics and constructed additional models in which varying combinations of the four remodeling aspects were represented.<unk>
T-1152	dyssynchronous nonfailing ; hf ; combinations ; remodeling
H-1152	-0.4291737675666809	▁m RI - based ▁models ▁; ▁dys syn chron ous ▁non fail ing ▁; ▁ HF ▁can ine ▁electro me chan ics
D-1152	-0.4291737675666809	mRI-based models ; dyssynchronous nonfailing ; HF canine electromechanics
P-1152	-0.4994 -3.2655 -0.2972 -0.1121 -0.5006 -0.3454 -0.1936 -0.0328 -0.0143 -0.0472 -0.0277 -0.0172 -0.0821 -0.1257 -0.1862 -0.1701 -0.7275 -0.0264 -0.1123 -0.2088 -0.1727 -1.5295 -1.3732 -0.2327
S-1095	We will then focus on two distinct populations of patients who are at risk for acute RV failure: those with chronic pulmonary arterial hypertension (PAH) and those with acute pulmonary embolism.<unk>
T-1095	patients ; acute rv failure ; chronic pulmonary arterial hypertension ; pah ; acute ; pulmonary embolism
H-1095	-0.2996058166027069	▁a cute ▁ RV ▁failure ▁; ▁chronic ▁pulmonar y ▁arterial ▁hyper tension ▁; PA h ▁; ▁a cute ▁pulmonar y ▁e mbol ism
D-1095	-0.2996058166027069	acute RV failure ; chronic pulmonary arterial hypertension ;PAh ; acute pulmonary embolism
P-1095	-0.7525 -0.0405 -0.2200 -0.3834 -0.0786 -0.3685 -0.6793 -0.0423 -0.0902 -0.0495 -0.5842 -0.0797 -0.3051 -0.3903 -0.9351 -0.3528 -0.0341 -0.0607 -0.0597 -0.1341 -0.2194 -0.0328 -0.6537 -0.6888 -0.2548
S-1097	Individuals with acute RV failure in the setting of pulmonary embolism represent a group with particularly high mortality, and the specific diagnostic and management strategies that are important for improved survival will be discussed.<unk>
T-1097	acute rv failure ; pulmonary embolism ; mortality ; diagnostic
H-1097	-0.27260538935661316	▁a cute ▁ RV ▁failure ▁; ▁pulmonar y ▁e mbol ism ▁; ▁mortal ity
D-1097	-0.27260538935661316	acute RV failure ; pulmonary embolism ; mortality
P-1097	-0.5277 -0.0221 -0.2004 -0.3293 -0.1065 -0.1651 -0.0960 -0.0746 -0.1487 -0.0535 -0.4417 -0.5680 -0.5873 -0.0575 -0.7531 -0.2302
S-937	Intriguingly, serum resistin levels in women undergoing anthracycline-containing chemotherapy increased significantly at 3 months and remained elevated at 6 months in those with subsequent cardiotoxicity.<unk>
T-937	resistin ; chemotherapy ; elevated ; cardiotoxicity
H-937	-0.573466956615448	▁se rum ▁resist in ▁levels ▁; ▁an thra cycli ne - conta ining ▁che mo therapy ▁; ▁cardio toxic ity
D-937	-0.573466956615448	serum resistin levels ; anthracycline-containing chemotherapy ; cardiotoxicity
P-937	-0.1732 -0.2749 -0.1022 -0.8199 -0.3918 -0.1172 -0.4298 -0.5496 -1.5038 -0.6303 -0.7281 -0.1167 -0.7874 -2.3162 -0.5307 -0.5333 -0.3256 -0.3377 -0.9759 -0.5167 -0.2716 -0.1840
S-405	Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003).<unk>
T-405	patients ; sst2 ; titrated ; cardiovascular event
H-405	-0.6898043751716614	▁s st 2 ▁ti tra ted ▁; ▁high - dos e ▁BB ▁; ▁cardiovascular ▁event ▁rate
D-405	-0.6898043751716614	sst2 titrated ; high-dose BB ; cardiovascular event rate
P-405	-0.0074 -2.4265 -0.0674 -2.3199 -0.0201 -0.0775 -0.2768 -0.1526 -0.0370 -0.6661 -0.1634 -1.0939 -0.2506 -0.3085 -0.4204 -0.0744 -3.8530 -0.2010
S-1677	Thus, we conclude that if Rad Q66P contributes to cardiomyopathy, it does so via a mechanism that is not related to its ability to inhibit L-type channel-dependent processes per se.<unk>
T-1677	rad ; q66p ; cardiomyopathy
H-1677	-0.7233433723449707	▁Rad ▁Q 66 p ▁; ▁cardio my o pathy ▁; ▁mechanism ▁; ▁l - type ▁channel - dependent
D-1677	-0.7233433723449707	Rad Q66p ; cardiomyopathy ; mechanism ; l-type channel-dependent
P-1677	-0.2230 -3.6843 -0.0783 -0.1689 -0.1219 -0.1826 -1.8451 -0.2597 -0.1485 -0.2339 -0.1140 -0.2114 -2.9397 -0.1147 -0.2448 -0.0880 -0.4405 -0.0365 -3.1746 -0.1565
S-1148	Among the most important are altered ventricular structure (both geometry and fiber/sheet orientation), abnormal Ca(2+) handling, slowed conduction, and reduced wall stiffness.<unk>
T-1148	ventricular ; wall stiffness
H-1148	-1.032375693321228	▁alter ed ▁vent ri cular ▁structure ▁; ▁fiber ▁; she et ▁ orientation ▁; ▁handling ▁; ▁slow ed ▁con duction ▁; ▁wall ▁sti ff ness
D-1148	-1.032375693321228	altered ventricular structure ; fiber ;sheet orientation ; handling ; slowed conduction ; wall stiffness
P-1148	-3.6377 -0.0839 -1.7484 -1.3998 -0.4430 -1.5307 -0.1930 -4.1606 -1.2851 -0.4773 -1.0624 -0.6492 -0.0064 -0.5357 -1.9791 -0.2515 -0.5249 -0.2560 -0.0594 -0.0449 -0.3836 -4.1304 -0.2497 -0.9420 -0.8989 -0.6609 -0.2797
S-1441	There was a trend toward a higher baseline SDQT-to-SDRR ratio in the HFVT(+) group compared with the HFVT(-) and HNorm groups (P = 0.09).<unk>
T-1441	baseline
H-1441	-0.8256357312202454	▁base line ▁; ▁SD QT - to - SD r ▁ratio ▁; ▁ HF VT ▁; ▁ HF VT ▁; ▁h Nor m ▁groups
D-1441	-0.8256357312202454	baseline ; SDQT-to-SDr ratio ; HFVT ; HFVT ; hNorm groups
P-1441	-0.0669 -0.0033 -0.3447 -0.5415 -2.8640 -0.3775 -0.1091 -0.0398 -0.9310 -2.9968 -0.0521 -0.0938 -0.3348 -0.7279 -1.9667 -0.1910 -0.5680 -1.2758 -2.9299 -0.2269 -1.6919 -1.3533 -0.0067 -0.9766 -0.5496 -0.2470
S-174	Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.<unk>
T-174	uptitration ; renin-angiotensin system blocker ; beta-blocker ; therapy ; patients ; hospitalized ; heart failure ; preserved left ventricular ejection fractions
H-174	-0.5808585286140442	▁re nin - angi oten sin ▁system ▁block er ▁; ▁beta - block er ▁ therapy ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction s
D-174	-0.5808585286140442	renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection fractions
P-174	-0.0245 -0.5110 -0.0621 -0.1987 -2.3373 -0.2525 -0.0401 -0.1841 -0.7577 -0.3259 -0.0890 -0.0651 -0.3114 -0.4318 -0.8969 -0.0423 -0.3316 -0.8943 -0.1432 -0.2831 -1.1985 -3.3376 -1.6409 -0.7651 -0.2698 -0.4046 -0.3385 -1.1476 -0.0171 -0.3049 -0.6235 -0.3568
S-1180	(Use of Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath Due to Lung Congestion; ACTRN12610001087044).<unk>
T-1180	use of exercise and medical therapies to improve cardiac function among patients with exertional shortness of breath due to lung congestion
H-1180	-0.5484679937362671	▁exercise ▁; ▁medical ▁Therapie s ▁; ▁Card iac ▁Fun ction ▁; ▁short ness ▁of ▁Breath ▁Du e ▁to ▁Lung ▁con gestion ▁; ACT RN
D-1180	-0.5484679937362671	exercise ; medical Therapies ; Cardiac Function ; shortness of Breath Due to Lung congestion ;ACTRN
P-1180	-0.6909 -0.3942 -0.0428 -0.7447 -0.0464 -0.3509 -1.1524 -0.2489 -1.4111 -0.0217 -0.2771 -1.1460 -0.3294 -0.4227 -0.2233 -0.9935 -0.0185 -0.7437 -0.4782 -1.1039 -0.0515 -1.2692 -0.7377 -0.4402 -0.7493 -0.1719
S-1326	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.<unk>
T-1326	functional electrical stimulation ; peripheral muscles ; endothelial function ; clinical ; heart failure ; patients ; preserved left ventricular ejection fraction
H-1326	-0.6648085117340088	▁electric al ▁stimul ation ▁; ▁per i pher al ▁muscle s ▁; ▁en dot heli al ▁function ▁; ▁heart ▁failure ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction
D-1326	-0.6648085117340088	electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; preserved left ventricular ejection fraction
P-1326	-1.5266 -0.0164 -0.2647 -0.0919 -0.6523 -0.0161 -0.2042 -0.0216 -0.2404 -0.5422 -0.0523 -0.3475 -0.0710 -2.4283 -0.1736 -0.0331 -0.4652 -0.1777 -2.7867 -0.0879 -0.7172 -3.0360 -0.0953 -0.0831 -0.2066 -3.4603 -1.2730 -0.4016 -0.2748 -0.3842 -0.5633 -1.2541 -0.0154 -1.0054 -0.2983
S-1139	The tachycardic response caused by methylatropine was considered to be the vagal tone, whereas the bradycardic response caused by propranolol was considered to be the sympathetic tone.<unk>
T-1139	tachycardic ; methylatropine ; vagal tone ; bradycardic ; propranolol ; sympathetic tone
H-1139	-0.5933234691619873	▁ta chy car dic ▁response ▁; ▁met hy la tropi ne ▁; ▁va gal ▁tone ▁; ▁bra dy car dic ▁; ▁propra no lol ▁; ▁sympa the tic ▁tone
D-1139	-0.5933234691619873	tachycardic response ; methylatropine ; vagal tone ; bradycardic ; propranolol ; sympathetic tone
P-1139	-0.4101 -0.9803 -1.1268 -0.3515 -0.9543 -0.2973 -0.0985 -0.7152 -1.1584 -0.0433 -0.4270 -0.1795 -0.0319 -0.0196 -1.2344 -0.3283 -1.0475 -0.2654 -1.0621 -0.6517 -1.9083 -0.5690 -0.0027 -0.1634 -0.7398 -0.0728 -1.6966 -0.3104 -1.0825 -0.3084 -0.1561
S-751	BACKGROUND: Current guidelines recommend cardiac resynchronization therapy (CRT) in mild heart failure (HF) patients with QRS prolongation and ejection fraction (EF) ≤30%.<unk>
T-751	cardiac resynchronization therapy ; crt ; mild heart failure ; hf ; patients ; qrs prolongation ; ejection fraction ; ef
H-751	-0.42576831579208374	▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁mild ▁heart ▁failure ▁; HF ▁; ▁QR s ▁; ▁e je ction ▁ fraction ▁; EF
D-751	-0.42576831579208374	cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs ; ejection fraction ;EF
P-751	-1.4000 -0.0128 -0.0490 -0.0148 -0.4237 -1.1723 -0.0941 -0.2560 -0.8588 -1.6774 -0.2064 -0.4555 -0.3300 -0.0725 -0.1703 -0.1301 -0.2496 -0.3433 -1.1810 -0.9270 -0.0565 -0.3044 -0.1186 -0.4061 -0.0079 -0.7574 -0.0318 -0.4184 -0.2212
S-509	Fractional flow reserve measurements and positron emission tomography imaging showed severe ischemia after bottleneck stenting covering over 50% of the left ventricle in the proximal LAD model.<unk>
T-509	fractional flow reserve ; positron emission tomography ; ischemia ; bottleneck stenting ; left ventricle ; lad
H-509	-0.49604275822639465	▁Fra ction al ▁flow ▁reserve ▁; ▁posi tron ▁e mission ▁tom ography ▁imagin g ▁; ▁ ische mia ▁; ▁bottle ne ck ▁sten ting ▁; ▁left ▁vent ric le ▁; ▁proxima l ▁ LAD ▁model
D-509	-0.49604275822639465	Fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ; proximal LAD model
P-509	-0.9389 -0.0029 -0.3236 -0.0113 -0.0400 -0.4019 -0.1024 -0.1876 -0.0534 -0.2477 -0.8902 -0.7074 -1.4420 -0.0871 -0.1645 -0.6481 -0.2231 -0.7207 -0.1854 -0.0530 -0.0259 -0.0945 -0.3179 -0.0999 -0.4473 -0.0584 -2.5901 -2.8863 -1.3975 -0.2589 -1.5427 -0.0161 -0.0390 -0.0093 -0.6537 -0.3472 -0.1375
S-962	Moreover, mitochondrial oxidative phosphorylation capacity, creatine kinase activity and oxidative stress markers were measured together with the examination of DNA fragmentation and ultrastructural changes.<unk>
T-962	mitochondrial oxidative phosphorylation capacity ; creatine ; kinase ; activity ; oxidative stress ; dna fragmentation
H-962	-0.3680698275566101	▁mito cho ndri al ▁oxid ative ▁ phos phor y lation ▁capacity ▁; ▁creati ne ▁kina se ▁activity ▁; ▁oxid ative ▁stress ▁marker s ▁; ▁DNA ▁fragment ation ▁; ▁ultra struct ural
D-962	-0.3680698275566101	mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation ; ultrastructural
P-962	-0.0112 -1.1138 -0.2746 -0.0297 -0.4776 -0.1966 -0.2609 -0.0762 -1.6865 -1.9242 -1.0383 -0.1595 -0.2833 -0.0352 -0.0316 -0.0124 -0.3231 -0.3735 -0.1553 -0.0332 -0.0888 -0.0913 -0.2628 -0.0617 -0.4197 -0.0453 -0.4135 -0.0690 -0.6674 -0.1552 -0.0867 -0.0048 -1.5173 -0.1343
S-442	We used Cox regression with time-varying covariates to evaluate the independent association between spironolactone use and death, hospitalization, severe hyperkalemia, and acute kidney injury.<unk>
T-442	cox regression ; covariates ; spironolactone ; death ; hospitalization ; hyperkalemia ; acute kidney injury
H-442	-0.44311755895614624	▁co x ▁re gression ▁; ▁spi rono lac tone ▁; ▁death ▁; ▁hospital ization ▁; ▁severe ▁hyper kal emia ▁; ▁a cute ▁ki dne y ▁injury
D-442	-0.44311755895614624	cox regression ; spironolactone ; death ; hospitalization ; severe hyperkalemia ; acute kidney injury
P-442	-0.1186 -0.3393 -0.0422 -0.0353 -0.3289 -2.1507 -0.0717 -0.3225 -0.1802 -0.5468 -2.1134 -0.1494 -0.5981 -0.1936 -0.1248 -0.4976 -0.4348 -1.1002 -0.2191 -0.2263 -0.0628 -0.0358 -0.0665 -1.0828 -0.0771 -0.4823 -0.4949 -0.3115
S-1633	We examined characteristics and outcomes (mortality/hospitalization, mortality, and cardiovascular mortality/HF hospitalization) by race using adjusted Cox models and explored an interaction with exercise training.<unk>
T-1633	outcomes ; mortality ; hospitalization ; mortality ; cardiovascular mortality ; hf ; hospitalization ; cox models ; exercise ; training
H-1633	-0.5773220658302307	mortal ity ▁; ▁mortal ity ▁; ▁cardiovascular ▁mortal ity ▁; HF ▁hospital ization ▁; ▁co x ▁models ▁; ▁exercise ▁training
D-1633	-0.5773220658302307	mortality ; mortality ; cardiovascular mortality ;HF hospitalization ; cox models ; exercise training
P-1633	-2.6103 -0.0540 -0.7147 -1.1848 -0.0821 -0.2671 -0.1518 -0.1625 -0.0556 -0.3036 -0.9164 -0.7707 -0.1729 -1.0988 -1.0222 -0.2761 -1.0045 -0.7386 -0.0433 -0.5334 -0.2409 -0.2969
S-1462	Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide.<unk>
T-1462	neprilysin inhibitors ; natriuretic peptide ; atrial natriuretic peptide ; b-type natriuretic peptide
H-1462	-0.4601193368434906	▁ne pri ly sin ▁inhibi tors ▁; ▁na tri ure tic ▁pe pti de ▁system ▁; ▁break down ▁; ▁at rial ▁na tri ure tic ▁pe pti de ▁; ▁b - type ▁na tri ure tic ▁pe pti de
D-1462	-0.4601193368434906	neprilysin inhibitors ; natriuretic peptide system ; breakdown ; atrial natriuretic peptide ; b-type natriuretic peptide
P-1462	-0.7264 -0.0751 -1.4929 -0.1400 -0.1052 -0.0511 -0.2828 -0.0400 -0.6140 -0.2188 -0.9499 -0.0713 -0.3757 -1.6535 -0.2996 -0.3005 -0.3454 -0.0218 -0.8326 -0.0728 -0.0543 -0.0302 -0.8759 -0.2110 -0.5372 -0.0469 -0.2304 -1.7308 -0.4467 -0.8026 -0.0472 -0.8851 -0.0155 -0.7303 -0.1334 -0.6259 -0.0659 -0.2444 -1.4634 -0.7526 -0.2658
S-500	This study shows that the TAPSE vs. PASP relationship is shifted downward in nonsurvivors with a similar distribution in HFrEF and HFpEF, and their ratio improves prognostic resolution.<unk>
T-500	tapse ; pasp ; downward ; hfref ; hfpef ; prognostic ; resolution
H-500	-0.5643457770347595	▁t p se ▁; ▁PAS p ▁relationship ▁; ▁non sur viv ors ▁; ▁h Fr EF ▁; ▁ HF p EF ▁; ▁prognos tic ▁resolution
D-500	-0.5643457770347595	tpse ; PASp relationship ; nonsurvivors ; hFrEF ; HFpEF ; prognostic resolution
P-500	-1.4710 -1.7430 -1.6484 -0.8123 -0.5157 -0.2246 -0.4000 -0.1972 -0.5179 -0.1164 -0.0515 -0.0692 -0.1064 -1.3826 -0.7229 -1.1070 -0.0780 -0.2127 -0.4546 -0.0259 -0.4069 -0.9136 -0.9491 -0.4747 -0.0094 -0.4159 -0.2105
S-1632	METHODS: We performed an analysis of HF-ACTION, which randomized 2331 patients with HF having an ejection fraction ≤35% to usual care with or without exercise training.<unk>
T-1632	hf-action ; randomized ; patients ; hf ; ejection fraction ; exercise ; training
H-1632	-0.8462270498275757	▁ HF - ac tion ▁; ▁ HF ▁; ▁e je ction ▁ fraction ▁; ▁usual ▁care ▁; ▁exercise ▁training
D-1632	-0.8462270498275757	HF-action ; HF ; ejection fraction ; usual care ; exercise training
P-1632	-0.9436 -0.4567 -0.1289 -1.1944 -1.3648 -0.3527 -1.0467 -0.8013 -0.4320 -2.3367 -1.1963 -0.1710 -0.7560 -0.0254 -0.4221 -3.7360 -1.5020 -0.4262 -0.1136 -0.3252 -0.5849 -0.3006
S-1041	Both epigenetic 'writer' proteins (histone acetyltransferases) and epigenetic 'erasers' (histone deacetylases) have been implicated in cardiac development and disease.<unk>
T-1041	epigenetic ; proteins ; histone acetyltransferases ; epigenetic ; histone deacetylases ; cardiac ; disease
H-1041	-0.5048395395278931	▁epi gene tic ▁; writer ▁; ▁protein s ▁; hi stone ▁a ce tyl transfer as es ▁; ▁epi gene tic ▁; eras ers ▁; hi stone ▁de ace ty las es ▁; ▁cardiac ▁development ▁; ▁disease
D-1041	-0.5048395395278931	epigenetic ;writer ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac development ; disease
P-1041	-1.4867 -0.1006 -0.0785 -0.4805 -4.8831 -0.8050 -0.3336 -0.0441 -0.2029 -0.4155 -0.1639 -0.0690 -0.3613 -1.9985 -0.1031 -0.2182 -0.2246 -0.3938 -0.2567 -0.0710 -0.0903 -0.4272 -0.0156 -0.0485 -0.3010 -1.2560 -0.5689 -0.0708 -0.4347 -0.4022 -0.1600 -0.0567 -0.5865 -0.0377 -0.5833 -0.8836 -0.4821 -0.3393 -0.2536
S-270	CONCLUSION: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute HF 4 years after admission.<unk>
T-270	elevated ; nt-probnp ; admission ; all-cause mortality ; patients ; acute hf ; admission
H-270	-0.28463882207870483	▁NT - pro b NP ▁levels ▁; ▁ad mission ▁; ▁all - ca use ▁mortal ity ▁; ▁a cute ▁ HF
D-270	-0.28463882207870483	NT-probNP levels ; admission ; all-cause mortality ; acute HF
P-270	-0.1364 -0.0557 -0.0510 -0.6973 -0.4554 -0.3486 -0.2551 -1.2347 -0.0300 -0.2906 -1.2531 -0.0432 -0.0041 -0.1668 -0.0741 -0.0519 -0.2366 -0.1732 -0.0823 -0.2183 -0.0997 -0.2690 -0.3194
S-1449	Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines.<unk>
T-1449	haematopoietic cell transplantation ; hct ; congestive heart failure ; chf ; anthracyclines
H-1449	-0.6694446802139282	▁ha e mato po ie tic ▁cell ▁transplant ation ▁; ▁gh t ▁; ▁con ges tive ▁heart ▁failure ▁; CH f ▁; ▁pre - H CT ▁; ▁an thra cycli nes
D-1449	-0.6694446802139282	haematopoietic cell transplantation ; ght ; congestive heart failure ;CHf ; pre-HCT ; anthracyclines
P-1449	-0.0336 -0.0783 -0.0664 -0.0663 -1.9886 -0.0520 -2.0786 -0.0519 -0.2433 -0.5335 -4.0556 -0.7380 -0.4946 -0.4330 -0.3180 -0.1095 -1.3403 -0.1814 -0.4090 -0.2953 -0.5076 -0.2688 -0.1219 -0.0150 -1.0883 -2.1840 -1.4638 -0.1107 -0.1207 -0.4583 -1.3683 -0.5611 -0.2562
S-956	In the present study, the cardioprotective effect of nicorandil was investigated on hemodynamic alterations and mitochondrial dysfunction induced by cumulative administration of doxorubicin in rats.<unk>
T-956	cardioprotective ; nicorandil ; hemodynamic ; mitochondrial dysfunction ; administration ; doxorubicin
H-956	-0.3904443085193634	▁cardio protec tive ▁effect ▁; ▁nic oran dil ▁; ▁hem o dynamic ▁; ▁mito cho ndri al ▁dys function ▁induc ed ▁; ▁cum ul ative ▁administration ▁; ▁do xor ubi cin ▁; ▁rat s
D-956	-0.3904443085193634	cardioprotective effect ; nicorandil ; hemodynamic ; mitochondrial dysfunction induced ; cumulative administration ; doxorubicin ; rats
P-956	-0.1033 -0.3143 -0.1061 -0.5002 -0.4994 -0.0843 -0.0474 -0.2927 -0.1100 -0.3308 -0.1755 -0.0113 -0.7599 -0.1147 -2.5680 -0.5171 -0.0581 -0.1828 -1.0156 -0.6882 -0.1102 -0.5463 -0.0664 -0.0378 -0.0334 -0.0304 -0.9773 -0.0689 -0.2484 -0.0583 -1.3688 -1.5171 -0.0047 -0.0415 -0.3124 -0.1542
S-643	Furthermore, in vivo inhibition of miR-25 by a specific antagomir evoked spontaneous cardiac dysfunction and sensitized the murine myocardium to heart failure in a Hand2-dependent manner.<unk>
T-643	in vivo ; mir-25 ; antagomir ; cardiac dysfunction ; murine ; myocardium ; heart failure
H-643	-0.5737793445587158	▁in ▁vivo ▁inhibi tion ▁; ▁mi r -25 ▁; ▁anta go mir ▁; ▁spontane ous ▁cardiac ▁dys function ▁; ▁mur ine ▁my o car dium ▁; ▁heart ▁failure
D-643	-0.5737793445587158	in vivo inhibition ; mir-25 ; antagomir ; spontaneous cardiac dysfunction ; murine myocardium ; heart failure
P-643	-0.8953 -0.0657 -0.3706 -0.0844 -0.5798 -0.0239 -1.7760 -0.1997 -0.3238 -3.4286 -0.0107 -0.8077 -0.4801 -0.5202 -0.0209 -0.0795 -0.1471 -1.0320 -0.2173 -0.0928 -0.0748 -1.0493 -0.1264 -0.6255 -1.7634 -0.4678 -0.6990 -0.1278 -0.8360 -0.2874
S-1258	OBJECTIVES: To evaluate the effectiveness and safety of Chinese herbal medicine (CHM) as an adjunctive treatment for patients with dilated cardiomyopathy (DCM) and heart failure.<unk>
T-1258	medicine ; patients ; dilated cardiomyopathy ; dcm ; heart failure
H-1258	-0.38320502638816833	▁Chinese ▁herbal ▁medicine ▁; CH m ▁; ▁ad ju nc tive ▁treatment ▁; ▁dil ated ▁cardio my o pathy ▁; DC m ▁; ▁heart ▁failure
D-1258	-0.38320502638816833	Chinese herbal medicine ;CHm ; adjunctive treatment ; dilated cardiomyopathy ;DCm ; heart failure
P-1258	-2.3066 -0.1540 -0.1426 -0.1595 -0.3129 -0.1494 -0.3032 -0.0513 -0.0438 -0.1332 -0.0136 -0.7477 -0.2492 -0.7684 -0.0814 -0.2567 -1.9904 -0.6168 -0.0570 -0.1636 -0.4415 -0.1219 -0.2710 -0.1306 -0.0429 -0.4077 -0.2297
S-347	This time, he had severe hypertension of 191/104 mm Hg, diabetes mellitus, and grade 2 to 3/6 systolic as well as diastolic murmurs were audible at the apex.<unk>
T-347	hypertension ; diabetes mellitus ; grade ; systolic ; diastolic murmurs ; apex
H-347	-0.34469306468963623	▁hyper tension ▁; ▁diabetes ▁mell itus ▁; ▁sy sto lic ▁; ▁dia sto lic ▁mur mur s
D-347	-0.34469306468963623	hypertension ; diabetes mellitus ; systolic ; diastolic murmurs
P-347	-0.9947 -0.0813 -0.1281 -1.0110 -0.0182 -0.1197 -0.3628 -0.4603 -0.1133 -0.4637 -0.1377 -0.4670 -0.2024 -0.7800 -0.3446 -0.0227 -0.1660 -0.4946 -0.1811
S-533	Postoperative survival of patients with preoperative hypoalbuminemia (<3.5 g/dl, n = 125) and those with normal albumin concentration (≥3.5 g/dl, n = 147) was compared.<unk>
T-533	postoperative ; patients ; preoperative ; hypoalbuminemia ; albumin
H-533	-0.6521419286727905	▁post operativ e ▁survival ▁; ▁pre operativ e ▁hypo album in emia ▁; ▁normal ▁album in
D-533	-0.6521419286727905	postoperative survival ; preoperative hypoalbuminemia ; normal albumin
P-533	-0.1731 -0.0211 -0.5383 -1.2215 -0.1889 -1.0091 -0.0410 -0.2319 -0.7578 -0.5998 -0.3138 -0.5993 -0.2670 -2.2580 -0.9714 -0.3267 -2.0698 -0.1499
S-1147	In addition to the left bundle branch block type of electrical activation, there are further remodeling aspects associated with dyssynchronous heart failure (HF) that affect the electromechanical behavior of the heart.<unk>
T-1147	left bundle branch block ; remodeling ; dyssynchronous heart failure ; hf ; heart
H-1147	-0.33872175216674805	▁bund le ▁bran ch ▁block ▁; ▁electric al ▁activa tion ▁; ▁dys syn chron ous ▁heart ▁failure ▁; HF ▁; ▁electro me chan ical ▁behavior ▁; ▁heart
D-1147	-0.33872175216674805	bundle branch block ; electrical activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
P-1147	-0.9682 -0.3492 -0.2720 -0.0719 -0.0584 -0.5902 -0.0719 -0.0369 -0.4760 -0.0638 -0.3474 -0.1405 -0.0146 -0.0090 -0.0900 -1.3739 -0.1135 -0.3609 -0.1599 -0.4940 -0.0378 -0.0931 -0.0228 -0.0089 -0.8297 -0.4161 -1.8116 -0.3710 -0.1697
S-1822	Still, patients with advanced heart failure should be managed by a "heart team," as indicated by guidelines; communication and collaboration among cardiologists, cardiovascular surgeons, and other medical staff responsible for patient care is necessary.<unk>
T-1822	patients ; heart failure ; heart ; cardiologists ; cardiovascular ; surgeons ; medical ; patient
H-1822	-0.7779929041862488	▁heart ▁failure ▁; heart ▁team ▁; ▁cardio logist s ▁; ▁cardiovascular ▁surge ons ▁; ▁medical ▁staff
D-1822	-0.7779929041862488	heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical staff
P-1822	-4.2774 -0.6278 -0.3820 -2.7620 -0.9633 -0.3641 -0.2526 -0.0975 -0.1229 -0.2385 -0.1820 -0.2082 -0.1392 -1.2272 -0.1987 -1.0357 -0.7457 -0.1790
S-1376	Baroreflex sensitivity and time domain heart rate variability (HRV) were both decreased in the CHF-INV group compared with sham-INV and were restored to sham levels by renal DNx.<unk>
T-1376	baroreflex sensitivity ; heart rate variability ; hrv ; renal dnx
H-1376	-0.4486154615879059	▁Baro re flex ▁ sensitiv ity ▁; ▁time ▁domain ▁; ▁heart ▁rate ▁variabil ity ▁; HR v ▁; ▁CHF - in v ▁; ▁sham - in v ▁; ▁renal ▁DN x
D-1376	-0.4486154615879059	Baroreflex sensitivity ; time domain ; heart rate variability ;HRv ; CHF-inv ; sham-inv ; renal DNx
P-1376	-0.0440 -0.1175 -0.1151 -1.5353 -0.0136 -0.0306 -0.1694 -0.0700 -0.0894 -1.8398 -0.4233 -0.0652 -0.2194 -0.2066 -0.4786 -0.8194 -1.7672 -0.3450 -0.0857 -0.1048 -0.3946 -0.5128 -1.0096 -0.1929 -0.3252 -0.3706 -0.3523 -0.2512 -1.7853 -0.2204 -0.1065 -0.5553 -0.1879
S-1542	When the two most commonly used bisphosphonates, alendronate and etidronate, were analysed separately, significant trends in the risk of heart failure were observed across refill compliance strata.<unk>
T-1542	bisphosphonates ; alendronate ; etidronate ; heart failure ; compliance
H-1542	-0.36420154571533203	▁bis phos phon ates ▁; ▁ale ndr onate ▁; ▁et id rona te ▁; ▁heart ▁failure ▁; ▁re fill ▁compliance
D-1542	-0.36420154571533203	bisphosphonates ; alendronate ; etidronate ; heart failure ; refill compliance
P-1542	-0.0479 -0.0473 -0.2200 -0.2001 -0.1927 -0.0429 -0.0443 -0.0856 -0.1153 -0.0082 -1.1348 -0.0182 -0.0254 -0.2361 -2.4421 -0.1515 -0.9890 -0.2681 -0.0155 -0.1709 -1.3148 -0.2417
S-206	The authors evaluated how often the nurse assessment of cognitive impairment at hospitalization was documented by the physician at the time of discharge in a cohort of elderly patients hospitalized for heart failure.<unk>
T-206	nurse ; hospitalization ; physician ; discharge ; patients ; hospitalized ; heart failure
H-206	-0.4887574017047882	▁nurse ▁assessment ▁; ▁cognitive ▁im pair ment ▁; ▁hospital ization ▁; ▁physician ▁; ▁dis charge ▁; ▁el der ly ▁patients ▁hospital ized ▁; ▁heart ▁failure
D-206	-0.4887574017047882	nurse assessment ; cognitive impairment ; hospitalization ; physician ; discharge ; elderly patients hospitalized ; heart failure
P-206	-0.2350 -0.9553 -0.8651 -0.0594 -0.0423 -0.1450 -0.1748 -0.4003 -0.1861 -0.1617 -0.1680 -0.4479 -0.2036 -0.0625 -0.0193 -0.1929 -2.9305 -0.0391 -0.0275 -0.7576 -2.4361 -0.7661 -0.5358 -0.6661 -0.1360 -0.3344 -0.2485
S-1111	Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure.<unk>
T-1111	carvedilol ; nonselective β-blocker ; selective β-blocker ; metoprolol ; thromboembolic events ; heart failure
H-1111	-0.5481711030006409	▁car vedi lol ▁; ▁β - block er ▁; ▁β - block er ▁; ▁met o pro lol ▁; ▁ thro mbo e mbol ic ▁events ▁; ▁heart ▁failure
D-1111	-0.5481711030006409	carvedilol ; β-blocker ; β-blocker ; metoprolol ; thromboembolic events ; heart failure
P-1111	-0.4824 -0.0046 -0.0977 -0.3389 -1.4671 -0.0867 -0.4286 -0.6795 -0.9328 -2.5315 -0.0628 -0.3597 -0.8076 -1.4232 -2.4083 -0.1441 -0.1276 -0.1931 -0.2644 -0.2225 -0.2601 -0.8144 -0.8235 -0.0775 -0.2502 -0.3447 -0.3186 -0.2280 -0.1719 -0.4466 -0.1947
S-716	After adjustment for baseline characteristics, standard criteria cardiac transplant survival was higher than ECCT at 1 (89% versus 86%; P=0.18) and 5 (77% versus 66%; P=0.035) years.<unk>
T-716	baseline ; cardiac transplant ; ecct
H-716	-0.6328654289245605	▁base line ▁; ▁cardiac ▁transplant ▁survival ▁; ▁ec CT
D-716	-0.6328654289245605	baseline ; cardiac transplant survival ; ecCT
P-716	-0.0415 -0.0600 -0.2909 -0.6719 -0.1377 -2.1001 -0.3041 -0.8682 -1.7844 -0.4986 -0.2042
S-1700	CONCLUSIONS: Composite measures of quality for HF, AMI, and PNA performed better than existing measures at explaining variation in future mortality and predicting future high and low performers.<unk>
T-1700	hf ; ami ; pna ; mortality
H-1700	-0.6787233948707581	▁ HF ▁; ▁ AMI ▁; ▁p na ▁; ▁mortal ity
D-1700	-0.6787233948707581	HF ; AMI ; pna ; mortality
P-1700	-2.7841 -0.8141 -0.1773 -0.4195 -0.7705 -0.1858 -0.5012 -0.2960 -0.6089 -1.3213 -0.0844 -0.5681 -0.2922
S-685	BACKGROUND: Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited.<unk>
T-685	patients ; heart failure ; hf ; evidence ; outcomes ; hf
H-685	-0.8404539227485657	▁dieta ry ▁recommendations ▁; ▁heart ▁failure ▁; HF ▁; ▁non - HF ▁; ▁ HF
D-685	-0.8404539227485657	dietary recommendations ; heart failure ;HF ; non-HF ; HF
P-685	-3.9434 -0.0824 -1.3760 -0.2521 -1.9117 -0.0724 -0.2644 -0.1691 -0.5804 -0.5153 -0.0385 -0.0732 -1.4939 -3.0509 -0.0952 -0.2022 -0.1669
S-1590	Because of remodeling of the arrhythmia substrate after AMI, early measurement of HR variability to identify those at high risk should likely be repeated later in order to assess the risk of fatal arrhythmia events.<unk>
T-1590	remodeling ; arrhythmia ; ami ; hr variability ; arrhythmia
H-1590	-0.48362502455711365	▁ar rhythm ia ▁substrat e ▁; ▁ AMI ▁; ▁HR ▁variabil ity ▁; ▁ar rhythm ia ▁events
D-1590	-0.48362502455711365	arrhythmia substrate ; AMI ; HR variability ; arrhythmia events
P-1590	-0.8310 -0.2669 -0.6534 -0.0799 -0.2048 -0.2170 -0.6778 -0.0699 -0.2276 -0.2690 -0.2184 -0.0258 -0.3997 -2.0630 -1.1904 -0.6325 -0.7902 -0.1863 -0.1855
S-933	Moreover, doxorubicin-induced cardiotoxicity was greater in the Hum-Retn mice than in littermate controls not expressing human resistin (Retn(-/-)).<unk>
T-933	doxorubicin-induced cardiotoxicity ; resistin ; retn
H-933	-0.529498279094696	▁do xor ubi cin - indu ced ▁cardio toxic ity ▁; ▁Hum - Re t n ▁mi ce ▁; ▁litt er mate ▁; ▁human ▁resist in
D-933	-0.529498279094696	doxorubicin-induced cardiotoxicity ; Hum-Retn mice ; littermate ; human resistin
P-933	-0.0082 -0.2099 -0.0748 -1.7298 -0.2722 -0.0235 -1.2441 -0.4564 -1.7694 -0.3854 -0.2003 -0.1121 -0.1340 -2.2112 -0.0879 -0.0590 -0.5559 -0.2259 -0.1580 -0.1198 -0.0553 -0.0745 -0.4737 -1.8741 -0.0549 -0.2993 -1.7568 -0.1995
S-919	METHODS AND RESULTS: Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD (target sodium, 50 mmol/2100 kcal) for 21 days.<unk>
T-919	patients ; hypertension ; compensated hfpef ; dash ; sodium
H-919	-0.8523796200752258	▁hyper tension ▁; ▁compensa ted ▁H FP EF ▁; ▁DAS h ▁; ▁s rd ▁; tar get ▁so dium
D-919	-0.8523796200752258	hypertension ; compensated HFPEF ; DASh ; srd ;target sodium
P-919	-3.6946 -0.4498 -0.1302 -0.1479 -0.0480 -0.9579 -2.1808 -1.0310 -0.1245 -0.0868 -0.3922 -0.6072 -1.3015 -0.8372 -0.4384 -2.2976 -0.0181 -0.0120 -1.2827 -1.6745 -0.1873
S-1154	The simulation results revealed that deranged Ca(2+) handling is the primary culprit in extending EMD in dyssynchronous HF, with the other aspects of remodeling contributing insignificantly.<unk>
T-1154	emd ; dyssynchronous hf ; remodeling ; insignificantly
H-1154	-0.4288488030433655	▁em d ▁; ▁dys syn chron ous ▁ HF
D-1154	-0.4288488030433655	emd ; dyssynchronous HF
P-1154	-2.9507 -0.4346 -0.1474 -0.1204 -0.0303 -0.0183 -0.1034 -0.2081 -0.0853 -0.3639 -0.2549
S-1302	While early research focused on the importance of diastolic dysfunction in the pathophysiology of HFpEF, recent studies have revealed that multiple non-diastolic abnormalities in cardiovascular function also contribute.<unk>
T-1302	diastolic dysfunction ; pathophysiology ; hfpef ; cardiovascular function
H-1302	-0.5172381401062012	▁dia sto lic ▁dys function ▁; ▁pat ho phy si ology ▁; ▁ HF p EF ▁; ▁non - dia sto lic ▁ab normal ities ▁; ▁cardiovascular ▁function
D-1302	-0.5172381401062012	diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular function
P-1302	-1.9036 -0.2287 -1.6865 -0.5597 -1.4727 -0.1114 -0.3478 -0.2241 -0.1022 -2.0686 -0.1049 -0.3244 -0.3685 -0.1997 -0.0117 -0.1590 -0.3447 -0.0682 -0.0724 -2.0553 -0.4968 -0.7877 -0.0968 -0.0595 -0.0413 -0.2006 -0.1000 -0.8588 -0.2887 -0.1730
S-1997	Patients were adults with ejection fraction ≤ 25%, cardiac index ≤ 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or listed for transplant.<unk>
T-1997	patients ; ejection fraction ; cardiac index ; inotropes ; medical ; transplant
H-1997	-0.5404056906700134	▁e je ction ▁ fraction ▁; ▁cardiac ▁index ▁; ▁in o trop es ▁; ▁in ot rope - dependent ▁; ▁medical
D-1997	-0.5404056906700134	ejection fraction ; cardiac index ; inotropes ; inotrope-dependent ; medical
P-1997	-0.4232 -0.1610 -0.1890 -1.3107 -0.0143 -0.4203 -0.2845 -0.0877 -0.3368 -0.0480 -0.7182 -0.2680 -1.4607 -0.1716 -0.0307 -1.7021 -0.0554 -0.6443 -0.1403 -0.4783 -0.3240 -2.9006 -0.2595
S-246	RATIONALE: High-density lipoprotein (HDL) exerts endothelial-protective effects via stimulation of endothelial cell (EC) nitric oxide (NO) production.<unk>
T-246	high-density lipoprotein ; hdl ; endothelial cell ; nitric oxide
H-246	-0.6399179697036743	▁high - dens ity ▁lipo prote in ▁; HD l ▁; ▁en dot heli al - protec tive ▁effects ▁; ▁en dot heli al ▁cell ▁; EC ▁; ▁ni tric ▁oxid e ▁; NO
D-246	-0.6399179697036743	high-density lipoprotein ;HDl ; endothelial-protective effects ; endothelial cell ;EC ; nitric oxide ;NO
P-246	-0.7736 -0.1346 -1.1740 -0.1009 -0.1495 -0.8886 -1.4351 -0.6931 -0.6350 -1.9834 -0.6050 -0.1027 -1.9856 -0.2681 -0.0423 -0.3675 -0.1370 -0.1553 -0.6608 -0.5703 -0.0611 -2.5484 -0.4836 -0.0409 -1.2177 -0.2998 -1.2991 -0.2107 -0.0122 -0.5696 -0.0351 -0.0655 -0.6968 -0.6584 -1.7433 -0.2323
S-1840	CONCLUSION: In this large cohort study, a higher risk for hHF was not observed in users of saxagliptin or sitagliptin compared with other selected antihyperglycemic agents.<unk>
T-1840	cohort study ; saxagliptin ; sitagliptin ; antihyperglycemic agents
H-1840	-0.6898150444030762	▁h HF ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁anti hy per gly ce mic ▁agents
D-1840	-0.6898150444030762	hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
P-1840	-0.0307 -1.9516 -0.1690 -0.1799 -0.1333 -0.6731 -2.4811 -0.1339 -1.8735 -0.4702 -0.1897 -1.7998 -0.2119 -0.0129 -0.9898 -0.4844 -0.9397 -0.1150 -1.4164 -0.1637 -0.5722 -0.1839
S-1608	This study aims to discover differentially expressed genes (DEGs) between non-ischemic or ischemic heart failure samples and healthy control, which may be used for diagnosis and treatment of heart failure.<unk>
T-1608	differentially expressed genes ; degs ; ischemic heart failure ; healthy ; diagnosis ; heart failure
H-1608	-0.828352689743042	▁d g s ▁; ▁non - ische mic ▁; ▁ ische mic ▁heart ▁failure ▁; ▁healthy ▁control ▁; ▁heart ▁failure
D-1608	-0.828352689743042	dgs ; non-ischemic ; ischemic heart failure ; healthy control ; heart failure
P-1608	-6.4926 -0.2604 -0.0430 -0.2894 -0.5436 -0.0870 -0.6965 -0.1565 -0.7218 -0.1648 -0.2167 -0.2042 -2.2083 -0.0658 -0.8365 -0.8662 -0.5673 -0.4994 -2.7220 -0.1077 -0.2381 -0.2360
S-653	Insulin resistance is a hallmark of type 2 diabetes, and insulin receptor substrates 1 and 2 (IRS1 and IRS2) are the major insulin-signaling components regulating cellular metabolism and survival.<unk>
T-653	insulin resistance ; type 2 diabetes ; insulin receptor substrates 1 ; irs1 ; irs2 ; cellular metabolism
H-653	-0.3392375707626343	▁in s ulin ▁resist ance ▁; ▁type ▁2 ▁diabetes ▁; ▁insulin ▁receptor ▁substrat es ▁; IR s 1 ▁; ▁i RS 2 ▁; ▁insulin - signal ing ▁; ▁cel lular ▁metabolism
D-653	-0.3392375707626343	insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRs1 ; iRS2 ; insulin-signaling ; cellular metabolism
P-653	-0.5248 -0.7567 -0.1589 -0.0813 -0.0145 -0.2234 -0.1325 -0.2436 -0.0585 -0.1734 -0.0247 -0.0077 -0.0651 -0.3995 -0.2826 -0.3384 -0.2091 -0.2782 -0.1378 -0.5654 -0.6426 -0.4953 -0.2212 -0.1046 -0.2714 -0.0228 -0.1005 -0.7648 -2.9716 -0.0161 -0.0748 -0.6422 -0.1906
S-1398	The purpose of this study was to determine whether a significant difference in outcome ratings exists from admission to discharge for hospitalized older adults with heart failure (HF) using Nursing Outcomes Classification (NOC).<unk>
T-1398	outcome ; admission ; discharge ; hospitalized ; heart failure ; hf ; nursing outcomes classification ; noc
H-1398	-0.46255648136138916	▁ad mission ▁to ▁dis charge ▁; ▁hospital ized ▁older ▁adults ▁; ▁heart ▁failure ▁; HF ▁; ▁Nur sing ▁out com es ▁classifica tion ▁; no c
D-1398	-0.46255648136138916	admission to discharge ; hospitalized older adults ; heart failure ;HF ; Nursing outcomes classification ;noc
P-1398	-0.1262 -0.0126 -0.4247 -0.0181 -0.0169 -0.2857 -1.3600 -0.1091 -2.0995 -0.3812 -0.4467 -0.3204 -0.1410 -0.3789 -0.2190 -0.3023 -0.4312 -0.0194 -1.0000 -0.8863 -0.0269 -0.7630 -0.0363 -0.3792 -1.0024 -1.0060 -0.5316 -0.2269
S-1432	8-fluo-cAMP binding by wild type and phosphomimic Ser77 and Ser83 mutant RIα proteins demonstrated reduced Kd for the double mutant as compared to WT RIα.<unk>
T-1432	8-fluo-camp ; phosphomimic ; ser77 ; ser83 ; riα ; proteins ; riα
H-1432	-0.7063600420951843	▁8- flu o - c AMP ▁ binding ▁; ▁wild ▁type ▁; ▁ phos pho mi mic ▁ser 77 ▁; ▁ser 83 ▁; ▁ser 83 ▁; ▁mu tant ▁; ▁RI α ▁protein s ▁; ▁double ▁mu tant ▁; ▁ WT ▁RI α
D-1432	-0.7063600420951843	8-fluo-cAMP binding ; wild type ; phosphomimic ser77 ; ser83 ; ser83 ; mutant ; RIα proteins ; double mutant ; WT RIα
P-1432	-0.2118 -0.5850 -0.4000 -0.1432 -0.8068 -0.6456 -0.7375 -0.0058 -0.1444 -1.3361 -0.3502 -0.1013 -0.0821 -0.0663 -0.5367 -0.1082 -1.0699 -0.6742 -0.1275 -0.0607 -0.1135 -1.1929 -0.0696 -1.9809 -0.8578 -0.1080 -4.0122 -0.3214 -0.6293 -1.2990 -0.8230 -2.3626 -0.0809 -0.1159 -2.1989 -0.4752 -0.2794 -0.1471 -1.1331 -1.7616 -1.1095 -1.2232 -0.4165 -0.1752
S-535	Multivariate analysis revealed that preoperative albumin was independently associated with mortality after LVAD implantation (hazard ratio 0.521, 95% confidence interval 0.290 to 0.934; p = 0.029.)<unk>
T-535	multivariate analysis ; preoperative ; albumin ; mortality ; lvad ; implantation ; hazard ratio ; confidence interval
H-535	-0.40318962931632996	▁pre operativ e ▁album in ▁; ▁mortal ity ▁; ▁l VAD ▁implant ation
D-535	-0.40318962931632996	preoperative albumin ; mortality ; lVAD implantation
P-535	-0.8320 -0.0284 -0.1972 -0.3713 -0.5865 -0.1910 -0.1647 -0.0309 -0.4114 -0.7754 -0.1322 -0.6811 -0.2976 -1.1116 -0.2367
S-854	CONCLUSIONS: In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.<unk>
T-854	patients ; systolic heart failure ; qrs duration ; crt ; death ; hospitalization ; heart failure ; mortality
H-854	-0.5942347645759583	▁sy sto lic ▁heart ▁failure ▁; ▁QR s ▁du ration ▁; ▁c RT ▁; ▁rate ▁of ▁death ▁; ▁hospital ization ▁; ▁heart ▁failure
D-854	-0.5942347645759583	systolic heart failure ; QRs duration ; cRT ; rate of death ; hospitalization ; heart failure
P-854	-2.1409 -0.1671 -0.7585 -1.7648 -0.1659 -0.1454 -0.1644 -1.1863 -0.2882 -0.0691 -0.1688 -0.8438 -2.6553 -0.2476 -0.4706 -0.1140 -0.8495 -0.0859 -0.2399 -0.1619 -0.3655 -0.2922 -0.2269 -1.0422 -0.2412
S-605	These groups were compared in Cox regression models stratified by propensity score decile and adjusted for oral glucocorticoid dosage, prior HF hospitalisations, and the use of loop diuretics.<unk>
T-605	cox regression models ; propensity score ; oral ; glucocorticoid ; hf ; hospitalisations ; loop diuretics
H-605	-0.4371945858001709	▁co x ▁re gression ▁models ▁; ▁pro pens ity ▁score ▁de cile ▁; ▁oral ▁gluco cor tico id ▁; ▁ HF ▁hospital isation s ▁; ▁loop ▁di ure tics
D-605	-0.4371945858001709	cox regression models ; propensity score decile ; oral glucocorticoid ; HF hospitalisations ; loop diuretics
P-605	-0.0289 -0.3626 -0.0290 -0.0439 -0.6200 -0.2310 -0.0022 -0.0679 -0.1322 -0.2150 -0.3366 -0.0279 -0.1034 -0.1061 -0.0598 -1.1785 -1.5607 -1.3847 -1.3840 -0.5364 -0.0418 -1.5402 -0.0698 -0.1141 -0.2450 -0.7073 -0.1704 -0.3768 -1.0403 -0.6695 -0.1670
S-1327	BACKGROUND: Functional electrical stimulation (FES) improves exercise capacity, quality of life, emotional stress, and endothelial function in chronic heart failure with impaired systolic function.<unk>
T-1327	functional electrical stimulation ; fes ; exercise capacity ; quality of life ; endothelial function ; chronic heart failure ; systolic function
H-1327	-0.33953437209129333	▁function al ▁electric al ▁stimul ation ▁; ▁f es ▁; ▁exercise ▁capacity ▁; ▁emotional ▁stress ▁; ▁en dot heli al ▁function ▁; ▁chronic ▁heart ▁failure ▁; ▁im pair ed ▁sy sto lic ▁function
D-1327	-0.33953437209129333	functional electrical stimulation ; fes ; exercise capacity ; emotional stress ; endothelial function ; chronic heart failure ; impaired systolic function
P-1327	-1.3150 -0.1119 -0.0315 -0.0191 -0.1261 -0.1185 -0.6554 -1.3078 -0.3402 -0.3318 -0.2805 -0.0397 -0.3163 -0.0717 -0.1237 -0.2055 -0.0855 -1.2116 -0.1509 -0.0106 -0.2058 -0.1514 -0.4453 -0.7029 -0.0572 -0.1818 -0.1415 -0.0069 -0.0076 -1.1142 -0.1684 -0.8976 -0.3793 -0.4452 -0.1254
S-910	Dialysis patients demonstrated the following 3-year event rates: HF hospitalization, 31%; all-cause hospitalization, 100%; mortality, 73%; and HF hospitalization or death, 82%.<unk>
T-910	dialysis ; patients ; hf ; hospitalization ; all-cause hospitalization ; mortality ; hf ; hospitalization ; death
H-910	-0.689622700214386	▁Dia lys is ▁; ▁ HF ▁hospital ization ▁; ▁hospital ization ▁; ▁mortal ity ▁; ▁ HF
D-910	-0.689622700214386	Dialysis ; HF hospitalization ; hospitalization ; mortality ; HF
P-910	-1.7750 -0.1848 -0.5099 -1.1081 -1.5476 -0.0933 -1.8695 -0.2096 -0.4035 -1.9433 -0.3543 -0.6192 -0.3049 -0.0362 -0.5591 -0.1529 -0.2129 -0.9844 -0.2343
S-2003	Key adverse events included reoperation for bleeding (14%), driveline infection (10%), gastrointestinal bleeding (8%), and debilitating stroke (modified Rankin Score > 3) (8%).<unk>
T-2003	adverse events ; reoperation ; bleeding ; driveline ; infection ; gastrointestinal bleeding ; stroke ; rankin score
H-2003	-0.411651611328125	▁re opera tion ▁; ▁ble ed ing ▁; ▁drive line ▁infection ▁; ▁gastro inte stin al ▁ble ed ing ▁; ▁de bilitat ing ▁stroke
D-2003	-0.411651611328125	reoperation ; bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke
P-2003	-1.7938 -0.8155 -0.0389 -0.7821 -0.3357 -0.3070 -0.1109 -0.3393 -0.0177 -0.0506 -2.4176 -0.2956 -0.0408 -0.0636 -0.4291 -0.0788 -0.4736 -0.4585 -0.0969 -0.2692 -0.0674 -0.0062 -0.0181 -0.2210 -1.0096 -0.1654
S-1936	OBJECTIVE: Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR).<unk>
T-1936	beta blockers ; all-cause mortality ; readmissions ; heart failure with reduced ejection fraction ; hfref ; heart rate
H-1936	-0.47807228565216064	▁Beta ▁block ers ▁; ▁read missions ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; HF r EF ▁; ▁heart ▁rate ▁; HR
D-1936	-0.47807228565216064	Beta blockers ; readmissions ; heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
P-1936	-0.2254 -0.3259 -0.1931 -0.3083 -3.0014 -0.0273 -0.3339 -0.2345 -0.0924 -0.1424 -0.6639 -0.2674 -0.0648 -0.3568 -0.0238 -0.3279 -0.4749 -0.2081 -0.6990 -0.2258 -2.5430 -0.0628 -0.8266 -0.0412 -0.5823 -0.1768
S-1149	In dyssynchronous HF, the electromechanical delay (EMD), the time interval between local myocyte depolarization and myofiber shortening onset, is prolonged.<unk>
T-1149	dyssynchronous hf ; electromechanical delay ; emd ; myocyte depolarization ; myofiber shortening
H-1149	-0.2935016453266144	▁dys syn chron ous ▁ HF ▁; ▁electro me chan ical ▁de lay ▁; EM d ▁; ▁my o cy te ▁de po lar ization ▁; ▁my o fi ber ▁short en ing ▁ons et
D-1149	-0.2935016453266144	dyssynchronous HF ; electromechanical delay ;EMd ; myocyte depolarization ; myofiber shortening onset
P-1149	-1.3523 -0.0179 -0.0026 -0.1370 -0.3327 -0.0949 -0.1391 -0.0051 -0.1253 -0.0397 -0.0189 -0.1136 -0.0210 -0.3053 -0.4921 -0.2797 -0.1852 -0.8444 -0.0867 -0.2857 -0.4339 -0.0643 -0.0318 -0.3124 -0.0869 -0.3558 -0.4930 -0.0927 -0.2953 -0.0340 -0.7123 -0.1852 -0.1563 -1.1875 -0.5956 -0.6184 -0.3250
S-879	Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).<unk>
T-879	qrs morphology ; outcomes ; cardiac resynchronization therapy ; resynchronization-defibrillation for ambulatory heart failure trial ; raft
H-879	-0.3610052466392517	▁QR s ▁ morph ology ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁re syn chron ization - Def i bril lation ▁; ▁Amb ulator y ▁Heart ▁Fail ure ▁Tri al ▁; RAF t
D-879	-0.3610052466392517	QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ;RAFt
P-879	-0.4628 -0.8347 -0.7310 -0.0251 -0.0640 -0.1794 -1.6162 -0.0123 -0.0387 -0.0143 -0.2434 -1.3627 -0.0567 -0.3929 -0.0725 -0.0155 -0.0196 -0.2008 -0.2745 -0.3853 -0.4332 -0.4618 -0.6024 -0.3750 -0.0670 -0.0164 -0.0651 -0.6452 -0.2272 -0.0504 -0.8419 -0.0196 -0.8741 -0.0042 -0.9944 -0.4562 -0.2207
S-1478	We discuss the need for strict statistical standards in biomarker studies, provide an overview of biomarker-guided clinical trial design, and discuss the therapeutic potential of a multimarker-based strategy.<unk>
T-1478	biomarker ; clinical ; therapeutic
H-1478	-0.4428897500038147	▁statistic al ▁standard s ▁; ▁bio mark er ▁studies ▁; ▁bio mark er - guide d ▁clinic al ▁trial ▁design ▁; ▁multi mark er - based ▁strategy
D-1478	-0.4428897500038147	statistical standards ; biomarker studies ; biomarker-guided clinical trial design ; multimarker-based strategy
P-1478	-0.5927 -0.0400 -0.1852 -0.0314 -0.2156 -0.2890 -0.0714 -0.2510 -2.3017 -0.2131 -0.5736 -0.0761 -0.1891 -0.3163 -0.0022 -0.0802 -0.5705 -0.1330 -0.2819 -1.1733 -0.5722 -3.4488 -0.0942 -0.2311 -0.2855 -0.0283 -0.1196 -0.2790 -0.1977
S-231	By imaging, the SAF cohort demonstrated a greater incidence of abnormal liver texture changes (96% vs 75%, p = 0.04) and nodularity (77% vs 42%, p = 0.02).<unk>
T-231	saf ; incidence ; liver ; nodularity
H-231	-0.842338502407074	▁ SAF ▁co hor t ▁; ▁ab normal ▁ liver ▁texture ▁; ▁no du lar ity
D-231	-0.842338502407074	SAF cohort ; abnormal liver texture ; nodularity
P-231	-1.7577 -0.0724 -1.6199 -1.3595 -0.6310 -0.1979 -0.1533 -0.0530 -0.4497 -0.8392 -1.7040 -1.0882 -2.1077 -0.9769 -0.9045 -0.1015 -0.8573 -0.2883
S-896	METHODS: A consecutive case series of 10 transplant ineligible patients receiving PD solely for HF volume management between 2007 and 2011 was evaluated with clinical data reviewed pre- and post-PD initiation.<unk>
T-896	transplant ; patients ; pd ; hf ; clinical
H-896	-0.5276000499725342	▁transplant ▁in elig ible ▁patients ▁; ▁PD ▁; ▁ HF ▁volume ▁management ▁; ▁clinic al ▁; ▁post - PD ▁initiat ion
D-896	-0.5276000499725342	transplant ineligible patients ; PD ; HF volume management ; clinical ; post-PD initiation
P-896	-0.7847 -0.6104 -0.0020 -1.3325 -1.0083 -0.4063 -1.3441 -0.2711 -0.2676 -0.1135 -0.3562 -0.6101 -0.5730 -1.1242 -0.0587 -0.7618 -1.3115 -0.0279 -0.1726 -0.3929 -0.0750 -0.3445 -0.1861
S-1004	Frailty according to the biological phenotype was defined as 3 or more of: weak grip strength, physical exhaustion, slowness, low activity and unintentional weight loss >10 lb in 1 year.<unk>
T-1004	frailty ; biological phenotype ; physical ; activity
H-1004	-0.3722005784511566	▁Fra il ty ▁; ▁bi ological ▁ph eno type ▁; ▁we ak ▁grip ▁; ▁physical ▁exhaust ion ▁; ▁slow ness ▁; ▁activity ▁; ▁un inten tional ▁weight ▁loss
D-1004	-0.3722005784511566	Frailty ; biological phenotype ; weak grip ; physical exhaustion ; slowness ; activity ; unintentional weight loss
P-1004	-0.5315 -0.1575 -0.4439 -0.2884 -0.7445 -0.1723 -2.0024 -0.6077 -0.6300 -0.2041 -0.2210 -0.0052 -0.1158 -1.8759 -0.0262 -0.4263 -0.0740 -0.2964 -0.4387 -0.3579 -0.2459 -0.1148 -0.1741 -0.2172 -0.0369 -0.0115 -0.1721 -0.0548 -0.2854 -0.2335
S-109	In conclusion, our data suggest that treatment with CRT-D does not reduce the risk of IE in patients with IC and that the benefit of CRT-D is attenuated after the development of IEs in this population.<unk>
T-109	crt-d ; patients ; ic ; crt-d ; ies
H-109	-0.7555456757545471	▁c RT - d ▁; ▁IE ▁; ▁IC ▁; ▁c RT - d ▁; ▁IE s
D-109	-0.7555456757545471	cRT-d ; IE ; IC ; cRT-d ; IEs
P-109	-1.4153 -1.7421 -0.1064 -0.8461 -0.1383 -2.0625 -0.2328 -0.6895 -0.2695 -0.5182 -2.1140 -0.1517 -0.9266 -0.2564 -1.1297 -0.1887 -0.6087 -0.2033
S-467	Conclusions—Low-volume EDs were more likely to discharge patients with heart failure home, but low-volume ED cases exhibited worse outcomes (driven largely by readmissions or repeat ED visits).<unk>
T-467	eds ; discharge ; patients ; heart failure ; outcomes ; driven ; readmissions
H-467	-0.6160120368003845	▁ED s ▁; ▁dis charge ▁; ▁heart ▁failure ▁home ▁; ▁low - volu me ▁ED ▁cases ▁; ▁read missions ▁; ▁repeat ▁ED ▁visit s
D-467	-0.6160120368003845	EDs ; discharge ; heart failure home ; low-volume ED cases ; readmissions ; repeat ED visits
P-467	-4.4538 -0.2522 -0.2336 -1.4428 -0.0113 -1.5072 -0.8328 -0.0467 -0.2239 -0.6048 -0.6308 -0.0294 -0.1564 -0.0889 -0.6049 -0.0985 -0.2699 -0.9255 -0.0161 -0.0929 -0.9565 -0.7842 -1.2427 -0.0610 -0.2898 -0.1597
S-1295	Based on the acute right heart failure with therapy refractory cardiogenic shock we decided within our heart team for an extra corporeal membrane oxygenation (ECMO) applied during CPR in the ICU.<unk>
T-1295	acute right heart failure ; therapy ; refractory cardiogenic shock ; heart ; extra corporeal membrane oxygenation ; ecmo ; cpr ; icu
H-1295	-0.3894895017147064	▁a cute ▁right ▁heart ▁failure ▁; ▁ therapy ▁re frac tory ▁cardio ge nic ▁shock ▁; ▁heart ▁team ▁; ▁corpore al ▁membran e ▁oxygen ation ▁; ▁ec mo ▁; ▁c PR ▁; ▁ ICU
D-1295	-0.3894895017147064	acute right heart failure ; therapy refractory cardiogenic shock ; heart team ; corporeal membrane oxygenation ; ecmo ; cPR ; ICU
P-1295	-0.5664 -0.0076 -0.2420 -0.6886 -0.0694 -0.2448 -0.5282 -0.0152 -0.0296 -0.0097 -0.0563 -0.3910 -0.0792 -0.0220 -0.4269 -0.4078 -1.0371 -2.3028 -0.2477 -1.2748 -0.0520 -0.0852 -0.1124 -0.3966 -0.2582 -0.3210 -0.3871 -0.7568 -0.3229 -0.1089 -0.8026 -0.3699 -0.9826 -0.0145 -0.2514 -0.1522
S-595	Here, we present a case report of a patient with right atrial myxoma and massive embolism to the pulmonary arteries treated surgically with right atrial mass removal and pulmonary embolectomy.<unk>
T-595	report ; patient ; right atrial myxoma ; massive embolism ; pulmonary arteries ; surgically ; right atrial ; pulmonary embolectomy
H-595	-0.37086066603660583	▁report ▁; ▁right ▁at rial ▁my xo ma ▁; ▁e mbol ism ▁; ▁pulmonar y ▁arteri es ▁; ▁right ▁at rial ▁mass ▁remo val ▁; ▁pulmonar y ▁e mbol ecto my
D-595	-0.37086066603660583	report ; right atrial myxoma ; embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
P-595	-1.0501 -0.2430 -0.0435 -0.1749 -0.0646 -2.0139 -0.1486 -0.1592 -0.1945 -2.0148 -0.0363 -0.3428 -0.3131 -0.0518 -0.0682 -0.0500 -0.2020 -0.3283 -0.0398 -0.2017 -0.2121 -0.0119 -0.0116 -0.0489 -0.1872 -0.0084 -0.0620 -0.0750 -0.0339 -0.4638 -2.5198 -0.6978 -0.1651
S-201	The guidelines are intended to assist practitioners in office-based or emergency room practice, who encounter children with undiagnosed heart disease and symptoms of possible HF, rather than those who have already received surgical palliation.<unk>
T-201	emergency room ; undiagnosed ; heart disease ; symptoms ; hf ; surgical palliation
H-201	-0.8409221172332764	▁un diagnos ed ▁heart ▁disease ▁; ▁ HF ▁; ▁sur g ical ▁palli ation
D-201	-0.8409221172332764	undiagnosed heart disease ; HF ; surgical palliation
P-201	-7.3093 -0.1517 -0.0254 -1.1787 -0.7778 -0.1792 -0.9853 -0.1060 -1.1732 -0.8072 -0.0359 -0.0094 -0.0789 -0.1429 -0.2680 -0.2258
S-745	This study aimed to verify the impact of heart magnetic resonance imaging on chelation choices and patient compliance in a single-institution cohort as well as its predictive value for heart failure and arrhythmias.<unk>
T-745	heart magnetic resonance imaging ; chelation ; patient ; compliance ; heart failure ; arrhythmias
H-745	-0.4886699616909027	▁heart ▁magnetic ▁res on ance ▁imagin g ▁; ▁che lation ▁choice s ▁; ▁compliance ▁; ▁heart ▁failure ▁; ▁ar rhythm ias
D-745	-0.4886699616909027	heart magnetic resonance imaging ; chelation choices ; compliance ; heart failure ; arrhythmias
P-745	-2.8010 -0.0367 -0.1642 -0.1240 -0.1235 -0.5390 -0.0838 -0.3954 -0.3473 -0.4725 -0.7070 -0.1017 -0.2892 -0.9137 -0.2367 -2.2827 -0.0731 -0.3970 -0.0373 -0.2941 -0.2726 -0.3880 -0.1587
S-897	RESULTS: The mean ejection fraction (EF) pre-PD was 24.5 ± 6.0% with the majority of patients having NYHA class IIIB symptoms and moderate-severe right ventricular dysfunction.<unk>
T-897	ejection fraction ; ef ; patients ; nyha class iiib ; symptoms ; right ventricular dysfunction
H-897	-0.6157049536705017	▁e je ction ▁ fraction ▁; EF ▁; ▁pre - PD ▁; ▁NY HA ▁class ▁III b ▁; ▁right ▁vent ri cular ▁dys function
D-897	-0.6157049536705017	ejection fraction ;EF ; pre-PD ; NYHA class IIIb ; right ventricular dysfunction
P-897	-0.2456 -0.2074 -0.0745 -0.7642 -0.0124 -0.2221 -0.2945 -0.1697 -0.1153 -0.0182 -0.0912 -0.1898 -1.7847 -0.6693 -0.6175 -0.1129 -0.6894 -0.2915 -0.3448 -3.7107 -1.5552 -0.7441 -0.4069 -2.1380 -0.3401 -0.1984
S-124	CPCs were measured as early-outgrowth colony-forming units (EO-CFUs) and circulating CD34+, VEGFR2+ and/or CD133+ cells.<unk>
T-124	cpcs ; early-outgrowth colony-forming units ; eo-cfus ; cells
H-124	-0.6909660696983337	▁c PC s ▁; ▁early - out g row th ▁colon y - form ing ▁unit s ▁; EO - C FU s ▁; ▁circula ting ▁CD 34 ▁; ▁v EG FR 2 ▁; ▁CD 133
D-124	-0.6909660696983337	cPCs ; early-outgrowth colony-forming units ;EO-CFUs ; circulating CD34 ; vEGFR2 ; CD133
P-124	-0.1193 -1.0258 -0.1330 -0.2467 -1.2010 -0.1740 -0.2421 -2.0321 -0.0393 -0.0424 -1.5835 -0.1147 -0.1779 -0.1209 -0.1198 -0.0131 -0.2043 -0.3484 -0.2521 -0.1405 -2.8661 -1.0332 -0.1553 -0.2104 -1.0395 -0.0825 -3.0900 -0.2185 -0.5028 -0.5598 -1.2051 -2.2882 -0.3005 -0.3896 -1.4768 -0.0605 -2.1207 -0.3259
S-168	Gene expression of Bax remained unchanged during the pacing period; Bcl-2 mRNA expression transiently decreased in moderate heart failure and their ratio (Bcl-2/Bax) was not significantly altered.<unk>
T-168	gene expression ; bax ; pacing ; bcl-2 ; mrna ; expression ; heart failure ; bcl-2 ; bax
H-168	-0.5764813423156738	▁Gene ▁expression ▁; ▁Bax ▁; ▁b cl -2 ▁m RNA ▁expression ▁; ▁heart ▁failure ▁; ▁b cl - 2/ Ba x
D-168	-0.5764813423156738	Gene expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
P-168	-1.4943 -0.1737 -0.6288 -0.0177 -0.1218 -0.4041 -0.2622 -0.2799 -0.1015 -0.0661 -0.3416 -0.1287 -2.0756 -0.1579 -0.2071 -1.5454 -0.2861 -0.1022 -0.3647 -3.6607 -0.1248 -0.5367 -0.1772
S-413	BACKGROUND: The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.<unk>
T-413	nitroxyl ; hno ; inotropic ; lusitropic ; vasodilator ; in vivo ; camp
H-413	-0.3842340409755707	▁ni tro x yl ▁; ▁h no ▁; ▁Angeli ▁; ▁salt ▁; ▁in o tropi c ▁; ▁ lusi tropi c ▁; ▁vaso dila tor ▁effects ▁; ▁c AMP
D-413	-0.3842340409755707	nitroxyl ; hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
P-413	-0.0087 -0.6754 -0.6036 -1.1481 -0.3806 -2.1677 -0.2535 -0.4771 -0.2045 -0.7679 -0.0891 -0.1643 -0.3051 -0.7210 -0.1160 -0.2436 -0.1644 -0.2199 -0.0092 -0.1991 -0.5479 -0.2386 -0.0962 -0.0702 -0.0933 -0.9378 -0.1406 -0.0163 -0.0799 -0.6184 -0.1529
S-1643	BACKGROUND: Even on optimal therapy including anticoagulation and rate control, major cardiovascular complications (stroke, cardiovascular death, and acute heart failure) are common in patients with atrial fibrillation (AF).<unk>
T-1643	therapy ; anticoagulation ; rate control ; cardiovascular ; complications ; stroke ; cardiovascular death ; acute heart failure ; patients ; atrial fibrillation
H-1643	-0.5224947929382324	▁antico ag ulation ▁; ▁rate ▁control ▁; ▁cardiovascular ▁complica tions ▁; stro ke ▁; ▁cardiovascular ▁death ▁; ▁a cute ▁heart ▁failure ▁; ▁at rial ▁fi bril lation ▁; AF
D-1643	-0.5224947929382324	anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
P-1643	-2.6395 -2.5500 -0.1713 -0.2435 -0.0022 -0.0725 -0.5874 -0.2744 -0.2163 -0.1504 -0.2482 -3.1456 -0.0292 -0.2987 -0.1590 -1.0817 -0.1165 -0.0054 -0.0209 -0.4811 -0.0365 -0.4129 -0.2660 -0.1267 -0.5947 -0.0528 -0.9578 -0.6759 -0.0356 -0.4101 -0.1346
S-309	We reviewed the evidence on clinical effects and cost-effectiveness of 2 types of continuous-flow LVADs (HeartMate II [HM II] and HeartWare), for BTT and DT patients.<unk>
T-309	evidence ; clinical ; continuous-flow lvads ; heartmate ii ; hm ii ; heartware ; btt ; dt ; patients
H-309	-0.7081918716430664	▁continuo us - flow ▁l VAD s ▁; He art Mate ▁II ▁; HM ▁II ▁; ▁Heart War e ▁; ▁b t ▁; ▁ DT
D-309	-0.7081918716430664	continuous-flow lVADs ;HeartMate II ;HM II ; HeartWare ; bt ; DT
P-309	-5.3909 -0.0545 -0.1123 -0.0256 -3.3345 -0.2939 -0.1893 -0.2528 -2.4537 -0.4173 -0.0908 -0.5710 -0.0538 -0.2652 -0.9962 -0.0871 -0.9674 -0.1048 -0.0382 -0.1773 -0.7235 -0.4380 -0.1485 -0.2092 -0.4509 -1.0273 -0.2471
S-753	METHODS AND RESULTS: The results of patients with baseline EF >30% (n=177) and those with EF ≤30% (n=431), as determined by a blinded core laboratory, were compared.<unk>
T-753	patients ; baseline ; ef ; ef ; core
H-753	-0.3557133972644806	▁base line ▁EF ▁; ▁EF ▁; ▁blind ed ▁core ▁laborator y
D-753	-0.3557133972644806	baseline EF ; EF ; blinded core laboratory
P-753	-0.0434 -0.0686 -2.0675 -0.1480 -0.3764 -0.4503 -0.6898 -0.0470 -0.1252 -0.0517 -0.1071 -0.2176 -0.2315
S-1499	Skeletal muscle mass assessed by relative appendicular lean mass index was significantly reduced compared with age-matched and sex-matched reference values (Z-score -1.46±0.22, p<0.0001).<unk>
T-1499	skeletal muscle ; lean mass ; z-score
H-1499	-0.5414057374000549	▁s kelet al ▁muscle ▁mass ▁; ▁relative ▁appen di cular ▁lean ▁mass ▁index ▁; ▁z - s core
D-1499	-0.5414057374000549	skeletal muscle mass ; relative appendicular lean mass index ; z-score
P-1499	-1.6101 -0.0191 -0.1483 -0.9366 -0.2309 -0.3985 -0.1423 -0.3703 -0.0355 -0.2502 -2.8755 -0.0680 -0.1739 -0.5553 -2.2077 -0.0759 -0.0217 -0.1845 -0.3205 -0.2032
S-693	CONCLUSIONS: Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores.<unk>
T-693	dash ; mortality ; hf ; nonsignificant
H-693	-0.6401692032814026	▁DAS h ▁die t ▁score s ▁; ▁mortal ity ▁; ▁ HF ▁; ▁Mediterrane an
D-693	-0.6401692032814026	DASh diet scores ; mortality ; HF ; Mediterranean
P-693	-0.0937 -0.4448 -4.1904 -0.1889 -0.0965 -0.0356 -0.0757 -0.7808 -0.0283 -0.0816 -0.3183 -0.0498 -0.5012 -0.7097 -0.1217 -3.0412 -0.1248
S-561	Quality of life was worse, but all-cause mortality was lowest in the youngest age group (3-year mortality rates across the respective age categories: 12%, 13%, 13%, 19%, and 31%, respectively).<unk>
T-561	quality of life ; all-cause mortality ; mortality
H-561	-0.621701717376709	▁quality ▁of ▁life ▁; ▁all - ca use ▁mortal ity
D-561	-0.621701717376709	quality of life ; all-cause mortality
P-561	-0.5155 -0.1953 -0.3562 -0.3181 -1.4482 -0.0226 -0.0334 -0.4127 -0.3249 -0.0881 -3.5892 -0.1564
S-197	CONCLUSIONS: In a large registry, we found that despite sex/EF differences in BNP values, there was no significant difference in the ability of BNP to predict inhospital mortality among these subgroups.<unk>
T-197	ef ; bnp ; bnp ; inhospital ; mortality
H-197	-0.6636322736740112	▁b p ▁; ▁in hospital ▁mortal ity
D-197	-0.6636322736740112	bp ; inhospital mortality
P-197	-1.5900 -1.6854 -0.5316 -1.3900 -0.0380 -0.2037 -0.0214 -0.3649 -0.1477
S-285	BACKGROUND: Among the various cardiovascular diseases, heart failure (HF) is projected to have the largest increases in incidence over the coming decades; therefore, improving HF prediction is of significant value.<unk>
T-285	cardiovascular diseases ; heart failure ; hf ; incidence ; hf
H-285	-0.528709888458252	▁cardiovascular ▁disease s ▁; ▁heart ▁failure ▁; HF ▁; ▁ HF
D-285	-0.528709888458252	cardiovascular diseases ; heart failure ;HF ; HF
P-285	-0.1465 -1.9164 -0.0490 -0.2036 -0.1803 -0.0767 -0.2292 -0.5202 -0.8883 -1.6714 -0.1065 -0.7484 -0.1367
S-402	METHODS AND RESULTS: A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment.<unk>
T-402	heart failure ; left ventricular systolic dysfunction ; post hoc analysis
H-402	-1.186867356300354	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁sy sto lic ▁dys function ▁; ▁BB
D-402	-1.186867356300354	heart failure ; left ventricular systolic dysfunction ; BB
P-402	-2.4585 -0.1922 -0.2498 -0.3561 -3.7672 -1.8706 -0.3225 -1.9537 -0.1806 -2.1026 -0.4732 -2.5015 -0.4056 -1.6687 -0.3062 -0.1809
S-1801	A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort.<unk>
T-1801	clcnka ; polymorphism ; rs10927887 ; p.arg83gly ; heart failure ; estimated glomerular filtration rate ; renastur
H-1801	-0.7479530572891235	▁CL n KA ▁poly morph ism ▁; ▁ar g 83 g ly ▁; ▁heart ▁failure ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁re NAS tur
D-1801	-0.7479530572891235	CLnKA polymorphism ; arg83gly ; heart failure ; glomerular filtration rate ; reNAStur
P-1801	-2.9973 -1.7533 -2.3866 -1.4227 -0.0909 -0.3294 -0.0788 -2.7220 -0.0058 -0.3439 -0.9700 -0.2662 -0.1525 -0.2355 -0.1880 -0.1090 -0.8937 -1.4445 -0.0369 -0.4836 -0.2383 -0.0454 -0.3024 -0.6293 -0.2423 -1.1376 -1.1731 -0.2638
S-706	CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk.<unk>
T-706	st2 ; functional capacity ; outcomes ; ambulatory ; patients ; hf
H-706	-0.6491000652313232	▁ST 2 ▁; ▁functional ▁capacity ▁; ▁outcome s ▁; ▁ambula tory ▁patients ▁; ▁ HF
D-706	-0.6491000652313232	ST2 ; functional capacity ; outcomes ; ambulatory patients ; HF
P-706	-1.3346 -0.0892 -0.3928 -3.6133 -0.0830 -0.3250 -1.3522 -0.0154 -0.1883 -1.2798 -0.0620 -1.2617 -0.1700 -0.1289 -0.0386 -0.4544 -0.2455
S-455	Importantly, 2 weeks after B treatment was started, increased cardiac VEGF expression and Akt and endothelial NO synthase activation were observed by comparing B-treated with drug-untreated failing hearts.<unk>
T-455	cardiac vegf expression ; endothelial no synthase activation ; hearts
H-455	-0.6592363119125366	▁b ▁treatment ▁; ▁cardiac ▁VE GF ▁expression ▁; ▁Akt ▁; ▁en dot heli al ▁NO ▁synth ase ▁activa tion ▁; ▁b - tre ated ▁; ▁fail ing ▁heart s
D-455	-0.6592363119125366	b treatment ; cardiac VEGF expression ; Akt ; endothelial NO synthase activation ; b-treated ; failing hearts
P-455	-1.1126 -4.8300 -0.2199 -0.4887 -1.5705 -0.5936 -0.0253 -0.1205 -0.0453 -0.1278 -0.0293 -2.6675 -0.1323 -0.0106 -0.8014 -0.1960 -1.8782 -1.2581 -0.1098 -0.2849 -1.2605 -0.1054 -0.1567 -0.0618 -0.1099 -1.0184 -0.0532 -0.5681 -0.0412 -0.3895 -0.1691
S-1046	Gene expression profiling of cultured cardiomyocytes in the presence or absence of JQ1 showed that the drug abrogated the induction of a substantial subset of phenylephrine-induced genes.<unk>
T-1046	gene expression ; cardiomyocytes ; jq1 ; drug ; genes
H-1046	-0.5425132513046265	▁Gene ▁expression ▁; ▁culture d ▁cardio my o cy tes ▁; ▁j q 1 ▁; ▁drug ▁ab roga ted ▁; ▁in duction ▁; ▁ phen yle ph rine - indu ced ▁gene s
D-1046	-0.5425132513046265	Gene expression ; cultured cardiomyocytes ; jq1 ; drug abrogated ; induction ; phenylephrine-induced genes
P-1046	-1.1874 -0.1318 -1.5107 -0.0641 -0.3421 -1.0649 -2.1920 -0.8335 -0.5637 -0.2145 -0.1172 -0.9797 -1.8785 -0.3736 -0.1014 -0.3892 -0.1245 -0.0097 -0.0699 -0.1651 -1.2323 -0.0030 -0.5263 -0.2397 -0.0671 -1.8196 -0.3767 -0.0235 -0.3801 -0.0054 -0.9412 -0.5045 -0.0442 -0.3773 -0.1335
S-824	On the basis of the assumption that exercise-induced PASP is a measure of right ventricular contractile reserve, patients were classified into 2 groups according to an exercise-induced PASP increase above or below the median.<unk>
T-824	exercise-induced pasp ; right ventricular contractile reserve ; patients ; exercise-induced pasp
H-824	-0.6401768326759338	▁exercise - indu ced ▁PAS p ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁exercise - indu ced ▁PAS p
D-824	-0.6401768326759338	exercise-induced PASp ; right ventricular contractile reserve ; exercise-induced PASp
P-824	-0.5480 -0.1458 -0.0771 -0.6405 -0.3527 -0.5237 -0.1403 -0.0424 -2.3375 -1.6178 -0.6699 -0.1629 -3.0386 -0.0576 -0.8239 -1.2819 -0.1198 -0.0516 -0.5733 -0.4112 -0.5107 -0.4344 -0.1627
S-1609	MATERIALS AND METHODS: Gene expression profile GSE9128 was downloaded from Gene Expression Omnibus, including 3 normal samples, 4 non-ischemic heart failure samples and 4 ischemic samples.<unk>
T-1609	gene expression profile ; gse9128 ; gene expression omnibus ; non-ischemic heart failure ; ischemic
H-1609	-0.43137800693511963	▁Gene ▁expression ▁profile ▁; ▁g se 91 28 ▁; ▁Gene ▁Express ion ▁Omni bus ▁; ▁non - ische mic ▁heart ▁failure ▁; ▁ ische mic ▁sample s
D-1609	-0.43137800693511963	Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure ; ischemic samples
P-1609	-0.9086 -0.2114 -0.0221 -2.0282 -0.5739 -0.8093 -0.1228 -0.1817 -0.2799 -0.3180 -0.1800 -0.0139 -0.0121 -0.0495 -0.2828 -0.2606 -0.0521 -0.5111 -0.1569 -1.4622 -0.0589 -1.5994 -0.2622 -0.3583 -0.3846 -0.8416 -0.0864 -0.2905 -0.1910
S-1784	Marked cardiac insulin-resistance by 2 weeks post-AAC was evidenced by a significant decrease in insulin-stimulated rates of glycolysis and glucose oxidation, and plasma membrane translocation of glucose transporter 4.<unk>
T-1784	cardiac ; insulin-resistance ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose
H-1784	-0.3105664849281311	▁cardiac ▁insulin - re si stance ▁; ▁a ac ▁; ▁insulin - stimul ated ▁rates ▁; ▁gly col ysis ▁; ▁gluco se ▁oxid ation ▁; ▁plasma ▁membran e ▁trans location ▁; ▁gluco se ▁transporter
D-1784	-0.3105664849281311	cardiac insulin-resistance ; aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
P-1784	-0.6917 -0.2659 -0.1172 -0.2988 -0.3043 -0.0066 -0.1723 -1.8302 -1.0618 -0.2401 -0.0780 -0.2424 -0.0175 -0.0803 -0.4780 -0.5056 -0.0750 -0.0657 -1.1982 -0.1709 -0.1432 -0.4944 -0.1244 -0.0789 -0.4697 -0.0434 -0.0108 -0.0626 -0.0355 -0.0892 -0.5195 -0.1405 -0.2567 -0.1119 -0.4889 -0.2104
S-920	We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial tonometry) and cardiovascular function with echocardiographic measures (all previously invasively validated).<unk>
T-920	baseline ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic ; invasively
H-920	-0.5750644207000732	▁base line ▁; ▁post - DAS h ▁; ▁s rd ▁; ▁central ▁blood ▁pressure ▁; ▁radi al ▁arterial ▁ton ometr y ▁; ▁cardiovascular ▁; ▁e cho car dio graphic ▁measure s
D-920	-0.5750644207000732	baseline ; post-DASh ; srd ; central blood pressure ; radial arterial tonometry ; cardiovascular ; echocardiographic measures
P-920	-0.0074 -0.0194 -0.0928 -0.1444 -0.0625 -0.0999 -0.4729 -0.3987 -0.9921 -0.3431 -0.9167 -1.1529 -3.2620 -0.5824 -0.1292 -0.0132 -0.0292 -0.3547 -3.1072 -0.0267 -0.1288 -0.2187 -0.2841 -1.0686 -0.1052 -0.3259 -0.6034 -1.2228 -0.7954 -1.3537 -0.1454 -0.3645 -0.1531
S-1924	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-1924	psychosocial ; exercise ; outcomes ; heart failure ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
H-1924	-0.6011303067207336	▁psycho social ▁factors ▁; ▁exercise ▁ad her ence ▁; ▁Heart ▁Fail ure ▁Patient s ▁; ▁Heart ▁Fail ure ▁; ▁control led ▁Tri al ▁Investiga ting ▁out com es ▁; ▁exercise ▁training ▁; HF - ac tion
D-1924	-0.6011303067207336	psychosocial factors ; exercise adherence ; Heart Failure Patients ; Heart Failure ; controlled Trial Investigating outcomes ; exercise training ;HF-action
P-1924	-1.3399 -0.2865 -1.1298 -0.5325 -0.5764 -0.2900 -0.1493 -0.0091 -0.2986 -1.6016 -0.3633 -0.0784 -0.8962 -0.0925 -0.7131 -0.7591 -0.2556 -0.0575 -0.5306 -3.0253 -0.0345 -1.4711 -0.0608 -0.8822 -0.1683 -0.6233 -0.3596 -0.0466 -0.9004 -0.4893 -0.3498 -0.5965 -0.3424 -0.0529 -1.0959 -1.3694 -0.7429 -0.2717
S-1186	A derivation cohort was formed of consecutive patients who had undergone coronary angiography with a primary diagnosis of systolic HF of unclear etiology (ejection fraction <50%).<unk>
T-1186	patients ; coronary angiography ; diagnosis ; systolic hf ; etiology ; ejection fraction
H-1186	-0.3578757345676422	▁deriva tion ▁co hor t ▁; ▁corona ry ▁ang i ography ▁; ▁primary ▁ diagnos is ▁; ▁sy sto lic ▁ HF ▁; ▁un clear ▁et i ology
D-1186	-0.3578757345676422	derivation cohort ; coronary angiography ; primary diagnosis ; systolic HF ; unclear etiology
P-1186	-0.4023 -0.0231 -0.0697 -0.7831 -0.6968 -0.3162 -1.5299 -0.0864 -0.0343 -0.7776 -0.4262 -0.1373 -0.8591 -0.3016 -0.0882 -0.7391 -0.5236 -0.0845 -0.0503 -0.4597 -0.2032 -0.0330 -0.2357 -0.0650 -0.0061 -0.0076 -0.5016 -0.0565 -1.0811 -0.1576
S-922	Effective arterial elastance (Ea) end-systolic elastance (Ees) and ventricular-arterial coupling (defined as the ratio Ees:Ea) were determined using previously published techniques.<unk>
T-922	arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees ; ea
H-922	-0.44010287523269653	▁arterial ▁elastan ce ▁; ▁e a ▁; ▁end - sy sto lic ▁elastan ce ▁; ▁e es ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁ratio ▁e es ▁; ▁e a
D-922	-0.44010287523269653	arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ratio ees ; ea
P-922	-0.9823 -0.7318 -0.2623 -0.1709 -0.5170 -0.1688 -0.2856 -0.2799 -0.1966 -1.3432 -0.3674 -1.0220 -0.3980 -0.2185 -0.1865 -0.4513 -0.0452 -0.2715 -1.3299 -0.4374 -0.1405 -0.3108 -0.0269 -0.0836 -0.0776 -0.0711 -0.3587 -0.1120 -1.3529 -0.0666 -1.3122 -0.3271 -0.4505 -0.7976 -0.2495
S-1653	Early rhythm control therapy will consist of usual care plus rhythm control therapy by antiarrhythmic drugs, catheter ablation, and a patient-operated electrocardiographic device to monitor the ongoing rhythm.<unk>
T-1653	rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic ; rhythm
H-1653	-0.2799171209335327	▁ rhythm ▁control ▁ therapy ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁cat heter ▁ab lation ▁; ▁electro car dio graphic ▁device ▁; ▁ rhythm
D-1653	-0.2799171209335327	rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
P-1653	-0.5745 -0.1349 -0.1202 -0.8496 -0.0385 -0.2734 -0.3497 -0.2572 -0.0740 -0.0896 -0.0219 -0.3148 -0.2051 -0.0016 -0.0075 -0.0651 -0.3529 -0.0427 -0.4720 -0.7397 -0.2843 -0.3825 -0.7428 -0.4823 -0.2794 -0.1997 -0.2019
S-1083	Cells were exposed to angiotensin II (AngII) and hypoxia, known activators of abnormal SCN5A mRNA splicing, or were induced to overexpress SCN5A variants.<unk>
T-1083	cells ; angiotensin ii ; angii ; hypoxia ; scn5a ; mrna splicing ; scn5a
H-1083	-0.6551095843315125	▁ang io ten sin ▁II ▁; ▁ang II ▁; ▁hypo xia ▁; ▁activa tors ▁; ▁ab normal ▁s cn 5 a ▁m RNA ▁s plic ing ▁; ▁induc ed ▁; ▁s cn 5 a
D-1083	-0.6551095843315125	angiotensin II ; angII ; hypoxia ; activators ; abnormal scn5a mRNA splicing ; induced ; scn5a
P-1083	-0.9111 -2.7714 -0.4776 -0.0884 -0.5178 -0.3209 -0.2963 -0.5706 -0.2642 -0.1197 -0.3141 -0.4452 -2.8003 -0.0247 -0.4934 -0.7177 -0.0592 -0.6730 -1.3517 -0.2509 -0.7952 -0.1430 -0.1809 -0.1053 -0.1491 -0.2022 -0.5777 -0.7009 -0.1216 -1.0703 -0.4455 -2.4213 -0.5197 -0.7871 -1.4988 -0.3971
S-1488	Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined.<unk>
T-1488	evidence ; hf with reduced ejection fraction ; hfref ; hf with preserved ejection fraction ; hfpef
H-1488	-0.4227055311203003	▁ HF ▁; ▁reduce d ▁e je ction ▁ fraction ▁; HF r EF ▁; ▁ HF ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1488	-0.4227055311203003	HF ; reduced ejection fraction ;HFrEF ; HF ; preserved ejection fraction ;HFpEF
P-1488	-2.1602 -0.2137 -0.2628 -1.0908 -0.0615 -0.0656 -0.3407 -0.1246 -0.6298 -0.0152 -0.3236 -1.0603 -0.3736 -0.2715 -0.1324 -1.4927 -0.1997 -0.2285 -0.6855 -0.2028 -0.0893 -0.1153 -0.3794 -0.1673 -0.4791 -0.0142 -0.2660 -0.9844 -0.0438 -0.1948 -0.6831 -0.1745
S-1298	CONCLUSION: Extracorporeal life support is feasible und effective for bridging therapy in patients with acute ischemic right heart failure with refractory cardiogenic shock and successful reperfusion therapy.<unk>
T-1298	extracorporeal life support ; therapy ; patients ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion ; therapy
H-1298	-0.27659568190574646	extra corp o real ▁life ▁support ▁; brid ging ▁ therapy ▁; ▁a cute ▁ ische mic ▁right ▁heart ▁failure ▁; ▁re frac tory ▁cardio ge nic ▁shock ▁; ▁reper fusion ▁ therapy
D-1298	-0.27659568190574646	extracorporeal life support ;bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
P-1298	-2.1827 -0.0621 -0.2585 -0.0378 -0.1090 -0.4888 -0.3073 -0.5335 -0.2509 -0.5954 -0.0258 -0.2341 -0.3077 -0.0417 -0.4310 -0.2509 -0.0609 -0.1142 -0.8704 -0.0460 -0.1435 -0.0013 -0.0052 -0.0802 -0.1572 -0.0943 -0.0177 -0.2698 -0.4563 -0.0147 -0.0386 -0.5937 -0.0265 -0.3758 -0.1974
S-1332	CONCLUSION: As in heart failure and reduced left ventricular ejection fraction, FES also improves exercise capacity, quality of life, emotional status, and endothelial function in HFpEF.<unk>
T-1332	heart failure ; reduced left ventricular ejection fraction ; fes ; exercise capacity ; quality of life ; endothelial function ; hfpef
H-1332	-0.46184882521629333	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁f es ▁; ▁exercise ▁capacity ▁; ▁emotional ▁status ▁; ▁en dot heli al ▁function ▁; ▁ HF p EF
D-1332	-0.46184882521629333	heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; emotional status ; endothelial function ; HFpEF
P-1332	-0.4285 -0.0962 -0.0845 -0.4978 -3.3054 -1.3577 -0.6766 -0.1511 -0.2951 -0.1897 -0.6530 -0.0139 -0.4168 -1.2603 -0.4882 -0.1368 -0.1511 -0.0603 -0.2156 -0.7305 -0.1016 -0.1648 -0.1520 -1.3080 -0.1605 -0.0169 -0.2920 -0.2316 -0.5416 -0.5996 -0.0290 -0.4600 -0.2671 -0.1689
S-1240	However, these differences were offset by higher expenditures due to hospitalizations for noncardiovascular diagnoses, implantable cardiac arrhythmia devices, and noncardiovascular drugs in the rate-control group.<unk>
T-1240	expenditures ; hospitalizations ; noncardiovascular ; diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular ; drugs ; rate-control
H-1240	-0.3427738547325134	▁ex pendi tures ▁; ▁non car dio vas cular ▁diagnose s ▁; ▁implant able ▁cardiac ▁ar rhythm ia ▁devices ▁; ▁non car dio vas cular ▁drugs
D-1240	-0.3427738547325134	expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
P-1240	-0.1875 -0.0154 -0.0561 -0.3079 -0.1014 -0.5954 -0.9398 -0.6549 -0.3366 -0.9329 -0.0208 -0.2133 -0.1420 -0.0100 -0.0459 -0.0240 -0.0806 -0.2544 -0.0816 -0.2905 -0.0231 -0.3441 -0.8743 -0.3340 -0.2529 -0.0546 -2.2486 -0.1749
S-220	Intubation rates declined from 3.6% in 1996 to 1.7% in 2008, a 53% (95% CI: 31%-68%, P < .001, R(2) = 0.83, P < .001) relative decrease.<unk>
T-220	intubation
H-220	-0.7626376152038574	▁in tub ation ▁rates
D-220	-0.7626376152038574	intubation rates
P-220	-0.0685 -0.0094 -0.1547 -1.6044 -2.5328 -0.2060
S-1541	By comparison, raloxifene, which is used for the same indication but has a different mechanism of action, was not associated with an increased risk of heart failure: adjusted HR 1.07 (95% CI 0.76-1.50).<unk>
T-1541	raloxifene ; heart failure
H-1541	-0.5068686008453369	▁ra lo xi fen e ▁; ▁mechanism ▁of ▁action ▁; ▁heart ▁failure
D-1541	-0.5068686008453369	raloxifene ; mechanism of action ; heart failure
P-1541	-0.1232 -0.1976 -0.0593 -1.8118 -0.6886 -0.2562 -0.0198 -0.1160 -0.0106 -0.2417 -2.1740 -0.3115 -0.8917 -0.1940
S-1814	We found that the hearts of TTA/TgTetMena mice were functionally and morphologically comparable to wild-type littermates, except for mildly increased heart mass in the transgenic mice.<unk>
T-1814	hearts ; heart mass ; transgenic
H-1814	-0.5369709134101868	▁heart s ▁; ▁t g t t t Men a ▁mi ce ▁; ▁wild - type ▁litt er mates ▁; ▁heart ▁mass ▁; ▁trans ge nic ▁mi ce
D-1814	-0.5369709134101868	hearts ; tgtttMena mice ; wild-type littermates ; heart mass ; transgenic mice
P-1814	-1.8441 -0.0616 -0.5484 -1.7572 -0.0930 -0.0579 -0.6631 -1.7282 -1.3695 -0.0770 -0.6922 -0.2950 -0.3171 -1.0270 -0.1496 -0.7899 -0.1287 -0.1421 -0.2769 -0.3073 -2.1041 -0.0905 -0.1929 -0.0449 -0.1537 -0.1120 -0.2449 -0.2336 -0.4119 -0.1948
S-1938	METHODS AND RESULTS: Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months.<unk>
T-1938	patients ; hfref ; exercise ; respiratory gas analysis ; baseline
H-1938	-0.7835284471511841	▁h f f ▁; ▁exercise ▁protocol ▁; ▁respirator y ▁gas ▁; ▁base line
D-1938	-0.7835284471511841	hff ; exercise protocol ; respiratory gas ; baseline
P-1938	-3.6192 -2.3900 -0.5713 -0.2674 -1.8547 -0.3626 -0.3014 -0.2386 -0.1183 -0.0125 -1.3162 -0.0116 -0.0646 -0.2931 -0.3314
S-1126	RESULTS: Among 295 patients not receiving guideline-recommended drugs for heart failure, chart review identified biomedical reasons for nonprescribing in 42%-58% of patients and contextual reasons in 11%-17%.<unk>
T-1126	patients ; drugs ; heart failure ; biomedical ; nonprescribing ; patients
H-1126	-0.428046315908432	▁guide line - re com mend ed ▁drugs ▁; ▁heart ▁failure ▁; ▁chart ▁review ▁; ▁bio medic al ▁reasons ▁; ▁non pre scribi ng
D-1126	-0.428046315908432	guideline-recommended drugs ; heart failure ; chart review ; biomedical reasons ; nonprescribing
P-1126	-4.3646 -0.0157 -0.1710 -0.0173 -0.1520 -0.0067 -0.0961 -0.0414 -0.9232 -0.4271 -0.0368 -0.3793 -0.5834 -0.2214 -0.1937 -0.1550 -0.0671 -0.0067 -1.0092 -0.4550 -0.4108 -0.0131 -0.2148 -0.0717 -0.8520 -0.2440
S-1169	Wasting of fat but not of lean mass was predictive of adverse outcome, suggesting that fat loss is either a surrogate of enhanced catabolism or adipose tissue is cardioprotective in the context of HF.<unk>
T-1169	lean mass ; adverse outcome ; adipose tissue ; cardioprotective ; hf
H-1169	-0.3368922770023346	▁was ting ▁; ▁fat ▁; ▁lean ▁mass ▁; ▁fat ▁loss ▁; ▁cata bol ism ▁; ▁adi pose ▁tissu e ▁; ▁cardio protec tive ▁; ▁ HF
D-1169	-0.3368922770023346	wasting ; fat ; lean mass ; fat loss ; catabolism ; adipose tissue ; cardioprotective ; HF
P-1169	-1.2179 -0.0145 -0.9849 -0.6950 -0.1903 -0.3789 -0.0177 -0.2079 -1.3166 -0.0407 -0.1530 -1.6009 -0.1568 -0.0967 -0.0642 -0.0107 -0.0401 -0.0914 -0.2050 -0.1564 -0.2849 -0.2142 -0.0955 -0.4652 -0.4006 -0.0420 -0.1502 -0.1407
S-97	However, hearts of fish lacking Nucleolin displayed severe developmental impairment, abnormal chamber patterning and functional deficits, ostensibly due to defects in cardiac looping and myocyte differentiation.<unk>
T-97	hearts ; nucleolin ; chamber patterning ; cardiac looping ; myocyte differentiation
H-97	-0.4543376564979553	▁heart s ▁; ▁fish ▁la cking ▁; ▁Nu cle olin ▁; ▁cha mber ▁pattern ing ▁; ▁functional ▁deficit s ▁; ▁cardiac ▁loop ing ▁; ▁my o cy te ▁differenti ation
D-97	-0.4543376564979553	hearts ; fish lacking ; Nucleolin ; chamber patterning ; functional deficits ; cardiac looping ; myocyte differentiation
P-97	-0.4111 -0.0372 -0.7600 -0.8307 -0.3342 -0.0121 -2.0141 -1.4461 -0.0443 -0.3642 -0.1895 -0.9216 -0.0038 -0.0449 -0.4431 -0.2011 -2.4982 -0.6863 -0.0843 -0.2119 -0.5468 -0.2609 -0.0460 -0.2712 -0.4613 -0.0589 -0.1825 -0.2902 -0.2903 -0.0461 -0.3603 -0.1854
S-1641	CONCLUSIONS: Black race in patients with chronic HF was associated with increased prevalence of modifiable risk factors, lower exercise performance, and increased HF hospitalization, but not increased mortality or a differential response to exercise training.<unk>
T-1641	patients ; chronic hf ; prevalence ; exercise ; hf ; hospitalization ; mortality ; exercise ; training
H-1641	-0.5478689670562744	▁black ▁race ▁; ▁chronic ▁ HF ▁; ▁modifi able ▁risk ▁factors ▁; ▁exercise ▁performance ▁; ▁ HF ▁hospital ization ▁; ▁mortal ity ▁; ▁exercise ▁training
D-1641	-0.5478689670562744	black race ; chronic HF ; modifiable risk factors ; exercise performance ; HF hospitalization ; mortality ; exercise training
P-1641	-0.1533 -0.0396 -0.1423 -2.7376 -0.3023 -0.1003 -0.2536 -4.2225 -0.0545 -0.6421 -0.0264 -0.1866 -0.8409 -0.2562 -0.2161 -0.1472 -0.1279 -1.7918 -0.2108 -0.4338 -0.4068 -0.0174 -0.3487 -0.5147 -0.1663 -0.2168 -0.2360
S-4	The results show a significant decline in adverse event rates for acute myocardial infarction and congestive heart failure, translating to an estimated 81,000 in-hospital adverse events averted in 2010–2011.<unk>
T-4	adverse event ; acute myocardial infarction ; congestive heart failure ; adverse events
H-4	-0.5069226026535034	▁advers e ▁event ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁in - hospital ▁advers e ▁events
D-4	-0.5069226026535034	adverse event ; acute myocardial infarction ; congestive heart failure ; in-hospital adverse events
P-4	-1.2935 -0.0922 -0.1507 -3.1634 -0.0337 -0.0425 -2.3665 -0.5156 -1.0112 -0.0505 -0.0765 -0.4156 -0.3088 -0.1523 -0.0049 -0.1461 -0.0433 -0.5258 -0.0545 -1.2327 -0.0891 -0.1982 -0.0077 -1.3355 -0.1067 -0.1602 -0.3831 -0.2332
S-935	Macrophages, but not cardiomyocytes, from Hum-Retn mice treated with doxorubicin in vitro showed dramatic induction of hRetn (human resistin) mRNA and protein expression.<unk>
T-935	macrophages ; cardiomyocytes ; doxorubicin ; in vitro ; resistin ; mrna ; protein expression
H-935	-0.485257089138031	▁Mac rop hage s ▁; ▁cardio my o cy tes ▁; ▁Hum - re t n ▁mi ce ▁; ▁do xor ubi cin ▁; ▁h Re t n ▁; ▁human ▁resist in ▁; ▁m RNA ▁; ▁protein ▁expression
D-935	-0.485257089138031	Macrophages ; cardiomyocytes ; Hum-retn mice ; doxorubicin ; hRetn ; human resistin ; mRNA ; protein expression
P-935	-0.7411 -0.0060 -0.0044 -0.0701 -0.1165 -0.1140 -1.1570 -0.3883 -0.1679 -0.1085 -0.2622 -0.2213 -0.2034 -1.7210 -0.3954 -0.0838 -0.4865 -0.1957 -0.3826 -0.1714 -1.4626 -0.1689 -0.8344 -0.3305 -0.7455 -3.9433 -0.0551 -0.0170 -0.2208 -1.8482 -0.0535 -0.1225 -0.7407 -0.0056 -0.0252 -0.7621 -0.2727 -0.0248 -0.5555 -0.2243
S-546	Of these LVADs, 225 were CF devices (203 HeartMate II devices, Thoratec Corp, Pleasanton, Calif; and 22 HVAD devices, HeartWare Intl, Inc, Framingham, Mass).<unk>
T-546	lvads ; heartmate ii ; thoratec corp ; pleasanton ; calif ; hvad ; heartware ; framingham
H-546	-0.4929148256778717	▁l VAD s ▁; ▁CF ▁devices ▁; ▁Heart Mate ▁II ▁devices ▁; ▁Thor a tec ▁Corp ▁; ▁Ple asan ton ▁; ▁Cali f ▁; ▁h VAD ▁devices ▁; ▁Heart War e ▁in t l ▁; ▁Fram ing ham ▁; ▁Mass
D-546	-0.4929148256778717	lVADs ; CF devices ; HeartMate II devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD devices ; HeartWare intl ; Framingham ; Mass
P-546	-2.0983 -0.1767 -0.1066 -0.1550 -1.6634 -0.8601 -0.0875 -3.4399 -0.0811 -0.6228 -0.3536 -0.1788 -0.1459 -0.1108 -0.0030 -0.3255 -0.1510 -0.0145 -0.0012 -0.0074 -0.6682 -0.1638 -0.0037 -0.0295 -1.0667 -1.0357 -1.4893 -0.1140 -1.5428 -0.1480 -0.0150 -0.0560 -0.0232 -0.0026 -0.2209 -1.3905 -0.0118 -0.0079 -1.3464 -0.1729 -0.4522 -0.1582
S-19	CONCLUSIONS: FM was associated with plasma NPs and total adiponectin at baseline; whereas changes in FM and FFM did not correlate to changes in NPs or adiponectin during follow up.<unk>
T-19	plasma nps ; adiponectin ; baseline ; ffm ; correlate ; nps ; adiponectin ; follow up
H-19	-0.5379883646965027	▁FM ▁; ▁plasma ▁ NP s ▁; ▁total ▁adi pon ect in ▁; ▁base line ▁; ▁FM ▁; ▁f m ▁; ▁ NP s ▁; ▁adi pon ect in
D-19	-0.5379883646965027	FM ; plasma NPs ; total adiponectin ; baseline ; FM ; fm ; NPs ; adiponectin
P-19	-1.0143 -0.1388 -2.2246 -0.7529 -0.0150 -0.0224 -0.1506 -3.0044 -0.1380 -0.0374 -0.4920 -0.8505 -0.4416 -0.0109 -0.0308 -0.3011 -1.0668 -0.1541 -0.8097 -1.5560 -0.2420 -1.1599 -0.0497 -0.0203 -0.2416 -0.1318 -0.0396 -0.5869 -0.3351 -0.4344 -0.2247
S-1378	To assess whether this was due to a withdrawal of sympathetic tone or an increase in parasympathetic tone, the heart rate response was measured after an intravenous bolus of metoprolol or atropine.<unk>
T-1378	sympathetic tone ; parasympathetic tone ; heart rate ; intravenous bolus ; metoprolol ; atropine
H-1378	-0.44567742943763733	▁withdraw al ▁of ▁sympa the tic ▁tone ▁; ▁para sy mpa the tic ▁tone ▁; ▁heart ▁rate ▁response ▁; ▁intra ven ous ▁bol us ▁of ▁met o pro lol ▁; ▁a tropi ne
D-1378	-0.44567742943763733	withdrawal of sympathetic tone ; parasympathetic tone ; heart rate response ; intravenous bolus of metoprolol ; atropine
P-1378	-0.9638 -0.0342 -0.4551 -0.0721 -1.7930 -0.1764 -0.4842 -0.1072 -0.3714 -0.6775 -0.3225 -2.7261 -0.2254 -1.0369 -0.1886 -0.8277 -0.0421 -0.4088 -0.1851 -1.2994 -0.0212 -0.6306 -0.0222 -0.0598 -0.4899 -0.1523 -0.2165 -0.2547 -0.3929 -0.1839 -0.0108 -0.0714 -0.1359 -0.4101 -0.1490
S-1533	In conclusion, the presence of EH denotes a distinct subset of HFpEF that is pathophysiologically similar to HF with reduced EF (HFrEF) and may benefit from HFrEF therapy.<unk>
T-1533	hfpef ; pathophysiologically ; hf with reduced ef ; hfref ; hfref ; therapy
H-1533	-0.7805067300796509	▁EH ▁; ▁ HF p EF ▁; ▁pat ho phy si ological ly ▁; ▁ HF ▁; ▁EF ▁; HF r EF ▁; ▁h Fr EF ▁ therapy
D-1533	-0.7805067300796509	EH ; HFpEF ; pathophysiologically ; HF ; EF ;HFrEF ; hFrEF therapy
P-1533	-0.0153 -0.1096 -0.8373 -0.6633 -0.1112 -0.6582 -0.0815 -4.4516 -0.1554 -0.1260 -1.3671 -0.3655 -0.9655 -0.3343 -0.2647 -0.3191 -0.1041 -3.8267 -0.0901 -1.9623 -0.1743 -0.3191 -0.2641 -1.2136 -1.3767 -1.0030 -1.4554 -0.0800 -0.5481 -0.1720
S-1520	CONCLUSIONS: In plasma collected from HF patients, immunoreactive NT-proBNP was present as multiple N- and C-terminally truncated fragments of the full length NT-proBNP molecule.<unk>
T-1520	plasma ; collected ; hf ; patients ; immunoreactive ; nt-probnp ; c-terminally ; nt-probnp
H-1520	-0.6505724191665649	▁plasma ▁collect ed ▁; ▁ HF ▁; ▁immun ore active ▁NT - pro b NP ▁; ▁N - ▁; ▁c - termin ally ▁tru nca ted ▁fragment s ▁; ▁NT - pro b NP
D-1520	-0.6505724191665649	plasma collected ; HF ; immunoreactive NT-probNP ; N- ; c-terminally truncated fragments ; NT-probNP
P-1520	-3.7671 -0.1959 -0.2678 -0.3117 -0.2500 -0.1785 -0.6946 -0.0073 -0.3785 -0.2518 -1.7117 -0.2004 -0.1250 -1.8026 -0.4245 -0.2834 -2.2185 -0.1047 -1.4905 -0.4082 -0.1328 -0.2406 -0.0267 -0.5553 -0.1303 -0.0252 -1.1444 -0.1327 -0.2474 -0.7937 -0.0920 -0.2455 -1.7065 -0.5314 -2.1099 -0.2336
S-1438	The beat-to-beat QT interval was measured on 3-min records of surface ECGs at baseline and during interventions (atrial pacing and esmolol, isoprenaline, and atropine infusion).<unk>
T-1438	qt interval ; ecgs ; baseline ; atrial pacing ; esmolol ; isoprenaline ; atropine ; infusion
H-1438	-0.5197352766990662	▁beat - to - beat ▁ QT ▁interval ▁; ▁surface ▁E CG s ▁; ▁base line ▁; at rial ▁pa cing ▁; ▁es mol ol ▁; ▁iso pren a line ▁; ▁a tropi ne ▁in fusion
D-1438	-0.5197352766990662	beat-to-beat QT interval ; surface ECGs ; baseline ;atrial pacing ; esmolol ; isoprenaline ; atropine infusion
P-1438	-0.0421 -0.0607 -0.0466 -0.0858 -0.2957 -0.2687 -0.5411 -0.2767 -0.3653 -1.3585 -3.1338 -0.5323 -0.2185 -0.4851 -0.0085 -0.0807 -0.4407 -4.6160 -0.0648 -0.0565 -0.2027 -0.1591 -1.1545 -0.4379 -1.2474 -0.4147 -0.0042 -0.0604 -0.3289 -0.0361 -0.6767 -0.0164 -0.3136 -0.1353 -0.0211 -0.2321 -1.0310 -0.2999
S-803	However, statistical improvement occurred in the total sample from the first to the second trial with large limits of agreement (mean difference, -.97s; 95% confidence interval, 3.00 to -4.94s; P<.01).<unk>
T-803	confidence interval
H-803	-0.67596036195755	▁trial ▁; ▁limit s ▁of ▁agreement
D-803	-0.67596036195755	trial ; limits of agreement
P-803	-2.8555 -1.0170 -0.0601 -0.0185 -0.1033 -0.0008 -1.0568 -0.2958
S-1377	Power spectral analysis indicated an increase in low-frequency/high-frequency (LF/HF) ratio in the CHF-INV compared with the sham-INV, which was normalized to sham levels by DNx.<unk>
T-1377	power spectral analysis ; hf ; dnx
H-1377	-0.5252317190170288	▁power ▁spec tral ▁; ▁low - fre que ncy ▁; ▁high - fre que ncy ▁; LF / HF ▁ratio ▁; ▁CHF - in v ▁; ▁sham - in v ▁; ▁sham ▁levels ▁; ▁DN x
D-1377	-0.5252317190170288	power spectral ; low-frequency ; high-frequency ;LF/HF ratio ; CHF-inv ; sham-inv ; sham levels ; DNx
P-1377	-0.0486 -0.5373 -0.0829 -1.1150 -0.5983 -0.1108 -0.6396 -0.4627 -0.0473 -0.5858 -0.9244 -0.1213 -0.4745 -0.3610 -0.0931 -0.3231 -0.4965 -3.3831 -0.0848 -0.1670 -0.1210 -0.2302 -0.1440 -0.3085 -0.6327 -0.0876 -0.4466 -0.4680 -0.2782 -0.5692 -0.2658 -3.5222 -0.2062 -0.4682 -0.1962 -0.2989 -0.7708 -0.2873
S-524	Although contractility remained unchanged, ventricular-arterial coupling was markedly improved (p = 0.002), resulting in a higher SV (p < 0.0001) in the ivabradine-treated patients.<unk>
T-524	contractility ; ventricular-arterial coupling ; patients
H-524	-0.44300469756126404	▁contract ility ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁i va bra dine - tre ated ▁patients
D-524	-0.44300469756126404	contractility ; ventricular-arterial coupling ; ivabradine-treated patients
P-524	-0.0142 -0.5014 -0.0993 -0.5947 -0.9192 -0.3445 -0.1632 -0.0244 -0.2102 -0.0757 -0.1921 -0.3323 -0.1909 -1.3793 -0.4281 -0.3241 -0.5566 -0.9559 -0.3625 -1.7120 -0.1883 -0.1773
S-721	OBJECTIVES: The study objectives were to quantify the change in 7-day follow-up visits and 30-day readmissions as part of a hospital quality improvement initiative and to characterize events at 7-day follow-up visits.<unk>
T-721	change ; follow-up ; readmissions ; hospital ; follow-up
H-721	-0.6939147114753723	▁follow - up ▁visit s ▁; ▁30- day ▁read missions ▁; ▁hospital ▁quality ▁improvement
D-721	-0.6939147114753723	follow-up visits ; 30-day readmissions ; hospital quality improvement
P-721	-1.7621 -0.0926 -0.0466 -0.4837 -0.0646 -0.1804 -2.5162 -0.2737 -0.4718 -0.0275 -0.2058 -0.5439 -1.2118 -0.2423 -2.7462 -0.2336
S-1511	BACKGROUND: The use of nonstandardized N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays can contribute to the misdiagnosis of heart failure (HF).<unk>
T-1511	n-terminal pro-b-type natriuretic peptide ; nt-probnp ; misdiagnosis ; heart failure ; hf
H-1511	-0.4297511577606201	▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁mis diagnos is ▁; ▁heart ▁failure ▁; HF
D-1511	-0.4297511577606201	N-terminal pro-B-type natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
P-1511	-3.9185 -0.0653 -0.0428 -0.0106 -0.0361 -0.0395 -1.0363 -0.1036 -0.4458 -0.0075 -0.5646 -0.0779 -0.3156 -0.1087 -0.5073 -1.5839 -0.3225 -0.2895 -0.0226 -0.0585 -0.5259 -0.2127 -0.4372 -0.1719 -0.1990 -0.6031 -0.7500 -0.2149 -0.1500 -0.6695 -0.0771 -0.4328 -0.1807
S-743	CONCLUSIONS: In the present preliminary study, cardiac magnetic resonance postcontrast T1 time is associated with prognosis in HFPEF, suggesting postcontrast T1 as possible biomarker for HFPEF.<unk>
T-743	cardiac magnetic resonance postcontrast t1 time ; prognosis ; hfpef ; postcontrast t1 ; biomarker ; hfpef
H-743	-0.591147243976593	▁cardiac ▁magnetic ▁res on ance ▁; ▁post contra st ▁t 1 ▁; ▁h FP EF ▁; ▁post contra st ▁t 1 ▁; ▁bio mark er ▁; ▁h FP EF
D-743	-0.591147243976593	cardiac magnetic resonance ; postcontrast t1 ; hFPEF ; postcontrast t1 ; biomarker ; hFPEF
P-743	-0.2806 -0.0624 -0.1680 -0.1074 -0.0595 -0.6796 -1.2819 -0.0714 -0.0487 -0.8046 -0.2210 -0.9968 -1.0574 -2.2861 -0.8810 -0.5273 -0.2485 -0.0814 -0.0612 -0.5609 -0.2147 -0.2254 -2.0491 -0.0449 -0.3003 -0.2554 -0.7473 -2.4092 -1.0622 -0.3374 -0.1943
S-698	METHODS AND RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care.<unk>
T-698	hf-action ; randomized ; patients ; left ventricular ejection fraction ; new york heart association class ii ; hf ; exercise ; training
H-698	-0.8801747560501099	HF - ac tion ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁New ▁York ▁Heart ▁association ▁; ▁IV ▁ HF ▁; ▁exercise ▁training
D-698	-0.8801747560501099	HF-action ; left ventricular ejection fraction ; New York Heart association ; IV HF ; exercise training
P-698	-2.2900 -0.2279 -1.7373 -1.7067 -0.3973 -0.2797 -3.2855 -2.0462 -0.5349 -0.2323 -0.3151 -0.3427 -1.2672 -0.0253 -0.2436 -0.3929 -0.6358 -1.4520 -0.6547 -0.5929 -0.9665 -0.2543 -0.3794 -1.1041 -0.2474 -0.6882 -2.0733 -0.2718
S-762	The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks.<unk>
T-762	myocardial dd ; collagen deposition ; titin ; obese ; diabetic ; zsf1 ; heart failure with preserved ejection fraction
H-762	-0.28583258390426636	▁my o card ial ▁ DD ▁; ▁collage n ▁de position ▁; ▁titi n ▁modification ▁; ▁obes e ▁; ▁diabet ic ▁z SF 1 ▁rat s ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction
D-762	-0.28583258390426636	myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic zSF1 rats ; heart failure ; preserved ejection fraction
P-762	-0.3331 -0.0666 -0.2757 -0.0452 -1.0631 -0.0991 -0.2282 -0.0938 -0.1245 -0.0596 -0.0814 -0.1645 -0.1179 -0.0434 -0.8588 -0.1973 -0.1138 -0.0705 -0.1661 -0.0314 -0.0061 -1.3111 -0.6189 -0.5518 -0.1932 -0.0793 -0.2646 -0.3167 -0.0626 -0.3655 -0.7613 -0.1835 -0.2728 -0.0270 -0.1157 -0.1833 -0.8203 -0.0125 -0.8620 -0.1911
S-1049	Detailed transcriptional analysis of cardiac tissue from mice that were either TAC- or sham-operated and treated with either JQ1 or vehicle revealed that BET inhibition suppresses a pathological cardiac gene expression programme.<unk>
T-1049	cardiac ; jq1 ; bet ; pathological ; cardiac ; gene expression
H-1049	-0.48069867491722107	▁cardiac ▁tissu e ▁; ▁mi ce ▁; ▁ TAC - ▁; ▁sham - opera ted ▁; ▁j q 1 ▁; ▁vehicle ▁; ▁ BET ▁inhibi tion ▁; ▁path ological ▁cardiac ▁gene ▁expression ▁programme
D-1049	-0.48069867491722107	cardiac tissue ; mice ; TAC- ; sham-operated ; jq1 ; vehicle ; BET inhibition ; pathological cardiac gene expression programme
P-1049	-2.5351 -1.1378 -0.6558 -0.2924 -0.5813 -0.1977 -0.1929 -0.3894 -0.0281 -0.3587 -1.2239 -0.1079 -0.0846 -0.0052 -0.1006 -0.1833 -0.7327 -2.3834 -0.3188 -0.0978 -0.1260 -0.2320 -0.4959 -0.0891 -0.5246 -0.0849 -0.3793 -0.1000 -0.1704 -0.6718 -1.2718 -0.0266 -0.2097 -0.5303 -0.3045
S-1624	Cox-proportional hazard models and negative binomial regression models were used to assess the relationship between the intervention and survival and utilization, controlling for demographic and health characteristics that were statistically different between groups after matching.<unk>
T-1624	cox-proportional hazard models ; negative binomial regression models ; health
H-1624	-0.4193389415740967	▁co x - propor tional ▁hazard ▁models ▁; ▁negative ▁bi nom ial ▁re gression ▁models ▁; ▁survival ▁; ▁health
D-1624	-0.4193389415740967	cox-proportional hazard models ; negative binomial regression models ; survival ; health
P-1624	-0.1178 -0.0725 -0.0474 -0.0252 -0.0249 -1.3284 -0.1796 -0.2884 -0.0282 -0.0312 -1.0982 -0.0067 -0.0243 -0.0100 -0.1650 -0.6175 -1.1243 -0.4232 -2.3857 -0.6158 -0.1920
S-277	Systolic blood pressure was significantly elevated and left ventricular (LV) hypertrophy was found in AT, AN, AS, and ANS mice, and there were no significant differences in those parameters between the four groups.<unk>
T-277	systolic blood pressure ; elevated ; left ventricular ; hypertrophy
H-277	-0.8711283206939697	▁Sy sto lic ▁blood ▁pressure ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁hyper trop hy ▁; ▁AT ▁; ▁AN ▁; ▁AS ▁; ▁ ANS
D-277	-0.8711283206939697	Systolic blood pressure ; left ventricular ;LV ; hypertrophy ; AT ; AN ; AS ; ANS
P-277	-1.6373 -0.1940 -0.7185 -2.4448 -0.3101 -0.2336 -0.3816 -3.3520 -1.0259 -0.6386 -0.6350 -0.9029 -1.4356 -1.0259 -0.1545 -1.1378 -0.2666 -0.7341 -0.6816 -0.9813 -0.4656 -1.6491 -0.5806 -0.6956 -0.0735 -0.9519 -0.2124
S-642	Conversely, conditional gene-targeted Hand2 mice demonstrated a marked resistance to pressure-overload-induced hypertrophy, fibrosis, ventricular dysfunction and induction of a fetal gene program.<unk>
T-642	hand2 ; hypertrophy ; fibrosis ; ventricular dysfunction ; gene
H-642	-0.45208415389060974	▁condition al ▁gene - tar get ed ▁hand 2 ▁mi ce ▁; ▁pressure - over load - indu ced ▁hyper trop hy ▁; ▁fibro sis ▁; ▁vent ri cular ▁dys function ▁; ▁fet al ▁gene ▁program
D-642	-0.45208415389060974	conditional gene-targeted hand2 mice ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene program
P-642	-0.0420 -0.0500 -1.9065 -0.1796 -0.0631 -0.2503 -0.0504 -1.0673 -0.0758 -0.4954 -0.3014 -0.2203 -0.0574 -0.1445 -0.0844 -0.5026 -0.4737 -0.1962 -0.7599 -0.4396 -0.1498 -2.1453 -0.2710 -0.0108 -0.9679 -0.1936 -0.4442 -0.7370 -0.3942 -0.1899 -1.0088 -0.2729 -0.4960 -0.0409 -0.8168 -1.0793 -0.3468 -0.2540
S-264	To our best knowledge, our study is the first research done to identify a predictive cutoff value for admission NT-proBNP to the prescriptive 4-year survival of patients admitted to ED with acute HF diagnosis.<unk>
T-264	admission ; nt-probnp ; patients ; acute hf ; diagnosis
H-264	-0.6708258986473083	▁ad mission ▁; ▁NT - pro b NP ▁; ▁ad mission ▁; ▁ED ▁; ▁a cute ▁ HF ▁ diagnos is
D-264	-0.6708258986473083	admission ; NT-probNP ; admission ; ED ; acute HF diagnosis
P-264	-1.5986 -0.0273 -1.6001 -0.1198 -0.0586 -0.0237 -0.5681 -0.2625 -0.1446 -2.4323 -0.3375 -0.2565 -3.8051 -0.1172 -0.1266 -0.0276 -0.2062 -0.2189 -1.7313 -0.3307 -0.8107 -0.3421 -0.2832
S-1943	Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus ≥70 bpm (17.5±5.5 versus 14.4±3.3 mL/min/kg, respectively; P value=0.038).<unk>
T-1943	peak oxygen consumption ; vo2max ; resting hr ; bpm ; p value
H-1943	-0.6160675883293152	▁Peak ▁oxygen ▁consum p tion ▁; VO 2 max ▁; ▁rest ing ▁HR
D-1943	-0.6160675883293152	Peak oxygen consumption ;VO2max ; resting HR
P-1943	-0.0445 -1.5852 -0.5174 -0.0620 -0.2980 -0.3079 -0.1958 -0.1613 -0.0498 -0.3976 -1.6657 -0.0566 -1.3916 -2.3568 -0.1510
S-1747	During follow-up, 271 patients (45%) reached a combined end point including death (heart failure related, n=142; sudden death, n=71; and noncardiac, n=22) or cardiac transplant (n=36).<unk>
T-1747	follow-up ; patients ; combined end point ; death ; heart failure ; death ; cardiac transplant
H-1747	-0.711223840713501	▁heart ▁failure ▁; ▁sud den ▁death ▁; ▁non card iac ▁; ▁cardiac ▁transplant
D-1747	-0.711223840713501	heart failure ; sudden death ; noncardiac ; cardiac transplant
P-1747	-8.0116 -0.0681 -0.4642 -0.1787 -0.0014 -0.6907 -0.1721 -0.0119 -0.1042 -0.0639 -0.2668 -0.0898 -0.0740 -0.2329 -0.2380
S-625	METHODS: We assessed the association between frailty, using the Health ABC Short Physical Performance Battery (HABC Battery) and the Gill index, and incident HF in 2825 participants aged 70 to 79 years.<unk>
T-625	frailty ; health abc short physical performance battery ; habc battery ; gill index ; hf
H-625	-0.689164400100708	▁fra il ty ▁; ▁health ▁ABC ▁; ▁short ▁physical ▁performance ▁Bat tery ▁; ▁h ABC ▁Bat tery ▁; ▁Gill ▁index ▁; ▁incident ▁; ▁ HF
D-625	-0.689164400100708	frailty ; health ABC ; short physical performance Battery ; hABC Battery ; Gill index ; incident ; HF
P-625	-4.6880 -0.1886 -0.7246 -0.1759 -0.4701 -0.3079 -0.9354 -0.9312 -0.6889 -0.2532 -1.0451 -0.0307 -0.0738 -1.3645 -1.3292 -1.9604 -0.0234 -0.0835 -0.1910 -0.0583 -0.1259 -0.6006 -1.1947 -0.5954 -0.1906 -0.2091 -0.1678
S-1053	This study implicates epigenetic readers in cardiac biology and suggests that the manipulation of cardiac gene control via the targeting of chromatin-dependent signal transduction could potentially abrogate pathological gene expression and HF progression.<unk>
T-1053	epigenetic ; cardiac ; cardiac ; gene ; signal transduction ; pathological ; gene expression ; hf
H-1053	-0.3711925446987152	▁epi gene tic ▁readers ▁; ▁cardiac ▁bi ology ▁; ▁cardiac ▁gene ▁control ▁; ▁chr omat in - dependent ▁signal ▁trans duction ▁; ▁path ological ▁gene ▁expression ▁; ▁ HF ▁progression
D-1053	-0.3711925446987152	epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; pathological gene expression ; HF progression
P-1053	-0.5850 -0.0580 -0.0568 -0.4199 -0.2562 -0.0793 -0.2247 -0.0856 -0.2182 -1.4956 -1.4298 -0.5534 -0.2084 -0.1523 -0.0305 -1.0426 -0.2445 -0.0405 -0.5778 -0.2072 -0.3083 -0.2698 -0.3462 -0.1187 -1.2755 -0.1148 -0.1711 -0.0904 -0.0743 -0.3870 -0.5572 -0.1988
S-1193	In conclusion, a simple clinical prediction rule can accurately identify patients with CAD and eliminate the need for angiography in a substantial proportion of patients with systolic HF, with potentially significant cost savings and risk avoidance.<unk>
T-1193	clinical ; rule ; patients ; cad ; angiography ; patients ; systolic hf ; cost
H-1193	-0.4703885018825531	▁clinic al ▁predict ion ▁rule ▁; ▁CAD ▁; ▁ang i ography ▁; ▁sy sto lic ▁ HF
D-1193	-0.4703885018825531	clinical prediction rule ; CAD ; angiography ; systolic HF
P-1193	-2.1643 -0.0236 -0.1220 -0.0169 -0.0566 -0.1805 -1.2978 -0.0816 -0.1738 -0.4394 -0.4255 -0.1309 -0.8894 -0.1588 -0.5571 -0.1445 -0.0372 -1.8194 -0.2182
S-1176	Work load-corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up tests) showed a slower increase in heart rate during exercise than in the placebo-treated group.<unk>
T-1176	chronotropic response ; heart rate ; exercise ; baseline ; follow-up ; tests ; heart rate ; exercise
H-1176	-0.5848250389099121	▁load - corre cted ▁chr ono tropi c ▁response ▁; ▁heart ▁rate ▁; ▁base line ▁; ▁follow - up ▁tests ▁; ▁heart ▁rate
D-1176	-0.5848250389099121	load-corrected chronotropic response ; heart rate ; baseline ; follow-up tests ; heart rate
P-1176	-0.9060 -0.2181 -0.0141 -0.0819 -0.8094 -0.2951 -0.9008 -0.9044 -0.9816 -0.2287 -1.8658 -0.0855 -0.3684 -0.2252 -0.0225 -0.2620 -0.1223 -0.1349 -0.0374 -0.0421 -0.5357 -2.4963 -0.0948 -2.8180 -0.1696
S-1961	One (10%) patient was admitted to hospital with gastrointestinal bleeding at month 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal heart failure 2 months post-procedure.<unk>
T-1961	patient ; hospital ; gastrointestinal bleeding ; patient ; ventricular tachycardia ; terminal heart failure
H-1961	-0.6719825267791748	▁hospital ▁; ▁gastro inte stin al ▁ble ed ing ▁; ▁die d ▁; ▁ince ssant ▁vent ri cular ▁ta chy car dia ▁storm ▁; ▁terminal ▁heart ▁failure
D-1961	-0.6719825267791748	hospital ; gastrointestinal bleeding ; died ; incessant ventricular tachycardia storm ; terminal heart failure
P-1961	-3.0192 -0.1479 -0.0589 -0.0485 -1.0991 -0.0506 -0.1412 -0.0989 -0.0705 -0.2454 -5.4472 -0.2282 -0.2666 -0.2315 -0.0079 -0.7682 -0.6008 -0.1183 -0.6279 -1.1102 -1.3011 -1.9000 -0.0035 -0.1934 -0.8051 -0.4297 -0.0834 -0.2121 -0.1721
S-1601	Catheter-based percutaneous revascularization with angioplasty and stenting showed modest clinical benefit for patients in small retrospective studies, but data from randomized clinical trials failed to confirm these beneficial results.<unk>
T-1601	percutaneous ; revascularization ; angioplasty ; stenting ; clinical ; patients ; randomized ; clinical
H-1601	-0.4537471830844879	▁Cat heter - based ▁per cuta ne ous ▁re vas cular ization ▁; ▁ang io plast y ▁; ▁sten ting
D-1601	-0.4537471830844879	Catheter-based percutaneous revascularization ; angioplasty ; stenting
P-1601	-1.3571 -0.0097 -0.1085 -0.0543 -0.1013 -0.0039 -0.1191 -0.3764 -0.0300 -0.0567 -0.3508 -0.2687 -0.4820 -0.0063 -2.5027 -0.4099 -0.3249 -0.4694 -0.0218 -0.1251 -2.6693 -0.1347
S-1251	In a pilot study, five patients with HF and T2D consumed ERC for 3 months; treadmill testing [VO2max (maximum oxygen consumption)] and SkM biopsies were performed.<unk>
T-1251	patients ; hf ; t2d ; erc ; vo2max ; maximum oxygen consumption ; skm ; biopsies
H-1251	-0.29070883989334106	▁ HF ▁; ▁t 2 d ▁; ▁ ERC ▁; ▁tre ad m ill ▁testing ▁; VO 2 max ▁; ▁oxygen ▁consum p tion ▁; ▁Sk m ▁bio psi es
D-1251	-0.29070883989334106	HF ; t2d ; ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
P-1251	-1.0988 -0.3080 -0.1138 -0.1206 -0.0357 -0.4659 -0.1443 -0.2573 -0.2654 -0.1088 -0.0374 -0.0763 -0.0794 -0.0341 -0.6872 -0.0451 -0.3260 -0.0583 -0.0207 -0.0948 -1.3369 -0.3918 -0.0405 -0.2340 -0.5660 -0.2916 -0.0781 -1.0059 -0.1999 -0.2150 -0.4086 -0.1564
S-758	CONCLUSIONS: Among subjects with mild HF, QRS prolongation, and LVEF >30%, CRT produced reverse remodeling and similar clinical benefit compared with subjects with more severe LV systolic dysfunction.<unk>
T-758	mild hf ; qrs prolongation ; lvef ; crt ; reverse remodeling ; clinical ; systolic dysfunction
H-758	-0.6224995255470276	▁ HF ▁; ▁QR s ▁prolong ation ▁; ▁LV EF ▁; ▁c RT ▁; ▁rever se ▁remodel ing ▁; ▁LV ▁sy sto lic ▁dys function
D-758	-0.6224995255470276	HF ; QRs prolongation ; LVEF ; cRT ; reverse remodeling ; LV systolic dysfunction
P-758	-0.3651 -0.1699 -0.1194 -0.1165 -1.9281 -0.6648 -0.0794 -0.1650 -0.4382 -0.1819 -0.0364 -1.1950 -2.6278 -0.1309 -0.0037 -0.0156 -0.0452 -0.0297 -0.1163 -2.6349 -2.6125 -0.1365 -0.7084 -0.2747 -1.3815 -0.4887 -0.1412
S-295	Patients requiring temporary RV support after LVAD insertion are a heterogeneous group of patients consisting of those in cardiogenic shock after myocardial infarction, to those with chronic decompensated heart failure.<unk>
T-295	patients ; rv support ; lvad ; patients ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
H-295	-0.5961335897445679	▁ RV ▁; ▁l VAD ▁ insertion ▁; ▁cardio ge nic ▁shock ▁; ▁my o card ial ▁in far ction ▁; ▁chronic ▁de com pensa ted ▁heart ▁failure
D-295	-0.5961335897445679	RV ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure
P-295	-1.1133 -0.6307 -1.2732 -3.0456 -0.2693 -2.1412 -0.0200 -0.4140 -0.2482 -0.0624 -0.0832 -1.0872 -0.3591 -0.9838 -0.3938 -1.5470 -0.0835 -0.0526 -0.5553 -0.2505 -0.3396 -0.4882 -0.1227 -0.3709 -0.0245 -0.0972 -0.7316 -0.1294 -0.5723 -0.3935
S-268	During the 4-year follow-up period, 76 patients died; survivors were significantly younger than non-survivors (64.26 ± 11.42 years vs 72.83 ± 11.07 years, P = .002).<unk>
T-268	follow-up ; patients
H-268	-1.3082715272903442	
D-268	-1.3082715272903442	
P-268	-2.4405 -0.1761
S-628	Compared to non-frail participants, moderate (HR 1.36, 95% CI 1.08-1.71) and severe frailty (HR 1.88, 95% CI 1.02-3.47) by Gill index was associated with a higher risk for HF.<unk>
T-628	frailty ; gill index ; hf
H-628	-0.8922592401504517	▁non - fra il ▁; ▁ha w t ▁; ▁Gill ▁index ▁; ▁ HF
D-628	-0.8922592401504517	non-frail ; hawt ; Gill index ; HF
P-628	-1.2241 -0.0422 -0.0446 -0.0817 -0.3972 -6.4811 -0.9749 -0.9904 -1.0344 -1.2417 -0.1662 -0.4274 -0.6533 -0.1158 -0.1621 -0.2392
S-1310	Between the periods 1996-1998 and 2005-2007, the prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55).<unk>
T-1310	prevalence ; hf ; ami ; adjusted odds ratio
H-1310	-0.6844205260276794	▁ HF ▁; ▁ AMI ▁; ▁adjust ed ▁odds ▁ratio
D-1310	-0.6844205260276794	HF ; AMI ; adjusted odds ratio
P-1310	-2.0142 -0.8081 -0.1764 -0.4737 -0.7133 -0.6133 -0.8460 -0.0683 -0.0556 -0.0175 -2.1862 -0.2404
S-1357	PURPOSE OF REVIEW: Chronic heart failure (CHF) is increasingly recognized as a multisystem disease with important comorbidities such as anemia, insulin resistance, autonomic dysbalance, or cardiac cachexia.<unk>
T-1357	chronic heart failure ; chf ; multisystem disease ; comorbidities ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
H-1357	-0.2384747713804245	▁Chro nic ▁heart ▁failure ▁; CH f ▁; ▁multi system ▁disease ▁; ▁an emia ▁; ▁insulin ▁resist ance ▁; ▁autonomi c ▁dys balance ▁; ▁cardiac ▁cache xia
D-1357	-0.2384747713804245	Chronic heart failure ;CHf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
P-1357	-0.2948 -0.0351 -1.2344 -0.0723 -0.2362 -0.2977 -0.4997 -0.2727 -0.4526 -0.0414 -1.1821 -0.1365 -0.0349 -0.0623 -0.1359 -0.0181 -0.0415 -0.0154 -0.2814 -0.0076 -0.4581 -0.1199 -0.0871 -0.1764 -0.0239 -0.0152 -0.2471 -0.2825 -0.1530
S-1214	Chronic β-AR stimulation via catecholamine infusions in rats enhanced PDE2 expression ~2-fold and cAMP hydrolytic activity ~4-fold, which correlated with blunted cardiac β-AR responsiveness.<unk>
T-1214	chronic ; β-ar ; catecholamine ; infusions ; pde2 ; expression ; camp ; activity ; correlated ; cardiac ; β-ar responsiveness
H-1214	-0.32975906133651733	▁Chro nic ▁β - AR ▁stimul ation ▁; ▁cate chol amine ▁in fusion s ▁; ▁rat s ▁; ▁p de 2 ▁expression ▁; ▁c AMP ▁hydro ly tic ▁activity ▁; ▁blu n ted ▁cardiac ▁β - AR ▁responsive ness
D-1214	-0.32975906133651733	Chronic β-AR stimulation ; catecholamine infusions ; rats ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac β-AR responsiveness
P-1214	-0.9379 -0.0104 -0.1830 -0.0350 -0.3115 -0.6673 -0.0732 -0.7609 -0.0241 -0.0751 -0.5854 -0.0580 -0.0198 -0.1571 -0.2734 -0.1066 -0.0487 -0.7404 -0.4534 -2.3905 -0.1611 -0.0455 -0.1162 -0.0303 -0.3963 -0.0362 -0.7039 -0.4492 -0.0837 -0.2234 -0.3441 -0.0744 -0.0713 -0.0408 -0.6213 -0.0402 -0.3186 -0.6691 -0.2372 -0.7399 -0.2057
S-1096	In chronic PAH, we will examine clinical circumstances common to hospitalized patients that may provoke acute RV decompensation, as well as pharmacologic therapies that are unique to RV failure management in PAH.<unk>
T-1096	chronic pah ; clinical ; hospitalized ; patients ; acute ; rv decompensation ; pharmacologic ; therapies ; rv failure ; pah
H-1096	-0.49877843260765076	▁chronic ▁p AH ▁; ▁hospital ized ▁patients ▁; ▁a cute ▁ RV ▁de com pensa tion ▁; ▁ pharma c ologic ▁ therapie s ▁; ▁ RV ▁failure ▁management ▁; ▁p AH
D-1096	-0.49877843260765076	chronic pAH ; hospitalized patients ; acute RV decompensation ; pharmacologic therapies ; RV failure management ; pAH
P-1096	-0.2381 -2.3215 -0.1665 -0.4750 -2.1989 -0.1685 -1.3731 -0.2305 -0.1816 -0.0135 -0.1489 -0.4665 -0.1858 -0.6860 -0.0418 -0.0972 -0.5283 -0.2239 -0.3355 -0.0948 -0.1763 -2.1190 -0.0854 -0.1339 -0.2412 -0.3206 -0.7018 -0.1194 -0.4190 -0.5469 -1.0965 -0.1161 -0.4064 -0.2999
S-767	Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD.<unk>
T-767	obese ; zsf1 ; heart failure with preserved ejection fraction ; lung ; preserved left ventricular ejection fraction ; left ventricular dd
H-767	-0.8606703281402588	▁z f 1 ▁groups ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction ▁; ▁lung ▁weight ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁ DD
D-767	-0.8606703281402588	zf1 groups ; heart failure ; ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular DD
P-767	-0.8495 -1.7094 -0.6163 -0.7607 -0.2546 -2.0119 -0.1618 -0.1601 -1.4880 -0.3469 -0.1836 -0.4718 -0.0140 -0.2725 -0.9893 -0.2887 -0.1276 -3.2298 -3.6684 -1.0517 -0.2651 -0.4569 -0.5026 -0.5543 -0.8140 -0.0241 -0.3402 -0.3640 -3.3453 -1.2550 -0.2510 -1.7095 -0.7371 -0.6262 -0.2216
S-470	Xanthine oxidase (XO) is increased in human and rat left ventricular (LV) myocytes with volume overload (VO) of mitral regurgitation and aortocaval fistula (ACF).<unk>
T-470	xanthine oxidase ; xo ; left ventricular ; myocytes ; volume overload ; vo ; mitral regurgitation ; aortocaval fistula ; acf
H-470	-0.40125760436058044	▁Xan thi ne ▁oxid ase ▁; XO ▁; ▁rat ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁my o cy tes ▁; ▁volume ▁over load ▁; VO ▁; ▁mit ral ▁re gur gi tation ▁; ▁a orto ca val ▁fi stu la ▁; ac f
D-470	-0.40125760436058044	Xanthine oxidase ;XO ; rat ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ;acf
P-470	-0.0053 -0.9855 -0.0826 -0.0261 -0.6555 -0.3374 -0.1620 -0.4266 -3.0716 -0.9610 -0.1583 -2.2592 -0.4140 -0.2782 -0.2734 -0.6604 -0.5576 -0.4166 -0.0621 -0.0547 -0.0873 -0.2448 -0.2483 -0.0841 -0.1345 -0.3900 -0.1073 -0.4631 -0.2659 -0.2590 -0.0164 -0.0080 -0.2532 -0.0144 -0.2041 -0.0129 -0.1595 -0.0109 -0.2059 -0.2765 -0.0310 -0.3149 -0.9531 -1.4284 -0.3113 -0.3736 -0.1527
S-1055	OBJECTIVE: The purpose of this article is to evaluate a free-breathing pulse sequence to quantify myocardial T1 changes in a swine model of tachycardia-induced heart failure.<unk>
T-1055	pulse ; myocardial t1 ; heart failure
H-1055	-0.36068373918533325	▁free - bre a thing ▁puls e ▁se que nce ▁; ▁my o card ial ▁t 1 ▁; ▁s win e ▁model ▁; ▁ta chy car dia - indu ced ▁heart ▁failure
D-1055	-0.36068373918533325	free-breathing pulse sequence ; myocardial t1 ; swine model ; tachycardia-induced heart failure
P-1055	-0.0063 -0.0828 -0.0725 -0.0792 -0.8526 -0.6596 -0.0969 -0.1470 -0.0673 -0.6723 -0.2041 -0.1744 -0.1774 -0.7067 -0.0391 -1.0856 -0.2778 -0.7959 -0.2688 -0.9920 -0.1372 -0.4095 -0.1808 -0.1676 -0.1493 -0.3279 -1.5801 -0.1678 -0.0065 -0.7700 -0.2923 -0.0553 -0.3820 -0.1787
S-229	The adults were more symptomatic than the PF cohort (New York Heart Association classes I and II or III and IV: 48% or 52% [SAF] vs 94% or 6% [PF], respectively, p <0.01).<unk>
T-229	symptomatic ; new york heart association classes ; saf
H-229	-1.0062600374221802	▁ PF ▁co hor t ▁; ▁New ▁York ▁Heart ▁association ▁; ▁ SAF ▁; ▁ PF
D-229	-1.0062600374221802	PF cohort ; New York Heart association ; SAF ; PF
P-229	-2.5194 -0.9749 -1.1435 -1.4020 -0.5469 -0.1630 -1.2763 -0.6196 -2.4472 -0.8361 -0.4916 -1.3672 -1.2772 -0.3924 -1.2471 -0.5814 -0.6491 -0.1776
S-1129	The most common contextual reasons were comanagement with other clinicians (32%-35% of patients), patient preferences and nonadherence (15%-24%), and clinician belief that the medication is not indicated in the patient (12%-20%).<unk>
T-1129	clinicians ; patients ; patient ; clinician ; medication ; patient
H-1129	-0.6649837493896484	▁co management ▁; ▁clinic ians ▁; ▁patient ▁preference s ▁; ▁non adh er ence ▁; ▁medication
D-1129	-0.6649837493896484	comanagement ; clinicians ; patient preferences ; nonadherence ; medication
P-1129	-2.5848 -0.2401 -0.3729 -1.6697 -0.0888 -0.1732 -2.6052 -0.2635 -0.0539 -0.2152 -0.0924 -0.0207 -0.2113 -0.1660 -0.3833 -2.1016 -0.4779 -0.2495
S-1727	Patients cared for by the high-volume physicians had lower mortality than those by the low-volume physicians (8.9% versus 9.7%; P<0.001); this relationship was strongest in low-volume hospitals.<unk>
T-1727	patients ; physicians ; mortality ; physicians ; hospitals
H-1727	-0.5319620966911316	▁patients ▁; ▁high - volu me ▁physician s ▁; ▁mortal ity ▁; ▁low - volu me ▁physician s
D-1727	-0.5319620966911316	patients ; high-volume physicians ; mortality ; low-volume physicians
P-1727	-3.8543 -0.4042 -0.6419 -0.0594 -0.2183 -0.1755 -0.5427 -0.0815 -0.2193 -0.8029 -0.0634 -0.2440 -0.0819 -0.0844 -0.1616 -0.0543 -1.4555 -0.0771 -1.2482 -0.1687
S-1307	METHODS AND RESULTS: Western Australian linked administrative health data were used to identify 20 812 consecutive patients, aged 40 to 84 years, without prior HF hospitalized with an index (first) AMI between 1996 and 2007.<unk>
T-1307	western ; administrative ; health ; patients ; hf ; hospitalized ; ami
H-1307	-0.8621138334274292	▁western ▁Australian ▁; ▁administrative ▁health ▁data ▁; ▁ HF ▁; ▁ AMI
D-1307	-0.8621138334274292	western Australian ; administrative health data ; HF ; AMI
P-1307	-1.3411 -1.5860 -0.6354 -0.1990 -1.2750 -1.6445 -0.4788 -1.1212 -0.9648 -0.6012 -0.8127 -0.9389 -0.2213 -0.2498
S-1825	The aims of the present consensus report are to strengthen the connection between certified, experienced centers and those that care for patients irrespective of disease phase and healthcare staff, as well as to raise awareness and provide information regarding conditions in Turkey.<unk>
T-1825	report ; connection ; patients ; disease ; healthcare ; conditions ; turkey
H-1825	-0.7680793404579163	▁report ▁; ▁conditions ▁; ▁tur key
D-1825	-0.7680793404579163	report ; conditions ; turkey
P-1825	-0.3064 -0.4208 -3.6593 -0.8263 -0.2021 -0.1351 -0.2486 -0.3459
S-463	Methods and Results—Retrospective cohort of all adults presenting to 93 EDs between 1999 and 2009 with a most responsible diagnosis of heart failure (n=44 925 ED visits; mean age, 76.4 years).<unk>
T-463	retrospective cohort ; eds ; diagnosis ; heart failure
H-463	-0.9368029832839966	▁ec s ▁; ▁ diagnos is ▁; ▁heart ▁failure
D-463	-0.9368029832839966	ecs ; diagnosis ; heart failure
P-463	-2.8460 -0.2560 -0.2241 -3.2806 -0.5455 -0.3571 -1.1181 -0.3353 -0.0979 -1.0330 -0.2114
S-1403	Validating and incorporating nursing-sensitive outcome measures in future prospective experimental research can contribute to the advancement of science regarding effective treatment of older adults hospitalized with HF, while highlighting the contribution of nursing care to outcomes.<unk>
T-1403	outcome ; prospective ; hospitalized ; hf ; nursing ; outcomes
H-1403	-0.9385504126548767	▁nur sing - sensitiv e ▁outcome ▁measure s ▁; ▁science ▁; ▁ HF
D-1403	-0.9385504126548767	nursing-sensitive outcome measures ; science ; HF
P-1403	-5.3064 -0.0124 -0.0831 -0.0031 -0.4053 -0.2187 -0.3802 -0.0356 -0.2086 -1.2400 -0.0922 -4.2888 -0.2699 -1.3341 -0.1998
S-1482	miRNAs are small noncoding RNAs that regulate expression of target genes by sequence-specific binding to the 3' untranslated region of messenger RNA, which results in degradation or translational repression.<unk>
T-1482	mirnas ; rnas ; expression ; genes ; messenger rna ; repression
H-1482	-0.4008437991142273	▁mi RNA s ▁; ▁non co ding ▁ RNA s ▁; ▁regula te ▁expression ▁; ▁gene s ▁; ▁un trans la ted ▁region ▁; ▁messenger ▁ RNA ▁; ▁degrada tion ▁; ▁translation al ▁re pression
D-1482	-0.4008437991142273	miRNAs ; noncoding RNAs ; regulate expression ; genes ; untranslated region ; messenger RNA ; degradation ; translational repression
P-1482	-0.0716 -0.0063 -0.0482 -0.4614 -1.1286 -0.0229 -0.8957 -0.3674 -0.0116 -0.0703 -0.3112 -0.9566 -0.7694 -0.0725 -0.5998 -1.1761 -0.0875 -0.3082 -3.1438 -0.0207 -0.1344 -0.0119 -0.4275 -0.6984 -0.0158 -0.0966 -0.0250 -1.0778 -0.6150 -0.0779 -0.2553 -0.3724 -0.0619 -0.0212 -0.0075 -0.2490 -0.1539
S-1173	METHODS: Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n = 30) or placebo (n = 31) for 7 days in this double-blind trial.<unk>
T-1173	patients ; hfpef ; ivabradine ; placebo ; double-blind
H-1173	-0.6444199681282043	▁ HF p EF ▁; ▁i va bra dine ▁; ▁place bo ▁; ▁double - blind
D-1173	-0.6444199681282043	HFpEF ; ivabradine ; placebo ; double-blind
P-1173	-1.2338 -1.1064 -0.0671 -1.2275 -0.1287 -0.0134 -1.3445 -0.2826 -0.1056 -0.3358 -2.0394 -0.0617 -0.5928 -0.1343 -0.0797 -0.0082 -2.6374 -0.2009
S-1335	BACKGROUND: Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized.<unk>
T-1335	cardiac ; cells ; cardiac ; cells ; cardiac functions ; myocardial infarction
H-1335	-0.5949659943580627	▁Card iac ▁c - K ▁; ▁cell s ▁; ▁cardiac ▁ex plant - der i ved ▁cell s ▁; ▁cardiac ▁function s ▁; ▁my o card ial ▁in far ction
D-1335	-0.5949659943580627	Cardiac c-K ; cells ; cardiac explant-derived cells ; cardiac functions ; myocardial infarction
P-1335	-1.9996 -0.0549 -0.0212 -0.0746 -2.0301 -3.7217 -1.5782 -0.0355 -0.5312 -0.1618 -0.2812 -0.0112 -0.1524 -0.1047 -0.2128 -0.2628 -2.3756 -0.0561 -0.2735 -0.3658 -0.5481 -0.1214 -0.3928 -0.9802 -0.1700 -1.1110 -0.1104 -0.0395 -0.3841 -0.3458 -0.3250 -0.2057
S-1022	However, levels of NPs are likely to be used also to guide treatment and to assess risk of adverse outcomes in other patients at risk of developing heart failure, including those with pulmonary embolism or diabetes, or receiving chemotherapy.<unk>
T-1022	nps ; adverse outcomes ; patients ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
H-1022	-0.846164345741272	NP s ▁; ▁pulmonar y ▁e mbol ism ▁; ▁diabetes ▁; ▁che mo therapy
D-1022	-0.846164345741272	NPs ; pulmonary embolism ; diabetes ; chemotherapy
P-1022	-2.2496 -0.0591 -0.6184 -6.5131 -0.1078 -0.1641 -0.0393 -0.5337 -0.1715 -0.2541 -0.6672 -1.1034 -0.1353 -0.2736 -0.3601 -0.2883
S-2022	It is crucial for nurses to understand the pathophysiology of HF and the importance that nursing actions have on enhancing medical management to alleviate symptoms and to deter the advancement of the pathophysiologic state.<unk>
T-2022	nurses ; pathophysiology ; hf ; nursing ; medical ; symptoms ; pathophysiologic
H-2022	-0.7089887261390686	▁nurse s ▁; ▁pat ho phy si ology ▁; ▁ HF ▁; ▁medical ▁management ▁; ▁pat ho phy si ologic ▁state
D-2022	-0.7089887261390686	nurses ; pathophysiology ; HF ; medical management ; pathophysiologic state
P-2022	-2.5433 -0.0886 -0.1360 -0.9434 -0.5522 -0.1554 -1.5634 -0.1053 -0.2524 -0.2619 -0.0615 -0.1535 -0.6728 -1.1942 -0.1610 -4.8442 -0.4933 -0.3051 -0.8596 -0.2654 -0.2316 -0.2704 -0.1924
S-1691	OBJECTIVE: To combine structure, process, and outcome measures into an empirically derived composite quality measure for heart failure (HF), acute myocardial infarction (AMI), and pneumonia (PNA).<unk>
T-1691	outcome ; heart failure ; hf ; acute myocardial infarction ; ami ; pneumonia ; pna
H-1691	-0.5543209314346313	▁em pir ically ▁; ▁com posit e ▁quality ▁; ▁heart ▁failure ▁; HF ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁pneu monia ▁; ▁p na
D-1691	-0.5543209314346313	empirically ; composite quality ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pna
P-1691	-3.1827 -0.0092 -0.0687 -0.4045 -2.8536 -0.0072 -0.1030 -0.3762 -3.0444 -0.3871 -0.0354 -0.1796 -0.2156 -0.0699 -0.0381 -0.0320 -1.7036 -0.7887 -0.8158 -0.0371 -0.0251 -0.2834 -0.1306 -0.1882 -0.1824 -0.0816 -0.0045 -1.1604 -0.3422 -0.2356 -0.5419 -0.4974 -0.2668
S-1618	OBJECTIVES: To evaluate mortality and healthcare utilization effects of an intervention that combined care management and telehealth, targeting individuals with congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus.<unk>
T-1618	mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
H-1618	-0.38476741313934326	▁mortal ity ▁; ▁health care ▁; ▁tele health ▁; ▁con ges tive ▁heart ▁failure ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁mell itus
D-1618	-0.38476741313934326	mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
P-1618	-0.5369 -0.0311 -0.2171 -0.0464 -0.1055 -1.3830 -3.2237 -1.1946 -0.3130 -0.0317 -0.0704 -0.0717 -0.6401 -0.0289 -0.1506 -0.0205 -0.0899 -0.0891 -0.0202 -0.0173 -0.3371 -1.2867 -0.2411 -0.0558 -0.0211 -0.0345 -0.3110 -0.2046
S-1043	The group utilized the recently developed first-in-class inhibitor JQ1, which displaces BETs from chromatin, resulting in the suppression of downstream signalling to RNA polymerase II (Pol II).<unk>
T-1043	jq1 ; bets ; chromatin ; downstream signalling ; rna ; polymerase ii ; pol ii
H-1043	-0.45237085223197937	▁inhibi tor ▁J Q 1 ▁; ▁ BET s ▁; ▁chr omat in ▁; ▁down stream ▁signal ling ▁; ▁ RNA ▁poly mera se ▁II ▁; Pol ▁II
D-1043	-0.45237085223197937	inhibitor JQ1 ; BETs ; chromatin ; downstream signalling ; RNA polymerase II ;Pol II
P-1043	-1.5914 -0.0243 -1.8322 -2.5816 -0.3478 -0.4635 -0.7579 -0.2508 -0.2804 -0.4698 -0.1529 -0.0781 -0.7924 -0.2769 -0.0384 -0.0032 -0.0835 -0.0678 -0.2162 -0.2153 -0.0395 -0.3329 -0.1018 -0.1103 -0.1408 -0.2415 -1.3547 -0.0590 -0.5093 -0.1569
S-942	OBJECTIVES: This study sought to investigate the efficacy and safety of catheter ablation for atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFPEF).<unk>
T-942	catheter ablation ; atrial fibrillation ; patients ; heart failure with preserved ejection fraction ; hfpef
H-942	-0.42108529806137085	▁cat heter ▁ab lation ▁; ▁at rial ▁fi bril lation ▁; AF ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f EF
D-942	-0.42108529806137085	catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hfEF
P-942	-1.8488 -0.0935 -0.0378 -0.3616 -0.4012 -0.0764 -0.1311 -0.8148 -0.0416 -0.3865 -0.3840 -0.1976 -0.2418 -0.4846 -0.0594 -0.1466 -0.1280 -0.1237 -0.1200 -0.0542 -0.3824 -0.2465 -0.4983 -0.0143 -0.5601 -0.9672 -1.0125 -1.8190 -0.7525 -0.2465
S-780	BACKGROUND: Despite the growing epidemic of heart failure with preserved ejection fraction (HFpEF), no valid measure of patients' health status (symptoms, function, and quality of life) exists.<unk>
T-780	epidemic ; heart failure with preserved ejection fraction ; hfpef ; patients ; health ; symptoms ; quality of life
H-780	-0.5057705044746399	▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁health ▁status
D-780	-0.5057705044746399	heart failure ; preserved ejection fraction ;HFpEF ; health status
P-780	-3.7071 -0.1123 -0.1440 -0.2724 -0.1041 -0.1601 -0.0502 -0.2758 -0.1724 -0.4313 -0.0205 -0.3075 -0.2283 -0.0133 -0.4738 -0.3930 -1.2253 -0.1124 -1.7511 -0.1605
S-104	We used multivariate Cox proportional hazards regression modeling to identify risk factors for the development of IE (comprising hospitalization for acute coronary syndromes and/or coronary interventions during the trial) among study patients.<unk>
T-104	multivariate cox proportional hazards regression modeling ; hospitalization ; acute coronary syndromes ; coronary interventions ; patients
H-104	-0.5102547407150269	▁co x ▁proportion al ▁hazard s ▁re gression ▁model ing ▁; ▁IE ▁; ▁hospital ization ▁; ▁a cute ▁corona ry ▁syndrome s ▁; ▁corona ry ▁intervention s
D-104	-0.5102547407150269	cox proportional hazards regression modeling ; IE ; hospitalization ; acute coronary syndromes ; coronary interventions
P-104	-0.0755 -0.3809 -0.0310 -0.0290 -0.9824 -0.2112 -0.2441 -0.0079 -0.7765 -0.4268 -0.3549 -6.1345 -0.2437 -1.3852 -0.2192 -0.1933 -0.0127 -0.0172 -0.4778 -0.1261 -0.0446 -0.1058 -0.2933 -0.4780 -0.0692 -0.3178 -0.2076 -0.6669 -0.2843
S-1209	BACKGROUND: Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guanosine monophosphate (cGMP) signaling is characteristic for failing hearts.<unk>
T-1209	cyclic adenosine monophosphate ; camp ; cyclic guanosine monophosphate ; cgmp ; hearts
H-1209	-0.3979535400867462	▁ cycli c ▁ad enos ine ▁mono phos pha te ▁; ▁c AMP ▁; ▁ cycli c ▁gua no sine ▁mono phos pha te ▁; ▁c g m ▁; ▁signal ing ▁; ▁fail ing ▁heart s
D-1209	-0.3979535400867462	cyclic adenosine monophosphate ; cAMP ; cyclic guanosine monophosphate ; cgm ; signaling ; failing hearts
P-1209	-1.1640 -0.0469 -0.6742 -0.1980 -0.2209 -0.0686 -0.0252 -0.0054 -0.3785 -0.2894 -0.4076 -0.3143 -0.2248 -0.2308 -2.1318 -0.0590 -0.4927 -0.9853 -0.0041 -0.6376 -0.0198 -0.0138 -0.4087 -0.1937 -0.2335 -0.1775 -0.5274 -1.0357 -0.5442 -1.5171 -0.2346 -0.2754 -0.0788 -0.0362 -0.4659 -0.0724 -0.4551 -0.2734
S-604	Subjects with RA receiving methotrexate were eligible to enter the study cohort if they added or switched to a TNF antagonist or another non-biological disease modifying antirheumatic drug (nbDMARD).<unk>
T-604	ra ; methotrexate ; tnf antagonist ; non-biological disease modifying antirheumatic drug ; nbdmard
H-604	-0.5087345242500305	▁RA ▁; ▁met ho tre xa te ▁; ▁t NF ▁anta gon ist ▁; ▁non - bi ological ▁disease ▁; ▁anti r heu matic ▁drug ▁; n b DM ARD
D-604	-0.5087345242500305	RA ; methotrexate ; tNF antagonist ; non-biological disease ; antirheumatic drug ;nbDMARD
P-604	-0.5325 -0.3669 -0.4526 -0.3837 -0.6627 -1.4454 -0.2611 -0.2839 -0.8258 -0.5866 -0.1305 -0.2412 -0.2238 -0.1258 -0.0946 -0.0753 -0.5208 -0.1757 -1.0041 -0.5166 -0.0464 -1.7578 -1.5411 -0.0946 -0.3707 -0.5438 -0.9604 -0.0045 -1.1653 -0.2205 -0.3933 -0.2717
S-1360	This intestinal dysfunction and disturbed intestinal barrier may lead to both the chronic inflammatory state and catabolic/anabolic imbalance as seen in cardiac cachexia, as a terminal stage of CHF, which carries a particularly poor prognosis.<unk>
T-1360	intestinal dysfunction ; intestinal ; lead ; chronic ; inflammatory ; catabolic ; anabolic ; cardiac cachexia ; terminal ; chf ; prognosis
H-1360	-0.35526779294013977	▁intestinal ▁dys function ▁; ▁disturb ed ▁intestinal ▁barrier ▁; ▁chronic ▁infla mma tory ▁state ▁; ▁cata bo lic ▁; ana bo lic ▁im balance ▁; ▁cardiac ▁cache xia ▁; ▁CHF
D-1360	-0.35526779294013977	intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
P-1360	-0.0743 -0.5230 -1.1369 -0.0878 -0.1440 -0.0190 -0.2520 -0.1087 -0.2635 -0.1409 -0.4779 -1.1606 -0.0386 -0.0411 -0.1284 -0.0424 -0.1759 -1.0727 -1.5099 -0.6875 -0.4471 -0.9705 -0.0507 -0.0211 -0.1184 -0.0208 -0.0121 -0.1054 -0.2142 -0.8668 -0.3019 -0.1543
S-998	The described report deals with the case of a patient with diagnosis of ischemic-hypertensive cardiomyiopathy based on the history of angina and inducible myocardial ischemia with normal coronary arteries.<unk>
T-998	report ; patient ; diagnosis ; ischemic-hypertensive cardiomyiopathy ; angina ; myocardial ischemia ; coronary arteries
H-998	-0.6148694157600403	▁report ▁; ▁ ische mic - hy per tensi ve ▁cardio my io pathy ▁; ▁ang ina ▁; ▁induc ible ▁my o card ial ▁ ische mia ▁; ▁corona ry ▁arteri es
D-998	-0.6148694157600403	report ; ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
P-998	-0.0350 -0.1607 -0.8103 -1.0340 -0.2674 -0.0777 -0.2880 -0.2066 -0.8764 -0.7175 -0.5378 -1.9569 -5.2594 -0.6193 -0.2496 -0.2152 -0.1898 -0.1755 -0.0008 -0.9666 -1.3288 -0.1906 -0.8972 -0.0559 -0.1441 -1.1204 -0.6939 -0.3254 -0.5716 -0.0469 -0.0647 -0.2440 -0.4068 -0.1708
S-1405	BACKGROUND: The sphingosine-1-phosphate receptor 1 (S1PR1) and β1-adrenergic receptor (β1AR) are G-protein-coupled receptors expressed in the heart.<unk>
T-1405	sphingosine-1-phosphate receptor 1 ; s1pr1 ; β1-adrenergic receptor ; β1ar ; g-protein-coupled receptors ; heart
H-1405	-0.4277145564556122	▁sp hing os ine -1 - phos pha te ▁receptor ▁; ▁s 1 PR ▁; ▁β 1- ad r energi c ▁receptor ▁; β 1 AR ▁; ▁g - prote in - co up led ▁receptor s ▁; ▁heart
D-1405	-0.4277145564556122	sphingosine-1-phosphate receptor ; s1PR ; β1-adrenergic receptor ;β1AR ; g-protein-coupled receptors ; heart
P-1405	-0.1287 -0.6178 -0.4128 -0.4808 -1.0547 -0.2427 -0.0234 -0.6913 -0.2812 -0.0078 -0.4906 -0.1842 -0.2562 -0.8901 -1.8200 -0.1755 -0.5471 -1.3026 -0.5053 -1.7334 -0.6525 -0.0148 -0.3742 -0.4865 -0.3643 -0.7116 -0.4773 -0.1433 -0.1103 -0.0377 -0.3526 -0.1386 -0.0137 -0.0913 -0.0081 -0.0493 -0.1558 -0.4310 -0.5532 -0.3430 -0.1805
S-484	E/e'septal correlated more strongly with PCWP (r = 0.53) compared with E/e'lateral (r = 0.41) and E/e'mean (r = 0.50; all p values <0.001).<unk>
T-484	septal ; correlated ; pcwp ; p values
H-484	-1.253198266029358	▁e ▁; sept al ▁cor related ▁; ▁PC WP ▁; ▁e / e ▁; lateral ▁; ▁e / e ▁; me an
D-484	-1.253198266029358	e ;septal correlated ; PCWP ; e/e ;lateral ; e/e ;mean
P-484	-0.9318 -5.3033 -0.4131 -0.0931 -2.0361 -0.1787 -0.1838 -0.3505 -2.0338 -0.1815 -0.4928 -2.8518 -0.0952 -4.0350 -0.3864 -0.2307 -0.5888 -3.1062 -0.0753 -5.1857 -0.1086 -0.4399 -0.4018 -0.3728
S-864	The risk of inappropriate therapy caused by atrial fibrillation was also reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p = 0.004).<unk>
T-864	therapy ; atrial fibrillation ; patients ; carvedilol ; metoprolol
H-864	-0.7239105105400085	▁ therapy ▁; ▁at rial ▁fi bril lation ▁; ▁car vedi lol ▁; ▁met o pro lol
D-864	-0.7239105105400085	therapy ; atrial fibrillation ; carvedilol ; metoprolol
P-864	-4.7670 -0.4209 -0.6057 -0.3578 -0.2078 -1.3997 -0.0909 -1.2103 -0.2460 -0.5734 -0.1022 -0.3538 -0.2946 -0.4301 -0.4208 -0.2029 -0.6004 -1.1812 -0.2886
S-1379	Bradycardia induced by intravenous metoprolol (indicative of cardiac sympathetic tone) was exacerbated in CHF-INV rabbits compared with sham-INV but was normalized in CHF-DNx.<unk>
T-1379	bradycardia ; intravenous ; metoprolol ; cardiac ; sympathetic tone
H-1379	-0.47378653287887573	▁Brad y car dia ▁induc ed ▁; ▁intra ven ous ▁met o pro lol ▁; ▁cardiac ▁sympa the tic ▁tone ▁; ▁CHF - in v ▁rabbi ts ▁; ▁sham - in v ▁; ▁CHF - DN x
D-1379	-0.47378653287887573	Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone ; CHF-inv rabbits ; sham-inv ; CHF-DNx
P-1379	-0.0138 -0.1181 -1.0807 -2.9192 -0.0652 -0.0726 -0.5922 -0.0536 -0.0510 -1.8805 -0.4855 -0.1545 -0.1889 -0.9479 -0.1756 -0.0538 -0.5240 -1.3752 -0.6052 -0.3807 -0.5279 -0.4402 -0.0696 -0.3584 -0.6110 -0.2338 -0.0504 -0.2185 -0.0581 -0.0940 -0.3657 -0.4849 -0.3710 -0.6184 -0.0781 -1.1813 -0.2028 -0.5383 -0.2370
S-569	The purpose of this study was to compare, through a single-centre, parallel-group, randomized controlled trial, the effects of Nordic walking and standard cardiac rehabilitation care on functional capacity and other outcomes in patients with moderate to severe heart failure.<unk>
T-569	randomized ; walking ; cardiac rehabilitation ; functional capacity ; outcomes ; patients ; severe heart failure
H-569	-0.9209830164909363	▁Nordic ▁walking ▁; ▁standard ▁cardiac ▁rehabilita tion ▁; ▁functional ▁capacity ▁; ▁heart ▁failure
D-569	-0.9209830164909363	Nordic walking ; standard cardiac rehabilitation ; functional capacity ; heart failure
P-569	-1.2709 -2.3771 -0.1059 -0.0995 -0.3928 -0.1760 -0.0876 -0.7105 -3.1279 -0.0608 -0.3232 -4.5336 -0.0981 -0.2703 -0.1804
S-1849	Outcomes will include proportion of eligible patients who were: prescribed a CPG-recommended pharmacological treatment; referred for device consideration; provided self-care education at discharge; and provided left ventricular function assessment.<unk>
T-1849	outcomes ; patients ; prescribed ; pharmacological ; discharge ; left ventricular function
H-1849	-0.4423505961894989	▁c p - re com mend ed ▁ pharma c ological ▁treatment ▁; ▁device ▁; ▁self - care ▁; ▁dis charge ▁; ▁left ▁vent ri cular ▁function ▁assessment
D-1849	-0.4423505961894989	cp-recommended pharmacological treatment ; device ; self-care ; discharge ; left ventricular function assessment
P-1849	-0.1721 -0.3373 -0.3361 -0.0449 -0.1541 -0.0047 -0.0565 -0.2328 -0.0128 -0.3080 -0.4221 -2.3110 -0.1767 -0.8832 -0.8045 -0.6513 -0.0697 -0.0309 -0.5168 -0.3408 -0.0463 -0.3944 -0.0305 -2.2456 -1.1522 -0.3240 -0.4595 -0.1285 -0.3503 -0.2730
S-820	CONCLUSIONS: GLS was a major parameter and stronger than LVEF and Sa in predicting adverse CV events and could offer an additional prognostic benefit over conventional clinical and echocardiographic systolic parameters in AF.<unk>
T-820	gls ; lvef ; prognostic ; clinical ; echocardiographic ; systolic
H-820	-0.92098069190979	▁g ls ▁; ▁LV EF ▁; ▁sa ▁; ▁advers e ▁CV ▁events ▁; ▁prognos tic ▁benefit ▁; ▁e cho car dio graphic ▁sy sto lic ▁parameter s ▁; ▁AF
D-820	-0.92098069190979	gls ; LVEF ; sa ; adverse CV events ; prognostic benefit ; echocardiographic systolic parameters ; AF
P-820	-0.1376 -1.7438 -0.1097 -0.2396 -0.4037 -0.0919 -0.0769 -0.4154 -4.3911 -0.1816 -1.9534 -0.7254 -0.2860 -3.0982 -0.1788 -2.3743 -0.2091 -1.4072 -0.6161 -1.2560 -1.6169 -0.8330 -2.7484 -0.0694 -0.8400 -1.0487 -0.0733 -0.8094 -0.2036 -0.2576 -0.1544
S-1254	ERC induced recovery/enhancement of DAPC protein levels, sarcomeric microstructure and, in a co-ordinated fashion, alterations in markers of SkM growth/differentiation consistent with myofibre regeneration.<unk>
T-1254	erc ; dapc protein ; sarcomeric microstructure ; skm ; myofibre regeneration
H-1254	-0.5798484683036804	ERC ▁induc ed ▁recovery ▁; ▁DAP C ▁protein ▁levels ▁; ▁sar come ric ▁micro structure ▁; ▁marker s ▁; ▁Sk m ▁growth ▁; ▁my o fi bre ▁regenera tion
D-1254	-0.5798484683036804	ERC induced recovery ; DAPC protein levels ; sarcomeric microstructure ; markers ; Skm growth ; myofibre regeneration
P-1254	-0.1237 -0.3647 -0.0643 -0.0151 -0.4030 -0.0343 -1.7373 -1.9381 -0.1986 -0.3655 -0.0272 -1.1170 -1.2479 -0.7386 -0.3875 -0.3205 -1.6896 -0.0242 -0.7365 -0.0842 -0.1644 -1.7776 -0.4851 -2.2435 -0.0475 -0.1178 -0.0952 -0.7356 -0.2034 -0.3374 -0.1500
S-644	Our results reveal that signalling cascades integrate with microRNAs to induce the expression of the bHLH transcription factor Hand2 in the postnatal mammalian myocardium with impact on embryonic gene programs in heart failure.<unk>
T-644	micrornas ; expression ; bhlh ; transcription factor ; hand2 ; myocardium ; gene ; heart failure
H-644	-0.4192841947078705	▁signal ling ▁casca des ▁; ▁micro RNA s ▁; ▁b hl h ▁tran scription ▁factor ▁; ▁hand 2 ▁; ▁post na tal ▁mamma lian ▁my o car dium ▁; ▁em bry o nic ▁gene ▁programs ▁; ▁heart ▁failure
D-644	-0.4192841947078705	signalling cascades ; microRNAs ; bhlh transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
P-644	-0.5679 -0.0539 -0.0110 -0.0978 -0.3681 -0.2318 -0.0125 -0.0460 -0.2306 -0.2123 -1.4358 -0.7385 -0.8865 -0.2625 -0.1135 -1.3084 -0.7005 -0.0941 -0.1101 -0.0161 -0.3180 -0.0145 -0.0329 -0.4109 -2.0132 -0.2064 -0.5868 -1.3971 -0.2382 -0.1209 -0.0928 -0.0961 -0.1576 -1.2211 -1.0060 -0.3316 -0.1133 -0.2191 -0.4714 -0.2254
S-1674	Specifically, we have tested whether Rad Q66P limits, or even eliminates, the inhibitory actions of Rad on CaV1.2 and CaV1.3, the two L-type channel isoforms known to be expressed in the heart.<unk>
T-1674	rad ; q66p ; rad ; cav1.2 ; cav1.3 ; l-type channel ; isoforms ; heart
H-1674	-0.5700477361679077	▁Rad ▁Q 66 p ▁limit s ▁; ▁inhibi tory ▁actions ▁; ▁Rad ▁on ▁ca v 1.2 ▁; ▁ca v 1.3 ▁; ▁l - type ▁channel ▁iso form s ▁; ▁heart
D-1674	-0.5700477361679077	Rad Q66p limits ; inhibitory actions ; Rad on cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
P-1674	-0.6933 -4.0248 -0.2721 -0.2149 -1.4067 -0.0622 -0.1202 -0.2923 -0.1049 -0.5429 -0.2174 -0.3120 -1.0247 -0.2508 -1.3766 -0.4067 -0.1035 -0.1446 -1.4719 -0.5746 -0.1409 -1.2688 -0.1456 -0.2429 -0.1228 -0.0235 -0.4024 -0.1550 -0.1928 -1.3888 -0.2936 -0.2473
S-512	EF declined from 64 to 41% in the LCX model and to 44% in the LAD model 4 wk after stenting with 12 and 21% infarcted left ventricle in the LCX and LAD models, respectively.<unk>
T-512	ef ; lcx ; lad ; stenting ; infarcted ; left ventricle ; lcx ; lad
H-512	-0.7460086345672607	▁EF ▁; ▁ LC x ▁model ▁; ▁ LAD ▁; ▁sten ting ▁; ▁in far cted ▁left ▁vent ric le ▁; ▁ LC x ▁; ▁ LAD ▁models
D-512	-0.7460086345672607	EF ; LCx model ; LAD ; stenting ; infarcted left ventricle ; LCx ; LAD models
P-512	-0.0716 -0.1807 -0.8326 -0.2233 -3.3104 -1.0151 -0.0621 -0.1155 -0.1345 -0.6285 -2.5183 -0.1275 -0.1710 -0.4317 -0.0245 -0.1083 -0.1413 -1.9475 -2.3660 -0.8793 -0.1575 -0.5094 -0.1289 -3.2503 -0.1470 -0.0315 -0.0709 -1.8128 -0.7467 -0.2356
S-1531	EH was also associated with increased LV compliance compared with CH (LV end-diastolic volume at an idealized LV end-diastolic pressure of 20 mm Hg β coefficient = 14.2; 95% CI 9.4 to 19.1 ml).<unk>
T-1531	lv compliance ; lv end-diastolic volume ; lv end-diastolic pressure ; β coefficient
H-1531	-0.898367166519165	▁EH ▁; ▁LV ▁compliance ▁; ▁ lv ▁; ▁end - dia sto lic ▁volume ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; ▁h g ▁β ▁co e ffi cient ▁; ▁CI
D-1531	-0.898367166519165	EH ; LV compliance ; lv ; end-diastolic volume ; LV ; end-diastolic pressure ; hg β coefficient ; CI
P-1531	-0.3904 -0.1066 -1.2458 -0.4763 -0.0758 -5.9253 -2.9472 -0.3341 -1.5924 -0.1068 -1.3739 -0.8670 -0.6500 -0.3510 -0.0879 -2.4845 -0.4806 -0.8154 -0.0964 -1.6072 -1.1436 -0.7633 -0.5961 -0.2306 -1.7804 -0.0084 -1.1039 -0.0264 -0.1106 -0.0282 -0.0557 -0.6516 -2.1838 -0.5945 -0.1513
S-360	Possible reasons for the modest reduction in MVA could be annular size reduction by the surgical ring implantation and mild restriction of leaflet motion by the leaflet resection and edge-to-edge anastomosis.<unk>
T-360	mva ; surgical ; implantation ; leaflet ; leaflet ; edge-to-edge anastomosis
H-360	-0.3234404921531677	▁m v ▁; ▁ann ular ▁size ▁re duction ▁; ▁sur g ical ▁ring ▁implant ation ▁; ▁le a flet ▁motion ▁; ▁le a flet ▁res ection ▁; ▁edge - to - ed ge ▁an asto mos is
D-360	-0.3234404921531677	mv ; annular size reduction ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
P-360	-0.4878 -2.1153 -0.3070 -1.4196 -0.0004 -0.2935 -0.8725 -0.0044 -0.2157 -0.3995 -0.0457 -0.0311 -0.0910 -0.1912 -0.0841 -0.1396 -0.3160 -0.1022 -0.0147 -1.1964 -0.0992 -0.5609 -0.0518 -0.0794 -0.6284 -0.0072 -0.2081 -0.0026 -0.0393 -0.1194 -0.1469 -0.0318 -0.1571 -0.0184 -0.0095 -0.3721 -1.3321 -0.2522 -0.1702
S-239	HART enrolled 902 patients in the New York Heart Association (NYHA) class II or III who had been recently hospitalized for HF to study the impact of self-management counseling on the primary outcome of death or HF hospitalization.<unk>
T-239	hart ; patients ; new york heart association ; nyha ; hospitalized ; hf ; primary outcome ; death ; hf ; hospitalization
H-239	-0.7681032419204712	▁h ART ▁; ▁New ▁York ▁Heart ▁association ▁; NY HA ▁; ▁hospital ized ▁; ▁ HF ▁; ▁self - management ▁counsel ing ▁; ▁ HF ▁hospital ization
D-239	-0.7681032419204712	hART ; New York Heart association ;NYHA ; hospitalized ; HF ; self-management counseling ; HF hospitalization
P-239	-1.7067 -0.4051 -0.3506 -1.9464 -0.7777 -2.4726 -0.3848 -0.2387 -0.6611 -0.9721 -0.2713 -3.5873 -0.1895 -0.1937 -0.2040 -0.2385 -0.4712 -0.2636 -0.0942 -0.0112 -0.6344 -0.1239 -0.3041 -2.0012 -0.7726 -2.1918 -0.2226 -0.3041 -0.2798
S-1783	In vivo assessment of cardiac function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'), and systolic dysfunction by 3 weeks (16% decrease in % ejection fraction).<unk>
T-1783	in vivo ; cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
H-1783	-0.9818342328071594	▁in ▁vivo ▁assessment ▁; ▁cardiac ▁function ▁; via ▁e cho card i ography ▁; ▁dia sto lic ▁dys function ▁; ▁e ▁; ▁e je ction ▁ fraction
D-1783	-0.9818342328071594	in vivo assessment ; cardiac function ;via echocardiography ; diastolic dysfunction ; e ; ejection fraction
P-1783	-2.2963 -0.0262 -1.3504 -0.7444 -0.0443 -0.2509 -0.1002 -2.8125 -0.0560 -0.6960 -0.5490 -0.2962 -0.9472 -0.1895 -0.4711 -0.1945 -1.5393 -0.6601 -0.9912 -0.1577 -0.8321 -5.5377 -1.5828 -4.2544 -0.6116 -0.6943 -0.0281 -0.4102 -0.1491
S-1038	show that the BET family bromodomain proteins (BETs), a family of acetyl-lysine reader proteins, are central to HF pathogenesis and that they are promising targets for the prevention of HF.<unk>
T-1038	bet ; bromodomain proteins ; bets ; acetyl-lysine reader proteins ; hf ; pathogenesis ; hf
H-1038	-0.5219711065292358	▁ BET ▁; ▁bro modo main ▁protein s ▁; BET s ▁; ▁a ce tyl - ly sine ▁reader ▁protein s ▁; ▁ HF ▁path ogen es is ▁; ▁ HF
D-1038	-0.5219711065292358	BET ; bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF pathogenesis ; HF
P-1038	-1.6627 -0.1624 -1.0880 -0.2127 -0.0531 -0.2844 -2.1430 -0.0653 -0.2888 -0.7295 -0.3575 -0.0873 -0.1589 -0.0786 -0.5708 -0.0965 -2.5074 -1.3733 -0.1830 -1.4747 -0.0429 -0.1780 -0.1763 -0.2506 -0.9014 -0.2103 -0.0663 -0.4952 -0.2094 -0.2856 -0.4932 -0.1257 -0.2122
S-42	Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion.<unk>
T-42	blood transfusions ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
H-42	-0.4542185962200165	▁trans fusion s ▁; ▁ir on ▁; ▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease ▁; ▁trans fusion
D-42	-0.4542185962200165	transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
P-42	-5.2152 -0.4907 -0.2062 -0.4954 -0.0540 -0.1018 -0.4849 -0.0287 -0.2880 -0.7397 -0.1490 -1.8123 -0.2965 -1.0077 -0.0404 -0.1440 -0.1443 -0.2982 -0.0350 -0.0497 -0.0889 -0.0111 -0.1795 -0.0709 -0.4076 -0.0293 -0.1535 -0.0185 -0.0384 -0.6203 -0.8308 -1.1253 -0.0214 -0.2922 -0.1424 -0.2401
S-202	The guidelines have been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and are accompanied by practical Recommendations for their application in the clinical setting, supplemented by online material.<unk>
T-202	grade ; clinical
H-202	-0.6094855070114136	▁Grad ing ▁of ▁re com mend ations ▁assessment ▁; ▁evaluation ▁; GRAD e
D-202	-0.6094855070114136	Grading of recommendations assessment ; evaluation ;GRADe
P-202	-2.6747 -0.1291 -0.3328 -0.3693 -0.1530 -0.0078 -0.0267 -0.8224 -0.5162 -1.4165 -0.5858 -0.2411 -0.2239 -1.4792 -0.1640
S-563	Three-year HF hospitalization rates were 24%, 15%, 15%, 22%, and 28% in ages 20 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70 years, respectively (p < 0.0001).<unk>
T-563	hf ; hospitalization
H-563	-1.1951053142547607	▁ HF
D-563	-1.1951053142547607	HF
P-563	-1.8695 -0.6514 -1.9139 -0.3456
S-1460	These definitions will form the foundation for describing a uniform nomenclature for right heart circulatory failure with a view to foster collaborative research initiatives and conjoint education in an effort to provide insight into mechanisms of disease unique to the right heart.<unk>
T-1460	right heart circulatory failure ; disease ; right heart
H-1460	-0.6578115820884705	▁right ▁heart ▁circula tory ▁failure ▁; ▁mechanism s ▁of ▁disease ▁; ▁right ▁heart
D-1460	-0.6578115820884705	right heart circulatory failure ; mechanisms of disease ; right heart
P-1460	-2.3288 -1.0650 -0.9725 -0.0401 -0.1217 -0.5758 -1.3277 -0.0404 -0.6833 -1.4306 -0.3210 -0.0501 -0.4624 -0.1641 -0.2836
S-1671	Ca(2+) influx via L-type voltage-gated Ca(2+) channels supports the plateau phase of ventricular action potentials and is the trigger for excitation-contraction (EC) coupling in the myocardium.<unk>
T-1671	ventricular action potentials ; excitation-contraction ; myocardium
H-1671	-0.47343382239341736	▁influ x ▁; ▁l - type ▁volta ge - ga ted ▁ca (2 +) ▁channel s ▁; ▁plate au ▁phase ▁; ▁vent ri cular ▁action ▁potential s ▁; ▁excita tion - con traction ▁; EC ▁; ▁coup ling ▁; ▁my o car dium
D-1671	-0.47343382239341736	influx ; l-type voltage-gated ca(2+) channels ; plateau phase ; ventricular action potentials ; excitation-contraction ;EC ; coupling ; myocardium
P-1671	-1.7316 -0.2397 -0.4828 -1.9190 -0.1583 -0.1033 -0.0600 -0.0415 -0.1321 -0.0682 -0.0369 -0.7039 -2.6069 -0.0383 -0.1587 -0.2067 -0.3623 -0.0300 -0.0185 -0.5113 -0.9244 -0.7573 -1.4524 -0.8300 -0.2398 -0.0914 -0.1663 -0.2326 -0.9023 -0.0910 -0.0934 -0.0609 -1.0256 -0.2130 -0.4830 -0.4425 -0.0085 -0.0263 -0.4328 -0.7279 -0.0429 -0.2714 -1.4054 -0.5240 -0.2494
S-1171	OBJECTIVES: The aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular filling in patients with heart failure with preserved ejection fraction (HFpEF).<unk>
T-1171	ivabradine ; exercise capacity ; left ventricular filling ; patients ; heart failure with preserved ejection fraction ; hfpef
H-1171	-0.35456210374832153	▁i va bra dine ▁; ▁exercise ▁capacity ▁; ▁left ▁vent ri cular ▁fill ing ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF
D-1171	-0.35456210374832153	ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; preserved ejection fraction ;HFpEF
P-1171	-0.0741 -1.2995 -0.1834 -0.1646 -0.2761 -0.1934 -0.0461 -0.1818 -0.0359 -1.7655 -0.9306 -0.3569 -1.6468 -0.0389 -0.1694 -0.7056 -0.0631 -0.1265 -0.1375 -0.0642 -0.0562 -0.0195 -0.1931 -0.1588 -0.4875 -0.0136 -0.6199 -0.2182 -0.0161 -0.2883 -0.5939 -0.2208
S-1733	Aldosterone antagonism in heart failure Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly in patients with systolic dysfunction.<unk>
T-1733	aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; patients ; systolic dysfunction
H-1733	-0.5391173362731934	▁al do ster one ▁anta gon ism ▁; ▁heart ▁failure ▁; ▁al do ster one ▁; ▁neuro hormon e ▁; ▁electro ly tes
D-1733	-0.5391173362731934	aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes
P-1733	-1.0069 -0.2255 -0.5094 -0.0138 -0.4867 -0.2719 -0.1861 -0.3813 -0.4320 -0.1764 -1.3329 -1.3950 -0.1079 -0.1676 -0.0231 -0.3812 -0.5831 -0.0648 -0.1594 -0.3979 -0.0043 -0.3942 -0.0984 -4.4500 -0.2282
S-1570	Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e') ratio.<unk>
T-1570	univariate analysis ; bnp ; estimated glomerular filtration rate ; hypertension ; transmitral ; e-wave ; diastolic mitral annular velocity
H-1570	-0.5269078612327576	▁b p ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁hyper tension ▁; ▁transmit ral ▁E - wa ve ▁; ear ly ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1570	-0.5269078612327576	bp ; glomerular filtration rate ; hypertension ; transmitral E-wave ;early diastolic mitral annular velocity
P-1570	-0.9755 -1.5827 -0.1858 -1.2353 -0.5107 -0.0193 -0.2338 -0.2210 -0.0527 -0.4325 -0.5599 -0.1030 -0.3040 -0.1648 -0.2073 -3.0007 -0.0872 -0.0561 -0.1168 -0.1181 -3.0104 -0.0048 -0.1509 -0.2325 -0.1885 -1.2715 -0.1411 -0.1827 -0.0009 -0.1004 -0.0879 -1.6109 -0.2386
S-1967	Dual inhibition of AT1 receptors and neprilysin blocks renin-angiotensin-aldosteron (RAS) axis and concurrently supports natural vasodilatory and diuretic effect of natriuretic peptides.<unk>
T-1967	at1 receptors ; neprilysin ; renin-angiotensin-aldosteron ; ras ; vasodilatory ; diuretic ; natriuretic peptides
H-1967	-0.49024340510368347	▁AT 1 ▁receptor s ▁; ▁nepri ly sin ▁block s ▁; ▁re nin - angi oten sin - al do ster on ▁; RAS ▁; ▁a xis ▁; ▁natural ▁vaso dila tory ▁; ▁di ure tic ▁; ▁na tri ure tic ▁pe pti des
D-1967	-0.49024340510368347	AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; axis ; natural vasodilatory ; diuretic ; natriuretic peptides
P-1967	-0.6649 -0.2432 -0.0056 -0.1865 -0.6851 -0.0483 -0.0781 -0.4023 -0.0349 -0.1067 -1.8556 -0.0079 -0.0829 -0.0849 -0.0357 -2.2951 -2.7907 -0.2891 -0.0543 -1.1140 -0.6856 -0.2497 -0.7302 -0.5484 -1.6203 -0.0228 -0.0048 -0.4664 -0.0663 -0.0469 -0.1695 -0.0918 -0.5087 -0.2050 -0.0579 -0.4080 -1.9555 -0.0133 -0.1429 -0.0685 -0.4274 -0.0554 -0.1581 -1.8024 -0.6917 -0.2879
S-1425	Nonetheless, β-blockade does not halt disease progression, suggesting that cAMP-dependent protein kinase (PKA) signaling downstream of β-adrenergic receptor activation may persist through unique post-translational states.<unk>
T-1425	β-blockade ; halt ; disease ; protein kinase ; pka ; β-adrenergic receptor
H-1425	-0.4445994794368744	▁β - block ade ▁; ▁disease ▁progression ▁; ▁c AMP - dependent ▁protein ▁kina se ▁; ▁p KA ▁; ▁down stream ▁; ▁β - ad r energi c ▁receptor ▁activa tion ▁; ▁post - trans la tional ▁states
D-1425	-0.4445994794368744	β-blockade ; disease progression ; cAMP-dependent protein kinase ; pKA ; downstream ; β-adrenergic receptor activation ; post-translational states
P-1425	-0.4531 -0.1387 -0.8558 -1.2146 -0.3001 -1.2507 -0.4306 -0.3442 -0.0042 -0.1429 -0.1666 -0.0389 -0.2296 -0.0497 -0.4271 -0.4821 -0.8481 -0.6067 -0.6202 -0.9993 -0.0048 -0.8506 -0.5672 -0.0537 -0.4036 -0.5903 -1.1140 -0.4598 -0.0109 -1.6995 -0.1302 -1.2219 -0.0912 -0.0321 -0.0210 -0.2198 -0.0145 -0.0211 -0.4471 -0.2271
S-47	Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism.<unk>
T-47	evidence ; erythropoiesis-stimulating agent ; therapy ; venous thromboembolism
H-47	-0.5386606454849243	▁er y thro po ies is - stimul ating ▁agent ▁ therapy ▁; ▁ve nous ▁ thro mbo e mbol ism
D-47	-0.5386606454849243	erythropoiesis-stimulating agent therapy ; venous thromboembolism
P-47	-0.2219 -0.0904 -0.5356 -0.2252 -2.8870 -0.4330 -0.3207 -0.0245 -0.1087 -0.3648 -0.9888 -0.0893 -0.3094 -0.7927 -1.0020 -0.1842 -0.4682 -1.3716 -0.8572 -0.1162 -0.5550 -0.2822 -0.1605
S-1638	After multivariable adjustment, black race was associated with increased mortality/hospitalization (hazard ratio [HR] 1.16, 95% CI 1.01-1.33) and cardiovascular mortality/HF hospitalization (HR 1.46, 95% CI 1.20-1.77).<unk>
T-1638	multivariable adjustment ; mortality ; hospitalization ; hazard ratio ; cardiovascular mortality ; hf ; hospitalization
H-1638	-0.38214579224586487	▁black ▁race ▁; ▁mortal ity ▁; hospital ization ▁; haz ard ▁ratio ▁; ▁cardiovascular ▁mortal ity ▁; HF ▁hospital ization
D-1638	-0.38214579224586487	black race ; mortality ;hospitalization ;hazard ratio ; cardiovascular mortality ;HF hospitalization
P-1638	-0.0077 -0.2134 -0.1425 -0.4423 -0.0298 -0.7474 -0.5572 -0.2551 -0.3744 -0.0176 -0.1909 -0.0110 -0.1557 -1.2183 -0.3668 -0.0656 -0.2979 -0.5993 -1.5232 -0.3354 -0.5487 -0.3067
S-504	In this study we developed a novel percutaneous one- and two-vessel model for chronic myocardial ischemia using a stent coated with a polytetrafluoroethylene tube formed in a bottleneck shape.<unk>
T-504	percutaneous ; chronic myocardial ischemia ; stent ; polytetrafluoroethylene
H-504	-0.43358245491981506	▁per cuta ne ous ▁; ▁two - ves sel ▁model ▁; ▁chronic ▁my o card ial ▁ ische mia ▁; ▁sten t ▁co ated ▁; ▁poly te tra flu oro e thy lene ▁tube ▁; ▁bottle ne ck ▁shape
D-504	-0.43358245491981506	percutaneous ; two-vessel model ; chronic myocardial ischemia ; stent coated ; polytetrafluoroethylene tube ; bottleneck shape
P-504	-1.6645 -0.0032 -0.0387 -0.1105 -3.1694 -0.2587 -0.0479 -0.0554 -0.1143 -0.2887 -0.5050 -0.1592 -1.7120 -0.2619 -1.0471 -0.0629 -0.1629 -1.2708 -1.3099 -0.1823 -0.0262 -0.1371 -0.0638 -0.0587 -0.1381 -0.2632 -0.1468 -0.0551 -0.3121 -0.2220 -0.5671 -1.1592 -0.1819 -0.1139 -0.4569 -0.0193 -0.0088 -0.0555 -0.7502 -0.3847 -0.2309
S-1456	A combined (clinical and genetic) CHF predictive model performed better [area under the curve (AUC), 0·79] than the genetic (AUC = 0·67) or the clinical (AUC = 0·69) models alone.<unk>
T-1456	clinical ; genetic ; chf ; area under the curve ; auc ; genetic ; auc ; clinical ; auc
H-1456	-0.5740200281143188	▁CHF ▁predict ive ▁model ▁; ▁cur ve ▁; AU c ▁; ▁genetic ▁; AU c ▁; ▁clinic al
D-1456	-0.5740200281143188	CHF predictive model ; curve ;AUc ; genetic ;AUc ; clinical
P-1456	-3.2259 -0.4035 -0.0458 -0.1872 -0.1665 -0.0555 -0.0936 -0.2921 -0.2387 -1.8696 -0.1796 -0.1124 -0.1711 -0.7097 -1.5312 -0.4983 -0.3610 -0.0598 -1.1145 -0.1645
S-1760	At multivariable logistic analysis, failure in detecting AT resulted significantly in reduced peak oxygen uptake and higher metabolic exercise and cardiac and kidney index score value, a powerful prognostic composite HF index (P<0.001).<unk>
T-1760	multivariable logistic analysis ; peak oxygen uptake ; metabolic exercise ; cardiac ; kidney ; prognostic ; hf index
H-1760	-0.571932315826416	▁logistic ▁analysis ▁; ▁pe ak ▁oxygen ▁up take ▁; ▁metabol ic ▁exercise ▁; ▁cardiac ▁; ▁ki dne y ▁index ▁; ▁ HF ▁index
D-1760	-0.571932315826416	logistic analysis ; peak oxygen uptake ; metabolic exercise ; cardiac ; kidney index ; HF index
P-1760	-2.1906 -2.1730 -0.3422 -1.3959 -0.0112 -1.1526 -0.1960 -0.0603 -0.1485 -0.5968 -0.0245 -0.2162 -0.0995 -0.0657 -0.6101 -0.0448 -0.5511 -0.0499 -0.1926 -1.4016 -1.6438 -0.1094 -0.5220 -0.3005 -0.1995
S-601	BACKGROUND: While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α, several trials of TNF antagonists showed no benefit and possibly worsening of disease in those with known severe HF.<unk>
T-601	heart failure ; hf ; tumor necrosis factor ; tnf ; tnf antagonists ; disease ; severe hf
H-601	-0.4129544198513031	▁heart ▁failure ▁; HF ▁; ▁tumor ▁nec rosi s ▁factor ▁; TN f ▁; ▁t NF ▁anta gon ists ▁; ▁ HF
D-601	-0.4129544198513031	heart failure ;HF ; tumor necrosis factor ;TNf ; tNF antagonists ; HF
P-601	-0.2702 -0.0812 -0.2451 -0.1504 -0.2643 -0.6178 -0.4112 -0.0577 -0.2769 -0.0268 -0.6095 -0.3126 -0.8269 -1.1343 -0.4928 -0.3061 -1.0385 -0.4023 -0.2526 -0.1707 -1.3546 -0.2769 -0.2180 -0.1134
S-1031	The Centers for Medicare and Medicaid Services (CMS) has operationalized hospital quality of care outcomes through publicly reported 30-day risk-standardized mortality and readmission rates and associated penalties for higher-than-expected rates.<unk>
T-1031	centers for medicare and medicaid services ; cms ; hospital ; outcomes ; reported ; mortality ; readmission ; penalties
H-1031	-0.4306640625	▁center s ▁for ▁Medica re ▁and ▁Medica id ▁services ▁; ▁c m ▁; ▁hospital ▁quality ▁of ▁care ▁outcome s ▁; ▁public ly ▁; ▁mortal ity ▁; ▁read mission ▁rates ▁; ▁penal ties
D-1031	-0.4306640625	centers for Medicare and Medicaid services ; cm ; hospital quality of care outcomes ; publicly ; mortality ; readmission rates ; penalties
P-1031	-1.2814 -0.0404 -0.0770 -0.0706 -0.0367 -0.1959 -0.0573 -0.1671 -0.2260 -0.5657 -0.2539 -0.8205 -0.9168 -3.5314 -0.7517 -0.1399 -0.1954 -0.2712 -0.0334 -0.3144 -0.1343 -0.0502 -0.2788 -0.9106 -0.0298 -0.2473 -0.7574 -0.0975 -0.4100 -0.9896 -0.0034 -0.0231 -0.4768 -0.2873
S-1416	We used Cox proportional hazard models with time-dependent covariates to analyze the effect of follow-up with a familiar physician within the first month after discharge on the primary outcome of death or urgent all-cause readmission over 6 months.<unk>
T-1416	cox proportional hazard models ; covariates ; follow-up ; physician ; discharge ; primary outcome ; death ; all-cause readmission
H-1416	-0.47098302841186523	▁co x ▁proportion al ▁hazard ▁models ▁; ▁follow - up ▁; ▁physician ▁; ▁dis charge ▁; ▁death ▁; ▁urgent ▁all - ca use ▁read mission
D-1416	-0.47098302841186523	cox proportional hazard models ; follow-up ; physician ; discharge ; death ; urgent all-cause readmission
P-1416	-0.0616 -0.1433 -0.0349 -0.0134 -0.4807 -0.4017 -0.3444 -0.2533 -0.1073 -0.0152 -0.3146 -1.4263 -0.2163 -0.0587 -0.0460 -0.2243 -4.6149 -0.1512 -1.5922 -0.4793 -0.0447 -0.0043 -0.6113 -0.6026 -0.0960 -0.1464 -0.2317
S-1187	Using multivariate logistic regression analysis, we derived a prediction rule for severe CAD (≥50% diameter stenosis in the left main, 3-vessel CAD, and 2-vessel CAD involving the proximal left anterior descending artery).<unk>
T-1187	multivariate logistic regression analysis ; rule ; cad ; stenosis ; 3-vessel cad ; 2-vessel cad ; left anterior descending artery
H-1187	-0.6963747143745422	▁logistic ▁re gression ▁; ▁rule ▁; ▁severe ▁CAD ▁; ▁diameter ▁sten osis ▁; ▁left ▁main ▁; ▁3- ves sel ▁CAD ▁; ▁2- ves sel ▁CAD ▁; ▁proxima l ▁left ▁anterior ▁descend ing ▁arter y
D-1187	-0.6963747143745422	logistic regression ; rule ; severe CAD ; diameter stenosis ; left main ; 3-vessel CAD ; 2-vessel CAD ; proximal left anterior descending artery
P-1187	-2.2645 -0.0474 -0.0126 -1.1398 -0.5303 -0.3128 -2.3586 -1.1325 -0.1566 -0.2201 -0.3000 -0.0796 -0.1902 -4.2876 -0.0551 -0.1831 -2.4610 -0.0813 -0.0269 -0.5233 -0.1536 -3.2328 -0.1505 -0.0472 -0.9411 -0.1532 -1.4238 -0.0394 -0.5770 -0.9636 -0.0738 -0.0358 -0.0546 -0.3015 -0.4025 -0.1559
S-1040	These activate a signal transduction cascade that converges on a defined set of transcription factors, and pathological changes in cardiomyocytes occur through an interplay between these transcription factors and epigenetic changes in chromatin structure.<unk>
T-1040	activate ; signal transduction ; transcription factors ; pathological ; cardiomyocytes ; transcription factors ; epigenetic ; chromatin structure
H-1040	-0.4826821982860565	▁signal ▁trans duction ▁casca de ▁; ▁tran scription ▁factors ▁; ▁path ological ▁changes ▁; ▁cardio my o cy tes ▁; ▁tran scription ▁factors ▁; ▁epi gene tic ▁changes ▁; ▁chr omat in ▁structure
D-1040	-0.4826821982860565	signal transduction cascade ; transcription factors ; pathological changes ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin structure
P-1040	-0.4719 -0.1265 -1.0662 -0.1244 -0.3305 -0.4040 -0.8921 -0.4430 -0.0588 -0.4486 -0.5114 -0.1120 -1.9436 -0.4886 -0.0575 -1.1714 -0.5871 -0.1587 -0.1779 -0.3208 -0.7900 -0.8045 -0.0659 -0.2266 -0.6602 -0.2032 -0.1195 -1.2813 -0.3711 -0.0542 -0.0393 -0.7334 -0.8379 -0.4595 -0.3524
S-926	CONCLUSIONS: In patients with hypertensive HFPEF, the sodium-restricted DASH diet was associated with favorable changes in ventricular diastolic function, arterial elastance, and ventricular-arterial coupling.<unk>
T-926	patients ; hypertensive hfpef ; dash ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
H-926	-0.5532675981521606	▁h f f ▁; ▁so dium - re strict ed ▁DAS h ▁die t ▁; ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling
D-926	-0.5532675981521606	hff ; sodium-restricted DASh diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
P-926	-4.7907 -0.5936 -0.5624 -0.6398 -0.0498 -0.5601 -0.0314 -0.0218 -0.0288 -0.0558 -0.3019 -0.6122 -3.2914 -0.1738 -0.1609 -1.1320 -0.5567 -0.0959 -1.0008 -0.1744 -0.8031 -1.2981 -0.1787 -0.1203 -0.0568 -0.0507 -0.2050 -0.8571 -0.7326 -0.1322 -0.1834 -0.0433 -0.0697 -0.0242 -0.1556 -0.5301 -0.1957
S-334	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular dilatation.<unk>
T-334	combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular dilatation
H-334	-0.3797220289707184	▁ann ular ▁size ▁re duction ▁; ▁surgery ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁opening ▁; ▁posterior ly ▁dis place d ▁papil lar y ▁muscle s ▁; ▁left ▁vent ri cular ▁di la tation
D-334	-0.3797220289707184	annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular dilatation
P-334	-0.2555 -0.0005 -0.2491 -0.1479 -0.0054 -0.3172 -0.0439 -0.1195 -0.0591 -0.1623 -0.5768 -0.3471 -0.0870 -2.4649 -0.3333 -0.0382 -0.1314 -0.0446 -0.3628 -0.1990 -0.2225 -0.1206 -0.0077 -0.1037 -0.3149 -3.4309 -0.2598 -0.1907 -0.0532 -0.1460 -0.7927 -0.8887 -0.3259 -0.1441 -0.0420 -0.2964 -0.0285 -1.5481 -0.6181 -0.1573 -0.2776 -0.3740 -0.0109 -0.5148 -0.2729
S-1735	The first was the Randomized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality significantly compared with placebo.<unk>
T-1735	randomized aldactone evaluation study ; symptomatic chronic advanced heart failure ; patients ; aldosterone antagonist ; spironolactone ; mortality ; placebo
H-1735	-0.5720193982124329	▁Rand om ized ▁al da cto ne ▁evaluation ▁study ▁; ▁chronic ▁advanced ▁heart ▁failure ▁; ▁al do ster one ▁anta gon ist ▁; ▁spi rono lac tone ▁; ▁mortal ity
D-1735	-0.5720193982124329	Randomized aldactone evaluation study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone ; mortality
P-1735	-2.4353 -0.6024 -0.0347 -0.6736 -0.1470 -0.5362 -0.0923 -0.4824 -1.0073 -0.2720 -2.1682 -1.0772 -1.9139 -0.0685 -1.5684 -0.1694 -0.5745 -0.5197 -0.0488 -0.4534 -0.1763 -0.5989 -0.2129 -0.0326 -0.0247 -0.0655 -0.1633 -0.6416 -0.5202 -0.0425 -0.7662 -0.2148
S-1305	Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia.<unk>
T-1305	incidence ; mortality ; outcomes ; heart failure ; acute myocardial infarction ; patients ; acute myocardial infarction ; western australia
H-1305	-0.6774836182594299	▁incide nce ▁; ▁mortal ity ▁outcome s ▁; ▁heart ▁failure ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁western ▁Australia
D-1305	-0.6774836182594299	incidence ; mortality outcomes ; heart failure ; acute myocardial infarction ; western Australia
P-1305	-3.0639 -0.0603 -1.5780 -0.1115 -0.0287 -0.3600 -0.0347 -0.9553 -0.2377 -0.0706 -0.3278 -0.0297 -0.0389 -3.0977 -0.8672 -1.3171 -0.0732 -0.0315 -0.1947 -0.1818 -0.4964 -2.0353 -1.1009 -0.3988 -0.2455
S-1450	We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling.<unk>
T-1450	chf ; hct ; polymorphisms ; genes ; anthracycline ; metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
H-1450	-0.4350779354572296	▁CHF ▁; ▁gh t ▁; ▁poly morph ism s ▁; ▁an thra cycli ne ▁metabolism ▁; ▁ir on ▁home osta sis ▁; ▁anti - oxid ant ▁de fen ce ▁; ▁my o card ial ▁remodel ling
D-1450	-0.4350779354572296	CHF ; ght ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
P-1450	-0.2593 -0.4243 -4.4618 -0.9342 -0.1475 -1.8062 -0.0351 -0.0552 -0.1601 -0.3185 -0.2634 -0.1563 -0.7286 -0.2767 -0.4066 -0.1180 -0.1276 -0.0254 -0.0586 -0.3560 -0.5080 -0.1928 -0.0030 -0.0412 -0.0443 -0.5125 -0.1858 -0.7493 -0.1730 -0.4111 -0.2515 -0.0887 -1.3372 -0.0453 -0.0819 -0.0421 -0.5888 -0.1569
S-559	They were less likely to adhere to medication (nonadherence in youngest vs. oldest: 24% vs. 7%, p = 0.001), salt intake, and other dietary measures (21% vs. 9%, p = 0.002).<unk>
T-559	medication
H-559	-0.8208256959915161	▁medication ▁; no nadh er ence ▁; ▁salt ▁in take
D-559	-0.8208256959915161	medication ;nonadherence ; salt intake
P-559	-0.5753 -0.5403 -0.6339 -2.6400 -0.1028 -0.5092 -0.4878 -1.9120 -0.1094 -0.1584 -1.9848 -0.1960
S-1278	Given the different pathophysiological origin, a multivariate assessment with the inclusion of all the aforementioned parameters should be encouraged, not only for diagnostic and prognostic purposes but also for evaluating the effect of interventions.<unk>
T-1278	pathophysiological ; diagnostic ; prognostic
H-1278	-1.0530908107757568	▁pat ho phy si ological ▁; ▁diagnostic ▁; ▁prognos tic
D-1278	-1.0530908107757568	pathophysiological ; diagnostic ; prognostic
P-1278	-1.1633 -1.7461 -0.1109 -1.6743 -0.5175 -0.9987 -3.3794 -0.7729 -0.0393 -0.7745 -1.2316 -0.2286
S-534	Survival after LVAD surgery was better in patients with normal albumin levels compared with those with hypoalbuminemia before surgery (3 and 12 months: 93.2% vs 82.4% and 88.4% vs 75.2%, respectively, p <0.001).<unk>
T-534	lvad ; surgery ; patients ; albumin ; hypoalbuminemia ; surgery
H-534	-0.8852331042289734	▁l VAD ▁surgery ▁; ▁album in ▁levels ▁; ▁hypo album in emia
D-534	-0.8852331042289734	lVAD surgery ; albumin levels ; hypoalbuminemia
P-534	-2.2592 -0.2843 -1.9076 -0.2183 -4.0428 -0.3951 -0.6565 -0.2637 -0.0883 -0.3981 -0.1628 -0.3168 -1.2028 -0.1971
S-717	In a multivariate model that included listing criteria, creatinine (hazard ratio, 1.05 per 0.1 mg/dL; 95% confidence interval, 1.02-1.09; P=0.001) was a significant predictor of post-transplant mortality.<unk>
T-717	multivariate model ; creatinine ; hazard ratio ; confidence interval ; mortality
H-717	-0.5680246353149414	▁creati nine ▁; haz ard ▁ratio ▁; ▁post - trans plant
D-717	-0.5680246353149414	creatinine ;hazard ratio ; post-transplant
P-717	-0.7764 -0.3421 -0.4132 -0.0676 -0.0633 -0.0060 -0.3901 -0.4575 -0.0538 -0.1237 -0.0719 -4.3282 -0.2906
S-977	The risk of death was significantly increased in patients with estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) (odds ratio 1.76, 95% confidence interval 1.38 to 2.25) even after adjustment for all confounders.<unk>
T-977	death ; patients ; estimated glomerular filtration rate ; odds ratio ; confidence interval
H-977	-0.8052194714546204	▁risk ▁of ▁death ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; odd s ▁ratio
D-977	-0.8052194714546204	risk of death ; glomerular filtration rate ;odds ratio
P-977	-1.4239 -0.2775 -0.8009 -0.4189 -0.7939 -1.4099 -0.0269 -0.7446 -0.5857 -0.0989 -0.7513 -3.2402 -0.0128 -0.0201 -1.8970 -0.3811
S-310	We systematically searched the scientific literature (January 2008-June 2012) and identified 14 clinical studies (approximately 2900 HM II and approximately 200 HeartWare patients), and 3 economic evaluations (HM II) using simulation models.<unk>
T-310	clinical ; hm ii ; heartware ; patients ; economic ; hm ii
H-310	-0.5289900898933411	▁scientific ▁literature ▁; ▁clinic al ▁studies ▁; ▁ HM ▁II ▁; ▁Heart War e ▁patients ▁; ▁economic ▁evaluation s ▁; HM ▁II
D-310	-0.5289900898933411	scientific literature ; clinical studies ; HM II ; HeartWare patients ; economic evaluations ;HM II
P-310	-1.2214 -1.2849 -0.0959 -2.1947 -0.0917 -0.1519 -0.0585 -0.3711 -0.0424 -0.9777 -0.1129 -0.8561 -0.0397 -0.0718 -1.6589 -0.1947 -0.0456 -0.1258 -0.1369 -0.2666 -0.6276 -0.5216 -1.2715 -0.2757
S-72	IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.<unk>
T-72	dopamine ; nesiritide ; renal function ; patients ; acute heart failure ; renal dysfunction
H-72	-0.36499980092048645	▁low - dos e ▁dop amine ▁; ▁low - dos e ▁nesi riti de ▁; ▁renal ▁function ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function
D-72	-0.36499980092048645	low-dose dopamine ; low-dose nesiritide ; renal function ; acute heart failure ; renal dysfunction
P-72	-0.5951 -0.0396 -1.4770 -0.1634 -0.1182 -0.6602 -0.0743 -0.0921 -0.0300 -0.5547 -0.0424 -0.3403 -0.0590 -0.8094 -0.3180 -0.1838 -0.4382 -0.2351 -0.0367 -0.0348 -0.5607 -0.0697 -0.2083 -0.0147 -0.5441 -1.8543 -0.4621 -0.2035
S-1591	Future randomized trials using HR variability/turbulence as one of the pre-defined inclusion criteria will show whether routine measurement of HR variability/turbulence will become a routine clinical tool for risk stratification of cardiac patients.<unk>
T-1591	randomized ; hr variability ; hr variability ; clinical ; risk stratification ; cardiac ; patients
H-1591	-1.0267152786254883	▁random ized ▁trial s ▁; ▁HR ▁variabil ity / tur bul ence ▁; ▁routine ▁measure ment ▁; ▁HR ▁variabil ity ▁; ▁tur bul ence ▁; ▁risk ▁strat ification ▁; ▁cardiac ▁patients
D-1591	-1.0267152786254883	randomized trials ; HR variability/turbulence ; routine measurement ; HR variability ; turbulence ; risk stratification ; cardiac patients
P-1591	-4.8633 -0.5298 -0.7248 -0.1221 -0.4246 -0.3198 -0.1467 -0.1690 -2.9423 -0.5160 -0.1331 -0.2952 -0.4009 -4.5818 -1.1045 -0.0986 -0.4151 -0.7534 -0.1502 -0.2631 -2.1755 -1.5181 -0.0219 -0.2468 -0.4860 -3.7704 -1.8779 -1.1148 -1.3201 -0.0367 -1.5548 -0.3123 -0.4921
S-313	Although complications after implantation are frequent, LVAD therapy is often highly effective across transplantation eligibility status and device, with 1-year survival reaching 86% for BTT and 78% for DT (compared with 25% for medical therapy).<unk>
T-313	complications ; implantation ; lvad therapy ; transplantation ; btt ; dt ; medical therapy
H-313	-0.4526762068271637	▁l VAD ▁ therapy ▁; ▁transplant ation ▁e ligi bility ▁status ▁; ▁device ▁; ▁b t ▁; ▁ DT ▁; ▁medical ▁ therapy
D-313	-0.4526762068271637	lVAD therapy ; transplantation eligibility status ; device ; bt ; DT ; medical therapy
P-313	-3.5343 -0.2311 -1.3155 -0.0613 -0.2666 -0.3299 -0.1221 -0.1610 -0.0221 -0.0771 -0.0546 -0.1982 -0.9345 -0.3129 -1.0109 -0.3811 -0.0581 -0.3182 -0.6273 -0.3846 -0.0289 -0.3437 -0.1199 -0.2350 -0.1880
S-580	METHODS: Clinical, biologic, and radial artery tonometry variables were prospectively obtained at admission and at day 3 to 5 in 53 consecutive patients with PH admitted to our ICU for clinical deterioration.<unk>
T-580	clinical ; artery tonometry ; prospectively ; admission ; patients ; icu ; clinical
H-580	-0.44902512431144714	▁radi al ▁arter y ▁ton ometr y ▁; ▁ad mission ▁; ▁PH ▁; ▁ ICU
D-580	-0.44902512431144714	radial artery tonometry ; admission ; PH ; ICU
P-580	-0.3700 -0.0362 -0.1534 -0.3086 -1.6297 -0.0106 -0.1026 -0.8329 -0.1001 -0.0245 -0.1595 -2.1166 -0.4926 -0.3944 -0.0334 -0.6190 -0.2493
S-2006	CONCLUSIONS: The results show that the fully magnetically levitated centrifugal-flow chronic LVAS is safe, with high 30-day and 6-month survival rates, a favorable adverse event profile, and improved quality of life and functional status.<unk>
T-2006	fully magnetically levitated centrifugal-flow chronic lvas ; adverse event ; quality of life ; functional status
H-2006	-0.906197726726532	▁magnet ically ▁le vita ted ▁centri fu gal - flow ▁chronic ▁l VAS ▁; ▁advers e ▁event ▁profile
D-2006	-0.906197726726532	magnetically levitated centrifugal-flow chronic lVAS ; adverse event profile
P-2006	-4.3040 -0.0587 -0.1462 -0.0183 -0.0660 -0.0543 -0.1539 -0.0502 -0.0819 -0.0290 -2.6141 -2.0384 -0.3512 -0.6424 -4.5773 -0.0769 -0.1933 -0.0927 -2.3917 -0.1833
S-995	ERK1/2 signalling requires a signalosome complex where a scaffold protein drives the assembly of these three kinases into a linear pathway to facilitate their sequential phosphorylation, ultimately targeting specific effector molecules.<unk>
T-995	signalosome complex ; scaffold protein ; drives ; kinases ; phosphorylation ; effector molecules
H-995	-0.7535205483436584	▁e RK 1/2 ▁signal ling ▁; ▁signal ▁; ▁sc af fold ▁protein ▁drive s ▁; ▁kina ses ▁; ▁sequenti al ▁ phos phor y lation ▁; ▁effect or ▁mole cules
D-995	-0.7535205483436584	eRK1/2 signalling ; signal ; scaffold protein drives ; kinases ; sequential phosphorylation ; effector molecules
P-995	-1.5288 -0.4280 -0.1568 -0.3557 -0.1431 -0.3715 -0.5010 -6.6990 -0.5965 -1.4144 -0.6946 -1.3456 -0.1201 -0.0988 -0.3521 -1.5315 -0.1016 -0.1820 -0.2586 -0.0306 -0.1232 -0.2502 -1.4899 -1.5660 -0.6450 -1.0551 -0.3942 -0.3029 -0.7306 -0.2597 -0.2119 -0.1739
S-672	Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases.<unk>
T-672	breast cancer ; patients ; medicare ; diagnosed ; breast cancer ; chemotherapy ; seer-medicare ; texas ; medicare
H-672	-0.5981577038764954	▁breast ▁cancer ▁patients ▁; ▁Medica re ▁coverage ▁; ▁stage ▁I - III ▁breast ▁cancer ▁; ▁che mo therapy ▁; ▁s EER - Medic are ▁; ▁Texas ▁cancer ▁Registr y - Medic are ▁database s
D-672	-0.5981577038764954	breast cancer patients ; Medicare coverage ; stage I-III breast cancer ; chemotherapy ; sEER-Medicare ; Texas cancer Registry-Medicare databases
P-672	-1.8231 -0.4141 -1.3915 -0.2059 -0.9046 -0.0618 -1.6182 -0.2730 -1.6041 -1.6879 -0.0413 -0.0305 -0.5253 -0.1816 -0.1762 -0.9830 -0.3214 -0.3739 -0.1979 -0.1963 -0.0907 -0.0379 -0.1547 -0.7737 -0.0826 -0.2571 -2.5275 -0.4197 -0.0176 -1.4133 -0.0662 -0.6339 -1.4358 -0.1320 -0.3187 -0.1606
S-186	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry.<unk>
T-186	ejection fraction ; b-type natriuretic peptide ; patients ; hospitalized ; heart failure ; inhospital ; outcomes ; get with the guideline-heart failure registry
H-186	-0.4297824501991272	▁e je ction ▁ fraction ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁levels ▁; ▁hospital ized ▁; ▁heart ▁failure ▁; ▁in hospital ▁outcome s ▁; ▁guide line - He art ▁Fail ure ▁Registr y
D-186	-0.4297824501991272	ejection fraction ; b-type natriuretic peptide levels ; hospitalized ; heart failure ; inhospital outcomes ; guideline-Heart Failure Registry
P-186	-0.7721 -0.2559 -0.0548 -0.3929 -0.0079 -0.2581 -0.8477 -0.0542 -0.9021 -0.0113 -1.0001 -0.1091 -0.3401 -0.0467 -0.1783 -0.9581 -0.3251 -0.3173 -2.9899 -0.6268 -0.3967 -0.5260 -0.1166 -0.4058 -0.1252 -0.0797 -0.4342 -0.0666 -0.3632 -0.4900 -0.0161 -0.0607 -1.2666 -0.4855 -0.3018 -0.0403 -0.5495 -0.3371 -0.3504 -0.3309
S-1215	In diseased cardiomyocytes, higher PDE2 activity could be further enhanced by stimulation of cGMP synthesis via nitric oxide donors, whereas specific PDE2 inhibition partially restored β-AR responsiveness.<unk>
T-1215	diseased ; cardiomyocytes ; pde2 ; activity ; cgmp synthesis ; nitric oxide ; donors ; pde2 inhibition ; β-ar responsiveness
H-1215	-0.5557821393013	▁disease d ▁cardio my o cy tes ▁; ▁p de 2 ▁activity ▁; ▁c g m ▁synth es is ▁; ▁ni tric ▁oxid e ▁donor s ▁; ▁p de 2 ▁inhibi tion ▁; ▁β - AR ▁responsive ness
D-1215	-0.5557821393013	diseased cardiomyocytes ; pde2 activity ; cgm synthesis ; nitric oxide donors ; pde2 inhibition ; β-AR responsiveness
P-1215	-2.5348 -0.2377 -0.2927 -2.0233 -1.2890 -0.3319 -0.2183 -0.1989 -0.7236 -1.9506 -0.1391 -0.4216 -0.1913 -0.0083 -0.3739 -1.0953 -0.9445 -0.1292 -1.3458 -0.2880 -0.0311 -0.3894 -0.1085 -0.1239 -0.2351 -0.1055 -0.2681 -0.4828 -1.6030 -0.1915 -1.2738 -0.1495 -0.3302 -0.1130 -0.0277 -0.3090 -0.8078 -0.3858 -0.3837 -0.1741
S-656	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).<unk>
T-656	l-dko ; cardiac ; irs1 ; irs2 ; proteins ; heart failure ; cardiac energy metabolism gene expression ; p38α ; mitogen-activated protein kinase ; p38
H-656	-0.4554901123046875	▁l - d KO ▁mi ce ▁; ▁cardiac ▁; ▁i RS 1 ▁; ▁i RS 2 ▁; ▁heart ▁failure ▁; ▁im pair ed ▁cardiac ▁energy ▁metabolism ▁; ▁p 38 α ▁mit ogen - activa ted ▁protein ▁kina se
D-656	-0.4554901123046875	l-dKO mice ; cardiac ; iRS1 ; iRS2 ; heart failure ; impaired cardiac energy metabolism ; p38α mitogen-activated protein kinase
P-656	-0.9897 -0.2728 -0.6703 -2.4844 -0.3495 -0.1522 -0.3495 -0.5055 -1.7167 -1.3652 -0.3814 -0.6251 -0.3160 -0.6715 -0.5287 -0.0587 -1.4347 -0.9107 -0.1095 -0.2933 -0.2121 -0.0123 -0.0145 -0.1746 -0.0901 -0.1396 -0.2547 -0.0428 -0.1482 -0.3807 -0.8811 -0.1844 -0.1572 -0.0494 -0.0816 -0.2101 -0.0217 -0.1950 -0.5794 -0.2048
S-251	ECs were incubated with HDL, and phosphorylation of eNOS-Ser(1177), eNOS-Thr(495), PKC-βII-Ser(660), and p70S6K-Ser(411) was evaluated.<unk>
T-251	ecs ; hdl ; phosphorylation
H-251	-0.517356276512146	▁EC s ▁; ▁HD l ▁; ▁ phos phor y lation ▁; ▁e NOS - Ser ▁; ▁e NOS - Th r ▁; ▁PK c - β II - Ser ▁; ▁p 70 s 6 k - Ser
D-251	-0.517356276512146	ECs ; HDl ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-βII-Ser ; p70s6k-Ser
P-251	-1.3503 -0.2019 -0.2187 -1.7016 -3.7637 -0.2063 -0.1010 -0.0764 -0.2173 -0.8037 -0.5943 -0.3360 -0.0142 -0.3627 -0.1832 -0.2736 -0.2331 -0.0387 -0.4299 -0.1203 -1.6074 -0.0075 -0.1668 -0.5297 -1.6949 -0.0956 -0.7630 -0.3543 -0.1269 -0.2669 -0.3303 -0.0416 -0.2254 -0.3749 -0.1196 -1.4570 -0.0512 -0.4799 -0.5479 -0.2263
S-829	Low PASP was associated with a significantly lower 6-minute walking distance, peak o2 per kilogram, and 1-, 3-, and 4-year survival rates (92%, 69%, and 48%, respectively, versus 96%, 92%, and 89%).<unk>
T-829	pasp ; 6-minute walking distance ; peak o2
H-829	-0.7857897281646729	▁low ▁PAS p ▁; ▁pe ak ▁o 2 ▁per ▁kilogram
D-829	-0.7857897281646729	low PASp ; peak o2 per kilogram
P-829	-1.9073 -0.8587 -0.3539 -0.2820 -0.5966 -0.0829 -0.0131 -0.1109 -1.7650 -0.5155 -2.7157 -0.2279
S-155	RESULTS: Twenty-one RCTs that enrolled 6317 patients were identified (11 studies evaluated STS (10 of which were HH, while 1 was HM), 9 studies assessed TM, and 1 study assessed both STS and TM).<unk>
T-155	rcts ; patients ; sts ; hh ; sts
H-155	-0.6834710240364075	▁s ts ▁; ▁ HH ▁; ▁ HM ▁; ▁s ts ▁; ▁TM
D-155	-0.6834710240364075	sts ; HH ; HM ; sts ; TM
P-155	-0.5255 -0.5620 -0.1526 -1.0255 -0.4174 -0.2838 -1.9761 -0.2676 -0.6005 -0.3283 -1.2779 -0.4170 -1.4831 -0.5432 -0.3914
S-417	In adult mouse ventricular myocytes, it dose dependently increased sarcomere shortening by 75% to 210% (50-500 μmol/L), with a ≈30% rise in the peak Ca(2+) transient only at higher doses.<unk>
T-417	ventricular myocytes ; sarcomere ; shortening
H-417	-0.618411660194397	▁mouse ▁; ▁vent ri cular ▁my o cy tes ▁; ▁sar com ere ▁; ▁pe ak ▁ca (2 +) ▁trans ient
D-417	-0.618411660194397	mouse ; ventricular myocytes ; sarcomere ; peak ca(2+) transient
P-417	-0.4654 -2.3812 -0.2629 -0.3451 -0.2711 -1.2562 -0.1242 -0.1424 -0.1932 -0.2068 -0.3998 -0.4913 -0.2115 -0.5149 -2.6873 -0.0367 -0.5375 -2.1134 -0.0341 -0.0471 -1.0052 -0.3630 -0.1332
S-1415	METHODS: We used data from linked administrative databases for all adults aged 20 years or more in the province of Alberta who were discharged alive from hospital between January 1999 and June 2009 with a first-time diagnosis of heart failure.<unk>
T-1415	administrative ; alberta ; discharged ; hospital ; diagnosis ; heart failure
H-1415	-0.35305485129356384	▁administrative ▁database s ▁; ▁province ▁of ▁Albert a ▁; ▁dis charge d ▁ali ve ▁; ▁hospital ▁; ▁first - time ▁ diagnos is ▁of ▁heart ▁failure
D-1415	-0.35305485129356384	administrative databases ; province of Alberta ; discharged alive ; hospital ; first-time diagnosis of heart failure
P-1415	-0.0444 -0.4149 -0.0599 -0.2237 -2.3668 -0.1835 -0.1006 -0.0818 -0.3978 -0.0731 -0.0444 -0.2091 -0.3280 -0.2989 -0.4503 -0.2089 -0.3309 -0.6938 -0.0560 -0.2766 -0.2465 -0.1683 -0.4123 -0.6903 -1.0068 -0.0801 -0.2484 -0.1894
S-1062	The animals with heart failure also had a difference histologically in the percentage of myocardial collagen compared with tissue from healthy control animals (control, 5.4% ± 1.0%; heart failure, 9.4% ± 1.6%; p < 0.001).<unk>
T-1062	heart failure ; histologically ; myocardial collagen ; healthy ; heart failure
H-1062	-0.7225179672241211	▁heart ▁failure ▁; ▁my o card ial ▁collage n ▁; ▁tissu e ▁; ▁control ▁; ▁heart ▁failure
D-1062	-0.7225179672241211	heart failure ; myocardial collagen ; tissue ; control ; heart failure
P-1062	-2.8232 -0.1186 -0.2981 -0.7497 -0.4129 -0.6616 -0.0571 -0.0365 -0.2944 -0.2395 -0.6317 -0.0965 -0.2292 -3.9017 -0.2848 -2.3094 -0.0900 -0.3299 -0.1629
S-757	After adjusting for important covariates, the CRT ON assignment remained independently associated with improved time to death or first HF hospitalization (hazard ratio, 0.54; P=0.035), whereas there was no significant interaction with LVEF.<unk>
T-757	covariates ; crt ; death ; hf ; hospitalization ; hazard ratio ; lvef
H-757	-0.7064700722694397	▁c RT ▁on ▁assign ment ▁; ▁time ▁to ▁death ▁; ▁first ▁ HF ▁hospital ization ▁; haz ard ▁ratio ▁; ▁LV EF
D-757	-0.7064700722694397	cRT on assignment ; time to death ; first HF hospitalization ;hazard ratio ; LVEF
P-757	-0.3389 -2.9472 -2.1803 -3.3963 -0.0765 -0.1243 -1.5481 -0.1472 -0.4593 -0.0742 -1.0205 -0.2736 -0.2563 -1.2574 -0.5481 -0.3516 -0.1811 -0.3084 -0.0058 -0.3158 -0.1957 -0.5428 -0.2020 -0.2038
S-1404	beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.<unk>
T-1404	beta1-adrenergic receptor ; sphingosine-1-phosphate receptor 1 ; s1pr1 ; downregulation ; cardiac ; hypertrophic ; heart failure ; s1pr1 ; cardiac ; gene ; therapy
H-1404	-0.39948856830596924	▁beta 1- ad r energi c ▁receptor ▁; ▁sp hing os ine -1 - phos pha te ▁receptor ▁; ▁s 1 PR ▁; ▁reciproc al ▁down regul ation ▁; ▁cardiac ▁hyper trop hic ▁response ▁; ▁heart ▁failure ▁; ▁s 1 PR 1 ▁cardiac ▁gene ▁ therapy
D-1404	-0.39948856830596924	beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 cardiac gene therapy
P-1404	-0.7665 -0.4829 -1.0618 -0.1806 -0.7866 -0.6498 -0.0017 -0.1555 -0.2478 -0.3573 -0.3446 -0.2735 -0.9118 -0.1615 -0.0184 -0.4271 -0.3520 -0.0041 -0.4836 -0.2263 -0.3247 -1.4294 -1.6477 -0.0617 -0.0090 -0.0242 -0.0754 -0.1162 -0.3041 -0.0616 -0.4234 -0.0373 -0.0871 -0.3433 -0.1517 -1.2557 -0.0803 -0.4780 -0.2217 -0.2221 -0.5975 -0.8488 -0.6526 -0.7387 -0.6376 -0.0569 -0.2614 -0.1340
S-1540	The relative risk (RR) of heart failure was significantly increased in users of bisphophonates: crude RR 1.71 [95% confidence interval (CI) 1.63-1.79]; adjusted hazard ratio (HR) 1.41 (95% CI 1.34-1.48).<unk>
T-1540	relative risk ; rr ; heart failure ; bisphophonates ; rr ; confidence interval ; hazard ratio
H-1540	-0.8713849782943726	▁relative ▁risk ▁; RR ▁; ▁heart ▁failure ▁; ▁bis pho phon ates ▁; ▁cru de ▁ RR ▁; ▁confidence ▁interval ▁; ▁CI ▁; ▁adjust ed ▁hazard ▁ratio ▁; HR
D-1540	-0.8713849782943726	relative risk ;RR ; heart failure ; bisphophonates ; crude RR ; confidence interval ; CI ; adjusted hazard ratio ;HR
P-1540	-0.1183 -0.6937 -0.3090 -1.6726 -0.4173 -1.1760 -0.2121 -0.2860 -0.2613 -0.6000 -0.5667 -0.6387 -0.3721 -0.0979 -0.0406 -0.6762 -0.5148 -0.3091 -5.3753 -0.1911 -0.3285 -4.4798 -0.3745 -4.2012 -0.0219 -0.9498 -0.0062 -0.6092 -0.7648 -0.5002 -0.2481
S-1621	PARTICIPANTS: High-cost Medicare fee-for-service beneficiaries (N = 1,767) enrolled in two Centers for Medicare and Medicaid Services demonstration participating clinics and a propensity-score matched control group.<unk>
T-1621	medicare ; centers for medicare and medicaid services ; clinics ; propensity-score
H-1621	-0.3845618963241577	▁Medica re ▁; ▁fee - for - service ▁beneficiar ies ▁; ▁center s ▁for ▁Medica re ▁; ▁Medica id ▁services ▁; ▁pro pens ity - s core
D-1621	-0.3845618963241577	Medicare ; fee-for-service beneficiaries ; centers for Medicare ; Medicaid services ; propensity-score
P-1621	-1.3027 -0.1206 -0.8253 -0.1605 -0.0774 -0.1007 -0.0728 -0.0285 -0.6514 -0.6214 -0.2244 -1.3930 -0.1673 -0.7256 -0.1092 -0.0379 -0.7401 -0.0971 -0.5003 -0.4173 -0.5403 -0.1085 -0.0180 -0.0402 -0.1353 -0.0194 -0.2880 -1.3780 -0.2511
S-1841	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol Introduction The uptake of Clinical Practice Guideline (CPG) recommendations that improve outcomes in heart failure (HF) remains suboptimal.<unk>
T-1841	physician ; heart failure ; clinical practice guideline ; cpg ; outcomes ; heart failure ; hf
H-1841	-0.47640663385391235	▁physician ▁ad her ence ▁; ▁guide line ▁; ▁heart ▁failure ▁; ▁clinic al ▁practice ▁guide line ▁; CP g ▁; ▁outcome s ▁; ▁heart ▁failure ▁; HF
D-1841	-0.47640663385391235	physician adherence ; guideline ; heart failure ; clinical practice guideline ;CPg ; outcomes ; heart failure ;HF
P-1841	-2.4244 -0.0772 -0.1049 -0.0399 -0.2457 -0.0418 -0.0225 -0.8181 -1.0215 -0.0608 -0.3990 -3.0337 -0.1162 -0.0664 -1.0823 -0.0365 -0.1725 -0.5169 -0.1981 -0.2434 -1.4478 -0.0194 -0.2675 -0.4152 -0.0612 -0.2653 -0.1338 -0.2823 -0.2013
S-967	In conclusion, nicorandil was effective against the development of doxorubicin-induced heart failure in rats as indicated by improvement of hemodynamic perturbations, mitochondrial dysfunction and ultrastructural changes without affecting its antitumor activity.<unk>
T-967	nicorandil ; heart failure ; hemodynamic ; mitochondrial dysfunction ; antitumor ; activity
H-967	-0.30343058705329895	▁nic oran dil ▁; ▁do xor ubi cin - indu ced ▁heart ▁failure ▁; ▁rat s ▁; ▁hem o dynamic ▁perturba tions ▁; ▁mito cho ndri al ▁dys function ▁; ▁ultra struct ural ▁; ▁anti tum or ▁activity
D-967	-0.30343058705329895	nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; ultrastructural ; antitumor activity
P-967	-0.0370 -0.0100 -0.1407 -0.1659 -0.0185 -0.1865 -0.0391 -1.7505 -0.2755 -0.0489 -0.9272 -0.7133 -0.1352 -0.3012 -0.0496 -0.0363 -0.2924 -0.2082 -0.0908 -0.0191 -0.3880 -0.0420 -0.1888 -0.0207 -2.0496 -0.4448 -0.0668 -0.2224 -0.7873 -0.1839 -0.0788 -0.0605 -0.0039 -1.3811 -0.0155 -0.0795 -0.0799 -0.1535 -0.2679 -0.1762
S-788	KCCQ summary scores were strongly associated with New York Heart Association class in both patients with HFpEF (r=-0.62; P<0.001) and HF with reduced EF (r=-0.55; P=0.27 for interaction).<unk>
T-788	kccq ; new york heart association class ; patients ; hfpef ; hf with reduced ef
H-788	-0.7731555700302124	▁k cc q ▁; ▁New ▁York ▁Heart ▁association ▁; ▁ HF p EF ▁; ▁ HF ▁; ▁EF
D-788	-0.7731555700302124	kccq ; New York Heart association ; HFpEF ; HF ; EF
P-788	-0.9955 -0.0423 -2.7769 -0.4070 -1.8898 -0.5930 -2.9293 -0.6422 -0.6026 -0.4848 -0.4969 -0.0475 -0.2809 -0.1000 -0.2021 -0.5704 -0.2935 -1.3102 -0.5463 -0.2520
S-1646	RATIONALE: Rhythm control therapy applied early after the first diagnosis of AF could preserve atrial structure and function and maintain sinus rhythm more effectively than the current practice of delayed rhythm control (when symptoms persist after otherwise effective rate control).<unk>
T-1646	rhythm control therapy ; diagnosis ; atrial ; sinus rhythm ; rhythm control ; symptoms ; rate control
H-1646	-0.4656219184398651	▁ Rhythm ▁control ▁ therapy ▁; ▁af ▁; ▁at rial ▁structure ▁; ▁function ▁; ▁sinus ▁ rhythm ▁; ▁de lay ed ▁ rhythm ▁control ▁; ▁rate ▁control
D-1646	-0.4656219184398651	Rhythm control therapy ; af ; atrial structure ; function ; sinus rhythm ; delayed rhythm control ; rate control
P-1646	-1.4839 -0.4974 -0.1978 -0.8700 -0.0509 -0.3327 -1.1998 -0.5861 -0.4190 -0.2510 -0.1175 -0.1131 -2.8392 -0.1104 -0.8274 -0.2195 -0.3325 -0.3546 -0.6718 -0.0091 -0.0312 -0.0858 -0.3737 -0.1666 -0.4840 -0.2318 -0.1332 -0.3579 -0.1553
S-83	CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.<unk>
T-83	acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic ; therapy
H-83	-0.2952941656112671	▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁low - dos e ▁dop amine ▁; ▁low - dos e ▁nesi riti de ▁; ▁renal ▁function ▁; ▁di ure tic ▁ therapy
D-83	-0.2952941656112671	acute heart failure ; renal dysfunction ; low-dose dopamine ; low-dose nesiritide ; renal function ; diuretic therapy
P-83	-0.2584 -0.0144 -0.7220 -0.0389 -0.2119 -0.0069 -0.2295 -0.8728 -0.3322 -0.0164 -0.0629 -0.7892 -0.0762 -0.0391 -0.3681 -0.1292 -0.1216 -0.0420 -0.4273 -0.0320 -0.6957 -0.0920 -0.5499 -0.1862 -1.2461 -0.5191 -0.4112 -0.0568 -0.0953 -0.2558 -0.5361 -0.1304 -0.3069 -0.1675
S-1161	METHODS: Subjects with advanced HF (n = 408) underwent prospective assessment of body composition (skinfold thickness, dual-energy X-ray absorptiometry), comprehensive echocardiography, and blood testing.<unk>
T-1161	hf ; prospective ; dual-energy x-ray absorptiometry ; echocardiography ; blood
H-1161	-0.46084392070770264	▁ HF ▁; ▁body ▁composition ▁; ▁s kin fold ▁thi ck ness ▁; ▁dual - ener gy ▁x - ray ▁ab sor pti ometr y ▁; ▁e cho card i ography ▁; ▁blood ▁testing
D-1161	-0.46084392070770264	HF ; body composition ; skinfold thickness ; dual-energy x-ray absorptiometry ; echocardiography ; blood testing
P-1161	-1.6912 -0.5827 -0.2523 -1.2938 -1.0929 -0.1829 -1.1192 -1.3244 -0.9600 -0.9686 -0.2540 -0.3516 -0.1886 -0.0897 -0.0463 -0.1595 -0.0463 -0.9753 -0.0939 -0.1290 -0.0488 -0.8864 -0.3076 -0.0626 -0.1190 -0.1764 -0.0389 -0.5300 -0.6204 -0.4576 -0.4675 -0.3277 -0.1974 -0.1196 -0.2263 -0.2021
S-1744	Patients were subdivided in 4 enrollment periods on the basis of heart failure treatment eras: (1) 1977-1984 (n=66); (2) 1985-1990 (n=102); (3) 1991-2000 (n=197); (4) 2001-2011 (n=238).<unk>
T-1744	patients ; heart failure
H-1744	-1.5526868104934692	▁Patient s ▁; ▁heart ▁failure
D-1744	-1.5526868104934692	Patients ; heart failure
P-1744	-6.0502 -0.4058 -0.6435 -1.3533 -0.0976 -2.0733 -0.2450
S-36	Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease.<unk>
T-36	acp ; red blood cell transfusion ; hemoglobin ; hemoglobin ; hospitalized ; patients ; coronary heart disease
H-36	-1.1000003814697266	▁a CP ▁; ▁restrict ive ▁red ▁blood ▁cell ▁trans fusion ▁strategy ▁; tri gger ▁hem o glob in ▁thre s hold ▁; ▁hem o glob in ▁levels ▁; ▁corona ry ▁heart ▁disease
D-36	-1.1000003814697266	aCP ; restrictive red blood cell transfusion strategy ;trigger hemoglobin threshold ; hemoglobin levels ; coronary heart disease
P-36	-1.0999 -0.8500 -0.3503 -1.4369 -0.0104 -1.1151 -1.7611 -1.6431 -0.7383 -0.1916 -0.6277 -0.2366 -1.9226 -0.0496 -2.1404 -0.7342 -2.5375 -1.4492 -1.1478 -0.2074 -1.7087 -0.2395 -5.0147 -0.6936 -2.1372 -0.8775 -0.4008 -0.7062 -1.2531 -0.1493 -0.9717 -2.2495 -0.4295 -0.3189
S-1032	The objective of the measure is to motivate hospitals to improve the quality of care they provide patients hospitalized for heart failure (HF) and other conditions such as acute myocardial infarction, pneumonia, with expected future expansion to other conditions.<unk>
T-1032	hospitals ; patients ; hospitalized ; heart failure ; hf ; conditions ; acute myocardial infarction ; pneumonia ; conditions
H-1032	-0.5656142830848694	▁hospital s ▁; ▁heart ▁failure ▁; HF ▁; ▁conditions ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁pneu monia
D-1032	-0.5656142830848694	hospitals ; heart failure ;HF ; conditions ; acute myocardial infarction ; pneumonia
P-1032	-2.7968 -0.2687 -0.1649 -2.2915 -0.0649 -0.3504 -0.1182 -0.3892 -1.4038 -0.1797 -0.0537 -0.0101 -1.9934 -0.6145 -0.5145 -0.0418 -0.0249 -0.1277 -0.2400 -0.2987 -0.0015 -0.7100 -0.6300 -0.2857
S-1962	INTERPRETATION: This first-in-man experience with an implanted left-to-right interatrial shunt demonstrates initial safety and early beneficial clinical and haemodynamic outcomes in patients with heart failure with reduced ejection fraction.<unk>
T-1962	implanted ; interatrial shunt ; clinical ; haemodynamic ; outcomes ; patients ; heart failure with reduced ejection fraction
H-1962	-0.5719283819198608	▁implant ed ▁left - to - right ▁inter at rial ▁shu nt ▁; ▁ha emo dynamic ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-1962	-0.5719283819198608	implanted left-to-right interatrial shunt ; haemodynamic ; heart failure ; ejection fraction
P-1962	-5.0012 -0.0529 -0.7396 -0.0224 -0.1292 -0.1266 -0.0741 -0.1350 -0.5662 -0.3559 -0.1764 -1.0139 -0.2240 -0.1150 -1.3648 -0.0263 -1.6397 -0.8737 -0.0773 -0.2988 -0.4130 -0.2939 -0.3498 -0.5156 -0.0267 -0.5640 -0.2660
S-742	T1 time also correlated with right ventricular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular ejection fraction: R=0.28; P=0.01).<unk>
T-742	t1 time ; correlated ; right ventricular-pulmonary arterial coupling ; pulmonary vascular resistance ; right ventricular ejection fraction
H-742	-0.5984024405479431	▁right ▁vent ri cular - pul mon ary ▁arterial ▁coup ling ▁; pul mon ary ▁vas cular ▁resist ance ▁; ▁right ▁vent ri cular ▁e je ction ▁ fraction
D-742	-0.5984024405479431	right ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
P-742	-0.2593 -2.5215 -0.6643 -0.2719 -0.2104 -0.7873 -1.2280 -0.0258 -0.4458 -0.1548 -0.2284 -0.2179 -1.8561 -0.6811 -0.0085 -0.3424 -0.3821 -0.1886 -0.1028 -0.7004 -0.0257 -1.8157 -0.9285 -0.4912 -0.6774 -0.2806 -0.2720 -1.5493 -0.0535 -0.9886 -0.1908
S-308	Left ventricular assist devices (LVADs) are used in chronic end-stage heart failure as "bridge to transplantation" (BTT) and, more recently, for transplant-ineligible patients as "destination therapy" (DT).<unk>
T-308	left ventricular assist devices ; lvads ; chronic end-stage heart failure ; bridge to transplantation ; btt ; patients ; destination therapy ; dt
H-308	-0.5066317319869995	▁le ft ▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁chronic ▁end - s tage ▁heart ▁failure ▁; bridge ▁to ▁transplant ation ▁; ▁b t ▁; ▁transplant - ine ligi ble ▁patients ▁; ▁de stin ation ▁ therapy ▁; DT
D-308	-0.5066317319869995	left ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy ;DT
P-308	-1.7056 -0.0085 -2.2789 -1.0679 -0.2610 -1.3606 -0.2361 -0.3858 -0.3129 -0.1185 -0.0726 -0.3015 -2.0841 -0.3845 -0.1022 -0.0334 -0.0092 -1.3779 -0.1966 -0.1416 -0.0653 -0.0969 -0.2099 -0.2210 -0.5703 -1.0523 -0.5151 -0.3177 -0.4507 -0.2356 -0.0825 -0.1140 -0.1387 -0.8427 -0.1844 -2.1592 -0.0717 -0.0235 -0.1828 -0.0563 -1.3731 -0.4263 -0.2941 -0.1682
S-1973	Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.<unk>
T-1973	exercise ; training ; peak oxygen consumption ; quality of life ; obese ; patients ; heart failure with preserved ejection fraction ; randomized ; clinical
H-1973	-0.4364166855812073	▁Cal o ric ▁re stri ction ▁; ▁aero bic ▁exercise ▁training ▁; ▁Peak ▁o xy gen ▁consum p tion ▁; ▁quality ▁of ▁life ▁; ▁Heart ▁Fail ure ▁; ▁Pres er ved ▁e je ction ▁Fra ction
D-1973	-0.4364166855812073	Caloric restriction ; aerobic exercise training ; Peak oxygen consumption ; quality of life ; Heart Failure ; Preserved ejection Fraction
P-1973	-0.7945 -0.1528 -0.7867 -0.2466 -0.0804 -0.0597 -0.2073 -0.1225 -0.5879 -0.7692 -0.5778 -1.1782 -0.0075 -0.2932 -1.5695 -0.3041 -1.0809 -0.0372 -0.0707 -0.3024 -0.5215 -0.0195 -0.5561 -0.2944 -3.1447 -0.1215 -0.0192 -0.1553 -0.0296 -0.1329 -0.1440 -0.5730 -0.1810 -0.0954 -0.2215 -0.0661 -0.9002 -0.1789
S-855	Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).<unk>
T-855	carvedilol ; metoprolol ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-855	-0.5140502452850342	▁car vedi lol ▁; ▁met o pro lol ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁ therapy ▁; ▁MAD IT - C RT ▁trial ▁; Mul ti center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy
D-855	-0.5140502452850342	carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADIT-CRT trial ;Multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
P-855	-0.4094 -0.0272 -0.1605 -0.3424 -0.0932 -0.0986 -0.0665 -0.3089 -0.4090 -0.4615 -0.0086 -1.3438 -0.1187 -1.0777 -0.0867 -0.1601 -1.6376 -2.7269 -1.3280 -0.3041 -0.6211 -0.0551 -0.3393 -0.0637 -2.1850 -0.0392 -2.4937 -1.3341 -1.3765 -0.1909 -1.8304 -0.0197 -0.0189 -0.1497 -0.0145 -0.2115 -0.3739 -0.1614 -0.1599 -0.1015 -0.2100 -0.4948 -0.3544 -0.0384 -0.5976 -0.0244 -0.0034 -0.2511 -0.3098 -0.8155 -0.2075
S-610	Oral glucocorticoids were associated with a dose-related gradient of HF risk: compared with no use, 1≤5 mg HR 1.30 (95% CI 0.91 to 1.85), ≥5 mg HR 1.54 (95% CI 1.09 to 2.19).<unk>
T-610	oral ; glucocorticoids ; hf
H-610	-0.8722609281539917	▁Oral ▁gluco cor tico ids ▁; ▁dose - related ▁gradi ent ▁; ▁ HF ▁risk ▁; ▁HR
D-610	-0.8722609281539917	Oral glucocorticoids ; dose-related gradient ; HF risk ; HR
P-610	-1.1637 -0.2169 -0.7672 -2.3231 -0.4667 -0.2069 -3.4270 -0.1303 -0.1196 -0.0450 -0.1126 -0.8099 -0.0799 -0.0663 -2.1379 -0.6383 -2.1640 -1.5117 -0.1860
S-523	After 8 months of treatment, HR was significantly reduced in the ivabradine group (p < 0.0001) and was accompanied by marked reduction in Ea (p < 0.0001) and improved TAC (p = 0.004) compared with placebo.<unk>
T-523	ivabradine ; ea ; tac ; placebo
H-523	-0.5605272650718689	▁HR ▁; ▁i va bra dine ▁group ▁; ▁ea ▁; ▁ TAC
D-523	-0.5605272650718689	HR ; ivabradine group ; ea ; TAC
P-523	-1.7140 -0.2287 -0.0354 -0.8844 -0.1743 -0.0295 -0.6040 -0.1354 -1.7843 -0.1380 -0.8575 -0.2950 -0.7876 -0.1792
S-862	Treatment with carvedilol was associated with a significantly decreased risk of inappropriate therapy compared with metoprolol (hazard ratio [HR]: 0.64 [95% confidence interval (CI): 0.48 to 0.85]; p = 0.002).<unk>
T-862	carvedilol ; therapy ; metoprolol ; hazard ratio ; confidence interval
H-862	-0.5691580176353455	▁car vedi lol ▁; ▁in appropria te ▁ therapy ▁; ▁met o pro lol ▁; haz ard ▁ratio
D-862	-0.5691580176353455	carvedilol ; inappropriate therapy ; metoprolol ;hazard ratio
P-862	-2.1594 -0.0795 -0.2891 -0.3662 -1.3583 -0.0036 -0.4532 -0.6971 -0.0566 -0.2018 -0.3516 -0.2562 -0.1955 -0.2975 -0.8019 -0.0278 -0.1184 -0.0089 -3.3925 -0.2681
S-1265	However, further studies with long-term follow-up, systemic adverse events evaluation, and other ethnic groups are still required to verify the efficacy and safety of CHM as an adjunctive treatment in all patients with DCM and heart failure.<unk>
T-1265	follow-up ; systemic ; adverse events ; patients ; dcm ; heart failure
H-1265	-0.7658647894859314	▁gh m ▁; ▁ad ju nc tive ▁treatment ▁; ▁d CM ▁; ▁heart ▁failure
D-1265	-0.7658647894859314	ghm ; adjunctive treatment ; dCM ; heart failure
P-1265	-5.6567 -0.1811 -0.2226 -0.2854 -0.2135 -0.1226 -0.0277 -1.9441 -0.1665 -0.3365 -1.8536 -0.1688 -0.5285 -0.0715 -0.2956 -0.1791
S-1325	CONCLUSIONS: This study shows for the first time that testosterone supplementation during a program of exercise rehabilitation is feasible and can positively impact on a range of key health outcomes in elderly male patients with CHF who have a low testosterone status.<unk>
T-1325	testosterone supplementation ; exercise rehabilitation ; health ; outcomes ; patients ; chf ; testosterone
H-1325	-0.4644681513309479	▁testosteron e ▁; ▁exercise ▁rehabilita tion ▁; ▁CHF ▁; ▁low ▁testosteron e ▁status
D-1325	-0.4644681513309479	testosterone ; exercise rehabilitation ; CHF ; low testosterone status
P-1325	-0.7407 -0.0681 -1.3969 -0.8194 -0.5483 -0.1214 -0.3844 -1.5157 -0.3046 -0.2603 -0.1538 -0.0757 -0.1668 -0.2874 -0.1236
S-1987	The change in peak VO2 was positively correlated with the change in percent lean body mass (r = 0.32; P = .003) and the change in thigh muscle:intermuscular fat ratio (r = 0.27; P = .02).<unk>
T-1987	change ; peak vo2 ; correlated ; change ; lean body mass ; change ; thigh ; muscle
H-1987	-0.45691201090812683	▁pe ak ▁VO 2 ▁; ▁change ▁; ▁lean ▁body ▁mass ▁; ▁th igh ▁muscle ▁; inter mus cular ▁fat ▁ratio
D-1987	-0.45691201090812683	peak VO2 ; change ; lean body mass ; thigh muscle ;intermuscular fat ratio
P-1987	-0.2144 -0.0236 -0.6963 -0.1168 -0.1321 -1.8656 -0.3306 -1.4585 -0.2237 -0.1045 -0.1429 -1.3023 -0.3422 -0.7791 -0.3606 -0.1842 -0.1304 -0.1947 -0.5613 -0.0324 -0.5586 -0.2972
S-189	METHODS: We included hospitals in Get With The Guidelines-Heart Failure that admitted 99,930 HF patients with reduced (EF <40%), borderline (EF 40%-49%), or preserved (EF ≥50%) EF.<unk>
T-189	hospitals ; get with the guidelines-heart failure ; hf ; patients ; ef ; ef ; ef ; ef
H-189	-0.7124813795089722	▁guide lines - He art ▁Fail ure ▁; ▁ HF ▁; ▁border line ▁; EF ▁; ▁EF
D-189	-0.7124813795089722	guidelines-Heart Failure ; HF ; borderline ;EF ; EF
P-189	-2.0449 -0.2228 -0.0694 -1.1549 -0.2643 -0.2520 -0.0616 -0.2205 -0.4182 -0.2851 -0.8869 -3.9674 -0.0075 -0.2985 -0.4909 -0.9982 -1.3683 -0.2372 -0.2886
S-2017	CONCLUSION: The Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model provides researchers and providers with a tool for conducting long-term cost-effectiveness analyses of disease management programs in heart failure.<unk>
T-2017	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; disease ; heart failure
H-2017	-0.8619539141654968	▁economic ▁analysis ▁; ▁Patient ▁management ▁Interven tions ▁; ▁Heart ▁Fail ure ▁; ▁cost - e ff ective ness ▁model ▁; ▁cost - effect ive ness ▁; ▁disease ▁management ▁; ▁heart ▁failure
D-2017	-0.8619539141654968	economic analysis ; Patient management Interventions ; Heart Failure ; cost-effectiveness model ; cost-effectiveness ; disease management ; heart failure
P-2017	-0.2018 -1.3852 -0.5498 -1.9910 -0.6168 -1.2630 -0.0266 -1.0082 -0.3748 -0.4422 -0.0343 -1.2186 -0.3731 -0.1323 -2.4473 -2.1932 -0.0665 -0.2138 -0.8696 -0.3457 -5.7309 -0.1693 -0.1280 -0.1996 -0.6048 -0.5764 -0.9199 -0.2437 -1.8749 -1.6739 -0.0784 -0.2234 -0.2674
S-385	CONCLUSIONS: The HFPSI uses readily available data to predict the 6-month risk of death and/or all-cause medical hospitalization in HF clinic outpatients and could potentially help allocate specialized HF resources within health systems.<unk>
T-385	hfpsi ; death ; medical ; hospitalization ; hf ; clinic ; outpatients ; hf ; health
H-385	-0.7222118973731995	▁ HF PSI ▁; ▁risk ▁of ▁death ▁; ▁medical ▁hospital ization ▁; ▁ HF ▁; ▁out patient s ▁; ▁ HF ▁resources ▁; ▁health ▁systems
D-385	-0.7222118973731995	HFPSI ; risk of death ; medical hospitalization ; HF ; outpatients ; HF resources ; health systems
P-385	-1.2129 -1.1166 -0.4246 -0.1952 -3.6226 -0.4241 -0.8318 -0.1319 -0.8477 -1.4379 -0.1570 -0.1621 -0.3131 -0.2673 -0.6415 -2.4964 -0.0377 -0.1317 -0.4008 -0.7760 -0.4199 -1.5616 -0.8969 -0.2477 -0.0948 -0.3708 -0.2789
S-1787	CONCLUSIONS: The development of cardiac insulin-resistance and decreased mitochondrial oxidative metabolism are early metabolic changes in the development of cardiac hypertrophy, which create an energy deficit that may contribute to the progression from hypertrophy to heart failure.<unk>
T-1787	cardiac ; insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; hypertrophy ; heart failure
H-1787	-0.3284394443035126	▁cardiac ▁insulin - re si stance ▁; ▁mito cho ndri al ▁oxid ative ▁metabolism ▁; ▁metabol ic ▁; ▁cardiac ▁hyper trop hy ▁; ▁energy ▁deficit ▁; ▁hyper trop hy ▁; ▁heart ▁failure
D-1787	-0.3284394443035126	cardiac insulin-resistance ; mitochondrial oxidative metabolism ; metabolic ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
P-1787	-0.1468 -0.1448 -0.1129 -0.1830 -1.4097 -0.0057 -0.0993 -0.5057 -1.1055 -0.2504 -0.0376 -0.1152 -0.1303 -0.1221 -0.1850 -0.3128 -0.0100 -0.9632 -0.2875 -0.4515 -0.0443 -0.7896 -0.1836 -0.0136 -0.0762 -0.1970 -1.0673 -0.1353 -1.1500 -0.1782 -0.2728 -0.0828 -0.2238 -0.1735
S-830	In the multivariate Cox model analysis adjusted for age and sex, PASP increase during exercise and peak o2 per kilogram remained independent prognostic markers (hazard ratio, 2.56 for peak o2 per kilogram and 2.84 for PASP increase).<unk>
T-830	multivariate cox model ; pasp ; exercise ; peak o2 ; prognostic ; hazard ratio ; peak o2 ; pasp
H-830	-0.7278337478637695	▁co x ▁model ▁; ▁PAS p ▁; ▁exercise ▁; ▁pe ak ▁o 2 ▁per ▁kilogram ▁; haz ard ▁ratio ▁; ▁pe ak ▁o 2 ▁per ▁kilogram ▁; ▁PAS p
D-830	-0.7278337478637695	cox model ; PASp ; exercise ; peak o2 per kilogram ;hazard ratio ; peak o2 per kilogram ; PASp
P-830	-0.0661 -0.6292 -0.1677 -0.3951 -3.5622 -0.3821 -0.5229 -1.7755 -0.1699 -0.0980 -0.0791 -0.0091 -0.1545 -0.8195 -0.3161 -0.6958 -7.2282 -0.4121 -0.0367 -0.4766 -0.0630 -0.1411 -0.0210 -0.2024 -0.6683 -0.4425 -1.0283 -0.8184 -0.4045 -0.5496 -0.2271
S-734	BACKGROUND: The underlying pathophysiology of heart failure with preserved ejection fraction (HFPEF) is incompletely understood, but myocardial extracellular matrix accumulation is thought to play a major role.<unk>
T-734	pathophysiology ; heart failure with preserved ejection fraction ; hfpef ; myocardial extracellular matrix
H-734	-0.5759409070014954	▁pat ho phy si ology ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁h f f ▁; ▁my o card ial ▁extra cel lular ▁matri x ▁accumula tion
D-734	-0.5759409070014954	pathophysiology ; heart failure ; preserved ejection fraction ; hff ; myocardial extracellular matrix accumulation
P-734	-2.6624 -0.9763 -0.0684 -1.9809 -0.0629 -0.3081 -0.2034 -0.0518 -0.1018 -0.0438 -0.1212 -0.1079 -0.0494 -0.2139 -0.0791 -0.5681 -0.0193 -0.3476 -1.4359 -1.1365 -0.6902 -0.7187 -0.4465 -0.0731 -0.6086 -0.0411 -1.7773 -0.8141 -0.1110 -0.0843 -1.3632 -1.5019 -0.4232 -0.7809 -0.1850
S-338	The mechanism is a combination of annular size reduction by surgery and diastolic mitral valve tethering, restricting the anterior leaflet opening due to posteriorly displaced papillary muscles with left ventricular (LV) dilatation.<unk>
T-338	combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet ; papillary muscles ; left ventricular ; dilatation
H-338	-0.4173221290111542	▁ann ular ▁size ▁re duction ▁; ▁surgery ▁; ▁dia sto lic ▁mit ral ▁val ve ▁te ther ing ▁; ▁anterior ▁le a flet ▁opening ▁; ▁posterior ly ▁dis place d ▁papil lar y ▁muscle s ▁; ▁left ▁vent ri cular ▁; LV
D-338	-0.4173221290111542	annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular ;LV
P-338	-0.3803 -0.0004 -0.2512 -0.1719 -0.0051 -0.3402 -0.0511 -0.1319 -0.0651 -0.1648 -0.6518 -0.3758 -0.0836 -2.5428 -0.3066 -0.0406 -0.1264 -0.0459 -0.3744 -0.1532 -0.2349 -0.1109 -0.0071 -0.1073 -0.3304 -3.5796 -0.2241 -0.1583 -0.0542 -0.1379 -0.6223 -0.7895 -0.2796 -0.1406 -0.0405 -0.2681 -0.0304 -1.6583 -0.4544 -0.0674 -0.5858 -0.2403 -1.7111 -0.2659
S-1346	A protocol was originally designed to study breathing control during and following cardiac arrest in humans, taking advantage of the period of pulseless ventricular fibrillation (PVF) produced while testing a newly implanted cardioverter-defibrillator device.<unk>
T-1346	breathing ; cardiac arrest ; advantage ; pulseless ventricular fibrillation ; pvf ; implanted ; cardioverter-defibrillator device
H-1346	-0.7374193072319031	▁breath ing ▁control ▁; ▁cardiac ▁arrest ▁; ▁puls e less ▁vent ri cular ▁fi bril lation ▁; PV f ▁; ▁cardio ver ter - de fi br illa tor ▁device
D-1346	-0.7374193072319031	breathing control ; cardiac arrest ; pulseless ventricular fibrillation ;PVf ; cardioverter-defibrillator device
P-1346	-2.9659 -0.1607 -0.3394 -0.4107 -0.6805 -0.0115 -0.2675 -2.3544 -0.1150 -0.0596 -2.6382 -0.6787 -0.3457 -2.0939 -0.2717 -1.6990 -0.2703 -0.0476 -1.0019 -0.2251 -0.8308 -0.0598 -0.3736 -0.0635 -0.0528 -0.4291 -1.9660 -1.4184 -0.1661 -0.8225 -0.5588 -0.2187
S-1672	Rad, a member of the RGK (Rem, Rem2, Rad, Gem/Kir) family of monomeric G proteins, regulates ventricular action potential duration and EC coupling gain through its ability to inhibit cardiac L-type channel activity.<unk>
T-1672	rad ; rgk ; rem ; rem2 ; rad ; monomeric g proteins ; ventricular action potential ; gain ; cardiac ; l-type channel ; activity
H-1672	-0.4644840657711029	▁Rad ▁; ▁re m ▁; ▁Rem 2 ▁; ▁Rad ▁; ▁Gem ▁; Kir ▁; ▁mono me ric ▁g ▁protein s ▁; ▁regula tes ▁vent ri cular ▁action ▁potential ▁du ration ▁; ▁EC ▁coup ling ▁gain ▁; ▁cardiac ▁l - type ▁channel ▁activity
D-1672	-0.4644840657711029	Rad ; rem ; Rem2 ; Rad ; Gem ;Kir ; monomeric g proteins ; regulates ventricular action potential duration ; EC coupling gain ; cardiac l-type channel activity
P-1672	-0.3219 -0.3317 -1.1299 -0.0514 -0.3394 -0.0431 -0.0353 -0.1355 -0.4059 -0.4113 -0.0884 -2.1845 -0.8239 -0.5193 -0.1496 -0.0363 -0.1284 -0.6236 -1.0855 -0.0305 -0.3041 -0.5189 -0.3729 -2.5821 -1.1695 -0.4307 -0.4103 -0.1034 -0.1476 -0.0300 -0.1437 -0.5625 -0.0230 -0.0202 -0.2678 -0.2484 -1.0934 -2.1137 -0.0907 -0.1445 -0.0417 -0.0873 -0.4425 -0.2131
S-1136	We investigated the long-term (4 wk) effects of the acetylcholinesterase inhibitor pyridostigmine on sympathovagal balance, cardiac remodeling, and cardiac function in the onset of HF following myocardial infarction.<unk>
T-1136	acetylcholinesterase inhibitor ; pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; hf ; myocardial infarction
H-1136	-0.5348424911499023	▁a ce tyl cho line ster ase ▁inhibi tor ▁py rido stig mine ▁; ▁sympa t hova gal ▁balance ▁; ▁cardiac ▁remodel ing ▁; ▁cardiac ▁function ▁; ▁ HF ▁; ▁my o card ial ▁in far ction
D-1136	-0.5348424911499023	acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; HF ; myocardial infarction
P-1136	-0.3753 -0.6787 -0.6836 -2.1780 -0.2315 -1.7124 -1.4735 -0.1436 -0.0285 -1.6261 -0.0277 -0.0010 -0.5055 -0.4365 -0.1038 -0.5532 -0.1113 -0.0709 -0.0789 -0.2694 -0.0366 -0.2237 -0.0468 -0.3041 -0.3456 -0.4595 -0.2241 -0.7956 -0.0826 -0.2404 -1.5312 -0.5892 -1.8418 -0.3182 -0.0713 -0.4129 -1.1997 -0.5750 -0.2714
S-1112	The aim of this study was, first, to assess whether there is a differential response in cardiac sympathetic activity by (123)I-meta-iodobenzylguanidine ((123)I-MIBG) imaging when either β-blocker is used.<unk>
T-1112	cardiac sympathetic activity ; β-blocker
H-1112	-0.5912337899208069	▁cardiac ▁sympa the tic ▁activity ▁; ▁i - meta - i odob enz yl guan i dine ▁; ▁i - mi BG ▁; ▁β - block er
D-1112	-0.5912337899208069	cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; β-blocker
P-1112	-1.8495 -0.8206 -1.5969 -0.2758 -0.0931 -0.1694 -0.3646 -0.1899 -0.0052 -0.1470 -0.1475 -0.6192 -0.6705 -3.9452 -0.1737 -0.4426 -0.0688 -0.0960 -0.0796 -0.0734 -0.8264 -1.3907 -0.4428 -1.0245 -0.0786 -0.5453 -0.3275 -0.4322 -0.2493
S-971	From the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry, we included all 36,284 patients who underwent primary isolated CABG from 2000 to 2008 in Sweden.<unk>
T-971	evidence-based ; heart disease ; therapies ; patients ; cabg ; sweden
H-971	-0.4614877998828888	▁Swedish ▁web - system ▁for ▁en han ce ment ▁and ▁development ▁of ▁e viden ce - based ▁care ▁; ▁Heart ▁disease ▁; ▁Reco mmende d ▁Therapie s ▁registr y ▁; ▁primary ▁isola ted ▁ca BG
D-971	-0.4614877998828888	Swedish web-system for enhancement and development of evidence-based care ; Heart disease ; Recommended Therapies registry ; primary isolated caBG
P-971	-0.9987 -0.9774 -0.0530 -0.0753 -0.5058 -1.2081 -0.0949 -0.7896 -0.0215 -0.1710 -0.0739 -0.2302 -0.9494 -0.0836 -0.0748 -0.0587 -0.0036 -0.4905 -0.5614 -0.4031 -0.6795 -0.3878 -0.8953 -0.0049 -0.0367 -0.2215 -0.0243 -0.8934 -0.0803 -0.3536 -1.6693 -0.0091 -0.0087 -1.0242 -1.0513 -1.7671 -0.1436
S-756	In the LVEF <30% subgroup, significant improvements in clinical composite response (P=0.02), reverse remodeling parameters, and time to death or first HF hospitalization (hazard ratio, 0.58; P=0.047) were observed.<unk>
T-756	lvef ; clinical ; reverse remodeling ; death ; hf ; hospitalization ; hazard ratio
H-756	-0.41793134808540344	▁LV EF ▁; ▁clinic al ▁com posit e ▁response ▁; ▁rever se ▁remodel ing ▁parameter s ▁; ▁time ▁to ▁death ▁; ▁ HF ▁hospital ization ▁; haz ard ▁ratio
D-756	-0.41793134808540344	LVEF ; clinical composite response ; reverse remodeling parameters ; time to death ; HF hospitalization ;hazard ratio
P-756	-0.1478 -0.3857 -0.1117 -2.3552 -0.0379 -0.5217 -0.0136 -0.0634 -0.3581 -0.1615 -0.0024 -0.0240 -0.0623 -0.0396 -0.2833 -0.0824 -0.1801 -1.9155 -0.1396 -0.3412 -0.0443 -1.8742 -0.1618 -1.5184 -0.3335 -0.7538 -0.0095 -0.3019 -0.0316 -0.4898 -0.2102
S-1569	In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels ≥ 100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels < 100 pg/mL (low BNP group).<unk>
T-1569	patients ; brain natriuretic peptide ; bnp ; bnp ; patients ; bnp ; bnp
H-1569	-0.8048647046089172	▁brain ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁b NP ▁; ▁b NP
D-1569	-0.8048647046089172	brain natriuretic peptide ; bNP ; bNP ; bNP
P-1569	-1.4384 -0.0059 -0.1638 -0.0366 -0.5376 -0.0478 -0.3787 -1.5696 -0.2906 -1.5157 -0.7000 -0.5534 -1.2471 -0.8557 -0.9695 -1.2682 -0.9645 -2.5796 -0.1698
S-79	MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).<unk>
T-79	outcomes ; coprimary end points ; end point ; change ; serum cystatin c ; renal function ; end point
H-79	-0.6289893984794617	▁co prima ry ▁end ▁points ▁; ▁cum ul ative ▁urin e ▁volume ▁; ▁de con gestion ▁end ▁point ▁; ▁se rum ▁cyst atin ▁C ▁; ▁en roll ment ▁; ren al ▁function ▁end ▁point
D-79	-0.6289893984794617	coprimary end points ; cumulative urine volume ; decongestion end point ; serum cystatin C ; enrollment ;renal function end point
P-79	-1.3888 -0.1710 -0.0566 -0.7887 -0.1065 -0.3072 -0.1995 -0.0777 -0.0721 -1.4287 -0.1258 -0.5021 -0.1906 -0.4443 -0.0170 -0.1053 -1.1854 -0.3609 -0.6952 -0.2163 -0.1900 -0.1253 -1.2405 -2.0807 -0.3179 -0.3739 -0.0367 -0.0523 -0.3628 -5.7675 -0.0405 -0.2343 -2.0117 -0.3573 -0.8243 -0.1882
S-493	We hypothesized that the relationship between TAPSE (longitudinal RV fiber shortening) and PASP (force generated by the RV) provides an index of in vivo RV length-force relationship, with their ratio better disclosing prognosis.<unk>
T-493	tapse ; longitudinal rv fiber shortening ; pasp ; rv ; in vivo ; rv ; prognosis
H-493	-0.6611422896385193	▁t p se ▁; long itud in al ▁ RV ▁fiber ▁short en ing ▁; ▁PAS p ▁; force ▁; ▁ RV ▁; ▁length - force ▁relationship ▁; ▁disc los ing ▁prognos is
D-493	-0.6611422896385193	tpse ;longitudinal RV fiber shortening ; PASp ;force ; RV ; length-force relationship ; disclosing prognosis
P-493	-1.6626 -1.4449 -2.2786 -0.1338 -0.6598 -0.3449 -1.4972 -0.3852 -0.3464 -1.3753 -2.4445 -0.8044 -0.3899 -0.1135 -0.3052 -0.6031 -0.3629 -0.1209 -0.3715 -0.6309 -0.4676 -0.5205 -0.3392 -1.7541 -0.1629 -0.0598 -0.7807 -0.5648 -0.6945 -0.0175 -0.0370 -0.2250 -0.6914 -0.3544 -0.1952
S-1210	Among the PDE superfamily, PDE2 has the unique property of being able to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis mediating a negative cross talk between cGMP and cAMP signaling.<unk>
T-1210	pde ; pde2 ; cgmp ; leading ; camp hydrolysis ; cross talk ; cgmp ; camp signaling
H-1210	-0.4418765604496002	▁p de ▁super family ▁; ▁p de 2 ▁; ▁c g m ▁; ▁c AMP ▁hydro lys is ▁; ▁negative ▁cross ▁talk ▁; ▁c g m ▁; ▁c AMP ▁signal ing
D-1210	-0.4418765604496002	pde superfamily ; pde2 ; cgm ; cAMP hydrolysis ; negative cross talk ; cgm ; cAMP signaling
P-1210	-0.1921 -0.9536 -0.7577 -0.3416 -0.1921 -0.2041 -0.7771 -0.0460 -0.1739 -0.0188 -0.4967 -1.3209 -0.1467 -0.0082 -3.5675 -0.0439 -0.2131 -0.3423 -0.1168 -1.0240 -0.1851 -0.1787 -0.1848 -0.0061 -0.6013 -0.9348 -0.1230 -0.0071 -0.6987 -0.1672 -0.1072 -0.2747 -0.1762
S-14	RESULTS: N-terminal proBNP (NT-proBNP), midregional proANP (MR-proANP), and total adiponectin were elevated in CHF (p<0.001) and correlated inversely to BMI and FM.<unk>
T-14	n-terminal probnp ; nt-probnp ; midregional proanp ; mr-proanp ; adiponectin ; elevated ; chf ; correlated ; bmi
H-14	-0.5813313722610474	▁na - termin al ▁pro b NP ▁; NT - pro b NP ▁; ▁mid region al ▁pro an p ▁; MR - pro an p ▁; ▁adi pon ect in ▁; ▁CHF ▁; ▁b mi ▁; ▁FM
D-14	-0.5813313722610474	na-terminal probNP ;NT-probNP ; midregional proanp ;MR-proanp ; adiponectin ; CHF ; bmi ; FM
P-14	-1.8824 -0.6195 -0.0437 -0.0041 -0.0135 -2.2218 -0.6791 -0.1746 -0.6587 -0.0143 -0.0677 -1.0738 -0.3147 -0.0980 -0.0451 -0.0671 -0.0218 -0.0067 -3.5822 -0.3998 -0.1401 -0.0763 -0.0222 -0.0183 -2.4949 -0.2235 -0.2288 -2.3988 -0.0204 -0.1140 -0.4124 -0.1867 -0.5735 -0.1569 -1.9758 -1.4666 -0.1788 -0.1448 -0.2498 -0.1822
S-900	There was a significant decrease in re-hospitalization from an average of 3.2 ± 2.5 to 0.1 ± 0.3 admissions per patient (p = 0.007) and reduced average length of stay from 37 ± 36.7 to 0.78 ± 2.3 days (p = 0.019).<unk>
T-900	re-hospitalization ; admissions ; patient
H-900	-0.5193648934364319	▁re - hospital ization ▁; ▁ad missions
D-900	-0.5193648934364319	re-hospitalization ; admissions
P-900	-0.2599 -0.1170 -0.0279 -0.2437 -0.4453 -0.0017 -0.0161 -3.3934 -0.1691
S-870	BACKGROUND: We investigated the protective effects of mitochondrial-targeted antioxidant and protective peptides, Szeto-Schiller (SS) 31 and SS20, on cardiac function, proteomic remodeling, and signaling pathways.<unk>
T-870	peptides ; szeto-schiller ; ss ; ss20 ; cardiac function ; proteomic remodeling ; signaling pathways
H-870	-0.35385674238204956	▁mito cho ndri al - tar get ed ▁antioxidant ▁; ▁protect ive ▁pe pti des ▁; ▁Sze to - Sch iller ▁; ▁SS 20 ▁; ▁cardiac ▁function ▁; ▁prote om ic ▁remodel ing ▁; ▁signal ing ▁path ways
D-870	-0.35385674238204956	mitochondrial-targeted antioxidant ; protective peptides ; Szeto-Schiller ; SS20 ; cardiac function ; proteomic remodeling ; signaling pathways
P-870	-0.8024 -1.4444 -0.2414 -0.0432 -0.0723 -0.0382 -0.3251 -0.0113 -0.1045 -0.2046 -0.4135 -0.0105 -0.0090 -0.2304 -1.0228 -0.6190 -0.0019 -0.0062 -0.0500 -0.6870 -0.2076 -0.3391 -2.0368 -1.2076 -0.4350 -0.0653 -0.3270 -0.3246 -0.3410 -0.3486 -0.2831 -0.0729 -0.0312 -1.0836 -0.0492 -0.1722 -0.0131 -0.0609 -0.2908 -0.1269
S-1291	HISTORY AND CLINICAL FINDINGS: We present a 41-year-old man with cardiac arrest in need of cardiopulmonary resuscitation (CPR) with the diagnosis of a posterior wall infarction, who was hospitalized in our cardiac centre.<unk>
T-1291	clinical ; cardiac arrest ; cardiopulmonary resuscitation ; cpr ; diagnosis ; posterior wall infarction ; hospitalized ; cardiac
H-1291	-0.35561299324035645	▁cardiac ▁arrest ▁; ▁cardio pul mon ary ▁res uscita tion ▁; ▁c PR ▁; ▁posterior ▁wall ▁in far ction ▁; ▁cardiac ▁centre
D-1291	-0.35561299324035645	cardiac arrest ; cardiopulmonary resuscitation ; cPR ; posterior wall infarction ; cardiac centre
P-1291	-1.4953 -0.0159 -0.0875 -0.2196 -0.1638 -1.2969 -0.0656 -0.0404 -0.0141 -0.2022 -0.2401 -0.4603 -0.9526 -0.2846 -0.0587 -0.4315 -0.0306 -0.1034 -0.1714 -0.8222 -0.4492 -0.4946 -0.2240 -0.2102
S-1702	BACKGROUND: The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure (HF) is unknown.<unk>
T-1702	incidence ; hyperkalemia ; mineralocorticoid receptor antagonists ; mineralocorticoid receptor antagonists ; heart failure ; hf
H-1702	-0.6021331548690796	▁hyper kal emia ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁race ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists ▁; ▁heart ▁failure ▁; HF
D-1702	-0.6021331548690796	hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ;HF
P-1702	-1.1421 -0.6313 -0.4417 -0.3638 -0.1523 -0.2924 -1.7430 -2.0907 -1.1944 -0.0086 -0.3120 -0.3656 -0.3851 -0.2553 -0.0791 -0.1132 -1.1034 -0.3358 -1.8571 -2.1240 -0.9067 -0.0166 -0.8842 -0.5321 -0.5995 -0.2120 -0.1436 -0.0515 -0.5307 -0.1273 -0.1270 -0.1466
S-37	(Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.<unk>
T-37	grade ; evidence ; acp ; erythropoiesis-stimulating agents ; patients ; anemia ; congestive heart failure ; coronary heart disease
H-37	-0.5485548377037048	▁er y thro po ies is - stimul ating ▁agents ▁; ▁an emia ▁; ▁con ges tive ▁heart ▁failure ▁; ▁corona ry ▁heart ▁disease
D-37	-0.5485548377037048	erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
P-37	-2.7454 -0.2169 -0.8681 -0.1047 -2.5826 -0.5727 -0.9111 -0.0317 -0.2407 -0.4992 -0.2452 -0.7462 -0.0808 -0.0805 -0.0208 -0.1639 -0.1734 -0.4378 -0.0746 -0.1881 -0.0213 -0.0925 -1.1339 -1.4386 -0.2913 -0.3004
S-1831	PATIENTS: Patients aged 18 years or older with type 2 diabetes who initiated therapy with saxagliptin, sitagliptin, pioglitazone, second-generation sulfonylureas, or long-acting insulin products from 2006 to 2013.<unk>
T-1831	patients ; patients ; type 2 diabetes ; therapy ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; insulin
H-1831	-0.5647138953208923	▁diabetes ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁second - genera tion ▁sul fon yl ure as ▁; ▁long - ac ting ▁insulin
D-1831	-0.5647138953208923	diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; long-acting insulin
P-1831	-4.2880 -0.2726 -0.3958 -0.1631 -0.6686 -2.6258 -0.3063 -1.0204 -0.2358 -0.1594 -2.0828 -0.2175 -0.0033 -0.8052 -0.0866 -0.2013 -0.2054 -1.0464 -0.0518 -0.1171 -0.0478 -0.1173 -0.4126 -0.5186 -0.0081 -0.0263 -0.3004 -1.2525 -0.0283 -0.0122 -0.0191 -0.0444 -1.1363 -0.3231
S-1082	METHODS AND RESULTS: UPR and SCN5A were analyzed in human ventricular systolic HF tissue samples and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).<unk>
T-1082	upr ; scn5a ; ventricular systolic hf ; human induced pluripotent stem cell-derived cardiomyocytes ; hipsc-cms
H-1082	-0.6086922287940979	▁u PR ▁; ▁s n 5 a ▁; ▁vent ri cular ▁sy sto lic ▁ HF ▁tissu e ▁sample s ▁; ▁induc ed ▁pluri potent ▁stem ▁cell - der i ved ▁cardio my o cy tes ▁; hi ps c - CM s
D-1082	-0.6086922287940979	uPR ; sn5a ; ventricular systolic HF tissue samples ; induced pluripotent stem cell-derived cardiomyocytes ;hipsc-CMs
P-1082	-0.0773 -1.6903 -0.2169 -0.0464 -1.4636 -0.1237 -0.1292 -0.2249 -2.9316 -1.1332 -0.2094 -1.4898 -0.1008 -0.8364 -0.7217 -1.1027 -1.4131 -0.2667 -1.6916 -0.0900 -0.2261 -0.4076 -0.0177 -0.0118 -0.0333 -0.0747 -0.3004 -0.1545 -0.0360 -0.1303 -0.1110 -0.2923 -1.9324 -0.5541 -0.1017 -0.1699 -0.3756 -1.6918 -2.9652 -0.6397 -0.1064 -0.2858 -0.0192 -0.5864 -0.2079
S-175	In ambulatory patients with heart failure (HF) and reduced ejection fraction (rEF), renin-angiotensin system (RAS) and β-blockers at guideline-recommended target dose reduce all-cause mortality and readmissions.<unk>
T-175	ambulatory ; patients ; heart failure ; hf ; reduced ejection fraction ; renin-angiotensin system ; ras ; β-blockers ; all-cause mortality ; readmissions
H-175	-0.5753335952758789	▁ambula tory ▁patients ▁; ▁heart ▁failure ▁; HF ▁; ▁e je ction ▁ fraction ▁; r EF ▁; ▁re nin - angi oten sin ▁system ▁; RAS ▁; ▁β - block ers
D-175	-0.5753335952758789	ambulatory patients ; heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ;RAS ; β-blockers
P-175	-2.4606 -0.0072 -1.2902 -0.3387 -0.4617 -0.0803 -0.2629 -0.0710 -0.1849 -0.6208 -0.2700 -0.0869 -0.5970 -0.0324 -0.3015 -0.5687 -0.4838 -0.0961 -0.0036 -1.4340 -0.1461 -0.1606 -2.4665 -0.5449 -0.0409 -0.6656 -0.1866 -0.4182 -0.1884 -0.0346 -0.1044 -0.0766 -4.6233 -0.2521
S-1847	We will classify interventions according to their level of application (ie, provider, organisation, systems level) and common underlying characteristics (eg, education, decision-support, financial incentives) using the Cochrane Effective Practice and Organisation of Care Taxonomy.<unk>
T-1847	financial ; cochrane effective practice and organisation of care taxonomy
H-1847	-0.5708536505699158	▁co ch rane ▁Effective ▁practice ▁; ▁organisation ▁of ▁care ▁tax ono my
D-1847	-0.5708536505699158	cochrane Effective practice ; organisation of care taxonomy
P-1847	-0.5501 -0.2012 -0.0380 -2.6263 -0.1767 -0.2458 -0.2057 -0.0321 -0.7948 -0.2323 -0.0554 -2.0347 -0.5873 -0.2115
S-802	RESULTS: Good agreement was observed, in general, for both the total sample and subgroups (COPD, CHF, CRF), with ICC values ranging from .85 to .98, and kappa coefficients from .49 to 1.00.<unk>
T-802	copd ; chf ; crf ; icc ; kappa coefficients
H-802	-0.5720255374908447	▁co PD ▁; ▁CHF ▁; ▁c RF ▁; ▁ICC ▁; ▁ka ppa ▁co ef fici ents
D-802	-0.5720255374908447	coPD ; CHF ; cRF ; ICC ; kappa coefficients
P-802	-1.1613 -4.1737 -0.2930 -0.0276 -0.2605 -0.1945 -1.4824 -0.5339 -0.2819 -0.4410 -0.1847 -0.0391 -0.1517 -0.0353 -0.0075 -0.0981 -0.6805 -0.2499
S-1913	METHODS: Patients (n = 5) with stable heart failure and a left ventricular ejection fraction of less than 45% completed a four-week aerobic training period with three trainings per week and an integrated dynamic resistance training of the lower limbs.<unk>
T-1913	patients ; stable heart failure ; left ventricular ejection fraction ; training ; training
H-1913	-0.7876246571540833	▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁aero bic ▁training ▁; ▁dynamic ▁resist ance ▁training ▁; ▁lower ▁lim bs
D-1913	-0.7876246571540833	heart failure ; left ventricular ejection fraction ; aerobic training ; dynamic resistance training ; lower limbs
P-1913	-4.1719 -0.1426 -0.1612 -0.1879 -3.6713 -2.0706 -0.8414 -0.1464 -0.3065 -0.1517 -1.7224 -0.0837 -0.2884 -1.0064 -0.8251 -0.6134 -0.6015 -0.9092 -0.2522 -0.0727 -0.9237 -0.4768 -0.1025 -0.3765 -0.5735 -0.3111 -0.2753
S-1865	CONCLUSION: The patient preferences identified in this study support the need to include information on implantable cardioverter-defibrillator deactivation at implant, with change in clinical status and within broader discussions about end-of-life treatment preferences.<unk>
T-1865	patient ; implantable cardioverter-defibrillator ; implant ; change ; clinical
H-1865	-0.6255478262901306	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant ▁; ▁clinic al ▁status ▁; ▁end - of - life
D-1865	-0.6255478262901306	implantable cardioverter-defibrillator deactivation ; implant ; clinical status ; end-of-life
P-1865	-3.3093 -0.0598 -0.5546 -0.0558 -0.3603 -0.0810 -0.0461 -0.8237 -2.8023 -1.1661 -0.0975 -0.1754 -0.0643 -0.2449 -0.4228 -0.7042 -0.7842 -1.8639 -0.0332 -0.2661 -0.4844 -0.1662 -0.1172 -0.0473 -0.1060 -0.1350 -2.3111 -0.2325
S-987	The remaining patients, which will be focused on below, have heart failure that is principally related to poor myocardial function and largely comprise those children with dilated poorly contracting ventricles, which can be related to specific aetiologies in some cases.<unk>
T-987	patients ; heart failure ; myocardial function ; dilated ; contracting ; ventricles ; aetiologies
H-987	-0.7318681478500366	▁heart ▁failure ▁; ▁my o card ial ▁function ▁; ▁dil ated ▁; ▁contract ing ▁vent ric les
D-987	-0.7318681478500366	heart failure ; myocardial function ; dilated ; contracting ventricles
P-987	-2.3202 -0.0884 -0.1370 -1.5271 -0.2205 -1.0148 -0.1703 -0.3671 -0.2216 -2.3030 -0.0255 -0.7822 -0.0992 -0.0366 -1.1999 -2.4356 -0.0361 -0.7199 -0.2005
S-1866	Using this process to help patients determine and communicate their implantable cardioverter-defibrillator deactivation preferences may reduce the number of patients experiencing distressing implantable cardioverter-defibrillator shocks at end of life.<unk>
T-1866	patients ; implantable cardioverter-defibrillator ; patients ; implantable cardioverter-defibrillator
H-1866	-0.6760339736938477	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁preference s ▁; ▁di stress ing ▁implant able ▁cardio ver ter - de fi br illa tor ▁shock s
D-1866	-0.6760339736938477	implantable cardioverter-defibrillator deactivation preferences ; distressing implantable cardioverter-defibrillator shocks
P-1866	-2.3791 -0.0439 -0.5138 -0.1163 -0.8490 -0.0638 -0.0633 -1.2788 -3.0068 -1.2778 -0.1672 -0.3188 -0.0567 -0.4272 -0.3360 -0.0668 -0.4213 -0.3234 -0.0365 -0.2492 -1.0948 -0.0809 -0.8993 -0.1542 -0.9377 -0.0907 -0.0516 -1.2264 -2.7761 -1.8869 -0.1808 -0.9164 -0.1376 -0.9619 -0.2701
S-809	OBJECTIVE: Although global left ventricular longitudinal systolic strain (GLS) is a sensitive measure of left ventricular mechanics, its relationship with adverse cardiovascular (CV) events in atrial fibrillation (AF) has not been evaluated.<unk>
T-809	global left ventricular longitudinal systolic strain ; gls ; left ventricular ; cardiovascular ; atrial fibrillation
H-809	-0.6560488939285278	▁global ▁left ▁vent ri cular ▁longitud in al ▁sy sto lic ▁strain ▁; ▁g ls ▁; ▁left ▁vent ri cular ▁mechanic s ▁; ▁advers e ▁cardiovascular ▁; CV ▁; ▁events ▁; ▁at rial ▁fi bril lation ▁; AF
D-809	-0.6560488939285278	global left ventricular longitudinal systolic strain ; gls ; left ventricular mechanics ; adverse cardiovascular ;CV ; events ; atrial fibrillation ;AF
P-809	-0.3734 -0.5987 -3.0652 -0.4723 -0.3338 -0.0284 -0.1842 -0.0552 -2.6432 -0.1586 -1.2035 -0.6604 -0.5161 -0.3487 -2.3750 -0.2634 -1.7000 -2.7488 -0.9146 -0.5145 -0.0634 -0.0352 -0.2464 -2.7141 -0.0352 -0.0815 -0.2827 -0.0329 -0.1705 -0.6955 -0.1491 -0.1278 -0.0488 -0.6341 -0.0516 -0.7317 -0.4861 -0.0250 -0.2734 -0.1990
S-1675	We have found that mouse Rad Q65P (the murine equivalent of human Rad Q66P) inhibits L-type currents conducted by CaV1.2 or CaV1.3 channels as potently as wild-type Rad (>95% inhibition of both channels).<unk>
T-1675	rad ; q65p ; murine ; rad ; q66p ; l-type currents ; cav1.2 ; cav1.3 ; wild-type rad
H-1675	-0.6657125353813171	▁mouse ▁Rad ▁Q 65 p ▁; ▁mur ine ▁equivalent ▁; ▁human ▁Rad ▁Q 66 p ▁; ▁l - type ▁current s ▁; ▁ca v 1.2 ▁; ▁ca v 1.3 ▁channel s ▁; ▁wild - type ▁Rad
D-1675	-0.6657125353813171	mouse Rad Q65p ; murine equivalent ; human Rad Q66p ; l-type currents ; cav1.2 ; cav1.3 channels ; wild-type Rad
P-1675	-0.1071 -1.1087 -4.6576 -0.1764 -0.2660 -0.1279 -0.2221 -0.1264 -0.8633 -0.4901 -0.5228 -0.7504 -2.7653 -0.2195 -0.1952 -0.1983 -2.5818 -0.2183 -0.5860 -1.1720 -0.1777 -0.2238 -0.1782 -0.6526 -0.4068 -0.0655 -0.4005 -0.4408 -0.3131 -2.3440 -0.1437 -0.1978 -0.6362 -0.0385 -0.3004 -0.2068 -1.0658 -0.1496
S-1108	Further adjustment for patient and MI characteristics yielded hazard ratios of 0.86 (95% CI: 0.66, 1.11) and 0.63 (95% CI: 0.45, 0.88) for early- and late-onset HF, respectively.<unk>
T-1108	patient ; mi ; hazard ratios ; hf
H-1108	-0.6524395942687988	▁MI ▁; ▁yi eld ed ▁hazard ▁ratio s ▁; ▁early - ons et ▁ HF
D-1108	-0.6524395942687988	MI ; yielded hazard ratios ; early-onset HF
P-1108	-2.9629 -0.3521 -0.3622 -0.0073 -0.1416 -1.5461 -0.0173 -0.1611 -0.2177 -2.8993 -0.0873 -0.3288 -0.6911 -0.5205 -0.1590 -0.2522 -0.3849
S-1693	RESEARCH DESIGN: Using national Medicare data, we created a cohort of older patients treated at an acute care hospital for HF (n=1,203,595), AMI (n=625,595), or PNA (n=1,234,299).<unk>
T-1693	medicare ; patients ; acute ; hospital ; hf ; ami ; pna
H-1693	-0.5980134606361389	▁Medica re ▁; ▁patients ▁; ▁a cute ▁care ▁hospital ▁; ▁ HF ▁; ▁ AMI ▁; ▁p na
D-1693	-0.5980134606361389	Medicare ; patients ; acute care hospital ; HF ; AMI ; pna
P-1693	-1.6753 -0.1246 -0.3583 -3.6696 -0.3105 -0.0748 -0.2746 -0.5771 -0.6505 -0.1440 -0.5871 -0.5382 -0.2043 -0.2728 -1.1109 -0.2564 -0.3862 -0.3813 -0.1620 -0.2019
S-404	Cardiovascular events were examined as a function of baseline sST2 status (low ≤35 versus high >35 ng/mL) and final achieved BB dose (high ≥50 versus low <50 mg daily equivalent dose of metoprolol succinate).<unk>
T-404	cardiovascular events ; baseline ; sst2 ; metoprolol succinate
H-404	-0.852773129940033	▁cardio vas cular ▁events ▁; ▁base line ▁s st 2 ▁status ▁; ▁BB ▁; ▁met o pro lol ▁suc cina te
D-404	-0.852773129940033	cardiovascular events ; baseline sst2 status ; BB ; metoprolol succinate
P-404	-2.7531 -0.7999 -0.1826 -0.5657 -0.2508 -0.0068 -0.0364 -0.0324 -2.5644 -0.2330 -0.3600 -0.2264 -5.4132 -1.2146 -3.4832 -0.1706 -0.1605 -0.4408 -0.0386 -0.0120 -0.1208 -0.4352 -0.1128
S-289	Adding cTnT and NT-proBNP to the ARIC HF model significantly improved all statistical parameters (AUCs increased by 0.040 and 0.057; the continuous NRIs were 50.7% and 54.7% in women and men, respectively).<unk>
T-289	ctnt ; nt-probnp ; aric ; hf ; aucs ; nris
H-289	-0.4616332948207855	▁c t n t ▁; ▁NT - pro b NP ▁; ▁a RIC ▁ HF ▁model ▁; AU c s ▁; ▁NR Is
D-289	-0.4616332948207855	ctnt ; NT-probNP ; aRIC HF model ;AUcs ; NRIs
P-289	-0.0054 -0.3414 -0.0094 -0.3866 -0.0705 -0.0692 -0.0634 -0.0221 -0.6987 -0.2964 -0.0504 -0.1654 -1.3619 -0.2335 -0.5838 -0.6468 -0.2062 -1.2451 -1.7431 -0.2395 -0.1357 -0.5020 -1.0392 -1.1567 -0.2683
S-1109	Declines in early-onset and late-onset HF were observed for HF with reduced EF (<50%) but not for HF with preserved EF, indicating a change in the case mix of HF after MI that requires new prevention strategies.<unk>
T-1109	hf ; hf with reduced ef ; hf with preserved ef ; change ; hf ; mi
H-1109	-0.5811282992362976	▁early - ons et ▁; ▁late - ons et ▁ HF ▁; ▁ HF ▁; ▁EF ▁; ▁ HF ▁; ▁ HF ▁; ▁MI
D-1109	-0.5811282992362976	early-onset ; late-onset HF ; HF ; EF ; HF ; HF ; MI
P-1109	-2.7477 -0.0931 -0.0397 -1.0606 -0.3428 -0.3897 -0.0716 -0.0348 -0.8423 -0.7975 -0.2667 -0.1078 -0.9413 -0.2339 -0.1049 -0.8152 -0.1212 -0.3887 -0.3116 -0.1370 -2.3516 -0.8741 -0.1657 -0.7446 -0.8647 -0.2606
S-255	Incubation of EC with HDL(NYHA-IIIb) triggered a lower stimulation of phosphorylation at eNOS-Ser(1177) and a higher phosphorylation at eNOS-Thr(495) when compared with HDL(healthy).<unk>
T-255	hdl ; nyha-iiib ; phosphorylation ; phosphorylation ; hdl ; healthy
H-255	-0.8079560995101929	▁in cuba tion ▁; ▁EC ▁; ▁HD l ▁; NY ha - III b ▁; ▁ phos phor y lation ▁; ▁e NOS - Ser ▁; ▁ phos phor y lation ▁; ▁e NOS - Th r ▁; ▁HD l
D-255	-0.8079560995101929	incubation ; EC ; HDl ;NYha-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDl
P-255	-0.7202 -0.0009 -0.0196 -0.9995 -1.6366 -0.1749 -2.8235 -3.1664 -0.1631 -2.6881 -1.1709 -0.1677 -0.0675 -0.0221 -0.2378 -0.4812 -0.4063 -1.2340 -1.0814 -1.0332 -0.2964 -0.0937 -0.1922 -0.1646 -0.1819 -0.5353 -0.7647 -0.7200 -1.7027 -1.1162 -1.3899 -0.2938 -0.0998 -0.1971 -0.0934 -1.2720 -0.0077 -0.6132 -2.2883 -2.4832 -0.8288 -0.3040
S-1118	In addition, treatment with carvedilol resulted in a lower von Willebrand factor than did metoprolol (149% ± 13% vs. 157% ± 13%, respectively, P = 0.01), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1118	carvedilol ; von willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
H-1118	-0.692733108997345	▁car vedi lol ▁; ▁von ▁Will e brand ▁factor ▁; ▁met o pro lol ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
D-1118	-0.692733108997345	carvedilol ; von Willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
P-1118	-3.2161 -0.1390 -0.7369 -0.2390 -0.1001 -3.2428 -0.2375 -0.0596 -0.0626 -0.2103 -0.4458 -0.1534 -0.1425 -0.7048 -0.3422 -1.0086 -1.5705 -0.9114 -0.2787 -1.3258 -0.2899 -0.0189 -0.0730 -0.1520 -2.5240 -0.3732 -0.1451
S-274	Although the mouse heart failure (HF) model of hypertensive heart disease (HHD) is useful to investigate the pathophysiology and new therapeutic targets for HHD, the model using simple experimental procedures and stable phenotypes has not been established.<unk>
T-274	heart failure ; hf ; hypertensive heart disease ; hhd ; pathophysiology ; therapeutic ; hhd ; stable ; phenotypes
H-274	-0.7735320925712585	▁mouse ▁heart ▁failure ▁; HF ▁; ▁hyper tensi ve ▁heart ▁disease ▁; ▁h h ▁; ▁pat ho phy si ology ▁; ▁h h
D-274	-0.7735320925712585	mouse heart failure ;HF ; hypertensive heart disease ; hh ; pathophysiology ; hh
P-274	-0.0434 -1.6611 -0.0201 -0.1904 -0.0964 -0.2174 -0.7722 -0.3382 -0.4191 -2.2614 -1.0377 -0.1711 -1.1445 -1.8563 -0.6515 -1.4536 -0.1851 -0.0933 -1.5644 -0.0699 -0.0508 -1.5472 -1.8718 -1.4945 -0.1269
2021-01-18 16:39:16 | INFO | fairseq.logging.progress_bar | :    101 / 142 wps=227
S-1551	Although sarcoplasmic reticular (SR) Ca(2+)-uptake, as well as protein content for SR Ca(2+)-pump and phospholamban, were reduced in the infarcted hearts; these changes were partially reversible with metoprolol.<unk>
T-1551	sarcoplasmic reticular ; protein ; phospholamban ; infarcted ; hearts ; metoprolol
H-1551	-0.4019084572792053	▁sar co plas mic ▁reti cular ▁; SR ▁; ▁ca (2 +) - up take ▁; ▁protein ▁; ▁SR ▁; ▁ca (2 +) - pump ▁; ▁ phos pho lam ban ▁; ▁in far cted ▁heart s ▁; ▁met o pro lol
D-1551	-0.4019084572792053	sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein ; SR ; ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
P-1551	-0.0361 -0.0535 -0.9261 -1.7805 -0.0226 -0.4238 -0.3443 -0.1079 -0.5900 -0.3121 -0.7428 -0.0151 -0.0984 -0.1843 -0.2093 -0.1235 -1.3547 -0.6456 -1.1677 -1.4080 -0.6610 -0.5151 -0.0139 -0.0581 -0.0545 -0.1188 -0.2968 -0.1199 -0.7980 -1.0382 -0.0724 -0.1968 -0.0183 -0.2446 -0.4593 -0.4568 -0.0436 -0.2486 -0.8096 -0.0787 -0.1891 -0.2537 -0.2392 -0.1526
S-794	OBJECTIVE: To investigate the within-day test-retest reliability of the Timed Up & Go (TUG) test in patients with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), and chronic renal failure (CRF).<unk>
T-794	tug ; patients ; chronic obstructive pulmonary disease ; copd ; chronic heart failure ; chf ; chronic renal failure ; crf
H-794	-0.8520162105560303	▁tests - re test ▁reli ability ▁; ▁Time d ▁up ▁& ▁go ▁; ▁t g ▁; ▁tests ▁; ▁advanced ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; co PD ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁chronic ▁renal ▁failure ▁; CR f
D-794	-0.8520162105560303	tests-retest reliability ; Timed up & go ; tg ; tests ; advanced chronic obstructive pulmonary disease ;coPD ; chronic heart failure ;CHf ; chronic renal failure ;CRf
P-794	-5.4725 -0.2866 -0.0862 -0.2728 -2.1645 -0.0086 -0.4659 -0.9051 -0.0923 -0.0469 -2.1431 -0.3410 -0.7037 -1.3316 -0.2531 -0.8067 -5.1097 -0.2036 -2.9733 -0.9558 -0.1312 -0.1027 -0.1576 -0.0304 -0.1627 -1.5520 -0.1978 -1.5416 -2.5177 -0.0856 -0.4854 -1.0438 -0.0350 -0.2060 -0.3659 -0.5858 -0.1114 -0.9206 -0.1038 -0.1210 -0.6380 -0.2533 -1.5341 -0.5398 -0.2946
S-1317	BACKGROUND: This study assessed the feasibility of a 12-week program of exercise, with and without intramuscular testosterone supplementation, in male patients with chronic heart failure (CHF) and low testosterone status and collected preliminary data for key health outcomes.<unk>
T-1317	exercise ; intramuscular testosterone supplementation ; patients ; chronic heart failure ; chf ; testosterone ; collected ; health ; outcomes
H-1317	-0.679693341255188	▁exercise ▁; ▁intra mus cular ▁testosteron e ▁supplement ation ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁low ▁testosteron e ▁status
D-1317	-0.679693341255188	exercise ; intramuscular testosterone supplementation ; chronic heart failure ;CHf ; low testosterone status
P-1317	-3.2358 -0.1931 -1.3768 -0.0053 -0.0801 -0.1061 -0.0446 -1.9657 -0.1926 -0.3654 -3.2339 -1.4074 -0.0617 -0.2319 -0.3796 -0.4843 -0.2084 -0.0761 -0.2060 -0.0559 -0.1690 -1.3777 -0.1754
S-117	In conclusion, patients hospitalized for HF who have preserved LVEF experience similar long-term mortality as patients with mild or moderate reductions in LVEF, whereas severely reduced LVEF remains an independent predictor of long-term mortality in this population.<unk>
T-117	patients ; hospitalized ; hf ; preserved lvef ; mortality ; patients ; lvef ; lvef ; mortality
H-117	-0.7112851738929749	▁hospital ized ▁; ▁ HF ▁; ▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁LV EF
D-117	-0.7112851738929749	hospitalized ; HF ; LVEF ; long-term mortality ; LVEF
P-117	-4.7534 -0.4464 -0.2039 -0.4223 -0.0725 -0.1172 -0.9423 -0.3692 -0.1957 -1.2810 -0.1932 -0.1284 -0.2695 -0.0699 -0.4043 -1.0436 -0.2179 -2.1622 -0.2215
S-818	In direct comparison, GLS outperformed left ventricular ejection fraction (LVEF) and systolic mitral annulus velocity (Sa) in predicting adverse CV events both in univariate and multivariate models (p ≤ 0.043).<unk>
T-818	gls ; left ventricular ejection fraction ; lvef ; systolic mitral annulus velocity ; multivariate models
H-818	-0.6810460686683655	▁g ls ▁out per form ed ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; LV EF ▁; ▁sy sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁; ▁sa ▁; ▁cv ▁events
D-818	-0.6810460686683655	gls outperformed left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa ; cv events
P-818	-0.1918 -1.6698 -1.2013 -0.1458 -0.1535 -0.2809 -0.1515 -2.7277 -1.1051 -0.4709 -0.4993 -0.3857 -0.5145 -1.2258 -0.0821 -0.5670 -0.4959 -0.3116 -0.1837 -1.0392 -0.1241 -0.7335 -0.9823 -0.1429 -0.3739 -0.1713 -0.0755 -0.0851 -0.3575 -0.0431 -1.0817 -3.7003 -1.5073 -0.8669 -0.1882
S-187	BACKGROUND: In heart failure (HF), there are known differences in plasma B-type natriuretic peptide (BNP) levels between reduced and preserved ejection fraction (EF), but few HF studies have explored sex differences.<unk>
T-187	heart failure ; hf ; plasma b-type natriuretic peptide ; bnp ; preserved ejection fraction ; ef ; hf
H-187	-0.5325106382369995	▁heart ▁failure ▁; HF ▁; ▁plasma ▁; ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁e je ction ▁ fraction ▁; EF ▁; ▁ HF ▁; ▁sex
D-187	-0.5325106382369995	heart failure ;HF ; plasma ; natriuretic peptide ; bNP ; ejection fraction ;EF ; HF ; sex
P-187	-0.6065 -0.0822 -0.2418 -0.4352 -0.1706 -0.8649 -0.9671 -1.1909 -0.3853 -0.1040 -0.4381 -0.0299 -0.3442 -1.6175 -0.3495 -1.3700 -0.7467 -0.2881 -0.7959 -0.3343 -0.0893 -0.3002 -0.0088 -0.3366 -1.2709 -0.2105 -0.1283 -0.1683 -0.9532 -0.8953 -1.1936 -0.1224
S-153	RM interventions included home telemonitoring (TM) (including implanted monitoring devices) with medical support provided during office hours or 24/7 and structured telephone support (STS) programmes delivered via human-to-human contact (HH) or human-to-machine interface (HM).<unk>
T-153	rm ; telemonitoring ; implanted ; medical ; structured telephone support ; sts ; human-to-human contact ; hh ; human-to-machine interface
H-153	-0.6216612458229065	▁RM ▁; ▁home ▁tele monitor ing ▁; ▁implant ed ▁monitoring ▁devices ▁; ▁medical ▁support ▁; ▁s s ▁; ▁contact ▁; HH ▁; ▁human - to - machine ▁interface ▁; HM
D-153	-0.6216612458229065	RM ; home telemonitoring ; implanted monitoring devices ; medical support ; ss ; contact ;HH ; human-to-machine interface ;HM
P-153	-1.1253 -0.7134 -0.5025 -0.6899 -0.1894 -0.0702 -0.3830 -1.7781 -0.1146 -0.0221 -0.1083 -0.6322 -0.3328 -1.9793 -0.4348 -3.0120 -0.7021 -0.3682 -3.2692 -0.3622 -0.9836 -0.2958 -0.2862 -0.0426 -0.0393 -0.0785 -0.0329 -0.1716 -0.6582 -0.0298 -0.3476 -0.1376
S-859	Using time-dependent Cox regression analysis, we compared patients treated with different types of beta-blockers or no beta-blockers on the primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy.<unk>
T-859	cox regression analysis ; patients ; beta-blockers ; beta-blockers ; primary endpoint ; therapy ; antitachycardia pacing ; atp ; shock therapy
H-859	-0.5790678262710571	▁co x ▁re gression ▁; ▁beta - block ers ▁; ▁beta - block ers ▁; ▁anti ta chy car dia ▁pa cing ▁; ▁a TP ▁; ▁shock ▁ therapy
D-859	-0.5790678262710571	cox regression ; beta-blockers ; beta-blockers ; antitachycardia pacing ; aTP ; shock therapy
P-859	-0.1752 -0.3357 -0.0259 -0.0149 -1.4328 -1.9112 -0.1467 -0.6511 -0.1532 -0.1653 -0.5372 -0.1261 -0.7537 -0.1996 -0.2169 -0.6202 -2.7276 -0.8638 -0.4975 -2.0511 -0.1648 -0.0768 -0.2337 -0.9220 -1.0496 -0.4220 -0.3942 -0.4311 -0.0776 -0.3299 -0.2438
S-1680	Two of the most ethically complex situations in pediatrics are those involving families whose religious beliefs preclude the provision of life-sustaining treatment and those involving young adults who have reached the age of legal majority and who face decisions about life-sustaining treatment.<unk>
T-1680	ethically ; legal ; decisions
H-1680	-0.5221295356750488	▁et h ically ▁; ▁pediatr ics ▁; ▁families ▁; ▁religious ▁belief s ▁; ▁life - s usta ining ▁treatment ▁; ▁legal ▁majority ▁; ▁decisions
D-1680	-0.5221295356750488	ethically ; pediatrics ; families ; religious beliefs ; life-sustaining treatment ; legal majority ; decisions
P-1680	-0.1831 -0.2340 -0.2161 -0.6802 -0.2202 -0.2121 -0.1615 -1.2206 -0.2119 -0.3061 -0.4474 -0.0937 -0.0888 -1.1330 -0.1187 -0.0882 -0.2785 -0.2130 -1.5599 -0.4207 -0.2162 -1.3285 -0.7656 -0.6639 -2.3461 -0.1674
S-1122	BACKGROUND: Little is known about how often contextual factors such as patient preferences and competing priorities impact prescribing of guideline-recommended medications, or about the extent to which these factors are documented in medical records and available to performance measurement systems.<unk>
T-1122	patient ; prescribing ; medications ; medical
H-1122	-0.5689528584480286	▁preference s ▁; ▁pre scribi ng ▁; ▁guide line - re com mend ed ▁medication s ▁; ▁medical ▁records
D-1122	-0.5689528584480286	preferences ; prescribing ; guideline-recommended medications ; medical records
P-1122	-3.9984 -0.1531 -0.1355 -2.4080 -0.3336 -0.2115 -0.4169 -0.0265 -0.0236 -0.1556 -0.0176 -0.5765 -0.0533 -0.1223 -0.2036 -0.0489 -0.6834 -0.1836 -0.0479 -1.9826 -0.1657
S-1241	The total cost per patient was not significantly different between rhythm-control ($72,764 [95% CI, $61,575-$85,145]) and rate-control ($78,767 [95% CI, $67,101-$92,139]) strategies.<unk>
T-1241	cost ; patient ; rhythm-control ; rate-control
H-1241	-0.437343955039978	▁cost ▁; ▁ rhythm - control ▁; ▁rate - control
D-1241	-0.437343955039978	cost ; rhythm-control ; rate-control
P-1241	-0.0640 -0.2549 -0.2842 -0.6380 -0.3896 -0.0495 -0.2161 -0.4460 -0.5396 -0.0859 -1.8149 -0.4655
S-393	Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m(2).<unk>
T-393	left ventricular ejection fraction ; egfr
H-393	-1.0810556411743164	▁media n ▁age ▁; ▁women ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁media n ▁e g f
D-393	-1.0810556411743164	median age ; women ; left ventricular ejection fraction ; median egf
P-393	-4.2211 -0.0443 -1.7746 -0.1324 -3.3788 -0.2400 -0.6410 -2.3849 -0.9433 -0.3382 -0.2496 -0.3871 -0.4384 -1.2791 -0.0403 -0.3932 -1.8420 -0.0344 -0.0684 -1.2367 -1.9286 -2.5483 -0.3196
S-1773	When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, respectively), hazard ratios were significantly lower in fit compared with unfit men in normal and overweight body mass index strata (P<0.002) but not in obese men.<unk>
T-1773	crf ; hazard ratios ; body mass index ; obese
H-1773	-0.49683690071105957	▁fit ▁; ▁un fit ▁; ▁c RF ▁distribution ▁; ▁hazard ▁ratio s ▁; ▁un fit ▁; ▁over weight ▁; ▁body ▁mass ▁index ▁; ▁obes e
D-1773	-0.49683690071105957	fit ; unfit ; cRF distribution ; hazard ratios ; unfit ; overweight ; body mass index ; obese
P-1773	-0.5754 -0.3537 -0.0240 -0.0886 -0.1951 -0.1593 -0.5057 -0.1075 -0.5222 -1.3418 -0.0150 -0.2204 -0.3706 -0.3972 -0.0645 -0.4754 -1.7302 -0.3552 -1.3284 -0.3974 -0.1129 -0.1792 -1.0111 -1.0356 -0.2253 -1.3951 -0.2277
S-852	The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15).<unk>
T-852	primary outcome ; patients ; crt ; hazard ratio ; confidence interval
H-852	-0.8575396537780762	▁c RT ▁group ▁; ▁control ▁group ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval
D-852	-0.8575396537780762	cRT group ; control group ; hazard ratio ; confidence interval
P-852	-0.6453 -2.6284 -1.6049 -0.2173 -0.4563 -0.4801 -0.2940 -0.4287 -0.0135 -0.7638 -1.8813 -0.4179 -1.8754 -0.2986
S-382	The HFPSI model included blood urea nitrogen, B-type natriuretic peptide, New York Heart Association class, diabetes status, history of atrial fibrillation/flutter, and all-cause hospitalization within the prior 1 and 2 to 6 months.<unk>
T-382	hfpsi ; blood urea nitrogen ; b-type natriuretic peptide ; new york heart association class ; diabetes ; atrial fibrillation ; all-cause hospitalization
H-382	-0.4753526747226715	▁ HF PSI ▁model ▁; ▁blood ▁u rea ▁nit rogen ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁New ▁York ▁Heart ▁association ▁; ▁diabetes ▁status ▁; ▁at rial ▁fi bril lation ▁; flu tter
D-382	-0.4753526747226715	HFPSI model ; blood urea nitrogen ; b-type natriuretic peptide ; New York Heart association ; diabetes status ; atrial fibrillation ;flutter
P-382	-1.8168 -1.4262 -1.2589 -0.5877 -0.1089 -0.6795 -0.0047 -0.6166 -0.1575 -0.2779 -0.1055 -1.3431 -0.0367 -0.4143 -0.0023 -0.4573 -0.0519 -0.3571 -0.0231 -0.2334 -1.0466 -0.1699 -0.0658 -0.3383 -1.4851 -0.5767 -0.5947 -0.1689 -0.7833 -0.1106 -0.1640 -0.0639 -0.2689 -0.1394 -1.0146 -0.9360 -0.3208 -0.0815 -0.5462 -0.1793
S-2	This study used the Medicare Patient Safety Monitoring System (MPSMS) database to assess national trends in adverse event rates between 2005 through 2011 for patients hospitalized with acute myocardial infarction, congestive heart failure, pneumonia, or conditions requiring surgery.<unk>
T-2	medicare patient safety monitoring system ; mpsms ; adverse event ; patients ; hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; conditions ; surgery
H-2	-0.6175439953804016	▁Medica re ▁Patient ▁Safety ▁monitoring ▁system ▁; MP SMS ▁; ▁advers e ▁event ▁rates ▁; ▁a cute ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁; ▁pneu monia
D-2	-0.6175439953804016	Medicare Patient Safety monitoring system ;MPSMS ; adverse event rates ; acute myocardial infarction ; congestive heart failure ; pneumonia
P-2	-0.1409 -0.0107 -0.6783 -0.9802 -0.5844 -0.3288 -0.4518 -0.9603 -1.1465 -0.5371 -1.2061 -0.1095 -0.1698 -3.0346 -0.5497 -1.4132 -0.0427 -2.4884 -0.6180 -1.2746 -0.0723 -0.0536 -0.3091 -0.2625 -0.1906 -0.0133 -0.1182 -0.0781 -0.5159 -0.0430 -0.3380 -0.0080 -0.8311 -1.8486 -0.2063
S-127	A decrease in CD34+VEGFR2+ cells was independently associated with increased functional capacity; a 10-cell decrease in CD34+VEGFR2+ cells was associated with an increase of 0.2 mL/kg/min in peak VO2 (P < 0.05).<unk>
T-127	cells ; functional capacity ; cells ; peak vo2
H-127	-1.2693599462509155	▁cd 34 ▁; ▁ve g f 2 ▁; ▁cell s ▁; ▁functional ▁capacity ▁; ▁cd 34 ▁; ▁ve g f 2 ▁; ▁cell s ▁; ▁pe ak ▁VO 2
D-127	-1.2693599462509155	cd34 ; vegf2 ; cells ; functional capacity ; cd34 ; vegf2 ; cells ; peak VO2
P-127	-2.7977 -0.6125 -3.2070 -2.5494 -0.8054 -2.6178 -0.3472 -1.3293 -1.2688 -0.0751 -0.2715 -1.9807 -0.0742 -0.1227 -5.9236 -0.6354 -2.5385 -3.4389 -0.8226 -3.1046 -0.4524 -1.0118 -1.4018 -0.0795 -0.2210 -0.0367 -0.0480 -0.7564 -0.4043 -0.1905 -0.2252
S-659	BACKGROUND: The objective of this study is to examine practice-level variation in rates of guideline-recommended treatment for outpatients with heart failure and reduced ejection fraction, and to examine the association between treatment variation and practice site, independent of patient factors.<unk>
T-659	outpatients ; heart failure and reduced ejection fraction ; patient
H-659	-0.4202572703361511	▁practice - level ▁variation ▁; ▁guide line - re com mend ed ▁treatment ▁; ▁out patient s ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-659	-0.4202572703361511	practice-level variation ; guideline-recommended treatment ; outpatients ; heart failure ; reduced ejection fraction
P-659	-1.5107 -0.2807 -0.5246 -1.2807 -0.5586 -1.5517 -0.0138 -0.1696 -0.0308 -0.4406 -0.0419 -0.1830 -0.6576 -0.2411 -0.1152 -0.0110 -0.0871 -0.4297 -0.2266 -0.0278 -0.1169 -0.0609 -0.0185 -0.0173 -0.1621 -0.0668 -0.2775 -0.0075 -3.2908 -0.2066
S-1311	The crude 28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P < 0.05) compared with those without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P < 0.001).<unk>
T-1311	case-fatality rate ; patients ; hf ; hf ; case-fatality rate
H-1311	-0.542044997215271	▁case - fat ality ▁rate ▁; ▁concurrent ▁ HF ▁; ▁ HF ▁; ▁case - fat ality ▁rate
D-1311	-0.542044997215271	case-fatality rate ; concurrent HF ; HF ; case-fatality rate
P-1311	-2.2690 -0.1826 -0.0760 -0.0839 -0.0839 -0.1952 -1.7012 -0.2721 -0.1022 -0.2989 -1.9026 -0.3299 -1.3679 -0.2592 -0.2989 -0.1364 -0.0700 -0.0975 -0.9046 -0.2089
S-1453	This cohort formed the sampling frame for selecting controls (without CHF) matched on: age, race/ethnicity, cumulative anthracycline exposure, stem cell source (allogeneic, autologous), and length of follow-up.<unk>
T-1453	frame ; chf ; anthracycline ; stem cell ; allogeneic ; autologous ; follow-up
H-1453	-0.5122148394584656	▁CHF ▁; ▁race / eth nici ty ▁; ▁cum ul ative ▁an thra cycli ne ▁exposure ▁; ▁stem ▁cell ▁source ▁; allo gene ic ▁; ▁auto logo us
D-1453	-0.5122148394584656	CHF ; race/ethnicity ; cumulative anthracycline exposure ; stem cell source ;allogeneic ; autologous
P-1453	-2.6470 -0.7271 -2.0035 -2.8180 -0.0886 -0.3209 -0.1752 -0.2857 -0.7155 -0.1798 -0.0271 -0.0327 -0.2369 -0.3767 -0.2234 -0.5781 -0.3549 -0.0330 -0.5906 -0.1358 -0.7365 -0.0169 -0.2798 -0.1843 -0.8860 -0.1936 -0.0102 -0.1151 -0.2310 -0.1625
S-765	Resting tension (Fpassive)-sarcomere length relations were obtained in small muscle strips before and after KCl-KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to Fpassive to be discerned.<unk>
T-765	resting tension ; fpassive ; muscle ; kcl-ki ; titin ; titin ; extracellular matrix ; fpassive
H-765	-0.6301810145378113	▁tension ▁; ▁f pass ive - sar com ere ▁length ▁relations ▁; ▁muscle ▁strip s ▁; ▁k c l - KI ▁; ▁un an chor s ▁titi n ▁; ▁titi n ▁; ▁extra cel lular ▁matri x ▁; ▁f pass ive
D-765	-0.6301810145378113	tension ; fpassive-sarcomere length relations ; muscle strips ; kcl-KI ; unanchors titin ; titin ; extracellular matrix ; fpassive
P-765	-2.4016 -0.3921 -3.2591 -0.8515 -0.0128 -3.1894 -0.2110 -0.5767 -0.3765 -0.1574 -0.3320 -0.5094 -2.1467 -0.0411 -0.0428 -0.3445 -1.7127 -0.6907 -0.0604 -0.0730 -0.1123 -1.3939 -2.0776 -0.0250 -0.0378 -0.3641 -0.1357 -0.0523 -0.2265 -0.5957 -0.0418 -0.2215 -1.2662 -0.4542 -0.0662 -0.0147 -0.3531 -0.7023 -0.8918 -0.1355 -0.0095 -0.3240 -0.2144
S-1547	In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks.<unk>
T-1547	heart failure ; myocardial infarction ; mi ; β-adrenoceptor blockade ; infarcted ; metoprolol
H-1547	-0.3826422691345215	▁rever si bility ▁; ▁heart ▁failure ▁; ▁my o card ial ▁in far ction ▁; MI ▁; ▁β - ad re no cept or ▁block ade ▁; ▁in far cted ▁rat s ▁; ▁met o pro lol
D-1547	-0.3826422691345215	reversibility ; heart failure ; myocardial infarction ;MI ; β-adrenoceptor blockade ; infarcted rats ; metoprolol
P-1547	-0.2797 -0.3911 -0.0462 -1.3407 -0.3547 -0.0913 -0.3166 -0.2783 -0.4518 -1.2804 -0.1624 -0.1920 -0.5319 -0.2222 -0.2378 -1.7183 -0.1212 -0.3355 -0.0462 -0.1488 -0.1440 -0.0919 -1.8750 -0.3892 -0.1129 -0.1866 -0.2272 -0.0644 -0.3263 -0.5107 -0.0799 -0.0805 -0.2331 -0.2492 -0.0760 -0.1980 -0.3280 -1.0603 -0.1429
S-1922	The combined aerobic and resistance training intervention with augmented feedback resulted in benefits in exercise capacity, muscle strength and quality of life, as well as an improvement of cardiac (NT-ProBNP) and inflammatory (IL6, hsCRP) biomarkers.<unk>
T-1922	training ; exercise capacity ; muscle ; quality of life ; cardiac ; nt-probnp ; inflammatory ; il6 ; hscrp ; biomarkers
H-1922	-0.5728991627693176	▁aero bic ▁; ▁resist ance ▁training ▁; ▁exercise ▁capacity ▁; ▁muscle ▁strength ▁; ▁cardiac ▁; NT - pro b NP ▁; ▁infla mma tory ▁; IL 6 ▁; ▁h s CR p
D-1922	-0.5728991627693176	aerobic ; resistance training ; exercise capacity ; muscle strength ; cardiac ;NT-probNP ; inflammatory ;IL6 ; hsCRp
P-1922	-0.0373 -1.6373 -0.3795 -0.0301 -0.0402 -0.7721 -0.6408 -2.1460 -0.0950 -0.2700 -0.4350 -0.6169 -0.3155 -2.2733 -0.2420 -0.7863 -0.0459 -1.4761 -1.0145 -0.1927 -0.3281 -0.5785 -0.7686 -0.0525 -0.3116 -1.9447 -0.4249 -0.2413 -0.0038 -0.0168 -0.3294 -0.1722 -0.5687 -0.2910
S-135	OBJECTIVE: To quantify the differential impact on hospital performance of three readmission metrics: all-cause readmission (ACR), 3M Potential Preventable Readmission (PPR), and Centers for Medicare and Medicaid 30-day readmission (CMS).<unk>
T-135	hospital ; readmission ; all-cause readmission ; acr ; potential preventable readmission ; ppr ; medicare ; medicaid ; readmission ; cms
H-135	-0.8447043299674988	▁read mission ▁; ▁a CR ▁; ▁potential ▁Prev en table ▁Read mission ▁; ▁p PR ▁; ▁center s ▁for ▁Medica re ▁; ▁Medica id ▁; ▁c m
D-135	-0.8447043299674988	readmission ; aCR ; potential Preventable Readmission ; pPR ; centers for Medicare ; Medicaid ; cm
P-135	-6.2161 -0.2505 -0.5957 -1.5022 -2.1499 -0.1655 -1.7562 -1.7117 -0.2960 -0.0976 -1.4404 -0.0746 -0.1696 -0.2383 -0.4582 -0.2248 -1.6167 -0.0867 -0.3906 -0.0830 -0.0115 -1.0726 -0.0696 -0.0539 -0.2932 -2.0994 -0.5215 -0.5636 -0.2868
S-218	Congestive heart failure visits declined from 1.6% of all ED visits in 1996 to 1.2% in 2008, a 26% relative decrease (95% CI: 21%-30%, P < .001, correlation coefficient R(2) = 0.94, P < .001).<unk>
T-218	congestive heart failure ; correlation coefficient
H-218	-0.8660717010498047	▁con ges tive ▁heart ▁failure ▁visit s ▁; ▁ED
D-218	-0.8660717010498047	congestive heart failure visits ; ED
P-218	-1.0228 -0.0232 -0.0321 -1.1661 -0.0935 -2.9566 -0.0734 -0.1531 -0.8504 -2.9921 -0.1634
S-1882	The exercise duration was increased from 8 min to 23 min after rehabilitation (P < 0.001); distance 6 minutes walking was increased from 394 m to 470 m (P < 0.05); score of Minnesota quality of life was decreased from 25 to 3 in exercise group (P < 0.01).<unk>
T-1882	exercise ; rehabilitation ; walking ; minnesota quality of life ; exercise
H-1882	-1.11881422996521	▁exercise ▁du ration ▁; ▁rehabilita tion ▁; ▁distance ▁; ▁walking
D-1882	-1.11881422996521	exercise duration ; rehabilitation ; distance ; walking
P-1882	-2.1746 -0.6077 -0.2254 -0.2194 -2.8505 -0.1593 -0.3402 -0.9291 -0.4901 -0.8807 -4.4184 -0.1304
S-637	Excessive secretion of arginine vasopressin (AVP) has the potential for deleterious effects on various physiologic processes in CHF Inhibition of AVP through vasopressin receptor antagonist therapy is a potentially beneficial new therapeutic approach to CHF.<unk>
T-637	arginine vasopressin ; avp ; physiologic ; chf ; avp ; vasopressin receptor antagonist ; therapy ; therapeutic ; chf
H-637	-0.6330071091651917	▁argi nine ▁vaso press in ▁; ▁a VP ▁; ▁physio logic ▁process es ▁; ▁CHF ▁in hib i tion ▁; ▁a VP ▁; ▁vaso press in ▁receptor ▁anta gon ist ▁ therapy ▁; ▁CHF
D-637	-0.6330071091651917	arginine vasopressin ; aVP ; physiologic processes ; CHF inhibition ; aVP ; vasopressin receptor antagonist therapy ; CHF
P-637	-4.8571 -0.3660 -0.5247 -0.4628 -0.8967 -0.6776 -0.6128 -0.4104 -0.6337 -0.3382 -0.8865 -2.5340 -0.2624 -0.5468 -0.0311 -1.6144 -0.0238 -0.5228 -0.0888 -1.1571 -0.2461 -0.3557 -0.1451 -0.2375 -0.1945 -0.5685 -0.0123 -0.2146 -0.2200 -0.2650 -0.7892 -0.0518 -0.6322 -0.7204 -0.3478 -0.3400
S-661	Practice rates of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers and an optimal combined treatment measure were determined for patients with heart failure and reduced ejection fraction and no documented contraindications.<unk>
T-661	angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; β-blockers ; patients ; heart failure and reduced ejection fraction
H-661	-0.4955238997936249	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁β - block ers ▁; ▁heart ▁failure ▁; ▁e je ction ▁ fraction
D-661	-0.4955238997936249	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
P-661	-4.2247 -2.4121 -0.8311 -0.3241 -0.3319 -0.0065 -0.0585 -0.1016 -0.0702 -0.0999 -0.1675 -0.2159 -0.9620 -0.9031 -0.6091 -0.5801 -0.0048 -0.1793 -0.1376 -0.3697 -0.1150 -0.0717 -0.3301 -0.1308 -0.4025 -1.5620 -0.1183 -0.2907 -0.1296 -0.1491 -0.1546 -0.4525 -0.0239 -0.5468 -0.2761
S-1205	(1) With therapies ranging from medication and physical therapy to implantable defibrillators and circulatory support, and possibly transplantation, accurate risk stratification of patient with heart failure and delivery of therapies appropriate to the level of their disease severity is becoming increasingly important.<unk>
T-1205	therapies ; medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; risk stratification ; patient ; heart failure ; therapies ; disease
H-1205	-0.5368874073028564	▁medication ▁; ▁physical ▁ therapy ▁; ▁implant able ▁de fi br illa tors ▁; ▁circula tory ▁support ▁; ▁transplant ation ▁; ▁heart ▁failure
D-1205	-0.5368874073028564	medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation ; heart failure
P-1205	-2.6288 -0.1362 -0.0014 -0.4788 -0.0224 -0.1724 -0.0726 -0.0095 -0.0778 -0.2159 -2.2440 -0.9894 -0.0678 -0.3125 -0.1855 -0.0155 -0.4167 -0.5349 -0.0923 -0.0730 -0.3953 -1.5304 -0.0592 -2.4545 -0.2353
S-918	We hypothesized that the sodium-restricted dietary approaches to stop hypertension diet (DASH/SRD) would improve left ventricular diastolic function, arterial elastance, and ventricular-arterial coupling in hypertensive HFPEF.<unk>
T-918	dietary approaches to stop hypertension ; dash ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive hfpef
H-918	-0.5425078272819519	▁so dium - re strict ed ▁dieta ry ▁; ▁stop ▁hyper tension ▁; DAS h ▁; ▁s rd ▁; ▁left ▁vent ri cular ▁dia sto lic ▁function ▁; ▁arterial ▁elastan ce ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁hyper tensi ve ▁H FP EF
D-918	-0.5425078272819519	sodium-restricted dietary ; stop hypertension ;DASh ; srd ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive HFPEF
P-918	-1.8766 -0.5066 -0.0204 -0.0418 -0.0888 -0.0802 -2.1146 -0.2005 -0.4684 -0.7780 -0.8073 -0.2560 -1.4352 -1.3390 -0.6598 -0.3040 -1.2509 -0.6774 -0.2496 -0.3274 -1.8312 -0.8204 -0.1179 -1.0967 -0.1467 -0.6878 -0.8275 -0.2309 -0.1223 -0.0506 -0.0489 -0.2359 -0.9491 -0.7353 -0.1287 -0.1420 -0.0415 -0.0521 -0.0095 -0.0430 -0.1903 -0.3154 -0.6289 -0.2378 -1.8944 -0.4613 -0.2701 -0.5039 -0.2804
S-166	After 7 weeks rapid right ventricular pacing, gene expressions of Bax, Bcl-2 and Caspase-3 were measured by RTQ-PCR from interventricular septum biopsies that were taken weekly in 21 beagle dogs during the development of heart failure.<unk>
T-166	right ventricular pacing ; gene expressions ; bax ; bcl-2 ; caspase-3 ; rtq-pcr ; interventricular septum ; biopsies ; heart failure
H-166	-0.4148932695388794	▁right ▁vent ri cular ▁pa cing ▁; ▁Bax ▁; ▁b cl -2 ▁; ▁Cas pas e -3 ▁; ▁RT q - PC r ▁; ▁interven tri cular ▁sept um ▁bio psi es ▁; ▁beag le ▁dog s ▁; ▁heart ▁failure
D-166	-0.4148932695388794	right ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTq-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
P-166	-0.2979 -2.5148 -0.5557 -0.2493 -0.3198 -0.0739 -0.3585 -2.2496 -0.1626 -0.1992 -0.2261 -0.3222 -0.1111 -0.0361 -0.0952 -0.0279 -0.3649 -0.0951 -0.4239 -3.4960 -0.0680 -0.2503 -0.4776 -0.1127 -0.0306 -0.1877 -0.0974 -0.3529 -0.0439 -0.2242 -0.0874 -0.1977 -0.1851 -0.0088 -0.2705 -1.0213 -0.0627 -0.3313 -0.6033 -0.2578 -0.2098 -0.1647
S-961	Rats were then sacrificed and hearts were rapidly excised for estimation of caspase-3 activity, phosphocreatine and adenine nucleotides contents in addition to cytochrome c, Bcl2, Bax and caspase 3 expression.<unk>
T-961	hearts ; caspase-3 ; activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; bax ; caspase 3 ; expression
H-961	-0.35654762387275696	▁rat s ▁; ▁heart s ▁; ▁ex ci sed ▁; ▁cas pas e -3 ▁activity ▁; ▁ phos pho creati ne ▁; ▁a den ine ▁nucleo ti des ▁; ▁cy to ch rom e ▁c ▁; ▁b cl 2 ▁; ▁Bax ▁; ▁cas pas e ▁3 ▁expression
D-961	-0.35654762387275696	rats ; hearts ; excised ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase 3 expression
P-961	-0.1495 -0.0531 -0.2329 -2.8597 -0.0257 -0.1900 -1.3020 -0.1441 -0.7719 -0.1356 -0.1088 -0.3265 -0.3462 -0.8716 -0.9687 -0.1504 -0.2480 -0.0558 -2.0783 -1.2810 -0.1946 -0.2102 -0.0215 -0.0052 -0.0226 -0.2002 -0.0728 -0.5791 -0.1621 -0.0110 -0.0265 -0.2032 -0.1056 -0.1063 -0.3884 -0.3934 -0.1308 -0.0945 -0.0359 -0.1081 -0.0126 -0.1401 -0.0659 -0.4125 -0.1911 -0.7224 -0.0141 -0.3105 -0.2297
S-1119	CONCLUSION: Compared with metoprolol, carvedilol resulted in greater reduction of sympathetic activity after 6 wk of treatment and lower von Willebrand factor concentrations in both Arg16/Gln27 and Gly16/Glu27 individuals.<unk>
T-1119	metoprolol ; carvedilol ; sympathetic activity ; von willebrand factor
H-1119	-0.5375307202339172	▁met o pro lol ▁; ▁car vedi lol ▁; ▁sympa the tic ▁activity ▁; ▁von ▁Will e brand ▁factor ▁; ▁ar g 16 ▁; ▁g l n 27 ▁; ▁g ly 16 ▁; ▁g lu 27
D-1119	-0.5375307202339172	metoprolol ; carvedilol ; sympathetic activity ; von Willebrand factor ; arg16 ; gln27 ; gly16 ; glu27
P-1119	-0.5351 -0.1232 -0.0825 -0.5711 -0.2486 -0.0955 -0.3271 -0.6472 -0.3995 -0.2321 -1.2558 -0.2744 -0.1542 -0.2400 -1.7351 -3.5380 -0.1891 -0.1267 -0.1331 -0.5986 -0.5814 -0.0094 -0.1747 -0.4770 -0.7557 -1.1818 -0.0670 -0.0263 -0.2258 -0.1943 -0.7896 -0.1357 -0.8068 -1.7325 -1.1069 -0.0279 -0.4296 -0.1969
S-1017	Despite neutral results in many acute HF trials, recent studies including RELAX-AHF, ASTRONAUT, and PRONTO have highlighted the role of appropriate timing of patient enrollment, targeting the "right" patients, and selecting appropriate end points and sites.<unk>
T-1017	acute hf ; relax-ahf ; astronaut ; pronto ; patient ; patients ; end points
H-1017	-0.6034426093101501	▁a cute ▁ HF ▁trial s ▁; ▁RELA X - a HF ▁; ▁ AST ron AUT ▁; ▁PR ONTO
D-1017	-0.6034426093101501	acute HF trials ; RELAX-aHF ; ASTronAUT ; PRONTO
P-1017	-0.2312 -0.0478 -0.7797 -0.4473 -2.1460 -0.0591 -0.1301 -0.7492 -1.5210 -0.0416 -0.0817 -1.5673 -0.1097 -0.4302 -0.7343 -1.0353 -0.5669 -0.1059 -0.4204 -0.0185 -1.8209 -0.2316
S-1832	MEASUREMENTS: Hospitalized HF, identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.x1, 404.x1, 404.x3, and 428.xx recorded as the principal discharge diagnosis.<unk>
T-1832	hospitalized ; hf ; international classification of diseases ; clinical ; principal ; discharge ; diagnosis
H-1832	-0.35416847467422485	▁hospital ized ▁ HF ▁; ▁international ▁classifica tion ▁of ▁Disease s ▁; ▁Nin th ▁re vision ▁; ▁Clinic al ▁Modifica tion ▁code s ▁; ▁principal ▁dis charge ▁ diagnos is
D-1832	-0.35416847467422485	hospitalized HF ; international classification of Diseases ; Ninth revision ; Clinical Modification codes ; principal discharge diagnosis
P-1832	-1.6133 -0.0208 -0.4936 -0.1348 -0.2071 -0.6726 -0.4519 -0.0140 -0.0572 -0.3877 -0.0104 -0.2416 -0.0106 -0.0089 -0.3636 -0.0425 -0.1337 -0.5610 -0.0156 -1.9718 -0.1499 -0.0976 -0.0701 -0.2531 -0.3286 -0.0576 -0.0333 -1.7341 -0.2331 -0.6106 -0.1751 -0.1775
S-1959	Pulmonary capillary wedge pressure was reduced from a mean of 23 mm Hg (SD 5) at baseline to 17 mm Hg (8) at 3 months (p=0·035), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.<unk>
T-1959	pulmonary capillary wedge pressure ; baseline ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
H-1959	-0.5638569593429565	▁Pul mon ary ▁cap illa ry ▁we dge ▁pressure ▁; ▁base line ▁; ▁right ▁at rial ▁pressure ▁; ▁pulmonar y ▁arterial ▁pressure ▁; ▁pulmonar y ▁resist ance
D-1959	-0.5638569593429565	Pulmonary capillary wedge pressure ; baseline ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
P-1959	-0.4977 -1.7003 -0.0402 -1.4102 -1.1118 -0.0215 -1.9926 -0.0603 -0.4421 -0.2334 -3.1129 -0.0159 -0.2149 -1.9271 -0.4330 -0.3027 -0.3261 -0.2019 -0.0349 -0.0494 -0.0666 -0.7014 -0.5081 -0.0079 -0.1399 -0.2020 -0.0540 -0.3668 -0.1762
S-1676	In addition, Rad Q65P attenuates the gating movement of both channels as effectively as wild-type Rad, indicating that the Q65P substitution does not differentially impair any of the three described modes of L-type channel inhibition by RGK proteins.<unk>
T-1676	rad ; q65p ; movement ; wild-type rad ; q65p ; l-type channel ; rgk proteins
H-1676	-0.790919840335846	▁Rad ▁; ▁Q 65 p ▁; ▁ga ting ▁movement ▁; ▁channel s ▁; ▁wild - type ▁Rad ▁; ▁Q 65 p ▁; ▁l - type ▁channel ▁inhibi tion ▁; ▁R GK ▁protein s
D-1676	-0.790919840335846	Rad ; Q65p ; gating movement ; channels ; wild-type Rad ; Q65p ; l-type channel inhibition ; RGK proteins
P-1676	-0.9317 -0.9678 -3.6325 -0.4331 -0.3308 -0.2080 -1.8196 -0.0201 -0.0921 -0.1508 -5.5390 -0.1606 -0.1612 -0.2166 -0.0349 -0.1478 -0.4908 -0.1525 -2.2758 -0.2550 -0.4441 -0.4383 -4.0050 -0.1099 -0.2242 -0.1862 -0.2802 -0.1617 -0.1602 -1.9317 -0.3871 -0.7214 -0.0528 -0.3700 -0.1884
S-876	SS20 had only modest effects on heart failure and this tracked with only partial attenuation of global proteomics changes; furthermore, actin cytoskeleton pathways were significantly protected in SS20, whereas mitochondrial and metabolic pathways essentially were not.<unk>
T-876	ss20 ; heart failure ; proteomics ; actin cytoskeleton ; ss20 ; mitochondrial ; metabolic pathways
H-876	-0.5573120713233948	▁SS 20 ▁; ▁heart ▁failure ▁; ▁global ▁prote o mics ▁; ▁act in ▁cy tos kelet on ▁path ways ▁; ▁SS 20 ▁; ▁mito cho ndri al ▁; ▁metabol ic ▁path ways
D-876	-0.5573120713233948	SS20 ; heart failure ; global proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
P-876	-1.7633 -0.2487 -0.9716 -1.5075 -0.4351 -0.3243 -2.6550 -0.8223 -0.9620 -0.0622 -1.2584 -0.0976 -0.1237 -0.2492 -1.7375 -0.1537 -0.1862 -0.2381 -0.0579 -0.4868 -0.2214 -0.1458 -0.5939 -0.1644 -1.8384 -0.2572 -0.0702 -0.3860 -0.1074 -0.0584 -0.0826 -0.1044 -0.3539 -0.2236
S-542	OBJECTIVES: New-onset aortic insufficiency (AI) can be encountered after instituting mechanical circulatory support and seems more common and severe with continuous flow (CF) left ventricular assist devices (LVADs) compared with pulsatile devices.<unk>
T-542	aortic insufficiency ; mechanical circulatory support ; continuous flow ; left ventricular assist devices ; lvads ; pulsatile devices
H-542	-0.5826873779296875	▁a or tic ▁insu ffi cie ncy ▁; AI ▁; ▁mechanic al ▁circula tory ▁support ▁; ▁continuo us ▁flow ▁; CF ▁; ▁left ▁vent ri cular ▁assist ▁devices ▁; ▁l VAD s ▁; ▁pulsa tile ▁devices
D-542	-0.5826873779296875	aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
P-542	-1.5558 -0.7899 -0.1579 -1.0392 -0.3954 -3.1588 -0.0812 -0.3297 -1.5609 -0.3607 -0.0212 -0.0237 -2.0079 -0.2191 -0.7629 -0.3265 -0.3810 -0.0584 -0.0217 -0.1276 -0.1805 -0.1631 -0.1439 -3.0168 -0.9182 -0.2055 -1.1719 -0.2008 -0.3461 -0.4125 -0.0297 -0.0693 -0.7378 -0.0935 -0.1296 -0.1546 -0.5394 -0.2495
S-1145	It was demonstrated that the long-term administration of pyridostigmine started right after coronary artery ligation augmented cardiac vagal and reduced sympathetic tone, attenuating cardiac remodeling and left ventricular dysfunction during the progression of HF in rats.<unk>
T-1145	administration ; pyridostigmine ; coronary artery ligation ; cardiac ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; hf
H-1145	-0.3952420651912689	▁py rido stig mine ▁; ▁corona ry ▁arter y ▁liga tion ▁; ▁cardiac ▁va gal ▁; ▁sympa the tic ▁tone ▁; ▁cardiac ▁remodel ing ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁ HF
D-1145	-0.3952420651912689	pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; HF
P-1145	-1.9705 -0.0578 -0.0011 -0.2079 -0.2144 -0.3104 -0.0444 -0.1600 -0.1534 -0.3554 -0.4194 -0.2906 -0.4110 -0.0382 -0.0072 -0.1424 -0.1658 -0.6659 -0.0896 -0.4145 -0.1964 -0.1954 -0.0848 -0.0619 -0.1707 -0.1108 -2.0681 -1.2257 -0.3783 -0.2945 -1.7980 -0.2492 -0.2791 -0.1307 -0.6775 -0.1878
S-1418	RESULTS: In the first month after discharge, 5336 (21.9%) of the 24 373 identified patients had no follow-up visits, 16 855 (69.2%) saw a familiar physician, and 2182 (9.0%) saw unfamiliar physician(s) exclusively.<unk>
T-1418	discharge ; patients ; follow-up ; physician ; physician
H-1418	-0.5124805569648743	▁dis charge ▁; ▁follow - up ▁visit s
D-1418	-0.5124805569648743	discharge ; follow-up visits
P-1418	-0.3455 -0.1418 -0.7023 -0.3409 -0.2196 -0.0341 -0.9236 -0.1079 -2.0876 -0.2215
S-1665	As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.<unk>
T-1665	life expectancy ; heart failure ; patients ; disease ; terminal heart failure
H-1665	-0.9808239936828613	▁heart ▁failure ▁; ▁end ▁stage ▁; ▁re frac tory ▁; ▁terminal ▁heart ▁failure
D-1665	-0.9808239936828613	heart failure ; end stage ; refractory ; terminal heart failure
P-1665	-4.6075 -0.1818 -0.3759 -5.9773 -0.2447 -0.3428 -0.0581 -0.0147 -0.1162 -0.3072 -0.4042 -1.4773 -0.1499 -0.1909 -0.2639
S-723	METHODS: We performed a single-center, retrospective chart review of all heart failure discharges at the University of Connecticut Health Center (398 patients) the year before (2008) and the year after (2011) a quality improvement initiative that included mandatory 7-day follow-up visits.<unk>
T-723	heart failure ; discharges ; university of connecticut health center ; patients ; follow-up
H-723	-0.8841621279716492	▁heart ▁failure ▁dis charge s ▁; ▁university ▁of ▁connect i cut ▁health ▁center ▁; ▁follow - up
D-723	-0.8841621279716492	heart failure discharges ; university of connecticut health center ; follow-up
P-723	-3.5981 -0.0914 -0.2795 -0.0295 -0.1282 -0.3099 -0.5830 -0.0313 -3.1738 -0.0724 -0.5984 -0.5654 -1.0575 -0.6805 -3.4812 -0.1959 -0.0366 -1.6733 -0.2132
S-1229	(A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF Study]; NCT00232180).<unk>
T-1229	outcomes ; patients ; new york heart association ; nyha ; heart failure ; eplerenone ; placebo ; heart failure ; medicines ; emphasis-hf
H-1229	-0.9376333355903625	▁New ▁York ▁Heart ▁association ▁; NY ha ▁; ▁class ▁II ▁Heart ▁Fail ure ▁; ▁e pler en one ▁; ▁place bo ▁; ▁standard ▁Heart ▁Fail ure ▁Medicine s ▁; EMP ha SIS - HF
D-1229	-0.9376333355903625	New York Heart association ;NYha ; class II Heart Failure ; eplerenone ; placebo ; standard Heart Failure Medicines ;EMPhaSIS-HF
P-1229	-5.3389 -1.3264 -5.1284 -0.3862 -0.0873 -1.5345 -1.6528 -0.1409 -2.1652 -0.1944 -2.3006 -0.5484 -0.0709 -0.1828 -0.6187 -0.1529 -0.6096 -0.0290 -0.0587 -1.0984 -0.0260 -0.0668 -0.2012 -2.0295 -0.5046 -0.0741 -0.2648 -0.0610 -0.2169 -0.3025 -2.3842 -2.1816 -0.0532 -0.2651 -1.2170 -0.2812
S-324	Echocardiograms were taken of the left ventricular base, midpapillary, and apex during baseline, IVC occlusion, and each BiVP setting for STE analysis of twist, apical and basal rotations, CS, RS, and synchrony.<unk>
T-324	echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; ivc occlusion ; bivp ; ste ; rs
H-324	-0.43673431873321533	▁e cho card i ogram s ▁; ▁left ▁vent ri cular ▁base ▁; ▁mid pap illa ry ▁; ▁ap ex ▁; ▁base line ▁; ▁IV c ▁oc clusi on ▁; ▁bi VP ▁; ▁twist ▁; ▁bas al ▁rota tions ▁; ▁RS
D-324	-0.43673431873321533	echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; IVc occlusion ; biVP ; twist ; basal rotations ; RS
P-324	-1.1168 -0.1366 -0.2982 -0.4011 -0.0423 -0.2255 -0.3001 -0.1815 -2.4049 -0.8340 -0.1844 -0.0704 -0.3382 -0.1104 -0.3619 -0.8593 -0.0459 -0.2833 -1.2020 -0.0217 -0.5729 -0.0092 -0.0187 -0.2604 -0.0396 -1.3800 -0.0070 -0.0509 -0.1345 -0.3737 -0.6335 -0.8193 -0.2493 -0.5020 -0.1878 -1.3494 -0.0114 -0.0053 -0.0189 -0.5150 -1.3266 -0.6511 -0.2449
S-1490	This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.<unk>
T-1490	evidence ; drugs ; drugs ; raas ; renin inhibitors ; endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
H-1490	-0.41130685806274414	▁drugs ▁; ▁RA as ▁; ▁direct ▁re nin ▁inhibi tors ▁; ▁neutral ▁en dop ep tida se ▁inhibi tors ▁; ▁vaso pe pti das e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers
D-1490	-0.41130685806274414	drugs ; RAas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
P-1490	-1.3948 -0.1953 -0.4967 -0.3155 -0.1398 -0.0012 -0.0208 -2.2099 -0.5346 -0.0377 -0.2876 -0.4452 -0.0145 -0.2429 -2.5869 -0.0655 -0.1961 -0.2161 -0.0497 -0.2953 -0.0451 -0.4633 -1.2169 -0.2478 -0.1850 -0.2226 -0.0861 -0.3793 -0.0358 -0.9697 -0.4143 -0.0689 -0.0033 -0.1051 -0.0728 -0.7139 -0.2421
S-1015	The last decade of acute heart failure (HF) research is characterized by disappointments in large phase 2 and 3 pharmacologic studies of therapeutics including calcium-sensitizing agents and antagonists of endothelin, vasopressin, and adenosine.<unk>
T-1015	acute heart failure ; hf ; pharmacologic ; therapeutics ; calcium-sensitizing agents ; antagonists ; endothelin ; vasopressin ; adenosine
H-1015	-0.5551384091377258	▁a cute ▁heart ▁failure ▁; HF ▁; ▁ pharma c ologic ▁studies ▁; ▁calci um - sensi t izing ▁agents ▁; ▁en do the lin ▁; ▁vaso press in ▁; ▁ad enos ine
D-1015	-0.5551384091377258	acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
P-1015	-0.2124 -0.0868 -2.0079 -0.0858 -0.4275 -0.2674 -0.5065 -0.8419 -0.0718 -0.2597 -0.3505 -1.5724 -0.3506 -1.1919 -0.0170 -0.2200 -0.0207 -3.7270 -0.1318 -0.1557 -0.2404 -0.1104 -0.1977 -1.9379 -2.0449 -0.2578 -0.0086 -0.0525 -0.5276 -0.6797 -0.0010 -0.0218 -0.0393 -0.5224 -0.2824
S-1047	In vivo experiments of HF induced in mice via phenylephrine or haemodynamic stress (using the surgical method of transverse aortic constriction (TAC)) showed that JQ1 protected against several pathological changes, including cardiac hypertrophy.<unk>
T-1047	in vivo ; hf ; phenylephrine ; haemodynamic ; surgical ; transverse aortic constriction ; tac ; jq1 ; pathological ; cardiac hypertrophy
H-1047	-0.40075352787971497	▁ HF ▁induc ed ▁; ▁mi ce ▁; ▁ phen yle ph rine ▁; ▁ha emo dynamic ▁stress ▁; ▁sur g ical ▁method ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC ▁; ▁j q 1 ▁; ▁cardiac ▁hyper trop hy
D-1047	-0.40075352787971497	HF induced ; mice ; phenylephrine ; haemodynamic stress ; surgical method ; transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
P-1047	-1.4256 -0.6447 -0.0765 -0.1115 -0.4222 -0.0671 -0.1641 -0.3113 -0.2307 -0.0622 -0.4966 -0.0909 -0.0272 -0.1403 -0.0038 -0.1255 -0.0058 -0.2365 -0.1091 -0.6309 -0.1205 -0.0179 -0.4072 -0.6226 -0.0003 -0.0865 -0.0447 -0.7208 -0.1485 -0.1782 -0.2727 -0.0804 -0.3840 -0.4888 -0.4361 -0.6989 -1.7307 -0.2198 -0.5281 -2.5800 -0.8396 -0.0483 -1.4362 -0.4161 -0.1444
S-1502	Muscle aerobic capacity, measured by the rate constant (k) of postexercise phosphocreatine resynthesis, was significantly impaired in Fontan adults versus controls (1.48±0.13 vs 2.40±0.33 min(-1), p=0.02).<unk>
T-1502	muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; fontan
H-1502	-0.6527555584907532	▁Mus cle ▁aero bic ▁capacity ▁; ▁rate ▁; ▁poste xer ci se ▁ phos pho creati ne ▁re syn the sis ▁; ▁Font an
D-1502	-0.6527555584907532	Muscle aerobic capacity ; rate ; postexercise phosphocreatine resynthesis ; Fontan
P-1502	-0.5297 -0.2105 -0.1181 -1.2712 -0.1636 -0.2098 -0.1676 -0.5051 -0.4957 -0.0996 -0.3301 -1.9540 -0.9316 -0.0423 -1.7729 -1.9682 -0.3450 -0.0633 -0.0828 -1.8764 -2.0505 -0.4525 -0.0882 -0.1074 -0.9861 -0.1494
S-1117	RESULTS: (123)I-MIBG cardiac washout was lower during carvedilol than metoprolol treatment (12.9% ± 3.9% vs. 22.1% ± 2.8%, respectively, P = 0.003), irrespective of β2-adrenergic receptor haplotype.<unk>
T-1117	cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
H-1117	-0.8393842577934265	▁i - mi g ▁; ▁cardiac ▁was hout ▁; ▁car vedi lol ▁; ▁met o pro lol ▁; ▁β 2- ad r energi c ▁receptor ▁ha plo type
D-1117	-0.8393842577934265	i-mig ; cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
P-1117	-0.0499 -0.2512 -0.2130 -3.7019 -1.4461 -1.1955 -3.4076 -0.3506 -0.2183 -0.5941 -0.1484 -0.4590 -0.2103 -0.3789 -0.1990 -0.1657 -0.5536 -1.3041 -2.2770 -1.4276 -0.9262 -0.2160 -1.5794 -0.2982 -0.0374 -0.1031 -0.1863 -2.7251 -0.3538 -0.2043
S-1306	BACKGROUND: Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneficial impact on the incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this contention.<unk>
T-1306	acute myocardial infarction ; ami ; incidence ; deaths ; heart failure ; hf ; ami
H-1306	-0.5953998565673828	▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁incide nce ▁; ▁death s ▁; ▁heart ▁failure ▁; HF ▁; ▁ AMI
D-1306	-0.5953998565673828	acute myocardial infarction ;AMI ; incidence ; deaths ; heart failure ;HF ; AMI
P-1306	-1.2600 -0.1334 -2.8778 -0.4906 -0.7963 -0.0965 -0.0998 -0.1671 -0.1790 -0.4030 -1.4587 -0.4729 -0.5388 -0.0582 -1.6833 -1.4892 -0.0831 -0.3864 -0.6146 -0.0868 -0.3634 -0.4499 -0.3926 -0.8789 -0.1635 -0.2720 -0.1801
S-655	H-DKO mice had reduced ventricular mass; developed cardiac apoptosis, fibrosis, and failure; and showed diminished Akt→forkhead box class O-1 signaling that was accompanied by impaired cardiac metabolic gene expression and reduced ATP content.<unk>
T-655	h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; cardiac metabolic gene expression ; atp
H-655	-0.6996033787727356	▁h - d KO ▁mi ce ▁; ▁vent ri cular ▁mass ▁; ▁cardiac ▁apo pto sis ▁; ▁fibro sis ▁; ▁failure ▁; ▁Akt ▁; ▁for k head ▁box ▁; ▁o -1 ▁signal ing ▁; ▁im pair ed ▁cardiac ▁metabol ic ▁gene ▁expression ▁; ▁ATP
D-655	-0.6996033787727356	h-dKO mice ; ventricular mass ; cardiac apoptosis ; fibrosis ; failure ; Akt ; forkhead box ; o-1 signaling ; impaired cardiac metabolic gene expression ; ATP
P-655	-0.6413 -0.5042 -0.7647 -2.7731 -0.5498 -0.1933 -0.2977 -3.1180 -1.4261 -0.9203 -0.1398 -0.0695 -0.1939 -0.3339 -0.4719 -1.5772 -0.5713 -0.0052 -0.3182 -0.6318 -5.3493 -0.2173 -0.3410 -0.8206 -1.6273 -0.4040 -1.0161 -0.1818 -0.2985 -0.2439 -1.3814 -0.3550 -0.1296 -0.1171 -0.3190 -0.0124 -0.0146 -0.0581 -0.0992 -0.1064 -1.7586 -0.0719 -0.1421 -0.4257 -1.0139 -0.1760
S-505	The bottleneck stent was implanted in the proximal left anterior descending (LAD) or proximal circumflex artery (LCX), or in both proximal LCX and mid LAD 1 wk later (2-vessel model), and pigs were followed for 4-5 wk.<unk>
T-505	bottleneck stent ; implanted ; lad ; circumflex artery ; lcx ; lcx ; lad
H-505	-0.6420385837554932	▁bottle ne ck ▁sten t ▁; ▁left ▁anterior ▁descend ing ▁; LAD ▁; ▁proxima l ▁circum flex ▁arter y ▁; LC X ▁; ▁ LC X ▁; ▁ LAD
D-505	-0.6420385837554932	bottleneck stent ; left anterior descending ;LAD ; proximal circumflex artery ;LCX ; LCX ; LAD
P-505	-0.0499 -0.0253 -0.0837 -0.6135 -0.4229 -0.3471 -4.4255 -0.3396 -0.0528 -0.0210 -0.4353 -0.4980 -0.2480 -0.6549 -0.0884 -0.1665 -0.5286 -0.2182 -0.3946 -0.6189 -0.2952 -1.8553 -0.3088 -1.7882 -0.3924 -1.8901 -0.3152 -0.5662 -0.2643 -1.7334 -0.2613
S-1827	BACKGROUND: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.<unk>
T-1827	hospitalized ; heart failure ; dipeptidyl peptidase-4 ; dpp-4 ; antihyperglycemic agents
H-1827	-0.7370409369468689	▁post marketing ▁trial s ▁; ▁hospital ized ▁heart ▁failure ▁; ▁h HF ▁; ▁di pe pti dy l ▁pep tida se -4 ▁; ▁d pp -4 ▁; ▁anti hy per gly ce mic ▁agents
D-1827	-0.7370409369468689	postmarketing trials ; hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dpp-4 ; antihyperglycemic agents
P-1827	-1.0632 -0.0265 -2.8548 -0.0784 -0.3183 -1.5828 -0.1285 -2.2657 -0.3978 -0.3054 -1.0225 -1.3668 -0.1811 -0.2523 -0.1006 -0.2088 -1.9809 -2.1290 -0.0478 -0.1691 -1.4734 -0.2082 -0.2168 -0.3399 -0.8910 -0.1232 -0.6917 -1.0296 -1.2937 -0.2220 -1.0940 -0.1204 -1.4654 -0.1926 -0.4918 -0.1996
S-380	METHODS AND RESULTS: Using a quality improvement database and multivariable Cox modeling, we derived the Heart Failure Patient Severity Index (HFPSI) in the University of Michigan HF clinic (UM cohort, n = 1,536; 314 reached primary outcome).<unk>
T-380	cox modeling ; heart failure patient severity index ; hfpsi ; university of michigan ; hf ; clinic ; primary outcome
H-380	-0.6728035807609558	▁co x ▁model ing ▁; ▁Heart ▁Fail ure ▁Patient ▁Sever ity ▁index ▁; HF PSI ▁; ▁university ▁of ▁Michigan ▁; ▁ HF ▁; um
D-380	-0.6728035807609558	cox modeling ; Heart Failure Patient Severity index ;HFPSI ; university of Michigan ; HF ;um
P-380	-0.7426 -0.4567 -0.3735 -0.1946 -0.2622 -0.5458 -0.3237 -0.0321 -0.4667 -1.0193 -0.0441 -0.6318 -0.2781 -1.5282 -0.6400 -0.1235 -0.6744 -0.0283 -0.0501 -0.6396 -1.3431 -1.2012 -1.2870 -1.9087 -2.4994 -0.1983
S-1216	Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and L-type Ca2(+) current amplitude, and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility.<unk>
T-1216	pde2 ; healthy ; cardiomyocytes ; camp ; inotropic effect ; acute ; β-ar ; contractility
H-1216	-0.40969789028167725	▁p de 2 ▁over expression ▁; ▁healthy ▁cardio my o cy tes ▁; ▁c AMP ▁levels ▁; ▁l - type ▁ca 2 ▁; ▁current ▁amplitud e ▁; ▁in o tropi c ▁effect ▁; ▁a cute ▁β - AR ▁stimul ation ▁; ▁bas al ▁contract ility
D-1216	-0.40969789028167725	pde2 overexpression ; healthy cardiomyocytes ; cAMP levels ; l-type ca2 ; current amplitude ; inotropic effect ; acute β-AR stimulation ; basal contractility
P-1216	-0.3362 -1.4568 -0.1582 -0.5488 -0.2084 -0.2343 -2.1618 -0.5022 -0.9353 -0.4870 -0.2320 -0.2420 -0.1006 -0.0088 -0.5352 -0.1383 -0.0868 -1.5869 -0.1225 -0.1523 -0.2322 -0.0889 -0.3672 -1.1425 -0.1463 -0.3313 -0.2854 -0.0561 -0.4884 -0.2693 -0.4617 -0.3351 -0.1612 -0.1555 -0.0195 -0.2049 -0.0187 -0.3657 -0.8819 -0.3317 -0.6137 -0.0062 -0.0447 -0.1477 -1.1678 -0.4488 -0.2491
S-863	The reduction in risk was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p = 0.009) and inappropriate shock therapy (HR: 0.54 [95% CI: 0.36 to 0.80]; p = 0.002).<unk>
T-863	atp ; shock therapy
H-863	-1.0407158136367798	▁in appropria te ▁ATP ▁; ▁in appropria te ▁shock ▁ therapy
D-863	-1.0407158136367798	inappropriate ATP ; inappropriate shock therapy
P-863	-3.4432 -0.0102 -0.6261 -0.2807 -0.1979 -2.6762 -0.0127 -0.3593 -3.3663 -0.3016 -0.0617 -1.9340 -0.2595
S-904	Cardiac resynchronization therapy (CRT) is often deferred in dialysis-dependent patients with heart failure (HF) because of a perceived lack of benefit and potentially higher risks, although the outcomes associated with CRT in dialysis have not been reported.<unk>
T-904	cardiac resynchronization therapy ; crt ; patients ; heart failure ; hf ; outcomes ; crt ; dialysis ; reported
H-904	-0.5735772848129272	▁Card iac ▁re syn chron ization ▁ therapy ▁; ▁c RT ▁; ▁di al ysis - dependent ▁patients ▁; ▁heart ▁failure ▁; HF
D-904	-0.5735772848129272	Cardiac resynchronization therapy ; cRT ; dialysis-dependent patients ; heart failure ;HF
P-904	-1.0928 -0.9491 -0.0100 -0.0341 -0.0052 -0.7676 -0.8815 -0.0861 -0.2409 -1.1515 -1.7992 -0.2859 -0.2452 -0.3088 -0.5471 -0.3879 -0.2310 -1.4164 -0.2838 -0.3324 -0.1281 -0.3685 -0.2981 -2.2941 -0.1943
S-1766	BACKGROUND: We evaluated the individual and joint associations among cardiorespiratory fitness (CRF), body mass index, and heart failure (HF) mortality, as well as the additive effect of an increasing number of cardiovascular risk factors on HF mortality in fit versus unfit men.<unk>
T-1766	joint ; cardiorespiratory fitness ; crf ; body mass index ; heart failure ; hf ; mortality ; cardiovascular ; hf ; mortality
H-1766	-0.49350687861442566	▁joint ▁associations ▁; ▁cardio re spira tory ▁fitness ▁; CR f ▁; ▁body ▁mass ▁index ▁; ▁heart ▁failure ▁; HF ▁; ▁mortal ity ▁; ▁cardiovascular ▁risk ▁factors ▁; ▁ HF ▁mortal ity ▁; ▁fit ▁; ▁un fit ▁men
D-1766	-0.49350687861442566	joint associations ; cardiorespiratory fitness ;CRf ; body mass index ; heart failure ;HF ; mortality ; cardiovascular risk factors ; HF mortality ; fit ; unfit men
P-1766	-1.6387 -0.2001 -0.3383 -0.0468 -0.2294 -0.4304 -0.0265 -2.6384 -0.2669 -0.5763 -1.0590 -0.1253 -0.0236 -0.0933 -0.0266 -0.2075 -1.0223 -0.1386 -0.3287 -0.6076 -0.9845 -0.2535 -0.0428 -0.5192 -0.3245 -0.5938 -0.0652 -0.2403 -0.2190 -0.2576 -0.5655 -0.0302 -0.6610 -0.9213 -1.2621 -0.0134 -0.0275 -1.9948 -0.5389 -0.2007
S-1221	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).<unk>
T-1221	eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; eplerenone ; patients ; hospitalization ; heart failure
H-1221	-0.564365565776825	▁e pler en one ▁; ▁hyper kal emia ▁; ▁renal ▁function ▁; ▁EM PHA SIS - HF ▁; ▁e pler en one ▁; ▁hospital ization ▁; ▁sur v I val ▁study ▁; ▁Heart ▁Fail ure
D-1221	-0.564365565776825	eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone ; hospitalization ; survIval study ; Heart Failure
P-1221	-0.4858 -0.9827 -1.4523 -0.1484 -0.2480 -0.8432 -1.3577 -0.4057 -0.1320 -0.2017 -0.3701 -0.5323 -0.4028 -0.0531 -1.0746 -0.0414 -0.0503 -0.5870 -0.3164 -0.4684 -1.0871 -0.0867 -0.2469 -1.8478 -0.2498 -0.3480 -1.5600 -0.2688 -2.6350 -0.0610 -0.3252 -0.7830 -0.3731 -0.1766 -0.0501 -0.3428 -0.2858
S-1585	Heart rate (HR) variability has been extensively studied in cardiac patients, especially in patients surviving an acute myocardial infarction (AMI) and also in patients with congestive heart failure (CHF) or left ventricular (LV) dysfunction.<unk>
T-1585	heart rate ; cardiac ; patients ; patients ; acute myocardial infarction ; ami ; patients ; congestive heart failure ; chf ; left ventricular ; dysfunction
H-1585	-0.4812304973602295	▁Heart ▁rate ▁; HR ▁; ▁cardiac ▁patients ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁con ges tive ▁heart ▁failure ▁; CH f ▁; ▁left ▁vent ri cular ▁; LV
D-1585	-0.4812304973602295	Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
P-1585	-0.9390 -0.0366 -0.6045 -0.5030 -0.8494 -1.2585 -0.8837 -0.1978 -0.1501 -0.0952 -2.3646 -0.7008 -1.0276 -0.1542 -0.0899 -0.4441 -0.2933 -0.3587 -0.0753 -0.3174 -0.0536 -0.1153 -0.0818 -0.5901 -0.0456 -0.2017 -0.2706 -0.6141 -0.1529 -0.0405 -1.7540 -0.5476 -0.1638 -0.4385 -0.0349 -1.1571 -0.1999
S-657	Using neonatal rat ventricular cardiomyocytes, we further found that chronic insulin exposure reduced IRS1 and IRS2 proteins and prevented insulin action through activation of p38, revealing a fundamental mechanism of cardiac dysfunction during insulin resistance and type 2 diabetes.<unk>
T-657	ventricular cardiomyocytes ; chronic ; insulin ; irs1 ; irs2 ; proteins ; insulin ; p38 ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
H-657	-0.39035147428512573	▁ne ona tal ▁rat ▁; ▁vent ri cular ▁cardio my o cy tes ▁; ▁chronic ▁insulin ▁exposure ▁; ▁i RS 1 ▁; ▁i RS 2 ▁protein s ▁; ▁insulin ▁action ▁; ▁p 38 ▁; ▁cardiac ▁dys function ▁; ▁insulin ▁resist ance ▁; ▁type ▁2 ▁diabetes
D-657	-0.39035147428512573	neonatal rat ; ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; p38 ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
P-657	-0.0688 -0.0168 -0.0063 -0.0714 -1.6780 -0.2527 -0.3536 -0.3141 -0.3149 -1.6026 -0.4653 -0.2116 -0.1105 -0.2771 -0.4377 -0.5728 -0.2823 -0.1389 -1.2643 -0.1403 -0.4793 -0.2236 -0.8872 -0.5086 -0.0557 -1.2837 -0.0435 -0.1901 -1.9736 -0.7622 -0.1550 -0.0931 -0.1230 -0.3409 -0.7448 -0.1564 -0.3151 -0.2128 -0.0366 -0.0685 -0.0173 -0.2547 -0.0832 -0.1377 -0.0600 -0.3288 -0.2310
S-323	Echocardiograms of the left ventricular midpapillary level were taken at varying atrioventricular delay (AVD) and interventricular delay (VVD) for STE analysis of regional circumferential strain (CS) and radial strain (RS).<unk>
T-323	echocardiograms ; left ventricular ; midpapillary ; atrioventricular delay ; avd ; interventricular delay ; vvd ; ste ; circumferential strain ; radial strain ; rs
H-323	-0.47592228651046753	▁e cho card i ogram s ▁; ▁left ▁vent ri cular ▁mid pap illa ry ▁level ▁; ▁at rio ven tri cular ▁de lay ▁; AV d ▁; ▁interven tri cular ▁de lay ▁; VV d ▁; ▁ STE ▁; ▁circum fer ential ▁strain ▁; CS ▁; ▁radi al ▁strain ▁; RS
D-323	-0.47592228651046753	echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ;AVd ; interventricular delay ;VVd ; STE ; circumferential strain ;CS ; radial strain ;RS
P-323	-1.4344 -0.1490 -0.3283 -0.4752 -0.1056 -0.3260 -0.3037 -0.0852 -2.4033 -0.9223 -0.3414 -0.6848 -0.1996 -1.4429 -0.0620 -1.0184 -0.2270 -0.2584 -0.3938 -0.2219 -1.3635 -0.4527 -0.2329 -0.0219 -0.4048 -0.7480 -0.7868 -0.1996 -0.0405 -1.0094 -0.1683 -0.1776 -0.0585 -0.5156 -0.1392 -0.3243 -0.3374 -1.1362 -0.6012 -0.3941 -0.9923 -0.2983 -0.0706 -0.2702 -0.3556 -0.1029 -0.2406 -0.0025 -0.0251 -0.9720 -1.1783 -0.0079 -0.5384 -0.1494
S-1870	METHODS: Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions < 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe.<unk>
T-1870	patients ; new york heart association ; nyha ; functional class ; hf ; ejection fractions ; chronic ; stable ; guideline-directed medical therapy ; gdmt ; united states ; canada ; europe
H-1870	-0.4971825182437897	▁New ▁York ▁Heart ▁association ▁; NY HA ▁; ▁ HF ▁; ▁e je ction ▁ fraction s ▁; ▁chronic ▁stable ▁guide line - direct ed ▁medical ▁ therapy ▁; GD MT
D-1870	-0.4971825182437897	New York Heart association ;NYHA ; HF ; ejection fractions ; chronic stable guideline-directed medical therapy ;GDMT
P-1870	-1.1105 -0.6245 -2.6051 -0.2804 -0.2781 -0.7327 -1.0770 -0.1375 -1.7760 -0.6674 -0.0845 -0.0223 -0.1137 -0.0627 -0.2284 -0.0037 -0.1427 -0.1069 -0.8540 -0.8965 -0.7697 -0.0251 -0.0910 -0.0125 -0.1619 -0.0257 -0.2390 -0.1286 -0.1806 -0.6023 -0.7368 -1.4811 -0.1483
S-889	In patients with non-LBBB and QRS ≥160 ms, the hazard ratio for the primary outcome was 0.52 (0.29-0.96; P=0.033); in patients with QRS <160 ms, the hazard ratio was 1.38 (0.88-2.14; P=0.155).<unk>
T-889	patients ; qrs ; hazard ratio ; primary outcome ; patients ; qrs ; hazard ratio
H-889	-0.7428036332130432	▁non - LB BB ▁; ▁QR s ▁; ▁hazard ▁ratio ▁; ▁primary ▁outcome
D-889	-0.7428036332130432	non-LBBB ; QRs ; hazard ratio ; primary outcome
P-889	-0.5834 -0.0724 -0.8340 -1.5767 -0.0769 -0.0911 -1.4424 -0.2590 -1.9417 -0.0231 -0.4900 -0.7976 -0.3066 -2.3326 -0.3146
S-1155	Mechanistically, we found that abnormal Ca(2+) handling in dyssynchronous HF slows myofiber shortening velocity at the early-activated septum and depresses both myofiber shortening and stretch rate at the late-activated lateral wall.<unk>
T-1155	dyssynchronous hf ; myofiber shortening ; septum ; myofiber shortening ; stretch ; wall
H-1155	-0.4774174690246582	▁dys syn chron ous ▁ HF ▁; ▁my o fi ber ▁short en ing ▁veloci ty ▁; ▁sept um ▁; ▁my o fi ber ▁short en ing ▁; ▁stretch ▁rate ▁; ▁late - activa ted ▁lateral ▁wall
D-1155	-0.4774174690246582	dyssynchronous HF ; myofiber shortening velocity ; septum ; myofiber shortening ; stretch rate ; late-activated lateral wall
P-1155	-5.0396 -0.0600 -0.0170 -0.1089 -0.5507 -0.1792 -0.2412 -1.6314 -0.1937 -0.3734 -0.0584 -0.3565 -0.5259 -0.1618 -0.0268 -0.2722 -0.2737 -2.0583 -0.0370 -0.1162 -1.1797 -0.1004 -0.2401 -0.0341 -0.2403 -0.4264 -0.1546 -0.5531 -0.1832 -0.0461 -0.5082 -1.0693 -0.0234 -0.0369 -0.0689 -0.0204 -0.5811 -0.5570 -0.3141
S-871	METHODS AND RESULTS: We applied an improved label-free shotgun proteomics approach to evaluate the global proteomics changes in transverse aortic constriction (TAC)-induced heart failure and the associated signaling pathway changes using ingenuity pathway analysis.<unk>
T-871	proteomics ; proteomics ; transverse aortic constriction ; tac ; heart failure ; signaling pathway ; ingenuity pathway analysis
H-871	-0.6514688730239868	▁label - free ▁shot gun ▁prote o mics ▁; ▁global ▁prote o mics ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC ▁; ▁heart ▁failure ▁; ▁signal ing ▁path way
D-871	-0.6514688730239868	label-free shotgun proteomics ; global proteomics ; transverse aortic constriction ;TAC ; heart failure ; signaling pathway
P-871	-2.9055 -0.0504 -0.0329 -0.6395 -0.1683 -2.1629 -1.1454 -0.0413 -0.3647 -0.2527 -1.4465 -1.0697 -0.0384 -0.2555 -0.0022 -0.0868 -0.0402 -1.0004 -0.0967 -0.1320 -1.2584 -0.0755 -0.3203 -0.4974 -0.4680 -3.3759 -0.0802 -0.6757 -0.1686 -0.1358 -0.0229 -0.3551 -2.6331 -0.1509
S-1342	CHF-derived c-Kit+ cells exhibited upregulated transforming growth factor-β (TGF-β) signaling, increased level of epithelial to mesenchymal transition markers, and diminished expression of pluripotency markers compared with shams.<unk>
T-1342	cells ; transforming growth factor-β ; tgf-β ; epithelial ; mesenchymal ; transition ; expression ; pluripotency markers
H-1342	-0.5902774930000305	▁CHF - der i ved ▁c - K ▁; ▁cell s ▁; ▁transform ing ▁growth ▁factor - β ▁; ▁t g - β ▁; ▁epi the li al ▁; ▁mes en chy mal ▁transition ▁marker s ▁; ▁pluri pote ncy ▁marker s ▁; ▁sham s
D-1342	-0.5902774930000305	CHF-derived c-K ; cells ; transforming growth factor-β ; tg-β ; epithelial ; mesenchymal transition markers ; pluripotency markers ; shams
P-1342	-0.0657 -0.5451 -3.2622 -0.0783 -0.3442 -0.0221 -0.1467 -2.1539 -5.3740 -1.7861 -0.1084 -0.5221 -0.1915 -0.0324 -1.6022 -0.0535 -0.4235 -0.1256 -0.5786 -0.1962 -0.5839 -0.4705 -0.2318 -0.8929 -2.1574 -0.4592 -0.3120 -0.0755 -0.1722 -0.0323 -0.9798 -0.2068 -0.0975 -0.0818 -0.2139 -0.0394 -0.4219 -0.6291 -0.0318 -0.0215 -0.2646 -0.0278 -1.1735 -0.0187 -0.0610 -0.2556 -0.2181
S-1428	Examination of PKA subunits demonstrated no change in type II regulatory (RIIα) or catalytic (Cα) subunit expression, although site specific RIIα (Ser96) and Cα (Thr197) phosphorylation were increased in HF.<unk>
T-1428	pka ; change ; riiα ; cα ; expression ; riiα ; ser96 ; cα ; thr197 ; phosphorylation ; hf
H-1428	-0.8616734147071838	▁p KA ▁; ▁regulator y ▁; RI i α ▁; ▁cata ly tic ▁; ▁c α ▁; ▁ phos phor y lation ▁; ▁ HF
D-1428	-0.8616734147071838	pKA ; regulatory ;RIiα ; catalytic ; cα ; phosphorylation ; HF
P-1428	-0.3119 -2.4658 -0.4493 -1.2563 -0.1341 -0.2456 -3.6160 -0.7444 -0.5011 -0.2229 -0.0673 -0.1791 -0.0836 -0.5266 -0.8015 -1.2587 -0.5715 -3.1885 -2.2064 -1.3287 -0.4299 -1.1449 -0.3562 -0.4107 -0.2086 -0.3599 -0.1956
S-178	In consecutive patients (209 HFrEF with left ventricular ejection fraction <40% and 108 HFpEF with left ventricular ejection fraction ≥40%), RAS- and β-blocker dose changes were followed during 6 months after an index HF hospitalization.<unk>
T-178	patients ; hfref ; left ventricular ejection fraction ; hfpef ; left ventricular ejection fraction ; β-blocker ; hf ; hospitalization
H-178	-0.7814307808876038	▁h Fr EF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ HF p EF ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ RAS - ▁; ▁β - block er ▁; ▁ HF
D-178	-0.7814307808876038	hFrEF ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; RAS- ; β-blocker ; HF
P-178	-0.6910 -1.3383 -1.1686 -0.1210 -0.0794 -3.9526 -1.6378 -1.2073 -0.3929 -0.3429 -0.4638 -1.2756 -0.0417 -0.1733 -0.4109 -0.4568 -0.1267 -0.1920 -0.0936 -0.1694 -4.0190 -2.2461 -1.1978 -0.4567 -0.6725 -0.8544 -0.9689 -0.0316 -0.4009 -0.2467 -0.0443 -0.2867 -1.2071 -0.1435 -0.1256 -0.2536 -0.1822 -1.7602 -1.9768 -0.3587 -0.7222 -0.3289
S-1410	This cross talk between these 2 distinct G-protein-coupled receptors appears to have physiological significance, because they interact and show reciprocal regulation in mouse hearts undergoing chronic β-adrenergic receptor stimulation and in a rat model of postischemic heart failure.<unk>
T-1410	cross talk ; g-protein-coupled receptors ; physiological ; significance ; regulation ; hearts ; chronic ; β-adrenergic receptor ; postischemic heart failure
H-1410	-0.5077470541000366	▁g - prote in - co up led ▁receptor s ▁; ▁physio logic al ▁; ▁reciproc al ▁regula tion ▁; ▁mouse ▁heart s ▁; ▁β - ad r energi c ▁receptor ▁; ▁rat ▁model ▁; ▁post ische mic ▁heart ▁failure
D-1410	-0.5077470541000366	g-protein-coupled receptors ; physiological ; reciprocal regulation ; mouse hearts ; β-adrenergic receptor ; rat model ; postischemic heart failure
P-1410	-0.2678 -0.2543 -0.1528 -0.4624 -0.1242 -0.0135 -0.2604 -0.0278 -0.0150 -0.2038 -0.3588 -3.2387 -0.3104 -0.0553 -0.3757 -0.1815 -0.0189 -0.0520 -0.0603 -0.1636 -0.0823 -0.7513 -0.0524 -0.1613 -2.9257 -0.0818 -0.8761 -0.9689 -1.3172 -0.3131 -0.0104 -1.2422 -1.0966 -1.0998 -0.6872 -0.0298 -0.8961 -0.1304 -1.2365 -0.1034 -0.4690 -0.1968
S-1524	Although concentric remodeling (CR) and concentric hypertrophy (CH) are common forms of left ventricular (LV) remodeling in heart failure with preserved ejection fraction (HFpEF), eccentric hypertrophy (EH) can also occur in these patients.<unk>
T-1524	concentric remodeling ; concentric hypertrophy ; left ventricular ; remodeling ; heart failure with preserved ejection fraction ; hfpef ; eccentric hypertrophy ; patients
H-1524	-0.3808315694332123	▁concentr ic ▁remodel ing ▁; CR ▁; ▁concentr ic ▁hyper trop hy ▁; CH ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁remodel ing ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁ecce n tric ▁hyper trop hy ▁; EH
D-1524	-0.3808315694332123	concentric remodeling ;CR ; concentric hypertrophy ;CH ; left ventricular ;LV ; remodeling ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
P-1524	-0.2871 -0.0108 -0.5040 -0.0392 -0.3341 -0.3123 -0.1744 -0.1140 -0.0118 -0.6172 -0.1157 -0.6800 -0.4349 -0.2262 -0.5210 -0.0837 -2.3985 -0.8409 -0.4887 -0.3646 -0.0835 -0.4261 -4.6880 -0.0180 -0.2332 -0.3201 -0.0590 -0.1449 -0.2026 -0.1215 -0.0813 -0.0322 -0.2661 -0.1692 -0.5229 -0.0214 -0.4396 -0.2137 -0.0191 -0.1976 -0.1085 -0.0112 -0.0147 -0.0810 -0.4132 -0.1168 -0.7953 -0.2870 -0.0047 -0.4947 -0.2762
S-1989	Body weight decreased by 7% (7 kg [SD, 1]) in the diet group, 3% (4 kg [SD, 1]) in the exercise group, 10% (11 kg [SD, 1] in the exercise + diet group, and 1% (1 kg [SD, 1]) in the control group.<unk>
T-1989	exercise ; exercise
H-1989	-1.0171765089035034	▁body ▁; ▁die t ▁group ▁; ▁exercise ▁group ▁; ▁exercise ▁; ▁die t ▁group
D-1989	-1.0171765089035034	body ; diet group ; exercise group ; exercise ; diet group
P-1989	-1.4565 -0.9085 -3.4907 -0.3392 -0.2531 -0.3310 -1.0651 -0.7798 -0.5893 -2.0518 -0.2874 -2.3562 -0.2690 -0.1879 -1.6527 -0.2566
S-1166	Risk of event was greater in subjects with RV dysfunction (hazard ratio: 3.09 [95% confidence interval (CI): 2.18 to 4.45]) and cachexia (hazard ratio: 2.90 [95% CI: 2.00 to 4.12]) in univariate and multivariate analyses.<unk>
T-1166	rv dysfunction ; hazard ratio ; confidence interval ; cachexia ; hazard ratio ; multivariate analyses
H-1166	-0.7908627986907959	▁risk ▁of ▁event ▁; ▁ RV ▁dys function ▁; haz ard ▁ratio ▁; ▁CI ▁; ▁cache xia ▁; haz ard ▁ratio
D-1166	-0.7908627986907959	risk of event ; RV dysfunction ;hazard ratio ; CI ; cachexia ;hazard ratio
P-1166	-0.9805 -1.6429 -0.1286 -0.4221 -0.2841 -0.3024 -1.2446 -1.4718 -0.2571 -0.5329 -0.1964 -0.1423 -0.4581 -5.3974 -0.5262 -0.0645 -1.4042 -0.6786 -0.1163 -0.2803 -0.0370 -1.2976 -0.3238
S-1945	Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0±3.2 mL/min/kg increase in VO2max compared to a 1.2±7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value=0.033).<unk>
T-1945	patients ; resting hr ; follow-up ; baseline ; vo2max ; patients ; resting hr ; p value
H-1945	-1.2611006498336792	▁rest ing ▁HR ▁; ▁base line ▁; ▁VO 2 max
D-1945	-1.2611006498336792	resting HR ; baseline ; VO2max
P-1945	-3.7725 -0.0470 -0.7438 -0.3927 -0.0571 -0.0998 -0.3013 -4.7925 -0.3017 -0.0620 -4.2259 -0.3368
S-1344	CONCLUSIONS: Taken together, our findings suggest that TGF-β inhibition positively modulates c-Kit+ cell phenotype and function in vitro, and this strategy may be considered in optimizing cardiac progenitor function and cell expansion protocols for clinical application.<unk>
T-1344	tgf-β ; cell ; phenotype ; in vitro ; cardiac progenitor function ; cell ; clinical
H-1344	-0.6685338616371155	▁t g - β ▁inhibi tion ▁; ▁c - K it + ▁cell ▁; ▁function ▁; ▁vi tro ▁; ▁cardiac ▁pro gen itor ▁function ▁; ▁cell ▁exp an sion ▁protocol s
D-1344	-0.6685338616371155	tg-β inhibition ; c-Kit+ cell ; function ; vitro ; cardiac progenitor function ; cell expansion protocols
P-1344	-0.2183 -0.4108 -0.2170 -0.3658 -0.6929 -0.2383 -0.0936 -0.0030 -0.2922 -3.7057 -1.5494 -2.5180 -1.6966 -1.3261 -2.0001 -0.6505 -2.4180 -0.4288 -0.3991 -0.0793 -0.0907 -0.1965 -0.3064 -0.2974 -0.2073 -0.3427 -0.0559 -0.2213 -0.1000 -0.1295 -0.1369 -0.5496 -0.1238
S-1920	NT-ProBNP (+233 to –733 ng/ml) and the inflammatory biomarkers (hsCRP and IL6) decreased in four of five patients (IL 6: +0.5 to –2 mg/l, hsCRP: +0.2 to –6.5 mg/l).<unk>
T-1920	nt-probnp ; inflammatory ; biomarkers ; hscrp ; il6 ; patients ; hscrp
H-1920	-0.5270671844482422	▁NT - pro b NP ▁; ▁infla mma tory ▁bio mark ers ▁; ▁h s CR p ▁; ▁il 6) ▁; ▁h s CR p ▁; ▁h s CR p
D-1920	-0.5270671844482422	NT-probNP ; inflammatory biomarkers ; hsCRp ; il6) ; hsCRp ; hsCRp
P-1920	-0.0544 -0.1055 -0.9288 -0.9098 -0.4331 -0.0957 -0.4712 -0.9184 -0.0560 -0.9043 -0.0517 -0.1858 -0.1426 -0.3452 -0.0325 -0.4624 -0.4453 -0.0921 -1.6145 -1.1557 -1.0215 -1.7401 -0.0268 -0.5557 -0.2490 -1.2974 -0.7909 -0.0302 -0.7046 -0.2551 -0.5994 -0.1903
S-1044	Investigating the role of BETs in an in vitro model of neurohormonally induced heart disease, the authors showed that nanomolar doses of JQ1 significantly blocked phenylephrine-mediated hypertrophy of cardiomyocytes and pathological gene induction.<unk>
T-1044	bets ; in vitro ; neurohormonally ; heart disease ; nanomolar ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological ; gene induction
H-1044	-0.3877200782299042	▁bet s ▁; ▁neuro hormon ally ▁induc ed ▁heart ▁disease ▁; ▁na nomo lar ▁dos es ▁; ▁j q 1 ▁; ▁ phen yle ph rine - media ted ▁hyper trop hy ▁; ▁cardio my o cy tes ▁; ▁path ological ▁gene ▁in duction
D-1044	-0.3877200782299042	bets ; neurohormonally induced heart disease ; nanomolar doses ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
P-1044	-1.4411 -0.0492 -0.1553 -0.6874 -0.0469 -0.0368 -0.0211 -0.0512 -1.9261 -1.0540 -0.2991 -0.0957 -0.0449 -0.5408 -0.8247 -0.0290 -0.3648 -0.6783 -3.1392 -0.4212 -0.1966 -1.3118 -0.0544 -0.6375 -0.2051 -0.0106 -0.2164 -0.0527 -0.0250 -0.0647 -0.0211 -0.7387 -0.2941 -0.0746 -0.3916 -0.2614 -0.0567 -0.0748 -0.2666 -0.0021 -0.0447 -0.1792 -0.0534 -0.0057 -0.5058 -0.1831
S-1878	CONCLUSIONS: BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF.<unk>
T-1878	bat ; functional status ; quality of life ; exercise capacity ; n-terminal pro-brain natriuretic peptide ; heart failure ; hospitalizations ; patients ; nyha functional class iii ; hf
H-1878	-0.48212867975234985	▁BAT ▁; ▁exercise ▁capacity ▁; ▁N - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁heart ▁failure ▁; ▁GD MT - tre ated ▁NY HA ▁; ▁ HF
D-1878	-0.48212867975234985	BAT ; exercise capacity ; N-terminal pro-brain natriuretic peptide ; heart failure ; GDMT-treated NYHA ; HF
P-1878	-0.4225 -0.4570 -1.5895 -0.1190 -0.2187 -1.7433 -0.0999 -0.0500 -0.0040 -0.0221 -0.0949 -0.1671 -0.1686 -0.0078 -0.3251 -0.0710 -0.3273 -0.0358 -0.1885 -0.6458 -0.1950 -1.2178 -0.0774 -0.9198 -1.4731 -1.4983 -0.1858 -0.0225 -0.1546 -1.0445 -0.3721 -0.4749 -2.2327 -0.2844 -0.2975 -0.1482
S-257	In addition, an elevated activation of p70S6K, PKC-βII by HDL(NYHA-IIIb), and a higher amount of malondialdehyde bound to HDL(NYHA-IIIb) compared with HDL(healthy) was measured.<unk>
T-257	elevated ; p70s6k ; pkc-βii ; hdl ; nyha-iiib ; malondialdehyde ; bound ; hdl ; nyha-iiib ; hdl ; healthy
H-257	-0.902839183807373	▁p 70 s 6 k ▁; ▁PK c - β II ▁; ▁HD l ▁; NY HA - III b ▁; ▁malo ndi alde hy de ▁ bound ▁; ▁HD l ▁; NY HA - III b ▁; ▁HD l
D-257	-0.902839183807373	p70s6k ; PKc-βII ; HDl ;NYHA-IIIb ; malondialdehyde bound ; HDl ;NYHA-IIIb ; HDl
P-257	-0.1064 -0.2046 -0.8328 -0.1138 -2.5959 -0.1007 -0.0487 -2.6755 -0.1025 -0.5916 -0.2781 -0.0695 -1.8883 -1.9942 -0.1463 -3.1286 -1.3837 -0.2409 -0.2652 -0.0487 -0.2498 -0.0574 -0.0349 -0.1665 -2.8536 -0.9382 -0.8572 -0.0066 -0.2045 -3.0437 -2.0268 -0.2165 -2.0313 -1.1502 -0.1710 -0.3440 -0.0240 -0.5210 -2.4130 -2.3530 -1.1791 -0.2610
S-1986	There was no statistically significant change in MLHF total score with exercise and with diet (main effect: exercise, -1 unit [95% CI, -8 to 5], P = .70; diet, -6 units [95% CI, -12 to 1], P = .08).<unk>
T-1986	change ; exercise ; exercise
H-1986	-1.1036689281463623	▁ ML HF ▁; ▁exercise ▁; ▁die t ▁; ▁exercise
D-1986	-1.1036689281463623	MLHF ; exercise ; diet ; exercise
P-1986	-1.1036 -0.2108 -1.3010 -0.4058 -2.2189 -0.1375 -2.7954 -0.2776 -0.7452 -0.7708 -2.9952 -0.2823
S-1374	Four treatment groups were used: nonpace, non-DNx [Sham-Innervated (Sham-INV)], nonpace DNx (sham-DNx), pace non-DNx (CHF-INV) or pace DNx (CHF-DNx).<unk>
T-1374	dnx ; dnx
H-1374	-1.0070537328720093	▁non pa ce ▁; ▁non - DN x ▁; ▁s ham - i nner vat ed ▁; ▁s ham - in v ▁; ▁non pa ce ▁DN x ▁; s ham - n x ▁; ▁pace ▁non - d x ▁; CH f - in v ▁; ▁pace ▁; ▁DN x ▁; CH f - in v
D-1374	-1.0070537328720093	nonpace ; non-DNx ; sham-innervated ; sham-inv ; nonpace DNx ;sham-nx ; pace non-dx ;CHf-inv ; pace ; DNx ;CHf-inv
P-1374	-1.4909 -0.1387 -0.0612 -0.3468 -0.3301 -0.2869 -4.5264 -1.0191 -0.3945 -1.6246 -2.0489 -0.1111 -2.8906 -0.0119 -0.3719 -0.1108 -0.4623 -0.8389 -1.8844 -0.0735 -0.2273 -0.2950 -0.4569 -0.5952 -0.1478 -0.0258 -1.3297 -0.2512 -0.2313 -1.9472 -0.7288 -0.0821 -5.3334 -1.1936 -0.1488 -1.0847 -1.5630 -0.0834 -4.0453 -0.7884 -0.2137 -4.7711 -0.8001 -0.0339 -0.0987 -0.1849 -0.2380 -1.2263 -1.4759 -0.8509 -0.1751 -0.3953 -3.3452 -0.6601 -0.0421 -2.9051 -0.2626 -1.9510 -0.2039
S-629	HABC Battery score was linearly associated with HF risk after adjusting for the Health ABC HF Model (HR 1.24, 95% CI 1.13-1.36 per SD decrease in score) and remained significant when controlled for death as a competing risk (HR 1.30; 95% CI 1.00-1.55).<unk>
T-629	habc battery ; hf ; health abc hf model ; death
H-629	-0.926777184009552	▁h ABC ▁; ▁bat tery ▁score ▁; ▁ HF ▁; ▁health ▁ABC ▁; ▁ HF ▁model ▁; ▁SD ▁; ▁ HF ▁; ▁death ▁; ▁competi ng ▁risk
D-629	-0.926777184009552	hABC ; battery score ; HF ; health ABC ; HF model ; SD ; HF ; death ; competing risk
P-629	-2.2685 -1.7973 -1.5504 -1.8938 -0.0974 -1.0070 -0.1264 -0.3282 -0.1314 -0.4355 -0.7703 -0.4394 -0.5736 -0.4665 -0.1904 -0.6497 -0.1366 -1.6374 -0.3835 -4.0464 -1.0361 -0.3417 -4.3839 -0.3161 -0.5696 -0.0940 -0.2990 -0.6782 -0.2286
S-1010	After adjustment for age, sex and ejection fraction, patients categorized as frail by the biological phenotype had a 2-fold increased risk of death compared to those with no frailty, whereas a 0.1 unit increase in the deficit index was associated with a 44% increased risk of death.<unk>
T-1010	ejection fraction ; patients ; frail ; biological phenotype ; death ; frailty ; deficit index ; death
H-1010	-0.6085697412490845	▁sex ▁; ▁e je ction ▁ fraction ▁; ▁fra il ▁; ▁bi ological ▁ph eno type ▁; ▁risk ▁of ▁death ▁; ▁fra il ty ▁; ▁deficit ▁index
D-1010	-0.6085697412490845	sex ; ejection fraction ; frail ; biological phenotype ; risk of death ; frailty ; deficit index
P-1010	-5.3357 -0.1618 -0.0142 -0.1523 -0.0457 -0.8591 -0.0060 -0.2186 -0.5385 -0.0462 -0.1159 -0.0419 -0.1277 -1.3357 -0.1586 -0.6555 -0.1720 -0.8177 -0.2684 -0.7512 -0.7601 -0.5833 -0.0637 -0.7532 -0.2381 -0.2167 -0.0415 -2.9662 -0.2030
S-836	The purpose of this study was to explore the relation of hemoglobin (Hgb) with HRQoL and training-induced changes in HRQoL in a cohort of patients in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION).<unk>
T-836	hemoglobin ; hgb ; hrqol ; hrqol ; patients ; heart failure ; outcomes ; exercise ; training ; hf-action
H-836	-0.5611557960510254	▁hem o glob in ▁; ▁h gb ▁; ▁HR Qo L ▁; ▁training - indu ced ▁changes ▁; ▁HR Qo L ▁; ▁Heart ▁Fail ure ▁; ▁control led ▁Tri al ▁Investiga ting ▁out com es ▁of ▁exercise ▁training ▁; HF - AC TION
D-836	-0.5611557960510254	hemoglobin ; hgb ; HRQoL ; training-induced changes ; HRQoL ; Heart Failure ; controlled Trial Investigating outcomes of exercise training ;HF-ACTION
P-836	-1.4806 -0.0794 -0.4812 -0.6876 -0.4147 -1.6455 -0.1705 -0.2801 -0.4896 -0.1190 -1.8373 -0.1738 -0.5741 -0.2617 -0.0300 -0.3759 -0.9826 -0.3623 -0.8162 -0.1322 -1.1319 -0.1740 -1.9568 -0.1428 -0.0112 -0.2435 -3.3687 -0.0447 -1.1222 -0.0282 -0.4325 -0.1030 -0.7332 -0.7167 -0.1049 -0.3211 -0.2259 -0.1166 -0.3861 -0.1995 -0.0347 -0.6224 -1.0569 -0.3868 -0.1932
S-1234	METHODS: In a substudy of the Atrial Fibrillation and Congestive Heart Failure trial, health care expenditures of patients from Québec randomized to rhythm and rate-control treatment strategies were compared from a single-payer perspective using a cost-minimization approach.<unk>
T-1234	atrial fibrillation ; congestive heart failure ; health care ; expenditures ; patients ; québec ; randomized ; rhythm ; rate-control
H-1234	-0.6492318511009216	▁at rial ▁Fi bril lation ▁; ▁con ges tive ▁Heart ▁Fail ure ▁trial ▁; ▁health ▁care ▁ex pendi tures ▁; ▁Québec ▁; ▁ rhythm ▁; ▁rate - control ▁; ▁treatment
D-1234	-0.6492318511009216	atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; Québec ; rhythm ; rate-control ; treatment
P-1234	-0.9006 -0.0158 -1.1327 -0.0595 -0.8843 -1.2097 -0.1202 -0.1833 -0.0778 -0.5414 -0.2361 -0.0449 -1.6317 -0.4837 -0.5201 -1.3449 -0.1200 -0.0055 -0.0968 -0.4421 -1.6763 -0.2525 -0.1547 -0.3474 -0.5366 -0.0066 -0.5091 -0.0529 -2.0822 -2.0461 -2.7603 -0.2996
S-1668	Every attempt should be made to identify and correct reversible causes for a worsening of heart failure, such as poor patient compliance, myocardial ischaemia, tachy- or bradyarrhythmias, valvular regurgitation, pulmonary embolism, infection, or renal dysfunction.<unk>
T-1668	heart failure ; patient ; compliance ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
H-1668	-0.5580869913101196	▁heart ▁failure ▁; ▁my o card ial ▁is cha emia ▁; ▁ta chy - ▁; ▁bra dy ar rhythm ias ▁; ▁val vu lar ▁re gur gi tation ▁; ▁pulmonar y ▁e mbol ism ▁; ▁infection ▁; ▁renal ▁dys function
D-1668	-0.5580869913101196	heart failure ; myocardial ischaemia ; tachy- ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
P-1668	-4.3059 -0.0993 -0.2989 -1.2264 -0.1417 -1.2397 -0.0884 -2.3715 -0.1515 -0.6959 -0.2663 -0.4411 -0.2790 -0.0386 -2.7575 -0.7281 -0.4622 -0.1015 -0.2360 -0.4764 -0.2470 -1.2586 -1.1465 -0.7179 -0.0106 -0.0472 -0.3343 -0.0318 -0.3513 -0.0037 -0.0298 -0.0416 -0.0288 -0.1711 -0.4068 -0.2735 -0.4749 -0.0030 -0.0918 -0.7003 -0.4210 -0.2425
S-640	Here we report that increased calcineurin/Nfat signalling and decreased miR-25 expression integrate to re-express the basic helix-loop-helix (bHLH) transcription factor dHAND (also known as Hand2) in the diseased human and mouse myocardium.<unk>
T-640	report ; calcineurin ; nfat ; mir-25 ; expression ; basic helix-loop-helix ; bhlh ; transcription factor ; dhand ; hand2 ; diseased ; myocardium
H-640	-0.6800820231437683	▁calci ne uri n ▁; ▁na fat ▁signal ling ▁; ▁mi R -25 ▁expression ▁; ▁basic ▁heli x - loop - heli x ▁; b hl h ▁; ▁tran scription ▁factor ▁d HAND ▁; ▁Hand 2 ▁; ▁disease d ▁human ▁; ▁mouse ▁my o car dium
D-640	-0.6800820231437683	calcineurin ; nafat signalling ; miR-25 expression ; basic helix-loop-helix ;bhlh ; transcription factor dHAND ; Hand2 ; diseased human ; mouse myocardium
P-640	-0.3897 -0.1001 -0.0318 -0.0788 -0.8371 -2.4952 -2.0159 -0.2687 -0.0662 -0.1388 -0.0670 -1.9243 -0.1533 -0.0403 -0.2638 -2.0217 -1.1819 -1.8437 -0.1514 -0.0755 -0.6004 -0.0544 -1.4762 -0.3777 -0.7925 -1.0608 -0.9098 -0.2348 -0.2553 -0.0687 -0.0111 -0.2966 -0.2698 -0.1332 -1.5238 -1.4847 -0.1083 -3.5562 -0.0824 -0.2889 -0.1686 -0.0276 -1.9625 -0.1137 -0.2150 -1.5368 -0.6159 -0.2725
S-1929	Exercise time at 3 and 12 months correlated with PSSS (r= 0.09 and r= 0.13, respectively) and BTES (r=-0.11 and r=-0.12, respectively), with higher exercise time associated with higher PSSS and lower BTES (All P<0.005).<unk>
T-1929	exercise ; correlated ; psss ; btes ; exercise ; psss ; btes
H-1929	-1.03801429271698	▁exercise ▁time ▁; ▁PS SS ▁; ▁b tes ▁; ▁exercise ▁; ▁PS SS ▁; ▁b tes
D-1929	-1.03801429271698	exercise time ; PSSS ; btes ; exercise ; PSSS ; btes
P-1929	-1.0232 -2.0534 -0.1827 -0.9964 -0.9559 -0.1062 -1.9484 -0.2490 -0.5359 -1.7698 -2.1911 -2.7538 -0.9977 -0.2201 -1.9190 -0.2423 -0.2894 -0.2499
S-269	The optimal NT-proBNP cutoff point for predicting 4-year survival at the time of admission was 2300 pg/mL, which had 85.9% sensitivity and 39.1% specificity (95% confidence interval, area under the curve: 0.639, P = .044).<unk>
T-269	nt-probnp ; admission ; sensitivity ; specificity ; confidence interval ; area under the curve
H-269	-0.5202773213386536	▁NT - pro b NP ▁cut off ▁point ▁; ▁ad mission ▁; ▁p g / m l
D-269	-0.5202773213386536	NT-probNP cutoff point ; admission ; pg/ml
P-269	-0.3532 -0.0471 -0.0613 -0.4557 -0.7092 -0.3586 -0.2280 -0.5035 -0.1793 -0.2039 -0.0694 -0.3900 -0.5155 -0.0140 -2.3005 -0.0078 -1.1897 -2.1479 -0.1503
S-1588	The prognostic power of various measures, except of those reflecting rapid R-R interval oscillations, has been almost identical, albeit some non-linear HR variability measures, such as short-term fractal scaling exponent have provided somewhat better prognostic information than the others.<unk>
T-1588	prognostic ; r-r interval ; hr variability ; short-term fractal scaling exponent ; prognostic
H-1588	-0.42401134967803955	▁prognos tic ▁power ▁; ▁r - r ▁interval ▁os cilla tions ▁; ▁non - line ar ▁HR ▁variabil ity ▁; ▁short - term ▁fra c tal ▁scal ing ▁ex ponent
D-1588	-0.42401134967803955	prognostic power ; r-r interval oscillations ; non-linear HR variability ; short-term fractal scaling exponent
P-1588	-1.0094 -0.2175 -0.0862 -0.2862 -1.6223 -0.1775 -1.1717 -0.1872 -2.6086 -0.1008 -0.0797 -0.2855 -0.7062 -0.0435 -0.0121 -0.0097 -0.8845 -0.2052 -0.0374 -0.5661 -0.1193 -0.0725 -0.1120 -1.0649 -0.2671 -0.1588 -0.0968 -0.0552 -0.1681 -0.0860 -0.8540 -0.2167
S-921	Diastolic function was quantified via the parametrized diastolic filling formalism that yields relaxation/viscoelastic (c) and passive/stiffness (k) constants through the analysis of Doppler mitral inflow velocity (E-wave) contours.<unk>
T-921	diastolic function ; diastolic filling formalism ; relaxation ; doppler mitral inflow velocity ; e-wave
H-921	-0.5438756942749023	▁Dia sto lic ▁function ▁; ▁dia sto lic ▁; ▁fill ing ▁formal ism ▁; ▁relax ation ▁; vis co ela stic ▁; ▁passiv e / sti ff ness ▁; ▁do pp ler ▁mit ral ▁in flow ▁veloci ty ▁; ▁e - wa ve
D-921	-0.5438756942749023	Diastolic function ; diastolic ; filling formalism ; relaxation ;viscoelastic ; passive/stiffness ; doppler mitral inflow velocity ; e-wave
P-921	-1.9873 -0.1400 -0.2572 -0.5579 -0.2869 -2.2050 -0.3509 -1.4339 -1.9504 -0.6339 -0.0444 -0.1049 -0.0652 -0.2325 -0.1822 -0.0211 -0.8328 -2.3388 -0.0263 -0.0053 -0.0053 -0.2234 -0.0022 -0.0301 -3.3207 -1.1816 -0.7973 -0.2289 -0.2294 -0.7228 -0.0129 -0.9163 -0.2819 -0.1243 -0.1530 -0.0491 -0.0185 -0.1261 -0.3855 -0.8671 -0.0710 -0.0948 -0.2948 -0.4385 -0.2420
S-1437	This study was performed in 29 subjects: 10 heart failure (HF) patients with spontaneous ventricular tachycardia [HFVT(+)], 10 HF patients without spontaneous VT [HFVT(-)], and 9 subjects with structurally normal hearts (HNorm).<unk>
T-1437	heart failure ; hf ; patients ; spontaneous ventricular tachycardia ; hf ; patients ; spontaneous vt ; hearts
H-1437	-0.9782708287239075	▁heart ▁failure ▁; HF ▁; ▁spontane ous ▁vent ri cular ▁ta chy car dia ▁; HF ▁; ▁ HF ▁; ▁spontane ous ▁ VT ▁; HF VT ▁; ▁structura lly ▁normal ▁heart s ▁; ▁h Nor m
D-1437	-0.9782708287239075	heart failure ;HF ; spontaneous ventricular tachycardia ;HF ; HF ; spontaneous VT ;HFVT ; structurally normal hearts ; hNorm
P-1437	-2.6782 -0.1972 -0.2193 -0.3821 -0.2526 -2.3949 -0.0691 -2.3886 -1.8588 -0.5543 -1.9236 -1.5186 -1.2347 -2.0991 -0.0797 -0.8117 -1.8125 -0.1776 -1.4834 -0.3523 -3.2214 -0.0282 -0.1531 -0.2067 -0.1037 -1.5600 -2.8957 -0.2959 -3.1751 -0.0334 -0.1089 -0.3625 -0.0340 -0.3944 -1.6904 -0.7696 -0.0041 -0.4539 -0.1731
S-819	Besides, the addition of GLS to a Cox model containing chronic heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke score, estimated glomerular filtration rate, LVEF and Sa provided an additional benefit in the prediction of adverse CV events (p=0.022).<unk>
T-819	gls ; cox model ; chronic heart failure ; hypertension ; diabetes ; stroke ; estimated glomerular filtration rate ; lvef
H-819	-0.4851876497268677	▁g ls ▁; ▁co x ▁model ▁; ▁chronic ▁heart ▁failure ▁; ▁hyper tension ▁; ▁diabetes ▁; ▁prior ▁stroke ▁score ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁LV EF ▁; ▁sa ▁; ▁advers e ▁CV ▁events
D-819	-0.4851876497268677	gls ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; sa ; adverse CV events
P-819	-0.1902 -1.8822 -0.1069 -0.1739 -0.1794 -0.0960 -0.2043 -0.7347 -1.1095 -0.1217 -0.2487 -0.2406 -0.2556 -0.1469 -0.3814 -0.0600 -0.1444 -0.3617 -0.3578 -0.1355 -0.4567 -0.4239 -0.0229 -0.6045 -0.3324 -0.0405 -0.2418 -0.2076 -0.1485 -0.1621 -1.4137 -0.8068 -3.5255 -0.0525 -1.2560 -1.2004 -0.2634 -0.1465
S-1387	The patient population was divided into three groups: the VAD group included patients receiving ventricular assist device support; the ECMO group included patients receiving extracorporeal membrane oxygenation membrane support for more than 14 days; and the ECMO+VAD group included patients receiving ECMO followed by VAD support.<unk>
T-1387	patient ; vad ; patients ; ventricular assist device ; ecmo ; patients ; extracorporeal membrane oxygenation ; ecmo ; vad ; patients ; ecmo ; vad
H-1387	-0.8127879500389099	▁ VAD ▁; ▁vent ri cular ▁assist ▁device ▁; ▁ec mo ▁; ▁extra corp o real ▁membran e ▁oxygen ation ▁membran e ▁; ▁ec mo ▁; ▁ VAD
D-1387	-0.8127879500389099	VAD ; ventricular assist device ; ecmo ; extracorporeal membrane oxygenation membrane ; ecmo ; VAD
P-1387	-0.9303 -0.2965 -1.1675 -1.2379 -1.4968 -0.2759 -1.7416 -0.4610 -1.3161 -0.8653 -1.5097 -0.5182 -2.2765 -0.2992 -0.5675 -0.4215 -0.1237 -0.0635 -0.8420 -0.6604 -0.0551 -0.0843 -1.2276 -1.4022 -1.6292 -0.6060 -0.9050 -0.2298 -0.8708 -0.3025
S-102	There are limited data regarding risk factors for the development of ischemic events (IEs) among patients with ischemic cardiomyopathy (IC) who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and their effect on the efficacy of the device.<unk>
T-102	ischemic events ; ies ; patients ; ischemic cardiomyopathy ; ic ; cardiac resynchronization therapy ; defibrillator ; crt-d
H-102	-0.4842720627784729	▁ ische mic ▁events ▁; IE s ▁; ▁ ische mic ▁cardio my o pathy ▁; IC ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁c RT - d
D-102	-0.4842720627784729	ischemic events ;IEs ; ischemic cardiomyopathy ;IC ; cardiac resynchronization therapy ; defibrillator ; cRT-d
P-102	-1.8273 -0.4834 -0.3357 -0.2042 -0.2818 -0.3053 -0.0361 -0.3053 -0.5563 -0.2956 -0.1551 -0.6815 -2.3846 -0.8542 -0.1300 -0.2499 -0.2726 -0.2578 -0.0533 -0.0169 -0.0165 -0.0099 -0.2740 -0.8306 -0.0313 -0.1902 -0.2001 -0.1222 -0.8289 -1.0456 -0.1123 -0.2944 -0.8051 -1.6076 -0.0615 -0.7909 -1.2487 -0.2456
S-2016	Simulations to evaluate the cost-effectiveness of heart failure disease management programs across 3 scenarios demonstrate how the model can be used to design a program in which short-term improvements in functioning and use of evidence-based treatments are sufficient to demonstrate good long-term value to the health care system.<unk>
T-2016	heart failure ; disease ; evidence-based ; health care
H-2016	-0.8831682801246643	▁cost - effect ive ness ▁; ▁heart ▁failure ▁; ▁management ▁; ▁evidence - based ▁treatment s ▁; ▁health ▁care ▁system
D-2016	-0.8831682801246643	cost-effectiveness ; heart failure ; management ; evidence-based treatments ; health care system
P-2016	-0.1601 -0.3793 -0.4535 -0.4087 -1.2067 -0.6725 -0.7356 -0.0815 -3.1930 -1.6174 -1.2357 -3.2428 -0.0624 -0.0051 -1.4779 -0.1551 -0.5445 -0.9360 -2.1183 -0.2237 -0.2356 -0.2844
S-930	To further our understanding of the role of human resistin in heart failure, we studied a humanized mouse model lacking murine resistin but transgenic for the human Retn gene (Hum-Retn mice), which exhibits basal and inflammation-stimulated resistin levels similar to humans.<unk>
T-930	resistin ; heart failure ; murine ; resistin ; transgenic ; retn ; gene ; resistin
H-930	-0.414524108171463	▁human ▁resist in ▁; ▁heart ▁failure ▁; ▁human ized ▁mouse ▁model ▁; ▁mur ine ▁resist in ▁; ▁trans ge nic ▁; ▁human ▁Ret n ▁gene ▁; ▁h um - re t n ▁mi ce ▁; ▁bas al ▁; ▁ inflammation - stimul ated ▁resist in ▁levels
D-930	-0.414524108171463	human resistin ; heart failure ; humanized mouse model ; murine resistin ; transgenic ; human Retn gene ; hum-retn mice ; basal ; inflammation-stimulated resistin levels
P-930	-1.5020 -0.7122 -0.4636 -0.3488 -0.1650 -0.0548 -0.3447 -1.6241 -0.1111 -0.2225 -0.7010 -0.3582 -0.0365 -0.0904 -0.2591 -0.7035 -0.1338 -0.4073 -0.0222 -0.0144 -0.1207 -1.9539 -0.0857 -0.0083 -0.3785 -0.1454 -1.3699 -0.0524 -0.0488 -1.8127 -0.0450 -0.0080 -0.1301 -0.2664 -0.4086 -0.0366 -0.0062 -0.5269 -0.0854 -0.0440 -0.1672 -0.0127 -0.4060 -0.2006 -0.3760 -0.5311 -2.1550 -0.2398
S-1745	Rates of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, β-blockers, and devices at final evaluation increased from 56%, 12%, 8% (period 1) to 97%, 86%, 17% (period 4), respectively (P<0.05).<unk>
T-1745	patients ; angiotensin-converting enzyme inhibitors ; angiotensin receptors blockers ; β-blockers
H-1745	-0.4340519905090332	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor s ▁block ers ▁; ▁β - block ers
D-1745	-0.4340519905090332	angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; β-blockers
P-1745	-0.3902 -2.0530 -1.1027 -0.3334 -0.3173 -0.0058 -0.0673 -0.1378 -0.0997 -0.0922 -0.2402 -0.1997 -1.0641 -0.3187 -0.3627 -0.7725 -0.0059 -0.1588 -0.6105 -0.3645 -0.4079 -0.1310 -0.0407 -0.2438 -0.2445 -1.6414 -0.3128
S-1815	Interestingly, TTA/TgTetMena mice were particularly susceptible to cardiac injury, as these animals experienced pronounced decreases in ejection fraction and fractional shortening as well as heart dilatation and hypertrophy after transverse aortic constriction (TAC).<unk>
T-1815	cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ; tac
H-1815	-0.4697704017162323	▁t g t t t Men a ▁mi ce ▁; ▁cardiac ▁injury ▁; ▁e je ction ▁ fraction ▁; ▁ fraction al ▁; ▁heart ▁di la tation ▁; ▁hyper trop hy ▁; ▁trans verse ▁a or tic ▁con stri ction ▁; TAC
D-1815	-0.4697704017162323	tgtttMena mice ; cardiac injury ; ejection fraction ; fractional ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
P-1815	-0.9921 -0.1282 -0.0521 -0.4056 -1.4268 -1.7835 -0.0710 -0.2901 -0.2834 -0.3259 -0.2430 -1.3122 -0.3895 -0.6677 -0.1648 -0.1415 -0.4314 -0.0186 -0.1927 -1.1864 -0.0033 -0.8359 -0.9475 -1.4100 -0.3165 -0.6564 -0.0056 -0.3514 -0.1469 -0.0479 -0.6371 -0.1851 -0.0009 -0.0874 -0.0347 -1.4830 -0.0881 -0.1017 -0.5108 -0.2724 -1.2879 -0.0795 -0.4451 -0.2285
S-882	METHODS AND RESULTS: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial showed that implantable cardioverter defibrillator-CRT was associated with a significant reduction in the primary end point of all-cause mortality or heart failure hospitalization.<unk>
T-882	resynchronization-defibrillation for ambulatory heart failure trial ; implantable ; primary end point ; all-cause mortality ; heart failure ; hospitalization
H-882	-0.40803980827331543	▁re syn chron ization - Def i bril lation ▁for ▁Amb ulator y ▁Heart ▁Fail ure ▁Tri al ▁; ▁implant able ▁cardio ver ter ▁de fi br illa tor - C RT ▁; ▁primary ▁end ▁point ▁; ▁mortal ity ▁; ▁heart ▁failure
D-882	-0.40803980827331543	resynchronization-Defibrillation for Ambulatory Heart Failure Trial ; implantable cardioverter defibrillator-CRT ; primary end point ; mortality ; heart failure
P-882	-0.0579 -0.0030 -0.0058 -0.2903 -0.0474 -0.1246 -0.1929 -0.3108 -0.2910 -0.6568 -0.0583 -0.0129 -0.0330 -0.2508 -0.1588 -0.0283 -0.9380 -0.0383 -0.1699 -0.1979 -0.0216 -0.2401 -0.0374 -0.2375 -0.1161 -0.4456 -1.8741 -0.6080 -0.0499 -0.1227 -1.3348 -0.8908 -0.1714 -3.0913 -0.4082 -0.1657 -1.1052 -1.0302 -0.0294 -0.1099 -0.4454 -0.2068 -1.1886 -0.1569
S-1505	In a sample of 659 heart failure patients from Italy, we performed confirmatory factor analysis (CFA) to test the original construct of the SCHFI v.6.2 scales (Self-Care Maintenance, Self-Care Management, and Self-Care Confidence), with limited success.<unk>
T-1505	heart failure ; patients ; italy ; confirmatory factor analysis ; cfa ; schfi v.6.2 ; self-care maintenance ; self-care management ; self-care confidence
H-1505	-0.6551758646965027	▁heart ▁failure ▁; ▁ital y ▁; ▁confirma tory ▁factor ▁analysis ▁; ▁c FA ▁; ▁ SCH fi ▁; ▁self - Car e ▁management ▁; ▁self - Car e ▁Confi den ce
D-1505	-0.6551758646965027	heart failure ; italy ; confirmatory factor analysis ; cFA ; SCHfi ; self-Care management ; self-Care Confidence
P-1505	-2.6560 -0.1408 -1.2384 -1.2793 -0.5723 -0.2377 -0.2712 -0.0045 -0.0208 -1.9722 -0.2840 -0.3307 -1.9707 -0.1586 -1.3450 -0.2624 -2.0274 -0.1159 -0.4548 -0.0765 -0.5858 -0.0751 -1.0560 -0.2331 -0.4992 -0.0462 -0.4191 -0.0422 -2.5804 -0.0317 -0.0500 -0.3863 -0.1967
S-244	In conclusion, indicators of functional status (6-MWT and NYHA class) were common to both patients with HFpEF and those with HFrEF, whereas gender and adherence to prescribed therapy were unique to patients having HFpEF in predicting death or HF hospitalization.<unk>
T-244	functional status ; 6-mwt ; nyha class ; patients ; hfpef ; hfref ; prescribed ; therapy ; patients ; hfpef ; death ; hf ; hospitalization
H-244	-0.7267663478851318	▁functional ▁status ▁; ▁mw t ▁; ▁NY ha ▁; ▁ HF p EF ▁; ▁h Fr EF ▁; ▁ad her ence ▁; ▁ therapy ▁; ▁ HF p EF ▁; ▁death ▁; ▁ HF
D-244	-0.7267663478851318	functional status ; mwt ; NYha ; HFpEF ; hFrEF ; adherence ; therapy ; HFpEF ; death ; HF
P-244	-2.7462 -0.0729 -0.1853 -0.8324 -0.3476 -0.0847 -0.1057 -0.9235 -0.9118 -0.4995 -0.5177 -0.0398 -0.2960 -0.0722 -1.4841 -1.0796 -0.6587 -0.1789 -3.6373 -0.1352 -0.0071 -0.1730 -0.8664 -0.5725 -0.1667 -0.8677 -0.3824 -0.0390 -0.1263 -0.1230 -5.0770 -0.1021 -0.1841 -0.4064 -1.9396 -0.3210
S-69	Age, renal dysfunction, chronic obstructive pulmonary disease, diabetes, peripheral vascular disease, decreased left ventricular ejection fraction, and ICD shocks during follow-up were strong predictors of mortality; ischemic cardiomyopathy and male sex were not.<unk>
T-69	renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; follow-up ; mortality ; ischemic cardiomyopathy
H-69	-0.311286062002182	▁renal ▁dys function ▁; ▁chronic ▁ob struct ive ▁pulmonar y ▁disease ▁; ▁diabetes ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁i CD ▁shock s ▁; ▁mortal ity ▁; ▁ ische mic ▁cardio my o pathy
D-69	-0.311286062002182	renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy
P-69	-0.0137 -0.0343 -0.4045 -0.1006 -0.0176 -0.0525 -0.0395 -0.0376 -0.0124 -0.0916 -1.2567 -0.1441 -0.0642 -0.1166 -0.0046 -0.0818 -0.0112 -0.1465 -0.3213 -0.1694 -0.7098 -0.1644 -0.1013 -2.5227 -0.7225 -0.3431 -0.0939 -0.1869 -0.2207 -0.6382 -0.0203 -0.3456 -0.1794 -1.1932 -0.2559 -0.0445 -0.2772 -1.0233 -0.0280 -0.1179 -0.3032 -0.1290 -0.0977 -0.1683 -0.8947 -0.2929 -0.2277 -0.6447 -0.1855
S-996	Interestingly, a number of different Raf-MEK1/2-ERK1/2 scaffold proteins have been identified, and their role in determining the adaptive or maladaptive cardiac remodelling is a promising field of investigation for the development of therapeutic strategies capable of selectively potentiating the adaptive response.<unk>
T-996	scaffold proteins ; cardiac remodelling ; field ; therapeutic
H-996	-0.5181134939193726	▁Raf - MEK 1/2 - er k 1/2 ▁sc af fold ▁protein s ▁; ▁adapt ive ▁; ▁mal adapt ive ▁cardiac ▁remodel ling ▁; ▁ therapeut ic
D-996	-0.5181134939193726	Raf-MEK1/2-erk1/2 scaffold proteins ; adaptive ; maladaptive cardiac remodelling ; therapeutic
P-996	-0.0124 -0.1045 -0.0150 -0.2854 -0.0629 -1.2538 -0.1819 -0.3476 -0.5934 -1.8928 -0.4053 -1.8452 -0.0509 -0.3096 -2.4573 -0.0181 -0.2821 -0.0422 -0.0461 -0.0232 -0.0606 -0.0620 -0.0226 -0.6185 -0.9369 -0.0756 -0.1665 -2.7513 -0.1016
S-1318	METHODS: Male patients with CHF (n = 41, age 67.2 years, range 51-84 years) with mean ± SD testosterone levels of 10.7 ± 2.6 nmol/L (309 ± 76 ng/dL) were randomly allocated to exercise with testosterone or placebo groups.<unk>
T-1318	patients ; chf ; testosterone ; exercise ; testosterone ; placebo
H-1318	-0.904532253742218	▁CHF ▁; ▁SD ▁testosteron e ▁levels ▁; ▁testosteron e
D-1318	-0.904532253742218	CHF ; SD testosterone levels ; testosterone
P-1318	-0.2706 -0.2006 -3.4305 -0.3065 -0.0697 -0.4973 -0.2688 -2.7452 -0.1058 -1.9386 -0.1163
S-341	In addition, because functional MS is dynamic and proportional to LV dilatation, treatment for heart failure (HF), acting to reduce the LV size, can potentially improve such functional MS. A 52-year-old man had HF with severe MR due to prolapse of a degenerative mitral valve in 2008.<unk>
T-341	functional ms ; lv dilatation ; heart failure ; hf ; functional ms ; hf ; prolapse ; degenerative mitral valve
H-341	-0.4994056224822998	▁functional ▁MS ▁; ▁LV ▁di la tation ▁; ▁treatment ▁for ▁heart ▁failure ▁; HF ▁; ▁LV ▁; ▁functional ▁MS ▁; ▁ HF ▁; ▁MR ▁; ▁pro lapse ▁; ▁de genera tive ▁mit ral ▁val ve
D-341	-0.4994056224822998	functional MS ; LV dilatation ; treatment for heart failure ;HF ; LV ; functional MS ; HF ; MR ; prolapse ; degenerative mitral valve
P-341	-1.4705 -0.2672 -0.1487 -1.3662 -0.1692 -0.0985 -0.0028 -0.2302 -2.9825 -0.5972 -0.3847 -0.0418 -0.2256 -0.8470 -0.0960 -1.0943 -0.5754 -1.9212 -0.5791 -0.2444 -0.2614 -0.1108 -0.0425 -1.8856 -0.1160 -0.0026 -0.0274 -0.8107 -0.5267 -0.0212 -0.0415 -0.1502 -0.0873 -0.4057 -0.0734 -0.4420 -0.1303
S-783	The associations between New York Heart Association class, a commonly used criterion standard, and KCCQ Overall Summary and Total Symptom domains were evaluated using Spearman correlations and 2-way ANOVA with differences between patients with HF with reduced EF and HFpEF tested with interaction terms.<unk>
T-783	new york heart association class ; kccq ; symptom ; spearman correlations ; 2-way anova ; patients ; hf with reduced ef ; hfpef
H-783	-0.7655547857284546	▁New ▁York ▁Heart ▁association ▁; ▁k cc q ▁; ▁symptom ▁; ▁Spe ar man ▁corre lation s ▁; ▁ HF ▁; ▁EF ▁; ▁ HF p EF
D-783	-0.7655547857284546	New York Heart association ; kccq ; symptom ; Spearman correlations ; HF ; EF ; HFpEF
P-783	-1.7414 -0.5208 -2.3206 -0.4223 -1.1990 -0.6574 -0.0771 -1.7137 -0.3561 -3.7277 -1.0928 -1.5420 -0.0067 -0.0032 -0.7363 -0.1244 -0.1405 -0.1293 -0.7423 -0.8127 -0.0931 -1.9776 -0.0882 -0.1808 -0.4775 -0.0371 -0.2232 -0.8177 -0.2397
S-1130	CONCLUSIONS: Contextual reasons for not prescribing angiotensin converting enzyme inhibitor / angiotensin-receptor blockers and β-blockers are present in two thirds of patients with heart failure who did not receive these medications, yet are poorly documented in medical records.<unk>
T-1130	prescribing ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; patients ; heart failure ; medications ; medical
H-1130	-0.7216446995735168	▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block ers ▁; ▁β - block ers ▁; ▁heart ▁failure
D-1130	-0.7216446995735168	angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; heart failure
P-1130	-0.8694 -3.2517 -1.5581 -0.1272 -0.1516 -0.0995 -0.0591 -0.0808 -0.8019 -0.3414 -0.2282 -0.0918 -2.9634 -1.8680 -0.2603 -0.8460 -0.0688 -0.9673 -0.8423 -0.4300 -0.3003 -0.3053 -0.0790 -0.3271 -0.2258 -0.4873 -0.9974 -0.1547 -2.4723 -0.3935
S-276	Eight-week-old C57BL/6 male mice were treated with ANG II infusion (AT), ANG II infusion and uninephrectomy (AN), ANG II infusion and salt loading (AS), or ANG II infusion, uninephrectomy, and salt loading (ANS).<unk>
T-276	ang ii infusion ; ang ii infusion ; uninephrectomy ; ang ii infusion ; salt loading ; ang ii infusion ; uninephrectomy ; salt loading
H-276	-0.8156631588935852	▁c 57 b ▁; ▁ang ▁II ▁in fusion ▁; ▁ang ▁II ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁ang ▁II ▁in fusion ▁; ▁salt ▁load ing ▁; ▁ang ▁II ▁in fusion ▁; ▁un ine ph r ecto my ▁; ▁salt ▁load ing ▁; ANS
D-276	-0.8156631588935852	c57b ; ang II infusion ; ang II infusion ; uninephrectomy ; ang II infusion ; salt loading ; ang II infusion ; uninephrectomy ; salt loading ;ANS
P-276	-1.0136 -0.3057 -1.4554 -0.2229 -3.5667 -1.2248 -0.0579 -0.0932 -0.3345 -3.8414 -1.2704 -0.1072 -0.1429 -0.2205 -0.1090 -0.1212 -1.7145 -0.2180 -0.4832 -1.6507 -0.3656 -2.6870 -1.3446 -0.1096 -0.2740 -0.2110 -0.4274 -0.0057 -0.0271 -0.7604 -2.9810 -1.4604 -0.0971 -0.2700 -0.3545 -0.1373 -0.1356 -1.7523 -0.1786 -1.2753 -1.8774 -0.6388 -0.6921 -0.0124 -0.0289 -1.6382 -0.4682 -1.2873 -0.3159
S-480	The ratio of early transmitral blood flow velocity over tissue Doppler early diastolic mitral annulus velocity (E/e') was found unreliable for estimating pulmonary capillary wedge pressure (PCWP) in patients with decompensated systolic heart failure (HF).<unk>
T-480	transmitral blood flow velocity ; tissue doppler ; diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcwp ; patients ; decompensated systolic heart failure ; hf
H-480	-0.5865287184715271	▁early ▁transmit ral ▁blood ▁flow ▁veloci ty ▁; ▁do pp ler ▁; ▁early ▁dia sto lic ▁mit ral ▁ann ulus ▁veloci ty ▁; ▁pulmonar y ▁cap illa ry ▁we dge ▁pressure ▁; PC WP ▁; ▁de com pensa ted ▁sy sto lic ▁heart ▁failure ▁; HF
D-480	-0.5865287184715271	early transmitral blood flow velocity ; doppler ; early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ;PCWP ; decompensated systolic heart failure ;HF
P-480	-2.2409 -1.0679 -0.8165 -4.0333 -0.0150 -0.1753 -0.0979 -0.3532 -1.8298 -0.0049 -0.3726 -0.5381 -1.9958 -1.5131 -0.6283 -1.0750 -0.9526 -0.0841 -0.2151 -0.1341 -0.0538 -0.0480 -0.1597 -0.0843 -0.0283 -0.3155 -0.2785 -0.0150 -0.7359 -0.0640 -0.1618 -0.2218 -0.5801 -1.2443 -0.1903 -2.0432 -0.1058 -0.0281 -0.0460 -0.5460 -0.1745 -0.9546 -0.7138 -0.0819 -0.5056 -0.0164 -0.4613 -0.1510
S-951	LV systolic indices (LV ejection fraction, LV strain/strain rate at systole) and diastolic indices (E/E', ratio of LV strain rate at diastole with early transmitral flow) were improved only in patients maintaining sinus rhythm at follow-up.<unk>
T-951	systolic ; lv ejection fraction ; lv strain ; strain ; systole ; diastolic ; lv strain rate ; diastole ; transmitral flow ; patients ; sinus rhythm ; follow-up
H-951	-0.8712766766548157	▁LV ▁sy sto lic ▁indice s ▁; LV ▁e je ction ▁ fraction ▁; ▁LV ▁; ▁strain ▁rate ▁; ▁sy stol e ▁; ▁dia sto lic ▁indice s ▁; ▁LV ▁; ▁strain ▁rate ▁; ▁dia stol e ▁; ▁early ▁transmit ral ▁flow ▁; ▁sinus ▁ rhythm
D-951	-0.8712766766548157	LV systolic indices ;LV ejection fraction ; LV ; strain rate ; systole ; diastolic indices ; LV ; strain rate ; diastole ; early transmitral flow ; sinus rhythm
P-951	-0.3818 -6.4572 -0.3397 -0.4164 -0.1843 -0.0250 -0.1093 -0.4114 -0.3414 -0.3506 -0.2372 -0.6134 -0.0113 -0.1695 -0.5030 -2.3442 -0.8367 -2.4712 -0.3732 -2.8499 -0.4535 -0.9812 -0.3164 -2.4000 -1.1590 -0.5755 -0.1179 -0.0203 -0.1132 -2.5894 -1.7190 -1.2720 -0.0227 -0.2212 -3.5261 -0.1257 -0.5617 -0.1781 -0.7046 -1.0939 -0.5577 -0.0602 -1.7556 -0.9311 -0.1246 -0.2396 -0.3782 -0.1963
S-1984	By main effects analysis, peak VO2 was increased significantly by both interventions: exercise, 1.2 mL/kg body mass/min (95% CI, 0.7 to 1.7), P < .001; diet, 1.3 mL/kg body mass/min (95% CI, 0.8 to 1.8), P < .001.<unk>
T-1984	peak vo2 ; exercise
H-1984	-0.6256871223449707	▁pe ak ▁VO 2 ▁; ▁exercise ▁; ▁body ▁mass
D-1984	-0.6256871223449707	peak VO2 ; exercise ; body mass
P-1984	-0.1626 -0.0347 -1.2883 -0.2262 -0.3201 -0.9060 -0.2889 -0.9392 -0.0872 -2.2517 -0.3775
S-1107	The age- and sex-adjusted risk declined from 1990-1996 to 2004-2010, with hazard ratios of 0.67 (95% confidence interval (CI): 0.54, 0.85) for early-onset HF and 0.63 (95% CI: 0.45, 0.86) for late-onset HF.<unk>
T-1107	hazard ratios ; confidence interval ; hf ; hf
H-1107	-0.8476841449737549	▁age ▁; ▁sex - ad just ed ▁risk ▁; ▁hazard ▁ratio s ▁; ▁early - ons et ▁ HF ▁; ▁late - ons et ▁ HF
D-1107	-0.8476841449737549	age ; sex-adjusted risk ; hazard ratios ; early-onset HF ; late-onset HF
P-1107	-2.2352 -4.9751 -1.3176 -0.1179 -0.0455 -0.0166 -0.0427 -0.3170 -0.2122 -2.8938 -0.0261 -0.1404 -0.1854 -3.5009 -0.1776 -0.0833 -1.0794 -0.5367 -0.2206 -0.3646 -2.7158 -0.1450 -0.1341 -1.0457 -0.4174 -0.2458 -0.2285 -0.3142
S-1698	In 2009, if an AMI patient had chosen a hospital in the worst versus best quintile of performance using 2005-2008 composite (vs. Hospital Compare) rankings, he or she would have had 1.61 (vs. 1.39) times the odds of dying in 30 days (P-value for difference <0.001).<unk>
T-1698	ami ; patient ; hospital ; hospital compare ; p-value
H-1698	-1.0390888452529907	▁ AMI ▁; ▁hospital ▁; ▁p - valu e
D-1698	-1.0390888452529907	AMI ; hospital ; p-value
P-1698	-0.9946 -0.1060 -1.0322 -0.7718 -0.3014 -5.6580 -0.3016 -0.3149 -0.2014 -1.4823 -0.2659
S-1517	RESULTS: Mass spectrometry identified the presence of several N- and C-terminally processed forms of circulating NT-proBNP, with physiological proteolysis between Pro2-Leu3, Leu3-Gly4, Pro6-Gly7, and Pro75-Arg76.<unk>
T-1517	mass spectrometry ; c-terminally ; nt-probnp ; physiological ; proteolysis
H-1517	-0.5867005586624146	▁Mass ▁spec tro met ry ▁; ▁N - ▁; ▁c - termin ally ▁process ed ▁form s ▁; ▁circula ting ▁NT - pro b NP ▁; ▁physio logic al ▁prote ol ysis ▁; ▁pro 2- ▁le u 3 ▁; ▁le u 3- g ly 4 ▁; ▁pro 6 - g ly 7 ▁; ▁pro 75 - Ar g 76
D-1517	-0.5867005586624146	Mass spectrometry ; N- ; c-terminally processed forms ; circulating NT-probNP ; physiological proteolysis ; pro2- leu3 ; leu3-gly4 ; pro6-gly7 ; pro75-Arg76
P-1517	-0.8166 -0.3079 -0.8843 -0.7477 -0.2406 -0.1636 -2.9678 -0.1050 -2.0634 -0.4830 -0.1052 -0.0966 -0.0243 -1.9768 -0.1925 -0.1710 -0.2805 -0.3002 -0.0865 -0.0594 -1.2912 -0.0578 -0.1207 -1.7337 -0.3158 -0.1751 -0.1027 -1.0969 -0.0653 -0.6264 -3.7779 -1.2809 -0.1498 -0.3439 -1.0649 -2.2920 -0.0231 -0.0697 -0.1194 -0.5254 -0.0266 -0.2474 -1.5910 -0.0989 -0.0780 -0.1398 -0.0756 -0.6290 -0.0294 -1.7371 -0.1459 -0.1153 -0.5964 -0.0630 -0.4458 -0.0149 -1.2848 -0.0060 -0.2535 -0.7003 -0.2045
S-292	A simple sex-specific model that includes age, race, cTnT, and NT-proBNP (which can be incorporated in a laboratory report) provides a good model, whereas adding cTnT and NT-proBNP to clinical characteristics results in an excellent HF prediction model.<unk>
T-292	ctnt ; nt-probnp ; report ; ctnt ; nt-probnp ; clinical ; hf
H-292	-0.2526625990867615	▁c t n t ▁; ▁NT - pro b NP ▁; ▁laborator y ▁report ▁; ▁c t n t ▁; ▁NT - pro b NP ▁; ▁ HF ▁predict ion ▁model
D-292	-0.2526625990867615	ctnt ; NT-probNP ; laboratory report ; ctnt ; NT-probNP ; HF prediction model
P-292	-0.2291 -0.2915 -0.0186 -0.4059 -0.1044 -0.2810 -0.0924 -0.0393 -0.7755 -0.1363 -0.1103 -0.0215 -0.1001 -0.0708 -0.2332 -0.0142 -0.3699 -0.0103 -0.6575 -0.0793 -0.5400 -0.0741 -0.0924 -0.7881 -0.1645 -0.2020 -0.6685 -0.3966 -0.4075 -0.0431 -0.1920 -0.4051 -0.3230
S-1329	METHODS: Thirty HFpEF patients, 18 female and 12 male, aged 69 ± 8 years, in New York Heart Association class II or III and with mean ejection fraction 63% ± 6%, were randomly (1:1) assigned to a 6-week FES program or placebo.<unk>
T-1329	hfpef ; patients ; new york heart association class ii ; ejection fraction ; fes ; placebo
H-1329	-0.8433110117912292	▁ HF p EF ▁; ▁New ▁York ▁Heart ▁association ▁; ▁mean ▁e je ction ▁ fraction ▁; ▁f es
D-1329	-0.8433110117912292	HFpEF ; New York Heart association ; mean ejection fraction ; fes
P-1329	-0.4343 -0.8300 -0.1091 -0.9054 -0.8577 -2.0790 -0.8618 -1.8739 -0.6022 -0.3809 -0.7436 -0.0436 -0.2280 -0.1348 -0.7397 -0.0171 -0.6246 -4.3062 -1.2276 -0.5386 -0.1714
S-1548	The depressed left ventricular (LV) systolic pressure, positive and negative rates of changes in pressure development, ejection fraction, fractional shortening and cardiac output, as well as increased LV end-diastolic pressure in 20 weeks MI animals were partially reversed by metoprolol.<unk>
T-1548	left ventricular ; systolic pressure ; ejection fraction ; fractional shortening ; cardiac output ; lv end-diastolic pressure ; mi ; metoprolol
H-1548	-0.4749715030193329	▁de press ed ▁left ▁vent ri cular ▁; LV ▁; ▁sy sto lic ▁pressure ▁; ▁pressure ▁; ▁e je ction ▁ fraction ▁; ▁ fraction al ▁short en ing ▁; ▁cardiac ▁output ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; ▁MI ▁; ▁met o pro lol
D-1548	-0.4749715030193329	depressed left ventricular ;LV ; systolic pressure ; pressure ; ejection fraction ; fractional shortening ; cardiac output ; LV ; end-diastolic pressure ; MI ; metoprolol
P-1548	-0.7600 -0.0182 -0.0431 -0.1176 -2.1536 -0.6108 -0.1941 -0.4192 -0.2785 -0.5706 -2.1149 -0.3791 -1.5963 -0.8576 -0.1936 -0.4932 -1.0085 -0.0522 -0.1719 -0.1086 -0.2565 -0.0122 -0.1603 -2.0602 -0.0022 -0.4136 -0.1203 -0.1723 -0.1105 -0.1640 -0.2464 -0.0122 -0.3241 -0.3443 -0.6199 -0.5611 -0.0431 -0.7948 -0.4334 -0.5472 -0.4061 -0.1776 -0.9795 -0.6876 -1.0942 -0.0677 -0.1560 -0.1790 -0.2781 -0.1825
S-1867	Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction" OBJECTIVES: The objective of this clinical trial was to assess the safety and efficacy of carotid baroreflex activation therapy (BAT) in advanced heart failure (HF).<unk>
T-1867	baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction ; clinical ; carotid ; baroreflex activation therapy ; bat ; heart failure ; hf
H-1867	-0.5154635310173035	▁bar ore flex ▁activity ▁Therapy ▁; ▁Heart ▁Fail ure ▁; ▁Red u ced ▁e je ction ▁Fra ction ▁; ▁clinic al ▁trial ▁; ▁caro tid ▁; ▁baro re flex ▁activa tion ▁ therapy ▁; BAT ▁; ▁advanced ▁heart ▁failure ▁; HF
D-1867	-0.5154635310173035	baroreflex activity Therapy ; Heart Failure ; Reduced ejection Fraction ; clinical trial ; carotid ; baroreflex activation therapy ;BAT ; advanced heart failure ;HF
P-1867	-2.1309 -0.3552 -0.4780 -1.1884 -0.4159 -0.2465 -0.8491 -0.3823 -0.0266 -0.1978 -0.3811 -0.0119 -1.1137 -0.4832 -0.0438 -0.0467 -0.2148 -0.0190 -0.5582 -2.4011 -0.1021 -0.7017 -0.1261 -0.3631 -0.0581 -1.4740 -0.6042 -1.6373 -0.2773 -1.5483 -0.1412 -1.0120 -0.1012 -0.1478 -0.1958 -0.1562 -0.5592 -0.3417 -0.0533 -0.5610 -0.0192 -0.3091 -0.1311
S-1748	A more recent enrollment period represented the most powerful independent predictor of favorable outcome {period 2 versus 1 (hazard ratio [HR], 0.64; P=0.04), period 3 versus 1 (HR, 0.35; P<0.001), period 4 versus 1 (HR, 0.14; P<001)}.<unk>
T-1748	outcome ; hazard ratio
H-1748	-0.8148816227912903	▁en roll ment ▁period ▁; haz ard ▁ratio ▁; HR
D-1748	-0.8148816227912903	enrollment period ;hazard ratio ;HR
P-1748	-1.2132 -0.0303 -0.2580 -1.4416 -0.4234 -3.4448 -0.6127 -0.0276 -0.3203 -0.3836 -1.2053 -0.4177
S-1793	LA is a heterogeneous region with HF risk factors of developed and nondeveloped countries, including lower risk of raised blood glucose levels, obesity, tobacco, and aging, whereas systemic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.<unk>
T-1793	hf ; blood glucose ; obesity ; systemic hypertension ; rheumatic fever ; disease
H-1793	-0.5206718444824219	▁ HF ▁; ▁raised ▁blood ▁gluco se ▁levels ▁; ▁obes ity ▁; ▁to ba cco ▁; ▁ aging ▁; ▁system ic ▁hyper tension ▁; SH ▁; ▁rhe u matic ▁fe ver ▁; ▁cha gas ▁; ▁disease ▁; ▁c ' d
D-1793	-0.5206718444824219	HF ; raised blood glucose levels ; obesity ; tobacco ; aging ; systemic hypertension ;SH ; rheumatic fever ; chagas ; disease ; c'd
P-1793	-2.1806 -0.2781 -0.3945 -3.9659 -1.9914 -0.0320 -0.4433 -0.1746 -0.1291 -1.4602 -0.1689 -0.1381 -0.0160 -0.6021 -0.0641 -0.1144 -0.0601 -0.0017 -0.2495 -0.0481 -0.0344 -0.1901 -0.0442 -0.1063 -0.7257 -0.0429 -0.1401 -0.0265 -0.0456 -0.0109 -0.0254 -0.1322 -0.6184 -0.0029 -0.6101 -1.7450 -0.2864 -1.0577 -2.1567 -0.0794 -0.9449 -0.3298
S-1772	Adjusted hazard ratios across high, moderate, and low CRF categories were 1.0, 1.63, and 3.97, respectively, whereas those of normal, overweight, and obese body mass index categories were 1.0, 1.56, and 3.71, respectively (P for trend <0.0001 for each).<unk>
T-1772	hazard ratios ; crf ; obese ; body mass index
H-1772	-0.7894105315208435	▁ad just ed ▁hazard ▁ratio s ▁; ▁c RF ▁; ▁over weight ▁; ▁obes e ▁body ▁mass ▁index
D-1772	-0.7894105315208435	adjusted hazard ratios ; cRF ; overweight ; obese body mass index
P-1772	-2.5962 -0.0051 -0.0751 -1.7826 -0.0358 -0.2141 -0.4258 -0.8142 -1.8154 -0.2580 -3.8547 -0.6236 -0.2385 -0.1390 -0.1983 -0.7980 -0.1951 -0.2271 -1.2028 -0.2889
S-789	One-year event-free rates by KCCQ category among patients with HFpEF were 0 to 25=13.8%, 26 to 50=59.1%, 51 to 75=73.8%, and 76 to 100=77.8% (log rank P<0.001), with no significant interaction by EF (P=0.37).<unk>
T-789	kccq ; patients ; hfpef ; log rank ; ef
H-789	-1.2197082042694092	▁k cc q ▁; ▁ HF p EF ▁; log ▁rank ▁; ▁EF
D-789	-1.2197082042694092	kccq ; HFpEF ;log rank ; EF
P-789	-2.6472 -0.0887 -3.1237 -0.3094 -0.9764 -0.8536 -0.0316 -0.9467 -0.2709 -4.9942 -1.9709 -0.3652 -0.9695 -0.3710 -0.3766
S-395	Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.<unk>
T-395	baseline ; egfr ; egfr ; egfr ; hypertension ; diuretics ; esrd
H-395	-0.6961076855659485	▁base line ▁e g FR ▁group ▁; ▁e g FR ▁group ▁; ▁e g FR ▁group ▁; ▁un control led ▁hyper tension ▁; ▁di ure tics ▁; ▁ec r
D-395	-0.6961076855659485	baseline egFR group ; egFR group ; egFR group ; uncontrolled hypertension ; diuretics ; ecr
P-395	-0.0464 -0.0040 -0.4385 -1.0203 -1.6062 -0.4984 -0.9563 -0.0438 -0.6692 -2.1157 -0.3684 -0.5864 -0.0694 -0.5363 -1.8856 -0.4026 -0.6240 -0.4588 -0.0124 -0.0227 -0.2726 -0.1829 -0.1701 -0.4059 -0.1238 -0.8771 -0.4103 -4.2441 -2.1245 -0.2389 -0.1637
S-1208	OBJECTIVES: This study investigated whether myocardial phosphodiesterase-2 (PDE2) is altered in heart failure (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (β-AR) signaling in healthy and diseased cardiomyocytes.<unk>
T-1208	myocardial ; phosphodiesterase-2 ; pde2 ; heart failure ; hf ; beta-adrenergic receptor ; β-ar ; healthy ; diseased ; cardiomyocytes
H-1208	-0.7033365964889526	▁my o card ial ▁ phos pho dies tera se -2 ▁; ▁p de 2 ▁; ▁heart ▁failure ▁; HF ▁; ▁p de 2 ▁; ▁beta - ad r energi c ▁receptor ▁; β - AR ▁; ▁cardio my o cy tes
D-1208	-0.7033365964889526	myocardial phosphodiesterase-2 ; pde2 ; heart failure ;HF ; pde2 ; beta-adrenergic receptor ;β-AR ; cardiomyocytes
P-1208	-0.6528 -0.1349 -0.5444 -0.2442 -0.5913 -0.0715 -3.9473 -2.1208 -0.3444 -3.2182 -0.6280 -0.2667 -0.3286 -1.4436 -0.6266 -0.1278 -0.6152 -0.0550 -0.3179 -0.1789 -0.2249 -0.2366 -1.0529 -1.3062 -0.3216 -1.3157 -0.0663 -0.3390 -0.5261 -1.8131 -0.6437 -0.0030 -0.5487 -0.2266 -0.0228 -0.2356 -0.7665 -2.2150 -1.2010 -0.3368 -0.1740 -0.2806 -0.4074 -0.2246
S-866	CONCLUSIONS: In heart failure patients undergoing either cardiac resynchronization therapy with a defibrillator or with an implantable cardioverter-defibrillator device, carvedilol was associated with a 36% lower rate of inappropriate ATP and shock therapy compared with metoprolol.<unk>
T-866	heart failure ; patients ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator ; carvedilol ; atp ; shock therapy ; metoprolol
H-866	-0.519473135471344	▁heart ▁failure ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁de fi br illa tor ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁device ▁; ▁car vedi lol ▁; ▁ATP ▁; ▁shock ▁ therapy ▁; ▁met o pro lol
D-866	-0.519473135471344	heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
P-866	-1.1032 -0.0799 -0.7955 -0.1081 -0.0206 -0.0449 -0.0173 -0.5087 -1.8144 -0.0891 -0.1891 -0.0404 -0.7695 -2.5202 -1.3826 -0.3609 -0.1828 -0.6302 -0.0098 -0.4359 -0.0689 -0.4725 -0.0788 -0.0913 -0.8310 -3.4044 -1.9284 -0.2890 -0.9170 -0.3134 -0.0440 -0.0404 -0.0794 -0.2313 -1.2342 -0.4155 -0.3972 -0.3606 -0.0499 -0.3801 -0.0686 -0.0851 -0.0968 -0.1391 -0.5780 -0.1977
S-1245	We have demonstrated recently that (-)-ERC (epicatechin-rich cocoa) improves SkM mitochondrial structure [Taub, Ramirez-Sanchez, Ciaraldi, Perkins, Murphy, Naviaux, Hogan, Ceballos, Maisel, Henry et al.<unk>
T-1245	epicatechin-rich cocoa ; skm ; mitochondrial structure ; taub ; ramirez-sanchez ; ciaraldi ; perkins ; murphy ; naviaux ; hogan ; ceballos ; maisel ; henry
H-1245	-0.2507789134979248	ERC ▁; ▁e pica tech in - rich ▁coco a ▁; ▁Sk m ▁; ▁mito cho ndri al ▁structure ▁; ▁ta ub ▁; ▁Ram i rez - s anche z ▁; ▁ci ar aldi ▁; ▁per kin s ▁; ▁Murphy ▁; ▁na vi aux ▁; ▁Hoga n ▁; ▁ce ball os ▁; ▁Mais el ▁; ▁Henry
D-1245	-0.2507789134979248	ERC ; epicatechin-rich cocoa ; Skm ; mitochondrial structure ; taub ; Ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel ; Henry
P-1245	-1.5298 -0.2406 -0.7371 -0.0066 -0.4721 -0.4300 -0.1191 -0.0048 -0.2043 -0.0293 -0.1434 -0.2772 -0.1676 -1.5595 -0.1410 -1.4211 -0.4520 -0.0273 -0.8003 -0.1387 -1.9736 -0.1531 -0.1896 -0.1574 -0.0119 -0.0211 -0.0158 -0.2620 -0.0097 -0.0071 -0.1017 -0.0231 -0.0064 -0.0012 -0.0615 -0.0693 -0.0071 -0.0032 -0.1685 -0.0137 -0.1022 -0.0073 -0.0171 -0.0777 -0.1668 -0.0054 -0.0033 -0.1727 -0.0137 -0.2525 -0.0303 -0.1693 -0.5298 -0.0005 -0.3884 -0.0118 -0.2457 -0.1918
S-1420	Taking into account all follow-up visits over the 6-month period, we found that the risk of death or urgent readmission was lower among patients who had all of their visits with a familiar physician than among those followed by unfamiliar physicians (adjusted HR 0.91, 95% CI 0.85-0.98).<unk>
T-1420	follow-up ; death ; readmission ; patients ; physician ; physicians
H-1420	-0.9453833103179932	▁follow - up ▁visit s ▁; ▁death ▁; ▁urgent ▁read mission
D-1420	-0.9453833103179932	follow-up visits ; death ; urgent readmission
P-1420	-1.8077 -0.1008 -0.0436 -1.8421 -0.0763 -0.3111 -3.1700 -0.1442 -0.2587 -1.3058 -0.1130 -2.9127 -0.2040
S-1816	By "turning off" Mena overexpression in TTA/TgTetMena mice either immediately prior to or immediately after TAC surgery, we discovered that normalizing Mena levels eliminated cardiac hypertrophy in TTA/TgTetMena animals but did not preclude post-TAC cardiac functional deterioration.<unk>
T-1816	mena overexpression ; tac ; surgery ; mena ; cardiac hypertrophy ; cardiac
H-1816	-0.6050787568092346	▁Men a ▁over expression ▁; ▁ TTA ▁; ▁t g t t t Men a ▁mi ce ▁; ▁ TAC ▁surgery ▁; ▁Men a ▁levels ▁; ▁cardiac ▁hyper trop hy ▁; ▁ TTA ▁; ▁t g t t t t Men a ▁; ▁post - TAC ▁cardiac
D-1816	-0.6050787568092346	Mena overexpression ; TTA ; tgtttMena mice ; TAC surgery ; Mena levels ; cardiac hypertrophy ; TTA ; tgttttMena ; post-TAC cardiac
P-1816	-0.9462 -0.1630 -0.9177 -0.1510 -0.1184 -0.5612 -0.0533 -1.0761 -0.3851 -0.0283 -0.0776 -0.8018 -1.4342 -1.7037 -0.0766 -0.1723 -0.1576 -0.1385 -0.6266 -0.1397 -2.9865 -0.1596 -3.8614 -0.0463 -0.3297 -0.1367 -0.2248 -0.8932 -0.0735 -0.8300 -0.1249 -0.2239 -0.0551 -0.8470 -0.2212 -0.0065 -0.0417 -0.2181 -0.4473 -1.4510 -1.4124 -0.0269 -0.6153 -0.7136 -0.0277 -0.5206 -1.1243 -1.9630 -0.3378
S-357	Repeated echocardiography 4 months later demonstrated a reduction in LV end-diastolic volume of 66 mL/m2, disappearance of MR, improvement of the mitral valve opening to an MVA of 1.7 cm2, and a mean pressure gradient of 4.6 mm Hg (Fig 1C).<unk>
T-357	echocardiography ; lv end-diastolic volume ; mitral valve opening ; mva
H-357	-0.48422059416770935	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁; ▁disappear ance ▁; ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁m VA ▁; ▁mean ▁pressure ▁gradi ent
D-357	-0.48422059416770935	echocardiography ; LV ; end-diastolic volume ; disappearance ; MR ; mitral valve opening ; mVA ; mean pressure gradient
P-357	-0.2920 -0.8208 -0.3502 -0.4638 -1.0010 -0.1502 -1.9723 -1.1842 -0.1245 -0.0510 -0.6595 -0.3991 -0.3891 -0.1721 -0.2056 -1.9949 -0.0067 -0.5550 -0.0249 -0.2809 -0.0663 -0.0947 -0.4320 -0.1151 -0.1461 -0.2634 -0.3345 -1.0104 -0.2417 -0.3943 -0.1979 -0.0208 -0.0607 -2.3202 -0.1518
S-901	SUMMARY: Objective criteriabased institution of PD for the treatment of diuretic refractory severe-end-stage HF was well tolerated and demonstrated favorable outcomes; these included improved clinical status, reduced hospitalizations and length of stay, with very few and easily treatable PDrelated complications.<unk>
T-901	pd ; diuretic ; hf ; outcomes ; clinical ; hospitalizations ; pdrelated ; complications
H-901	-0.5696517825126648	▁PD ▁; ▁di ure tic ▁re frac tory ▁severe - end - s tage ▁ HF
D-901	-0.5696517825126648	PD ; diuretic refractory severe-end-stage HF
P-901	-4.6834 -0.1500 -0.1232 -0.0465 -0.1162 -0.0112 -0.0151 -0.0759 -0.6421 -0.1506 -1.0892 -0.1036 -0.0236 -0.0098 -0.2086 -0.0481 -2.6338 -0.1230
S-1785	Overall ATP production rates were decreased at 2 and 3 weeks post-AAC (by 37% and 47%, respectively) because of a reduction in mitochondrial oxidation of glucose, lactate, and fatty acids that was not accompanied by an increase in myocardial glycolysis rates.<unk>
T-1785	atp ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial ; glycolysis
H-1785	-0.4066716730594635	▁ATP ▁production ▁rates ▁; ▁post - a ac ▁; ▁mito cho ndri al ▁oxid ation ▁; ▁gluco se ▁; ▁lac tate ▁; ▁fa tty ▁acid s ▁; ▁my o card ial ▁gly col ysis
D-1785	-0.4066716730594635	ATP production rates ; post-aac ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
P-1785	-0.3020 -0.1172 -1.4480 -0.4426 -0.9342 -0.0331 -0.3038 -0.8557 -0.1987 -0.0970 -1.8867 -0.6352 -0.0174 -0.2251 -0.0859 -0.3488 -0.0895 -0.6308 -0.3201 -0.0104 -0.0387 -0.3124 -0.0208 -0.2915 -0.0213 -0.0230 -0.2625 -0.8891 -0.1373 -0.9695 -0.1354 -0.2627 -0.1468 -0.6229 -1.3113 -0.2126
S-1226	RESULTS: In all high-risk subgroups, patients treated with eplerenone had an increased risk of potassium >5.5 mmol/l but not of potassium >6.0 mmol/l, and of hospitalization for hyperkalemia or discontinuation of study medication due to adverse events.<unk>
T-1226	patients ; eplerenone ; potassium ; potassium ; hospitalization ; hyperkalemia ; medication ; adverse events
H-1226	-0.7900398969650269	▁e pler en one ▁; ▁po tas s ium ▁; ▁po tas s ium ▁; ▁hyper kal emia ▁; ▁medication
D-1226	-0.7900398969650269	eplerenone ; potassium ; potassium ; hyperkalemia ; medication
P-1226	-0.3598 -0.2154 -1.1646 -0.1059 -0.2298 -0.2468 -0.3952 -0.3628 -1.9991 -0.1217 -0.4174 -0.4013 -0.2224 -2.8306 -0.2051 -4.1020 -0.5752 -0.1943 -0.3887 -1.8796 -0.7036 -0.2596
S-1347	A patient aged in his 60s with New York Heart Association class III heart failure (HF) (left ventricular ejection fraction of 25%) who was originally part of this study displayed permanent periodic breathing (PB) and was then excluded from the final data analysis; his response is presented in this report.<unk>
T-1347	patient ; new york heart association class iii ; heart failure ; hf ; left ventricular ejection fraction ; periodic breathing ; pb ; report
H-1347	-1.055367350578308	▁New ▁York ▁Heart ▁association ▁; ▁heart ▁failure ▁; HF ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁permanent ▁periodic ▁breath ing ▁; PB
D-1347	-1.055367350578308	New York Heart association ; heart failure ;HF ; left ventricular ejection fraction ; permanent periodic breathing ;PB
P-1347	-3.8123 -1.3062 -3.0205 -0.5626 -0.5443 -3.3308 -1.0882 -0.2309 -0.8795 -0.1612 -1.2238 -0.0656 -3.8350 -1.3904 -0.8006 -0.0965 -0.1899 -0.0921 -1.4181 -0.0317 -0.3846 -2.0300 -0.2029 -2.5182 -0.1063 -0.2618 -0.1992 -0.6401 -0.1824
S-514	The implantation of a novel bottleneck stent in the proximal LAD or LCX is a novel porcine model of reversible myocardial ischemia (open stent) and ischemic heart failure (occluded stent) and is feasible for the development of new therapeutic approaches.<unk>
T-514	implantation ; bottleneck stent ; lad ; lcx ; myocardial ischemia ; stent ; ischemic heart failure ; stent ; therapeutic
H-514	-0.3732644319534302	▁bottle ne ck ▁sten t ▁; ▁proxima l ▁ LAD ▁; ▁ LC X ▁; ▁rever sible ▁my o card ial ▁ ische mia ▁; open ▁sten t ▁; ▁ ische mic ▁heart ▁failure ▁; ▁sten t
D-514	-0.3732644319534302	bottleneck stent ; proximal LAD ; LCX ; reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
P-514	-0.5326 -0.0256 -0.0581 -0.6019 -0.3411 -0.3542 -0.1390 -0.0167 -0.1834 -0.0093 -0.2633 -0.2783 -0.0773 -1.6130 -0.3121 -0.7495 -0.0046 -0.7865 -0.3200 -0.6917 -0.0538 -0.1668 -0.9484 -0.8530 -0.1680 -0.6593 -0.2428 -0.1395 -0.2721 -0.2183 -0.2017 -0.0641 -0.4729 -0.0199 -0.3721 -1.5188 -0.1488 -0.4787 -0.2002
S-1705	Potassium increased with spironolactone in non-AAs (4.29±0.5-4.55±0.49 mmol/L) but not in AAs (4.32±0.54-4.31±0.49 mmol/L; race by treatment interaction, P=0.03) during the first month and remained higher throughout the trial.<unk>
T-1705	potassium ; spironolactone ; aas
H-1705	-0.457345575094223	▁po tas s ium ▁; ▁spi rono lac tone ▁; ▁non - AA s ▁; ▁AA s ▁; ▁race ▁; ▁treatment
D-1705	-0.457345575094223	potassium ; spironolactone ; non-AAs ; AAs ; race ; treatment
P-1705	-0.3626 -0.0542 -0.2680 -0.7894 -0.1200 -0.5154 -0.0805 -0.2666 -0.2015 -0.1070 -0.5029 -0.0617 -0.0728 -0.0600 -0.1077 -3.1575 -0.1394 -0.2101 -0.3023 -1.2602 -0.8064 -0.8396 -0.2334
S-1978	Of 577 initially screened participants, 100 older obese participants (mean [SD]: age, 67 years [5]; body mass index, 39.3 [5.6]) with chronic, stable HFPEF were enrolled (366 excluded by inclusion and exclusion criteria, 31 for other reasons, and 80 declined participation).<unk>
T-1978	obese ; body mass index ; chronic ; stable ; hfpef
H-1978	-1.27374267578125	▁obes e ▁participants ▁; ▁body ▁mass ▁index ▁; ▁chronic ▁; ▁stable ▁H FP EF
D-1978	-1.27374267578125	obese participants ; body mass index ; chronic ; stable HFPEF
P-1978	-3.0142 -0.2810 -2.9410 -0.2313 -1.1498 -0.0787 -0.0683 -0.2776 -3.3190 -0.9409 -1.4583 -3.2442 -1.0798 -0.5157 -1.5282 -0.2520
S-456	To test whether the proangiogenic effects of B act via activation of VEGF pathway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk) or a control adenovirus (Ad-C), at the start of the treatment with B.<unk>
T-456	proangiogenic ; vegf pathway ; intravenously ; injected ; adenoviral ; vegf receptor ; adenovirus
H-456	-0.5272939801216125	▁pro angi ogen ic ▁effects ▁; ▁b ▁act ▁; ▁activa tion ▁; ▁ve GF ▁path way ▁; ▁rat s ▁; ▁a den ovi ral ▁ve ctor ▁; ▁de co y ▁; ▁ve GF ▁receptor ▁; ▁ad - f lk ▁; ▁control ▁ade no virus ▁; ▁ad - c
D-456	-0.5272939801216125	proangiogenic effects ; b act ; activation ; veGF pathway ; rats ; adenoviral vector ; decoy ; veGF receptor ; ad-flk ; control adenovirus ; ad-c
P-456	-0.0320 -0.1896 -0.7923 -0.3037 -0.7658 -0.5003 -0.7987 -1.5457 -0.7157 -1.5999 -0.0271 -1.9479 -0.4555 -1.3044 -0.0423 -0.1914 -0.3985 -0.5544 -0.0525 -0.2368 -0.2271 -0.0156 -1.4565 -0.3008 -0.1067 -0.1686 -0.2096 -0.0327 -0.0019 -0.3602 -1.6886 -1.1332 -2.4348 -0.0093 -0.2703 -0.1100 -0.0768 -0.5599 -0.0292 -0.2090 -0.6922 -0.0307 -0.0138 -0.0083 -0.3086 -0.1858 -0.0407 -0.8317 -2.1975 -0.1999
S-552	CONCLUSIONS: Surgical treatment of post-LVAD AI with aortic valve oversewing or leaflet repair or by bioprosthetic aortic valve replacement is effective at restoring functional capacity for CF LVAD patients who develop symptomatic, severe AI and can be performed safely with good results.<unk>
T-552	surgical ; post-lvad ai ; aortic valve ; leaflet ; bioprosthetic aortic valve replacement ; functional capacity ; lvad ; patients ; symptomatic
H-552	-0.705046534538269	▁post - L VAD ▁AI ▁; ▁a or tic ▁val ve ▁over se wing ▁; ▁le a flet ▁repair ▁; ▁bio pro sthetic ▁a or tic ▁val ve ▁replace ment ▁; ▁CF ▁l VAD ▁; ▁AI
D-552	-0.705046534538269	post-LVAD AI ; aortic valve oversewing ; leaflet repair ; bioprosthetic aortic valve replacement ; CF lVAD ; AI
P-552	-1.6555 -0.0217 -4.7176 -0.0739 -1.1196 -0.2321 -0.0933 -0.3796 -0.1516 -3.1592 -0.1822 -0.4101 -0.0993 -0.0368 -0.1585 -0.0123 -0.0351 -0.0062 -0.1259 -0.0684 -0.1133 -0.0273 -0.0284 -0.4408 -0.2290 -0.0834 -2.8137 -0.1582 -0.2059 -0.0599 -0.2645 -0.9245 -2.7814 -0.1263 -0.6839 -4.3156 -0.6183 -0.1782
S-822	BACKGROUND: This study sought to analyze a new approach to assess exercise-induced pulmonary artery systolic pressure (PASP) increase by means of stress Doppler echocardiography as a possible measure of right ventricular contractile reserve in patients with severe pulmonary hypertension and right heart failure.<unk>
T-822	exercise-induced pulmonary artery systolic pressure ; pasp ; stress doppler echocardiography ; right ventricular contractile reserve ; patients ; pulmonary hypertension ; right heart failure
H-822	-0.6123762130737305	▁exercise - indu ced ▁pulmonar y ▁arter y ▁; ▁sy sto lic ▁pressure ▁; PAS p ▁; ▁stress ▁; ▁do pp ler ▁e cho card i ography ▁; ▁right ▁vent ri cular ▁contract ile ▁reserve ▁; ▁pulmonar y ▁hyper tension ▁; ▁right ▁heart ▁failure
D-822	-0.6123762130737305	exercise-induced pulmonary artery ; systolic pressure ;PASp ; stress ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
P-822	-0.8699 -0.1688 -0.0710 -0.6004 -0.0921 -0.1082 -0.3409 -0.1205 -3.5841 -3.7754 -0.4069 -1.9094 -0.3249 -0.5563 -0.2597 -0.4062 -0.2812 -0.2379 -1.5746 -0.6371 -0.0030 -0.2644 -0.0866 -1.0082 -1.3821 -0.2959 -0.5413 -0.2182 -0.0121 -1.5052 -0.8660 -0.2777 -0.1026 -1.8065 -0.0368 -0.2283 -0.6773 -0.1007 -0.7105 -0.2309 -0.2012 -0.0691 -0.3325 -0.0999 -0.6125 -0.1743
S-1844	Methods and analysis We will conduct a literature search in the databases of MEDLINE, EMBASE, HEALTHSTAR, CINAHL, Cochrane Library, Campbell Collaboration, Joanna Briggs Institute Evidence Based Practice, Centre for Reviews and Dissemination and Evidence Based Practice Centres.<unk>
T-1844	medline ; embase ; healthstar ; cinahl ; cochrane library ; campbell collaboration ; joanna briggs institute evidence based practice ; centre for reviews and dissemination ; evidence based practice centres
H-1844	-0.5209378600120544	▁MED line ▁; ▁ EMBA se ▁; ▁HE al th STAR ▁; ▁c ina hl ▁; ▁co ch rane ▁Library ▁; ▁Campbell ▁; ▁Joan na ▁Brig gs ▁institut e ▁; ▁e viden ce ▁base d ▁practice ▁; ▁review s ▁and ▁Disse mination ▁; ▁e viden ce ▁base d ▁practice
D-1844	-0.5209378600120544	MEDline ; EMBAse ; HEalthSTAR ; cinahl ; cochrane Library ; Campbell ; Joanna Briggs institute ; evidence based practice ; reviews and Dissemination ; evidence based practice
P-1844	-1.3808 -0.6409 -0.1481 -0.8877 -0.0215 -2.3623 -0.0820 -1.4090 -0.8449 -1.9377 -0.8911 -0.1512 -1.0815 -1.0000 -0.7976 -0.1633 -0.0523 -0.0377 -0.0036 -0.5624 -0.1077 -0.0023 -1.1957 -0.1958 -0.0055 -0.2013 -0.0476 -0.1049 -0.0946 -0.5045 -1.8221 -0.0896 -0.0126 -0.2833 -0.0891 -0.1365 -1.5999 -1.2634 -0.4715 -0.5158 -0.2230 -0.0894 -0.3177 -0.8006 -0.1265 -0.0397 -0.5013 -0.0494 -0.1611 -0.8397 -0.2201
S-1123	METHODS: Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker.<unk>
T-1123	mixed-methods study ; health care ; systolic heart failure ; prescribed ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
H-1123	-0.7759976387023926	▁veteran s ▁; ▁VA ▁health ▁care ▁systems ▁; ▁sy sto lic ▁heart ▁failure ▁; ▁β - block er ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin - recept or ▁block er
D-1123	-0.7759976387023926	veterans ; VA health care systems ; systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
P-1123	-6.4038 -0.0422 -0.2403 -2.8548 -0.8564 -1.5963 -0.1428 -0.2549 -0.5193 -0.0931 -1.5736 -2.2914 -0.2547 -0.1307 -0.7500 -0.0545 -0.3842 -0.6681 -0.0922 -0.4205 -2.2301 -1.3351 -0.1450 -0.2810 -0.0599 -0.0314 -0.0681 -0.4865 -0.0576 -0.1804 -0.0424 -2.6859 -1.7255 -0.3407 -0.3727 -0.0953 -0.3425 -0.2852 -0.4261 -0.7721 -0.2287
S-647	The base of treatment of heart failure is the blockade of the neuro-hormonal system, which includes the use of angiotensin converting enzyme inhibitors (angiotensin receptor blockers in case of angiotensin converting enzyme inhibitors intolerance), beta receptor blockers and mineralocorticoid receptor antagonists.<unk>
T-647	heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ; angiotensin receptor blockers ; angiotensin converting enzyme inhibitors ; beta receptor blockers ; mineralocorticoid receptor antagonists
H-647	-0.4954673945903778	▁heart ▁failure ▁; ▁block ade ▁; ▁neuro - hormon al ▁system ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁ang io ten sin ▁convert ing ▁enzym e ▁inhibi tors ▁in tolerance ▁; ▁beta ▁receptor ▁block ers ▁; ▁mineral o cor tico id ▁receptor ▁anta gon ists
D-647	-0.4954673945903778	heart failure ; blockade ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
P-647	-3.9740 -0.1654 -0.2929 -0.2556 -0.0405 -0.8070 -0.1107 -0.2077 -0.0332 -0.0450 -0.0624 -0.3978 -0.0427 -1.0501 -1.4067 -0.3778 -0.2494 -0.1567 -0.0417 -0.1017 -0.7050 -0.1241 -0.4041 -0.4090 -0.8989 -0.8270 -0.0337 -0.2319 -0.1368 -0.2025 -0.0283 -1.2449 -1.4631 -0.2999 -0.5738 -0.1499 -0.0833 -0.0907 -0.6076 -0.1599 -0.2610 -0.0662 -0.4098 -0.1133 -0.0078 -0.2547 -0.0817 -0.2250 -0.0275 -0.1548 -2.9146 -2.2626 -1.0549 -0.0038 -0.2491 -0.1900 -1.5776 -0.6859 -0.1990
S-330	CONCLUSIONS: In an open chest model, twist, RS, RS synchrony, and CS analyzed by STE may be noninvasive surrogates for changes in CO. During RVPO, changes in RS synchrony and CS with varying regional strain contributions may be the primary mechanism in which BiVP improves CO.<unk>
T-330	chest ; rs ; rs synchrony ; ste ; noninvasive ; rvpo ; rs synchrony ; strain ; bivp
H-330	-0.6659013628959656	▁open ▁che st ▁model ▁; ▁twist ▁; ▁RS ▁; ▁RS ▁synchron y ▁; ▁ STE ▁; ▁change ▁; ▁ RV PO ▁; ▁RS ▁synchron y ▁; ▁CS ▁; ▁bi VP ▁; ▁co
D-330	-0.6659013628959656	open chest model ; twist ; RS ; RS synchrony ; STE ; change ; RVPO ; RS synchrony ; CS ; biVP ; co
P-330	-0.1624 -1.9559 -0.0263 -0.1149 -0.1522 -0.0002 -0.2363 -0.2833 -0.3384 -0.7680 -0.0162 -0.1933 -0.1715 -1.2145 -1.9035 -0.1282 -3.2648 -0.3200 -1.1532 -0.3906 -1.3322 -0.0648 -0.5539 -0.0245 -0.2194 -0.0909 -1.7538 -0.1441 -1.7838 -1.5083 -0.3659 -1.2374 -0.5409 -0.2271
S-498	Given the TAPSE, PASP, and TAPSE-to-PASP ratio (TAPSE/PASP) collinearity, separate Cox regression and Kaplan-Meier analyses were performed: one with TAPSE and PASP as individual measures, and the other combining them in ratio form.<unk>
T-498	tapse ; pasp ; tapse ; pasp ; cox regression ; kaplan-meier analyses ; tapse ; pasp
H-498	-0.7437460422515869	▁t AP se ▁; ▁PAS p ▁; ▁t AP se - to - PAS p ▁ratio ▁; TA ps e ▁; PAS p ▁; ▁co x ▁re gression ▁; ▁Ka plan - me ier ▁; ▁t AP se ▁; ▁PAS p
D-498	-0.7437460422515869	tAPse ; PASp ; tAPse-to-PASp ratio ;TApse ;PASp ; cox regression ; Kaplan-meier ; tAPse ; PASp
P-498	-1.5459 -2.2147 -2.2917 -0.2848 -0.7888 -0.4520 -0.3018 -1.0295 -1.1480 -1.3333 -0.2226 -0.0855 -0.0508 -0.7624 -0.3870 -0.0344 -0.2197 -1.4314 -2.7833 -0.7287 -0.4911 -1.6322 -0.3163 -0.3672 -0.1950 -0.4554 -0.0355 -0.0533 -0.1735 -0.3031 -0.3185 -0.0680 -0.5574 -0.7342 -0.7224 -1.9413 -1.3125 -1.1437 -0.2232 -1.1761 -0.3232 -1.0568 -0.2849
S-1880	METHODS: We performed symptom limited maximal CPET in 10 patients with CHF, randomly divided into two groups: 5 patients as control without exercise and 5 exercise patients used Δ50%W intensity to exercise 30 min/d, 5 d/w, x12 w. Before and after 12 w rehabilitation, we evaluated functions.<unk>
T-1880	symptom ; cpet ; patients ; chf ; patients ; exercise ; exercise ; patients ; exercise ; rehabilitation
H-1880	-0.7868527173995972	▁c PET ▁; ▁CHF ▁; ▁exercise ▁; ▁exercise
D-1880	-0.7868527173995972	cPET ; CHF ; exercise ; exercise
P-1880	-1.0088 -0.7464 -0.1952 -0.0835 -0.4405 -0.7928 -0.3748 -0.7881 -3.2491 -0.1892
S-1080	BACKGROUND: Human heart failure (HF) increases alternative mRNA splicing of the type V, voltage-gated cardiac Na+ channel α-subunit (SCN5A), generating variants encoding truncated, nonfunctional channels that are trapped in the endoplasmic reticulum.<unk>
T-1080	heart failure ; hf ; mrna splicing ; cardiac ; scn5a ; endoplasmic reticulum
H-1080	-0.5351161360740662	▁human ▁heart ▁failure ▁; HF ▁; ▁m RNA ▁s plic ing ▁; ▁v ▁; ▁volta ge - ga ted ▁cardiac ▁na + ▁channel ▁α - sub un it ▁; ▁s cn 5 a ▁; ▁tru nca ted ▁; ▁non function al ▁channel s ▁; ▁en do plas mic ▁reti culum
D-1080	-0.5351161360740662	human heart failure ;HF ; mRNA splicing ; v ; voltage-gated cardiac na+ channel α-subunit ; scn5a ; truncated ; nonfunctional channels ; endoplasmic reticulum
P-1080	-1.1911 -0.8740 -0.0716 -0.3188 -0.4593 -0.2874 -0.0285 -0.0862 -0.0781 -0.0174 -0.1337 -0.2222 -2.3986 -0.8252 -0.0033 -0.0123 -0.1255 -0.1298 -0.0766 -0.7532 -0.1679 -4.4851 -0.6543 -2.9828 -0.0332 -0.0226 -0.2581 -1.3649 -0.3848 -0.0866 -1.6597 -0.1002 -0.4615 -0.2153 -0.2964 -0.0351 -0.0074 -0.7506 -2.0104 -0.2403 -0.0342 -0.0605 -0.0267 -0.2492 -0.5277 -0.4725 -0.4143 -1.0830 -0.0267 -0.0088 -0.4111 -0.2014
S-988	Particular topics of debate in paediatric heart failure concern: the diagnosis and management of myocarditis versus dilated cardiomyopathy the most appropriate investigations for new onset heart failure cellular responses to heart failure the increasing population of anthracycline treated survivors of childhood malignant disease treatment strategies.<unk>
T-988	heart failure ; diagnosis ; myocarditis ; dilated cardiomyopathy ; heart failure ; heart failure ; anthracycline ; disease
H-988	-0.866123378276825	▁pa e dia tric ▁heart ▁failure ▁; ▁my o card itis ▁; ▁dil ated ▁cardio my o pathy ▁; ▁heart ▁failure ▁; ▁an thra cycli ne ▁; ▁child hood ▁malign ant ▁disease
D-988	-0.866123378276825	paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; anthracycline ; childhood malignant disease
P-988	-1.3539 -0.0697 -3.8180 -1.4002 -2.6012 -0.0768 -0.3012 -1.0959 -0.2509 -1.3935 -0.2386 -0.2950 -0.6375 -0.0391 -0.2466 -1.1775 -0.3543 -0.1789 -0.3065 -3.3960 -0.0723 -0.5178 -3.5341 -0.4815 -0.6966 -0.1320 -0.2314 -1.3975 -0.2443 -0.0713 -0.9261 -0.6439 -1.0423 -0.2256
S-2010	METHODS: We developed the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model, a Web-based simulation tool designed to integrate data on demographic, clinical, and laboratory characteristics; use of evidence-based medications; and costs to generate predicted outcomes.<unk>
T-2010	tools for economic analysis of patient management interventions in heart failure cost-effectiveness model ; clinical ; evidence-based ; medications ; costs ; outcomes
H-2010	-0.660965085029602	▁economic ▁analysis ▁; ▁Patient ▁management ▁Interven tions ▁; ▁Heart ▁Fail ure ▁; ▁cost - e ff ective ness ▁model ▁; ▁evidence - based ▁medication s ▁; ▁costs
D-2010	-0.660965085029602	economic analysis ; Patient management Interventions ; Heart Failure ; cost-effectiveness model ; evidence-based medications ; costs
P-2010	-0.2229 -1.1187 -0.7300 -2.0291 -0.5430 -0.8971 -0.0215 -1.0263 -0.2252 -0.2994 -0.0180 -1.5607 -0.3316 -0.1467 -1.9893 -2.3089 -0.1754 -0.1382 -0.4791 -0.5932 -2.8509 -0.0323 -0.0084 -0.2224 -0.0428 -0.3316 -0.0871 -0.5362 -0.2022
S-1020	The measurement of natriuretic peptides (NPs), B-type NP or N-terminal pro-B-type NP, can be an important tool in the diagnosis of acute heart failure in patients presenting to an Emergency Department (ED) with acute dyspnea, according to international guidelines.<unk>
T-1020	natriuretic peptides ; nps ; b-type np ; n-terminal pro-b-type np ; diagnosis ; acute heart failure ; patients ; emergency department ; acute dyspnea
H-1020	-0.382203608751297	▁na tri ure tic ▁pe pti des ▁; NP s ▁; ▁b - type ▁ NP ▁; ▁N - termin al ▁pro - B - type ▁ NP ▁; ▁a cute ▁heart ▁failure ▁; ▁Emer gen cy ▁department ▁; ED ▁; ▁a cute ▁dys pne a
D-1020	-0.382203608751297	natriuretic peptides ;NPs ; b-type NP ; N-terminal pro-B-type NP ; acute heart failure ; Emergency department ;ED ; acute dyspnea
P-1020	-0.0053 -0.3384 -0.1291 -0.5649 -0.0320 -0.2999 -2.1066 -0.3703 -0.3803 -0.0416 -0.1013 -1.4363 -0.0678 -0.6725 -0.3713 -0.0179 -0.1222 -3.2163 -0.0935 -0.0127 -0.0026 -0.0110 -0.0447 -1.4033 -0.1210 -0.3680 -0.2082 -0.0094 -0.2890 -0.0852 -0.1453 -1.2029 -0.0556 -0.1319 -0.1621 -0.1210 -0.0106 -0.3696 -0.1896 -0.6484 -0.1548 -0.0499 -0.1018 -1.0696 -0.0963 -0.1591 -0.5003 -0.2544
S-1275	Besides the widely accepted peak oxygen consumption (peak VO2) and VEN/VCO2 slope, other exercise variables - exercise oscillatory ventilation (EOV) and partial pressure of end-tidal CO2, (PETCO2) - should gain attention in the interpretation of cardiopulmonary exercise testing.<unk>
T-1275	peak oxygen consumption ; peak vo2 ; exercise ; exercise oscillatory ventilation ; eov ; partial pressure of end-tidal co2 ; petco2 ; gain ; cardiopulmonary exercise testing
H-1275	-0.5071308612823486	▁pe ak ▁oxygen ▁consum p tion ▁; ▁pe ak ▁VO 2 ▁; ▁ ven ▁; ▁v co 2 ▁s lope ▁; ▁exercise ▁; ▁os cilla tory ▁ventilation ▁; ▁e OV ▁; ▁parti al ▁pressure ▁; ▁end - ti dal ▁CO 2 ▁; PET co 2 ▁; ▁cardio pul mon ary ▁exercise ▁testing
D-1275	-0.5071308612823486	peak oxygen consumption ; peak VO2 ; ven ; vco2 slope ; exercise ; oscillatory ventilation ; eOV ; partial pressure ; end-tidal CO2 ;PETco2 ; cardiopulmonary exercise testing
P-1275	-0.0184 -0.0030 -1.6734 -0.3106 -0.0606 -0.2990 -0.2891 -0.4577 -0.0045 -2.5455 -1.1786 -0.1732 -0.4081 -0.4145 -2.3637 -1.5998 -0.3831 -0.0718 -0.0312 -0.0454 -0.2858 -0.1040 -0.5094 -1.1882 -0.0725 -0.0319 -0.0140 -0.1820 -0.5402 -0.8821 -0.1631 -1.3690 -0.0164 -0.0526 -0.4956 -0.3593 -0.0662 -0.0172 -0.2679 -2.4025 -0.1407 -0.1869 -0.2174 -0.6441 -0.8434 -0.3647 -0.7555 -0.1909 -0.5285 -0.0892 -1.1349 -0.2558 -0.4086 -0.2733
S-1536	DESIGN: In this nationwide retrospective cohort study from Denmark, all users of bisphosphonates and raloxifene between 1996 and 2006 (n = 102 342) were included in the 'exposed' group and three age- and gender-matched subjects (n = 307.026) from the general population comprised the control group.<unk>
T-1536	retrospective cohort study ; denmark ; bisphosphonates ; raloxifene
H-1536	-0.9378451108932495	▁Denmark ▁; ▁bis phos phon ates ▁; ▁ra lo xi fen e ▁; ▁general ▁population
D-1536	-0.9378451108932495	Denmark ; bisphosphonates ; raloxifene ; general population
P-1536	-7.1681 -0.3248 -0.1501 -0.0550 -0.4524 -0.2556 -0.3172 -0.0413 -0.5088 -0.1430 -2.6618 -0.5864 -1.0363 -0.7311 -0.4992 -0.8090 -0.2032
S-365	At this time, he had severe hypertension, moderate LV dilatation, LV dysfunction, mild MR, and significant MS. As the mitral valve demonstrated restricted closure and opening without any clear organic lesion, being consistent with systolic and diastolic tethering, a functional etiology of MR and MS was considered.<unk>
T-365	hypertension ; lv dilatation ; lv dysfunction ; mitral valve ; organic ; lesion ; systolic ; diastolic tethering ; etiology
H-365	-0.3665445148944855	▁hyper tension ▁; ▁LV ▁di la tation ▁; ▁LV ▁dys function ▁; ▁MR ▁; ▁MS ▁; ▁mit ral ▁val ve ▁; ▁ closure ▁; ▁opening ▁; ▁organic ▁les ion ▁; ▁sy sto lic ▁; ▁dia sto lic ▁te ther ing ▁; ▁MR ▁; ▁MS
D-365	-0.3665445148944855	hypertension ; LV dilatation ; LV dysfunction ; MR ; MS ; mitral valve ; closure ; opening ; organic lesion ; systolic ; diastolic tethering ; MR ; MS
P-365	-1.3660 -0.0721 -0.0586 -0.4047 -0.1105 -0.1242 -0.0071 -0.2003 -0.0550 -0.0794 -0.3599 -0.0933 -0.4639 -0.1040 -0.9222 -1.5593 -0.2104 -0.0606 -1.2513 -0.1365 -0.1350 -1.6976 -0.0192 -0.1657 -0.7687 -0.1887 -0.6435 -0.5163 -0.0681 -0.1973 -0.3687 -0.0539 -0.3437 -0.2744 -0.1183 -0.3655 -0.5586 -0.0294 -0.0478 -0.0232 -0.2092 -1.7565 -0.2905 -0.1525 -0.1120 -0.1176
S-1196	Currently, tolvaptan is indicated for the treatment of severe hyponatremia in most countries, including the United States, but in Japan the indication is broader; it can be used in congestive heart failure patients in addition to standard or optimal diuretic therapy, regardless of their serum sodium levels or systolic function.<unk>
T-1196	tolvaptan ; hyponatremia ; united states ; japan ; congestive heart failure ; patients ; diuretic ; therapy ; serum sodium ; systolic function
H-1196	-0.5020310878753662	▁to lv ap tan ▁; ▁hypo na trem ia ▁; ▁unit ed ▁states ▁; ▁japan ▁; ▁con ges tive ▁heart ▁failure ▁; ▁di ure tic ▁ therapy ▁; ▁se rum ▁so dium ▁levels ▁; ▁sy sto lic ▁function
D-1196	-0.5020310878753662	tolvaptan ; hyponatremia ; united states ; japan ; congestive heart failure ; diuretic therapy ; serum sodium levels ; systolic function
P-1196	-0.0633 -0.2800 -0.6853 -0.5357 -0.1670 -2.2161 -0.1016 -0.2168 -0.6812 -0.2493 -2.0534 -0.0886 -0.0556 -0.1777 -2.3431 -0.3116 -0.0547 -0.1567 -0.0668 -0.7619 -0.0394 -0.9329 -1.0685 -0.2428 -0.2691 -1.2487 -0.1577 -0.3869 -0.0366 -0.1635 -0.0419 -0.2438 -0.0810 -0.1772 -0.3075 -0.1461 -1.3837 -1.1888 -0.5212 -0.1772
S-429	METHODS AND RESULTS: Global longitudinal strain of left ventricle was added to standard echocardiographic measurements in 334 consecutive patients (224 men; mean, 65±12 years) who underwent baseline echocardiography before CRT and underwent follow-up echocardiograms at 1 year.<unk>
T-429	longitudinal ; strain ; left ventricle ; echocardiographic ; patients ; baseline ; echocardiography ; crt ; follow-up ; echocardiograms
H-429	-0.6957115530967712	▁longitud in al ▁strain ▁; ▁left ▁vent ric le ▁; ▁e cho car dio graphic ▁measure ments ▁; ▁base line ▁e cho card i ography ▁; ▁c RT ▁; ▁follow - up ▁e cho card i ogram s
D-429	-0.6957115530967712	longitudinal strain ; left ventricle ; echocardiographic measurements ; baseline echocardiography ; cRT ; follow-up echocardiograms
P-429	-2.7822 -0.2877 -0.0618 -2.2199 -1.1839 -0.1347 -3.2202 -2.6702 -1.6341 -0.2192 -0.2860 -0.5415 -0.9166 -1.4380 -0.7415 -0.9392 -0.1188 -0.2217 -0.0369 -0.0244 -0.4630 -0.7383 -0.4367 -0.4625 -0.6467 -0.1694 -0.2788 -1.6413 -0.3483 -0.1316 -0.0981 -0.0377 -0.1529 -0.7117 -0.3830 -0.6212 -0.0970 -0.2640 -0.3168 -0.1511
S-1267	This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10).<unk>
T-1267	platelet-activating factor ; paf ; metabolic ; enzymes ; follow-up ; patients ; diagnosed ; heart failure ; hf ; healthy
H-1267	-0.9336820244789124	▁plate let - activa ting ▁factor ▁; PA f ▁; ▁metabol ic ▁enzym es ▁; ▁heart ▁failure ▁; HF
D-1267	-0.9336820244789124	platelet-activating factor ;PAf ; metabolic enzymes ; heart failure ;HF
P-1267	-2.0641 -3.3982 -0.2125 -0.0336 -0.3506 -0.0422 -0.7596 -0.9338 -1.0911 -0.3072 -0.0571 -0.0288 -0.0945 -0.0606 -0.3163 -4.3417 -0.1851 -0.5032 -2.3272 -2.3615 -0.1384
S-1281	We reviewed our institutional experience between 2008 and 2012 with acute care surgery (ACS) consultations and procedures within 1 year of OHT in recipients bridged to transplantation with medical therapy (MT, n = 169), including intravenous inotropes, and ventricular assist devices (VADs, n = 74).<unk>
T-1281	acute care surgery ; acs ; consultations ; oht ; transplantation ; medical therapy ; intravenous ; inotropes ; ventricular assist devices ; vads
H-1281	-0.5044974088668823	▁a cute ▁care ▁surgery ▁; AC s ▁; ▁o HT ▁; ▁transplant ation ▁; ▁medical ▁ therapy ▁; ▁intra ven ous ▁in o trop es ▁; ▁vent ri cular ▁assist ▁devices ▁; VAD s
D-1281	-0.5044974088668823	acute care surgery ;ACs ; oHT ; transplantation ; medical therapy ; intravenous inotropes ; ventricular assist devices ;VADs
P-1281	-0.0972 -0.1473 -0.8440 -1.4366 -0.2567 -1.3856 -0.6732 -0.2786 -0.7875 -4.6732 -0.1687 -0.4956 -0.1014 -0.2680 -0.0148 -0.3897 -0.0523 -0.2238 -0.7252 -0.0228 -0.3538 -0.0199 -0.4676 -0.2437 -0.6206 -0.1835 -0.3073 -0.6248 -0.1463 -0.6045 -0.0287 -0.6795 -0.0069 -0.1058 -0.4802 -0.2466
S-1178	CONCLUSIONS: In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from improved left ventricular filling pressure response to exercise as reflected by the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity.<unk>
T-1178	patients ; hfpef ; ivabradine ; exercise capacity ; left ventricular filling pressure ; exercise ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
H-1178	-0.5766974091529846	▁ HF p EF ▁; ▁i va bra dine ▁; ▁exercise ▁capacity ▁; ▁left ▁vent ri cular ▁; ▁fill ing ▁pressure ▁response ▁; ▁exercise ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1178	-0.5766974091529846	HFpEF ; ivabradine ; exercise capacity ; left ventricular ; filling pressure response ; exercise ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
P-1178	-1.6675 -1.1683 -0.1732 -1.4790 -0.2268 -0.1199 -2.2348 -0.4735 -0.1684 -0.1732 -0.5297 -0.1084 -0.2774 -0.3891 -2.6195 -1.1976 -0.1888 -1.7105 -0.4876 -0.0281 -0.3220 -1.1530 -0.2134 -0.6859 -0.2389 -0.6035 -0.0034 -0.1218 -0.3780 -0.2350 -0.4008 -0.7826 -0.0877 -0.5923 -0.0416 -0.1561 -0.2348 -0.4706 -0.0056 -0.1525 -0.3484 -0.3956 -1.3153 -2.0332 -0.5074 -1.6915 -0.0007 -0.0349 -0.1850 -0.4464 -0.1519
S-1489	The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear.<unk>
T-1489	renin-angiotensin-aldosterone system ; raas ; hfref ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; evidence ; hfpef
H-1489	-0.361820787191391	▁re nin - angi oten sin - al do ster one ▁system ▁; RA as ▁; ▁h Fr EF ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; ▁ang io ten sin ▁receptor ▁block ers ▁; ▁al do ster one ▁block ade ▁; ▁ HF p EF
D-1489	-0.361820787191391	renin-angiotensin-aldosterone system ;RAas ; hFrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
P-1489	-0.0133 -0.1196 -0.1242 -0.0643 -0.3763 -0.6926 -0.1525 -0.0423 -0.9245 -0.4696 -0.0317 -0.0329 -0.4521 -0.3035 -0.4228 -0.1287 -2.3284 -1.3221 -0.7373 -0.0894 -0.0125 -1.7776 -0.7237 -0.1843 -0.2860 -0.0057 -0.0619 -0.0498 -0.0177 -0.0547 -0.1226 -0.0641 -0.2070 -0.0160 -2.1042 -0.8500 -0.1317 -0.0300 -0.2101 -0.1176 -0.1242 -0.0216 -0.3032 -0.6148 -0.0182 -0.0941 -0.2478 -0.4107 -0.3530 -0.3509 -0.0493 -0.5699 -0.3572 -0.1683
S-583	At admission, the LVET was shorter in patients with unfavorable outcome (median, 228 milliseconds [25th-75th percentiles, 212-278 milliseconds] vs 257 milliseconds [237-277 milliseconds], P = .032), whereas other tonometric indices were similar.<unk>
T-583	admission ; lvet ; patients ; outcome ; tonometric
H-583	-0.46953293681144714	▁ad mission ▁; ▁l VET ▁; ▁un favor able ▁outcome ▁; ▁to no metric ▁indice s
D-583	-0.46953293681144714	admission ; lVET ; unfavorable outcome ; tonometric indices
P-583	-0.4159 -0.0641 -0.3057 -1.4940 -1.2161 -0.4173 -0.9127 -0.0982 -0.0751 -0.1302 -0.6775 -1.0775 -0.1253 -0.0940 -0.4128 -0.0468 -0.5824 -0.3059
S-182	After correction for age, heart rate, blood pressure, renal function, and spironolactone use, this association remained significant for RAS blockers (HR 0.54, 95% CI 0.31 to 0.93, p = 0.027) but not for β-blockers (HR 0.65, 95% CI 0.39 to 1.09, p = 0.101).<unk>
T-182	heart rate ; blood pressure ; renal function ; spironolactone ; ras blockers ; β-blockers
H-182	-0.4475904703140259	▁heart ▁rate ▁; ▁blood ▁pressure ▁; ▁renal ▁function ▁; ▁spi rono lac tone ▁; ▁ RAS ▁block ers ▁; ▁β - block ers
D-182	-0.4475904703140259	heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; β-blockers
P-182	-3.5378 -0.0157 -0.2154 -1.4232 -0.8248 -0.1882 -0.0647 -0.3024 -0.2175 -0.0590 -0.0182 -0.1139 -0.0544 -0.1724 -0.2358 -0.0457 -1.0542 -0.0728 -0.2211 -0.9524 -0.0604 -0.2886 -0.2196 -0.6286 -0.2030
S-1553	The results suggest that partial improvement of cardiac performance by β-adrenoceptor blockade at advanced stages of heart failure may be due to partial reversal of changes in SR Ca(2+)-pump function whereas partial to complete reverse cardiac remodeling may be due to partial reduction in the elevated levels of plasma catecholamines.<unk>
T-1553	cardiac ; β-adrenoceptor blockade ; heart failure ; reverse ; cardiac remodeling ; elevated ; plasma catecholamines
H-1553	-0.39044657349586487	▁cardiac ▁performance ▁; ▁β - ad re no cept or ▁block ade ▁; ▁heart ▁failure ▁; ▁rever sal ▁of ▁changes ▁; ▁SR ▁ca (2 +) - pump ▁function ▁; ▁rever se ▁cardiac ▁remodel ing ▁; ▁plasma ▁cate chol amine s
D-1553	-0.39044657349586487	cardiac performance ; β-adrenoceptor blockade ; heart failure ; reversal of changes ; SR ca(2+)-pump function ; reverse cardiac remodeling ; plasma catecholamines
P-1553	-0.9692 -0.2529 -0.1571 -0.0543 -0.0606 -0.2407 -0.2700 -0.1438 -1.9118 -0.6911 -0.1242 -0.4857 -0.1893 -0.6331 -0.1693 -0.2139 -1.5202 -0.1817 -2.0003 -0.5760 -0.2279 -0.1017 -0.7736 -0.7671 -0.0091 -0.0407 -0.0721 -1.1680 -0.1461 -0.0181 -0.0131 -0.2239 -0.0647 -0.0504 -0.2960 -0.3249 -0.1389 -0.0271 -0.4587 -0.0654 -0.3619 -0.2041
S-666	The adjusted median rate ratio was 1.11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy, 1.08 (95% confidence interval, 1.05-1.15) for β-blockers therapy, and 1.17 (1.13-1.26) for optimal combined treatment.<unk>
T-666	rate ratio ; confidence interval ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; therapy ; confidence interval ; β-blockers ; therapy
H-666	-0.5125377178192139	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁ therapy ▁; ▁β - block ers ▁ therapy
D-666	-0.5125377178192139	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers therapy ; β-blockers therapy
P-666	-2.4442 -2.2938 -0.6583 -0.1186 -0.3296 -0.0032 -0.0496 -0.0548 -0.0278 -0.0436 -0.3722 -0.1407 -0.7205 -0.4791 -0.2961 -0.1560 -0.0082 -0.2296 -0.0955 -2.5015 -0.0720 -0.5686 -0.3543 -0.0657 -0.1685 -0.0791 -1.7562 -0.1971 -0.6890 -0.4024
S-874	Concomitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial damage induced by TAC, in parallel with global attenuation of mitochondrial proteome changes, with an average of 84% protection of mitochondrial and 69% of nonmitochondrial protein changes.<unk>
T-874	ss31 ; congestive heart failure ; phenotypes ; mitochondrial ; tac ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein
H-874	-0.6678932905197144	▁SS 31 ▁; ▁con ges tive ▁heart ▁failure ▁ph eno type s ▁; ▁mito cho ndri al ▁damage ▁induc ed ▁; ▁ TAC ▁; ▁mito cho ndri al ▁prote ome ▁changes ▁; ▁mito cho ndri al ▁; ▁non mi to cho ndri al ▁protein ▁changes
D-874	-0.6678932905197144	SS31 ; congestive heart failure phenotypes ; mitochondrial damage induced ; TAC ; mitochondrial proteome changes ; mitochondrial ; nonmitochondrial protein changes
P-874	-0.3486 -0.3475 -0.8614 -0.0726 -0.0752 -0.0829 -1.8157 -0.1425 -1.4177 -0.3168 -0.7223 -0.0952 -0.1720 -0.0439 -2.5193 -1.0303 -0.0685 -0.4708 -0.2207 -0.1014 -0.7610 -0.0716 -0.0229 -0.2349 -0.5167 -2.3804 -1.1110 -0.0612 -0.5871 -0.5100 -1.8902 -0.5152 -1.4278 -2.3211 -1.0332 -0.0431 -0.3058 -0.4282 -0.2327 -0.1399 -2.6407 -1.2176 -0.0232 -0.3857 -0.9541 -0.5236 -0.1267
S-1552	Depressed myofibrillar Ca(2+)-stimulated ATPase activity, as well as mRNA levels for SR Ca(2+)-pump, phospholamban and α-myosin heavy chain, were unaffected whereas increased mRNA level for β-myosin heavy chain was partially reversed by metoprolol.<unk>
T-1552	myofibrillar ; atpase ; activity ; mrna ; phospholamban ; α-myosin heavy chain ; mrna ; β-myosin heavy chain ; metoprolol
H-1552	-0.4427246153354645	▁my o fi bril lar ▁ca (2 +) - stimul ated ▁ATP ase ▁activity ▁; ▁m RNA ▁levels ▁; ▁SR ▁ca (2 +) - pump ▁; ▁ phos pho lam ban ▁; ▁α - my os in ▁heavy ▁chain ▁; ▁m RNA ▁level ▁; ▁β - my os in ▁heavy ▁chain ▁; ▁met o pro lol
D-1552	-0.4427246153354645	myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; α-myosin heavy chain ; mRNA level ; β-myosin heavy chain ; metoprolol
P-1552	-4.0732 -0.2066 -0.1873 -0.2978 -0.5964 -0.6722 -0.7629 -0.0522 -0.0655 -0.0475 -0.0767 -1.4327 -2.3133 -0.4381 -0.2680 -0.0137 -0.0673 -0.1008 -0.1866 -1.0973 -1.0061 -0.3785 -0.0162 -0.0725 -0.0973 -0.1624 -0.4115 -0.1785 -1.0250 -0.7867 -0.0486 -0.1947 -0.1581 -0.0525 -0.5451 -0.1621 -0.3340 -0.6297 -0.0151 -0.4968 -0.0115 -0.0878 -1.3432 -0.1663 -0.7139 -0.0301 -0.7514 -0.1715 -0.1662 -0.4044 -0.0205 -0.4217 -0.2460 -0.0869 -0.2827 -0.3973 -0.4386 -0.2104
S-250	METHODS AND RESULTS: HDL was isolated from 16 healthy controls (HDL(healthy)) and 16 patients with CHF-NYHA-III (HDL(NYHA-IIIb)) before and after ET, as well as from 8 patients with CHF-NYHA-II (HDL(NYHA-II)).<unk>
T-250	hdl ; healthy ; hdl ; healthy ; patients ; chf-nyha-iii ; hdl ; nyha-iiib ; patients ; chf-nyha-ii ; hdl ; nyha-ii
H-250	-1.2686643600463867	▁HD L ▁; ▁gh - NY HA - III ▁; HD l ▁; NY HA - III b ▁; ▁CHF - NY HA - II ▁; HD l ▁; NY HA - II
D-250	-1.2686643600463867	HDL ; gh-NYHA-III ;HDl ;NYHA-IIIb ; CHF-NYHA-II ;HDl ;NYHA-II
P-250	-3.1084 -3.2842 -0.2173 -4.6755 -1.9967 -0.3471 -1.4504 -0.2557 -0.0893 -0.1842 -3.4974 -1.8127 -0.4139 -3.9633 -0.8303 -0.0946 -0.1243 -0.4365 -0.3809 -2.4762 -0.1899 -0.4840 -1.1546 -0.1373 -0.2275 -0.1099 -3.9436 -1.8567 -0.6001 -3.4789 -1.0035 -0.1440 -0.3440 -0.9150 -0.1752
S-420	In anesthetized dogs with coronary microembolization-induced HF, CXL-1020 reduced left ventricular end-diastolic pressure and myocardial oxygen consumption while increasing ejection fraction from 27% to 40% and maximal ventricular power index by 42% (both P<0.05).<unk>
T-420	anesthetized ; coronary microembolization-induced hf ; cxl-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; maximal ventricular power index
H-420	-0.5616891980171204	▁an est het ized ▁dog s ▁; ▁corona ry ▁micro e mbol ization - indu ced ▁ HF ▁; ▁c XL -10 20 ▁; ▁left ▁vent ri cular ▁; ▁end - dia sto lic ▁pressure ▁; ▁my o card ial ▁oxygen ▁consum p tion ▁; ▁e je ction ▁ fraction ▁; ▁vent ri cular ▁power ▁index
D-420	-0.5616891980171204	anesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular ; end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
P-420	-0.4865 -0.3657 -3.2235 -0.1941 -0.4778 -0.0330 -0.2812 -0.0627 -0.0227 -1.0394 -0.3219 -0.0126 -0.2240 -0.3391 -0.0060 -0.3067 -0.2792 -0.0962 -0.1352 -1.0499 -0.3322 -0.2813 -0.0882 -0.2124 -0.3660 -2.6935 -1.1047 -0.2458 -1.1373 -0.8385 -0.1333 -0.9225 -0.5402 -0.9251 -0.5175 -0.1039 -0.3564 -0.1246 -1.0801 -0.0562 -0.7543 -0.5724 -0.0168 -0.6694 -0.1921 -0.0100 -0.1705 -0.1107 -0.9566 -0.0283 -0.2055 -4.3430 -1.5157 -0.6799 -0.1304 -0.2293 -0.7320 -0.2442
S-805	For the total sample, a standard error of measurement value of approximately 1.6 seconds, an absolute value of MDC at the 95% confidence level (MDC95%) of approximately 4.5 seconds, and a relative value of MDC at the 95% confidence level (MDC95%%) of approximately 35% were found between the first 2 trials, with similar values found for the subgroups.<unk>
T-805	standard error of measurement ; mdc ; mdc
H-805	-1.0041120052337646	▁m d ▁; ▁m d ▁; ▁m d ▁; ▁relative ▁value ▁; ▁m d ▁; ▁m d
D-805	-1.0041120052337646	md ; md ; md ; relative value ; md ; md
P-805	-1.4326 -0.8831 -0.3126 -1.0312 -0.6667 -0.7565 -1.6848 -0.4952 -1.8239 -2.2688 -1.2187 -0.3285 -0.3361 -0.5006 -1.3165 -0.8111 -0.4111 -2.5197 -0.2805
S-1061	RESULTS: In the study cohort, differences were found between the baseline and heart failure T1-mapping values before the administration of contrast agent (960 ± 96 and 726 ± 94 ms, respectively; p = 0.02) and after contrast agent administration (546 ± 180 and 300 ± 171 ms, respectively; p = 0.005).<unk>
T-1061	baseline ; heart failure ; t1-mapping ; administration ; administration
H-1061	-0.5176324248313904	▁base line ▁; ▁heart ▁failure ▁; ▁t 1- ma pping ▁; ▁administration ▁; ▁contrast ▁agent
D-1061	-0.5176324248313904	baseline ; heart failure ; t1-mapping ; administration ; contrast agent
P-1061	-0.0173 -0.1020 -0.2263 -0.7945 -0.2030 -1.2890 -0.6763 -0.2264 -0.1756 -0.0234 -0.7087 -0.1726 -1.4476 -0.1875 -0.2293 -2.1282 -0.1918
S-1794	Main etiologies of HF in LA are idiopathic dilated cardiomyopathy (from 1.3% to 37%), C'D (from 1.3% to 21%), ischemic (from 68% to 17%), SH (from 14% to 76%), valvular (from 3% to 22%), and alcohol related (from 1.1% to 8%).<unk>
T-1794	etiologies ; hf ; idiopathic dilated cardiomyopathy ; ischemic ; valvular
H-1794	-0.6149905323982239	▁et i ologie s ▁; ▁ HF ▁; ▁la ▁; ▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁c ' d ▁; ▁ ische mic ▁; ▁SH ▁; ▁val vu lar ▁; ▁alcohol
D-1794	-0.6149905323982239	etiologies ; HF ; la ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
P-1794	-3.5798 -0.1255 -0.4231 -0.0987 -0.4835 -0.5004 -0.2462 -0.2057 -1.5069 -1.4971 -1.4030 -0.0402 -0.1326 -0.7132 -0.3310 -0.0958 -0.8199 -1.8862 -0.5455 -0.0948 -0.1055 -0.2304 -3.4452 -0.2333 -0.0733 -0.1390 -0.1967 -0.0804 -0.1561 -0.6855 -0.2116 -0.8980 -0.1372 -0.5391 -0.2684 -0.6428 -0.4445 -0.1538
S-697	We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF.<unk>
T-697	st2 ; functional capacity ; clinical ; outcomes ; ambulatory ; patients ; hf ; heart failure ; outcomes ; exercise ; training ; hf-action ; randomized ; exercise ; training ; hf
H-697	-0.5942620635032654	▁ST 2 ▁levels ▁; ▁functional ▁capacity ▁; ▁clinic al ▁outcome s ▁; ▁ambula tory ▁patients ▁; ▁ HF ▁; ▁Heart ▁Fail ure ▁; ▁control led ▁Tri al ▁Investiga ting ▁out com es ▁of ▁exercise ▁training ▁; ▁ HF - ac tion ▁; ▁exercise ▁training ▁; ▁ HF
D-697	-0.5942620635032654	ST2 levels ; functional capacity ; clinical outcomes ; ambulatory patients ; HF ; Heart Failure ; controlled Trial Investigating outcomes of exercise training ; HF-action ; exercise training ; HF
P-697	-0.3813 -0.2202 -0.2511 -0.2453 -2.1041 -0.0813 -0.3285 -5.5109 -0.0789 -0.1374 -0.0450 -0.2383 -0.0761 -0.0390 -0.8998 -0.1865 -0.1544 -0.1192 -0.1541 -0.6692 -0.1735 -0.0155 -0.2074 -2.5787 -0.0358 -1.1696 -0.0236 -0.5431 -0.0892 -0.7895 -1.3128 -0.1164 -0.7910 -0.2424 -0.1359 -0.2782 -1.0749 -0.1782 -0.2977 -1.3650 -0.9871 -0.8676 -2.1347 -0.0729 -0.5586 -0.1692 -0.3888 -0.3546 -0.2463
S-1879	Preliminary report of using cardiopulmonary exercise testing guide exercise rehabilitation in patients with chronic heart failure OBJECTIVE: The exercise rehabilitation in patient with chronic heart failure (CHF) is standard clinical practice, but it is rare using CardioPulmonary Exercise Testing (CPET) guide to prescribe exercise rehabilitation in China.<unk>
T-1879	report ; cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ; exercise rehabilitation ; patient ; chronic heart failure ; chf ; clinical ; cardiopulmonary exercise testing ; cpet ; exercise rehabilitation ; china
H-1879	-0.7910171747207642	▁report ▁; ▁cardio pul mon ary ▁exercise ▁testing ▁; ▁exercise ▁rehabilita tion ▁; ▁patients ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; ▁Card io P ul mon ary ▁exercise ▁testing ▁; ▁c PET ▁; ▁exercise ▁rehabilita tion ▁; ▁China
D-1879	-0.7910171747207642	report ; cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ;CHf ; CardioPulmonary exercise testing ; cPET ; exercise rehabilitation ; China
P-1879	-0.3977 -0.2076 -0.1994 -0.5655 -1.9960 -0.3293 -1.3284 -0.1283 -0.2415 -1.4569 -0.8345 -0.0946 -0.2850 -2.5318 -0.5843 -0.1461 -1.3524 -0.1303 -0.2247 -0.6740 -0.7977 -0.2654 -1.9938 -0.9016 -3.1374 -0.3402 -1.8402 -0.0270 -1.4316 -1.1403 -0.1809 -0.3009 -0.2685 -0.3594 -1.1422 -0.4983 -0.1206 -1.1358 -1.8779 -0.7039 -0.2597
S-1704	AA participants were significantly younger, less likely to have an ischemic HF pathogenesis, more likely to be NYHA functional class IV, and more likely to have a higher estimated glomerular filtration rate and heart rate, less hypertension, diabetes mellitus, or history of myocardial infarction compared with non-AA participants.<unk>
T-1704	aa ; ischemic hf ; pathogenesis ; nyha functional class iv ; estimated glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
H-1704	-0.49576321244239807	▁ ische mic ▁ HF ▁path ogen es is ▁; ▁NY HA ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁heart ▁rate ▁; ▁hyper tension ▁; ▁diabetes ▁mell itus ▁; ▁my o card ial ▁in far ction
D-1704	-0.49576321244239807	ischemic HF pathogenesis ; NYHA ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
P-1704	-3.4874 -0.3333 -0.0650 -0.4453 -0.2715 -0.2658 -0.2531 -0.0880 -0.7803 -0.1468 -0.4207 -0.5354 -0.1805 -3.7335 -0.3431 -0.0122 -0.2343 -0.1938 -0.0439 -0.1912 -0.7094 -0.0707 -0.1592 -0.2287 -0.0403 -0.1167 -0.0349 -0.0244 -0.0411 -0.1906 -2.0652 -0.2072 -0.7839 -0.0496 -0.0435 -0.1581 -0.3714 -1.7544 -0.2604
S-837	Using data from HF-ACTION, a randomized controlled trial of exercise training in patients with HF and low left ventricular ejection fractions, HRQoL was measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at baseline, 3 and 12 months, and annually up to 4 years.<unk>
T-837	hf-action ; randomized ; exercise ; training ; patients ; hf ; left ventricular ejection fractions ; hrqol ; kansas city cardiomyopathy questionnaire ; kccq ; baseline
H-837	-0.5845323801040649	▁ HF - ac tion ▁; ▁exercise ▁training ▁; ▁ HF ▁; ▁low ▁left ▁vent ri cular ▁e je ction ▁ fraction s ▁; ▁HR Qo L ▁; ▁Kansas ▁City ▁Card i om yo pathy ▁Question naire ▁; ▁k cc q
D-837	-0.5845323801040649	HF-action ; exercise training ; HF ; low left ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire ; kccq
P-837	-0.8040 -0.3105 -0.0754 -0.9850 -0.8101 -0.2468 -0.5554 -0.0976 -0.1806 -0.9095 -0.1230 -0.1336 -1.1276 -1.0962 -3.3863 -1.4202 -0.5905 -0.0948 -0.3932 -0.3468 -0.6495 -0.0073 -0.1804 -0.1484 -0.2263 -0.0403 -1.0931 -0.0767 -0.0260 -0.0787 -1.8146 -0.1344 -0.2535 -1.8375 -0.7933 -0.8875 -0.0357 -0.1722 -0.8738 -0.0859 -1.4757 -0.3414 -0.2154
S-752	To assess the effect of CRT in less severe systolic dysfunction, outcomes in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study were evaluated in which patients with left ventricular (LV) ejection fraction (LVEF) >30% were included.<unk>
T-752	crt ; systolic dysfunction ; outcomes ; resynchronization reverses remodeling in systolic left ventricular dysfunction ; reverse ; patients ; left ventricular ; ejection fraction ; lvef
H-752	-0.6521883606910706	▁c RT ▁; ▁sy sto lic ▁dys function ▁; ▁re syn chron ization ▁re VE rse s ▁re model ing ▁; ▁Sy sto lic ▁left ▁v En tri cular ▁dys function ▁; ▁re VERS e ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction ▁; LV EF
D-752	-0.6521883606910706	cRT ; systolic dysfunction ; resynchronization reVErses remodeling ; Systolic left vEntricular dysfunction ; reVERSe ; left ventricular ;LV ; ejection fraction ;LVEF
P-752	-0.3982 -2.3956 -0.1549 -2.5050 -0.1802 -1.8130 -1.1063 -1.3521 -0.1833 -0.0719 -0.0489 -0.0052 -0.2200 -0.0127 -0.9889 -0.0441 -0.0369 -0.3975 -1.2963 -0.0346 -0.2919 -0.6783 -0.0262 -0.9876 -0.5778 -0.3002 -5.0531 -1.2105 -0.2334 -0.3236 -1.5678 -0.2055 -0.7990 -1.5099 -0.0813 -0.3726 -0.6195 -1.7903 -0.3757 -0.1409 -0.2202 -0.6645 -0.8041 -0.0444 -0.4203 -0.1975 -0.5516 -0.0391 -0.3272 -0.1133 -0.2524 -0.2957 -0.2450
S-1803	The following variables were significantly associated with an estimated glomerular filtration rate of (eGFR) <60 ml/min./1.73 m(2): age, type 2 diabetes, total cholesterol, LDL-cholesterol, and the CLCNKA GG genotype (p=0.03; OR=1.65, 95% CI=1.04-2.62).<unk>
T-1803	estimated glomerular filtration rate ; egfr ; type 2 diabetes ; cholesterol ; ldl-cholesterol ; clcnka ; genotype
H-1803	-0.6193355917930603	▁glo mer ular ▁filtr ation ▁rate ▁; ▁e g FR ▁; ▁type ▁2 ▁diabetes ▁; ▁total ▁cholesterol ▁; ▁l DL - ch olesterol ▁; ▁CL n KA ▁ GG
D-1803	-0.6193355917930603	glomerular filtration rate ; egFR ; type 2 diabetes ; total cholesterol ; lDL-cholesterol ; CLnKA GG
P-1803	-0.9235 -1.0733 -0.0217 -0.5620 -0.2465 -0.0426 -0.3367 -0.3182 -0.8009 -2.8313 -0.2169 -2.2866 -0.2101 -0.0674 -0.0766 -0.3449 -0.0978 -0.1766 -1.3948 -1.6252 -0.1864 -0.6505 -0.0049 -0.1756 -0.8528 -1.3278 -0.6318 -0.3669 -0.2091 -0.9531 -0.1870
S-474	Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P < 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P < 0.05), and a twofold increase in lung weight (P < 0.05) in treated and untreated ACF groups versus the sham group.<unk>
T-474	echocardiography ; lv end-diastolic dimension ; lv end-diastolic pressure ; wall stress ; lung ; acf
H-474	-0.7480757832527161	▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁ dimension ▁; ▁LV ▁; ▁end - dia sto lic ▁pressure ▁; wall ▁stress ▁; ▁lung ▁weight ▁; ▁un tre ated ▁a CF ▁groups ▁; ▁sham ▁group
D-474	-0.7480757832527161	echocardiography ; LV ; end-diastolic dimension ; LV ; end-diastolic pressure ;wall stress ; lung weight ; untreated aCF groups ; sham group
P-474	-0.5421 -0.2331 -0.6841 -0.5007 -0.8568 -0.1352 -1.6784 -1.2115 -0.1412 -0.1071 -1.3264 -0.6752 -1.5858 -2.8415 -0.1402 -0.0988 -2.1199 -0.7331 -0.3763 -0.1180 -1.7359 -0.8694 -1.4601 -0.9796 -0.3907 -0.5902 -0.2352 -0.1401 -1.3161 -0.1712 -0.1220 -3.2744 -0.1873 -0.1083 -1.1722 -0.5120 -0.7730 -0.3062 -0.0613 -0.2621 -0.4272 -0.2194
S-488	E/e'lateral showed good diagnostic performance only in patients with s'lateral of >4.5 cm/s (n = 77, 59%; AUC = 0.82; 95% CI 0.71 to 0.92; s'lateral of ≤4.5 cm/s: AUC = 0.54; 95% CI 0.38 to 0.70; p = 0.005).<unk>
T-488	diagnostic ; patients ; auc ; auc
H-488	-1.7719734907150269	▁e - lateral ▁; ▁s ' lateral ▁; ▁a UC ▁; ▁s ' lateral ▁; ▁a UC
D-488	-1.7719734907150269	e-lateral ; s'lateral ; aUC ; s'lateral ; aUC
P-488	-1.2688 -6.9306 -0.6762 -0.2562 -1.4676 -4.8737 -0.1584 -0.2610 -0.3132 -3.4159 -0.6074 -1.1220 -5.1812 -0.2392 -0.4460 -0.4146 -4.5286 -0.9265 -0.5804
S-443	Among 2,538 eligible patients with a median follow-up of 2.5 years, 521 patients (22%) initiated spironolactone, which was not associated with risk of hospitalization (adjusted hazard ratio 0.91, 95% confidence interval 0.77 to 1.08) or death (adjusted hazard ratio 0.93, confidence interval 0.60 to 1.44).<unk>
T-443	patients ; follow-up ; patients ; spironolactone ; hospitalization ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval
H-443	-0.8368492722511292	▁spi rono lac tone ▁; ▁risk ▁of ▁hospital ization ▁; ▁ad just ed ▁hazard ▁ratio
D-443	-0.8368492722511292	spironolactone ; risk of hospitalization ; adjusted hazard ratio
P-443	-3.2639 -0.0407 -0.0900 -0.1207 -0.3627 -2.1104 -0.5337 -0.2767 -0.2062 -0.4727 -1.7367 -0.0122 -0.0119 -0.7560 -0.0511 -3.7869 -0.3937
S-1239	Rate-control patients had fewer cardiac procedures (146 vs. 238, P < 0.001), driven by fewer cardioversions, and lower costs related to antiarrhythmic drugs (CAD $48 per patient [95% confidence interval {CI}, $21-$96] vs. $1319 per patient [95% CI, $1124-$1522]).<unk>
T-1239	rate-control ; patients ; cardiac ; driven ; cardioversions ; costs ; antiarrhythmic drugs ; cad ; patient ; confidence interval ; patient
H-1239	-0.5924856066703796	▁rate - control ▁patients ▁; ▁cardiac ▁procedure s ▁; ▁cardio version s ▁; ▁costs ▁; ▁anti ar rhythm ic ▁drugs ▁; ▁c p
D-1239	-0.5924856066703796	rate-control patients ; cardiac procedures ; cardioversions ; costs ; antiarrhythmic drugs ; cp
P-1239	-0.1092 -0.3926 -0.0180 -2.1350 -0.4114 -0.8310 -0.4123 -0.0401 -0.1981 -0.8728 -0.0462 -0.1072 -0.1460 -0.3050 -0.1849 -0.0756 -0.2085 -0.1801 -0.0517 -0.0788 -0.4476 -2.5074 -2.1141 -2.7507 -0.1880
S-906	We constructed a descriptive assessment of these patients (n = 15) and performed a case-control analysis matching for age, gender, bundle branch morphology, diabetes mellitus, cardiomyopathy origin, and β-blocker and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use.<unk>
T-906	patients ; bundle branch morphology ; diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin ii receptor blocker
H-906	-0.47429966926574707	▁diabetes ▁mell itus ▁; ▁cardio my o pathy ▁; ▁β - block er ▁; ▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tor ▁; ▁ang io ten sin ▁II ▁receptor ▁block er
D-906	-0.47429966926574707	diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
P-906	-5.4750 -0.0471 -0.5296 -0.2087 -0.0295 -1.0787 -0.3878 -0.1386 -0.5030 -0.5028 -0.0428 -0.2216 -0.3130 -0.1193 -0.0416 -0.8872 -0.8756 -0.0960 -0.2800 -0.0049 -0.0503 -0.0446 -0.0417 -0.0376 -0.1781 -0.0978 -0.2050 -0.0314 -1.5798 -1.2014 -0.1205 -0.4401 -0.0034 -0.1117 -0.2424 -1.1267 -0.2539
S-1737	Another study, the Eplerenone Post myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, demonstrated a significant reduction in mortality and hospitalizations for patients randomized to the aldosterone antagonist eplerenone.<unk>
T-1737	eplerenone post myocardial infarction heart failure efficacy and survival study ; ephesus ; post-myocardial infarction ; patients ; heart failure ; mortality ; hospitalizations ; patients ; randomized ; aldosterone antagonist ; eplerenone
H-1737	-0.5467334985733032	▁e pler en one ▁; ▁post ▁my o card ial ▁in far ction ▁; ▁Heart ▁failure ▁Ef fica cy ▁; ▁su rvi val ▁study ▁; EP he SUS ▁; ▁post - my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁mortal ity ▁; ▁hospital ization s ▁; ▁al do ster one ▁anta gon ist ▁e pler en one
D-1737	-0.5467334985733032	eplerenone ; post myocardial infarction ; Heart failure Efficacy ; survival study ;EPheSUS ; post-myocardial infarction ; heart failure ; mortality ; hospitalizations ; aldosterone antagonist eplerenone
P-1737	-0.7009 -0.0147 -0.6405 -0.0271 -0.8657 -0.2017 -3.0294 -0.8534 -1.3410 -0.0983 -0.0998 -0.3059 -0.1243 -1.1864 -1.9785 -0.0437 -1.8300 -0.0690 -0.0410 -0.8943 -1.1993 -0.0431 -0.0172 -0.2920 -0.3701 -1.7464 -1.6319 -0.5410 -0.1074 -0.0308 -0.0879 -2.1373 -0.5255 -2.2055 -0.0931 -0.0788 -0.4392 -0.2155 -0.8495 -1.0705 -0.0770 -0.4871 -0.3424 -0.0421 -0.2299 -0.2889 -0.2919 -0.1972 -0.1741 -0.5062 -0.2893 -0.3230 -0.0338 -0.2466 -0.1381 -0.4630 -0.1277 -0.1601 -0.4569 -0.1537 -0.5205 -0.3204
S-856	OBJECTIVES: The goal of this study was to evaluate the effects of carvedilol and metoprolol on the endpoint of inappropriate implantable cardioverter-defibrillator therapy in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy) study.<unk>
T-856	carvedilol ; metoprolol ; endpoint ; implantable cardioverter-defibrillator ; therapy ; madit-crt ; multicenter automatic defibrillator implantation with cardiac resynchronization therapy
H-856	-0.5477965474128723	▁car vedi lol ▁; ▁met o pro lol ▁; ▁implant able ▁; ▁cardio ver ter - de fi br illa tor ▁ therapy ▁; ▁MAD - c RT ▁; Mul ti center ▁Automat ic ▁Def ib rilla tor ▁Implant ation ▁; ▁Card iac ▁re syn chron ization ▁Therapy
D-856	-0.5477965474128723	carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-cRT ;Multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
P-856	-1.7287 -0.0684 -0.2104 -0.2774 -0.0982 -0.0713 -0.0679 -0.2396 -0.1755 -1.8047 -0.0209 -1.6106 -0.3435 -0.1385 -0.9022 -0.0835 -0.1734 -1.1674 -2.8499 -1.5745 -0.3052 -0.6128 -0.0452 -0.1304 -0.1041 -2.6968 -2.0260 -1.8906 -0.0855 -1.0626 -0.0232 -0.0371 -0.2178 -0.0063 -0.2872 -0.6531 -0.2020 -0.1117 -0.1450 -0.1853 -0.4178 -0.4410 -0.0566 -0.6524 -0.0285 -0.0058 -0.2697 -0.3271 -0.6099 -0.1468
S-1749	Each period was associated with a 42% risk reduction versus the previous one (HR, 0.58; 95% confidence interval, 0.50-0.67; P<0.001), reflecting marked decreases in heart failure-related mortality and sudden death (period 4 versus 1: HR, 0.10; P<001 and HR, 0.13; P<0.0001, respectively).<unk>
T-1749	confidence interval ; heart ; mortality ; death
H-1749	-0.5841845870018005	▁risk ▁re duction ▁; HR ▁; ▁heart ▁failure - related ▁mortal ity ▁; ▁sud den ▁death
D-1749	-0.5841845870018005	risk reduction ;HR ; heart failure-related mortality ; sudden death
P-1749	-1.4400 -0.4340 -0.0239 -0.4878 -0.8886 -0.3999 -2.2513 -0.9916 -0.6362 -0.0160 -0.4426 -0.0678 -0.3894 -0.0169 -0.0020 -1.0922 -0.7017 -0.2333
S-924	The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 ± 35 to 138 ± 30 and 130 ± 16 to 123 ± 18 mm Hg; both P=0.02), and central end-systolic pressure trended lower (116 ± 18 to 111 ± 16 mm Hg; P=0.12).<unk>
T-924	dash ; clinic ; brachial systolic pressure ; central end-systolic pressure
H-924	-0.8866844773292542	▁DAS h ▁; ▁s rd ▁; ▁bra chi al ▁sy sto lic ▁pressure ▁; ▁central ▁end - sy sto lic ▁pressure
D-924	-0.8866844773292542	DASh ; srd ; brachial systolic pressure ; central end-systolic pressure
P-924	-0.0097 -0.2914 -0.9441 -0.5970 -0.5069 -0.1348 -3.7307 -0.7779 -0.2447 -1.5895 -0.3025 -1.8972 -0.6396 -0.1145 -0.2711 -1.9141 -0.1767 -1.5883 -0.4382 -0.8820 -0.6528 -2.4858 -0.2042
S-558	RESULTS: The youngest patients with HF were more likely to be obese (youngest vs. oldest: body mass index ≥35 kg/m(2): 23% vs. 6%), of black ethnicity (18% vs. 2%), and have idiopathic-dilated cardiomyopathy (62% vs. 9%) (all p < 0.0001).<unk>
T-558	patients ; hf ; obese ; body mass index ; idiopathic-dilated cardiomyopathy
H-558	-0.437429279088974	▁ HF ▁; ▁obes e ▁; ▁body ▁mass ▁index ▁; ▁black ▁et hni city ▁; ▁ idio pathi c - dila ted ▁cardio my o pathy
D-558	-0.437429279088974	HF ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
P-558	-1.5836 -0.1537 -0.3969 -1.4152 -0.2900 -0.1689 -0.6330 -0.2072 -0.1026 -0.1944 -0.7421 -0.0484 -0.1138 -0.2769 -0.1228 -0.1807 -0.0685 -0.2298 -1.4274 -0.2021 -0.0115 -0.0295 -0.5200 -1.8117 -0.5102 -0.2184 -0.4340 -0.1550
S-113	All-cause mortality at 4 years after hospitalization for HF was assessed by LVEF (categorized as preserved [≥50%], mildly [40% to 49%], moderately [30% to 39%], and severely [<30%] reduced) among 1,620 patients enrolled in the Heart Failure Survey in ISrael.<unk>
T-113	all-cause mortality ; hospitalization ; hf ; lvef ; patients ; heart failure survey ; israel
H-113	-0.8729283809661865	▁mortal ity ▁; ▁hospital ization ▁; ▁ HF ▁; ▁LV EF ▁; ▁Heart ▁Fail ure ▁Survey ▁; ▁i ra el
D-113	-0.8729283809661865	mortality ; hospitalization ; HF ; LVEF ; Heart Failure Survey ; irael
P-113	-3.7292 -0.0726 -0.2396 -3.5651 -0.3884 -0.2930 -0.1614 -0.1783 -0.2071 -0.0860 -0.2986 -0.1498 -3.9882 -0.6645 -0.1246 -0.9486 -0.7429 -1.9801 -0.8757 -0.0287 -0.2194 -0.2627
S-1743	METHODS AND RESULTS: From 1977 to 2011, 603 consecutive patients (age, 53±12 years; 73% men; left ventricular ejection fraction, 32±10%) fulfilling World Health Organization criteria for idiopathic dilated cardiomyopathy, including negative coronary angiography, were followed up for 8.8±6.3 years.<unk>
T-1743	patients ; left ventricular ejection fraction ; world health organization ; idiopathic dilated cardiomyopathy ; coronary angiography ; followed up
H-1743	-0.6445444226264954	▁ idio pathi c ▁dil ated ▁cardio my o pathy ▁; ▁negative ▁corona ry ▁ang i ography
D-1743	-0.6445444226264954	idiopathic dilated cardiomyopathy ; negative coronary angiography
P-1743	-2.8696 -2.0160 -0.2088 -0.3279 -0.6561 -0.0819 -0.2684 -1.7145 -0.5221 -0.2186 -0.1571 -0.6001 -0.8682 -0.0530 -0.0189 -0.5332 -0.5953 -0.4126 -0.1240
S-27	The European Society of Cardiology guidelines based definition of HFPEF requires a presence of signs and symptoms of heart failure, preserved LV ejection fraction of a non-dilated left ventricle, and evidence of diastolic dysfunction (impaired LV relaxation or increased LV diastolic stiffness) with elevated LV filling pressures.<unk>
T-27	european society of cardiology ; hfpef ; symptoms ; heart failure ; preserved lv ejection fraction ; non-dilated left ventricle ; evidence ; diastolic dysfunction ; lv relaxation ; lv diastolic stiffness ; elevated ; lv filling pressures
H-27	-0.6561984419822693	▁european ▁society ▁of ▁Card i ology ▁; ▁h f f ▁; ▁heart ▁failure ▁; ▁LV ▁e je ction ▁ fraction ▁; ▁non - dila ted ▁left ▁vent ric le ▁; ▁dia sto lic ▁dys function ▁; impa i red ▁LV ▁relax ation ▁; ▁LV ▁; ▁dia sto lic ▁sti ff ness ▁; ▁eleva ted ▁LV ▁fill ing ▁pressure s
D-27	-0.6561984419822693	european society of Cardiology ; hff ; heart failure ; LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ;impaired LV relaxation ; LV ; diastolic stiffness ; elevated LV filling pressures
P-27	-0.0895 -0.0885 -0.0434 -2.1611 -0.3308 -0.1523 -0.5332 -1.8981 -1.2006 -0.6355 -0.3890 -0.9229 -0.0920 -0.1514 -2.7399 -0.1194 -0.0939 -0.0366 -1.2723 -0.0185 -0.2634 -1.8117 -0.0577 -0.0166 -0.0094 -0.1468 -1.9513 -2.8292 -0.8771 -0.2701 -2.1920 -0.3636 -0.9946 -0.7144 -0.7017 -0.1597 -0.2721 -0.0931 -0.0094 -0.0788 -0.3762 -0.0235 -0.0967 -0.8733 -1.2795 -2.6373 -0.4646 -0.9602 -0.1338 -1.0883 -0.7220 -0.3244 -1.9066 -0.0102 -0.3175 -0.6924 -0.0154 -0.2025 -0.0724 -0.8216 -0.2277
S-1408	Although classic signaling paradigms suggest that simultaneous activation of β1ARs and S1PR1s in a myocyte would simply result in opposing action on cAMP production, in this report we have uncovered a direct interaction between these 2 receptors, with regulatory involvement of G-protein-coupled receptor kinase-2.<unk>
T-1408	β1ars ; s1pr1s ; myocyte ; camp ; report ; receptors ; g-protein-coupled receptor ; kinase-2
H-1408	-0.34915509819984436	▁signal ing ▁paradigm s ▁; ▁β 1 AR s ▁; ▁s 1 PR 1 s ▁; ▁my o cy te ▁; ▁c AMP ▁production ▁; ▁report ▁; ▁receptor s ▁; ▁regulator y ▁; ▁g - prote in - co up led ▁receptor ▁kina se -2
D-1408	-0.34915509819984436	signaling paradigms ; β1ARs ; s1PR1s ; myocyte ; cAMP production ; report ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
P-1408	-1.3656 -0.0915 -0.1414 -0.1621 -0.3211 -0.6705 -0.8960 -0.9627 -0.5609 -0.2790 -0.2976 -0.4846 -0.3465 -1.3865 -0.1352 -0.1491 -0.8645 -0.1205 -0.1209 -0.2472 -0.0892 -0.0717 -0.3914 -0.0527 -0.3312 -0.1638 -0.2693 -1.4588 -0.1844 -0.2157 -0.1562 -0.0389 -0.1904 -0.3889 -0.2117 -0.1046 -0.3443 -0.0870 -0.0245 -0.2622 -0.0285 -0.0078 -0.1086 -0.1605 -0.4598 -0.7952 -0.2097
S-1270	At follow-up, PAF-CPT and PAF levels marginally increased (P = .1), lyso-PAF-AT (P < .001) remained downregulated, while PAF-AH (P = .004) and Lp-PLA2 (P < .001) remained elevated compared with the controls.<unk>
T-1270	follow-up ; paf-cpt ; paf ; lyso-paf-at ; downregulated ; paf-ah ; lp-pla2 ; elevated
H-1270	-0.9832831621170044	▁p f - c pt ▁; ▁PA f ▁levels ▁; ▁lys o - pa f - AT ▁; ▁PA f - AH ▁; ▁l p - PLA 2
D-1270	-0.9832831621170044	pf-cpt ; PAf levels ; lyso-paf-AT ; PAf-AH ; lp-PLA2
P-1270	-4.9336 -0.4288 -0.2626 -1.7740 -0.9657 -0.1091 -2.6802 -1.3131 -2.3518 -0.3312 -0.1491 -0.0578 -0.2062 -1.0484 -1.0451 -1.0220 -0.7919 -0.1853 -4.6903 -1.1562 -0.2158 -0.4888 -0.1446 -1.3729 -0.0023 -0.1276 -0.0106 -0.2262 -1.0956 -0.3118
S-570	METHODS: Between 2008 and 2009, 54 patients (aged 62.4 ± 11.4 years) with heart failure (mean ejection fraction = 26.9% ± 5.0%) were randomly assigned to standard cardiac rehabilitation care (n = 27) or Nordic walking (n = 27); both groups performed 200 to 400 minutes of exercise per week for 12 weeks.<unk>
T-570	patients ; heart failure ; ejection fraction ; cardiac rehabilitation ; walking ; exercise
H-570	-0.46274319291114807	▁heart ▁failure ▁; me an ▁e je ction ▁ fraction ▁; ▁standard ▁cardiac ▁rehabilita tion ▁; ▁Nordic ▁walking
D-570	-0.46274319291114807	heart failure ;mean ejection fraction ; standard cardiac rehabilitation ; Nordic walking
P-570	-2.7861 -0.1092 -0.1741 -0.5707 -0.1823 -0.0381 -0.1878 -0.0660 -0.4942 -0.0080 -0.1795 -0.2349 -0.3427 -0.1489 -0.1294 -0.8458 -0.4962 -1.5629 -0.4928 -0.2053
S-1836	The DRS-stratified hazard ratios were 0.74 (CI, 0.64 to 0.85) for sitagliptin versus pioglitazone, 0.86 (CI, 0.77 to 0.95) for sitagliptin versus sulfonylureas, and 0.71 (CI, 0.64 to 0.78) for sitagliptin versus insulin.<unk>
T-1836	hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
H-1836	-0.8440488576889038	▁d RS - stra t ified ▁hazard ▁ratio s ▁; ▁si tag lip tin ▁; ▁pi og lita zone ▁; ▁si tag lip tin ▁; ▁sul fon yl ure as ▁; ▁insulin
D-1836	-0.8440488576889038	dRS-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; insulin
P-1836	-0.2248 -1.8205 -0.1246 -0.0184 -0.1172 -0.0856 -2.7950 -0.0536 -0.0901 -0.1261 -2.1636 -0.3267 -0.5466 -3.3357 -0.3389 -0.0139 -1.7080 -0.2194 -0.2318 -0.1273 -1.9969 -0.7477 -0.5080 -3.5156 -0.3059 -0.1196 -0.3099 -0.5002 -0.0095 -0.0840 -0.2241 -5.3392 -0.3241 -0.2451
S-1501	Overall, skeletal muscle mass T-score (derived from comparison with young normal reference mean) was -1.47±0.21; 4/16 Fontan subjects had sarcopenic range muscle wasting (T-score <-2.0) and 9/16 had less marked, but clinically significant wasting (T-score <-1.0 but ≥-2.0).<unk>
T-1501	skeletal muscle ; t-score ; fontan ; sarcopenic range muscle wasting ; t-score ; clinically ; t-score
H-1501	-0.8166325092315674	▁skelet al ▁muscle ▁mass ▁; ▁t - s core ▁; ▁figure ▁; ▁sar co pen ic ▁range ▁; ▁muscle ▁was ting ▁; ▁t - s core
D-1501	-0.8166325092315674	skeletal muscle mass ; t-score ; figure ; sarcopenic range ; muscle wasting ; t-score
P-1501	-0.3897 -0.0386 -0.9957 -0.1491 -0.9231 -0.2120 -0.1566 -0.0417 -0.3937 -0.1241 -4.2586 -0.1810 -3.0580 -0.0354 -1.2167 -0.3576 -0.0344 -1.0299 -3.7135 -1.9037 -0.0586 -0.1921 -0.5011 -0.0787 -0.0266 -0.3642 -2.2923 -0.1388
S-1323	The exercise with testosterone group showed improvements from baseline in peak oxygen uptake (P < .01), Beck Depression Inventory (P < .05), leg strength (P < .05), and several Medical Outcomes Study Short-Form quality of life domains (P < .05), which were generally not apparent in the exercise with placebo group.<unk>
T-1323	exercise ; testosterone ; baseline ; peak oxygen uptake ; beck depression inventory ; leg ; medical outcomes study short-form ; quality of life ; exercise ; placebo
H-1323	-0.3655547499656677	▁exercise ▁; ▁testosteron e ▁group ▁; ▁base line ▁; ▁pe ak ▁oxygen ▁up take ▁; ▁Beck ▁de pression ▁in ven tory ▁; ▁leg ▁strength ▁; ▁medical ▁out com es ▁; ▁short - Form ▁quality ▁of ▁life ▁; ▁exercise ▁; ▁place bo ▁group
D-1323	-0.3655547499656677	exercise ; testosterone group ; baseline ; peak oxygen uptake ; Beck depression inventory ; leg strength ; medical outcomes ; short-Form quality of life ; exercise ; placebo group
P-1323	-2.1767 -0.4924 -0.1199 -0.0901 -0.3561 -0.2014 -0.0020 -0.0192 -0.2125 -0.0156 -0.0116 -1.0301 -0.3055 -0.0772 -0.1199 -0.0386 -0.6038 -0.0366 -0.3398 -0.1440 -0.0071 -0.1572 -0.0796 -0.5511 -0.1802 -0.0857 -1.9401 -1.1344 -0.0835 -0.1636 -0.2231 -0.0312 -0.7001 -0.2793 -0.0619 -0.1195 -0.7754 -1.6358 -0.5428 -0.1055 -0.0485 -0.2569 -0.2984 -0.2306
S-181	Both RAS- and β-blocker uptitrations were associated with significant reductions in the composite end-point of all-cause mortality or HF readmissions in HFrEF (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.22 to 0.60 and HR 0.51, 95% CI 0.32 to 0.81, respectively).<unk>
T-181	β-blocker ; uptitrations ; composite end-point ; all-cause mortality ; hf ; readmissions ; hfref ; hazard ratio ; confidence interval
H-181	-0.6770995855331421	▁ RAS - ▁; ▁β - block er ▁up ti tra tions ▁; ▁com posit e ▁end - point ▁; ▁all - ca use ▁mortal ity ▁; ▁ HF ▁; ▁read missions ▁; ▁h Fr ef ▁; haz ard ▁ratio ▁; HR
D-181	-0.6770995855331421	RAS- ; β-blocker uptitrations ; composite end-point ; all-cause mortality ; HF ; readmissions ; hFref ;hazard ratio ;HR
P-181	-1.1124 -0.0269 -0.1754 -1.8938 -0.0945 -0.0500 -0.2307 -0.1615 -0.3453 -0.0653 -0.1676 -0.1365 -0.2563 -6.4566 -0.0073 -0.0507 -0.1619 -0.0783 -0.3199 -1.0046 -1.5571 -0.0550 -0.0048 -0.1642 -0.1780 -0.0609 -0.0804 -0.3211 -0.1148 -1.2621 -2.5208 -0.0646 -0.1302 -0.6914 -1.2953 -1.9239 -0.2744 -0.5058 -0.3750 -0.0091 -0.1751 -2.7830 -2.1911 -0.2588
S-1927	METHODS AND RESULTS: Of patients enrolled in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION), 2279 (97.8%) completed surveys to assess social support and barriers to exercise, resulting in the perceived social support score (PSSS) and barriers to exercise score (BTES).<unk>
T-1927	patients ; heart failure ; outcomes ; exercise ; training ; hf-action ; exercise ; perceived social support score ; psss ; barriers to exercise score ; btes
H-1927	-0.6418452858924866	▁Heart ▁Fail ure ▁; ▁control led ▁Tri al ▁Investiga ting ▁out com es ▁of ▁exercise ▁training ▁; HF - ac tion ▁; ▁social ▁support ▁; ▁barrier s ▁to ▁exercise ▁; ▁p s s ▁; ▁barrier s ▁to ▁exercise ▁score ▁; ▁b tes
D-1927	-0.6418452858924866	Heart Failure ; controlled Trial Investigating outcomes of exercise training ;HF-action ; social support ; barriers to exercise ; pss ; barriers to exercise score ; btes
P-1927	-2.7834 -0.3944 -0.0250 -0.2944 -3.5375 -0.0532 -1.1600 -0.0465 -0.9551 -0.0602 -0.5326 -0.9247 -0.0844 -0.6728 -0.4127 -0.2302 -0.4039 -0.4987 -0.0679 -1.0550 -1.1590 -0.3390 -0.1725 -0.6846 -0.2445 -0.6689 -0.0153 -0.3692 -0.1343 -0.4814 -2.5169 -0.7744 -0.3974 -0.2271 -0.9298 -0.0318 -0.4609 -0.7206 -0.4285 -0.4835 -1.9625 -0.1447 -0.4699 -0.2319
S-703	In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL).<unk>
T-703	univariable analysis ; st2 ; death ; hospitalization ; hazard ratio ; cardiovascular death ; hf ; hospitalization ; hazard ratio ; all-cause mortality ; hazard ratio ; hazard ratios
H-703	-0.7646061182022095	▁ST 2 ▁; ▁hospital ization ▁; haz ard ▁ratio ▁; ▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; haz ard ▁ratio ▁; ▁all - ca use ▁mortal ity ▁; haz ard ▁ratio ▁; ▁log 2
D-703	-0.7646061182022095	ST2 ; hospitalization ;hazard ratio ; cardiovascular death ; HF hospitalization ;hazard ratio ; all-cause mortality ;hazard ratio ; log2
P-703	-2.0158 -0.1959 -0.3311 -3.6293 -0.5106 -0.3098 -1.1160 -0.3810 -0.0403 -0.4000 -0.2076 -2.2422 -0.0769 -0.1724 -0.1017 -2.2276 -0.7954 -0.2302 -1.4264 -0.7474 -0.0398 -0.7263 -0.9021 -0.0767 -0.0056 -0.1991 -0.0690 -0.0975 -0.5936 -1.5871 -0.8612 -0.0589 -1.3027 -2.2028 -0.4481 -1.5769 -0.3857
S-1495	DESIGN AND PATIENTS: Sixteen New York Heart Association Class I/II Fontan adults (30±2 years) underwent cardiopulmonary exercise testing and lean mass quantification with dual x-ray absorptiometry (DXA); eight had calf muscle (31)P magnetic resonance spectroscopy as did eight healthy age-matched and sex-matched controls.<unk>
T-1495	patients ; new york heart association class i ; fontan ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dxa ; calf ; muscle ; magnetic resonance spectroscopy ; healthy
H-1495	-0.5450331568717957	▁New ▁York ▁Heart ▁association ▁; ▁cardio pul mon ary ▁exercise ▁testing ▁; ▁lean ▁mass ▁; ▁dual ▁x - ray ▁ab sor pti ometr y ▁; ▁d XA ▁; ▁cal f ▁muscle ▁; ▁magnetic ▁res on ance ▁spec tros copy
D-1495	-0.5450331568717957	New York Heart association ; cardiopulmonary exercise testing ; lean mass ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
P-1495	-2.1644 -0.6942 -3.4788 -0.4447 -0.4933 -0.2219 -0.6119 -1.4682 -0.1705 -1.0457 -0.5473 -0.1267 -0.0441 -0.0596 -0.6312 -1.4629 -0.0087 -0.0973 -0.2682 -0.0515 -1.2427 -0.6586 -0.1122 -0.1684 -0.3560 -0.2705 -0.6130 -0.1248 -0.0616 -0.0125 -0.2764 -0.1249 -0.3163 -0.0941 -0.2058 -0.0621 -0.4643 -0.0593 -1.5579 -1.3200 -0.1537
S-73	OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.<unk>
T-73	placebo ; dopamine ; nesiritide ; bolus ; diuretic ; therapy ; renal function ; patients ; acute heart failure ; renal dysfunction
H-73	-0.4525168836116791	▁low - dos e ▁dop amine ▁; ▁low - dos e ▁nesi riti de ▁; ▁di ure tic ▁ therapy ▁; ▁renal ▁function ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function
D-73	-0.4525168836116791	low-dose dopamine ; low-dose nesiritide ; diuretic therapy ; renal function ; acute heart failure ; renal dysfunction
P-73	-3.2951 -0.0413 -0.7709 -0.2002 -0.0648 -0.4980 -0.1689 -0.1795 -0.0350 -0.4782 -0.0598 -0.1019 -0.0334 -0.7025 -0.1298 -1.1260 -0.1778 -0.2310 -1.0002 -0.1796 -0.2242 -0.1401 -0.6736 -0.2265 -0.0422 -0.0357 -0.3813 -0.0797 -0.2648 -0.0184 -0.6186 -2.4062 -0.5699 -0.2305
S-847	METHODS: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony.<unk>
T-847	randomized ; crt ; patients ; new york heart association class iii ; heart failure ; left ventricular ejection fraction ; qrs duration ; echocardiographic ; evidence ; left ventricular dyssynchrony
H-847	-1.0197043418884277	▁c RT ▁; ▁New ▁York ▁Heart ▁association ▁; ▁heart ▁failure ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁QR s ▁du ration ▁; ▁e cho car dio graphic ▁evidence ▁; ▁left ▁vent ri cular ▁dys syn chron y
D-847	-1.0197043418884277	cRT ; New York Heart association ; heart failure ; left ventricular ejection fraction ; QRs duration ; echocardiographic evidence ; left ventricular dyssynchrony
P-847	-1.1575 -3.6035 -0.1952 -1.9253 -1.4097 -1.4315 -0.5066 -0.3257 -4.5625 -1.6845 -0.1860 -0.1344 -4.3360 -1.6988 -0.7281 -0.1739 -0.2717 -0.1767 -2.0092 -0.0773 -0.2077 -0.0517 -0.9257 -0.3436 -0.0720 -0.2280 -0.1767 -0.6400 -1.6397 -1.8637 -0.8334 -0.4322 -0.3112 -0.1381 -3.8886 -2.5739 -0.7286 -0.7344 -0.1109 -0.0058 -0.5170 -0.6302 -0.2001
S-482	Therefore, 130 consecutive patients with a left ventricular (LV) ejection fraction of <35% and stable HF underwent right-sided cardiac catheterization and transthoracic echocardiography with measurement of transmitral flow velocities (E, A) and mitral annulus velocities during systole (s') and diastole (e').<unk>
T-482	patients ; left ventricular ; ejection fraction ; stable hf ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus velocities ; systole ; diastole
H-482	-0.369398832321167	▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction ▁; ▁ HF ▁; ▁right - side d ▁cardiac ▁cat heter ization ▁; ▁trans t hora cic ▁e cho card i ography ▁; ▁transmit ral ▁flow ▁veloci ties ▁; ▁mit ral ▁ann ulus ▁veloci ties ▁; ▁sy stol e ▁; ▁dia stol e
D-482	-0.369398832321167	left ventricular ;LV ; ejection fraction ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
P-482	-0.1553 -3.5196 -0.6288 -0.3079 -0.4245 -0.7863 -0.5511 -0.2238 -0.0743 -0.0647 -1.1687 -0.0348 -0.3406 -0.7722 -0.3391 -0.1678 -0.0837 -0.1058 -0.1391 -0.3599 -0.1376 -0.7123 -0.0211 -0.4104 -0.1077 -0.0035 -0.4711 -0.1245 -0.1890 -0.1775 -1.0400 -0.6243 -0.2863 -0.6883 -0.1354 -0.0628 -0.9880 -0.0354 -0.0509 -0.0434 -0.2029 -0.1063 -0.1257 -0.0442 -0.0371 -0.1054 -0.0354 -0.2292 -0.5593 -0.0400 -1.0107 -0.2761 -0.2489 -0.0472 -0.4547 -0.7745 -0.2007
S-1367	For patients with acute coronary syndromes, data have been derived from a great number of studies, whereas in patients with stable CAD, only a limited amount of recent data is available; although limited, these data show that elevations in BNP and NT-proBNP levels are associated with the extent of CAD, thus providing prognostic information for an unfavourable clinical outcome.<unk>
T-1367	patients ; acute coronary syndromes ; patients ; stable ; cad ; bnp ; nt-probnp ; cad ; prognostic ; clinical ; outcome
H-1367	-0.5061137676239014	▁a cute ▁corona ry ▁syndrome s ▁; ▁CAD ▁; ▁b NP ▁; ▁NT - pro b NP ▁levels ▁; ▁CAD
D-1367	-0.5061137676239014	acute coronary syndromes ; CAD ; bNP ; NT-probNP levels ; CAD
P-1367	-0.1321 -0.0378 -0.5668 -0.1104 -0.0749 -0.0664 -0.3509 -2.9471 -0.4455 -1.7549 -0.6271 -0.1530 -0.0758 -0.0981 -0.0217 -0.7255 -0.3210 -0.2944 -0.2936 -1.1093 -0.6915 -0.2367
S-1269	At baseline, patients with HF had lower median activities of lyso-PAF-AT (P < .001) and PAF-CPT (P = .07) in parallel with PAF levels (P = .05) and higher activities of PAF-AH (P = .02) and Lp-PLA2 (P < .001) than controls.<unk>
T-1269	baseline ; patients ; hf ; lyso-paf-at ; paf-cpt ; paf ; paf-ah ; lp-pla2
H-1269	-0.7669625282287598	▁base line ▁; ▁ HF ▁; ▁lys o - pa f - AT ▁; ▁PA f - c pt ▁; ▁PA f ▁levels ▁; ▁PA f - AH ▁; ▁l p - PLA 2
D-1269	-0.7669625282287598	baseline ; HF ; lyso-paf-AT ; PAf-cpt ; PAf levels ; PAf-AH ; lp-PLA2
P-1269	-0.5290 -0.0083 -0.2591 -0.5132 -0.1385 -0.1878 -1.9654 -0.0653 -0.2392 -1.2918 -0.8143 -0.6442 -0.3507 -0.1099 -2.5670 -0.9574 -0.2657 -3.0979 -0.5522 -0.1108 -2.4415 -1.1767 -1.3034 -0.1249 -3.2570 -0.9722 -0.1534 -0.2392 -0.1512 -1.4789 -0.0023 -0.1111 -0.0079 -0.1537 -1.0810 -0.2888
S-549	After medical therapy had failed, 4 patients underwent redo sternotomy for aortic valve procedures (1 bioprosthetic valve replacement, 1 Dacron patch closure, and 2 aortic valve repairs), and 2 patients underwent transcatheter aortic valve procedure, with 1 requiring revision by open surgery for aortic valve replacement.<unk>
T-549	medical therapy ; patients ; redo sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve ; patients ; transcatheter aortic valve procedure ; surgery ; aortic valve
H-549	-0.5252867341041565	▁medical ▁ therapy ▁; ▁redo ▁ster no to my ▁; ▁a or tic ▁val ve ▁procedure s ▁; ▁bio pro sthetic ▁val ve ▁replace ment ▁; ▁da cro n ▁patch ▁ closure ▁; ▁a or tic ▁val ve ▁repair s ▁; ▁trans cat heter ▁a or tic ▁val ve ▁procedure ▁; ▁open ▁surgery ▁; ▁a or tic ▁val ve ▁replace ment
D-549	-0.5252867341041565	medical therapy ; redo sternotomy ; aortic valve procedures ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve procedure ; open surgery ; aortic valve replacement
P-549	-0.1018 -1.0739 -0.0426 -0.2205 -2.0289 -0.9790 -0.0062 -0.1370 -2.6144 -0.2311 -0.0113 -0.1665 -0.2630 -3.4588 -0.1094 -0.4800 -0.1991 -0.2133 -0.1567 -0.1332 -0.0427 -3.6838 -0.1402 -0.6015 -0.0622 -0.2323 -0.3286 -0.0536 -0.0098 -0.0336 -0.0827 -0.0032 -0.1975 -0.0167 -0.2001 -0.0706 -2.6497 -0.1461 -0.1726 -0.1454 -0.4194 -0.0084 -0.0721 -0.0054 -0.1769 -0.2342 -0.1324 -3.2451 -0.1355 -0.4989 -0.5001 -0.4048 -0.6573 -0.2494 -0.0383 -0.2405 -0.1079 -3.2521 -0.1918 -0.1818 -0.0459 -0.6076 -0.1877
S-263	OBJECTIVE: The main objective of this study was to determine a predictive cutoff value for plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the long-term (4-year) survival of patients with acute heart failure (HF) at the time of admission to the emergency department (ED).<unk>
T-263	plasma n-terminal pro-b-type natriuretic peptide ; nt-probnp ; patients ; acute heart failure ; hf ; admission ; emergency department
H-263	-0.3680137097835541	▁cut off ▁value ▁; ▁plasma ▁N - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁a cute ▁heart ▁failure ▁; HF ▁; ▁ad mission ▁; ▁emergency ▁department ▁; ED
D-263	-0.3680137097835541	cutoff value ; plasma N-terminal pro-b-type natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; admission ; emergency department ;ED
P-263	-1.3325 -0.2427 -0.3551 -0.2008 -0.8215 -2.7285 -0.0821 -0.0221 -0.0079 -0.0336 -0.0493 -1.4810 -0.1262 -0.3755 -0.0075 -0.3074 -0.1186 -0.2280 -0.0477 -0.3293 -0.8352 -0.1990 -0.2875 -0.0149 -0.0431 -0.4728 -0.1909 -0.2788 -0.4803 -0.4139 -0.7448 -0.0407 -0.1649 -0.4169 -0.3677 -0.7694 -0.0180 -0.3770 -0.1247 -0.0070 -0.4230 -0.1718 -0.2652 -0.1879
S-286	We evaluated whether cardiac troponin T (cTnT) measured with a high-sensitivity assay and N-terminal pro-B-type natriuretic peptide (NT-proBNP), biomarkers strongly associated with incident HF, improve HF risk prediction in the Atherosclerosis Risk in Communities (ARIC) study.<unk>
T-286	cardiac troponin t ; ctnt ; n-terminal pro-b-type natriuretic peptide ; nt-probnp ; biomarkers ; hf ; hf ; atherosclerosis risk in communities ; aric
H-286	-0.41714760661125183	▁cardiac ▁trop onin ▁t ▁; ▁c t n t ▁; ▁high - sensitiv ity ▁as say ▁; ▁N - termin al ▁pro - b - type ▁na tri ure tic ▁pe pti de ▁; NT - pro b NP ▁; ▁incident ▁ HF ▁; ▁ HF ▁risk ▁predict ion ▁; ▁Ath eros cle rosi s ▁risk ▁in ▁communities ▁; ARI c
D-286	-0.41714760661125183	cardiac troponin t ; ctnt ; high-sensitivity assay ; N-terminal pro-b-type natriuretic peptide ;NT-probNP ; incident HF ; HF risk prediction ; Atherosclerosis risk in communities ;ARIc
P-286	-0.0515 -0.1300 -0.2686 -0.8103 -0.4193 -0.4983 -0.1364 -0.0044 -0.6743 -0.3116 -1.6479 -0.0295 -0.0039 -0.0100 -0.2833 -0.0664 -0.0820 -1.4059 -0.0713 -0.0346 -0.0036 -0.0208 -0.0586 -1.6600 -0.1747 -0.3901 -0.0037 -0.3916 -0.0583 -0.2716 -0.0239 -0.7227 -1.2813 -0.2586 -0.5435 -0.0189 -0.0429 -0.4849 -0.1370 -0.0980 -0.1990 -0.2839 -0.2207 -0.1067 -0.3127 -0.1527 -1.5968 -0.1171 -0.0338 -0.1202 -0.0975 -0.1547 -2.5125 -1.1607 -0.0558 -0.9482 -1.3321 -0.1090 -0.3767 -0.7341 -1.3159 -0.5164 -0.2387
S-1167	Increased body mass index was associated with a lower event rate (HR per kg/m(2): 0.92 [95% CI: 0.88 to 0.96]), and this protection was mediated by a higher fat mass (0.91 [95% CI: 0.87 to 0.96]) but not a fat-free mass index (0.97 [95% CI: 0.92 to 1.03]).<unk>
T-1167	body mass index ; fat mass ; fat-free mass
H-1167	-0.767193615436554	▁body ▁mass ▁index ▁; ▁event ▁rate ▁; HR ▁; ▁fat ▁mass ▁; ▁fat - free ▁mass ▁index
D-1167	-0.767193615436554	body mass index ; event rate ;HR ; fat mass ; fat-free mass index
P-1167	-0.7074 -0.6133 -0.2049 -0.2651 -1.4634 -0.2125 -0.2237 -2.5463 -0.7026 -3.2051 -1.1591 -0.5622 -1.0314 -0.5977 -0.0900 -0.1741 -0.1718 -0.4047 -0.2415
S-797	PARTICIPANTS: Subjects (N=235, 64% men; median age, 70y [interquartile range, 61-77y]; median body mass index, 25.6kg/m(2) [interquartile range, 22.8-29.4kg/m(2)]) with advanced COPD (n=95), CHF (n=68), or CRF (n=72).<unk>
T-797	interquartile range ; body mass index ; interquartile range ; copd ; chf ; crf
H-797	-1.4292809963226318	▁co d ▁; ▁CHF ▁; ▁c RF
D-797	-1.4292809963226318	cod ; CHF ; cRF
P-797	-5.3481 -2.2013 -0.5864 -1.2727 -0.5999 -0.1662 -1.9329 -0.4321 -0.3241
S-911	In the case-control analysis, controls demonstrated superior reverse remodeling (+9.2 ± 9.5% increase in ejection fraction), decreased mortality (73% vs 44%, p = 0.038), and all-cause hospitalizations (76% vs 100%, p = 0.047), with no difference in HF hospitalizations (p = 0.39), compared with dialysis patients.<unk>
T-911	reverse remodeling ; ejection fraction ; mortality ; all-cause hospitalizations ; hf ; hospitalizations ; dialysis ; patients
H-911	-0.44179680943489075	▁rever se ▁remodel ing ▁; ▁e je ction ▁ fraction ▁; ▁mortal ity ▁; ▁ HF ▁; ▁di al ysis
D-911	-0.44179680943489075	reverse remodeling ; ejection fraction ; mortality ; HF ; dialysis
P-911	-0.0198 -0.1558 -0.1430 -0.0607 -0.1819 -0.0173 -0.1811 -0.1276 -0.4190 -0.0153 -0.2159 -0.2844 -0.0758 -0.2552 -2.6440 -0.4652 -0.9466 -0.9143 -0.0751 -0.4269 -1.9240 -0.1708
S-1530	After adjustment for covariates, EH was associated with reduced LV contractility compared with CH: lower LVEF (β coefficient = -3.2; 95% confidence interval [CI] -5.4 to -1.1%) and ratio of systolic blood pressure to end-systolic volume (β coefficient = -1.0; 95% CI -1.5 to -0.5 mm Hg/ml).<unk>
T-1530	covariates ; lv contractility ; lvef ; β coefficient ; confidence interval ; systolic blood pressure ; end-systolic volume ; β coefficient
H-1530	-1.3065598011016846	▁EH ▁; ▁LV ▁contract ility ▁; ▁LV EF ▁; ▁LV EF ▁; ▁ratio ▁of ▁sy sto lic ▁blood ▁pressure ▁; ▁end - sy sto lic ▁volume ▁; β ▁co e ffi cient
D-1530	-1.3065598011016846	EH ; LV contractility ; LVEF ; LVEF ; ratio of systolic blood pressure ; end-systolic volume ;β coefficient
P-1530	-1.1578 -0.1806 -3.0679 -0.4999 -0.1456 -0.1683 -4.6452 -1.3068 -0.1962 -5.3850 -1.4713 -0.1961 -5.0577 -0.2220 -1.7757 -0.3889 -1.1429 -2.8875 -0.3637 -0.1508 -0.8172 -0.1055 -1.1229 -1.4274 -1.4717 -0.5821 -0.9170 -4.4399 -0.1134 -0.1564 -0.0586 -0.1017 -2.5046 -0.1947
S-348	Echocardiography demonstrated moderately dilated LV with an end-diastolic volume index of 84 mL/m2, reduced LV ejection fraction of 0.40, mild MR, and limited mitral valve opening, resulting in a significant MS with an MVA of 1.2 cm2 and a mean pressure gradient of 8.4 mm Hg (Fig 1B).<unk>
T-348	echocardiography ; dilated lv ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mva
H-348	-0.6163661479949951	▁e cho card i ography ▁; ▁dil ated ▁LV ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁LV ▁e je ction ▁ fraction ▁; ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁MS ▁; ▁m VA ▁; ▁pressure ▁gradi ent
D-348	-0.6163661479949951	echocardiography ; dilated LV ; end-diastolic volume index ; LV ejection fraction ; MR ; mitral valve opening ; MS ; mVA ; pressure gradient
P-348	-0.8052 -0.2108 -0.7580 -0.3236 -0.4780 -0.0836 -5.1680 -0.0400 -0.5935 -0.1307 -0.1310 -0.0590 -1.1782 -0.5188 -0.4480 -0.1164 -0.3374 -0.2069 -3.2711 -0.3650 -0.1464 -0.0991 -0.8549 -0.0304 -0.1515 -0.8450 -0.1837 -0.2236 -0.0409 -0.6726 -0.1325 -0.1750 -0.2347 -1.1334 -0.1373 -0.4650 -1.3549 -0.1699 -1.3609 -0.0217 -0.0591 -2.6040 -0.1842
S-74	DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m2), randomized within 24 hours of admission.<unk>
T-74	double-blind ; clinical ; renal optimization strategies evaluation ; rose ; hospitalized ; patients ; acute heart failure ; renal dysfunction ; estimated glomerular filtration rate ; randomized ; admission
H-74	-0.4138658046722412	▁double - blind ▁; ▁place bo - control led ▁clinic al ▁trial ▁; ▁re nal ▁Optim ization ▁Strategie s ▁Evalua tion ▁; ROS e ▁; ▁a cute ▁heart ▁failure ▁; ▁renal ▁dys function ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁ad mission
D-74	-0.4138658046722412	double-blind ; placebo-controlled clinical trial ; renal Optimization Strategies Evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration rate ; admission
P-74	-3.1827 -0.0371 -0.0779 -0.9102 -0.4607 -0.1687 -0.0768 -0.0321 -0.1377 -0.3022 -0.0798 -0.1621 -0.1915 -0.1765 -0.1192 -0.9452 -0.1376 -1.2429 -0.0195 -1.0583 -0.1266 -0.4672 -0.1205 -0.1358 -0.2530 -0.1099 -0.0314 -0.6869 -0.0509 -0.1933 -0.0077 -0.1639 -1.3247 -0.4770 -0.2999 -0.8490 -0.0112 -0.3266 -0.2240 -0.0325 -1.0140 -1.6272 -0.1999 -0.1796 -0.1927
S-1051	Further molecular analysis revealed that BETs play a crucial role in chromatin-mediated signal transduction to Pol II, co-activating transcription factor networks that are known to be causal in HF pathogenesis, including nuclear factor of activated T cells (NFAT), nuclear factor-κB (NF-κB) and the transcription factor GATA4.<unk>
T-1051	bets ; signal transduction ; pol ii ; transcription factor ; hf ; pathogenesis ; nuclear factor of activated t cells ; nfat ; nuclear factor-κb ; nf-κb ; transcription factor ; gata4
H-1051	-0.4607889950275421	▁bet s ▁; ▁chr omat in - media ted ▁signal ▁trans duction ▁; ▁pol ▁II ▁; ▁co - activa ting ▁tran scription ▁factor ▁network s ▁; ▁ HF ▁path ogen es is ▁; ▁nuclear ▁factor ▁; ▁activa ted ▁T ▁cell s ▁; ▁na FAT ▁; ▁nuclear ▁factor - κ b ▁; NF - κ b ▁; ▁tran scription ▁factor ▁g ATA 4
D-1051	-0.4607889950275421	bets ; chromatin-mediated signal transduction ; pol II ; co-activating transcription factor networks ; HF pathogenesis ; nuclear factor ; activated T cells ; naFAT ; nuclear factor-κb ;NF-κb ; transcription factor gATA4
P-1051	-1.6685 -0.1316 -0.2983 -0.2227 -0.0271 -1.2898 -0.2021 -0.0927 -0.1386 -0.1593 -0.0501 -0.1255 -0.5384 -0.6489 -0.3016 -0.3752 -1.3240 -0.0657 -0.0228 -0.3050 -0.7109 -0.6442 -0.0726 -0.0514 -0.1574 -0.2961 -0.2683 -0.7412 -0.1803 -0.2636 -0.1374 -0.7686 -0.2949 -0.0057 -0.0258 -1.5060 -0.1427 -0.0184 -1.5248 -0.4884 -0.0384 -0.3616 -0.7997 -1.4425 -0.1073 -0.0513 -0.0685 -0.4293 -1.1418 -0.4479 -0.1216 -0.7338 -0.2070 -1.0017 -0.3307 -0.2076 -0.8553 -0.8079 -0.0375 -2.8492 -0.1617 -0.0276 -0.7229 -0.2510
S-33	Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events.<unk>
T-33	outcomes ; mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
H-33	-0.3869565427303314	▁mortal ity ▁; ▁hospital ization ▁; ▁exercise ▁ tolerance ▁; ▁quality ▁of ▁life ▁; ▁cardiovascular ▁events ▁; ▁my o card ial ▁in far ction ▁; ▁con ges tive ▁heart ▁failure ▁ex ace rb ation ▁; ▁ar rhythm ia ▁; ▁cardiac ▁death ▁; ▁hyper tension ▁; ▁ve nous ▁ thro mbol ic ▁events ▁; ▁ ische mic ▁cerebro vas cular ▁events
D-33	-0.3869565427303314	mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death ; hypertension ; venous thrombolic events ; ischemic cerebrovascular events
P-33	-3.8343 -0.0419 -0.1176 -0.5730 -0.2941 -0.1210 -0.0299 -0.1265 -0.0032 -0.1270 -0.8970 -0.0454 -0.1297 -0.2069 -0.0983 -0.3412 -0.1758 -0.6360 -0.2673 -0.7559 -0.0548 -0.0670 -0.5425 -0.2923 -0.2299 -0.0088 -0.1647 -0.0637 -0.8436 -0.0522 -0.2873 -0.0531 -0.0252 -0.0930 -0.6381 -0.0201 -0.3489 -0.3219 -0.2790 -0.0540 -1.2015 -0.8472 -0.6072 -0.1779 -0.1326 -0.1097 -0.4934 -0.2158 -0.3421 -2.0619 -0.4473 -0.4656 -0.4060 -0.2935 -0.2075 -0.0812 -0.4717 -0.0991 -0.3814 -0.8819 -0.5635 -0.2418
S-562	Compared with the referent age group of 60 to 69 years, both all-cause and cardiovascular mortality were lower in the youngest group even after multivariable adjustment (hazard ratio: 0.60, 95% confidence interval: 0.36 to 1.00; p = 0.049, and hazard ratio: 0.71, 95% confidence interval: 0.42 to 1.18, p = 0.186, respectively).<unk>
T-562	cardiovascular mortality ; multivariable adjustment ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
H-562	-0.889087438583374	▁all - ca use ▁; ▁cardiovascular ▁mortal ity ▁; ▁hazard ▁ratio
D-562	-0.889087438583374	all-cause ; cardiovascular mortality ; hazard ratio
P-562	-3.8604 -0.1225 -0.0158 -0.3002 -0.4134 -0.0493 -0.2896 -0.1386 -0.8085 -4.0445 -0.0844 -1.1683 -0.2626
S-128	We found an interaction effect (P = 0.02) between EO-CFUs and diabetes: in patients without diabetes, a 10-EO-CFU increase was independently associated with increased peak VO2 of 0.28 mL/kg/min (P = 0.01), and in patients with diabetes, a decrease in EO-CFUs was associated with an increased peak VO2 (P < 0.05).<unk>
T-128	eo-cfus ; diabetes ; patients ; diabetes ; peak vo2 ; patients ; diabetes ; eo-cfus ; peak vo2
H-128	-0.9717586040496826	▁interaction ▁effect ▁; ▁ EO - c fu s ▁; ▁diabetes ▁; ▁10- EO - C FU ▁; ▁pe ak ▁VO 2 ▁; ▁diabetes ▁; ▁ EO - C FU s ▁; ▁pe ak ▁VO 2
D-128	-0.9717586040496826	interaction effect ; EO-cfus ; diabetes ; 10-EO-CFU ; peak VO2 ; diabetes ; EO-CFUs ; peak VO2
P-128	-4.6228 -0.1835 -0.2505 -1.0619 -0.2671 -0.1863 -2.5733 -2.6250 -0.7927 -0.2690 -0.0588 -0.1486 -4.5387 -0.4811 -0.3362 -2.9805 -1.5563 -0.2978 -0.1919 -0.0258 -0.6520 -0.2490 -0.3748 -1.6794 -0.3232 -1.8089 -0.3487 -0.2377 -3.3480 -1.7414 -0.7654 -0.2635 -0.0424 -0.0425 -0.6094 -0.3037 -0.4315 -0.2573
S-1212	METHODS: Immunoblotting, radioenzymatic- and fluorescence resonance energy transfer-based assays, video edge detection, epifluorescence microscopy, and L-type Ca2(+) current measurements were performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively.<unk>
T-1212	immunoblotting ; video edge detection ; epifluorescence microscopy ; myocardial tissues ; cardiomyocytes ; hf
H-1212	-0.4162259101867676	▁immun o blo tting ▁; ▁radio en zy matic - ▁and ▁fluor esc ence ▁res on ance ▁energy ▁transfer - based ▁as say s ▁; ▁video ▁edge ▁det ection ▁; ▁epi flu o resc ence ▁micro s copy ▁; ▁l - type ▁ca 2 ▁; ▁my o card ial ▁tissu es ▁; ▁isola ted ▁cardio my o cy tes ▁; ▁ HF
D-1212	-0.4162259101867676	immunoblotting ; radioenzymatic- and fluorescence resonance energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; l-type ca2 ; myocardial tissues ; isolated cardiomyocytes ; HF
P-1212	-0.3439 -0.0645 -0.0200 -0.1976 -0.1389 -0.5127 -1.5985 -0.5701 -0.4730 -0.2778 -2.7094 -0.0195 -0.1042 -0.0423 -0.2305 -0.0630 -0.1780 -0.2475 -0.1519 -0.8095 -0.2012 -1.1613 -0.1180 -0.1603 -0.1905 -1.4071 -0.0127 -0.6664 -0.0433 -0.1418 -0.1120 -0.5252 -0.6798 -0.2920 -0.0648 -1.0293 -0.0594 -0.7949 -0.2193 -1.1208 -0.0543 -0.1198 -0.2176 -0.0597 -0.2435 -2.1433 -0.1284 -0.7031 -0.1202 -0.3030 -0.2094 -0.0928 -1.1307 -0.0077 -0.0566 -0.8558 -0.5559 -0.2255 -0.0959 -0.1672 -0.6826 -0.2787 -0.2990 -0.1349
S-1649	DESIGN: The EAST (Early treatment of Atrial fibrillation for Stroke prevention Trial) will randomize approximately 3,000 patients with recent onset AF at risk for stroke (CHA2DS2VASc score ≥2) to either guideline-mandated usual care or to usual care plus early rhythm control therapy in a prospective, randomized, open, blinded outcome assessment trial.<unk>
T-1649	east ; early treatment of atrial fibrillation for stroke prevention trial ; randomize ; patients ; stroke ; rhythm control therapy ; prospective ; randomized ; outcome
H-1649	-0.8034889101982117	▁e ast ▁; ▁at rial ▁fi bril lation ▁; ▁Stro ke ▁pre vention ▁Tri al
D-1649	-0.8034889101982117	east ; atrial fibrillation ; Stroke prevention Trial
P-1649	-1.5598 -0.0568 -0.2544 -2.6520 -0.1295 -0.4684 -0.0245 -0.4374 -0.6320 -0.2775 -0.0431 -0.0852 -0.0055 -0.9376 -0.0277 -5.8825 -0.1855
S-1980	MAIN OUTCOMES AND MEASURES: Exercise capacity measured as peak oxygen consumption (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure (MLHF) Questionnaire (score range: 0-105, higher scores indicate worse heart failure-related QOL; co-primary outcome).<unk>
T-1980	outcomes ; exercise capacity ; peak oxygen consumption ; vo2 ; co-primary outcome ; qol ; minnesota ; heart failure ; heart ; qol ; co-primary outcome
H-1980	-0.7011305689811707	▁exercise ▁capacity ▁; ▁pe ak ▁oxygen ▁consum p tion ▁; VO 2 ▁; ▁co - prima ry ▁outcome ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁; ML HF
D-1980	-0.7011305689811707	exercise capacity ; peak oxygen consumption ;VO2 ; co-primary outcome ; Minnesota Living with Heart Failure ;MLHF
P-1980	-1.5962 -0.1549 -0.1839 -0.0191 -0.0169 -1.9678 -0.2934 -0.0398 -0.3654 -0.1875 -0.1779 -0.1762 -0.2506 -4.0604 -0.2225 -0.0751 -0.0444 -0.3671 -0.2842 -4.7690 -0.3808 -0.6308 -0.3139 -0.2415 -0.0853 -0.2067 -0.4346 -0.6742 -2.5918 -0.2223
S-878	The global attenuation of TAC-induced proteomic alterations by the mitochondrial-targeted peptide SS31 suggests that perturbed mitochondrial function may be an upstream signal to many of the pathway alterations in TAC and supports the potential clinical application of mitochondrial-targeted peptide drugs for the treatment heart failure.<unk>
T-878	proteomic ; mitochondrial-targeted peptide ; ss31 ; mitochondrial function ; tac ; clinical ; mitochondrial-targeted peptide ; drugs ; heart failure
H-878	-0.6221074461936951	▁ TAC - indu ced ▁prote om ic ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁SS 31 ▁; ▁per tur bed ▁mito cho ndri al ▁function ▁; ▁up stream ▁signal ▁; ▁path way ▁altera tions ▁; ▁ TAC ▁; ▁mito cho ndri al - tar get ed ▁pe pti de ▁drugs ▁; ▁heart ▁failure
D-878	-0.6221074461936951	TAC-induced proteomic ; mitochondrial-targeted peptide SS31 ; perturbed mitochondrial function ; upstream signal ; pathway alterations ; TAC ; mitochondrial-targeted peptide drugs ; heart failure
P-878	-0.7089 -0.0440 -0.3469 -0.1559 -2.0093 -1.0243 -1.4583 -0.3832 -0.8424 -1.2894 -3.0643 -1.1882 -0.1389 -0.1265 -0.1009 -0.5317 -0.0206 -0.0868 -0.3646 -1.2241 -0.8626 -0.2074 -0.1951 -0.3128 -0.0684 -0.1356 -0.9653 -3.1355 -1.3160 -0.0860 -0.6369 -0.2779 -0.3293 -0.0036 -0.0707 -0.2000 -0.0907 -0.0827 -1.6932 -0.0936 -0.2804 -0.1044 -0.0600 -0.1409 -2.7426 -2.3525 -1.7837 -0.1351 -0.0759 -0.0791 -0.3246 -0.0098 -0.1400 -0.3211 -0.8197 -0.3105 -0.2122 -1.6263 -0.0880 -0.2677 -0.2012
S-55	Both patients with low left ventricular ejection fraction and patients with HF with preserved left ventricular ejection fraction are admitted to the hospital frequently and serially and keep physicians busy, in the acute and outpatient settings, for their management, also prompting them to search for better ways to deal with this worldwide epidemic and its impact on medical resources and financial costs.<unk>
T-55	patients ; left ventricular ejection fraction ; patients ; hf ; preserved left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient ; epidemic ; medical ; financial costs
H-55	-0.8630232214927673	▁low ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ HF ▁; ▁pres er ved ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁hospital ▁; ▁physician s ▁; ▁a cute ▁; ▁out patient ▁; ▁financial ▁costs
D-55	-0.8630232214927673	low left ventricular ejection fraction ; HF ; preserved left ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient ; financial costs
P-55	-2.1603 -1.5730 -4.2452 -1.3296 -0.8858 -0.2476 -0.4097 -0.2989 -1.0342 -0.0189 -0.2272 -1.1287 -0.1681 -0.1849 -4.4085 -0.0823 -0.1839 -0.2421 -3.1062 -1.8400 -0.7683 -0.2381 -0.5361 -0.2897 -0.9271 -0.0158 -0.4286 -1.5684 -0.1576 -1.7313 -0.0496 -0.2331 -0.8144 -0.0266 -0.6398 -0.1122 -0.1205 -1.2673 -1.1814 -0.5666 -0.5178 -0.2816
S-494	Two hundred ninety-three HF patients with reduced (HFrEF, n = 247) or with preserved left ventricular (LV) ejection fraction (HFpEF, n = 46) underwent echo-Doppler studies and N-terminal pro-brain-type natriuretic peptide assessment and were tracked for adverse events.<unk>
T-494	hf ; patients ; hfref ; left ventricular ; ejection fraction ; hfpef ; echo-doppler ; n-terminal pro-brain-type natriuretic peptide ; adverse events
H-494	-0.6038541793823242	▁ HF ▁; HF ▁; ▁left ▁vent ri cular ▁; LV ▁; ▁e je ction ▁ fraction ▁; HF p EF ▁; ▁e cho - D opp ler ▁studies ▁; ▁N - termin al ▁pro - bra in - type ▁na tri ure tic ▁pe pti de
D-494	-0.6038541793823242	HF ;HF ; left ventricular ;LV ; ejection fraction ;HFpEF ; echo-Doppler studies ; N-terminal pro-brain-type natriuretic peptide
P-494	-1.4259 -0.4564 -0.8892 -4.1429 -0.6672 -1.1903 -2.6990 -0.8419 -0.5374 -0.1763 -1.0623 -0.4159 -0.0840 -0.4895 -0.1377 -0.6050 -0.0356 -0.2053 -0.5472 -0.3927 -0.4672 -0.1590 -0.0683 -0.5321 -0.1561 -1.6419 -0.0139 -0.4420 -0.6423 -0.1094 -1.9000 -0.0685 -0.0254 -0.0043 -0.0229 -0.0738 -0.2465 -0.1209 -0.0609 -0.1313 -0.0138 -0.2858 -0.1912 -1.3108 -0.0662 -0.1758 -1.4397 -1.9465 -0.2705
S-464	Cases seen in low-volume EDs had less comorbidities and were less likely to be hospitalized (54.5%) than those seen in medium (61.8%; adjusted odds ratio [aOR] 1.16, [95% confidence interval {CI} 1.10–1.23]) or high-volume EDs (73.6%; aOR, 1.95 [95% CI, 1.83–2.07]).<unk>
T-464	eds ; comorbidities ; hospitalized ; adjusted odds ratio ; aor ; confidence interval ; eds ; aor
H-464	-0.6614731550216675	▁low - volu me ▁ED s ▁; ▁hospital ized ▁; ▁high - volu me ▁ED s
D-464	-0.6614731550216675	low-volume EDs ; hospitalized ; high-volume EDs
P-464	-0.9554 -0.0706 -0.3000 -0.1279 -0.6077 -0.0758 -0.2616 -1.2862 -0.6164 -0.2246 -3.6332 -0.1164 -0.5534 -0.0962 -1.0038 -0.0724 -1.6102 -0.2946
S-715	Compared with the patients who underwent standard criteria cardiac transplant, ECCT patients were older (median, 66.6 years versus 53.2 years; P<0.001), with higher frequency of diabetes mellitus (46.4% versus 24.6%; P<0.001) and chronic kidney disease (median estimated glomerular filtration rate, 55 versus 61.6 mL/min; P=0.001).<unk>
T-715	patients ; cardiac transplant ; ecct ; patients ; diabetes mellitus ; chronic kidney disease ; estimated glomerular filtration rate
H-715	-0.5053579211235046	▁cardiac ▁transplant ▁; ▁EC CT ▁; ▁diabetes ▁mell itus ▁; ▁chronic ▁ki dne y ▁disease ▁; ▁glo mer ular ▁filtr ation ▁rate
D-715	-0.5053579211235046	cardiac transplant ; ECCT ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
P-715	-0.6565 -0.1017 -0.2860 -0.7630 -0.8843 -1.0249 -1.1503 -0.0361 -0.1564 -0.1802 -0.3097 -0.0602 -0.5726 -0.1993 -2.0639 -0.3925 -0.1795 -0.5701 -0.0073 -0.4811 -0.3435 -0.1158 -1.3152 -0.2787
S-631	Addition of HABC Battery scores to the Health ABC HF Risk Model improved discrimination (change in C-index, 0.014; 95% CI 0.018-0.010) and appropriately reclassified 13.4% (net-reclassification-improvement 0.073, 95% CI 0.021-0.125; P = .006) of participants (8.3% who developed HF and 5.1% who did not).<unk>
T-631	habc battery ; health abc hf risk model ; change ; c-index ; net-reclassification-improvement ; hf
H-631	-0.762892484664917	▁h abb ▁; ▁bat tery ▁score s ▁; ▁health ▁ABC ▁; ▁ HF ▁; ▁risk ▁model ▁; ▁discrimina tion ▁; ▁c - index ▁; ▁ HF
D-631	-0.762892484664917	habb ; battery scores ; health ABC ; HF ; risk model ; discrimination ; c-index ; HF
P-631	-1.6297 -2.5248 -1.5398 -0.5723 -0.0510 -1.9968 -0.0563 -0.1202 -0.4506 -0.3588 -0.4468 -0.3948 -0.1713 -0.8595 -3.2335 -0.2434 -0.2238 -0.7718 -0.3041 -0.2269 -0.1870 -0.2206 -0.1663 -0.2498 -1.7166 -1.7531 -0.6726 -0.2184
S-1507	Construct validity of individual scales showed excellent fit indices: CFI = .92, RMSEA = .05 for the Self-Care Maintenance Scale; CFI = .95, RMSEA = .07 for the Self-Care Management Scale; CFI = .99, RMSEA = .02 for the Self-Care Confidence scale.<unk>
T-1507	cfi ; rmsea ; self-care maintenance ; cfi ; rmsea ; self-care management ; cfi ; rmsea ; self-care confidence
H-1507	-0.9815993905067444	▁c fi ▁; ▁RM se a ▁; ▁self - Car e ▁management ▁Scal e ▁; ▁c fi ▁; ▁RM se a ▁; ▁self - Car e ▁management ▁Scal e ▁; ▁c f ▁; ▁RM se a ▁; ▁self - Car e ▁Confi den ce ▁scale
D-1507	-0.9815993905067444	cfi ; RMsea ; self-Care management Scale ; cfi ; RMsea ; self-Care management Scale ; cf ; RMsea ; self-Care Confidence scale
P-1507	-1.5753 -3.6835 -0.0572 -1.1993 -1.2619 -0.2186 -0.0373 -0.3797 -0.1255 -0.7036 -0.2433 -3.7587 -1.7157 -0.0461 -0.0643 -0.1581 -3.5831 -0.0369 -3.1698 -0.9536 -0.2349 -0.0599 -0.4937 -0.1024 -0.7219 -0.1462 -1.9569 -3.3177 -0.0326 -0.1651 -0.5633 -4.2078 -0.0716 -2.6867 -0.9017 -0.2399 -0.1074 -0.5713 -0.0985 -0.9089 -0.1532 -4.2906 -0.0687 -0.0509 -0.3441 -0.3587 -0.3092
S-1876	Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 ± 14 m vs. 1.5 ± 13.2 m; p = 0.004), quality-of-life score (–17.4 ± 2.8 points vs. 2.1 ± 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution).<unk>
T-1876	patients ; bat ; patients ; quality-of-life ; nyha functional class ; change
H-1876	-1.1967476606369019	▁BAT ▁; ▁quality - of - life ▁score ▁; ▁NY HA
D-1876	-1.1967476606369019	BAT ; quality-of-life score ; NYHA
P-1876	-0.7155 -0.7584 -4.4781 -0.2355 -0.0555 -0.3824 -0.3675 -1.0615 -0.4103 -3.6516 -0.9629 -2.2284 -0.2501
S-537	Subgroup analysis of patients with preoperative hypoalbuminemia and postoperative normalization of albumin levels (n = 81) showed improved survival compared with those who remained hypoalbuminemia (n = 44) or those who had decreasing albumin levels during LVAD support (n = 40; 3-month survival: 92.6% vs 63.6% and 65.0%; p <0.01).<unk>
T-537	patients ; preoperative ; hypoalbuminemia ; postoperative ; albumin ; hypoalbuminemia ; albumin ; lvad
H-537	-0.6713120341300964	▁pre operativ e ▁hypo album in emia ▁; ▁post operativ e ▁normal ization ▁; ▁album in ▁levels ▁; ▁l VAD
D-537	-0.6713120341300964	preoperative hypoalbuminemia ; postoperative normalization ; albumin levels ; lVAD
P-537	-1.0063 -0.1840 -0.2298 -0.3464 -0.9359 -0.4946 -0.2685 -0.1274 -0.0336 -0.1011 -0.3437 -0.4545 -0.3358 -1.1417 -0.7024 -0.5981 -0.0819 -0.3178 -5.9916 -0.2723 -0.6451 -0.1562
S-1717	A 1-day decrease in length of stay was associated with an absolute increase in 30-day rehospitalization of 1.56 percentage points (95% confidence interval (CI) = 0.30-2.82) for acute myocardial infarction (AMI) with major complications and 0.81 percentage points (95% CI = 0.03-1.60) for kidney infection or urinary tract infection (UTI) without major complications.<unk>
T-1717	rehospitalization ; confidence interval ; acute myocardial infarction ; ami ; complications ; kidney infection ; urinary tract infection ; uti ; complications
H-1717	-0.6476513147354126	▁re hospital ization ▁; ▁a cute ▁my o card ial ▁in far ction ▁; AMI ▁; ▁ki dne y ▁infection ▁; ▁urin ary ▁tract ▁infection ▁; UTI
D-1717	-0.6476513147354126	rehospitalization ; acute myocardial infarction ;AMI ; kidney infection ; urinary tract infection ;UTI
P-1717	-2.9114 -0.0114 -0.1952 -0.2553 -0.4048 -0.1519 -2.1933 -0.5646 -1.0922 -0.0721 -0.0738 -0.2126 -0.4025 -0.2473 -0.4006 -0.3517 -3.5462 -1.1545 -0.1820 -1.4708 -0.0761 -0.0260 -0.0227 -0.3454 -0.9964 -0.6214 -0.0281 -0.4594 -0.3121
S-54	Management of patients with heart failure (HF), stemming from ischemic and nonischemic cardiomyopathies, continues to be problematic, despite the inroads made in the pharmacological armamentarium, by implantable cardioverter defibrillators, cardiac resynchronization therapy, and the eventual resort to cardiac transplantation, and left and/or right ventricular assist devices.<unk>
T-54	patients ; heart failure ; hf ; ischemic ; nonischemic cardiomyopathies ; pharmacological ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; right ventricular assist devices
H-54	-0.5107167959213257	▁heart ▁failure ▁; HF ▁; ▁ ische mic ▁; ▁non ische mic ▁cardio my o pathi es ▁; ▁ pharma c ological ▁arma ment arium ▁; ▁cardio ver ter ▁de fi br illa tors ▁; ▁cardiac ▁re syn chron ization ▁ therapy ▁; ▁cardiac ▁transplant ation ▁; ▁left ▁; ▁right ▁vent ri cular ▁assist ▁devices
D-54	-0.5107167959213257	heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; left ; right ventricular assist devices
P-54	-4.2520 -0.0432 -0.3180 -0.4124 -0.1935 -0.4882 -0.1725 -0.1076 -0.8133 -0.0646 -0.9365 -0.4326 -0.4893 -1.3564 -0.8064 -0.1072 -0.5930 -0.3651 -1.6005 -0.1017 -0.1661 -0.3979 -0.3470 -0.0231 -0.0464 -0.1380 -1.0148 -0.0377 -0.2746 -0.1345 -0.5584 -2.5544 -1.0211 -0.1382 -0.2775 -0.0554 -0.0134 -0.0210 -0.0069 -0.2147 -0.6005 -0.0389 -0.3333 -0.5118 -0.0555 -0.1923 -0.3055 -0.3343 -1.3361 -0.0714 -2.1109 -0.6942 -0.0960 -0.6754 -0.0753 -0.4113 -0.1731
S-230	SAF versus PF mean catheterization findings were central venous pressure 18 ± 6 versus 14 ± 3 mm Hg (p <0.01), SVR index 1,680 ± 368 versus 1,960 ± 550 dyn s/cm(5)/m(2) (p = 0.02), and cardiac index 2.7 ± 0.8 versus 2.8 ± 0.7 L/min/m(2) (p = 0.25).<unk>
T-230	saf ; catheterization ; central venous pressure ; svr ; cardiac index
H-230	-1.4457556009292603	▁ SAF ▁; ▁ PF ▁; ▁ PF ▁; ▁central ▁ve nous ▁pressure ▁; ▁g g ▁; ▁s VR ▁index ▁; ▁dyn ▁; ▁cardiac ▁index
D-230	-1.4457556009292603	SAF ; PF ; PF ; central venous pressure ; gg ; sVR index ; dyn ; cardiac index
P-230	-2.4158 -0.5600 -0.4776 -1.3995 -0.3078 -0.7877 -5.6468 -0.8584 -0.7952 -1.1523 -0.3422 -1.6265 -1.0109 -0.3263 -5.3481 -0.3126 -0.2191 -0.5161 -2.0557 -1.1474 -0.3400 -4.5722 -1.5339 -4.0203 -0.5412 -0.4257 -0.2959
S-193	Women compared with men had higher admission median BNP levels with the greatest difference among reduced EF and smallest difference among preserved EF (median BNP in women vs men: EF reduced 1,259 vs 1,113 pg/mL, borderline 821 vs 732 pg/mL, and preserved 559 vs 540 pg/mL; P < .001 all comparisons).<unk>
T-193	admission ; bnp ; reduced ef ; preserved ef ; bnp ; ef
H-193	-0.9075193405151367	▁ad mission ▁media n ▁; ▁b NP ▁levels ▁; ▁EF ▁; ▁pres er ved ▁EF ▁; ▁b NP ▁; ▁EF ▁; ▁border line ▁; ▁p g / m L
D-193	-0.9075193405151367	admission median ; bNP levels ; EF ; preserved EF ; bNP ; EF ; borderline ; pg/mL
P-193	-0.1603 -0.1301 -0.4333 -0.0586 -2.0800 -1.2905 -1.1840 -0.4350 -0.1451 -0.5876 -0.1510 -5.0205 -0.0841 -0.2071 -1.2244 -0.2899 -2.0301 -1.0359 -0.1661 -2.8542 -0.4904 -0.8306 -0.0048 -0.3217 -1.1363 -0.0611 -3.2269 -0.0057 -0.9727 -1.2433 -0.2718
S-435	The score was associated with heart failure admission, heart transplantation/LV assist device, or death (hazard ratio, 0.97; 95% confidence interval, 0.95-0.98; P<0.001) and all-cause death (hazard ratio, 0.97; 95% confidence interval, 0.96-0.98; P<0.001), independent of age, sex, ischemic cause, and initial functional class.<unk>
T-435	heart failure ; admission ; heart transplantation ; lv assist device ; death ; hazard ratio ; confidence interval ; death ; hazard ratio ; confidence interval ; ischemic ; functional class
H-435	-0.8954435586929321	▁heart ▁failure ▁ad mission ▁; ▁heart ▁transplant ation ▁; LV ▁assist ▁device ▁; ▁death ▁; haz ard ▁ratio
D-435	-0.8954435586929321	heart failure admission ; heart transplantation ;LV assist device ; death ;hazard ratio
P-435	-2.3177 -0.2317 -0.3851 -0.0203 -0.1722 -1.9110 -0.5975 -0.3871 -0.4144 -1.2984 -1.4836 -0.4411 -0.3653 -1.7646 -0.4919 -0.7248 -0.2938 -0.0781 -4.2671 -0.2631
S-475	LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF + allopurinol rats, all of which occurred in the absence of changes in the maximum O2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer.<unk>
T-475	lv ejection fraction ; shortening ; systolic elastance ; contractile efficiency ; acf ; acf ; allopurinol ; cardiomyocytes ; extracellular flux analyzer
H-475	-0.3407648205757141	▁LV ▁e je ction ▁ fraction ▁; ▁veloci ty ▁; ▁circum fer ential ▁short en ing ▁; ▁sy sto lic ▁elastan ce ▁; ▁contract ile ▁efficiency ▁; ▁a CF ▁; ▁allo puri nol ▁rat s ▁; ▁o 2 ▁consum p tion ▁rate ▁; ▁isola ted ▁cardio my o cy tes ▁; ▁extra cel lular ▁flux ▁anal y zer
D-475	-0.3407648205757141	LV ejection fraction ; velocity ; circumferential shortening ; systolic elastance ; contractile efficiency ; aCF ; allopurinol rats ; o2 consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
P-475	-0.0777 -0.1673 -0.1125 -0.1198 -0.6518 -0.0156 -0.2640 -0.0090 -0.0427 -1.0729 -0.7841 -1.0792 -0.0618 -0.0490 -0.2041 -0.0698 -0.3557 -2.2605 -0.1565 -0.7649 -0.0995 -0.2090 -0.1928 -0.0352 -2.2603 -0.4255 -0.1307 -0.4677 -0.7413 -0.0536 -1.4397 -0.2891 -0.1927 -0.1422 -0.0345 -0.2840 -0.6079 -0.2648 -0.3409 -0.0919 -0.1956 -0.0101 -0.1455 -0.0559 -0.0054 -0.0421 -0.6930 -0.3237 -0.1374 -0.2531 -0.1495 -0.3342 -0.3583 -0.0350 -0.1504 -0.0507 -0.1781 -0.0786 -0.4187 -0.2082
S-1526	We prospectively studied 402 patients with HFpEF, divided into 4 groups based on LV structure: normal geometry (no LV hypertrophy [LVH] and relative wall thickness [RWT] ≤0.42); CR (no LVH and RWT >0.42); CH (LVH and RWT >0.42); and EH (LVH and RWT ≤0.42).<unk>
T-1526	prospectively ; patients ; hfpef ; lv hypertrophy ; lvh ; relative wall thickness ; rwt ; lvh ; rwt ; lvh ; rwt ; lvh ; rwt
H-1526	-1.0074009895324707	▁ HF p EF ▁; ▁LV ▁structure ▁; ▁normal ▁ge ometr y ▁; ▁LV ▁; ▁hyper trop hy ▁; LV h ▁; ▁relative ▁wall ▁thi ck ness ▁; RW t ▁; ▁CR ▁; ▁LV h ▁; ▁r w t ▁; ▁ec ▁; LV h ▁; ▁r w t
D-1526	-1.0074009895324707	HFpEF ; LV structure ; normal geometry ; LV ; hypertrophy ;LVh ; relative wall thickness ;RWt ; CR ; LVh ; rwt ; ec ;LVh ; rwt
P-1526	-1.6707 -2.0450 -0.0319 -0.7411 -0.2766 -1.7091 -3.4614 -0.2942 -3.2267 -0.0924 -0.0410 -0.0987 -0.0984 -2.1948 -1.7244 -1.4182 -0.3013 -0.9593 -0.0573 -0.9677 -2.0397 -0.0660 -0.0048 -1.2904 -0.4054 -0.2005 -0.3493 -0.1596 -0.5439 -0.2165 -0.1580 -3.2986 -0.0448 -1.1670 -1.7217 -0.0536 -1.9863 -0.3374 -0.2187 -0.1651 -5.3050 -0.4007 -3.1693 -2.0868 -0.1109 -2.1606 -0.3002 -0.1757 -0.5457 -0.2776
S-1463	LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction.<unk>
T-1463	lcz696 ; angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor ; prodrug ; angiotensin receptor antagonist ; valsartan ; hypertension ; heart failure with preserved ejection fraction ; outcomes ; heart failure with reduced ejection fraction
H-1463	-0.5615963339805603	▁ang io ten sin ▁receptor ▁nepri ly sin ▁inhibi tor ▁; ▁nepri ly sin ▁inhibi tor ▁pro drug ▁; ▁ang io ten sin ▁receptor ▁anta gon ist ▁val sar tan ▁; ▁hyper tension ▁; ▁pilot ▁trial ▁; ▁heart ▁failure ▁; ▁pres er ved ▁e je ction ▁ fraction ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction
D-1463	-0.5615963339805603	angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; pilot trial ; heart failure ; preserved ejection fraction ; heart failure ; reduced ejection fraction
P-1463	-1.3992 -3.8563 -1.9429 -0.4106 -0.0057 -1.8086 -0.2345 -0.2780 -0.3350 -0.0396 -0.4148 -0.0442 -0.1830 -0.4090 -0.2955 -0.0663 -0.0801 -0.1117 -0.0962 -0.0555 -1.8150 -1.2194 -0.2808 -0.0094 -0.1282 -0.1823 -0.5090 -1.5272 -0.1894 -0.0797 -0.2360 -0.1201 -0.2051 -0.2174 -2.9412 -0.1077 -0.4833 -0.3142 -0.0793 -0.2757 -0.9640 -0.0643 -0.1722 -0.0336 -0.3135 -0.1845 -0.2551 -0.0078 -0.9997 -3.9049 -0.2697 -0.4121 -1.8141 -0.0582 -0.0308 -0.2938 -0.2710 -0.3002 -0.0143 -0.5518 -0.3542
S-343	His blood pressure was 120/70 mm Hg, he underwent mitral valve plasty for degenerative MR, he had P3 prolapse with 2 chordal ruptures and he underwent triangular resection, edge-to-edge anastomosis, and ring annuloplasty with a Physio Ring 30 (Edwards Lifesciences, Irvine, CA) of just size.<unk>
T-343	blood pressure ; mitral valve plasty ; degenerative mr ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; physio ring 30 ; edwards lifesciences ; irvine
H-343	-0.22032196819782257	▁blood ▁pressure ▁; ▁mit ral ▁val ve ▁plast y ▁; ▁de genera tive ▁MR ▁; ▁p 3 ▁pro lapse ▁; ▁chor dal ▁rup tures ▁; ▁tri ang ular ▁res ection ▁; ▁edge - to - ed ge ▁an asto mos is ▁; ▁ring ▁ann ulo plast y ▁; ▁Ph y sio ▁Ring ▁; ▁ed ward s ▁life science s ▁; ▁ir vine
D-343	-0.22032196819782257	blood pressure ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio Ring ; edwards lifesciences ; irvine
P-343	-1.1202 -0.0846 -0.1124 -0.3273 -0.0617 -0.5241 -0.0824 -0.0367 -0.4084 -0.2418 -0.0130 -0.0101 -0.0152 -0.1287 -0.2561 -0.3838 -0.0633 -0.0228 -0.0416 -0.1388 -0.2199 -0.2480 -0.0269 -0.0518 -0.1186 -0.2146 -0.1405 -0.0008 -0.0879 -0.0080 -0.1896 -0.0079 -0.0281 -0.0698 -0.1109 -0.0280 -0.0927 -0.0111 -0.0220 -0.5685 -0.3653 -0.1507 -0.0101 -0.0190 -0.6770 -0.0902 -0.1499 -0.1245 -0.6108 -0.0159 -0.0632 -0.7810 -0.8445 -1.9142 -0.0033 -0.0106 -0.1349 -0.0500 -0.0010 -0.2955 -0.1741 -0.0009 -1.1265 -0.1684
S-1320	Outcomes included an incremental shuttle walk test, peak oxygen uptake, muscular strength, echocardiographic measures, N-terminal pro-brain natriuretic peptide, inflammatory markers, depression (Beck Depression Inventory), and health-related quality of life (Minnesota Living with Heart Failure Questionnaire and Medical Outcomes Study Short-Form).<unk>
T-1320	outcomes ; incremental shuttle walk test ; peak oxygen uptake ; muscular ; echocardiographic ; n-terminal pro-brain natriuretic peptide ; inflammatory ; beck depression inventory ; health-related quality of life ; minnesota living with heart failure questionnaire ; medical outcomes study short-form
H-1320	-0.38817155361175537	▁shu ttle ▁walk ▁test ▁; ▁pe ak ▁oxygen ▁up take ▁; ▁muscular ▁strength ▁; ▁e cho car dio graphic ▁measure s ▁; ▁N - termin al ▁pro - bra in ▁na tri ure tic ▁pe pti de ▁; ▁infla mma tory ▁marker s ▁; ▁depression ▁; ▁be ck ▁de pression ▁in ven tory
D-1320	-0.38817155361175537	shuttle walk test ; peak oxygen uptake ; muscular strength ; echocardiographic measures ; N-terminal pro-brain natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory
P-1320	-0.0746 -0.0126 -0.0931 -0.3118 -0.2555 -0.0111 -0.0100 -0.6191 -0.1751 -0.0349 -0.2935 -0.1946 -0.7268 -0.2009 -0.0094 -0.4098 -1.0173 -1.2403 -0.9943 -1.3707 -0.0317 -0.2042 -2.1084 -0.0586 -0.1189 -0.0028 -0.0354 -0.0611 -0.2066 -0.1035 -0.0066 -0.2162 -0.0796 -0.3316 -0.0450 -0.4431 -1.1212 -0.2741 -0.0505 -1.0777 -0.0408 -0.1470 -0.0228 -0.2032 -0.4314 -0.1593 -1.0010 -0.1564 -0.4495 -0.2420 -0.2435 -0.2586 -0.0146 -3.0732 -0.2741
S-116	Interaction term analysis showed that the risk associated with severely reduced LVEF was evident only among patients ≤75 years (HR 1.49, p = 0.003), whereas among older patients, there was no difference in the risk of long-term mortality between those with preserved versus severely reduced LVEF (HR 1.02 [p = 0.86]; p value for age-by-LVEF interaction = 0.03).<unk>
T-116	interaction term analysis ; lvef ; patients ; patients ; mortality ; lvef ; p value
H-116	-0.9118556380271912	▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁pres er ved ▁; ▁LV EF ▁; ▁age - by - LV EF
D-116	-0.9118556380271912	LVEF ; long-term mortality ; preserved ; LVEF ; age-by-LVEF
P-116	-6.5173 -0.2949 -0.1511 -3.3309 -0.1339 -0.1001 -0.1690 -0.0267 -0.2910 -1.3800 -0.2141 -0.3185 -0.2408 -3.2016 -0.2225 -0.7947 -2.2656 -0.0882 -0.0844 -0.0698 -0.4281 -0.3110 -1.0317 -0.2187
S-763	METHODS AND RESULTS: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization.<unk>
T-763	wistar-kyoto ; zsf1 ; obese ; zsf1 ; obese ; zsf1 ; followed up ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
H-763	-0.8322542905807495	▁w star - k yo to ▁; ▁lean ▁z SF 1 ▁; ▁obes e ▁z SF 1 ▁; ▁obes e ▁Z SF 1 ▁; ▁high - fat ▁die t ▁; ▁metabol ic ▁; ▁renal ▁; ▁e cho car dio graphic ▁evaluation s ▁; ▁hem o dynamic ally
D-763	-0.8322542905807495	wstar-kyoto ; lean zSF1 ; obese zSF1 ; obese ZSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic evaluations ; hemodynamically
P-763	-1.8779 -3.7610 -0.0686 -4.3743 -0.9180 -0.0698 -0.2188 -0.3719 -1.4617 -1.9387 -1.2353 -0.1370 -0.2465 -0.0499 -0.9407 -2.2453 -0.8399 -0.1364 -1.2171 -0.0388 -2.1620 -1.3964 -0.9980 -0.1012 -0.0264 -0.0705 -0.2654 -2.5662 -0.4479 -0.5326 -1.2221 -0.0141 -0.2475 -0.0212 -0.1889 -0.0333 -0.3454 -0.9508 -0.8673 -1.0930 -1.7391 -0.0984 -0.1886 -0.8803 -0.0819 -0.0273 -0.0780 -1.8409 -0.1477
S-384	Kaplan-Meier curves and log-rank testing demonstrated excellent risk stratification, particularly between a large, low-risk group (40% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 8%/12%/12%) and a small, high-risk group (10% of patients, 6-month event rates in the UM/VA/VA-RT cohorts 57%/58%/79%).<unk>
T-384	kaplan-meier curves ; log-rank testing ; risk stratification ; patients ; patients
H-384	-1.0306050777435303	▁Ka plan - me ier ▁cur ves ▁; ▁log - rank ▁testing ▁; ▁UM / VA ▁; VA - RT ▁co hor ts
D-384	-1.0306050777435303	Kaplan-meier curves ; log-rank testing ; UM/VA ;VA-RT cohorts
P-384	-0.2548 -0.1025 -0.0504 -0.5378 -0.6323 -0.2521 -0.7934 -0.2040 -0.6558 -0.1005 -0.1262 -0.3958 -0.2321 -4.3399 -1.8964 -1.6254 -1.9746 -3.7870 -0.6776 -1.6515 -1.7359 -1.0247 -0.3767 -2.0286 -0.3090
S-950	Multivariate Cox regression analyses revealed that AF type (other than long-standing persistent AF) and lack of hypertension were independently associated with maintenance of sinus rhythm (hazard ratio [HR]: 1.81, 95% confidence interval [CI]: 1.03 to 3.17, p = 0.04; HR: 0.49, 95% CI: 0.24 to 0.96, p = 0.04, respectively).<unk>
T-950	multivariate cox regression analyses ; hypertension ; sinus rhythm ; hazard ratio ; confidence interval
H-950	-0.9137934446334839	▁multi varia te ▁co x ▁re gression ▁; ▁AF ▁type ▁; ▁lack ▁of ▁hyper tension ▁; ▁maintenance ▁; ▁sinus ▁ rhythm ▁; haz ard ▁ratio ▁; ▁HR
D-950	-0.9137934446334839	multivariate cox regression ; AF type ; lack of hypertension ; maintenance ; sinus rhythm ;hazard ratio ; HR
P-950	-3.6662 -0.3362 -0.4701 -0.2584 -0.5926 -0.0812 -0.0346 -0.7553 -1.0789 -1.3807 -0.1631 -5.2883 -0.0546 -0.3495 -0.1360 -0.1490 -1.3058 -1.7883 -0.7104 -0.1810 -0.2972 -0.3891 -0.0464 -0.0814 -0.0042 -0.2548 -5.1822 -1.2025 -0.2621
S-1228	CONCLUSIONS: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m(2) and potassium <5.0 mmol/l, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.<unk>
T-1228	patients ; chronic ; hf-ref ; nyha functional class ii ; egfr ; potassium ; eplerenone ; hyperkalemia
H-1228	-0.7176305055618286	▁chronic ▁ HF - re f ▁; ▁NY HA ▁; ▁functional ▁class ▁II ▁; ▁e g f ▁; ▁po tas s ium ▁; ▁e pler en one ▁; ▁hyper kal emia ▁; ▁w RF
D-1228	-0.7176305055618286	chronic HF-ref ; NYHA ; functional class II ; egf ; potassium ; eplerenone ; hyperkalemia ; wRF
P-1228	-1.3128 -0.5064 -0.7317 -0.1205 -0.7727 -1.0348 -0.2508 -0.4536 -0.8029 -0.4846 -4.8237 -0.0386 -2.1947 -0.3607 -0.2874 -2.0463 -1.6088 -0.0682 -0.2657 -0.2259 -0.1813 -0.4369 -0.1646 -0.1340 -0.8133 -0.4667 -0.0549 -0.3448 -1.7690 -0.6566 -0.2143 -0.2089 -0.4622 -1.0541 -0.2405 -0.2418
S-12	METHODS: Body composition with regard to FFM, FM, and body fat distribution was assessed by dual energy X-ray absorptiometry (DXA) in 19 non-diabetic patients with chronic heart failure (CHF) and CC and 38 controls (non-cachectic CHF and individuals with prior myocardial infarction-both n = 19) who were followed for 12 months.<unk>
T-12	ffm ; dual energy x-ray absorptiometry ; dxa ; patients ; chronic heart failure ; chf ; non-cachectic chf ; myocardial
H-12	-0.4588685929775238	▁f f ▁; ▁FM ▁; ▁body ▁fat ▁distribution ▁; ▁dual ▁energy ▁x - ray ▁ab sor pti ometr y ▁; ▁d XA ▁; ▁non - dia be tic ▁patients ▁; ▁chronic ▁heart ▁failure ▁; CH f ▁; cc ▁; ▁non - ca che ctic ▁CHF ▁; ▁my o card ial ▁in far ction - bo th
D-12	-0.4588685929775238	ff ; FM ; body fat distribution ; dual energy x-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;CHf ;cc ; non-cachectic CHF ; myocardial infarction-both
P-12	-0.5520 -0.8135 -1.2261 -2.3297 -0.3274 -0.1780 -1.1896 -0.0146 -0.3289 -0.3203 -0.0288 -1.2293 -0.2433 -0.2235 -0.0561 -1.1693 -0.6431 -0.2157 -0.2545 -0.5101 -0.6383 -0.7000 -0.2252 -0.7102 -0.0988 -0.4708 -0.5694 -0.0579 -1.0555 -0.1852 -0.1552 -0.8871 -0.0776 -0.2471 -0.7651 -0.3369 -0.1297 -0.8535 -0.2328 -1.7942 -0.0748 -0.0012 -0.3454 -0.3553 -0.0215 -0.1182 -1.1888 -0.2296 -0.4703 -0.0319 -0.0360 -0.2448 -0.2894 -0.3451 -0.1066 -0.0644 -0.4712 -0.1752
S-1707	After adjustment for differences in baseline characteristics and achieved study drug dose, spironolactone reduced the combined end point of death or hospitalization for HF in non-AAs (hazard ratio, 0.63; 95% confidence interval, 0.55-0.73) but not in AAs (hazard ratio, 1.07; 95% confidence interval, 0.67-1.71; P value for interaction=0.032).<unk>
T-1707	baseline ; drug ; spironolactone ; combined end point ; death ; hospitalization ; hf ; hazard ratio ; confidence interval ; aas ; hazard ratio ; confidence interval ; p value
H-1707	-0.42562657594680786	▁base line ▁; ▁drug ▁dose ▁; ▁spi rono lac tone ▁; ▁end ▁point ▁of ▁death ▁; ▁hospital ization ▁; ▁ HF ▁; haz ard ▁ratio ▁; ▁AA s
D-1707	-0.42562657594680786	baseline ; drug dose ; spironolactone ; end point of death ; hospitalization ; HF ;hazard ratio ; AAs
P-1707	-0.0389 -0.1011 -0.3629 -1.1326 -1.1325 -0.2640 -0.1655 -0.0374 -0.0954 -0.1622 -0.1253 -0.7813 -0.1437 -0.4780 -0.7123 -0.0733 -0.4085 -0.3375 -0.1313 -0.3569 -0.1131 -0.1395 -2.2962 -0.3872 -0.0356 -0.2150 -0.7670 -0.1268 -1.4177 -0.2300
S-823	METHODS AND RESULTS: In this prospective study, patients with invasively diagnosed pulmonary arterial hypertension or inoperable chronic thromboembolic pulmonary hypertension and impaired right ventricular pump function despite a stable targeted pulmonary arterial hypertension medication underwent a broad panel of noninvasive assessments, including stress echocardiography and cardiopulmonary exercise testing.<unk>
T-823	prospective study ; patients ; invasively ; diagnosed ; pulmonary arterial hypertension ; inoperable ; chronic thromboembolic pulmonary hypertension ; right ventricular ; pump ; stable ; pulmonary arterial hypertension ; medication ; noninvasive ; stress echocardiography ; cardiopulmonary exercise testing
H-823	-0.35670560598373413	▁pulmonar y ▁arterial ▁hyper tension ▁; ▁in opera ble ▁chronic ▁ thro mbo e mbol ic ▁pulmonar y ▁hyper tension ▁; ▁im pair ed ▁right ▁vent ri cular ▁pump ▁; ▁pulmonar y ▁arterial ▁hyper tension ▁medication ▁; ▁stress ▁e cho card i ography ▁; ▁cardio pul mon ary ▁exercise ▁testing
D-823	-0.35670560598373413	pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; impaired right ventricular pump ; pulmonary arterial hypertension medication ; stress echocardiography ; cardiopulmonary exercise testing
P-823	-0.2021 -0.0303 -0.0277 -0.3975 -0.1021 -0.0904 -0.3874 -0.0349 -0.2198 -0.2498 -0.1666 -0.0664 -1.5160 -0.1622 -0.0623 -0.0656 -0.0458 -0.1006 -0.6186 -0.2309 -0.1272 -1.0723 -0.0142 -0.0095 -0.0632 -2.3597 -1.1539 -0.1747 -0.4890 -1.2121 -0.5880 -0.0441 -0.0270 -0.5261 -0.1668 -1.5456 -0.2943 -0.0450 -0.0163 -0.2808 -0.6605 -0.4392 -0.6238 -0.1578 -0.0255 -0.1305 -0.1588 -0.0400 -0.1536 -0.7109 -0.3004 -0.1611
S-1930	For cardiovascular death or HF hospitalization, there was a significant interaction between the randomization group and BTES (P=0.035), which corresponded to a borderline association between increasing BTES and cardiovascular death or HF hospitalization in the exercise group (hazard ratio 1.25, 95% confidence interval 0.99, 1.59), but no association in the usual care group (hazard ratio 0.83, 95% confidence interval 0.66, 1.06).<unk>
T-1930	cardiovascular death ; hf ; hospitalization ; randomization ; btes ; btes ; cardiovascular death ; hf ; hospitalization ; exercise ; hazard ratio ; confidence interval ; hazard ratio ; confidence interval
H-1930	-0.6186333298683167	▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁b tes ▁; ▁b tes ▁; ▁cardiovascular ▁death ▁; ▁ HF ▁hospital ization ▁; ▁exercise ▁group ▁; haz ard ▁ratio
D-1930	-0.6186333298683167	cardiovascular death ; HF hospitalization ; btes ; btes ; cardiovascular death ; HF hospitalization ; exercise group ;hazard ratio
P-1930	-1.4383 -1.7810 -0.0890 -0.1216 -0.1107 -0.9736 -0.4160 -0.2818 -1.5761 -0.4353 -0.0830 -2.4080 -0.3365 -0.0693 -0.7008 -1.6139 -0.0688 -0.0548 -0.1838 -1.4891 -0.3511 -0.0992 -0.3602 -0.4315 -0.6328 -0.3645 -0.1929 -0.0376 -1.6585 -0.1994
S-466	Of patients hospitalized at the time of their index ED visit, low-volume ED cases exhibited a higher risk of 30-day death/all-cause readmission (24.3%) than those seen in medium (21.9%; aOR, 0.83 [95% CI, 0.76–0.91]) or high-volume EDs (18.1%; aOR, 0.77 [95% CI, 0.70–0.85]).<unk>
T-466	patients ; hospitalized ; death ; all-cause readmission ; aor ; eds ; aor
H-466	-1.080620527267456	▁index ▁ED ▁; ▁low - volu me ▁ED ▁cases ▁; ▁30- day ▁death ▁; all - ca use ▁read mission ▁; ▁high - volu me ▁ED s
D-466	-1.080620527267456	index ED ; low-volume ED cases ; 30-day death ;all-cause readmission ; high-volume EDs
P-466	-2.5717 -4.4271 -0.9801 -2.0879 -0.0428 -0.2930 -0.0994 -1.9006 -0.2073 -0.1558 -4.9573 -0.3164 -2.7463 -0.5349 -2.0992 -0.0887 -0.0066 -0.1068 -1.0204 -0.1096 -0.2280 -3.1769 -0.0699 -0.4102 -0.0559 -0.8625 -0.1528 -1.3094 -0.3203
S-1863	Patients identified three stages where they felt implantable cardioverter-defibrillator deactivation should be discussed: (1) prior to implantation, (2) with any significant deterioration but while they were of sound mind to engage in and communicate their preferences and (3) at end of life, where patients wished further review of their previously established preferences and decisions about implantable cardioverter-defibrillator deactivation.<unk>
T-1863	patients ; implantable cardioverter-defibrillator ; implantation ; engage ; patients ; decisions ; implantable cardioverter-defibrillator
H-1863	-0.8872862458229065	▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion ▁; ▁implant able ▁cardio ver ter - de fi br illa tor ▁de activa tion
D-1863	-0.8872862458229065	implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator deactivation
P-1863	-1.5397 -0.0660 -0.5067 -0.1099 -0.6159 -0.0735 -0.0496 -1.5700 -3.7553 -1.5773 -0.1492 -0.1295 -0.0774 -0.4328 -0.6045 -2.8325 -2.8177 -0.5779 -0.1004 -0.5005 -0.0617 -0.0347 -1.0534 -3.1757 -1.7730 -0.1631 -0.3508 -0.2451 -0.5648 -1.8105 -0.1867
S-739	Cardiac magnetic resonance T1 time (hazard ratio, 0.99; 95% confidence interval, 0.98-0.99; P=0.046), left atrial area (hazard ratio, 1.08; 95% confidence interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P=0.03) were significantly associated with cardiac events.<unk>
T-739	cardiac magnetic resonance ; t1 time ; hazard ratio ; confidence interval ; left atrial area ; hazard ratio ; confidence interval ; pulmonary vascular resistance ; hazard ratio ; confidence interval ; cardiac events
H-739	-0.6589073538780212	▁Card iac ▁magnetic ▁res on ance ▁; ▁left ▁at rial ▁area ▁; haz ard ▁ratio ▁; ▁pulmonar y ▁vas cular ▁resist ance ▁; ▁cardiac ▁events
D-739	-0.6589073538780212	Cardiac magnetic resonance ; left atrial area ;hazard ratio ; pulmonary vascular resistance ; cardiac events
P-739	-1.3787 -0.9906 -0.1144 -0.2641 -0.3126 -0.3743 -0.8370 -3.2958 -0.2515 -0.1753 -0.1194 -0.2370 -2.4621 -0.1885 -0.0756 -0.2460 -0.5552 -0.1144 -0.5420 -0.5539 -0.6943 -0.0888 -0.4838 -1.5143 -1.4779 -0.2213 -0.2216
S-1755	METHODS AND RESULTS: We recruited and prospectively followed up, in 14 dedicated HF units, 3058 patients with systolic (left ventricular ejection fraction <40%) HF in stable clinical conditions, New York Heart Association class I to III, who underwent clinical, laboratory, echocardiographic, and cardiopulmonary exercise test investigations at study enrollment.<unk>
T-1755	prospectively ; followed up ; hf ; patients ; systolic ; left ventricular ejection fraction ; hf ; stable ; clinical ; conditions ; new york heart association class i ; clinical ; echocardiographic ; cardiopulmonary exercise test
H-1755	-0.6443438529968262	▁ HF ▁unit s ▁; ▁sy sto lic ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ HF ▁; ▁New ▁York ▁Heart ▁association ▁; ▁laborator y ▁; ▁e cho car dio graphic ▁; ▁cardio pul mon ary ▁exercise ▁test
D-1755	-0.6443438529968262	HF units ; systolic ; left ventricular ejection fraction ; HF ; New York Heart association ; laboratory ; echocardiographic ; cardiopulmonary exercise test
P-1755	-0.9798 -0.6316 -0.1035 -0.0937 -0.3182 -1.3679 -0.0791 -0.2947 -0.1171 -1.9702 -0.0676 -4.4837 -1.0334 -0.6186 -0.1899 -0.2238 -0.3202 -0.8706 -0.0145 -0.2633 -0.3782 -0.4910 -0.0944 -1.4089 -0.4256 -1.1837 -0.6982 -0.6205 -3.0329 -0.0683 -0.0880 -0.0523 -0.3082 -0.4946 -1.2695 -0.5717 -0.0744 -0.1266 -0.1137 -0.3318 -0.0384 -0.3183 -1.7166 -0.8614 -0.1870
S-1666	Patients with end stage heart failure fall into stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification; they are characterised by advanced structural heart disease and pronounced symptoms of heart failure at rest or upon minimal physical exertion, despite maximal medical treatment according to current guidelines.<unk>
T-1666	patients ; end stage heart failure ; abcd classification ; american college of cardiology ; acc ; american heart association ; aha ; new york heart association ; nyha ; heart disease ; symptoms ; heart failure ; physical ; medical treatment
H-1666	-0.8436006903648376	▁end ▁stage ▁heart ▁failure ▁; ▁ABC d ▁classifica tion ▁; ▁American ▁college ▁of ▁Card i ology ▁; ▁a cc ▁; American ▁Heart ▁association ▁; ▁ AHA ▁; ▁New ▁York ▁Heart ▁association ▁; NY HA ▁; ▁structura l ▁heart ▁disease ▁; ▁heart ▁failure ▁; ▁physical ▁ex er tion ▁; ▁medical
D-1666	-0.8436006903648376	end stage heart failure ; ABCd classification ; American college of Cardiology ; acc ;American Heart association ; AHA ; New York Heart association ;NYHA ; structural heart disease ; heart failure ; physical exertion ; medical
P-1666	-5.3522 -0.1425 -2.8252 -0.2570 -0.3811 -0.9943 -0.4077 -1.3008 -0.0286 -0.3502 -0.6884 -0.3744 -0.0987 -2.2079 -0.4524 -0.0473 -0.1841 -0.2606 -0.1029 -0.2545 -1.5859 -1.7448 -0.3370 -0.2923 -1.0201 -0.1773 -0.0837 -1.6295 -0.7200 -2.8913 -0.4877 -0.2870 -0.7648 -0.4410 -0.3535 -1.3348 -0.2220 -1.4327 -2.2583 -0.3015 -3.2936 -0.3849 -0.9379 -0.2973 -0.3264 -0.1192 -0.0721 -0.6558 -0.0838 -1.4647 -0.3119
S-345	The MVA was obtained by a continuity equation (LV end-diastolic volume - LV end-systolic volume = mitral filling flow volume = MVA × velocity time integral of mitral filling flow by continuous wave Doppler echocardiography), which can be utilized even in the presence of MR. His mitral valve plasty was successfully performed without major concerns.<unk>
T-345	mva ; continuity equation ; lv end-diastolic volume ; lv end-systolic volume ; mitral filling flow ; mva ; mitral filling flow ; continuous wave doppler echocardiography ; mitral valve plasty
H-345	-0.5697243213653564	▁m VA ▁; ▁end - dia sto lic ▁volume ▁; ▁LV ▁; ▁end - sy sto lic ▁volume ▁; ▁mit ral ▁fill ing ▁flow ▁volume ▁; ▁m VA ▁; ▁veloci ty ▁time ▁; ▁mit ral ▁fill ing ▁flow ▁; ▁wa ve ▁do pp ler ▁e cho card i ography ▁; ▁MR ▁; ▁mit ral ▁val ve ▁plast y
D-345	-0.5697243213653564	mVA ; end-diastolic volume ; LV ; end-systolic volume ; mitral filling flow volume ; mVA ; velocity time ; mitral filling flow ; wave doppler echocardiography ; MR ; mitral valve plasty
P-345	-1.2449 -2.3247 -0.2245 -2.2620 -0.0656 -3.1572 -1.0927 -0.8095 -0.4570 -0.0576 -0.8022 -1.0683 -0.3521 -0.0448 -1.7298 -0.5785 -0.5682 -0.6862 -0.0678 -0.1257 -0.2054 -0.6127 -0.0345 -0.0636 -1.1745 -0.1157 -0.7399 -2.2259 -0.1674 -0.0174 -0.0127 -0.5094 -0.3307 -0.2287 -0.1719 -0.4313 -0.0216 -0.0257 -0.1069 -1.1206 -0.0280 -0.9243 -0.0241 -0.1822 -0.0892 -0.3921 -0.5212 -0.2804 -0.5900 -0.2597 -0.0719 -0.9275 -0.3133 -0.0834 -1.9244 -0.1281 -0.1168 -0.8031 -0.2854 -0.2025
S-157	Compared with usual care, although not reaching statitistical significance, RM trended to reduce all-cause mortality for STS HH (HR: 0.77, 95% credible interval (CrI): 0.55, 1.08), TM during office hours (HR: 0.76, 95% CrI: 0.49, 1.18) and TM24/7 (HR: 0.49, 95% CrI: 0.20, 1.18).<unk>
T-157	significance ; rm ; all-cause mortality ; sts ; hh ; cri ; cri ; cri
H-157	-1.720263957977295	▁stati tis tical ▁; ▁RM ▁; ▁s ts ▁; ▁ HH ▁; ▁c r I ▁; ▁office ▁hours ▁; ▁t 24 /7
D-157	-1.720263957977295	statitistical ; RM ; sts ; HH ; crI ; office hours ; t24/7
P-157	-6.2769 -0.7027 -1.2816 -0.4494 -4.1766 -0.3924 -1.9108 -0.8970 -1.0892 -2.9867 -0.3276 -0.2378 -3.5097 -0.0836 -3.0394 -0.2061 -2.5701 -1.1763 -0.4732 -4.5741 -0.9764 -0.1422 -3.5366 -0.2701
S-381	We externally validated the HFPSI in the Ann Arbor Veterans' Affairs HF clinic (VA cohort, n = 445; 106 outcomes) and explored "real-time" HFPSI use (VA-RT cohort, n = 486; 141 outcomes) by tracking VA patients for 6 months from their most recently calculated HFPSI, rather than using an arbitrary start date for the cohort.<unk>
T-381	hfpsi ; hf ; clinic ; outcomes ; hfpsi ; outcomes ; tracking ; patients ; hfpsi
H-381	-1.184469223022461	▁external ly ▁valida ted ▁; ▁ HF PSI ▁; ▁Ann ▁ar bor ▁Veteran s ' ▁Affairs ▁; ▁ HF ▁; ▁ha w p ▁; ▁va - RT ▁co hor t ▁; ▁VA ▁; ▁ HF PSI ▁; ▁ HF PSI
D-381	-1.184469223022461	externally validated ; HFPSI ; Ann arbor Veterans' Affairs ; HF ; hawp ; va-RT cohort ; VA ; HFPSI ; HFPSI
P-381	-4.3651 -0.1528 -1.0221 -0.1003 -0.7821 -0.6903 -0.7758 -0.3912 -0.1119 -0.1559 -0.7653 -0.1072 -0.5078 -0.0682 -3.5910 -1.1267 -0.6324 -1.4560 -0.9100 -0.9881 -3.4905 -2.8705 -1.2740 -0.3058 -1.6522 -0.8843 -1.1220 -1.8978 -1.2569 -0.4100 -0.3110 -3.9496 -1.2458 -1.5954 -0.9331 -0.8830 -0.7677 -1.8063 -1.2369 -1.4871 -1.3983 -0.2691
S-1706	Compared with AAs, non-AAs were more likely to attain maximal spironolactone dose (13.9% versus 5.8%; P=0.04) and had higher rates of hyperkalemia (potassium>5.5 mmol/L; 9.7% versus 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<0.001).<unk>
T-1706	aas ; spironolactone ; hyperkalemia ; potassium ; hypokalemia ; potassium
H-1706	-0.8984681367874146	▁AA s ▁; ▁non - AA s ▁; ▁spi rono lac tone ▁dose ▁; ▁hyper kal emia ▁; po tas s ium
D-1706	-0.8984681367874146	AAs ; non-AAs ; spironolactone dose ; hyperkalemia ;potassium
P-1706	-0.7932 -0.2391 -0.2331 -2.7621 -0.0617 -0.3011 -0.0773 -0.2339 -0.6157 -0.0609 -0.5777 -0.2805 -1.5872 -0.1602 -2.3956 -1.0547 -0.2623 -0.2370 -1.5085 -0.6698 -0.2154 -1.9166 -4.9976 -0.3219
S-115	Multivariate analysis showed that patients with preserved LVEF had a similar risk of long-term mortality as patients with mild or moderate reduction in LVEF (hazard ratio [HR] 0.92 [p = 0.40] and 1.01 [p = 0.90], respectively) while severely reduced LVEF conferred increased increase rate compared with preserved LVEF (HR 1.20, p = 0.04).<unk>
T-115	multivariate analysis ; patients ; preserved lvef ; mortality ; patients ; lvef ; hazard ratio ; lvef ; preserved lvef
H-115	-0.8352254629135132	▁pres er ved ▁LV EF ▁; ▁long - term ▁mortal ity ▁; ▁LV EF ▁; haz ard ▁ratio ▁; ▁LV EF ▁; ▁pres er ved ▁LV EF
D-115	-0.8352254629135132	preserved LVEF ; long-term mortality ; LVEF ;hazard ratio ; LVEF ; preserved LVEF
P-115	-5.6872 -0.2090 -0.2437 -1.0526 -0.3193 -0.2037 -0.9124 -0.1492 -0.0935 -0.2958 -0.0626 -0.2790 -2.2249 -0.4154 -0.3976 -0.1380 -0.1599 -0.0031 -0.2818 -3.4736 -0.5262 -0.4347 -3.1394 -0.0819 -0.4396 -0.6014 -0.4660 -1.6401 -0.2899
S-242	In patients having HFpEF, predictors of primary outcome were male gender (odds ratio [OR] 3.45, p = 0.004), NYHA class III (OR 3.05, p = 0.008), distance covered on a 6-minute walk test (6-MWT) of <620 feet (OR 2.81, p = 0.013), and <80% adherence to prescribed medications (OR 2.61, p = 0.018).<unk>
T-242	patients ; hfpef ; primary outcome ; odds ratio ; nyha class iii ; 6-minute walk test ; 6-mwt ; feet ; prescribed ; medications
H-242	-1.0555694103240967	▁ HF p EF ▁; ▁primary ▁outcome ▁; ▁w ha ▁; ▁distance ▁; ▁walk ▁test ▁; ▁mw t ▁; ▁ad her ence ▁; ▁medication s
D-242	-1.0555694103240967	HFpEF ; primary outcome ; wha ; distance ; walk test ; mwt ; adherence ; medications
P-242	-1.5383 -0.4005 -0.0217 -1.1721 -0.2775 -4.6007 -0.4127 -0.2586 -6.0761 -0.4562 -0.8471 -4.5469 -0.4259 -1.6880 -0.2317 -0.3197 -2.0029 -0.3579 -0.8157 -0.4440 -0.2023 -0.0163 -0.3291 -0.4241 -0.0747 -0.3294 -0.2304
S-492	Abstract Echo-derived pulmonary arterial systolic pressure (PASP) and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE; from the end of diastole to end-systole) are of basic relevance in the clinical follow-up of heart failure (HF) patients, carrying two- to threefold increase in cardiac risk when increased and reduced, respectively.<unk>
T-492	echo-derived pulmonary arterial systolic pressure ; pasp ; right ventricular ; rv ; tricuspid annular plane systolic excursion ; tapse ; diastole ; end-systole ; clinical ; follow-up ; heart failure ; hf ; patients ; cardiac
H-492	-0.639956533908844	▁e cho - der i ved ▁pulmonar y ▁arterial ▁sy sto lic ▁pressure ▁; PAS p ▁; ▁right ▁vent ri cular ▁; RV ▁; ▁tri cus pid ▁ann ular ▁plane ▁sy sto lic ▁ excursion ▁; TA PS e ▁; ▁end - sy stol e ▁; ▁heart ▁failure ▁; HF ▁; ▁cardiac ▁risk
D-492	-0.639956533908844	echo-derived pulmonary arterial systolic pressure ;PASp ; right ventricular ;RV ; tricuspid annular plane systolic excursion ;TAPSe ; end-systole ; heart failure ;HF ; cardiac risk
P-492	-1.2428 -0.0112 -0.0598 -0.1510 -0.1685 -0.2053 -0.0852 -0.0907 -0.2170 -2.4084 -0.1559 -2.3463 -0.3196 -0.2786 -1.1538 -0.7002 -0.1504 -0.0172 -1.8354 -0.5712 -0.2325 -0.3368 -0.7303 -0.2557 -0.5173 -0.5864 -0.0380 -0.0724 -0.0024 -0.0138 -0.6855 -0.2210 -2.4841 -0.3166 -0.0169 -0.2686 -0.6878 -2.4102 -1.3878 -0.0610 -3.2711 -0.1861 -1.3952 -0.1391 -0.3733 -0.5531 -3.3609 -0.0792 -0.1798 -0.1138 -0.4896 -0.3227 -0.6894 -0.3181 -0.2328
S-1190	The independent predictors of severe CAD included diabetes (odds ratio 5.1, p = 0.005), electrocardiographic Q waves or left bundle branch block (odds ratio 3.8, p = 0.02), and ≥2 nondiabetes risk factors: age (men ≥55 or women ≥65 years), dyslipidemia, hypertension, and tobacco use (odds ratio 4.8, p = 0.02).<unk>
T-1190	cad ; diabetes ; odds ratio ; electrocardiographic q waves ; left bundle branch block ; odds ratio ; nondiabetes ; dyslipidemia ; hypertension ; odds ratio
H-1190	-0.5778905749320984	▁severe ▁CAD ▁; ▁diabetes ▁; ▁electro car dio graphic ▁; ▁wa ves ▁; ▁left ▁bund le ▁bran ch ▁block ▁; ▁non dia bete s ▁risk ▁factors ▁; ▁dys li pide mia ▁; ▁hyper tension ▁; ▁to ba cco
D-1190	-0.5778905749320984	severe CAD ; diabetes ; electrocardiographic ; waves ; left bundle branch block ; nondiabetes risk factors ; dyslipidemia ; hypertension ; tobacco
P-1190	-3.5466 -1.7067 -0.0996 -1.1377 -0.1265 -0.0077 -0.4736 -0.2211 -0.1837 -1.1312 -1.5838 -0.2618 -0.0929 -0.1970 -0.0327 -0.3686 -0.0485 -0.0940 -0.1105 -0.2005 -0.3175 -2.3851 -0.0947 -0.0236 -2.4587 -0.0609 -0.2368 -1.1417 -0.0910 -0.0546 -0.7130 -0.1244 -0.0970 -0.0494 -0.1958 -0.0404 -0.7142 -0.3656 -2.0294 -0.2969
S-485	The area under the receiver operating characteristic curve (AUC) of E/e' ratios for PCWP estimation was 0.79 (95% confidence interval [CI] 0.70 to 0.87) for E/e'septal, 0.72 (95% CI 0.63 to 0.82) for E/elateral, and 0.79 (95% CI 0.70 to 0.87) for E/emean (all p values <0.0001).<unk>
T-485	area under the receiver operating characteristic curve ; auc ; pcwp ; confidence interval ; septal ; p values
H-485	-1.2511999607086182	▁receive r ▁; ▁operating ▁character istic ▁cur ve ▁; AU c ▁; ▁e / e ▁; ▁ratio s ▁; ▁PC WP ▁; ▁e / e ▁; sept al ▁; ▁e / e lateral ▁; ▁e / eme an
D-485	-1.2511999607086182	receiver ; operating characteristic curve ;AUc ; e/e ; ratios ; PCWP ; e/e ;septal ; e/elateral ; e/emean
P-485	-3.3191 -0.1015 -1.8873 -0.6100 -0.7781 -0.5397 -0.3828 -0.6236 -0.2349 -3.1459 -3.1499 -0.1078 -0.9753 -2.7674 -0.0985 -1.9297 -0.2805 -0.1191 -0.0798 -0.5349 -2.5349 -0.2111 -1.1157 -4.0562 -0.1390 -4.9708 -1.0133 -0.0152 -0.1859 -1.0788 -4.7047 -0.2488 -2.0508 -0.3421 -0.7852 -4.1892 -0.0305 -0.1161 -0.2112 -0.3826
S-680	Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95% CI, 1.05 to 1.68) increased the risk of CHF.<unk>
T-680	patients ; coronary artery disease ; hypertension ; trastuzumab ; administration ; chf
H-680	-1.0004783868789673	▁tras tuz um ab - tre ated ▁patients ▁; ▁corona ry ▁arter y ▁disease ▁; ▁gh ▁; ▁hyper tension ▁; ▁CHF
D-680	-1.0004783868789673	trastuzumab-treated patients ; coronary artery disease ; gh ; hypertension ; CHF
P-680	-0.2038 -0.0462 -0.0639 -0.0973 -1.2266 -0.7839 -0.1819 -1.5586 -0.1894 -2.1671 -0.0422 -0.0586 -0.2344 -1.6671 -0.1015 -4.9977 -1.8139 -0.6228 -0.0210 -0.1743 -6.2581 -0.2589 -0.2418
S-754	In the LVEF >30% subgroup, there was a trend for improvement in the clinical composite response with CRT ON versus CRT OFF (P=0.06) and significant reductions in LV end systolic volume index (-6.7 ± 21.1 versus 2.1 ± 17.6 mL/m(2); P=0.01) and LV mass (-20.6 ± 50.5 versus 5.0 ± 42.4 g; P=0.04) after 12 months.<unk>
T-754	lvef ; clinical ; crt ; crt ; systolic volume index ; lv mass
H-754	-0.7435333728790283	▁LV EF ▁; ▁clinic al ▁com posit e ▁response ▁; ▁c RT ▁ON ▁; ▁c RT ▁OFF ▁; ▁LV ▁; ▁end ▁sy sto lic ▁volume ▁index ▁; ▁LV ▁mass
D-754	-0.7435333728790283	LVEF ; clinical composite response ; cRT ON ; cRT OFF ; LV ; end systolic volume index ; LV mass
P-754	-1.6938 -0.3744 -0.0652 -1.4867 -0.0338 -0.7459 -0.0089 -0.0726 -0.5513 -0.1160 -0.3429 -0.9430 -1.8585 -0.1807 -0.4524 -1.3611 -0.8255 -0.1790 -0.9519 -0.9695 -1.9461 -1.3168 -0.1420 -0.8629 -0.4236 -0.2834 -0.1774 -3.0664 -0.5996 -0.8822 -0.1360
S-1343	We show that intervention with TGF-β signaling by inhibiting TGF-β receptor type I or Smad 2/3 using small-molecule inhibitors improved c-Kit+ cell yield, attenuated epithelial to mesenchymal transition markers, stimulated the pluripotency marker Nanog, and improved efficiency of c-Kit+ cell differentiation toward cardiomyocyte-like cells in vitro.<unk>
T-1343	tgf-β signaling ; tgf-β receptor type i ; cell ; yield ; epithelial ; mesenchymal ; transition ; pluripotency marker ; nanog ; cell ; cells ; in vitro
H-1343	-0.5515599250793457	▁t g - β ▁signal ing ▁; ▁t g - β ▁receptor ▁; ▁s mad ▁; ▁small - mo le cule ▁inhibi tors ▁; ▁c - K it ▁; ▁cell ▁yi eld ▁; ▁epi the li al ▁; ▁mes en chy mal ▁transition ▁marker s ▁; ▁pluri pote ncy ▁marker ▁na nog ▁; ▁c - K it ▁; ▁cell ▁differenti ation ▁; ▁cardio my o cy te - like ▁cell s
D-1343	-0.5515599250793457	tg-β signaling ; tg-β receptor ; smad ; small-molecule inhibitors ; c-Kit ; cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit ; cell differentiation ; cardiomyocyte-like cells
P-1343	-0.3014 -0.8921 -0.3425 -0.8243 -0.3311 -0.1329 -0.1689 -0.8351 -1.3013 -1.3046 -2.4108 -0.0778 -1.2766 -0.2090 -0.0456 -0.2702 -0.3771 -0.0558 -0.0727 -1.1901 -0.3755 -0.2258 -0.0663 -0.1050 -0.0014 -0.2510 -2.5229 -2.2926 -1.7878 -1.8293 -0.0207 -0.0059 -0.1470 -0.0594 -0.4657 -0.2354 -0.0319 -0.2254 -0.0308 -1.2358 -0.3042 -0.0832 -0.0210 -0.1523 -0.0389 -0.1435 -0.0955 -0.0457 -0.0098 -0.0708 -0.0696 -0.0188 -0.3056 -0.0034 -0.0726 -2.1973 -2.4068 -1.6788 -1.2105 -0.1161 -0.0723 -0.2769 -0.0686 -0.9650 -0.1981 -0.1109 -0.3628 -1.4714 -1.6547 -0.6526 -0.0230 -0.8461 -0.1813
S-243	In patients having HFrEF, the predictors were being on diuretics (OR 3.06, p = 0.001), having ≥3 co-morbidities (OR 2.11, p = 0.0001), distance covered on a 6-MWT of <620 feet (OR 1.94, p = 0.001), NYHA class III (OR 1.90, p = 0.001), and age >65 years (OR 1.63, p = 0.01).<unk>
T-243	patients ; hfref ; diuretics ; co-morbidities ; 6-mwt ; feet ; nyha class iii
H-243	-1.0809893608093262	▁h Fr f ▁; ▁di ure tics ▁; ▁co - mor bid ities ▁; ▁distance ▁; ▁mw t ▁; ▁NY HA ▁class ▁III
D-243	-1.0809893608093262	hFrf ; diuretics ; co-morbidities ; distance ; mwt ; NYHA class III
P-243	-1.3646 -1.5159 -1.6882 -0.1997 -0.2293 -0.4346 -2.1242 -0.2524 -0.3085 -0.3306 -0.3971 -0.0572 -0.1065 -0.3142 -4.4390 -0.4426 -2.8183 -0.3439 -0.2240 -3.1329 -1.3180 -1.3803 -1.6704 -1.6867 -0.2458
S-344	After the surgery, HF disappeared and postoperative echocardiography confirmed a normal sized LV with an end-diastolic volume index of 71 mL/m2, normal LV ejection fraction of 0.70, no MR and preserved mitral valve opening with a mitral valve area (MVA) of 1.8 cm2, and a mean pressure gradient of 4.4 mm Hg (Fig 1A).<unk>
T-344	surgery ; hf ; postoperative ; echocardiography ; end-diastolic volume index ; lv ejection fraction ; mitral valve opening ; mitral valve area ; mva
H-344	-0.5356795787811279	▁ HF ▁; ▁post operativ e ▁e cho card i ography ▁; ▁LV ▁; ▁end - dia sto lic ▁volume ▁index ▁; ▁LV ▁e je ction ▁ fraction ▁; ▁MR ▁; ▁mit ral ▁val ve ▁opening ▁; ▁mit ral ▁val ve ▁area ▁; ▁m VA ▁; ▁mean ▁pressure ▁gradi ent ▁; ▁f g
D-344	-0.5356795787811279	HF ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ejection fraction ; MR ; mitral valve opening ; mitral valve area ; mVA ; mean pressure gradient ; fg
P-344	-1.9679 -0.2361 -0.4098 -0.4784 -0.1828 -0.1260 -0.2348 -0.5976 -0.5212 -0.3528 -0.4923 -0.1168 -1.8581 -0.0767 -0.0765 -0.0612 -1.3516 -0.3348 -0.4346 -0.2611 -0.5021 -0.1241 -2.6674 -0.5899 -0.2360 -0.0973 -1.2761 -0.0174 -0.1328 -0.1212 -0.0676 -0.6785 -0.1185 -0.8886 -0.1659 -0.7132 -0.1602 -0.8305 -0.4722 -0.9700 -0.1565 -0.3267 -0.2627 -0.2109 -1.4969 -0.3722 -0.5743 -0.2664 -0.0268 -0.0300 -0.5668 -3.5404 -0.0743 -0.4419 -0.1147
S-519	METHODS: Among the patients with systolic heart failure (ejection fraction ≤35%) randomized to either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial), 275 patients (n = 132, placebo; n = 143, ivabradine 7.5 mg twice a day) were included in the echocardiographic substudy.<unk>
T-519	patients ; systolic heart failure ; ejection fraction ; randomized ; placebo ; ivabradine ; shift ; systolic heart failure treatment with the if inhibitor ivabradine trial ; patients ; placebo ; ivabradine ; echocardiographic
H-519	-0.7061783075332642	▁sy sto lic ▁heart ▁failure ▁; ej ection ▁ fraction ▁; ▁place bo ▁; ▁i va bra dine ▁; ▁SHI ft ▁; Sy sto lic ▁Heart ▁Fail ure ▁Treatment ▁; ▁if ▁in hib itor ▁i va bra dine ▁Tri al ▁; ▁i va bra dine ▁; ▁e cho car dio graphic
D-519	-0.7061783075332642	systolic heart failure ;ejection fraction ; placebo ; ivabradine ; SHIft ;Systolic Heart Failure Treatment ; if inhibitor ivabradine Trial ; ivabradine ; echocardiographic
P-519	-3.1645 -0.1813 -0.7808 -2.4507 -0.0899 -0.1206 -5.1198 -0.0128 -0.4306 -0.0090 -0.1233 -1.7846 -0.1921 -0.0694 -0.0082 -2.7867 -0.3687 -0.0941 -0.0861 -0.1481 -0.9774 -0.1183 -0.9813 -0.0372 -0.2924 -0.8786 -0.3158 -0.0136 -0.7431 -0.1521 -1.6240 -0.0847 -0.0075 -0.0616 -0.4013 -0.9793 -0.1686 -0.0424 -1.5700 -0.0124 -0.4054 -1.1542 -2.4526 -0.4907 -0.0915 -0.3855 -0.2033 -0.4559 -0.7647 -1.3494 -1.3711 -0.6799 -0.1401
S-499	Hazard ratios for variables retained in the multivariate regression were as follows: TAPSE/PASP </≥ 0.36 mm/mmHg [hazard ratio (HR): 10.4, P < 0.001]; TAPSE </≥ 16 mm (HR: 5.1, P < 0.01); New York Heart Association functional class </≥ 3 (HR: 4.4, P < 0.001); E/e' (HR: 4.1, P < 0.001).<unk>
T-499	hazard ratios ; multivariate regression ; tapse ; pasp ; hazard ratio ; tapse ; new york heart association functional class
H-499	-1.1426303386688232	▁Hazard ▁ratio s ▁; ▁t p se ▁; ▁pas p ▁; haz ard ▁ratio ▁; ▁t p se ▁; ▁New ▁York ▁Heart ▁association ▁; ▁functional ▁class
D-499	-1.1426303386688232	Hazard ratios ; tpse ; pasp ;hazard ratio ; tpse ; New York Heart association ; functional class
P-499	-1.9666 -0.0266 -0.2331 -0.1925 -1.4439 -2.1951 -1.5680 -0.5673 -3.6133 -0.0537 -0.1146 -1.3573 -0.7422 -0.0329 -0.1840 -0.7548 -1.0094 -0.7444 -0.0905 -3.6665 -0.6089 -2.2642 -0.7688 -0.5670 -5.1895 -0.1538 -1.5968 -0.2881
S-390	Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)-group I: ≥60 mL/min per 1.73 m(2), group II: 30 to 59 mL/min per 1.73 m(2), group III: 15 to 29 mL/min per 1.73 m(2), group IV: <15 mL/min per 1.73 m(2).<unk>
T-390	renal function ; the chronic kidney disease epidemiology collaboration ; patients ; estimated glomerular filtration rate ; egfr
H-390	-0.7326496839523315	▁Ren al ▁function ▁; ▁Chro nic ▁Kid ney ▁Disease ▁Epidemi ology
D-390	-0.7326496839523315	Renal function ; Chronic Kidney Disease Epidemiology
P-390	-1.5201 -0.0971 -0.4071 -0.3912 -0.0144 -0.0690 -0.5126 -0.3918 -0.4176 -0.1688 -0.1760 -4.9833 -0.3756
S-1968	Large-scale prospective randomized multicenter trial PARADIGM-HF with more than 8000 individuals with stabilized chronic heart failure with systolic dysfunction (LV EF 40%, later 35%), mostly in functional class NYHA II-III with elevated BNP/NT-pro BNP has shown 20% decrease in primary endpoint (cardiovascular death or hospitalization for heart failure) in a group treated by ARNI (LCZ696; sacubiltril - valsartan).<unk>
T-1968	prospective ; randomized ; paradigm-hf ; chronic heart failure ; systolic dysfunction ; lv ef ; functional class ; nyha ; elevated ; bnp ; nt-pro bnp ; primary endpoint ; cardiovascular death ; hospitalization ; heart failure ; arni ; lcz696 ; sacubiltril ; valsartan
H-1968	-0.7283805012702942	▁PARA DIG m - HF ▁; ▁chronic ▁heart ▁failure ▁; ▁sy sto lic ▁dys function ▁; LV ▁EF ▁; ▁NY HA ▁II - III ▁; ▁b NP ▁; ▁b NP ▁; ▁primary ▁end point ▁; car dio vas cular ▁death ▁; ▁hospital ization ▁; ▁heart ▁failure ▁; ▁ar ni ▁; ▁sa cubi lt ril ▁; ▁val sar tan
D-1968	-0.7283805012702942	PARADIGm-HF ; chronic heart failure ; systolic dysfunction ;LV EF ; NYHA II-III ; bNP ; bNP ; primary endpoint ;cardiovascular death ; hospitalization ; heart failure ; arni ; sacubiltril ; valsartan
P-1968	-5.3577 -0.2880 -0.3908 -0.0787 -0.1301 -0.3714 -2.1691 -2.0260 -0.1556 -0.2384 -1.3553 -0.1307 -1.8103 -0.3193 -0.7868 -0.1625 -0.8654 -0.7009 -0.1128 -2.1804 -0.4943 -0.3172 -0.0553 -0.0081 -0.0794 -1.3616 -0.6259 -0.1860 -2.5342 -0.8855 -0.1274 -0.6111 -0.1018 -0.0549 -0.1976 -1.4881 -1.1456 -1.2041 -0.1755 -1.6280 -0.0745 -0.2109 -0.2106 -0.7743 -0.2077 -0.1097 -0.3795 -1.3915 -1.2787 -0.0937 -1.0590 -0.3057 -1.1867 -0.1669 -0.1524 -1.6624 -0.1718 -0.1164 -0.9823 -0.2563
S-432	LV reverse remodeling (n=161; 48%) was associated with pre-CRT LV end-diastolic dimension index <3.1 cm/m(2), global longitudinal strain of left ventricle <-7%, left atrial area <26 cm(2), right ventricular end-diastolic area index <10.0 cm(2)/m(2), right atrial area <20 cm(2), and right ventricular fractional area change ≥35%.<unk>
T-432	lv reverse remodeling ; lv end-diastolic dimension ; longitudinal ; strain ; left ventricle ; left atrial area ; right ventricular end-diastolic area index ; right atrial ; right ventricular fractional area ; change
H-432	-0.822395384311676	▁rever se ▁remodel ing ▁; ▁pre - C RT ▁LV ▁; ▁end - dia sto lic ▁ dimension ▁; ▁global ▁longitud in al ▁strain ▁; ▁left ▁vent ric le ▁; ▁left ▁at rial ▁area ▁; ▁right ▁vent ri cular ▁; ▁end - dia sto lic ▁area ▁; ▁right ▁at rial ▁area ▁; ▁right ▁vent ri cular ▁ fraction al ▁area ▁change
D-432	-0.822395384311676	reverse remodeling ; pre-CRT LV ; end-diastolic dimension ; global longitudinal strain ; left ventricle ; left atrial area ; right ventricular ; end-diastolic area ; right atrial area ; right ventricular fractional area change
P-432	-1.1646 -0.0808 -0.1030 -0.0352 -0.1807 -0.2381 -0.0086 -1.1495 -0.5068 -3.0537 -0.5722 -1.1619 -0.0770 -0.9407 -1.3002 -1.2044 -3.4639 -0.1693 -0.3698 -1.8455 -0.0240 -0.1414 -0.0542 -1.0899 -0.4318 -0.1676 -4.7075 -2.6376 -1.6066 -0.1239 -0.4360 -0.7068 -0.1862 -0.1784 -0.1952 -0.0523 -3.4199 -0.8661 -0.1859 -0.6268 -3.2657 -0.0800 -0.7334 -1.1653 -1.5419 -0.4788 -0.6195 -0.0649 -1.1688 -0.1488 -0.1717 -0.4034 -0.1116 -3.4158 -0.9333 -0.2829 -0.7905 -0.0072 -0.0648 -0.0753 -0.1491 -0.4715 -0.2027
S-1703	METHODS AND RESULTS: We assessed hyperkalemia and outcomes in African Americans (AAs; n=120) and non-AAs (n=1543; white 93%) with New York Heart Association (NYHA) class III or IV HF and left ventricular dysfunction who were randomized to spironolactone, titrated to 25 or 50 mg daily or placebo, in the Randomized Aldactone Evaluation Study (RALES).<unk>
T-1703	hyperkalemia ; outcomes ; african americans ; aas ; new york heart association ; nyha ; hf ; left ventricular dysfunction ; randomized ; spironolactone ; titrated ; placebo ; randomized aldactone evaluation study ; rales
H-1703	-0.6916121244430542	▁hyper kal emia ▁; ▁African ▁American s ▁; AA s ▁; ▁non - AA s ▁; ▁New ▁York ▁Heart ▁association ▁; NY HA ▁; ▁IV ▁ HF ▁; ▁left ▁vent ri cular ▁dys function ▁; ▁spi rono lac tone ▁; ▁al da cto ne ▁evaluation ▁study ▁; RAL es
D-1703	-0.6916121244430542	hyperkalemia ; African Americans ;AAs ; non-AAs ; New York Heart association ;NYHA ; IV HF ; left ventricular dysfunction ; spironolactone ; aldactone evaluation study ;RALes
P-1703	-2.0249 -0.9411 -0.6617 -0.1738 -1.1669 -1.2030 -0.1098 -0.0725 -1.3670 -0.0632 -0.0367 -1.0893 -0.1082 -0.4264 -0.0241 -0.0524 -3.4651 -0.7888 -1.6980 -0.5218 -0.1690 -0.4238 -0.9644 -0.1235 -2.0022 -0.1738 -0.1274 -0.0576 -0.0316 -2.5025 -1.6390 -0.6906 -0.2906 -1.9199 -0.2244 -0.5610 -0.0202 -0.1060 -0.0576 -0.1729 -3.2279 -0.0909 -0.5812 -0.0946 -0.6087 -1.0612 -0.7117 -0.0047 -0.1999 -0.2602 -0.1783
S-654	To determine the role of IRS1 and IRS2 in the heart and examine whether hyperinsulinemia causes myocardial insulin resistance and cellular dysfunction via IRS1 and IRS2, we generated heart-specific IRS1 and IRS2 gene double-knockout (H-DKO) mice and liver-specific IRS1 and IRS2 double-knockout (L-DKO) mice.<unk>
T-654	irs1 ; irs2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; irs1 ; irs2 ; heart-specific irs1 and irs2 gene double-knockout ; h-dko ; liver-specific irs1 and irs2 double-knockout ; l-dko
H-654	-0.7288334965705872	▁i RS 1 ▁; ▁i RS 2 ▁; ▁hyper insu line mia ▁; ▁my o card ial ▁insulin ▁resist ance ▁; ▁cel lular ▁dys function ▁; ▁i RS 2 ▁; ▁i RS 2 ▁; ▁i RS 1 ▁; ▁i RS 2 ▁double - k no ckou t ▁; ▁l - d KO ▁; ▁mi ce
D-654	-0.7288334965705872	iRS1 ; iRS2 ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS2 ; iRS2 ; iRS1 ; iRS2 double-knockout ; l-dKO ; mice
P-654	-0.9187 -0.2701 -0.4678 -0.4201 -0.6876 -0.8319 -0.1029 -0.2568 -3.2313 -0.3358 -0.6689 -3.6485 -0.1867 -0.4371 -0.1583 -1.7762 -0.1572 -0.4354 -0.3580 -0.0621 -0.1509 -2.2321 -0.0471 -0.2962 -1.3837 -0.2020 -0.3824 -0.1427 -1.2851 -0.2238 -1.2093 -0.6208 -0.8130 -0.2976 -1.9994 -0.6914 -1.6200 -0.1845 -1.3843 -0.7449 -0.4555 -1.1536 -0.0595 -0.8465 -0.0370 -0.0505 -0.0300 -0.2949 -1.9681 -0.1398 -0.5796 -0.8021 -1.6573 -0.7892 -0.2656 -0.7771 -0.3146
S-1364	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide – Diagnostic role in stable coronary artery disease B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are released from ventricular cardiomyocytes in response to an increase in ventricular wall stress and to myocardial ischemia.<unk>
T-1364	b-type natriuretic peptide ; n-terminal pro-b-type natriuretic peptide ; diagnostic ; stable ; coronary artery disease ; b-type natriuretic peptide ; bnp ; nt-probnp ; ventricular cardiomyocytes ; ventricular ; wall stress ; myocardial ischemia
H-1364	-0.6422345638275146	▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁N - termin al ▁pro - B - type ▁na tri ure tic ▁pe pti de ▁; ▁stable ▁corona ry ▁arter y ▁disease ▁; ▁b - type ▁na tri ure tic ▁pe pti de ▁; ▁b NP ▁; ▁N - termin al ▁fragment ▁; NT - pro b NP ▁; ▁vent ri cular ▁cardio my o cy tes ▁; ▁vent ri cular ▁wall ▁stress ▁; ▁my o card ial ▁ ische mia
D-1364	-0.6422345638275146	b-type natriuretic peptide ; N-terminal pro-B-type natriuretic peptide ; stable coronary artery disease ; b-type natriuretic peptide ; bNP ; N-terminal fragment ;NT-probNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
P-1364	-1.8939 -0.2559 -2.1034 -0.0225 -1.2449 -0.2689 -0.3129 -0.0785 -0.3825 -1.6205 -0.1688 -2.3595 -0.0560 -0.0431 -0.0029 -0.0496 -0.0663 -1.2088 -0.1533 -0.6681 -0.0180 -0.8353 -0.2028 -0.3889 -0.1071 -0.4921 -1.0165 -0.2277 -1.3844 -0.7360 -0.0675 -0.2061 -0.3804 -1.8434 -0.8471 -1.8672 -1.6948 -0.5421 -0.0074 -1.2809 -0.2169 -0.4743 -0.0986 -0.6656 -1.5085 -0.1975 -1.4256 -0.8299 -0.2273 -1.8735 -0.0323 -0.0476 -0.0012 -0.1961 -0.2177 -1.1108 -0.0188 -0.0598 -0.5581 -0.6141 -0.4060 -1.1385 -0.5350 -0.5230 -1.2828 -0.8064 -0.4254 -0.1780 -0.2100 -0.2218 -1.1465 -1.3428 -0.6698 -1.4145 -0.0839 -0.1434 -1.5363 -0.1832 -1.3676 -0.1095 -0.1565 -1.0541 -1.2903 -0.6272 -0.2567
S-665	The unadjusted practice-level prescription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median, 85%; interquartile range, 75%-89%), from 49% to 100% for β-blockers (median, 92%; interquartile range, 83%-95%), and from 37% to 100% for optimal combined treatment (median, 79%; interquartile range, 66%-85%).<unk>
T-665	prescription ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; interquartile range ; β-blockers ; interquartile range ; interquartile range
H-665	-0.5126526355743408	▁ang io ten sin - con ver ting ▁enzym e ▁inhibi tors ▁; angi oten sin ▁receptor ▁block ers ▁; ▁inter quart ile ▁range ▁; ▁β - block ers
D-665	-0.5126526355743408	angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile range ; β-blockers
P-665	-2.4267 -2.0867 -0.6969 -0.1360 -0.2446 -0.0050 -0.0907 -0.0582 -0.0426 -0.0540 -0.3303 -0.1226 -0.9292 -0.8256 -0.2403 -0.1919 -0.0061 -0.2903 -0.1529 -0.7426 -1.3576 -0.0023 -0.5335 -0.4390 -0.8472 -1.1154 -0.0501 -0.2233 -0.2493 -1.0462 -0.3552
S-1177	Therapy with ivabradine (β = 0.34, p = 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (β = -0.30, p = 0.02) were independent correlates of increase in exercise capacity, and therapy with ivabradine (β = 0.32, p = 0.007) was independently correlated with increase in peak oxygen uptake.<unk>
T-1177	therapy ; ivabradine ; change ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity ; correlates ; exercise capacity ; therapy ; ivabradine ; correlated ; peak oxygen uptake
H-1177	-0.5868546962738037	▁i va bra dine ▁; ▁treatment ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty ▁; ▁exercise ▁capacity ▁; ▁i va bra dine ▁; ▁pe ak ▁oxygen ▁up take
D-1177	-0.5868546962738037	ivabradine ; treatment ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity ; exercise capacity ; ivabradine ; peak oxygen uptake
P-1177	-0.7704 -1.4383 -0.1438 -0.1387 -0.1865 -3.3661 -0.2201 -1.7212 -0.0057 -0.1845 -0.6848 -0.3598 -0.8545 -1.2928 -0.1760 -1.8613 -0.0642 -0.1514 -0.1621 -1.8821 -0.0035 -0.1431 -0.5262 -0.3852 -1.1189 -0.9332 -0.2523 -0.6667 -0.0007 -0.0266 -0.1296 -0.3183 -1.6808 -0.1172 -0.3693 -0.2775 -1.7056 -0.3023 -0.1958 -0.1735 -0.8207 -0.0062 -0.8487 -0.3413 -0.0879 -0.2427 -0.2439
S-45	Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032).<unk>
T-45	evidence ; transfusion ; mortality ; relative risk ; mortality ; patients ; acute coronary syndrome
H-45	-0.4431910216808319	▁liberal ▁trans fusion ▁protocol s ▁; ▁short - term ▁mortal ity ▁rates ▁; ▁aggressiv e ▁protocol s ▁; ▁relative ▁risk ▁; ▁a cute ▁corona ry ▁syndrome
D-45	-0.4431910216808319	liberal transfusion protocols ; short-term mortality rates ; aggressive protocols ; relative risk ; acute coronary syndrome
P-45	-1.4196 -0.0756 -0.4999 -0.5569 -0.0901 -0.2069 -1.0259 -0.1893 -0.1709 -0.3365 -0.1009 -0.7760 -0.3895 -2.3646 -0.1544 -0.0941 -0.0686 -0.2533 -0.0397 -0.3908 -0.3453 -1.7234 -0.1420 -0.1592 -0.0728 -0.0492 -0.4170 -0.2970
S-1419	The risk of death or unplanned readmission during the 6-month observation period was lower among patients who saw a familiar physician (43.6%; adjusted hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.83-0.91) or an unfamiliar physician (43.6%; adjusted HR 0.90, 95% CI 0.83-0.97) for early follow-up visits, as compared with patients who had no follow-up visits (62.9%).<unk>
T-1419	death ; readmission ; patients ; physician ; hazard ratio ; confidence interval ; physician ; follow-up ; patients ; follow-up
H-1419	-1.2009693384170532	▁risk ▁of ▁death ▁; ▁un plan ned ▁read mission ▁; ▁physician ▁; ▁adjust ed ▁hazard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; ▁CI ▁; ▁un fa milia r ▁physician ▁; ▁follow - up
D-1419	-1.2009693384170532	risk of death ; unplanned readmission ; physician ; adjusted hazard ratio ;HR ; confidence interval ; CI ; unfamiliar physician ; follow-up
P-1419	-4.2504 -0.9330 -1.5687 -0.1466 -0.0267 -0.1360 -0.2590 -1.2263 -0.1276 -0.5568 -4.7231 -0.2540 -5.1972 -0.0095 -0.6829 -0.0040 -0.1572 -1.8579 -0.1655 -5.2403 -0.2691 -0.2457 -3.5260 -0.3429 -0.4871 -0.1905 -0.0280 -0.0207 -1.6467 -0.2482 -4.1649 -0.2798 -0.0250 -2.7701 -0.2667
S-1409	METHODS AND RESULTS: In HEK (human embryonic kidney) 293 cells overexpressing both β1AR and S1PR1, we demonstrated that β1AR downregulation can occur after stimulation with sphingosine-1-phosphate (an S1PR1 agonist), whereas S1PR1 downregulation can be triggered by isoproterenol (a β-adrenergic receptor agonist) treatment.<unk>
T-1409	hek ; human embryonic kidney ; cells ; β1ar ; s1pr1 ; β1ar ; downregulation ; sphingosine-1-phosphate ; s1pr1 agonist ; s1pr1 ; downregulation ; isoproterenol ; β-adrenergic receptor agonist
H-1409	-0.8115357160568237	▁h ek ▁; ▁em bry o nic ▁ki dne y ▁; ▁β 1 AR ▁; ▁s 1 PR 1 ▁; ▁down regul ation ▁; ▁sp hing os ine -1 - phos pha te ▁; ▁s 1 PR 1 ▁; ▁down regul ation ▁; ▁iso prot eren ol ▁; ▁β - ad r energi c ▁receptor ▁ago nist
D-1409	-0.8115357160568237	hek ; embryonic kidney ; β1AR ; s1PR1 ; downregulation ; sphingosine-1-phosphate ; s1PR1 ; downregulation ; isoproterenol ; β-adrenergic receptor agonist
P-1409	-1.4851 -1.4932 -0.1862 -1.7771 -0.2051 -0.1181 -0.0731 -0.1183 -0.7605 -0.1174 -0.3053 -4.0978 -1.3043 -2.4627 -0.1088 -0.4897 -0.8103 -0.7815 -2.0490 -0.7481 -4.7725 -0.3554 -0.1788 -0.3466 -2.3553 -0.7138 -0.2088 -0.1555 -0.9450 -0.1874 -0.0182 -0.5682 -0.1386 -0.1254 -0.4823 -0.2894 -0.7396 -1.2377 -1.2581 -1.0772 -1.1417 -0.4285 -0.3024 -0.0525 -0.5297 -1.8421 -1.3960 -0.1639 -0.6862 -0.0778 -0.3522 -0.5877 -2.2419 -0.6925 -0.0249 -0.1779 -0.0442 -1.2972 -0.1958
S-1330	Assessment was performed at baseline and after completion of training protocol and included 6-minute walked distance, quality of life (Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure Questionnaire), depressive symptoms (Beck Depression Inventory and Zung self-rated depression scores), B-type natriuretic peptide, endothelial function (flow-mediated dilatation), and left ventricular diastolic function.<unk>
T-1330	baseline ; training ; 6-minute walked distance ; quality of life ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; symptoms ; beck depression inventory ; zung self-rated depression scores ; b-type natriuretic peptide ; endothelial function ; flow-mediated dilatation ; left ventricular diastolic function
H-1330	-0.5756809711456299	▁base line ▁; ▁walk ▁distance ▁; Kan sas ▁City ▁Card i om yo pathy ▁; ▁Minnesota ▁Living ▁with ▁Heart ▁Fail ure ▁Question naire ▁; ▁ depressiv e ▁symptoms ▁; ▁be ck ▁de pression ▁in ven tory ▁; ▁z ung ▁self - rat ed ▁depression ▁score s ▁; ▁na tri ure tic ▁pe pti de ▁; ▁en dot heli al ▁function ▁; flow - media ted ▁di la tation ▁; ▁left ▁vent ri cular ▁dia sto lic ▁function
D-1330	-0.5756809711456299	baseline ; walk distance ;Kansas City Cardiomyopathy ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; zung self-rated depression scores ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; left ventricular diastolic function
P-1330	-1.3959 -0.0438 -0.2127 -4.1959 -0.0530 -0.2377 -1.8010 -0.0007 -0.1901 -1.9096 -0.0565 -0.4452 -2.4240 -1.8607 -0.8856 -0.1017 -1.4442 -0.7552 -0.2252 -0.1272 -0.0202 -1.7661 -0.1339 -0.1635 -0.5360 -0.0147 -0.0738 -1.0933 -0.0930 -0.9404 -0.0449 -0.4650 -0.1620 -0.2231 -0.0600 -0.0009 -0.2347 -0.3597 -0.2029 -0.1557 -0.0076 -0.0161 -0.0030 -0.3993 -1.1337 -0.0368 -0.4923 -0.8301 -0.4033 -0.1394 -0.2208 -0.0839 -0.3299 -0.8292 -0.2079 -0.0708 -2.8156 -0.3130 -0.0163 -0.8763 -0.2474 -0.9043 -0.0659 -0.0769 -0.1268 -0.1253 -0.1624 -0.0132 -0.5464 -0.1968 -1.9898 -0.7290 -0.5269 -1.4837 -0.1021 -1.1650 -1.8632 -0.6315 -0.1875
S-976	Odds ratios with 95% confidence intervals for cardiovascular events after adjustment for age, gender, atrial fibrillation, left ventricular ejection fraction, diabetes mellitus, peripheral vascular disease, and history of myocardial infarction, heart failure, or stroke was 1.24 (1.06 to 1.45) in patients with an estimated glomerular filtration rate of 15 to 45 ml/min/1.73 m(2) but became nonsignificant after acute kidney injury was introduced into the statistical model.<unk>
T-976	odds ratios ; confidence intervals ; cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; patients ; estimated glomerular filtration rate ; nonsignificant ; acute kidney injury
H-976	-0.4771321415901184	▁Odd s ▁ratio s ▁; ▁cardiovascular ▁events ▁; ▁at rial ▁fi bril lation ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁diabetes ▁mell itus ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁my o card ial ▁in far ction ▁; ▁heart ▁failure ▁; ▁stroke ▁; ▁glo mer ular ▁filtr ation ▁rate
D-976	-0.4771321415901184	Odds ratios ; cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration rate
P-976	-4.1328 -0.1063 -0.0996 -0.1034 -0.6073 -0.1967 -0.3973 -0.3353 -0.5671 -0.0978 -0.6316 -0.0408 -0.8059 -0.2141 -0.2602 -3.1654 -0.7355 -0.5093 -0.0783 -0.1342 -0.1868 -0.8234 -0.0178 -0.1830 -0.0414 -0.0191 -0.0673 -0.1286 -0.0041 -0.0899 -0.0419 -0.0567 -0.6611 -0.1632 -0.7340 -0.1581 -0.2882 -0.1676 -0.8855 -0.0305 -0.0279 -0.3372 -0.2451 -0.1507 -0.5455 -0.0454 -0.2118 -0.4763 -0.4367 -0.5929 -0.5242 -0.0055 -0.2876 -0.1573 -0.0639 -4.8897 -0.2314
S-925	In conjunction, diastolic function improved (c=24.3 ± 5.3 to 22.7 ± 8.1 g/s; P=0.03; k=252 ± 115 to 170 ± 37 g/s(2); P=0.03), Ea decreased (2.0 ± 0.4 to 1.7 ± 0.4 mm Hg/mL; P=0.007), and ventricular-arterial coupling improved (Ees:Ea=1.5 ± 0.3 to 1.7 ± 0.4; P=0.04).<unk>
T-925	diastolic function ; ea ; ventricular-arterial coupling ; ees ; ea
H-925	-0.9625211954116821	▁in ▁con jun ction ▁; ▁dia sto lic ▁function ▁; ▁ea ▁; ▁vent ri cular - arte rial ▁coup ling ▁; ▁e es
D-925	-0.9625211954116821	in conjunction ; diastolic function ; ea ; ventricular-arterial coupling ; ees
P-925	-0.8702 -0.7439 -0.0517 -0.0390 -0.3344 -0.6170 -0.5358 -1.3378 -0.8041 -0.2241 -4.9286 -0.2743 -6.0555 -1.1572 -0.2353 -0.2811 -0.0443 -0.1209 -0.0894 -0.1481 -0.5135 -1.2681 -1.4576 -1.6587 -0.2725
S-1835	The hazard ratios from the disease risk score (DRS)-stratified analyses were 0.83 (95% CI, 0.70 to 0.99) for saxagliptin versus sitagliptin, 0.63 (CI, 0.47 to 0.85) for saxagliptin versus pioglitazone, 0.69 (CI, 0.54 to 0.87) for saxagliptin versus sulfonylureas, and 0.61 (CI, 0.50 to 0.73) for saxagliptin versus insulin.<unk>
T-1835	hazard ratios ; disease risk score ; drs ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
H-1835	-0.9893897175788879	▁hazard ▁ratio s ▁; ▁disease ▁risk ▁score ▁; ▁d RS - stra t ified ▁analyse s ▁; ▁sax ag lip tin ▁; ▁si tag lip tin ▁; ▁sax ag lip tin ▁; ▁pi og lita zone ▁; ▁sax ag lip tin ▁; ▁sul fon yl ure as ▁; ▁sax ag lip tin ▁; ▁insulin
D-1835	-0.9893897175788879	hazard ratios ; disease risk score ; dRS-stratified analyses ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
P-1835	-4.2457 -0.0242 -0.0709 -0.2802 -0.8707 -0.5992 -0.5106 -0.3470 -0.3175 -0.6262 -6.4583 -0.0311 -0.0736 -0.0385 -0.7737 -0.0372 -0.1753 -0.7583 -0.3070 -1.5161 -3.0735 -0.2862 -2.0240 -0.9720 -0.9424 -3.1383 -0.2427 -1.1474 -0.5333 -1.9573 -3.8562 -0.2391 -0.0319 -1.0856 -0.0977 -0.1573 -0.1622 -0.6381 -0.7561 -2.0133 -4.1545 -0.3421 -0.1121 -0.2129 -0.2780 -0.0163 -0.0888 -0.3132 -1.3615 -0.7591 -1.8589 -3.5432 -0.4288 -0.0458 -0.2643 -0.2103
S-106	Independent predictors for the development of IE among study patients included previous revascularization (coronary artery bypass surgery: hazard ratio [HR] 1.88, p = 0.003; percutaneous coronary intervention: HR 3.21, p <0.001) and increased systolic blood pressure (HR 1.67, p = 0.02), whereas a left bundle branch block pattern on the baseline electrocardiogram was associated with reduced risk for IE (HR 0.62, p = 0.02).<unk>
T-106	patients ; revascularization ; coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline ; electrocardiogram
H-106	-0.5934360027313232	▁re vas cular ization ▁; co ron ary ▁arter y ▁by pass ▁surgery ▁; ▁hazard ▁ratio ▁; ▁per cuta ne ous ▁corona ry ▁intervention ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁left ▁bund le ▁bran ch ▁block ▁pattern ▁; ▁base line ▁electro card i ogram
D-106	-0.5934360027313232	revascularization ;coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram
P-106	-1.8151 -0.0325 -0.1371 -0.1670 -0.3983 -1.5246 -0.2784 -0.0877 -0.1806 -0.0773 -0.2946 -0.8134 -0.6564 -0.3199 -1.4637 -0.0036 -0.1589 -0.0537 -0.0011 -0.0924 -0.1199 -1.2094 -0.0817 -0.4909 -0.2324 -4.0426 -0.1279 -1.5247 -2.6504 -0.7040 -0.3169 -1.7236 -0.0272 -0.5261 -0.3728 -0.0894 -0.0750 -0.1726 -0.2716 -0.0028 -0.0311 -0.0408 -0.5472 -0.4433 -0.1326 -3.1320 -0.2464
S-1262	Compared with biomedical treatment alone, biomedical treatment plus CHM showed significant improvement in effective rate (relative risk, 1.26; 95% confidence interval [CI], 1.19-1.34), left ventricular ejection fraction (%) (mean difference, 5.88; 95% CI, 3.92-7.85), left ventricular diastolic end diameter (mm) (mean difference, -2.78; 95% CI, -5.15 to -0.42), and other outcome measures.<unk>
T-1262	biomedical ; biomedical ; relative risk ; confidence interval ; left ventricular ejection fraction ; left ventricular diastolic end diameter ; outcome
H-1262	-1.112637996673584	▁bio medic al ▁treatment ▁; ▁bio medic al ▁treatment ▁; ▁CH m ▁; ▁effective ▁rate ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁left ▁vent ri cular ▁dia sto lic ▁end ▁diameter
D-1262	-1.112637996673584	biomedical treatment ; biomedical treatment ; CHm ; effective rate ; left ventricular ejection fraction ; left ventricular diastolic end diameter
P-1262	-0.5192 -0.2603 -0.0156 -3.1380 -0.2889 -3.1215 -0.2544 -0.0144 -3.2277 -0.1419 -2.5679 -0.1339 -0.1878 -3.9478 -0.0837 -0.1603 -2.4901 -2.6295 -0.8423 -0.3398 -0.3712 -0.3420 -0.1991 -1.4331 -0.0465 -0.2036 -2.5214 -2.4770 -1.0064 -0.3574 -2.8971 -0.2239 -0.8183 -1.0246 -0.0169 -2.6180 -0.2460
S-1114	METHODS: In this prospective, randomized, open-label crossover study with masked outcome assessments, stable heart failure patients (left ventricular ejection fraction < 40%) homozygous for the Arg16/Gln27 (n = 13) or Gly16/Glu27 haplotype (n = 8) of the β2-receptor were randomized to equipotent dosages of carvedilol or metoprolol for two 6-wk periods.<unk>
T-1114	prospective ; randomized ; crossover study ; outcome ; stable heart failure ; patients ; left ventricular ejection fraction ; homozygous ; haplotype ; β2-receptor ; randomized ; carvedilol ; metoprolol
H-1114	-0.829562783241272	▁heart ▁failure ▁; ▁le ft ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁ar g 16 ▁; ▁g l n 27 ▁; ▁g ly 16 ▁; ▁g lu 27 ▁ha plo type ▁; ▁β 2- recept or ▁; ▁car vedi lol ▁; ▁met o pro lol
D-1114	-0.829562783241272	heart failure ; left ventricular ejection fraction ; arg16 ; gln27 ; gly16 ; glu27 haplotype ; β2-receptor ; carvedilol ; metoprolol
P-1114	-6.3066 -0.0607 -1.1500 -1.9603 -0.0793 -3.9999 -1.0655 -0.8665 -0.1738 -0.3208 -0.1978 -1.7781 -0.0344 -0.1865 -0.3489 -0.0089 -0.1110 -0.5468 -0.6925 -0.6925 -0.0297 -0.0192 -0.1168 -0.3391 -0.8652 -0.0881 -0.3142 -2.3194 -2.5415 -0.0625 -0.2019 -0.0866 -4.0633 -0.1332 -0.7715 -0.7062 -0.0257 -0.1355 -0.3329 -3.9932 -0.1131 -0.5052 -0.1298 -0.5224 -0.1504 -0.2879 -0.7713 -0.2344 -0.2075
S-465	Of patients treated and released, low-volume ED cases exhibited higher risk of death/hospitalization/ED visit in the subsequent 7 (22.0%) and 30 days (44.9%) than medium (16.3%; aOR, 0.81 [95% CI, 0.73–0.90], and 35.3%; aOR, 0.79 [95% CI, 0.73–0.86]) or high-volume ED cases (13.0%; aOR, 0.69 [95% CI, 0.61–0.78], and 30.2%; aOR, 0.67 [95% CI, 0.61–0.74]).<unk>
T-465	patients ; death ; hospitalization ; aor ; aor ; aor ; aor
H-465	-1.3478789329528809	▁low - volu me ▁ED ▁cases ▁; ▁death ▁; hospital ization ▁; ED
D-465	-1.3478789329528809	low-volume ED cases ; death ;hospitalization ;ED
P-465	-4.1608 -0.0735 -0.6409 -0.1649 -2.0608 -0.2316 -0.2096 -4.3051 -1.0082 -0.8012 -0.3445 -0.4630 -1.9848 -3.4003 -0.3690
S-1625	RESULTS: At 2 years, participants offered the Health Buddy Program had 15% lower risk-adjusted all-cause mortality (hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.74-0.98; P = .03) and had reductions in the number of quarterly inpatient admissions from baseline to the study period that were 18% greater than those of matched controls during this same time period (-0.035 vs -0.003; difference-in-differences = -0.032, 95% CI = -0.054 to -0.010, P = .005).<unk>
T-1625	health buddy program ; all-cause mortality ; hazard ratio ; confidence interval ; inpatient ; admissions ; baseline
H-1625	-0.48898953199386597	▁health ▁Budd y ▁program ▁; ▁risk - ad just ed ▁all - ca use ▁mortal ity ▁; haz ard ▁ratio ▁; HR ▁; ▁confidence ▁interval ▁; ▁CI ▁; ▁in patient ▁ad missions ▁; ▁base line ▁; ▁match ed ▁control s
D-1625	-0.48898953199386597	health Buddy program ; risk-adjusted all-cause mortality ;hazard ratio ;HR ; confidence interval ; CI ; inpatient admissions ; baseline ; matched controls
P-1625	-0.6185 -0.3836 -0.1011 -1.4561 -0.2336 -2.8657 -0.1688 -0.0731 -0.0067 -0.0371 -0.1289 -0.0750 -0.0039 -0.2351 -0.2315 -0.0472 -0.3683 -0.0106 -0.2946 -0.0058 -0.4057 -0.5954 -0.3756 -1.5016 -0.2191 -0.4702 -2.8961 -0.6185 -2.1706 -0.2670 -0.0214 -0.0206 -0.4337 -0.0003 -0.0089 -0.6965 -0.4621 -0.0098 -0.5614 -0.0844 -1.0913 -0.2822
S-691	Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01).<unk>
T-691	multivariable-adjusted hazard ratios ; dash
H-691	-0.9732029438018799	▁multi vari able - ad just ed ▁hazard ▁ratio s ▁; ▁DAS h ▁; ▁die t ▁score
D-691	-0.9732029438018799	multivariable-adjusted hazard ratios ; DASh ; diet score
P-691	-2.8194 -0.1900 -0.1793 -0.2309 -0.0777 -0.0574 -0.0868 -1.5031 -0.0379 -0.1255 -0.1236 -4.0685 -0.5059 -0.9705 -4.8447 -0.3557 -0.5058 -1.5138 -0.2942
S-287	METHODS: Using sex-specific models, we added cTnT and NT-proBNP to age and race ("laboratory report" model) and to the ARIC HF model (includes age, race, systolic blood pressure, antihypertensive medication use, current/former smoking, diabetes, body mass index, prevalent coronary heart disease, and heart rate) in 9868 participants without prevalent HF; area under the receiver operating characteristic curve (AUC), integrated discrimination improvement, net reclassification improvement (NRI), and model fit were described.<unk>
T-287	ctnt ; nt-probnp ; report ; aric ; hf ; systolic blood pressure ; antihypertensive medication ; diabetes ; body mass index ; coronary heart disease ; heart rate ; hf ; area under the receiver operating characteristic curve ; auc ; integrated discrimination improvement ; net reclassification improvement ; nri
H-287	-0.4354431629180908	▁c t n t ▁; ▁NT - pro b NP ▁; labora tory ▁report ▁; ▁a RIC ▁ HF ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁anti hy per tensi ve ▁medication ▁; ▁smoking ▁; ▁diabetes ▁; ▁body ▁mass ▁index ▁; ▁corona ry ▁heart ▁disease ▁; ▁heart ▁rate ▁; ▁ HF ▁; ▁receive r ▁operating ▁character istic ▁cur ve ▁; AU C ▁; ▁discrimina tion ▁; ▁net ▁re class ification ▁improvement ▁; ▁n RI
D-287	-0.4354431629180908	ctnt ; NT-probNP ;laboratory report ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; HF ; receiver operating characteristic curve ;AUC ; discrimination ; net reclassification improvement ; nRI
P-287	-0.0057 -0.1877 -0.0130 -0.2508 -0.0956 -0.0513 -0.0364 -0.0143 -0.2858 -0.1621 -0.0819 -1.0524 -0.0050 -0.0131 -0.1948 -0.5033 -0.3972 -0.5666 -0.4164 -0.2620 -1.4071 -0.2235 -0.8028 -1.1689 -0.2538 -0.1269 -0.0275 -1.0093 -0.2538 -0.4399 -0.1590 -0.2706 -0.2673 -1.0883 -0.0483 -0.1041 -0.0467 -0.4330 -0.0360 -0.0427 -0.0633 -0.1533 -0.0168 -0.3476 -1.1911 -0.1137 -0.6398 -0.0326 -0.4175 -0.4900 -0.6942 -0.1321 -2.4014 -0.0180 -0.1988 -0.1077 -0.0489 -0.0562 -0.0610 -0.2843 -3.5182 -1.9668 -0.1054 -0.4124 -0.0355 -0.7566 -0.0085 -0.0282 -0.0211 -0.1186 -1.9395 -0.2347 -2.2505 -0.3820 -0.8645 -0.1778
S-1222	OBJECTIVES: The study sought to investigate the safety and efficacy of eplerenone in patients at high risk for hyperkalemia or worsening renal function (WRF) in EMPHASIS-HF, a trial that enrolled patients at least 55 years old with heart failure and reduced ejection fraction (HF-REF), in New York Heart Association (NYHA) functional class II and with an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m(2) and serum potassium <5.0 mmol/l.<unk>
T-1222	eplerenone ; patients ; hyperkalemia ; renal function ; emphasis-hf ; patients ; heart failure and reduced ejection fraction ; hf-ref ; new york heart association ; nyha ; functional class ; estimated glomerular filtration rate ; egfr ; serum potassium
H-1222	-0.49457263946533203	▁e pler en one ▁; ▁hyper kal emia ▁; ▁renal ▁function ▁; ▁w RF ▁; ▁EM PHA SIS - HF ▁; ▁heart ▁failure ▁; ▁reduce d ▁e je ction ▁ fraction ▁; HF - re f ▁; ▁New ▁York ▁Heart ▁association ▁; NY HA ▁; ▁glo mer ular ▁filtr ation ▁rate ▁; ▁e g f ▁; ▁se rum ▁po tas s ium
D-1222	-0.49457263946533203	eplerenone ; hyperkalemia ; renal function ; wRF ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ;HF-ref ; New York Heart association ;NYHA ; glomerular filtration rate ; egf ; serum potassium
P-1222	-0.4218 -0.5760 -1.2103 -0.0961 -0.1547 -0.3877 -1.0595 -0.1678 -0.0669 -1.2172 -0.2596 -0.3049 -2.2753 -0.4882 -0.3330 -1.0364 -0.0231 -1.2090 -0.0270 -0.0653 -0.0988 -2.0201 -0.4443 -0.0593 -0.3106 -0.0115 -0.0093 -0.2526 -0.0784 -0.2169 -0.0179 -0.1642 -1.6873 -0.0267 -0.4351 -1.1475 -0.0662 -0.5901 -0.2209 -1.1720 -0.4457 -0.1326 -0.1767 -0.4131 -0.1849 -0.7783 -1.0374 -0.0256 -0.2612 -0.2063 -0.0281 -0.2683 -0.2910 -1.7293 -1.5687 -0.2828 -0.1121 -0.3460 -0.2656 -0.3542 -0.2806 -1.0415 -0.8066 -0.2066
S-81	Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36).<unk>
T-81	nesiritide ; nesiritide ; placebo ; change ; cystatin c ; nesiritide ; placebo
H-81	-1.0806523561477661	▁low - dos e ▁nesi riti de ▁; ▁72 - ho ur ▁cum ul ative ▁urin e ▁volume ▁; nesi riti de ▁; ▁place bo ▁; ▁cyst atin ▁c ▁level ▁; nesi riti de ▁; ▁place bo
D-81	-1.0806523561477661	low-dose nesiritide ; 72-hour cumulative urine volume ;nesiritide ; placebo ; cystatin c level ;nesiritide ; placebo
P-81	-1.5865 -0.1134 -2.0502 -0.5007 -0.6571 -0.0801 -1.0068 -0.2560 -4.9590 -0.1399 -0.1845 -2.5129 -0.8974 -0.0829 -0.0273 -1.5878 -0.2347 -0.2700 -0.2296 -0.6964 -0.5187 -1.0181 -0.2941 -4.5341 -0.1826 -0.1911 -0.8126 -0.6066 -3.0205 -0.5807 -0.2439 -1.5952 -0.6299 -0.8893 -0.4035 -3.7073 -0.2132 -4.3288 -0.3020
S-572	RESULTS: Compared with standard care, Nordic walking led to higher functional capacity (Δ 125.6 ± 59.4 m vs Δ 57.0 ± 71.3 m travelled during 6MWT; P = 0.001), greater self-reported physical activity (Δ 158.5 ± 118.5 minutes vs Δ 155.5 ± 125.6 minutes; P = 0.049), increased right grip strength (Δ 2.3 ± 3.5 kg vs Δ 0.3 ± 3.1 kg; P = 0.026), and fewer depressive symptoms (Hospital Anxiety and Depression Scale score = Δ -1.7 ± 2.4 vs Δ -0.8 ± 3.1; P = 0.014).<unk>
T-572	walking ; functional capacity ; 6mwt ; physical ; activity ; symptoms ; hospital anxiety and depression scale
H-572	-0.8570581674575806	▁standard ▁care ▁; ▁Nordic ▁walking ▁led ▁; ▁functional ▁capacity ▁; ▁self - report ed ▁physical ▁activity ▁; ▁right ▁grip ▁strength ▁; ▁ depressiv e ▁symptoms ▁; Hospital ▁an xie ty ▁and ▁de pression ▁Scal e
D-572	-0.8570581674575806	standard care ; Nordic walking led ; functional capacity ; self-reported physical activity ; right grip strength ; depressive symptoms ;Hospital anxiety and depression Scale
P-572	-3.0064 -2.6463 -0.2079 -0.0319 -2.3494 -0.6991 -0.2663 -1.2393 -0.0424 -0.3269 -1.7919 -0.1019 -0.0271 -0.0486 -0.0899 -0.1245 -0.3394 -1.3736 -1.0403 -1.7893 -0.3991 -2.7783 -0.1910 -0.4299 -3.3638 -0.3116 -0.5280 -0.4182 -0.1654 -0.5992 -0.4940 -0.5026 -0.1329 -1.7503 -0.0195 -1.7670 -0.3176
S-1225	METHODS: This was a pre-specified analysis of subgroups of patients at high risk of hyperkalemia or WRF (patients ≥ 75 years of age, with diabetes, with eGFR <60 ml/min/1.73 m(2), and with systolic blood pressure < median of 123 mm Hg), examining the major safety measures (potassium >5.5, >6.0, and <3.5 mmol/l; hyperkalemia leading to study-drug discontinuation or hospitalization; and hospitalization for WRF) as well as the primary outcome (hospitalization for HF or cardiovascular mortality).<unk>
T-1225	patients ; hyperkalemia ; patients ; diabetes ; egfr ; systolic blood pressure ; potassium ; hyperkalemia ; leading ; hospitalization ; hospitalization ; primary outcome ; hospitalization ; hf ; cardiovascular mortality
H-1225	-0.9400888085365295	▁hyper kal emia ▁; ▁w RF ▁; ▁diabetes ▁; ▁e g FR ▁; ▁sy sto lic ▁blood ▁pressure ▁; ▁h g ▁; po tas s ium ▁; ▁hyper kal emia ▁; ▁hospital ization ▁; ▁w RF ▁; hospital ization ▁; ▁ HF ▁; ▁cardiovascular ▁mortal ity
D-1225	-0.9400888085365295	hyperkalemia ; wRF ; diabetes ; egFR ; systolic blood pressure ; hg ;potassium ; hyperkalemia ; hospitalization ; wRF ;hospitalization ; HF ; cardiovascular mortality
P-1225	-1.9312 -0.7328 -0.4778 -0.1262 -0.3656 -1.1199 -0.2190 -0.2738 -0.0946 -0.0270 -0.5853 -1.8943 -0.0817 -2.5880 -0.2384 -1.4548 -2.8570 -0.5485 -0.1727 -4.4400 -0.0336 -0.3333 -3.6663 -0.2762 -0.2191 -1.2556 -0.0750 -4.9114 -1.8232 -0.4025 -0.2250 -3.7755 -0.1461 -0.3353 -0.3152 -1.6796 -0.3348 -3.7113 -0.1848 -0.2541 -0.0810 -0.0749 -0.1281 -0.0938 -0.0823 -0.0381 -0.2345 -0.2050
S-1268	The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants.<unk>
T-1268	paf ; biosynthetic enzymes ; lyso-paf acetyltransferase ; lyso-paf-at ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; paf-cpt ; catabolic isoenzymes ; paf-acetylhydrolase ; paf-ah ; lipoprotein-associated phospholipase a2 ; lp-pla2 ; leukocytes
H-1268	-0.8718898296356201	▁PA f ▁; ▁bio syn the tic ▁enzym es ▁; lys o - pa f ▁a ce tyl transfer ase ▁; lys o - pa f - AT ▁; ▁di thi oth rei tol ▁; ▁d t ▁; ▁cd p ▁cho line ▁; ▁1- al kyl -2 - ace tyl - s n - gly cer ol ▁cho line phos pho transfer ase ▁; ▁p f - c pt ▁; ▁cata bo lic ▁iso en zy mes ▁; ▁p f - ace tyl hydro lase ▁; ▁p f - AH ▁; ▁lipo prote in - as soci ated ▁ phos pho lipa se ▁a 2 ▁; ▁l p - PLA 2 ▁; ▁se rum ▁; ▁leuk o cy tes
D-1268	-0.8718898296356201	PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-AT ; dithiothreitol ; dt ; cdp choline ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; pf-cpt ; catabolic isoenzymes ; pf-acetylhydrolase ; pf-AH ; lipoprotein-associated phospholipase a2 ; lp-PLA2 ; serum ; leukocytes
P-1268	-2.8548 -0.8616 -0.4108 -2.3252 -0.1873 -1.5631 -0.3272 -0.0597 -0.1615 -0.2765 -0.7610 -0.0727 -0.2202 -1.0497 -1.6908 -0.4301 -0.9446 -3.0420 -0.2934 -2.2648 -0.1997 -2.2674 -0.0353 -0.1519 -0.5473 -1.4882 -1.2315 -0.8595 -0.1842 -0.0547 -3.0202 -2.2322 -0.0706 -1.8291 -0.1986 -0.5727 -0.3261 -0.6762 -3.4509 -0.0818 -0.0790 -0.0747 -0.5686 -1.4296 -0.0673 -0.3284 -0.1865 -0.2102 -1.7516 -0.7217 -0.0985 -0.0204 -0.0233 -0.3663 -1.3326 -3.0081 -2.9495 -0.2009 -0.1832 -3.2988 -4.7076 -2.8051 -2.0081 -0.2850 -2.1048 -1.0409 -0.0791 -1.8958 -0.6134 -0.4907 -0.0805 -0.6672 -0.2275 -0.0121 -1.2977 -0.3833 -0.9925 -0.2681 -3.1214 -1.0958 -0.0606 -0.3666 -1.4320 -0.3622 -0.7325 -0.1751 -2.1776 -1.3349 -0.0687 -1.0620 -0.1975 -0.0486 -0.5695 -0.4531 -0.2435 -0.0828 -0.0269 -0.2272 -0.2025 -0.5602 -1.0883 -2.1252 -1.9009 -1.8232 -0.0194 -0.1812 -0.4523 -0.0019 -0.0825 -0.0080 -1.9895 -1.4211 -1.6752 -0.0991 -0.3796 -0.3362 -0.0704 -0.1205 -0.3166 -0.4678 -0.2046
S-1175	RESULTS: The ivabradine group demonstrated significant improvement between baseline and follow-up exercise capacity (4.2 ± 1.8 METs vs. 5.7 ± 1.9 METs, p = 0.001) and peak oxygen uptake (14.0 ± 6.1 ml/min/kg vs. 17.0 ± 3.3 ml/min/kg, p = 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity to peak early diastolic mitral annular velocity (3.1 ± 2.7 vs. 1.3 ± 2.0, p = 0.004).<unk>
T-1175	ivabradine ; baseline ; follow-up ; exercise capacity ; mets ; mets ; peak oxygen uptake ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
H-1175	-0.401413232088089	▁i va bra dine ▁group ▁; ▁base line ▁; ▁follow - up ▁exercise ▁capacity ▁; ▁pe ak ▁oxygen ▁up take ▁; ▁exercise - indu ced ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁flow ▁veloci ty ▁; ▁pe ak ▁early ▁dia sto lic ▁mit ral ▁ann ular ▁veloci ty
D-1175	-0.401413232088089	ivabradine group ; baseline ; follow-up exercise capacity ; peak oxygen uptake ; exercise-induced ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
P-1175	-0.0180 -1.2232 -0.2093 -0.1197 -0.5363 -0.1345 -0.0067 -0.0594 -0.1418 -0.0432 -0.0866 -0.0091 -0.6198 -0.1056 -0.2576 -0.1225 -0.0052 -1.4721 -0.2345 -0.1247 -0.2192 -2.3383 -0.2543 -0.0264 -0.5716 -0.7668 -0.5401 -0.0061 -0.4036 -0.3358 -0.3297 -0.4877 -1.4801 -0.1461 -0.9033 -0.0611 -0.1214 -0.2033 -0.4402 -0.0067 -0.3388 -0.5053 -0.5055 -0.9919 -1.2146 -0.2803 -1.2160 -0.0005 -0.0328 -0.1744 -0.3004 -0.1415
S-1455	Multivariate analysis revealed that the odds of CHF was higher in females [Odds Ratio (OR) = 2·9, P < 0·01], individuals with pre-HCT chest radiation (OR = 4·7, P = 0·05), hypertension (OR = 2·9, P = 0·01), and with variants of genes coding for the NAD(P)H-oxidase subunit RAC2 (rs13058338, 7508T→A; OR = 2·8, P < 0·01), HFE (rs1799945, 63C→G; OR = 2·5, P = 0·05) or the doxorubicin efflux transporter ABCC2 (rs8187710, 1515G→A; OR = 4·3, P < 0·01).<unk>
T-1455	multivariate analysis ; chf ; odds ratio ; chest ; hypertension ; genes ; rac2 ; doxorubicin efflux transporter ; abcc2
H-1455	-1.027091383934021	▁CHF ▁; Od ds ▁Ra tio ▁; ▁pre - H CT ▁; ▁che st ▁radi ation ▁; ▁hyper tension ▁; ▁gene s ▁co ding ▁; ▁ NAD ( p h - oxid ase ▁; ▁ RAC 2 ▁; ▁h fe ▁; ▁do xor ubi cin ▁ eff lux ▁transporter ▁; ▁ab c 2
D-1455	-1.027091383934021	CHF ;Odds Ratio ; pre-HCT ; chest radiation ; hypertension ; genes coding ; NAD(ph-oxidase ; RAC2 ; hfe ; doxorubicin efflux transporter ; abc2
P-1455	-0.8889 -0.2299 -2.1981 -0.1074 -1.0691 -0.5539 -0.1774 -2.5906 -0.0268 -1.9750 -1.8723 -1.5901 -2.5162 -0.1415 -0.0261 -0.3587 -0.1209 -1.5033 -0.1761 -0.1842 -2.5697 -0.0524 -0.0888 -0.9484 -0.1670 -0.3805 -0.0098 -2.8910 -0.7528 -4.4861 -1.4036 -0.3090 -3.6986 -1.8900 -1.6201 -0.6025 -0.3891 -0.0773 -2.2589 -1.5291 -0.0714 -1.6576 -1.7030 -0.0431 -0.4255 -0.4127 -0.1049 -0.8211 -0.2965 -1.7596 -1.7972 -0.2535 -0.3365 -2.0230 -0.3530
S-1958	From baseline to 3 month follow-up, we recorded improvements in NYHA classification (from class III to class II in seven [78%] of nine patients, from class III to class I in one [11%] patient, and no change in one [11%] patient; p=0·0004); quality of life, as assessed by the Duke Activity Status Index (from a mean score of 13 [SD 6·2] to 24·8 [12·9]; p=0·016) and the Kansas City Cardiomyopathy Questionnaire (from a mean score of 44·3 [SD 9·8] to 79·1 [13·0]; p=0·0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318 m [134]; p=0·016).<unk>
T-1958	baseline ; follow-up ; nyha classification ; patients ; patient ; change ; patient ; quality of life ; duke activity status index ; kansas city cardiomyopathy questionnaire ; 6 min walk test
H-1958	-1.4417985677719116	▁base line ▁; ▁base line ▁; ▁NY HA ▁classifica tion ▁; ▁class ▁III ▁; ▁class ▁III ▁; ▁change ▁; ▁Duke ▁activity ▁status ▁index ▁; ▁Kansas ▁City ▁Card i om yo pathy ▁; ▁walk ▁test ▁distance
D-1958	-1.4417985677719116	baseline ; baseline ; NYHA classification ; class III ; class III ; change ; Duke activity status index ; Kansas City Cardiomyopathy ; walk test distance
P-1958	-0.1352 -0.0636 -0.1211 -5.0488 -0.2019 -0.1254 -1.6393 -1.2575 -2.2560 -0.1580 -0.1799 -3.4942 -2.5403 -0.2391 -2.9430 -3.5706 -0.1668 -5.7891 -0.1656 -3.3587 -0.4952 -0.4559 -1.2804 -0.1703 -2.2682 -0.2900 -2.7296 -0.1134 -0.2255 -1.9157 -1.5836 -1.8831 -3.1134 -0.6966 -0.3812 -2.0074 -0.2828
S-80	RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830 ; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72).<unk>
T-80	placebo ; dopamine ; dopamine ; placebo ; change ; cystatin c ; dopamine ; placebo
H-80	-1.206512689590454	▁place bo ▁; ▁low - dos e ▁dop amine ▁; ▁72 - ho ur ▁cum ul ative ▁urin e ▁volume ▁; dop amine ▁; ▁place bo ▁; ▁cyst atin ▁c ▁level ▁; ▁dop amine ▁; ▁place bo ▁; ▁cyst atin ▁c ▁level
D-80	-1.206512689590454	placebo ; low-dose dopamine ; 72-hour cumulative urine volume ;dopamine ; placebo ; cystatin c level ; dopamine ; placebo ; cystatin c level
P-80	-5.2436 -0.6265 -0.1129 -0.1661 -0.0600 -1.4066 -0.2922 -0.7027 -0.5217 -0.1209 -2.5688 -0.1157 -0.1430 -1.9354 -0.9070 -0.0995 -0.0436 -1.8120 -0.2531 -0.3102 -0.1318 -2.5801 -0.7191 -0.1323 -5.1525 -0.3698 -0.1221 -1.0841 -0.8122 -2.8739 -0.7316 -0.1815 -5.1087 -0.6282 -0.2282 -3.4475 -0.4187 -0.2994 -1.9044 -1.5855 -3.4030 -1.1494 -2.2892 -0.2918
S-66	High confidence in estimates was found for age (hazard ratio [HR], 1.45 for 10-year increase; 95% confidence interval [CI], 1.35-1.56), baseline glomerular filtration rate (HR, 1.25 for 15-mL/min decrease; 95% CI, 1.15-1.35), chronic obstructive pulmonary disease (HR, 1.54; 95% CI, 1.38-1.71), diabetes (HR, 1.56; 95% CI, 1.37-1.79), peripheral vascular disease (HR, 1.43; 95% CI, 1.2-1.72), left ventricular ejection fraction (HR, 0.77 for 10% increase; 95% CI, 0.73-0.83), and appropriate or inappropriate ICD shocks (HR, 2.34; 95% CI 1.59-3.44) New York Heart Association class, atrial fibrillation, and congestive HF were strongly associated with mortality but the confidence in estimates was low.<unk>
T-66	hazard ratio ; confidence interval ; baseline ; glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; icd shocks ; new york heart association class ; atrial fibrillation ; congestive hf ; mortality
H-66	-0.8925521969795227	▁figure ▁; haz ard ▁ratio ▁; ▁base line ▁glo mer ular ▁filtr ation ▁rate ▁; ▁base line ▁glo mer ular ▁filtr ation ▁rate ▁; ▁diabetes ▁; ▁diabetes ▁; ▁per i pher al ▁vas cular ▁disease ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁i CD ▁shock s ▁; ▁New ▁York ▁Heart ▁association ▁; ▁at rial ▁fi bril lation ▁; ▁con ges tive ▁ HF
D-66	-0.8925521969795227	figure ;hazard ratio ; baseline glomerular filtration rate ; baseline glomerular filtration rate ; diabetes ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; New York Heart association ; atrial fibrillation ; congestive HF
P-66	-5.2348 -0.2059 -2.8959 -0.1239 -0.0107 -0.1446 -0.7272 -0.0425 -3.7414 -0.5688 -0.0104 -0.4892 -0.2563 -0.1192 -0.1904 -1.6296 -0.0999 -5.0657 -0.5459 -0.0112 -0.7893 -0.2396 -0.1279 -0.2389 -4.2910 -0.1160 -3.9878 -0.1188 -3.0954 -0.2102 -0.1299 -0.0829 -1.1526 -0.4381 -1.3573 -0.1966 -0.2523 -2.5225 -1.3751 -0.3780 -0.0740 -0.1093 -0.0976 -1.0092 -0.0257 -0.2992 -2.7215 -3.7264 -0.7515 -0.0522 -0.1993 -1.8660 -0.6794 -1.3846 -0.5255 -0.7962 -0.1874 -0.3144 -0.2998 -0.0895 -1.4308 -0.1880 -0.0434 -0.1438 -0.0690 -0.1648 -0.0808 -0.7617 -0.2820
S-1761	At multivariable analysis, the following variables were significantly associated with primary study end point: peak oxygen uptake (% pred; P<0.001; hazard ratio [HR]=0.977; confidence interval [CI]=0.97-0.98), ventilatory efficiency slope (P=0.01; HR=1.02; CI=1.01-1.03), hemoglobin (P<0.05; HR=0.931; CI=0.87-1.00), left ventricular ejection fraction (P<0.001; HR=0.948; CI=0.94-0.96), renal function (modification of diet in renal disease; P<0.001; HR=0.990; CI=0.98-0.99), sodium (P<0.05; HR=0.967; CI=0.94-0.99), and AT nonidentification (P<0.05; HR=1.41; CI=1.06-1.89).<unk>
T-1761	multivariable analysis ; end point ; peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
H-1761	-0.9078367352485657	▁pe ak ▁oxygen ▁up take ▁; ▁hazard ▁ratio ▁; ▁confidence ▁interval ▁; ▁ventilator y ▁efficiency ▁s lope ▁; ▁hem o glob in ▁; ▁left ▁vent ri cular ▁e je ction ▁ fraction ▁; ▁renal ▁function ▁; ▁change ▁of ▁die t ▁in ▁renal ▁disease ▁; ▁so dium
D-1761	-0.9078367352485657	peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; change of diet in renal disease ; sodium
P-1761	-0.1443 -0.0128 -1.7475 -0.4130 -0.3011 -0.1425 -2.2481 -0.0192 -0.1140 -2.0576 -0.4427 -0.1649 -2.8127 -0.3568 -0.1459 -0.0662 -0.0483 -0.1346 -2.2852 -0.1996 -0.8058 -0.9055 -0.1617 -5.0084 -1.5413 -1.3826 -0.5842 -0.1019 -0.1259 -0.1650 -1.0046 -0.0327 -0.1665 -0.5031 -0.8746 -0.1762 -5.2740 -1.3661 -0.4587 -0.1052 -0.9502 -0.0403 -1.6308 -0.3261 -0.1817 -1.6782 -3.8037 -0.3641
S-1331	RESULTS: A significant improvement in 6-minute walked distance (F = 21.61, P = .001), Kansas City Cardiomyopathy Questionnaire summary (F = 8.68, P = .006), Minnesota Living with Heart Failure Questionnaire (F = 6.43, P = .017), Beck Depression Inventory (F = 6.66, P = .015), Zung (F = 6.25, P = .019), and flow-mediated dilatation diameter (F = 11.98, P = .002) was observed in the FES group compared with placebo group; B-type natriuretic peptide also declined but not significantly (F = 0.249, P = .622), and there was a tendency toward lower mitral E/e' wave ratio (F = 3.066, P = .091).<unk>
T-1331	6-minute walked distance ; kansas city cardiomyopathy questionnaire ; minnesota living with heart failure questionnaire ; beck depression inventory ; flow-mediated dilatation ; fes ; placebo ; b-type natriuretic peptide ; mitral
H-1331	-0.5181483626365662	▁Kansas ▁City ▁; ▁card i om yo pathy ▁; ▁Minnesota ▁; ▁Heart ▁Fail ure ▁Question naire ▁; ▁Beck ▁de pression ▁in ven tory ▁; ▁z ung ▁; ▁flow - media ted ▁di la tation ▁diameter ▁; ▁f es ▁group ▁; ▁place bo ▁; ▁na tri ure tic ▁pe pti de ▁; ▁mit ral ▁e / e ▁; ▁wa ve ▁ratio
D-1331	-0.5181483626365662	Kansas City ; cardiomyopathy ; Minnesota ; Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; fes group ; placebo ; natriuretic peptide ; mitral e/e ; wave ratio
P-1331	-0.2207 -0.4126 -1.3780 -2.5297 -0.1314 -0.3838 -1.0752 -1.0052 -0.5427 -1.8170 -0.5069 -0.7198 -0.2150 -0.0429 -1.5695 -0.0579 -0.1124 -0.1194 -0.5015 -0.0534 -0.2962 -0.1502 -0.0048 -0.1574 -0.2963 -0.5670 -0.1364 -0.0412 -0.1024 -0.1873 -0.2236 -0.1203 -0.1868 -0.0192 -0.0077 -0.1252 -1.4950 -0.9645 -1.2303 -0.0536 -1.1906 -0.1339 -0.7686 -0.6218 -0.2153 -0.1604 -0.3047 -0.0249 -0.0779 -0.4855 -0.2746 -0.8861 -0.0595 -2.3422 -1.7784 -0.0182 -2.1738 -0.0820 -0.0907 -0.0242 -0.4157 -0.2357
2021-01-18 16:40:37 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-01-18 16:40:37 | INFO | fairseq_cli.generate | Translated 2,024 sentences (39,551 tokens) in 191.0s (10.60 sentences/s, 207.08 tokens/s)
2021-01-18 16:40:37 | WARNING | fairseq_cli.generate | If you are using BPE on the target side, the BLEU score is computed on BPE tokens, not on proper words.  Use --sacrebleu for standard 13a BLEU tokenization
Generate test with beam=5: BLEU4 = 49.84, 67.4/53.9/45.0/37.7 (BP=1.000, ratio=1.004, syslen=39551, reflen=39387)
